Document,Phrase,CardVal,RefinedWord,RefinedVal,ManRefWord,ManRefVal
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,discussed,0.42584902,as,0.54987454,cardiology,0.42584902
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,internal,0.33825016,artery,0.46088225,artery,0.46088225
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,internal-validation,0.32116336,venous-return,0.45430973,venous-return,0.45430973
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,allows,0.20518643,of,0.5544299,flow,0.40244576
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,healthcare,0.47028068,cardiology,0.47028068,cardiology,0.47028068
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,providers,0.5168287,cardiology,0.5168287,cardiology,0.5168287
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,healthcare-providers,0.48351508,cardiology,0.48351508,cardiology,0.48351508
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,present,0.34922045,of,0.63723874,anomaly,0.40175247
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,particular,0.34937102,of,0.6936578,anomalous,0.4519893
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,concerns,0.41936314,great,0.5325278,cardiology,0.41936314
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,according,0.3426876,as,0.48304257,rai,0.3796531
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.32085416,of,0.605934,flow,0.3956796
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,using,0.20786116,with,0.58010674,flow,0.41007757
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-model,0.22683395,venous-return,0.36088276,venous-return,0.36088276
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction,0.345095,heart-disease,0.4934518,heart-disease,0.4934518
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-models,0.23241714,single-ventricle,0.35599178,single-ventricle,0.35599178
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction-models,0.28052905,congenital-heart-disease,0.44657955,congenital-heart-disease,0.44657955
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,left,0.3872844,left,1.0,left-atrial,0.6573896
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ventricular-ejection,0.45086157,ventricular,0.8827383,ventricular,0.8827383
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,external,0.29746136,of,0.4755252,anomalous,0.3880807
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,external-validation,0.31959862,venous-return,0.4819317,venous-return,0.4819317
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction,0.345095,heart-disease,0.4934518,heart-disease,0.4934518
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictor,0.24674982,as,0.45541835,chd,0.39992505
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictor-variables,0.23739848,congenital-heart-disease,0.47714326,congenital-heart-disease,0.47714326
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,including,0.2742056,of,0.6619886,congenital,0.3605199
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,male,0.3213997,with,0.46579415,mi,0.43337548
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,characteristics-including,0.27410764,of,0.55792254,anomalous,0.4131521
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,male-sex,0.1750514,chd,0.3287017,chd,0.3287017
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.32085416,of,0.605934,flow,0.3956796
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospitalizations,0.45230448,chd,0.5185937,chd,0.5185937
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf-hospitalizations,0.51139414,heart-failure,0.6202102,heart-failure,0.6202102
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular-death,0.55456674,chd,0.6699116,chd,0.6699116
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction,0.345095,heart-disease,0.4934518,heart-disease,0.4934518
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-models,0.23241714,single-ventricle,0.35599178,single-ventricle,0.35599178
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction-models,0.28052905,congenital-heart-disease,0.44657955,congenital-heart-disease,0.44657955
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,common,0.21206799,of,0.500178,anomaly,0.44165826
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf-risk,0.3819933,chd,0.6754271,chd,0.6754271
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,terminal,0.16295928,of,0.5041194,l-transposition,0.41455114
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prohormone,0.27568027,atrial,0.47738105,atrial,0.47738105
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic,0.48098868,ventricular,0.6719714,ventricular,0.6719714
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood,0.32078606,blood,1.0,blood,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic-blood,0.44296455,blood,0.691996,blood,0.691996
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood-pressure,0.37952203,blood,0.65126884,blood,0.65126884
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic-blood-pressure,0.42961985,blood,0.62121356,blood,0.62121356
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,might,0.24242394,of,0.5952132,anomalous,0.3600717
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,benefit,0.3251614,return,0.474311,heart-failure,0.40887886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,patients-might,0.3774119,congenital-heart-disease,0.5480596,congenital-heart-disease,0.5480596
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,handling,0.27404976,of,0.48745817,heart-failure,0.3839382
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,missing,0.28011686,of,0.53369325,anomaly,0.43782362
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,data,0.31118363,of,0.5086956,mi,0.36251363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,missing-data,0.28085497,congenital-heart-disease,0.44279695,congenital-heart-disease,0.44279695
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood,0.32078606,blood,1.0,blood,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,urea,0.16199692,blood,0.42514712,blood,0.42514712
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nitrogen,0.13745444,total,0.37970564,cholesterol,0.35112154
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood-urea,0.22035475,blood-clot,0.6525449,blood-clot,0.6525449
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,urea-nitrogen,0.13079393,blood-flow,0.37584522,blood-flow,0.37584522
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood-urea-nitrogen,0.20123094,blood,0.54801726,blood,0.54801726
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic,0.30789188,of,0.5083823,congenital-heart-disease,0.39102057
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature,0.36901063,of,0.4653955,anomaly,0.4380433
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,review,0.438658,of,0.54425275,cardiology,0.438658
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic-literature,0.32297635,of,0.5008236,congenital-heart-disease,0.39650857
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature-review,0.37814057,congenital-heart-disease,0.4297125,congenital-heart-disease,0.4297125
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic-literature-review,0.34087515,of,0.4580175,congenital-heart-disease,0.41816264
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assess,0.37312466,of,0.49566716,pulmonary,0.375783
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,statistical,0.32752115,of,0.40241736,congenital-heart-disease,0.36489835
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.4594617,cardiology,0.4594617,cardiology,0.4594617
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,reported,0.2535432,of,0.6039252,l-transposition,0.37000108
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,detail,0.35711303,of,0.52554643,anomalous,0.43140408
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,overall,0.28817955,of,0.5869458,chd,0.41920155
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,low,0.33154353,with,0.5951388,flow,0.4108625
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.20263225,dorv,0.3384785,dorv,0.3384785
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,overall-low,0.20265011,venous-return,0.40514672,venous-return,0.40514672
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias,0.21969397,weak,0.34950268,lai,0.32676864
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias-assessment,0.398519,venous-return,0.4265928,venous-return,0.4265928
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessment-tool,0.41843995,cardiology,0.41843995,cardiology,0.41843995
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-models,0.23241714,single-ventricle,0.35599178,single-ventricle,0.35599178
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assess,0.37312466,of,0.49566716,pulmonary,0.375783
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular-death,0.55456674,chd,0.6699116,chd,0.6699116
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.4594617,cardiology,0.4594617,cardiology,0.4594617
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.32085416,of,0.605934,flow,0.3956796
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ranked,0.37995976,as,0.51157963,cardiology,0.37995976
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,according,0.3426876,as,0.48304257,rai,0.3796531
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.4594617,cardiology,0.4594617,cardiology,0.4594617
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,non,0.3477749,with,0.61364555,mi,0.46788454
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,may,0.26963884,of,0.58654004,anomalous,0.366544
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,march,0.39432454,cardiology,0.39432454,cardiology,0.39432454
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospitalization,0.4883753,failure,0.53211665,heart-failure,0.51238096
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf-hospitalization,0.50036544,heart-failure,0.62627625,heart-failure,0.62627625
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.20263225,dorv,0.3384785,dorv,0.3384785
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature,0.36901063,of,0.4653955,anomaly,0.4380433
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,databases,0.38172573,cardiology,0.38172573,cardiology,0.38172573
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.20263225,dorv,0.3384785,dorv,0.3384785
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registration,0.31536373,heartbeat,0.3267731,heartbeat,0.3267731
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,number,0.2521113,total,0.48291022,l-transposition,0.33454442
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registration-number,0.365533,heartbeat,0.41406253,heartbeat,0.41406253
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,utility,0.2794286,of,0.49793997,flow,0.31422362
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nyha,0.4289499,congestive,0.58286214,congestive,0.58286214
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,class,0.2877068,of,0.3977759,d-transposition,0.36031434
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nyha-class,0.37124214,heart-failure,0.5203762,heart-failure,0.5203762
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,natriuretic,0.381192,atrial,0.6450516,atrial,0.6450516
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,peptide,0.22390819,atrial,0.42872304,atrial,0.42872304
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,natriuretic-peptide,0.30771548,atrial,0.5734308,atrial,0.5734308
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,mainly,0.28163683,of,0.6151813,deposits,0.44905117
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,justify,0.23711805,of,0.36755955,congenital-heart-disease,0.31894612
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospital,0.5604328,cardiology,0.5604328,cardiology,0.5604328
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,setting,0.5175974,failure,0.54691184,cardiology,0.5175974
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospital-setting,0.4837858,venous-return,0.51661444,venous-return,0.51661444
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart,0.57664216,heart,1.0,heart,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart-rate,0.43613237,heartbeat,0.713904,heartbeat,0.713904
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart,0.57664216,heart,1.0,heart,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,generally,0.29403654,with,0.608389,deposits,0.39144385
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,economic,0.29339665,great,0.4144292,single-ventricle,0.33241546
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,value,0.3260533,of,0.52001536,flow,0.37269968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,duplicated,0.21653174,l-transposition,0.56444937,l-transposition,0.56444937
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,citations,0.40793592,total,0.42257315,cardiology,0.40793592
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,composite,0.22068933,failure,0.39251378,hypoplastic-left-heart,0.38025624
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,endpoints,0.28787833,failure,0.4535117,heart-failure,0.3982118
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,certain,0.2610966,of,0.63117075,l-transposition,0.42081705
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,therapies,0.36136723,failure,0.47599852,heart-failure,0.42514777
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cause-mortality,0.32417238,heart-disease,0.5488442,heart-disease,0.5488442
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast,0.276626,with,0.4104613,mi,0.39556238
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,discriminatory,0.20530923,of,0.40653515,heart-failure,0.32456607
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ability,0.2123124,of,0.53612673,cardiac,0.340167
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,deemed,0.40265262,as,0.505542,cardiology,0.40265262
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,including,0.2742056,of,0.6619886,congenital,0.3605199
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.20263225,dorv,0.3384785,dorv,0.3384785
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias,0.21969397,weak,0.34950268,lai,0.32676864
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast,0.276626,with,0.4104613,mi,0.39556238
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ability,0.2123124,of,0.53612673,cardiac,0.340167
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,yet,0.32307938,as,0.52449846,cardiac,0.34347042
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,within,0.30995527,of,0.57602364,deposits,0.42065546
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,understand,0.30193475,great,0.4775984,anomalous,0.3542228
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,sodium,0.23421176,of,0.40018386,cholesterol,0.38060108
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,slr,0.18177438,stiff,0.40751296,venous-return,0.3935372
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,searched,0.3371359,isolated,0.36040172,cardiology,0.3371359
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,robustness,0.2293376,heartbeat,0.41836193,heartbeat,0.41836193
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,results,0.29712585,of,0.53157276,blood,0.36869162
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registered,0.3751458,cardiology,0.3751458,cardiology,0.3751458
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prospero,0.2839881,cardiology,0.2839881,cardiology,0.2839881
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,propose,0.18777283,of,0.46277136,anomalous,0.37135097
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,payers,0.4499864,cardiology,0.4499864,cardiology,0.4499864
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,n,0.21850443,with,0.47536123,mi,0.3790054
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,majority,0.28791377,of,0.48508087,l-transposition,0.36823815
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,lack,0.27131414,of,0.6011338,l-transposition,0.36177164
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,incorporation,0.24355794,of,0.44410712,l-transposition,0.38163653
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,id,0.35301208,intact,0.4460395,arrythmia,0.3941226
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,extent,0.2738167,of,0.64978826,deposits,0.4439485
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,determined,0.24003299,of,0.6221287,flow,0.40728092
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,demands,0.39159468,great,0.47017017,cardiology,0.39159468
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,creatinine,0.33032572,cholesterol,0.43090975,cholesterol,0.43090975
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,co,0.36334935,with,0.46287042,cardiac,0.45921996
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,calibration,0.31922334,venous-return,0.39590418,venous-return,0.39590418
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bmi,0.27502015,chd,0.49532586,chd,0.49532586
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,based,0.2494699,of,0.5443143,flow,0.34116954
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,background,0.2325702,of,0.51277274,congenital,0.3895001
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,application,0.3034747,of,0.54379797,flow,0.3922925
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,age,0.33659208,with,0.44369304,chd,0.42829025
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resulting,0.18480285,of,0.6416826,anomalous,0.46019152
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,volumetric,0.25147688,flow,0.5471731,flow,0.5471731
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,matrix,0.19602376,deposits,0.43658155,deposits,0.43658155
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,captures,0.3192318,of,0.46913648,heartbeat,0.44105428
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,procedure,0.36597854,d-transposition,0.44744885,d-transposition,0.44744885
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,data,0.31118363,of,0.5086956,mi,0.36251363
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,diagnostic-clinical,0.42931372,congenital-heart-disease,0.49139196,congenital-heart-disease,0.49139196
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,magnetic,0.30615485,anomalous,0.42478612,anomalous,0.42478612
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resonance,0.3363875,anomalous,0.43202996,anomalous,0.43202996
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,provides,0.22296365,of,0.5261056,flow,0.32656315
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,high,0.28122714,of,0.57459104,flow,0.3923195
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,spatial,0.27024955,of,0.5094393,anomalous,0.43555915
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resolution,0.22951236,of,0.46130672,tof,0.40459827
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac-magnetic,0.47206485,cardiac,0.6445676,cardiac,0.6445676
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,magnetic-resonance,0.28411427,anomalous,0.4479651,anomalous,0.4479651
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resonance-imaging,0.32959193,tof,0.39892417,tof,0.39892417
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,high-spatial,0.24507074,tof,0.43245733,tof,0.43245733
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,spatial-resolution,0.24250573,anomalous,0.4409847,anomalous,0.4409847
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac-magnetic-resonance,0.4053229,cardiac,0.50606585,cardiac,0.50606585
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,magnetic-resonance-imaging,0.31361923,anomalous,0.41087624,anomalous,0.41087624
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,high-spatial-resolution,0.24760842,tof,0.47332364,tof,0.47332364
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,top,0.40076846,with,0.45628595,cardiology,0.40076846
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,average,0.3160447,total,0.53346545,beats,0.33409712
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dice,0.32051048,great,0.40511793,heartbeat,0.3806455
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,index,0.27677816,total,0.43109894,mi,0.39722836
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,achieved,0.22746107,of,0.5726348,l-transposition,0.3770222
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,index-scores,0.25524265,artery-disease,0.38985807,artery-disease,0.38985807
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,robust,0.13868469,weak,0.46394548,heartbeat,0.35403174
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dilated,0.38440502,ventricle,0.58307534,ventricle,0.58307534
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,convolutional,0.30860516,venous-return,0.43876672,venous-return,0.43876672
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,architecture,0.21789135,irregular,0.49668017,deposits,0.39629874
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,neural-network,0.2583411,heartbeat,0.44916824,heartbeat,0.44916824
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,network-architecture,0.24877037,irregular,0.39590973,venous-return,0.34778196
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,anonymized,0.3778921,congenital-heart,0.38965827,congenital-heart,0.38965827
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cine,0.44621083,mitral,0.55117816,mitral,0.55117816
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,sequencing,0.23510775,isolated,0.42495134,l-transposition,0.3606252
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,provides,0.22296365,of,0.5261056,flow,0.32656315
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,reproducible,0.19868155,of,0.41789025,blood-flow,0.41288352
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,advanced,0.34864503,with,0.51267695,congestive,0.41393596
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fully,0.24119267,of,0.5259341,isomerism,0.3538288
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,automatic,0.28944573,heartbeat,0.5578543,heartbeat,0.5578543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pipeline,0.31322083,flow,0.36466506,flow,0.36466506
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fully-automatic,0.29986864,heartbeat,0.48641053,heartbeat,0.48641053
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,automatic-processing,0.27610308,heartbeat,0.44159335,heartbeat,0.44159335
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,independent,0.28915384,of,0.5904635,cad,0.4052443
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,independent-test,0.29302192,venous-return,0.46350747,venous-return,0.46350747
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,test-set,0.2495839,congenital-heart-disease,0.38465905,congenital-heart-disease,0.38465905
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,initial,0.36733395,of,0.6574379,cardiac,0.43063313
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,element,0.21579163,l-transposition,0.42461568,l-transposition,0.42461568
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,consists,0.17647596,of,0.54870045,anomalous,0.31613857
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ary,0.40140855,l-transposition,0.47778052,l-transposition,0.47778052
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,per,0.42462003,single,0.5002958,cardiology,0.42462003
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,group,0.2849201,with,0.5052614,mi,0.411738
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,per-group,0.25972062,venous-return,0.38584906,venous-return,0.38584906
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,data,0.31118363,of,0.5086956,mi,0.36251363
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training-data,0.41366336,venous-return,0.4406841,venous-return,0.4406841
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,data-set,0.33313137,congenital-heart-disease,0.39762664,congenital-heart-disease,0.39762664
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training-data-set,0.39473984,congenital-heart-disease,0.45195186,congenital-heart-disease,0.45195186
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,classifier,0.26326174,cad,0.36912674,cad,0.36912674
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,quantify,0.2039063,of,0.45878464,flow,0.36393017
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,measures,0.2977168,of,0.4417776,venous-return,0.3984164
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,manual,0.33213076,blood-flow,0.4233244,blood-flow,0.4233244
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,evaluation,0.3957072,of,0.5653497,cardiology,0.3957072
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,final,0.35061413,of,0.54912525,cardiology,0.35061413
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,element,0.21579163,l-transposition,0.42461568,l-transposition,0.42461568
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,group,0.2849201,with,0.5052614,mi,0.411738
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,healthy-group,0.2241053,congenital-heart-disease,0.43191332,congenital-heart-disease,0.43191332
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,rv,0.34965062,right-ventricle,0.6898135,right-ventricle,0.6898135
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,results-demonstrate,0.35938346,of,0.5512711,venous-return,0.45336813
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,extraction,0.25589973,of,0.42793012,flow,0.40312088
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,groups,0.2612025,with,0.4941169,mi,0.3908207
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,staging,0.29892582,rai,0.49285498,rai,0.49285498
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease-staging,0.2420262,disease,0.68509203,artery-disease,0.54107153
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium,0.38313717,myocardial,0.8277121,myocardial,0.8277121
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,combining,0.238502,with,0.56878334,flow,0.37439224
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,semantic,0.31043303,artery-disease,0.40357578,artery-disease,0.40357578
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease-classification,0.29208606,disease,0.63653195,artery-disease,0.543869
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,wise,0.4430913,great,0.4545446,cardiology,0.4430913
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cavities,0.1858696,irregular,0.4426181,deposits,0.43817985
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,university,0.5321148,cardiology,0.5321148,cardiology,0.5321148
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,hospital,0.5604328,cardiology,0.5604328,cardiology,0.5604328
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,university-hospital,0.6147145,cardiology,0.6147145,cardiology,0.6147145
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,structure,0.23256482,of,0.49829155,isomerism,0.4853079
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,right,0.35970405,right,1.0,right-atrial,0.63516104
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricle,0.37064588,ventricle,1.0,ventricle,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,right-ventricle,0.39534324,right-ventricle,1.0,right-ventricle,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,observer,0.39363903,heartbeat,0.5110883,heartbeat,0.5110883
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,bias,0.21969397,weak,0.34950268,lai,0.32676864
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,observer-bias,0.26136854,heartbeat,0.4081143,heartbeat,0.4081143
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,morphological,0.23301639,of,0.51360136,anomaly,0.4440594
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,left,0.3872844,left,1.0,left-atrial,0.6573896
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricle,0.37064588,ventricle,1.0,ventricle,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,left-ventricle,0.41379184,right-ventricle,0.93247366,right-ventricle,0.93247366
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,functional,0.2048316,of,0.51558334,l-transposition,0.40613407
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,deliver,0.3069721,of,0.4499455,single-ventricle,0.34460065
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,accurate,0.25226092,of,0.4756247,anomalous,0.40025836
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium,0.38313717,myocardial,0.8277121,myocardial,0.8277121
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,voxel,0.22677933,blood-flow,0.38558042,blood-flow,0.38558042
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,utilized,0.28006944,of,0.59412074,flow,0.39086547
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,presented,0.34475142,with,0.61236936,anomaly,0.42759705
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,expense,0.2859899,of,0.48295042,heart-attack,0.31849948
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,examined,0.2811494,of,0.66699874,flow,0.35738647
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,efficient,0.19720647,of,0.49297506,l-transposition,0.3745634
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dijon,0.44532004,cardiology,0.44532004,cardiology,0.44532004
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,curtails,0.22003035,of,0.5051259,heart-attack,0.39130694
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,basis,0.31584507,of,0.5813806,anomaly,0.41688916
Physiological Assessment of Coronary Lesions in 2020.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Physiological Assessment of Coronary Lesions in 2020.,data,0.31118363,of,0.5086956,mi,0.36251363
Physiological Assessment of Coronary Lesions in 2020.,demonstrating,0.24106917,of,0.67624867,l-transposition,0.42949137
Physiological Assessment of Coronary Lesions in 2020.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Physiological Assessment of Coronary Lesions in 2020.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Physiological Assessment of Coronary Lesions in 2020.,determine,0.2686271,of,0.55401844,flow,0.329725
Physiological Assessment of Coronary Lesions in 2020.,lesion,0.23653449,plaque,0.5741841,plaque,0.5741841
Physiological Assessment of Coronary Lesions in 2020.,functional,0.2048316,of,0.51558334,l-transposition,0.40613407
Physiological Assessment of Coronary Lesions in 2020.,significance,0.3123301,of,0.55474335,anomaly,0.39406294
Physiological Assessment of Coronary Lesions in 2020.,functional-significance,0.27889264,of,0.5413098,venous-return,0.41830903
Physiological Assessment of Coronary Lesions in 2020.,beyond,0.29394823,of,0.53781354,anomaly,0.34910303
Physiological Assessment of Coronary Lesions in 2020.,fractional,0.25586453,flow,0.49457574,flow,0.49457574
Physiological Assessment of Coronary Lesions in 2020.,flow,0.27540267,flow,1.0,flow,1.0
Physiological Assessment of Coronary Lesions in 2020.,reserve,0.34704673,flow,0.54728127,flow,0.54728127
Physiological Assessment of Coronary Lesions in 2020.,fractional-flow,0.25302547,flow,0.59655213,flow,0.59655213
Physiological Assessment of Coronary Lesions in 2020.,flow-reserve,0.26608926,flow,0.74085367,flow,0.74085367
Physiological Assessment of Coronary Lesions in 2020.,fractional-flow-reserve,0.2719248,flow,0.6390742,flow,0.6390742
Physiological Assessment of Coronary Lesions in 2020.,ffrct,0.3984943,coronary,0.588354,coronary,0.588354
Physiological Assessment of Coronary Lesions in 2020.,invasive,0.31703418,disease,0.41993856,pulmonary,0.41691405
Physiological Assessment of Coronary Lesions in 2020.,angiography,0.49931985,coronary,0.6580566,coronary,0.6580566
Physiological Assessment of Coronary Lesions in 2020.,guided,0.3821546,of,0.46321762,anomalous,0.4271319
Physiological Assessment of Coronary Lesions in 2020.,percutaneous,0.43564647,coronary,0.5513066,coronary,0.5513066
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,intervention,0.4565987,mi,0.49382597,mi,0.49382597
Physiological Assessment of Coronary Lesions in 2020.,guided-percutaneous,0.4088369,coronary,0.5483123,coronary,0.5483123
Physiological Assessment of Coronary Lesions in 2020.,percutaneous-coronary,0.4862611,coronary,0.7447014,coronary,0.7447014
Physiological Assessment of Coronary Lesions in 2020.,coronary-intervention,0.5721458,coronary-artery,0.8104472,coronary-artery,0.8104472
Physiological Assessment of Coronary Lesions in 2020.,percutaneous-coronary-intervention,0.52613914,coronary-artery,0.75745726,coronary-artery,0.75745726
Physiological Assessment of Coronary Lesions in 2020.,evaluating,0.35043377,of,0.6040422,congenital-heart-disease,0.3742532
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,stenosis,0.41158026,stenosis,1.0,stenosis,1.0
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.4281009,insufficiency,0.46599698,single-ventricle,0.44307077
Physiological Assessment of Coronary Lesions in 2020.,coronary-stenosis,0.46641546,coronary-artery,0.8759171,coronary-artery,0.8759171
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Physiological Assessment of Coronary Lesions in 2020.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Physiological Assessment of Coronary Lesions in 2020.,assessment-remains,0.44559306,cardiology,0.44559306,cardiology,0.44559306
Physiological Assessment of Coronary Lesions in 2020.,invasive,0.31703418,disease,0.41993856,pulmonary,0.41691405
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,ct,0.4218498,right,0.43045115,clot,0.42958376
Physiological Assessment of Coronary Lesions in 2020.,coronary-ct,0.54251164,coronary-artery,0.8596413,coronary-artery,0.8596413
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,artery,0.42758748,artery,1.0,artery,1.0
Physiological Assessment of Coronary Lesions in 2020.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Physiological Assessment of Coronary Lesions in 2020.,coronary-artery,0.5136894,coronary-artery,1.0,coronary-artery,1.0
Physiological Assessment of Coronary Lesions in 2020.,artery-disease,0.31822538,artery-disease,1.0,artery-disease,1.0
Physiological Assessment of Coronary Lesions in 2020.,coronary-artery-disease,0.45213443,coronary-artery-disease,1.0,coronary-artery-disease,1.0
Physiological Assessment of Coronary Lesions in 2020.,acute,0.3642026,infarction,0.6294521,infarction,0.6294521
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,syndromes,0.35324928,syndrome,0.84828067,syndrome,0.84828067
Physiological Assessment of Coronary Lesions in 2020.,acute-coronary,0.553609,coronary,0.8235702,coronary,0.8235702
Physiological Assessment of Coronary Lesions in 2020.,acute-coronary-syndromes,0.5023141,heart-syndrome,0.75875103,heart-syndrome,0.75875103
Physiological Assessment of Coronary Lesions in 2020.,technical,0.41502,great,0.4460855,cardiology,0.41502
Physiological Assessment of Coronary Lesions in 2020.,aspects,0.32818246,of,0.5406859,congenital-heart-disease,0.3922746
Physiological Assessment of Coronary Lesions in 2020.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Physiological Assessment of Coronary Lesions in 2020.,rest,0.47806644,return,0.5845196,contractions,0.50151086
Physiological Assessment of Coronary Lesions in 2020.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Physiological Assessment of Coronary Lesions in 2020.,hyperemia,0.20058694,blood-flow,0.63030165,blood-flow,0.63030165
Physiological Assessment of Coronary Lesions in 2020.,residual,0.20644298,of,0.55126905,clot,0.49418566
Physiological Assessment of Coronary Lesions in 2020.,ischemia,0.3786124,infarction,0.7500457,infarction,0.7500457
Physiological Assessment of Coronary Lesions in 2020.,post,0.3914922,failure,0.52308416,mi,0.5076717
Physiological Assessment of Coronary Lesions in 2020.,optical,0.26125413,anomalous,0.45746398,anomalous,0.45746398
Physiological Assessment of Coronary Lesions in 2020.,coherence,0.3214059,anomalous,0.4371044,anomalous,0.4371044
Physiological Assessment of Coronary Lesions in 2020.,tomography,0.3269008,coronary,0.38573277,coronary,0.38573277
Physiological Assessment of Coronary Lesions in 2020.,optical-coherence,0.26532197,anomalous,0.4469647,anomalous,0.4469647
Physiological Assessment of Coronary Lesions in 2020.,coherence-tomography,0.34166628,venous-return,0.41583002,venous-return,0.41583002
Physiological Assessment of Coronary Lesions in 2020.,optical-coherence-tomography,0.3050639,venous-return,0.4388365,venous-return,0.4388365
Physiological Assessment of Coronary Lesions in 2020.,interventional,0.68403965,cardiology,0.68403965,cardiology,0.68403965
Physiological Assessment of Coronary Lesions in 2020.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Physiological Assessment of Coronary Lesions in 2020.,toolbox,0.30145234,cardiology,0.30145234,cardiology,0.30145234
Physiological Assessment of Coronary Lesions in 2020.,improve,0.31483245,great,0.49610043,flow,0.35876963
Physiological Assessment of Coronary Lesions in 2020.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Physiological Assessment of Coronary Lesions in 2020.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Physiological Assessment of Coronary Lesions in 2020.,improve-patient,0.45518965,congestive-heart-failure,0.55052346,congestive-heart-failure,0.55052346
Physiological Assessment of Coronary Lesions in 2020.,patient-care,0.49764198,cardiology,0.49764198,cardiology,0.49764198
Physiological Assessment of Coronary Lesions in 2020.,hyperemic,0.20515372,blood-flow,0.63729745,blood-flow,0.63729745
Physiological Assessment of Coronary Lesions in 2020.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Physiological Assessment of Coronary Lesions in 2020.,ratios,0.16654095,double,0.37118572,tof,0.36179096
Physiological Assessment of Coronary Lesions in 2020.,exciting,0.39812633,great,0.577788,cardiology,0.39812633
Physiological Assessment of Coronary Lesions in 2020.,technological,0.38485312,great,0.5247618,cardiology,0.38485312
Physiological Assessment of Coronary Lesions in 2020.,future,0.43508387,great,0.53022015,cardiology,0.43508387
Physiological Assessment of Coronary Lesions in 2020.,enable,0.2581166,of,0.5376558,flow,0.36284363
Physiological Assessment of Coronary Lesions in 2020.,detailed,0.34579298,of,0.54393613,anomalous,0.44207406
Physiological Assessment of Coronary Lesions in 2020.,pre,0.4298201,mi,0.50940144,mi,0.50940144
Physiological Assessment of Coronary Lesions in 2020.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Physiological Assessment of Coronary Lesions in 2020.,intelligence,0.331039,congenital-heart-disease,0.4281336,congenital-heart-disease,0.4281336
Physiological Assessment of Coronary Lesions in 2020.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
Physiological Assessment of Coronary Lesions in 2020.,artificial-intelligence,0.30402216,venous-return,0.48337245,venous-return,0.48337245
Physiological Assessment of Coronary Lesions in 2020.,alternative,0.22123054,as,0.5288507,l-transposition,0.39336166
Physiological Assessment of Coronary Lesions in 2020.,ffr,0.31979406,coronary-artery-disease,0.5529546,coronary-artery-disease,0.5529546
Physiological Assessment of Coronary Lesions in 2020.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Physiological Assessment of Coronary Lesions in 2020.,assess,0.37312466,of,0.49566716,pulmonary,0.375783
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.4281009,insufficiency,0.46599698,single-ventricle,0.44307077
Physiological Assessment of Coronary Lesions in 2020.,refine,0.31979707,of,0.41570166,cardiology,0.31979707
Physiological Assessment of Coronary Lesions in 2020.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Physiological Assessment of Coronary Lesions in 2020.,practice,0.5339576,cardiology,0.5339576,cardiology,0.5339576
Physiological Assessment of Coronary Lesions in 2020.,clinical-practice,0.51884663,cardiology,0.51884663,cardiology,0.51884663
Physiological Assessment of Coronary Lesions in 2020.,ffr,0.31979406,coronary-artery-disease,0.5529546,coronary-artery-disease,0.5529546
Physiological Assessment of Coronary Lesions in 2020.,non,0.3477749,with,0.61364555,mi,0.46788454
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.56409866,coronary,1.0,coronary,1.0
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.4281009,insufficiency,0.46599698,single-ventricle,0.44307077
Physiological Assessment of Coronary Lesions in 2020.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Physiological Assessment of Coronary Lesions in 2020.,underutilized,0.37132612,great,0.5053288,congestive-heart-failure,0.3716861
Physiological Assessment of Coronary Lesions in 2020.,ffroct,0.3282466,coronary,0.4418358,coronary,0.4418358
Physiological Assessment of Coronary Lesions in 2020.,ffrangio,0.44376963,aortic-stenosis,0.47868407,aortic-stenosis,0.47868407
Physiological Assessment of Coronary Lesions in 2020.,current,0.39557698,of,0.4991414,flow,0.39574015
Physiological Assessment of Coronary Lesions in 2020.,practice,0.5339576,cardiology,0.5339576,cardiology,0.5339576
Physiological Assessment of Coronary Lesions in 2020.,current-practice,0.44204965,venous-return,0.4842474,venous-return,0.4842474
Physiological Assessment of Coronary Lesions in 2020.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Physiological Assessment of Coronary Lesions in 2020.,scenarios,0.29720244,venous-return,0.37911326,venous-return,0.37911326
Physiological Assessment of Coronary Lesions in 2020.,clinical-scenarios,0.39456442,congenital-heart-disease,0.49260777,congenital-heart-disease,0.49260777
Physiological Assessment of Coronary Lesions in 2020.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Physiological Assessment of Coronary Lesions in 2020.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
Physiological Assessment of Coronary Lesions in 2020.,well-established,0.26044455,as,0.5690939,l-transposition,0.35309997
Physiological Assessment of Coronary Lesions in 2020.,serial,0.3982912,of,0.52507734,cardiac,0.45085734
Physiological Assessment of Coronary Lesions in 2020.,lesions,0.24537848,plaque,0.5478143,plaque,0.5478143
Physiological Assessment of Coronary Lesions in 2020.,robust,0.13868469,weak,0.46394548,heartbeat,0.35403174
Physiological Assessment of Coronary Lesions in 2020.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
Physiological Assessment of Coronary Lesions in 2020.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Physiological Assessment of Coronary Lesions in 2020.,arteries,0.33855987,arteries,1.0,arteries,1.0
Physiological Assessment of Coronary Lesions in 2020.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Physiological Assessment of Coronary Lesions in 2020.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Physiological Assessment of Coronary Lesions in 2020.,left,0.3872844,left,1.0,left-atrial,0.6573896
Physiological Assessment of Coronary Lesions in 2020.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Physiological Assessment of Coronary Lesions in 2020.,left-main,0.37897542,left-heart,0.67230344,left-heart,0.67230344
Physiological Assessment of Coronary Lesions in 2020.,latest,0.47072,of,0.47338623,cardiology,0.47072
Physiological Assessment of Coronary Lesions in 2020.,developments,0.4323659,great,0.5226431,cardiology,0.4323659
Physiological Assessment of Coronary Lesions in 2020.,indispensable,0.2812745,of,0.49054986,l-transposition,0.3261209
Physiological Assessment of Coronary Lesions in 2020.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
Physiological Assessment of Coronary Lesions in 2020.,including,0.2742056,of,0.6619886,congenital,0.3605199
Physiological Assessment of Coronary Lesions in 2020.,non,0.3477749,with,0.61364555,mi,0.46788454
Physiological Assessment of Coronary Lesions in 2020.,essential,0.26315036,of,0.53323644,cardiac,0.32177997
Physiological Assessment of Coronary Lesions in 2020.,component,0.2266389,of,0.52326363,deposits,0.38395098
Physiological Assessment of Coronary Lesions in 2020.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Physiological Assessment of Coronary Lesions in 2020.,helpful,0.30800843,great,0.4485933,anomalous,0.35723174
Physiological Assessment of Coronary Lesions in 2020.,despite,0.3297603,of,0.5583629,cardiac,0.39134312
Physiological Assessment of Coronary Lesions in 2020.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
Physiological Assessment of Coronary Lesions in 2020.,catheterization,0.5711642,coronary-artery,0.66038465,coronary-artery,0.66038465
Physiological Assessment of Coronary Lesions in 2020.,laboratory,0.4092068,of,0.41161877,cardiology,0.4092068
Physiological Assessment of Coronary Lesions in 2020.,catheterization-laboratory,0.5292245,venous-return,0.58842164,venous-return,0.58842164
Physiological Assessment of Coronary Lesions in 2020.,also,0.36015856,of,0.65908813,flow,0.41040578
Physiological Assessment of Coronary Lesions in 2020.,emerging,0.36684948,great,0.54574025,cardiology,0.36684948
Physiological Assessment of Coronary Lesions in 2020.,additional,0.34573856,of,0.63162684,cardiac,0.39887685
Physiological Assessment of Coronary Lesions in 2020.,advances,0.40024865,great,0.516971,cardiology,0.40024865
Physiological Assessment of Coronary Lesions in 2020.,stable,0.34140018,with,0.5258521,cardiac,0.42552614
Physiological Assessment of Coronary Lesions in 2020.,cad,0.4859606,cad,0.99999994,cad,0.99999994
Physiological Assessment of Coronary Lesions in 2020.,stable-cad,0.30364737,cad,0.511055,cad,0.511055
Physiological Assessment of Coronary Lesions in 2020.,multivessel,0.5251677,coronary,0.8041064,coronary,0.8041064
Physiological Assessment of Coronary Lesions in 2020.,cad,0.4859606,cad,0.99999994,cad,0.99999994
Physiological Assessment of Coronary Lesions in 2020.,multivessel-cad,0.50801635,coronary,0.76437473,coronary,0.76437473
Physiological Assessment of Coronary Lesions in 2020.,review,0.438658,of,0.54425275,cardiology,0.438658
Physiological Assessment of Coronary Lesions in 2020.,outlines,0.39831454,of,0.5073837,cardiology,0.39831454
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.4281009,insufficiency,0.46599698,single-ventricle,0.44307077
Physiological Assessment of Coronary Lesions in 2020.,intervention,0.4565987,mi,0.49382597,mi,0.49382597
Physiological Assessment of Coronary Lesions in 2020.,non,0.3477749,with,0.61364555,mi,0.46788454
Physiological Assessment of Coronary Lesions in 2020.,cad,0.4859606,cad,0.99999994,cad,0.99999994
Physiological Assessment of Coronary Lesions in 2020.,review,0.438658,of,0.54425275,cardiology,0.438658
Physiological Assessment of Coronary Lesions in 2020.,virtual,0.31086695,heartbeat,0.37507218,heartbeat,0.37507218
Physiological Assessment of Coronary Lesions in 2020.,today,0.5557161,cardiology,0.5557161,cardiology,0.5557161
Physiological Assessment of Coronary Lesions in 2020.,realized,0.34353083,of,0.5717856,d-transposition,0.4004805
Physiological Assessment of Coronary Lesions in 2020.,purpose,0.27727276,of,0.5072116,congenital,0.37470472
Physiological Assessment of Coronary Lesions in 2020.,procedure,0.36597854,d-transposition,0.44744885,d-transposition,0.44744885
Physiological Assessment of Coronary Lesions in 2020.,pci,0.49271637,coronary,0.6839608,coronary,0.6839608
Physiological Assessment of Coronary Lesions in 2020.,nhpr,0.225058,rai,0.32266295,rai,0.32266295
Physiological Assessment of Coronary Lesions in 2020.,infarct,0.44430172,infarction,0.8466009,infarction,0.8466009
Physiological Assessment of Coronary Lesions in 2020.,indications,0.46750736,of,0.52539456,cardiology,0.46750736
Physiological Assessment of Coronary Lesions in 2020.,however,0.30646515,of,0.624624,mi,0.41109186
Physiological Assessment of Coronary Lesions in 2020.,focusing,0.29023415,of,0.5571873,anomalous,0.39552477
Physiological Assessment of Coronary Lesions in 2020.,field,0.348202,great,0.42638397,flow,0.40816107
Physiological Assessment of Coronary Lesions in 2020.,benefits,0.33820245,great,0.48839658,single-ventricle,0.3833536
Physiological Assessment of Coronary Lesions in 2020.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Physiological Assessment of Coronary Lesions in 2020.,abound,0.37380418,great,0.5931499,deposits,0.44153163
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,although,0.27773374,of,0.6190036,cardiac,0.39186808
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,well-established,0.26044455,as,0.5690939,l-transposition,0.35309997
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,editorial,0.4794634,cardiology,0.4794634,cardiology,0.4794634
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,review,0.438658,of,0.54425275,cardiology,0.438658
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,highlights,0.3278191,of,0.5411649,l-transposition,0.33406124
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,progress,0.48163038,great,0.5096084,cardiology,0.48163038
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,common,0.21206799,of,0.500178,anomaly,0.44165826
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,many,0.34462097,great,0.5654564,deposits,0.36972266
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,areas,0.32283562,deposits,0.49041492,deposits,0.49041492
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,everyday,0.41402903,cardiology,0.41402903,cardiology,0.41402903
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,everyday-life,0.33920544,heart-disease,0.43558058,heart-disease,0.43558058
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,intelligence,0.331039,congenital-heart-disease,0.4281336,congenital-heart-disease,0.4281336
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,artificial-intelligence,0.30402216,venous-return,0.48337245,venous-return,0.48337245
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trialed,0.43562925,return,0.4712746,arrythmia,0.4437126
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,suggests,0.19146639,of,0.59897435,anomalous,0.37192833
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,recently,0.3336877,as,0.5378315,cad,0.34116387
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,improvements,0.3280268,great,0.45946363,single-ventricle,0.39016998
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,date,0.42987648,return,0.43881068,cardiology,0.42987648
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",unsorted,0.1795745,isolated,0.4088927,flow,0.40099704
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cortical,0.20930958,of,0.44888413,hypoplastic-left,0.43812016
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissue,0.23668498,of,0.5202017,venous,0.46895027
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",liver,0.3089201,heart,0.53057235,heart,0.53057235
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cortical-tissue,0.20464376,blood-flow,0.4974157,blood-flow,0.4974157
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",neurodegenerative,0.2799778,disease,0.5945789,artery-disease,0.42222476
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",ataxia,0.2070389,syndrome,0.48823625,syndrome,0.48823625
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",slowing,0.3158311,of,0.5035058,bradycardia,0.48302567
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",pick,0.3450958,return,0.4430427,deposits,0.3837317
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",type,0.18854949,of,0.48202556,aortic,0.35779506
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",pick-disease,0.22391278,disease,0.6928247,artery-disease,0.6380793
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",disease-type,0.18390858,disease,0.7783489,artery-disease,0.5646132
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",type-c,0.10645756,isolated,0.39804122,sv,0.38661885
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized,0.22630745,with,0.4408154,flow,0.3602917
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual,0.26980293,double,0.5549829,anomalous,0.3839286
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.23505399,paivs,0.45162478,paivs,0.45162478
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",enable,0.2581166,of,0.5376558,flow,0.36284363
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutically,0.24577515,of,0.48143375,blood-clot,0.32670185
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",relevant,0.3264072,of,0.5628227,anomalous,0.34380507
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",efficiencies,0.20807686,of,0.38873595,flow,0.35017002
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutically-relevant,0.22080065,of,0.526832,blood-clot,0.35009196
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",targeted,0.29431283,of,0.52138686,cardiac,0.3262151
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",point,0.29296726,of,0.5126515,anomaly,0.38572568
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutations,0.2006272,defect,0.46113265,congenital,0.42577744
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",point-mutations,0.22489177,double,0.4557984,septal-defect,0.38875768
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",relevant,0.3264072,of,0.5628227,anomalous,0.34380507
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cell,0.21863139,of,0.48460138,flow,0.38218224
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",types,0.20959784,of,0.5479486,deposits,0.41371265
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cell-types,0.22992575,of,0.456706,l-transposition,0.3966235
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissue,0.23668498,of,0.5202017,venous,0.46895027
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse-brain,0.14449635,congenital-heart,0.38348144,congenital-heart,0.38348144
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain-tissue,0.24444778,blood-clot,0.5180695,blood-clot,0.5180695
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",depends,0.21898639,of,0.60277516,anomalous,0.37883127
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aav,0.19647306,paivs,0.3987279,paivs,0.3987279
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",packaging,0.23160644,of,0.37257755,d-transposition,0.341635
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",capacity,0.18606538,of,0.46851358,flow,0.42008954
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aav-packaging,0.21822333,plaque-deposits,0.39277208,plaque-deposits,0.39277208
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized,0.22630745,with,0.4408154,flow,0.3602917
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.30619597,of,0.44014573,single-ventricle,0.41750336
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vectors,0.20899034,l-transposition,0.42368472,l-transposition,0.42368472
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.22157396,right,0.42594445,blood,0.3759402
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editing,0.3228857,l-transposition,0.4868375,l-transposition,0.4868375
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",corrects,0.22158836,defect,0.38172877,congenital,0.3462431
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base-editing,0.26011845,l-transposition,0.48140386,l-transposition,0.48140386
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",length,0.20891969,interrupted,0.42926398,d-transposition,0.36449188
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.22157396,right,0.42594445,blood,0.3759402
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.53549296,cardiology,0.53549296,cardiology,0.53549296
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",length-base,0.16943921,d-transposition,0.4554748,d-transposition,0.4554748
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adenine,0.17813024,l-transposition,0.44576216,l-transposition,0.44576216
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.22157396,right,0.42594445,blood,0.3759402
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.53549296,cardiology,0.53549296,cardiology,0.53549296
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adenine-base,0.13877547,isomerism,0.421358,isomerism,0.421358
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.30619597,of,0.44014573,single-ventricle,0.41750336
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",via,0.2561984,of,0.50595546,flow,0.41023284
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adeno,0.26648027,paivs,0.39714867,paivs,0.39714867
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",retina,0.28602222,arteries,0.42529228,arteries,0.42529228
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",heart,0.57664216,heart,1.0,heart,1.0
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.22157396,right,0.42594445,blood,0.3759402
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editing,0.3228857,l-transposition,0.4868375,l-transposition,0.4868375
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base-editing,0.26011845,l-transposition,0.48140386,l-transposition,0.48140386
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.22157396,right,0.42594445,blood,0.3759402
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.53549296,cardiology,0.53549296,cardiology,0.53549296
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual,0.26980293,double,0.5549829,anomalous,0.3839286
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.23505399,paivs,0.45162478,paivs,0.45162478
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse-brain,0.14449635,congenital-heart,0.38348144,congenital-heart,0.38348144
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",interest,0.3943884,great,0.62165374,cardiology,0.3943884
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",split,0.23127976,single,0.4945128,l-transposition,0.44642204
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cytosine,0.13926375,l-transposition,0.480802,l-transposition,0.480802
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",splicing,0.22061571,l-transposition,0.4313478,l-transposition,0.4313478
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",inteins,0.23389056,d-transposition,0.4890612,d-transposition,0.4890612
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",skeletal,0.2737545,cardiac,0.56529033,cardiac,0.56529033
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",skeletal-muscle,0.24555282,cardiac,0.53675044,cardiac,0.53675044
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissues,0.16733295,of,0.47614664,arteries,0.46764413
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple-tissues,0.23184349,single,0.5057518,congenital-heart-disease,0.4731988
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",increasing,0.35820884,of,0.6603997,flow,0.41165438
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",lifespan,0.17068991,premature,0.3609498,l-transposition,0.30797678
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",efficient,0.19720647,of,0.49297506,l-transposition,0.3745634
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",introduction,0.3353318,of,0.5877248,l-transposition,0.4046045
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",causes,0.22412287,of,0.55089116,congenital,0.49946666
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",niemann,0.22660169,cholesterol,0.3796077,cholesterol,0.3796077
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",associated,0.20417106,with,0.60998726,congenital,0.4144575
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",viruses,0.24790695,paivs,0.52708817,paivs,0.52708817
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",also,0.36015856,of,0.65908813,flow,0.41040578
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",show,0.19476143,of,0.51487744,anomalous,0.38152152
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.30619597,of,0.44014573,single-ventricle,0.41750336
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.23505399,paivs,0.45162478,paivs,0.45162478
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",use,0.3219829,with,0.55726266,flow,0.40877783
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",treatment,0.30650938,of,0.52012336,congestive,0.36983645
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",trans,0.2826451,isomerism,0.47475028,isomerism,0.47475028
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",success,0.3629353,failure,0.51737463,stenosis,0.4255092
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",report,0.3478901,of,0.56646246,anomaly,0.43710455
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",reconstituted,0.18762632,isolated,0.51423967,anomalous,0.39390302
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",precludes,0.18886268,of,0.60137224,anomalous,0.4169211
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",neurodegeneration,0.23566623,disease,0.5336287,plaque-deposits,0.44471723
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutation,0.19931707,defect,0.4727108,anomaly,0.40015864
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",limited,0.29959464,of,0.6210327,deposits,0.40452772
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",full,0.27856892,return,0.5029486,flow,0.3643403
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",facilitate,0.2564506,of,0.4863937,flow,0.32320783
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dosages,0.2675975,with,0.41354024,rai,0.32670832
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",deliver,0.3069721,of,0.4499455,single-ventricle,0.34460065
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",application,0.3034747,of,0.54379797,flow,0.3922925
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",ability,0.2123124,of,0.53612673,cardiac,0.340167
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also,0.36015856,of,0.65908813,flow,0.41040578
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,revealed,0.223917,of,0.55371094,anomalous,0.36589023
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.36483914,disease,0.5073898,cardiac,0.4724245
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,sequelae,0.2675125,insufficiency,0.58357763,congenital,0.5127677
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,sequelae-related,0.2955205,insufficiency,0.51392365,congenital,0.4906374
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,current,0.39557698,of,0.4991414,flow,0.39574015
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,literature,0.36901063,of,0.4653955,anomaly,0.4380433
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,exists,0.1978538,of,0.5387765,anomalous,0.3617807
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,regarding,0.4430421,of,0.5573762,cardiology,0.4430421
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also,0.36015856,of,0.65908813,flow,0.41040578
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,lesions,0.24537848,plaque,0.5478143,plaque,0.5478143
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cause-significant,0.37309295,chd,0.53368276,chd,0.53368276
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,less,0.30277786,with,0.57537794,mi,0.38854462
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,commonly,0.22061068,as,0.5649959,anomaly,0.38373345
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,affected,0.19571082,of,0.60785514,anomaly,0.4406134
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,species,0.21520105,of,0.4892193,deposits,0.38121843
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,less-commonly,0.15092346,as,0.4819561,l-transposition,0.37639958
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,arboviral,0.33202535,paivs,0.48652118,paivs,0.48652118
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neuroinvasive,0.2841169,paivs,0.53286886,paivs,0.53286886
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west,0.45728073,cardiology,0.45728073,cardiology,0.45728073
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile,0.272192,great,0.4461627,paivs,0.37281996
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.21554038,paivs,0.45592806,paivs,0.45592806
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.26741225,disease,0.482216,thrombosis,0.44838145
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile,0.3323595,plaque-deposits,0.43468702,plaque-deposits,0.43468702
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile-virus,0.21973509,paivs,0.46358478,paivs,0.46358478
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus-infection,0.20643803,disease,0.41989592,congenital-heart-disease,0.4192987
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile-virus,0.2645483,paivs,0.48977637,paivs,0.48977637
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,prior,0.4127312,with,0.61325395,mi,0.4958433
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.2168059,paivs,0.5041736,paivs,0.5041736
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.26741225,disease,0.482216,thrombosis,0.44838145
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv-infection,0.23546591,disease,0.40958774,plaque-deposits,0.39963365
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also,0.36015856,of,0.65908813,flow,0.41040578
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,briefly,0.48887277,with,0.5008134,cardiology,0.48887277
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,discussed,0.42584902,as,0.54987454,cardiology,0.42584902
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west,0.45728073,cardiology,0.45728073,cardiology,0.45728073
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile,0.272192,great,0.4461627,paivs,0.37281996
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.21554038,paivs,0.45592806,paivs,0.45592806
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile,0.3323595,plaque-deposits,0.43468702,plaque-deposits,0.43468702
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile-virus,0.21973509,paivs,0.46358478,paivs,0.46358478
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile-virus,0.2645483,paivs,0.48977637,paivs,0.48977637
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,commonly,0.22061068,as,0.5649959,anomaly,0.38373345
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,affected,0.19571082,of,0.60785514,anomaly,0.4406134
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,birds,0.24451996,paivs,0.43318164,paivs,0.43318164
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,affected-birds,0.20053029,congenital-heart-disease,0.43816072,congenital-heart-disease,0.43816072
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.26741225,disease,0.482216,thrombosis,0.44838145
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,involve,0.17349622,of,0.46675503,anomalous,0.34978855
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,viral,0.25421232,of,0.4126552,paivs,0.3762645
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathogenesis,0.23665535,disease,0.5221031,syndrome,0.4540013
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,severe,0.29645193,insufficiency,0.65468115,stenosis,0.5520288
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,systemic,0.28270477,pulmonary-venous,0.5600716,pulmonary-venous,0.5600716
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,systemic-disease,0.24458666,artery-disease,0.6983664,artery-disease,0.6983664
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,renal,0.43551624,pulmonary,0.5641475,pulmonary,0.5641475
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,leading,0.25149748,of,0.59935343,congenital,0.40424997
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,renal-injury,0.33540127,insufficiency,0.51957196,aortic-coarctation,0.5181258
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central,0.34112307,of,0.50945216,venous,0.47422168
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nervous,0.30080134,cardiac,0.48913407,cardiac,0.48913407
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central-nervous,0.2418323,congenital-heart-disease,0.46254572,congenital-heart-disease,0.46254572
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nervous-system,0.18423605,congenital-heart-disease,0.49702293,congenital-heart-disease,0.49702293
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central-nervous-system,0.18305418,congenital-heart-disease,0.51315117,congenital-heart-disease,0.51315117
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal,0.31228805,of,0.5431563,congenital-heart-disease,0.397049
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,experimental-animal,0.27131695,blood-flow,0.4574826,blood-flow,0.4574826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal-models,0.30730113,congenital-heart-disease,0.41481268,congenital-heart-disease,0.41481268
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.36483914,disease,0.5073898,cardiac,0.4724245
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic-disease,0.41125482,disease,0.6669117,heart-disease,0.63079685
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.2168059,paivs,0.5041736,paivs,0.5041736
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.26741225,disease,0.482216,thrombosis,0.44838145
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv-infection,0.23546591,disease,0.40958774,plaque-deposits,0.39963365
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.21554038,paivs,0.45592806,paivs,0.45592806
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,propagation,0.22916555,of,0.4872983,flow,0.44104272
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus-propagation,0.19048241,plaque-deposits,0.43399155,plaque-deposits,0.43399155
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,major-cause,0.26318866,chd,0.48994496,chd,0.48994496
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,avian,0.2624635,paivs,0.48541147,paivs,0.48541147
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,species,0.21520105,of,0.4892193,deposits,0.38121843
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal,0.31228805,of,0.5431563,congenital-heart-disease,0.397049
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal-models,0.30730113,congenital-heart-disease,0.41481268,congenital-heart-disease,0.41481268
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animals,0.22729439,of,0.44251478,arteries,0.4176624
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human-animals,0.25192386,paivs,0.38977855,paivs,0.38977855
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,0.3477749,with,0.61364555,mi,0.46788454
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human-non,0.21881616,congenital-heart-disease,0.37656122,congenital-heart-disease,0.37656122
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrates,0.28321278,of,0.41371334,l-transposition,0.4098589
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.2168059,paivs,0.5041736,paivs,0.5041736
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.2168059,paivs,0.5041736,paivs,0.5041736
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,maintenance,0.27256006,of,0.54740524,venous-return,0.3779762
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrate,0.30290103,of,0.4390307,l-transposition,0.40122578
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host,0.19921786,of,0.45659927,l-transposition,0.39435467
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrate-host,0.29142368,congenital-heart-disease,0.40603006,congenital-heart-disease,0.40603006
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,review,0.438658,of,0.54425275,cardiology,0.438658
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,summarizes,0.3328934,of,0.45781466,cardiology,0.3328934
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,prominent,0.29253632,abnormal,0.5569648,deposits,0.46347803
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,manifestation,0.26932746,disease,0.5920149,syndrome,0.5903858
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,seen,0.46511754,with,0.6698557,septal,0.47136146
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,caused,0.1752007,of,0.53973085,congenital,0.42777976
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,particularly,0.31718573,of,0.62868786,deposits,0.41094124
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,diverse,0.3032622,of,0.5461366,cardiac,0.3471622
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,natural,0.16362667,of,0.532617,anomalous,0.3907894
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infections,0.29786497,disease,0.45983067,thrombosis,0.45491943
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,known,0.28223497,as,0.60071135,mi,0.41831112
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge,0.32453293,of,0.4580958,congenital-heart-disease,0.38427317
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gaps,0.30158007,great,0.3833747,beats,0.36071926
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge-gaps,0.35206974,congenital-heart-disease,0.4357188,congenital-heart-disease,0.4357188
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge,0.32453293,of,0.4580958,congenital-heart-disease,0.38427317
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gains,0.24871597,of,0.42147768,l-transposition,0.3466885
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge-gains,0.33135307,congenital-heart-disease,0.42552805,congenital-heart-disease,0.42552805
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host,0.19921786,of,0.45659927,l-transposition,0.39435467
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animals,0.22729439,of,0.44251478,arteries,0.4176624
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host-animals,0.17091829,great,0.37855393,heart-attack,0.3650483
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,future,0.43508387,great,0.53022015,cardiology,0.43508387
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,directions,0.35161418,flow,0.41702956,flow,0.41702956
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,susceptible,0.12967366,attack,0.43882957,heart-attack,0.34819096
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,0.3477749,with,0.61364555,mi,0.46788454
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurotropic,0.16214296,paivs,0.37684888,paivs,0.37684888
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nature,0.28114077,of,0.5463233,anomalous,0.4306179
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.36483914,disease,0.5073898,cardiac,0.4724245
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.2168059,paivs,0.5041736,paivs,0.5041736
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,0.3477749,with,0.61364555,mi,0.46788454
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrates,0.28321278,of,0.41371334,l-transposition,0.4098589
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nature,0.28114077,of,0.5463233,anomalous,0.4306179
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,transmission,0.18465236,of,0.4158437,congenital-heart-disease,0.34923676
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,time,0.350901,return,0.5513821,venous-return,0.44564146
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,similarly,0.2457779,with,0.6309897,contractions,0.41134822
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,serve,0.23708555,as,0.69219697,heart-attack,0.28737742
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,relationship,0.21630949,of,0.4831799,anomalous,0.3835627
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,ranging,0.30711752,with,0.48008,beats,0.3630554
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,occur,0.18988883,of,0.53400475,anomaly,0.42337352
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,kidneys,0.21000513,heart,0.4900558,heart,0.4900558
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,intestinal,0.20000894,pulmonary-venous,0.4246543,pulmonary-venous,0.4246543
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,humans,0.21283677,of,0.49299914,congenital-heart-disease,0.41938835
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,however,0.30646515,of,0.624624,mi,0.41109186
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,horses,0.24351081,congenital-heart-disease,0.398634,congenital-heart-disease,0.398634
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,heart,0.57664216,heart,1.0,heart,1.0
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gap,0.27240363,defect,0.42741,atresia-with,0.36236483
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,eyes,0.2776898,left,0.40562743,valve,0.38538334
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,continues,0.44289586,arrythmia,0.48696196,arrythmia,0.48696196
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,alligators,0.25853956,arteriosus,0.40995967,arteriosus,0.40995967
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,addressed,0.43890664,of,0.5700326,cardiology,0.43890664
Photoplethysmography based atrial fibrillation detection: a review.,sensors,0.23341918,great,0.41634512,heartbeat,0.34583208
Photoplethysmography based atrial fibrillation detection: a review.,record,0.3503227,heartbeat,0.4047115,heartbeat,0.4047115
Photoplethysmography based atrial fibrillation detection: a review.,blood,0.32078606,blood,1.0,blood,1.0
Photoplethysmography based atrial fibrillation detection: a review.,volume,0.3012385,flow,0.5655429,flow,0.5655429
Photoplethysmography based atrial fibrillation detection: a review.,variations,0.26953718,of,0.53369737,anomalous,0.4837823
Photoplethysmography based atrial fibrillation detection: a review.,blood-volume,0.28099215,blood-flow,0.73786986,blood-flow,0.73786986
Photoplethysmography based atrial fibrillation detection: a review.,challenges,0.3502283,great,0.545295,single-ventricle,0.3562941
Photoplethysmography based atrial fibrillation detection: a review.,towards,0.26525512,of,0.5319467,isomerism,0.33325064
Photoplethysmography based atrial fibrillation detection: a review.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Photoplethysmography based atrial fibrillation detection: a review.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
Photoplethysmography based atrial fibrillation detection: a review.,clinical-applications,0.35320938,of,0.44522208,heart-failure,0.3673975
Photoplethysmography based atrial fibrillation detection: a review.,deep,0.25718108,venous,0.51692,venous,0.51692
Photoplethysmography based atrial fibrillation detection: a review.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Photoplethysmography based atrial fibrillation detection: a review.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Photoplethysmography based atrial fibrillation detection: a review.,used,0.23211285,as,0.56584436,flow,0.35934073
Photoplethysmography based atrial fibrillation detection: a review.,deep-learning,0.30304694,venous-return,0.43025902,venous-return,0.43025902
Photoplethysmography based atrial fibrillation detection: a review.,learning-approaches,0.28315347,single-ventricle,0.4005476,single-ventricle,0.4005476
Photoplethysmography based atrial fibrillation detection: a review.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Photoplethysmography based atrial fibrillation detection: a review.,rhythm,0.4790222,tachycardia,0.7063014,tachycardia,0.7063014
Photoplethysmography based atrial fibrillation detection: a review.,disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
Photoplethysmography based atrial fibrillation detection: a review.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Photoplethysmography based atrial fibrillation detection: a review.,cardiac-rhythm,0.5791,cardiac,0.77980703,cardiac,0.77980703
Photoplethysmography based atrial fibrillation detection: a review.,rhythm-disorder,0.45772067,tachycardia,0.5931906,tachycardia,0.5931906
Photoplethysmography based atrial fibrillation detection: a review.,disorder-associated,0.21086964,abnormal,0.50122905,congenital,0.47456533
Photoplethysmography based atrial fibrillation detection: a review.,af,0.46920872,fibrillation,0.7902067,fibrillation,0.7902067
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.22305535,of,0.4642575,flow,0.35575604
Photoplethysmography based atrial fibrillation detection: a review.,using,0.20786116,with,0.58010674,flow,0.41007757
Photoplethysmography based atrial fibrillation detection: a review.,ppg,0.15979934,heartbeat,0.42014855,heartbeat,0.42014855
Photoplethysmography based atrial fibrillation detection: a review.,implement,0.40329465,as,0.4053181,cardiology,0.40329465
Photoplethysmography based atrial fibrillation detection: a review.,optical,0.26125413,anomalous,0.45746398,anomalous,0.45746398
Photoplethysmography based atrial fibrillation detection: a review.,sensors,0.23341918,great,0.41634512,heartbeat,0.34583208
Photoplethysmography based atrial fibrillation detection: a review.,optical-sensors,0.22664335,heartbeat,0.38625866,heartbeat,0.38625866
Photoplethysmography based atrial fibrillation detection: a review.,possible,0.37040615,of,0.6754589,anomalous,0.44165242
Photoplethysmography based atrial fibrillation detection: a review.,using,0.20786116,with,0.58010674,flow,0.41007757
Photoplethysmography based atrial fibrillation detection: a review.,low,0.33154353,with,0.5951388,flow,0.4108625
Photoplethysmography based atrial fibrillation detection: a review.,possible-using,0.3513846,venous-return,0.4871753,venous-return,0.4871753
Photoplethysmography based atrial fibrillation detection: a review.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Photoplethysmography based atrial fibrillation detection: a review.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Photoplethysmography based atrial fibrillation detection: a review.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
Photoplethysmography based atrial fibrillation detection: a review.,patient-management,0.49347812,cardiology,0.49347812,cardiology,0.49347812
Photoplethysmography based atrial fibrillation detection: a review.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Photoplethysmography based atrial fibrillation detection: a review.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Photoplethysmography based atrial fibrillation detection: a review.,wearable-devices,0.32403013,venous-return,0.47007155,venous-return,0.47007155
Photoplethysmography based atrial fibrillation detection: a review.,leading,0.25149748,of,0.59935343,congenital,0.40424997
Photoplethysmography based atrial fibrillation detection: a review.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Photoplethysmography based atrial fibrillation detection: a review.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Photoplethysmography based atrial fibrillation detection: a review.,risk-factor,0.36270565,chd,0.60697746,chd,0.60697746
Photoplethysmography based atrial fibrillation detection: a review.,large,0.31318635,great,0.5879582,deposits,0.4134889
Photoplethysmography based atrial fibrillation detection: a review.,prospective,0.36785108,congenital-heart-disease,0.4437966,congenital-heart-disease,0.4437966
Photoplethysmography based atrial fibrillation detection: a review.,trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
Photoplethysmography based atrial fibrillation detection: a review.,grade,0.29756713,stenosis,0.4388027,stenosis,0.4388027
Photoplethysmography based atrial fibrillation detection: a review.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Photoplethysmography based atrial fibrillation detection: a review.,wearable-devices,0.32403013,venous-return,0.47007155,venous-return,0.47007155
Photoplethysmography based atrial fibrillation detection: a review.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Photoplethysmography based atrial fibrillation detection: a review.,transformative,0.3818013,great,0.45912677,l-transposition,0.41140565
Photoplethysmography based atrial fibrillation detection: a review.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Photoplethysmography based atrial fibrillation detection: a review.,would,0.35497403,of,0.55908126,flow,0.3796509
Photoplethysmography based atrial fibrillation detection: a review.,allow,0.28258905,of,0.5533963,flow,0.40086067
Photoplethysmography based atrial fibrillation detection: a review.,devices-would,0.4125207,venous-return,0.5000129,venous-return,0.5000129
Photoplethysmography based atrial fibrillation detection: a review.,today,0.5557161,cardiology,0.5557161,cardiology,0.5557161
Photoplethysmography based atrial fibrillation detection: a review.,possible,0.37040615,of,0.6754589,anomalous,0.44165242
Photoplethysmography based atrial fibrillation detection: a review.,thanks,0.43597662,great,0.6044537,cardiology,0.43597662
Photoplethysmography based atrial fibrillation detection: a review.,today-possible,0.4935165,arrythmia,0.5685977,arrythmia,0.5685977
Photoplethysmography based atrial fibrillation detection: a review.,possible-thanks,0.46233165,great,0.5405603,venous-return,0.53449965
Photoplethysmography based atrial fibrillation detection: a review.,secondary,0.296139,failure,0.5610231,congenital,0.42706454
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.49447083,infarction,0.7648172,infarction,0.7648172
Photoplethysmography based atrial fibrillation detection: a review.,prevention,0.37483034,thrombosis,0.45537552,thrombosis,0.45537552
Photoplethysmography based atrial fibrillation detection: a review.,secondary-stroke,0.32697338,heart-attack,0.46863478,heart-attack,0.46863478
Photoplethysmography based atrial fibrillation detection: a review.,stroke-prevention,0.48102027,infarction,0.5766852,infarction,0.5766852
Photoplethysmography based atrial fibrillation detection: a review.,secondary-stroke-prevention,0.4348383,congestive-heart-failure,0.5501429,congestive-heart-failure,0.5501429
Photoplethysmography based atrial fibrillation detection: a review.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Photoplethysmography based atrial fibrillation detection: a review.,rhythm,0.4790222,tachycardia,0.7063014,tachycardia,0.7063014
Photoplethysmography based atrial fibrillation detection: a review.,cardiac-rhythm,0.5791,cardiac,0.77980703,cardiac,0.77980703
Photoplethysmography based atrial fibrillation detection: a review.,ppg,0.15979934,heartbeat,0.42014855,heartbeat,0.42014855
Photoplethysmography based atrial fibrillation detection: a review.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Photoplethysmography based atrial fibrillation detection: a review.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Photoplethysmography based atrial fibrillation detection: a review.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Photoplethysmography based atrial fibrillation detection: a review.,af,0.46920872,fibrillation,0.7902067,fibrillation,0.7902067
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.22305535,of,0.4642575,flow,0.35575604
Photoplethysmography based atrial fibrillation detection: a review.,early,0.34221643,of,0.5714519,mi,0.3991026
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.22305535,of,0.4642575,flow,0.35575604
Photoplethysmography based atrial fibrillation detection: a review.,early-detection,0.27171588,congenital-heart-disease,0.41892868,congenital-heart-disease,0.41892868
Photoplethysmography based atrial fibrillation detection: a review.,today,0.5557161,cardiology,0.5557161,cardiology,0.5557161
Photoplethysmography based atrial fibrillation detection: a review.,equip,0.39446676,great,0.4440429,cardiology,0.39446676
Photoplethysmography based atrial fibrillation detection: a review.,prevent,0.21931013,of,0.49340016,thrombosis,0.361466
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.49447083,infarction,0.7648172,infarction,0.7648172
Photoplethysmography based atrial fibrillation detection: a review.,cardioembolic,0.52204657,infarction,0.74813735,infarction,0.74813735
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.49447083,infarction,0.7648172,infarction,0.7648172
Photoplethysmography based atrial fibrillation detection: a review.,user,0.31136972,venous-return,0.3720078,venous-return,0.3720078
Photoplethysmography based atrial fibrillation detection: a review.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Photoplethysmography based atrial fibrillation detection: a review.,thorough,0.34654474,of,0.5185302,anomaly,0.44233644
Photoplethysmography based atrial fibrillation detection: a review.,account,0.27722406,of,0.53262895,anomalous,0.4109847
Photoplethysmography based atrial fibrillation detection: a review.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Photoplethysmography based atrial fibrillation detection: a review.,known,0.28223497,as,0.60071135,mi,0.41831112
Photoplethysmography based atrial fibrillation detection: a review.,technology-known,0.48041865,great,0.4991697,cardiology,0.48041865
Photoplethysmography based atrial fibrillation detection: a review.,signal,0.21521182,abnormal,0.44133407,heartbeat,0.40503716
Photoplethysmography based atrial fibrillation detection: a review.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Photoplethysmography based atrial fibrillation detection: a review.,signal-processing,0.29727483,heartbeat,0.43431708,heartbeat,0.43431708
Photoplethysmography based atrial fibrillation detection: a review.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Photoplethysmography based atrial fibrillation detection: a review.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Photoplethysmography based atrial fibrillation detection: a review.,increased,0.32251194,of,0.64014816,mi,0.42637154
Photoplethysmography based atrial fibrillation detection: a review.,morbidity,0.31568646,chd,0.50165594,chd,0.50165594
Photoplethysmography based atrial fibrillation detection: a review.,heart,0.57664216,heart,1.0,heart,1.0
Photoplethysmography based atrial fibrillation detection: a review.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Photoplethysmography based atrial fibrillation detection: a review.,heart-rate,0.43613237,heartbeat,0.713904,heartbeat,0.713904
Photoplethysmography based atrial fibrillation detection: a review.,early,0.34221643,of,0.5714519,mi,0.3991026
Photoplethysmography based atrial fibrillation detection: a review.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Photoplethysmography based atrial fibrillation detection: a review.,early-screening,0.29922923,congenital-heart-disease,0.39525148,congenital-heart-disease,0.39525148
Photoplethysmography based atrial fibrillation detection: a review.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Photoplethysmography based atrial fibrillation detection: a review.,easy,0.19053811,stiff,0.45042825,heartbeat,0.36654496
Photoplethysmography based atrial fibrillation detection: a review.,atrial,0.52708566,atrial,1.0,atrial,1.0
Photoplethysmography based atrial fibrillation detection: a review.,fibrillation,0.5347377,fibrillation,1.0,fibrillation,1.0
Photoplethysmography based atrial fibrillation detection: a review.,atrial-fibrillation,0.46922478,fibrillation,0.887709,fibrillation,0.887709
Photoplethysmography based atrial fibrillation detection: a review.,continuous,0.27512568,of,0.5723764,flow,0.484856
Photoplethysmography based atrial fibrillation detection: a review.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Photoplethysmography based atrial fibrillation detection: a review.,continuous-monitoring,0.37143725,venous-return,0.53961515,venous-return,0.53961515
Photoplethysmography based atrial fibrillation detection: a review.,af,0.46920872,fibrillation,0.7902067,fibrillation,0.7902067
Photoplethysmography based atrial fibrillation detection: a review.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Photoplethysmography based atrial fibrillation detection: a review.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Photoplethysmography based atrial fibrillation detection: a review.,work,0.41337943,return,0.5383546,cardiology,0.41337943
Photoplethysmography based atrial fibrillation detection: a review.,wearables,0.38487607,heartbeat,0.43166375,heartbeat,0.43166375
Photoplethysmography based atrial fibrillation detection: a review.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Photoplethysmography based atrial fibrillation detection: a review.,summary,0.39694136,of,0.48017746,cardiology,0.39694136
Photoplethysmography based atrial fibrillation detection: a review.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Photoplethysmography based atrial fibrillation detection: a review.,sleep,0.34347007,heartbeat,0.50327885,heartbeat,0.50327885
Photoplethysmography based atrial fibrillation detection: a review.,review,0.438658,of,0.54425275,cardiology,0.438658
Photoplethysmography based atrial fibrillation detection: a review.,recently,0.3336877,as,0.5378315,cad,0.34116387
Photoplethysmography based atrial fibrillation detection: a review.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Photoplethysmography based atrial fibrillation detection: a review.,presented,0.34475142,with,0.61236936,anomaly,0.42759705
Photoplethysmography based atrial fibrillation detection: a review.,photoplethysmography,0.3149511,blood-flow,0.61154103,blood-flow,0.61154103
Photoplethysmography based atrial fibrillation detection: a review.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Photoplethysmography based atrial fibrillation detection: a review.,majority,0.28791377,of,0.48508087,l-transposition,0.36823815
Photoplethysmography based atrial fibrillation detection: a review.,limitations,0.32701084,great,0.5122291,flow,0.36943486
Photoplethysmography based atrial fibrillation detection: a review.,introduced,0.295581,of,0.506906,l-transposition,0.39756888
Photoplethysmography based atrial fibrillation detection: a review.,initiation,0.2995841,of,0.5214617,fibrillation,0.36621535
Photoplethysmography based atrial fibrillation detection: a review.,inform,0.41591924,great,0.4179291,cardiology,0.41591924
Photoplethysmography based atrial fibrillation detection: a review.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Photoplethysmography based atrial fibrillation detection: a review.,followed,0.3600078,with,0.62115055,flow,0.4018712
Photoplethysmography based atrial fibrillation detection: a review.,fitness,0.30565488,return,0.38242427,chd,0.37588483
Photoplethysmography based atrial fibrillation detection: a review.,extracted,0.24302739,isolated,0.6058264,deposits,0.3322685
Photoplethysmography based atrial fibrillation detection: a review.,evidenced,0.26034257,as,0.61487734,flow,0.39925444
Photoplethysmography based atrial fibrillation detection: a review.,discussion,0.49886382,of,0.5109613,cardiology,0.49886382
Photoplethysmography based atrial fibrillation detection: a review.,crucial,0.22890398,of,0.48424307,anomalous,0.3442307
Photoplethysmography based atrial fibrillation detection: a review.,consumer,0.36834857,great,0.41929862,cardiology,0.36834857
Photoplethysmography based atrial fibrillation detection: a review.,cases,0.2687057,of,0.51801866,congenital,0.5119436
Photoplethysmography based atrial fibrillation detection: a review.,capable,0.15713497,of,0.49807632,l-transposition,0.3187266
Photoplethysmography based atrial fibrillation detection: a review.,body,0.2371722,of,0.4173455,heartbeat,0.41062886
Photoplethysmography based atrial fibrillation detection: a review.,author,0.39858195,anomaly,0.4089887,anomaly,0.4089887
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass,0.21939,tof,0.43280137,tof,0.43280137
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.26987028,flow,0.60937023,flow,0.60937023
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.350901,return,0.5513821,venous-return,0.44564146
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",course,0.4188035,of,0.49587014,blood,0.42017996
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dataset,0.29588008,single,0.35144186,heartbeat,0.33722848
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-mass,0.11791277,blood-flow,0.40048668,blood-flow,0.40048668
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass-cytometry,0.2118517,flow,0.52493876,flow,0.52493876
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-course,0.20859893,of,0.51580864,blood-flow,0.4281054
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",source,0.28251278,as,0.48821616,deposits,0.35806987
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",r,0.2358357,right,0.57001424,clot,0.39889696
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",package,0.3077857,cardiology,0.3077857,cardiology,0.3077857
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",via,0.2561984,of,0.50595546,flow,0.41023284
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",source-r,0.20264971,venous-return,0.37575468,venous-return,0.37575468
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",r-package,0.22208415,venous-return,0.31375217,venous-return,0.31375217
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",embryonic,0.26874045,hypoplastic,0.47355694,hypoplastic,0.47355694
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem,0.2528829,hypoplastic,0.38906342,hypoplastic,0.38906342
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cells,0.18534905,of,0.46541262,deposits,0.38651246
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",differentiating,0.21003744,of,0.48626158,heart-syndrome,0.31746706
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mouse-embryonic,0.19126445,l-transposition,0.41233054,l-transposition,0.41233054
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",embryonic-stem,0.26775277,hypoplastic,0.47438627,hypoplastic,0.47438627
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem-cells,0.27633932,hypoplastic-left-heart,0.3973474,hypoplastic-left-heart,0.3973474
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",technologies,0.34567022,great,0.44040805,cardiology,0.34567022
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",present,0.34922045,of,0.63723874,anomaly,0.40175247
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",opportunities,0.35945243,great,0.5308876,cardiology,0.35945243
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-technologies,0.38209537,great,0.44275618,single-ventricle,0.38759786
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",present-new,0.44456437,cardiology,0.44456437,cardiology,0.44456437
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui,0.1802465,outlet,0.32291698,heartbeat,0.30145517
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",based,0.2494699,of,0.5443143,flow,0.34116954
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",software,0.36227515,cardiology,0.36227515,cardiology,0.36227515
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",tool,0.29163375,as,0.4623517,artery-disease,0.31557494
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",software-tool,0.3549311,congenital-heart-disease,0.38154823,congenital-heart-disease,0.38154823
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vitro,0.17831118,of,0.48112682,clot,0.34754837
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem,0.2528829,hypoplastic,0.38906342,hypoplastic,0.38906342
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",differentiation,0.23174062,of,0.45291108,l-transposition,0.3816795
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem-cell,0.3073024,failure,0.40953812,single-ventricle,0.40389973
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-differentiation,0.19273852,of,0.3881557,l-transposition,0.34373647
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",change,0.3422248,of,0.5410254,flow,0.4111107
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",across,0.2607503,of,0.44814807,flow,0.3484614
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.350901,return,0.5513821,venous-return,0.44564146
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",points,0.2814706,of,0.4826713,venous,0.38039982
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",across-time,0.22992475,venous-return,0.43265462,venous-return,0.43265462
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-points,0.20965667,single,0.36874315,arteries,0.35039324
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.350901,return,0.5513821,venous-return,0.44564146
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",course,0.4188035,of,0.49587014,blood,0.42017996
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-time,0.30011094,of,0.3896142,blood-flow,0.36385584
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-course,0.20859893,of,0.51580864,blood-flow,0.4281054
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",unique,0.20165175,of,0.5631099,anomalous,0.44501823
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",populations,0.25156635,of,0.4330697,congenital-heart-disease,0.343602
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-populations,0.25118166,of,0.43572348,congenital-heart-disease,0.42510954
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",previously,0.21411541,as,0.54924536,l-transposition,0.42639655
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",published,0.36480254,of,0.4442843,cardiology,0.36480254
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",scrnaseq,0.19806217,heartbeat,0.29460523,heartbeat,0.29460523
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dataset,0.29588008,single,0.35144186,heartbeat,0.33722848
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",previously-published,0.32664487,of,0.4902569,venous-return,0.40298006
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",uses,0.27331725,of,0.5380335,flow,0.38064915
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graph,0.28920713,heartbeat,0.39088234,heartbeat,0.39088234
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",layout,0.29178113,irregular,0.43061817,double-outlet,0.3890925
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graph-layout,0.27521786,venous-return,0.43790227,venous-return,0.43790227
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",sequential,0.21590228,of,0.5333091,l-transposition,0.4229314
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.350901,return,0.5513821,venous-return,0.44564146
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",ordering,0.4303154,anomalous,0.4588198,anomalous,0.4588198
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-ordering,0.36270824,anomalous,0.5361592,anomalous,0.5361592
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",signaling,0.2453397,of,0.40737927,contractions,0.3417532
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dynamics,0.26244372,of,0.47602248,anomalous,0.462408
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-signaling,0.22350955,of,0.40551755,congenital-heart-disease,0.33100727
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",rna,0.18219137,of,0.4053282,l-transposition,0.40229958
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",sequencing,0.23510775,isolated,0.42495134,l-transposition,0.3606252
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-rna,0.16736257,plaque-deposits,0.3428796,plaque-deposits,0.3428796
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",rna-sequencing,0.20743823,isolated,0.36053908,l-transposition,0.34617046
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",obtained,0.31282532,of,0.62274206,blood,0.41646662
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.21863139,of,0.48460138,flow,0.38218224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-analysis,0.27116424,of,0.42150775,flow,0.38198268
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis-methods,0.23253706,artery-disease,0.39796847,artery-disease,0.39796847
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",visualize,0.21779141,intact,0.40161893,flow,0.38954836
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cellular,0.25397572,of,0.55018497,cardiac,0.40519243
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",trajectories,0.2145915,anomalous,0.42744148,anomalous,0.42744148
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",three,0.27802917,of,0.6048713,l-transposition,0.36917683
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",germ,0.20221196,hypoplastic,0.37017423,hypoplastic,0.37017423
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",layers,0.1665476,deposits,0.53088176,deposits,0.53088176
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",three-germ,0.17357804,anomaly,0.44136748,anomaly,0.44136748
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",germ-layers,0.19924481,septal-defect,0.43238464,septal-defect,0.43238464
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",resulting,0.18480285,of,0.6416826,anomalous,0.46019152
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",makes,0.27261916,of,0.5783402,anomalous,0.37299928
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",one,0.3148334,single,0.6951874,anomaly,0.3884908
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",particular,0.34937102,of,0.6936578,anomalous,0.4519893
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",challenge,0.2694021,great,0.4729702,single-ventricle,0.2998554
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",one-particular,0.29033262,anomalous,0.49185514,anomalous,0.49185514
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",many,0.34462097,great,0.5654564,deposits,0.36972266
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dynamic,0.26735556,of,0.4784561,blood-flow,0.47322053
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",processes,0.23021427,of,0.4836276,deposits,0.42042395
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical,0.2735249,venous-return,0.37626457,venous-return,0.37626457
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",user,0.31136972,venous-return,0.3720078,venous-return,0.3720078
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",interface,0.2116723,deposits,0.33724806,deposits,0.33724806
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical-user,0.31793302,venous-return,0.53309625,venous-return,0.53309625
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",user-interface,0.26364428,venous-return,0.41018903,venous-return,0.41018903
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical-user-interface,0.28189185,venous-return,0.49037564,venous-return,0.49037564
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.31693935,return,0.4643785,venous-return,0.35410056
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass,0.21939,tof,0.43280137,tof,0.43280137
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.26987028,flow,0.60937023,flow,0.60937023
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass-cytometry,0.2118517,flow,0.52493876,flow,0.52493876
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",side,0.25860035,left,0.5740862,isomerism,0.37933958
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map-analysis,0.33396077,heart-disease,0.40124336,heart-disease,0.40124336
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",based,0.2494699,of,0.5443143,flow,0.34116954
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",commands,0.3351277,stiff,0.45448405,arrythmia,0.42596912
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.27540267,flow,1.0,flow,1.0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.26987028,flow,0.60937023,flow,0.60937023
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow-cytometry,0.2276194,flow,0.5899704,flow,0.5899704
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map-analysis,0.33396077,heart-disease,0.40124336,heart-disease,0.40124336
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step,0.29224294,of,0.50852585,l-transposition,0.37552184
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step-analysis,0.3600766,single,0.4442404,cad,0.41651148
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",development,0.2877805,of,0.53581744,congenital,0.35419804
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vivo-development,0.28838494,atresia,0.44178683,atresia,0.44178683
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",protocol,0.38874236,with,0.41014993,cardiology,0.38874236
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",takes,0.32704192,of,0.5360304,heartbeat,0.36071226
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map-algorithm,0.35893178,venous-return,0.45385548,venous-return,0.45385548
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",resistance,0.17926447,failure,0.42967105,d-transposition,0.40630686
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",drug-resistance,0.20165798,l-transposition,0.4498592,l-transposition,0.4498592
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",detailed,0.34579298,of,0.54393613,anomalous,0.44207406
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",description,0.2815786,of,0.50286245,anomalous,0.45285577
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",complex,0.29298759,of,0.46002102,anomalous,0.41282338
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",nature,0.28114077,of,0.5463233,anomalous,0.4306179
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",biological,0.25037947,of,0.5642135,blood-clot,0.34982628
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",discovery,0.32526702,of,0.46573353,d-transposition,0.33412263
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.31693935,return,0.4643785,venous-return,0.35410056
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.27540267,flow,1.0,flow,1.0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",developed,0.25309682,of,0.5174131,congestive-heart-failure,0.37625062
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.27540267,flow,1.0,flow,1.0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",min,0.29087996,with,0.5172597,beats,0.46503627
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",h,0.20228642,of,0.4345476,mi,0.34808266
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",approach,0.24478336,of,0.42712367,l-transposition,0.40473902
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dimensional,0.25604147,anomalous,0.48529866,anomalous,0.48529866
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single,0.2571312,single,1.0,anomalous,0.40611145
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.27540267,flow,1.0,flow,1.0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui,0.1802465,outlet,0.32291698,heartbeat,0.30145517
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.23442824,of,0.53198564,flow,0.34824157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",scrnaseq,0.19806217,heartbeat,0.29460523,heartbeat,0.29460523
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",side,0.25860035,left,0.5740862,isomerism,0.37933958
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.31693935,return,0.4643785,venous-return,0.35410056
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.27540267,flow,1.0,flow,1.0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step,0.29224294,of,0.50852585,l-transposition,0.37552184
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single,0.2571312,single,1.0,anomalous,0.40611145
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",approach,0.24478336,of,0.42712367,l-transposition,0.40473902
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",using,0.20786116,with,0.58010674,flow,0.41007757
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",use,0.3219829,with,0.55726266,flow,0.40877783
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",track,0.40586048,return,0.49282968,cardiac,0.41771996
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",text,0.2975557,interrupted,0.31581414,anomaly,0.31069732
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",synthetic,0.18357235,of,0.46145016,d-transposition,0.35330465
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",provide,0.3065295,of,0.4983799,flow,0.3409845
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",open,0.23789045,intact,0.48107803,l-transposition,0.35275602
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",oncogenesis,0.27072084,congenital,0.38281292,congenital,0.38281292
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mesoderm,0.30833027,truncus,0.46751487,truncus,0.46751487
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",including,0.2742056,of,0.6619886,congenital,0.3605199
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",illustrate,0.31012124,of,0.5076244,anomalous,0.41516486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",high,0.28122714,of,0.57459104,flow,0.3923195
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",facilitate,0.2564506,of,0.4863937,flow,0.32320783
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",experiments,0.20130633,of,0.4657672,flow,0.3524469
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",endoderm,0.28494418,truncus,0.45298433,truncus,0.45298433
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",emergence,0.26180625,of,0.5167847,l-transposition,0.40268755
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",ectoderm,0.2652182,truncus,0.43597692,truncus,0.43597692
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",complete,0.20676532,of,0.51385504,l-transposition,0.42622632
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",challenging,0.29561728,great,0.56316066,anomalous,0.40406942
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",applied,0.31181335,of,0.5047146,flow,0.3948964
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",advantageous,0.19441757,great,0.51860315,l-transposition,0.37116176
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yet,0.32307938,as,0.52449846,cardiac,0.34347042
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,available,0.34700432,with,0.5165225,cardiology,0.34700432
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using,0.20786116,with,0.58010674,flow,0.41007757
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pcr,0.18917134,isolated,0.34562874,l-transposition,0.34398216
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,methods-using,0.24093863,with,0.41740525,congenital-heart-disease,0.33455065
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,virus,0.21554038,paivs,0.45592806,paivs,0.45592806
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.22305535,of,0.4642575,flow,0.35575604
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using,0.20786116,with,0.58010674,flow,0.41007757
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,arboviral,0.33202535,paivs,0.48652118,paivs,0.48652118
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,virus-detection,0.24771932,congenital-heart-disease,0.3879122,congenital-heart-disease,0.3879122
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enriching,0.24104497,of,0.480433,heart-attack,0.32264143
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna,0.18219137,of,0.4053282,l-transposition,0.40229958
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.25421232,of,0.4126552,paivs,0.3762645
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequences,0.24094251,interrupted,0.4493138,l-transposition,0.419291
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,targeted-rna,0.22632125,of,0.35197356,l-transposition,0.31186467
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna-viral,0.1737041,paivs,0.32834223,paivs,0.32834223
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,successfully,0.25479004,great,0.48915762,d-transposition,0.41823155
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enriched,0.20288235,isolated,0.518345,deposits,0.38186842
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using,0.20786116,with,0.58010674,flow,0.41007757
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,additional,0.34573856,of,0.63162684,cardiac,0.39887685
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,target,0.23866604,of,0.4775706,blood,0.34112448
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.20440927,of,0.4079965,flow,0.31504443
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,step,0.29224294,of,0.50852585,l-transposition,0.37552184
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,additional-target,0.26534554,of,0.4720046,l-transposition,0.3754905
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,target-enrichment,0.1892874,plaque-deposits,0.37447953,plaque-deposits,0.37447953
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment-step,0.13823587,venous-return,0.32472602,venous-return,0.32472602
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,haemorrhagic,0.22095206,thrombosis,0.54598343,thrombosis,0.54598343
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fever,0.36858597,tachycardia,0.5483808,tachycardia,0.5483808
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.25421232,of,0.4126552,paivs,0.3762645
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,panels,0.3430713,with,0.3930747,cardiology,0.3430713
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,increase,0.32113555,of,0.60061187,flow,0.4086165
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,simultaneously,0.20312542,single,0.5868935,flow,0.44001055
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,retaining,0.20488471,of,0.6146524,l-transposition,0.3589853
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.245471,isolated,0.40467238,l-transposition,0.32923272
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,spiked,0.3182441,blood,0.43519294,blood,0.43519294
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,primer,0.23864782,of,0.3291873,ivs,0.31122118
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.20440927,of,0.4079965,flow,0.31504443
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,median,0.25360596,total,0.41341874,single-ventricle,0.38815683
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,tenfold,0.21267335,of,0.45799437,contractions,0.3643459
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.20440927,of,0.4079965,flow,0.31504443
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yellow,0.26013663,intact,0.440071,deposits,0.34777737
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fever,0.36858597,tachycardia,0.5483808,tachycardia,0.5483808
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.24790695,paivs,0.52708817,paivs,0.52708817
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yellow-fever,0.27440423,great,0.3774771,blood,0.37461323
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,spectrum,0.23148498,anomalous,0.45348546,anomalous,0.45348546
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogen,0.20034528,disease,0.4754871,heart-attack,0.35139495
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.22305535,of,0.4642575,flow,0.35575604
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogen-detection,0.25686643,disease,0.43841416,congenital-heart-disease,0.39824623
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,portable,0.30875987,double-outlet,0.33706075,double-outlet,0.33706075
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,nanopore,0.25625947,great,0.3487458,flow,0.33728954
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencers,0.32464027,tof,0.38882577,tof,0.38882577
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogen,0.20034528,disease,0.4754871,heart-attack,0.35139495
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,identification,0.20758381,of,0.5418171,d-transposition,0.3482393
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.24790695,paivs,0.52708817,paivs,0.52708817
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,developed,0.25309682,of,0.5174131,congestive-heart-failure,0.37625062
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.245471,isolated,0.40467238,l-transposition,0.32923272
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.23510775,isolated,0.42495134,l-transposition,0.3606252
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic-sequencing,0.22415861,isolated,0.38573486,l-transposition,0.35548735
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,directly,0.2335313,of,0.58113813,flow,0.38857496
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,applicable,0.2708452,of,0.44810876,flow,0.3393516
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.25421232,of,0.4126552,paivs,0.3762645
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,outbreaks,0.28908056,paivs,0.44527772,paivs,0.44527772
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specifically,0.26984817,of,0.59676015,mi,0.3534019
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specifically-targeted,0.25620362,of,0.4800492,mi,0.3127473
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specific,0.26268506,of,0.6059094,flow,0.40644997
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pcr,0.18917134,isolated,0.34562874,l-transposition,0.34398216
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specific-pcr,0.16512099,l-transposition,0.35117078,l-transposition,0.35117078
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.245471,isolated,0.40467238,l-transposition,0.32923272
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,next,0.49132466,of,0.51130736,cardiology,0.49132466
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mean,0.30953988,total,0.5000684,artery,0.37085557
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,demonstrating,0.24106917,of,0.67624867,l-transposition,0.42949137
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infecting,0.21643946,isolated,0.49256742,l-transposition,0.40478683
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.24790695,paivs,0.52708817,paivs,0.52708817
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,shotgun,0.14704457,isolated,0.3704514,heart-attack,0.34449983
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.23510775,isolated,0.42495134,l-transposition,0.3606252
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,shotgun-sequencing,0.20336944,single,0.42674154,l-transposition,0.36666533
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generation,0.25683564,of,0.5394852,contractions,0.39260584
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.23510775,isolated,0.42495134,l-transposition,0.3606252
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generation-sequencing,0.23325722,single,0.4848892,l-transposition,0.3668645
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,titre,0.18172973,plaque-deposits,0.34047866,plaque-deposits,0.34047866
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infections,0.29786497,disease,0.45983067,thrombosis,0.45491943
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,proved,0.24453852,of,0.5691227,l-transposition,0.3651338
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,useful,0.19749163,great,0.46134508,anomalous,0.31390148
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,samples,0.20068786,isolated,0.4879529,blood,0.4540816
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,plasma-samples,0.2382548,blood,0.4557323,blood,0.4557323
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,narrow,0.28448087,irregular,0.5579173,anomalous,0.49497515
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,scope,0.45081684,great,0.4884477,cardiology,0.45081684
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,narrow-scope,0.30575776,d-transposition,0.4063906,d-transposition,0.4063906
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mngs,0.21846017,deposits,0.4040727,deposits,0.4040727
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,alone,0.25829685,with,0.6517836,mi,0.40645403
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mngs,0.21846017,deposits,0.4040727,deposits,0.4040727
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,lengthy,0.301514,interrupted,0.47947103,l-transposition,0.35234666
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,protocols,0.34805608,of,0.4228298,cardiology,0.34805608
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infected,0.1929965,isolated,0.4683736,paivs,0.41344762
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infected-patients,0.29665512,congenital-heart-disease,0.47900552,congenital-heart-disease,0.47900552
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,including,0.2742056,of,0.6619886,congenital,0.3605199
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,powassan,0.3039681,paivs,0.45413548,paivs,0.45413548
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genomic,0.23843989,of,0.42904675,l-transposition,0.41207945
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,surveillance,0.36192033,disease,0.43086565,congenital-heart-disease,0.38097486
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genome,0.2711001,l-transposition,0.42332953,l-transposition,0.42332953
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,coverage,0.33765912,great,0.43980598,blood,0.37224364
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genome-coverage,0.27426565,great,0.42430645,l-transposition,0.40463895
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generally,0.29403654,with,0.608389,deposits,0.39144385
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,needed,0.42938864,as,0.567801,cardiology,0.42938864
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,field,0.348202,great,0.42638397,flow,0.40816107
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,use,0.3219829,with,0.55726266,flow,0.40877783
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,field-use,0.26204136,flow,0.36882338,flow,0.36882338
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,either,0.20727676,with,0.6436424,l-transposition,0.41341084
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,benchtop,0.2830972,tof,0.4156311,tof,0.4156311
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,laboratory,0.4092068,of,0.41161877,cardiology,0.4092068
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic-laboratory,0.41599187,congenital-heart-disease,0.4352147,congenital-heart-disease,0.4352147
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,samples,0.20068786,isolated,0.4879529,blood,0.4540816
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,capture,0.32566327,flow,0.4278125,flow,0.4278125
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,probes,0.2526161,with,0.4374656,flow,0.3484616
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,capture-probes,0.24108115,single,0.36146495,flow,0.34417105
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low,0.33154353,with,0.5951388,flow,0.4108625
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low-cost,0.22001064,great,0.41285038,venous-return,0.30941987
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high,0.28122714,of,0.57459104,flow,0.3923195
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high-cost,0.36661112,heart-failure,0.4448601,heart-failure,0.4448601
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequences,0.24094251,interrupted,0.4493138,l-transposition,0.419291
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna,0.18219137,of,0.4053282,l-transposition,0.40229958
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.22305535,of,0.4642575,flow,0.35575604
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low,0.33154353,with,0.5951388,flow,0.4108625
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high,0.28122714,of,0.57459104,flow,0.3923195
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,zika,0.25226712,paivs,0.4671148,paivs,0.4671148
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yielding,0.20112503,of,0.5396658,anomalous,0.33049893
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,usutu,0.27659255,paivs,0.48329017,paivs,0.48329017
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,simple,0.2050616,single,0.48191768,anomalous,0.4230147
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,priori,0.2820307,of,0.4199662,venous-return,0.4017774
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogens,0.23321638,disease,0.41366285,paivs,0.37078077
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,notably,0.28817534,of,0.64324886,deposits,0.40474877
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,making,0.3548795,of,0.57845646,flow,0.39122948
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,limited,0.29959464,of,0.6210327,deposits,0.40452772
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fast,0.28443596,single,0.49633968,heartbeat,0.4428159
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,emerging,0.36684948,great,0.54574025,cardiology,0.36684948
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,ebola,0.2997242,paivs,0.4289347,paivs,0.4289347
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,dna,0.1729775,of,0.4467932,l-transposition,0.44180506
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,deployable,0.25002992,stiff,0.3962701,venous-return,0.3723029
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,dengue,0.24405986,paivs,0.44960868,paivs,0.44960868
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cross,0.28978038,double,0.48992044,anomalous,0.35670662
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,contamination,0.27118695,of,0.49959168,deposits,0.4386675
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,comparable,0.21267173,with,0.5389043,arteries,0.33967346
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,co,0.36334935,with,0.46287042,cardiac,0.45921996
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,chikungunya,0.26711097,paivs,0.43791443,paivs,0.43791443
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,broad,0.28305992,great,0.535347,anomalous,0.37478346
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,breadth,0.24100408,great,0.42170992,lai,0.344017
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,infinium,0.24601749,single,0.35001898,tof,0.31550422
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.19042948,l-transposition,0.4452315,l-transposition,0.4452315
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,k,0.28914,anomalous,0.35770777,anomalous,0.35770777
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,beadchip,0.23049799,cad,0.33796442,cad,0.33796442
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,human-methylation,0.21933512,l-transposition,0.47307202,l-transposition,0.47307202
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.24932492,paivs,0.39438307,paivs,0.39438307
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,might,0.24242394,of,0.5952132,anomalous,0.3600717
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,provide,0.3065295,of,0.4983799,flow,0.3409845
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic-accuracy,0.3361726,congenital-heart-disease,0.42620343,congenital-heart-disease,0.42620343
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.19042948,l-transposition,0.4452315,l-transposition,0.4452315
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,data,0.31118363,of,0.5086956,mi,0.36251363
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,yielded,0.15376228,of,0.5085689,lai,0.28203836
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.20828351,l-transposition,0.34763592,l-transposition,0.34763592
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,revealed,0.223917,of,0.55371094,anomalous,0.36589023
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,forest-classification,0.34323975,rai,0.42548954,rai,0.42548954
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification-algorithm,0.31711498,venous-return,0.4157463,venous-return,0.4157463
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.16579244,chd,0.36980623,chd,0.36980623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across,0.2607503,of,0.44814807,flow,0.3484614
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,sample,0.27855045,of,0.48495537,blood,0.39323854
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,sources,0.3096738,of,0.47692496,deposits,0.42191344
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three-different,0.17349479,hypoplastic-left-heart,0.4551201,hypoplastic-left-heart,0.4551201
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,different-sample,0.16657774,single,0.37749022,venous-return,0.36571217
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,might,0.24242394,of,0.5952132,anomalous,0.3600717
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,interact,0.22691844,with,0.46296287,heart-attack,0.3055455
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral,0.25941038,venous,0.56411976,venous,0.56411976
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,blood,0.32078606,blood,1.0,blood,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,mononuclear,0.16104987,blood,0.47744167,blood,0.47744167
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral-blood,0.22077957,blood,0.6257005,blood,0.6257005
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,blood-mononuclear,0.21898656,blood,0.60236514,blood,0.60236514
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,mononuclear-cells,0.20776284,isolated,0.4298861,deposits,0.42761052
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral-blood-mononuclear,0.20262979,blood,0.5562571,blood,0.5562571
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,central,0.34112307,of,0.50945216,venous,0.47422168
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,airway,0.2880329,pulmonary,0.5942069,pulmonary,0.5942069
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial,0.16618782,of,0.3820966,atresia,0.37996423
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,central-airway,0.27075583,pulmonary,0.5778835,pulmonary,0.5778835
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,airway-epithelial,0.18457034,pulmonary,0.48622438,pulmonary,0.48622438
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial-cells,0.15732202,blood-clot,0.36690652,blood-clot,0.36690652
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.16579244,chd,0.36980623,chd,0.36980623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,signatures,0.19695002,of,0.4672624,anomalous,0.4125278
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,exerted,0.16718982,of,0.5055257,contractions,0.44563764
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,wide,0.31815493,great,0.5828745,l-transposition,0.39044523
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna,0.1729775,of,0.4467932,l-transposition,0.44180506
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.19042948,l-transposition,0.4452315,l-transposition,0.4452315
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna-methylation,0.16816717,l-transposition,0.5131399,l-transposition,0.5131399
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific,0.26268506,of,0.6059094,flow,0.40644997
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.16579244,chd,0.36980623,chd,0.36980623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classify,0.19261536,as,0.39506868,artery-disease,0.33047467
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmc,0.09047422,blood,0.3676474,blood,0.3676474
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nec,0.30793804,atresia-with,0.5009454,atresia-with,0.5009454
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.20828351,l-transposition,0.34763592,l-transposition,0.34763592
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.19042948,l-transposition,0.4452315,l-transposition,0.4452315
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,associated-methylation,0.26086828,l-transposition,0.44279915,l-transposition,0.44279915
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.16579244,chd,0.36980623,chd,0.36980623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nasal,0.25327867,septal,0.49049202,septal,0.49049202
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial,0.16618782,of,0.3820966,atresia,0.37996423
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nasal-epithelial,0.1620861,atresia,0.403178,atresia,0.403178
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial-cells,0.15732202,blood-clot,0.36690652,blood-clot,0.36690652
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.33560252,pulmonary,0.50573623,pulmonary,0.50573623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across,0.2607503,of,0.44814807,flow,0.3484614
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across-tissues,0.17819214,of,0.42404297,blood-flow,0.40632224
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,lower,0.26859394,with,0.5748005,venous,0.42565888
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,error,0.29040614,heartbeat,0.36637402,heartbeat,0.36637402
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification-error,0.31446403,venous-return,0.43878928,venous-return,0.43878928
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,overlap,0.19607264,with,0.4524176,anomaly,0.40907073
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across,0.2607503,of,0.44814807,flow,0.3484614
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis-across,0.2176879,venous-return,0.41772208,venous-return,0.41772208
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,top,0.40076846,with,0.45628595,cardiology,0.40076846
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.33560252,pulmonary,0.50573623,pulmonary,0.50573623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,obtained,0.31282532,of,0.62274206,blood,0.41646662
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,unique,0.20165175,of,0.5631099,anomalous,0.44501823
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathophysiological,0.29236275,disease,0.4513361,heart-syndrome,0.42778695
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,bag,0.26304576,intact,0.49592465,clot,0.46579236
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,errors,0.2912968,l-transposition,0.39197582,l-transposition,0.39197582
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna,0.1729775,of,0.4467932,l-transposition,0.44180506
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.19042948,l-transposition,0.4452315,l-transposition,0.4452315
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna-methylation,0.16816717,l-transposition,0.5131399,l-transposition,0.5131399
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.20828351,l-transposition,0.34763592,l-transposition,0.34763592
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.33560252,pulmonary,0.50573623,pulmonary,0.50573623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma-risk,0.29916477,chd,0.5385929,chd,0.5385929
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific,0.26268506,of,0.6059094,flow,0.40644997
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific-markers,0.21679354,of,0.4560269,deposits,0.3235653
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis-based,0.22293341,of,0.4096641,heart-failure,0.3601469
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.24932492,paivs,0.39438307,paivs,0.39438307
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.16579244,chd,0.36980623,chd,0.36980623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,controls,0.23145974,with,0.5052294,mi,0.41936132
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathway-levels,0.2665397,congenital-heart-disease,0.37083077,congenital-heart-disease,0.37083077
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,jointly,0.42110226,of,0.4856688,cardiology,0.42110226
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,efficacy,0.20913124,of,0.47294754,lai,0.34146488
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,results,0.29712585,of,0.53157276,blood,0.36869162
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,results-using,0.3529383,with,0.5411493,venous-return,0.4505809
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pivotal,0.2833194,of,0.42851168,myocardial,0.30667037
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,role,0.263546,of,0.49928063,anomalous,0.31226397
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,changes,0.30126634,of,0.5562258,flow,0.44305104
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological-changes,0.32151052,disease,0.53831047,deposits,0.4922459
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,optimal,0.22326279,of,0.49022785,single-ventricle,0.35533518
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subset,0.24246489,of,0.51671314,mi,0.37440532
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,measured,0.2266986,of,0.539739,flow,0.4470259
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,may,0.26963884,of,0.58654004,anomalous,0.366544
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,play,0.20504072,of,0.37973475,anomalous,0.28665382
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,role,0.263546,of,0.49928063,anomalous,0.31226397
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,key-role,0.2565612,of,0.44771314,anomalous,0.31697574
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,investigate,0.20519872,of,0.48247698,anomalous,0.30501914
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,shared,0.28743762,of,0.5515948,l-transposition,0.3773327
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,current,0.39557698,of,0.4991414,flow,0.39574015
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,current-study,0.3032135,venous-return,0.47522396,venous-return,0.47522396
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cpg,0.107448645,l-transposition,0.28565943,l-transposition,0.28565943
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,sites,0.22877486,of,0.48146656,deposits,0.4619514
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cpg-sites,0.14570703,l-transposition,0.35588703,l-transposition,0.35588703
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,also,0.36015856,of,0.65908813,flow,0.41040578
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,discovered,0.31728885,isolated,0.57236284,d-transposition,0.4346332
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.18570352,of,0.37526885,l-transposition,0.36793822
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,interaction,0.23807403,weak,0.5032127,isomerism,0.33030224
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.18570352,of,0.37526885,l-transposition,0.36793822
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs,0.104963064,blood,0.3718202,blood,0.3718202
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell,0.21863139,of,0.48460138,flow,0.38218224
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,junction,0.20580661,stenosis,0.41587254,stenosis,0.41587254
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell-junction,0.22271244,atrioventricular-septal-defect,0.45740148,atrioventricular-septal-defect,0.45740148
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.16579244,chd,0.36980623,chd,0.36980623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.24932492,paivs,0.39438307,paivs,0.39438307
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmc,0.09047422,blood,0.3676474,blood,0.3676474
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nec,0.30793804,atresia-with,0.5009454,atresia-with,0.5009454
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.33560252,pulmonary,0.50573623,pulmonary,0.50573623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.18570352,of,0.37526885,l-transposition,0.36793822
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs,0.104963064,blood,0.3718202,blood,0.3718202
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell,0.21863139,of,0.48460138,flow,0.38218224
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,warranted,0.36467054,of,0.50301933,cardiology,0.36467054
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,value,0.3260533,of,0.52001536,flow,0.37269968
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,suggests,0.19146639,of,0.59897435,anomalous,0.37192833
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,studied,0.2428486,of,0.63097596,anomalous,0.39203623
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,profiles,0.15556863,of,0.5306897,flow,0.4074694
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,p,0.29391026,with,0.4559728,congestive,0.4058217
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,multi,0.3120417,single,0.49181098,cad,0.38921657
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,goal,0.42704034,return,0.44766816,cardiology,0.42704034
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,found,0.2675444,with,0.6275196,deposits,0.41920424
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,focused,0.3452875,of,0.5549927,cardiology,0.3452875
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epigenome,0.28528282,l-transposition,0.41702634,l-transposition,0.41702634
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dataset,0.29588008,single,0.35144186,heartbeat,0.33722848
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,curve,0.23990677,stenosis,0.35901296,stenosis,0.35901296
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,context,0.3526281,of,0.54966336,congenital-heart-disease,0.38638416
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,compare,0.27648047,of,0.5052448,venous-return,0.3454308
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classifiers,0.28955632,congenital-heart-disease,0.36196706,congenital-heart-disease,0.36196706
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,auc,0.18832418,chd,0.29138696,chd,0.29138696
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,area,0.34147155,left,0.4808709,stenosis,0.41823816
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aecs,0.24482472,pulmonary,0.41639698,pulmonary,0.41639698
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aec,0.19832122,eb,0.38021573,eb,0.38021573
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,additionally,0.26417398,of,0.6596129,flow,0.38005078
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.51873946,tachycardia,0.60360324,tachycardia,0.60360324
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,based,0.2494699,of,0.5443143,flow,0.34116954
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemic,0.26001304,bradycardia,0.44818652,bradycardia,0.44818652
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,detection,0.22305535,of,0.4642575,flow,0.35575604
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,systems,0.2822709,of,0.44318485,flow,0.3656453
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,reliably,0.21260893,single,0.48468763,heartbeat,0.39655703
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive,0.31703418,disease,0.41993856,pulmonary,0.41691405
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.3005559,bradycardia,0.5573702,bradycardia,0.5573702
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,alarming,0.42729884,great,0.5622651,cardiology,0.42729884
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,using,0.20786116,with,0.58010674,flow,0.41007757
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,short,0.27641132,interrupted,0.5895587,d-transposition,0.38685596
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,excerpts,0.43325603,cardiology,0.43325603,cardiology,0.43325603
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,current,0.39557698,of,0.4991414,flow,0.39574015
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,used,0.23211285,as,0.56584436,flow,0.35934073
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,personalised,0.45734936,cardiology,0.45734936,cardiology,0.45734936
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,medicine,0.64505804,cardiology,0.64505804,cardiology,0.64505804
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,current-study,0.3032135,venous-return,0.47522396,venous-return,0.47522396
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,personalised-medicine,0.5418916,cardiology,0.5418916,cardiology,0.5418916
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,detect,0.19525596,of,0.45315933,flow,0.34090838
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,nocturnal,0.23096764,bradycardia,0.45265102,bradycardia,0.45265102
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.3005559,bradycardia,0.5573702,bradycardia,0.5573702
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,using,0.20786116,with,0.58010674,flow,0.41007757
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,visualisation,0.22848487,blood-flow,0.44250366,blood-flow,0.44250366
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,clinicians,0.494618,cardiology,0.494618,cardiology,0.494618
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,tight,0.2589523,weak,0.5059737,flow,0.3822725
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,reduces,0.1488205,of,0.53557026,heart-attack,0.33165377
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose-monitoring,0.343567,blood,0.44054043,blood,0.44054043
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,raw,0.20777354,of,0.39154416,clot,0.30473775
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.51873946,tachycardia,0.60360324,tachycardia,0.60360324
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,signal,0.21521182,abnormal,0.44133407,heartbeat,0.40503716
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg-signal,0.39629966,heartbeat,0.5552225,heartbeat,0.5552225
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,previous,0.37261367,with,0.5284412,mi,0.42555177
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,based,0.2494699,of,0.5443143,flow,0.34116954
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,studies-based,0.35489005,cardiology,0.35489005,cardiology,0.35489005
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood,0.32078606,blood,1.0,blood,1.0
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood-glucose,0.25967306,blood,0.565806,blood,0.565806
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose-levels,0.23231122,blood,0.4314711,blood,0.4314711
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood-glucose-levels,0.24586922,blood,0.5410793,blood,0.5410793
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,consecutive,0.30386817,total,0.4805001,d-transposition,0.38766134
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,days,0.30872357,return,0.45523614,beats,0.4033618
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,consecutive-days,0.30087125,total,0.4671174,venous-return,0.4066456
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,monitored,0.3408969,with,0.53855443,flow,0.4368319
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hours,0.38191575,return,0.507182,infarction,0.42204177
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,crucial,0.22890398,of,0.48424307,anomalous,0.3442307
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic,0.3646236,heart-failure,0.5228808,heart-failure,0.5228808
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic-patients,0.35447633,heart-failure,0.597598,heart-failure,0.597598
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.51873946,tachycardia,0.60360324,tachycardia,0.60360324
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,signal,0.21521182,abnormal,0.44133407,heartbeat,0.40503716
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg-signal,0.39629966,heartbeat,0.5552225,heartbeat,0.5552225
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemic,0.26001304,bradycardia,0.44818652,bradycardia,0.44818652
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,event,0.39566028,mi,0.544716,mi,0.544716
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.3005559,bradycardia,0.5573702,bradycardia,0.5573702
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,affects,0.1426264,of,0.5773267,anomaly,0.35788298
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic,0.3646236,heart-failure,0.5228808,heart-failure,0.5228808
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic-patients,0.35447633,heart-failure,0.597598,heart-failure,0.597598
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wearable-devices,0.32403013,venous-return,0.47007155,venous-return,0.47007155
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,failed,0.28042597,failure,0.5587824,mi,0.3746816
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,strong,0.22168292,weak,0.8655887,anomalous,0.40474734
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,inter,0.39922974,of,0.47223324,cardiology,0.39922974
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,specific,0.26268506,of,0.6059094,flow,0.40644997
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,specific-conditions,0.23540974,congenital-heart-disease,0.40915817,congenital-heart-disease,0.40915817
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,significantly,0.23700657,with,0.568532,mi,0.39826992
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,significantly-associated,0.23136258,of,0.5940436,deposits,0.3958858
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,results,0.29712585,of,0.53157276,blood,0.36869162
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,advance,0.4594765,as,0.5027088,cardiology,0.4594765
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive,0.31703418,disease,0.41993856,pulmonary,0.41691405
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,intelligibility,0.29066283,congenital-heart,0.47742537,congenital-heart,0.47742537
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,problem,0.34362,great,0.4967915,anomaly,0.450875
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy-subjects,0.23467843,congenital-heart-disease,0.4751811,congenital-heart-disease,0.4751811
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,g,0.21858013,single,0.41386712,ivs,0.37229383
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,deploy,0.25279692,attack,0.37498468,venous-return,0.34819484
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,electrocardiogram,0.52747107,tachycardia,0.6152849,tachycardia,0.6152849
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,intelligence,0.331039,congenital-heart-disease,0.4281336,congenital-heart-disease,0.4281336
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,artificial-intelligence,0.30402216,venous-return,0.48337245,venous-return,0.48337245
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.3005559,bradycardia,0.5573702,bradycardia,0.5573702
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject,0.33580956,of,0.55199313,anomaly,0.39822626
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heterogeneity,0.22733976,of,0.46007073,anomaly,0.38874698
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject,0.33580956,of,0.55199313,anomaly,0.39822626
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,visualise,0.19380185,deposits,0.37943614,deposits,0.37943614
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,tracking,0.3586566,single,0.45548296,heartbeat,0.43777645
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,time,0.350901,return,0.5513821,venous-return,0.44564146
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,st,0.46681005,mi,0.5837832,mi,0.5837832
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,series,0.28858227,of,0.55379033,d-transposition,0.419505
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,seizure,0.31857672,arrythmia,0.5814773,arrythmia,0.5814773
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,result,0.27978757,of,0.60232913,anomaly,0.4674588
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,real,0.3591983,great,0.53489023,flow,0.42211816
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,present,0.34922045,of,0.63723874,anomaly,0.40175247
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,part,0.37925124,of,0.6214935,anomaly,0.4202423
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,overcoming,0.22958507,great,0.49687195,l-transposition,0.36349025
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,non,0.3477749,with,0.61364555,mi,0.46788454
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,irritability,0.26972654,tachycardia,0.5266887,tachycardia,0.5266887
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,interval,0.278329,congestive,0.41789418,congestive,0.41789418
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,however,0.30646515,of,0.624624,mi,0.41109186
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heartbeats,0.39623898,heartbeat,0.91514754,heartbeat,0.91514754
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heart,0.57664216,heart,1.0,heart,1.0
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,fluctuations,0.26904,of,0.46820867,heartbeat,0.46759564
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,feasibility,0.2594404,great,0.45960844,venous-return,0.38982585
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,fatal,0.27300152,disease,0.54406464,congenital-heart-disease,0.4957137
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,even,0.3054184,with,0.6390622,deposits,0.4270071
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,electrophysiology,0.57355845,cardiology,0.57355845,cardiology,0.57355845
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,e,0.21868992,double,0.39788574,eb,0.38260236
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,deep,0.25718108,venous,0.51692,venous,0.51692
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,confusion,0.39987078,arrythmia,0.51448786,arrythmia,0.51448786
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,complications,0.3646976,thrombosis,0.54964757,thrombosis,0.54964757
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,additionally,0.26417398,of,0.6596129,flow,0.38005078
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,toxicity,0.22547536,of,0.46452966,cardiac,0.36057627
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,among,0.2573181,of,0.57348,chd,0.4274787
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,induced-cardiac,0.4804756,cardiac,0.7158556,cardiac,0.7158556
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,repeat,0.37678185,abnormal,0.4185363,cardiac,0.39661732
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.3185379,venous-return,0.33729267,venous-return,0.33729267
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,using,0.20786116,with,0.58010674,flow,0.41007757
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.34226567,blood-flow,0.37891927,blood-flow,0.37891927
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann-analysis,0.3440869,congenital-heart-disease,0.4298815,congenital-heart-disease,0.4298815
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis-using,0.25346792,with,0.41950685,flow,0.383027
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergone,0.2888326,d-transposition,0.4931532,d-transposition,0.4931532
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stereotactic,0.35614443,single-ventricle,0.4092852,single-ventricle,0.4092852
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ablative,0.35747328,rai,0.43294019,rai,0.43294019
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiotherapy,0.33234203,rai,0.45297807,rai,0.45297807
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,neutral,0.12817192,weak,0.46329015,isomerism,0.38586035
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,structure,0.23256482,of,0.49829155,isomerism,0.4853079
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,confirmed,0.27861494,of,0.58156097,anomalous,0.39478707
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose-neutral,0.17494263,single,0.37140483,isomerism,0.3357945
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,including,0.2742056,of,0.6619886,congenital,0.3605199
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.34226567,blood-flow,0.37891927,blood-flow,0.37891927
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage,0.19545637,with,0.46458423,rai,0.38722774
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.25414947,hlhs,0.4131226,hlhs,0.4131226
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.2738869,rai,0.45392853,rai,0.45392853
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,modulate,0.1707263,of,0.4374981,contractions,0.31312442
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,confounding,0.28707254,chd,0.44823384,chd,0.44823384
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,behaviors,0.19597729,of,0.40426326,heartbeat,0.32855248
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,locally,0.22723794,with,0.5052427,deposits,0.40757084
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,advanced,0.34864503,with,0.51267695,congestive,0.41393596
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,non,0.3477749,with,0.61364555,mi,0.46788454
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,locally-advanced,0.2892752,disease,0.45070323,rai,0.42533606
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,advanced-non,0.33296528,venous-return,0.4156873,venous-return,0.4156873
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cell,0.21863139,of,0.48460138,flow,0.38218224
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cell-lung,0.20791534,pulmonary,0.48390204,pulmonary,0.48390204
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,lung-cancer,0.22815667,pulmonary,0.44066906,pulmonary,0.44066906
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial-neural,0.22358572,congenital-heart-disease,0.49487492,congenital-heart-disease,0.49487492
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,neural-network,0.2583411,heartbeat,0.44916824,heartbeat,0.44916824
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial-neural-network,0.22481197,congenital-heart-disease,0.4687531,congenital-heart-disease,0.4687531
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,input,0.31766397,of,0.44965258,flow,0.4458027
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.3236165,of,0.44937658,rai,0.36969757
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.34226567,blood-flow,0.37891927,blood-flow,0.37891927
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation-dosimetry,0.28135353,single,0.3831071,blood-flow,0.3698504
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,substructures,0.2458094,deposits,0.48229864,deposits,0.48229864
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,significantly,0.23700657,with,0.568532,mi,0.39826992
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,longer,0.2500613,interrupted,0.5135091,right-atrial,0.39419138
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.16415215,rai,0.35907423,rai,0.35907423
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.3236165,of,0.44937658,rai,0.36969757
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation-dose,0.2581082,single,0.41469175,single-ventricle,0.35254818
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.34965062,right-ventricle,0.6898135,right-ventricle,0.6898135
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,toxicity,0.22547536,of,0.46452966,cardiac,0.36057627
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.34226567,blood-flow,0.37891927,blood-flow,0.37891927
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage,0.19545637,with,0.46458423,rai,0.38722774
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.25414947,hlhs,0.4131226,hlhs,0.4131226
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.16415215,rai,0.35907423,rai,0.35907423
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,using,0.20786116,with,0.58010674,flow,0.41007757
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,substructures,0.2458094,deposits,0.48229864,deposits,0.48229864
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergone,0.2888326,d-transposition,0.4931532,d-transposition,0.4931532
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.2738869,rai,0.45392853,rai,0.45392853
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.25414947,hlhs,0.4131226,hlhs,0.4131226
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.3185379,venous-return,0.33729267,venous-return,0.33729267
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann-analysis,0.3440869,congenital-heart-disease,0.4298815,congenital-heart-disease,0.4298815
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.3236165,of,0.44937658,rai,0.36969757
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation-dose,0.2581082,single,0.41469175,single-ventricle,0.35254818
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,mean,0.30953988,total,0.5000684,artery,0.37085557
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,mean-dose,0.28104612,heart-failure,0.34914953,heart-failure,0.34914953
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,maximum,0.22974399,of,0.4677399,contractions,0.41615498
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,maximum-dose,0.22086929,venous-return,0.361542,venous-return,0.361542
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,present,0.34922045,of,0.63723874,anomaly,0.40175247
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,test-accuracy,0.2651549,heartbeat,0.42945105,heartbeat,0.42945105
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,single,0.2571312,single,1.0,anomalous,0.40611145
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,institution,0.5022785,cardiology,0.5022785,cardiology,0.5022785
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,single-institution,0.34139448,single-ventricle,0.49478585,single-ventricle,0.49478585
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.34965062,right-ventricle,0.6898135,right-ventricle,0.6898135
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,might,0.24242394,of,0.5952132,anomalous,0.3600717
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,risk-might,0.33814567,chd,0.5376192,chd,0.5376192
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,right,0.35970405,right,1.0,right-atrial,0.63516104
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ventricle,0.37064588,ventricle,1.0,ventricle,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,right-ventricle,0.39534324,right-ventricle,1.0,right-ventricle,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,power,0.3026112,of,0.4390515,contractions,0.3698677
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,meier,0.25710624,double-outlet,0.32691965,double-outlet,0.32691965
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,less,0.30277786,with,0.57537794,mi,0.38854462
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,less-well,0.21525696,as,0.47683185,deposits,0.32687074
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predictor,0.24674982,as,0.45541835,chd,0.39992505
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetric,0.30903906,blood-flow,0.37964386,blood-flow,0.37964386
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.16415215,rai,0.35907423,rai,0.35907423
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,data,0.31118363,of,0.5086956,mi,0.36251363
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,support,0.36322898,return,0.46409142,flow,0.36807415
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,data-support,0.36489826,venous-return,0.43765014,venous-return,0.43765014
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,whole,0.2498735,of,0.548425,blood,0.49452528
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,heart,0.57664216,heart,1.0,heart,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,whole-heart,0.45181188,heart,0.607929,heart,0.607929
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,overall,0.28817955,of,0.5869458,chd,0.41920155
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,overall-survival,0.17263418,heart-failure,0.41449922,heart-failure,0.41449922
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,negatively,0.18867487,with,0.50144655,cholesterol,0.3726651
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predicted,0.16610277,of,0.49135727,single-ventricle,0.35252047
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,negatively-predicted,0.17258412,of,0.48109537,heart-failure,0.34479272
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.3185379,venous-return,0.33729267,venous-return,0.33729267
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.2738869,rai,0.45392853,rai,0.45392853
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.3236165,of,0.44937658,rai,0.36969757
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.34965062,right-ventricle,0.6898135,right-ventricle,0.6898135
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.16415215,rai,0.35907423,rai,0.35907423
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predicted,0.16610277,of,0.49135727,single-ventricle,0.35252047
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,heart,0.57664216,heart,1.0,heart,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,warranted,0.36467054,of,0.50301933,cardiology,0.36467054
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,subvolumes,0.26359278,blood-flow,0.4560659,blood-flow,0.4560659
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,small,0.28269485,great,0.5440953,deposits,0.39470115
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,results,0.29712585,of,0.53157276,blood,0.36869162
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,received,0.3772288,with,0.53732973,single-ventricle,0.39404702
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,prioritizing,0.36039472,great,0.42699945,congenital-heart-disease,0.41993433
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,organ,0.27081648,failure,0.5063345,heart,0.4739595
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,objective,0.2960808,of,0.5255821,flow,0.39260852
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,minimizing,0.23482302,of,0.5178264,flow,0.34466708
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,materials,0.28523445,deposits,0.41271186,deposits,0.41271186
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,kaplan,0.28892285,lai,0.36063018,lai,0.36063018
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,introduction,0.3353318,of,0.5877248,l-transposition,0.4046045
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,importance,0.3199574,of,0.5794183,anomaly,0.34929916
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,however,0.30646515,of,0.624624,mi,0.41109186
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,early,0.34221643,of,0.5714519,mi,0.3991026
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,considered,0.31302214,as,0.6929809,anomaly,0.43040824
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,characterized,0.12166704,isolated,0.60163844,anomalous,0.39773136
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,associations,0.28502855,chd,0.42755333,chd,0.42755333
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,association,0.34312242,of,0.45371312,chd,0.39406395
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,assess,0.37312466,of,0.49566716,pulmonary,0.375783
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analyzed,0.25776637,of,0.58131987,flow,0.35350555
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,additionally,0.26417398,of,0.6596129,flow,0.38005078
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,based,0.2494699,of,0.5443143,flow,0.34116954
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,image,0.3220324,heartbeat,0.45858762,heartbeat,0.45858762
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,quantification,0.21082784,of,0.4907973,flow,0.38184565
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,revealed,0.223917,of,0.55371094,anomalous,0.36589023
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,correlations,0.25538507,weak,0.4737602,anomalous,0.41380128
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,based-image,0.25150383,heartbeat,0.4021685,heartbeat,0.4021685
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,image-quantification,0.26287794,heartbeat,0.43539572,heartbeat,0.43539572
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,positive-correlations,0.28999078,weak,0.44501963,congenital-heart-disease,0.39670616
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.43551624,pulmonary,0.5641475,pulmonary,0.5641475
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,pathologies,0.32107803,disease,0.5931432,congenital,0.5365187
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,remain,0.33880928,intact,0.5185459,cardiac,0.3884099
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,poorly,0.23539765,as,0.51719266,deposits,0.39493018
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,defined,0.2335411,as,0.60751194,stenosis,0.33817482
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,poorly-defined,0.16572474,irregular,0.5554471,deposits,0.4412416
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,representing,0.22292884,of,0.60317135,deposits,0.33212742
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ckd,0.33941793,chd,0.58349866,chd,0.58349866
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced-injury,0.2159126,infarction,0.46719074,infarction,0.46719074
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion,0.36306685,myocardial,0.7064705,myocardial,0.7064705
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,showed,0.21619865,with,0.57298803,flow,0.33828264
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase,0.32113555,of,0.60061187,flow,0.4086165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion-injury,0.27395442,myocardial-infarction,0.694208,myocardial-infarction,0.694208
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury-model,0.24190447,infarction,0.4060843,infarction,0.4060843
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,implicates,0.14092585,of,0.5207428,l-transposition,0.32875377
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aryl,0.18685502,isomerism,0.42326018,isomerism,0.42326018
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hydrocarbon,0.19454046,cholesterol,0.43720394,cholesterol,0.43720394
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aryl-hydrocarbon,0.19364287,isomerism,0.4163831,isomerism,0.4163831
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hydrocarbon-receptor,0.21556172,of,0.43405315,cholesterol,0.4055971
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aryl-hydrocarbon-receptor,0.21125847,isomerism,0.40419084,isomerism,0.40419084
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood,0.32078606,blood,1.0,blood,1.0
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urea,0.16199692,blood,0.42514712,blood,0.42514712
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,nitrogen,0.13745444,total,0.37970564,cholesterol,0.35112154
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood-urea,0.22035475,blood-clot,0.6525449,blood-clot,0.6525449
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urea-nitrogen,0.13079393,blood-flow,0.37584522,blood-flow,0.37584522
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood-urea-nitrogen,0.20123094,blood,0.54801726,blood,0.54801726
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic,0.22543724,double,0.39561963,plaque-deposits,0.3700761
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,line,0.3054644,right,0.471364,venous,0.4344638
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,expressing,0.19233966,of,0.42866248,septal-defect,0.35725144
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic-mouse,0.18248247,plaque-deposits,0.42071024,plaque-deposits,0.42071024
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mouse-line,0.14721653,of,0.42130077,plaque-deposits,0.35406625
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,line-expressing,0.19051391,septal-defect,0.45706078,septal-defect,0.45706078
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,translationally,0.2295084,of,0.41956344,l-transposition,0.3556835
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal,0.31228805,of,0.5431563,congenital-heart-disease,0.397049
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,translationally-relevant,0.22528245,of,0.49103057,l-transposition,0.3500723
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal-models,0.30730113,congenital-heart-disease,0.41481268,congenital-heart-disease,0.41481268
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum,0.2084733,cholesterol,0.504964,cholesterol,0.504964
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21275091,cholesterol,0.40690023,cholesterol,0.40690023
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.20965305,cholesterol,0.4141973,cholesterol,0.4141973
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.1473688,cholesterol,0.35933048,cholesterol,0.35933048
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,acute,0.3642026,infarction,0.6294521,infarction,0.6294521
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney-injury,0.2502795,heart-failure,0.4967494,heart-failure,0.4967494
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,acute-kidney-injury,0.2745259,myocardial-infarction,0.5462832,myocardial-infarction,0.5462832
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum,0.2084733,cholesterol,0.504964,cholesterol,0.504964
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21275091,cholesterol,0.40690023,cholesterol,0.40690023
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.20965305,cholesterol,0.4141973,cholesterol,0.4141973
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.1473688,cholesterol,0.35933048,cholesterol,0.35933048
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter,0.22805995,l-transposition,0.36128733,l-transposition,0.36128733
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter-gene,0.19508913,l-transposition,0.37343934,l-transposition,0.37343934
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,gene-mouse,0.11072618,congenital-heart-disease,0.37879747,congenital-heart-disease,0.37879747
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,distal,0.17987399,right,0.5650882,artery,0.51595354
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.43551624,pulmonary,0.5641475,pulmonary,0.5641475
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tubules,0.15091349,deposits,0.46992096,deposits,0.46992096
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal-tubules,0.26844573,failure,0.45200494,hypoplastic-left-heart,0.42334855
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,persisted,0.24391823,of,0.5315399,bradycardia,0.39079505
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,despite,0.3297603,of,0.5583629,cardiac,0.39134312
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,using,0.20786116,with,0.58010674,flow,0.41007757
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney-diseases,0.29658636,heart-disease,0.63771087,heart-disease,0.63771087
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21275091,cholesterol,0.40690023,cholesterol,0.40690023
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.20965305,cholesterol,0.4141973,cholesterol,0.4141973
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.1473688,cholesterol,0.35933048,cholesterol,0.35933048
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,following,0.33078983,with,0.61268795,cardiac,0.4240192
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,using,0.20786116,with,0.58010674,flow,0.41007757
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,fed,0.28105107,with,0.48279458,cholesterol,0.39400005
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,showed,0.21619865,with,0.57298803,flow,0.33828264
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,fed-mice,0.16629829,septal-defect,0.34443647,septal-defect,0.34443647
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice-showed,0.17512415,plaque-deposits,0.4074196,plaque-deposits,0.4074196
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dioxin,0.25770712,cholesterol,0.38545588,cholesterol,0.38545588
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,derivative,0.13566533,isolated,0.4292621,isomerism,0.42140648
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic-kidney,0.2801576,congestive-heart-failure,0.55901396,congestive-heart-failure,0.55901396
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney-disease,0.27286986,heart-disease,0.6544356,heart-disease,0.6544356
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic-kidney-disease,0.2773272,heart-disease,0.64825976,heart-disease,0.64825976
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.10942434,cholesterol,0.3355891,cholesterol,0.3355891
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase,0.32113555,of,0.60061187,flow,0.4086165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,coincided,0.219856,of,0.5705139,deposits,0.37575328
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.10942434,cholesterol,0.3355891,cholesterol,0.3355891
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter,0.22805995,l-transposition,0.36128733,l-transposition,0.36128733
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter-gene,0.19508913,l-transposition,0.37343934,l-transposition,0.37343934
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,canonical,0.23425424,of,0.41577253,anomalous,0.36816582
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.16325097,chd,0.35457432,chd,0.35457432
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ligand,0.16372266,isomerism,0.41228968,isomerism,0.41228968
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-ligand,0.17518552,isomerism,0.38179144,isomerism,0.38179144
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aki,0.29377794,heart-failure,0.5061077,heart-failure,0.5061077
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal,0.31228805,of,0.5431563,congenital-heart-disease,0.397049
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal-models,0.30730113,congenital-heart-disease,0.41481268,congenital-heart-disease,0.41481268
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.43551624,pulmonary,0.5641475,pulmonary,0.5641475
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tubules,0.15091349,deposits,0.46992096,deposits,0.46992096
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal-tubules,0.26844573,failure,0.45200494,hypoplastic-left-heart,0.42334855
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21275091,cholesterol,0.40690023,cholesterol,0.40690023
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.20965305,cholesterol,0.4141973,cholesterol,0.4141973
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.1473688,cholesterol,0.35933048,cholesterol,0.35933048
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase,0.32113555,of,0.60061187,flow,0.4086165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,significant-increase,0.3630761,of,0.56957304,mi,0.47602522
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,discrete,0.22295417,irregular,0.52934086,anomalous,0.4839994
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,0.26268506,of,0.6059094,flow,0.40644997
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic,0.22543724,double,0.39561963,plaque-deposits,0.3700761
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic-mice,0.21044208,plaque-deposits,0.42988455,plaque-deposits,0.42988455
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.10942434,cholesterol,0.3355891,cholesterol,0.3355891
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,uremic,0.24681911,insufficiency,0.5059016,heart-syndrome,0.46157768
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,toxicity,0.22547536,of,0.46452966,cardiac,0.36057627
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,demonstrates,0.2093551,of,0.5866501,anomalous,0.37929255
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,results,0.29712585,of,0.53157276,blood,0.36869162
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,results-demonstrate,0.35938346,of,0.5512711,venous-return,0.45336813
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,provide,0.3065295,of,0.4983799,flow,0.3409845
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hypothesis,0.22202998,of,0.46284312,congenital-heart-disease,0.35420966
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,promoter,0.1920777,l-transposition,0.39260304,l-transposition,0.39260304
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tethered,0.18371211,with,0.47000217,isomerism,0.41318503
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,promoter-tethered,0.19948448,l-transposition,0.45185435,l-transposition,0.45185435
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,generating,0.22067916,of,0.54831296,l-transposition,0.3617708
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,insights,0.31122142,great,0.47418073,anomalous,0.36447477
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,emerging,0.36684948,great,0.54574025,cardiology,0.36684948
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,drinking,0.27975997,of,0.40325743,mi,0.35350513
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,water,0.24220353,of,0.46924597,flow,0.42210716
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,drinking-water,0.2331394,outlet,0.37385848,plaque,0.30742478
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dependent-activation,0.27364883,of,0.54613173,mi,0.41031376
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cerebral,0.3113555,infarction,0.58542037,infarction,0.58542037
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cortex,0.22341068,right,0.45752528,ventricle,0.45642415
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cerebral-cortex,0.1848124,blood-flow,0.506754,blood-flow,0.506754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,myocytes,0.3514763,ventricular,0.61161995,ventricular,0.61161995
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cardiac-myocytes,0.48043454,cardiac,0.7614292,cardiac,0.7614292
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,artificially,0.14517105,isolated,0.4600545,heartbeat,0.37203175
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increased,0.32251194,of,0.64014816,mi,0.42637154
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,artificially-increased,0.24996899,of,0.58453846,heart-attack,0.44470555
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.16325097,chd,0.35457432,chd,0.35457432
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,responsive,0.23913951,weak,0.46599144,tachycardia,0.32311696
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-responsive,0.22653307,weak,0.3388173,l-transposition,0.32220167
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.16325097,chd,0.35457432,chd,0.35457432
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induction,0.22081468,of,0.52603287,l-transposition,0.39831883
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-induction,0.213049,of,0.3973124,l-transposition,0.3565828
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.16325097,chd,0.35457432,chd,0.35457432
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-activation,0.15285102,of,0.39180735,contractions,0.35913754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,0.26268506,of,0.6059094,flow,0.40644997
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,manifestations,0.32852295,disease,0.62007797,syndrome,0.60876584
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,probe,0.24611104,single,0.46016064,flow,0.36584496
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,probe-tissue,0.24948527,blood-flow,0.4966732,blood-flow,0.4966732
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion,0.36306685,myocardial,0.7064705,myocardial,0.7064705
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ckd,0.33941793,chd,0.58349866,chd,0.58349866
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.10942434,cholesterol,0.3355891,cholesterol,0.3355891
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aki,0.29377794,heart-failure,0.5061077,heart-failure,0.5061077
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.16325097,chd,0.35457432,chd,0.35457432
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,0.26268506,of,0.6059094,flow,0.40644997
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,warrant,0.34599757,of,0.49606943,cardiac,0.34735847
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,use,0.3219829,with,0.55726266,flow,0.40877783
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urine,0.28969184,blood,0.57622874,blood,0.57622874
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,uremia,0.35543376,insufficiency,0.6598294,congestive,0.57180446
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,time,0.350901,return,0.5513821,venous-return,0.44564146
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,thus,0.30240285,of,0.6779618,flow,0.4474225
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,subjected,0.18238434,isolated,0.5451176,flow,0.38988888
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,response,0.2306606,of,0.52661085,contractions,0.38512754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,relationship,0.21630949,of,0.4831799,anomalous,0.3835627
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,recapitulated,0.21005884,with,0.45073724,septal-defect,0.4264293
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,proximal,0.19377108,arteries,0.5245569,arteries,0.5245569
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,pattern,0.22120216,irregular,0.5954343,flow,0.4913214
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,microvasculature,0.2604742,blood-flow,0.6581689,blood-flow,0.6581689
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mediator,0.17603539,as,0.51975054,pulmonary,0.304783
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ischemia,0.3786124,infarction,0.7500457,infarction,0.7500457
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,investigation,0.31772497,of,0.61667234,anomaly,0.36676937
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,inhibiting,0.19827786,of,0.5194954,contractions,0.3771227
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,humans,0.21283677,of,0.49299914,congenital-heart-disease,0.41938835
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,however,0.30646515,of,0.624624,mi,0.41109186
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hepatocytes,0.21273908,myocardial,0.37797526,myocardial,0.37797526
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,excretion,0.1983739,cholesterol,0.40167654,cholesterol,0.40167654
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,details,0.42918324,cardiology,0.42918324,cardiology,0.42918324
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,changes,0.30126634,of,0.5562258,flow,0.44305104
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,adenine,0.17813024,l-transposition,0.44576216,l-transposition,0.44576216
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,bai,0.14070688,lai,0.45271218,lai,0.45271218
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,predicts,0.17337668,of,0.50220644,anomalous,0.37529898
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.27191585,heart-failure,0.4188889,heart-failure,0.4188889
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.2739641,congenital-heart-disease,0.47659093,congenital-heart-disease,0.47659093
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,previously,0.21411541,as,0.54924536,l-transposition,0.42639655
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,previously-published,0.32664487,of,0.4902569,venous-return,0.40298006
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,old,0.37853727,intact,0.4796161,mi,0.4757865
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years-old,0.29338634,congenital-heart-disease,0.41010988,congenital-heart-disease,0.41010988
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.34347007,heartbeat,0.50327885,heartbeat,0.50327885
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,heart,0.57664216,heart,1.0,heart,1.0
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,heart-health,0.5641563,heart-disease,0.6285029,heart-disease,0.6285029
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,health-study,0.37753487,heart-disease,0.469068,heart-disease,0.469068
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,per,0.42462003,single,0.5002958,cardiology,0.42462003
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,standard,0.29642093,with,0.46176666,single-ventricle,0.33840466
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,per-standard,0.2691034,venous-return,0.40115204,venous-return,0.40115204
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.27191585,heart-failure,0.4188889,heart-failure,0.4188889
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.2739641,congenital-heart-disease,0.47659093,congenital-heart-disease,0.47659093
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.27191585,heart-failure,0.4188889,heart-failure,0.4188889
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.2739641,congenital-heart-disease,0.47659093,congenital-heart-disease,0.47659093
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,p,0.29391026,with,0.4559728,congestive,0.4058217
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted,0.3251242,chd,0.47266376,chd,0.47266376
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,hazard,0.22378854,chd,0.45025742,chd,0.45025742
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ratio,0.18660581,total,0.40182298,tof,0.36502323
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted-hazard,0.31520608,chd,0.51562583,chd,0.51562583
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,hazard-ratio,0.19644472,venous-return,0.44212234,venous-return,0.44212234
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted-hazard-ratio,0.27782047,venous-return,0.49239644,venous-return,0.49239644
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,overnight,0.3908714,return,0.53270113,arrythmia,0.5121995
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.34347007,heartbeat,0.50327885,heartbeat,0.50327885
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,electroencephalogram,0.33058625,bradycardia,0.48902467,bradycardia,0.48902467
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep-electroencephalogram,0.31070578,heartbeat,0.4998542,heartbeat,0.4998542
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.33659208,with,0.44369304,chd,0.42829025
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,norms,0.3480126,return,0.38488844,venous-return,0.35808614
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age-norms,0.22619508,congenital-heart-disease,0.40579426,congenital-heart-disease,0.40579426
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,excess,0.19790238,of,0.545664,anomaly,0.39830765
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.33659208,with,0.44369304,chd,0.42829025
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain-age,0.24738325,congenital-heart-disease,0.45159373,congenital-heart-disease,0.45159373
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,comparing,0.26645347,with,0.5715135,single-ventricle,0.3825506
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.37727773,bradycardia,0.49027538,bradycardia,0.49027538
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg-features,0.27181503,heartbeat,0.4568079,heartbeat,0.4568079
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.33659208,with,0.44369304,chd,0.42829025
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,index,0.27677816,total,0.43109894,mi,0.39722836
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain-age,0.24738325,congenital-heart-disease,0.45159373,congenital-heart-disease,0.45159373
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.27191585,heart-failure,0.4188889,heart-failure,0.4188889
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.2739641,congenital-heart-disease,0.47659093,congenital-heart-disease,0.47659093
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.33659208,with,0.44369304,chd,0.42829025
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain-age,0.24738325,congenital-heart-disease,0.45159373,congenital-heart-disease,0.45159373
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.34347007,heartbeat,0.50327885,heartbeat,0.50327885
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,microstructure,0.18455547,deposits,0.5015905,deposits,0.5015905
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.34347007,heartbeat,0.50327885,heartbeat,0.50327885
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.37727773,bradycardia,0.49027538,bradycardia,0.49027538
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep-eeg,0.2571798,heartbeat,0.4624358,heartbeat,0.4624358
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,chronological,0.28066152,of,0.45980784,congenital-heart-disease,0.38554943
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.33659208,with,0.44369304,chd,0.42829025
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,chronological-age,0.29344448,congenital-heart-disease,0.45737326,congenital-heart-disease,0.45737326
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,quantified,0.22473742,of,0.5224161,flow,0.42425463
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,using,0.20786116,with,0.58010674,flow,0.41007757
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,patterns,0.22309256,of,0.55208683,anomalous,0.46585032
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,independent,0.28915384,of,0.5904635,cad,0.4052443
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,predictor,0.24674982,as,0.45541835,chd,0.39992505
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,independent-predictor,0.29390222,venous-return,0.49250972,venous-return,0.49250972
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,show,0.19476143,of,0.51487744,anomalous,0.38152152
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,based,0.2494699,of,0.5443143,flow,0.34116954
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,biomarker,0.22552925,as,0.44500005,artery-disease,0.3425546
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation,0.27843946,beats,0.4367276,beats,0.4367276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,increase,0.32113555,of,0.60061187,flow,0.4086165
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation-increase,0.25634992,of,0.47924435,anomalous,0.41242018
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca,0.30898777,mi,0.48457235,mi,0.48457235
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,bai,0.14070688,lai,0.45271218,lai,0.45271218
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.34347007,heartbeat,0.50327885,heartbeat,0.50327885
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.33659208,with,0.44369304,chd,0.42829025
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.37727773,bradycardia,0.49027538,bradycardia,0.49027538
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation,0.27843946,beats,0.4367276,beats,0.4367276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca,0.30898777,mi,0.48457235,mi,0.48457235
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,underwent,0.31797755,with,0.45424697,d-transposition,0.45269838
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,part,0.37925124,of,0.6214935,anomaly,0.4202423
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,n,0.21850443,with,0.47536123,mi,0.3790054
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,measures,0.2977168,of,0.4417776,venous-return,0.3984164
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,individual,0.26860815,of,0.6520203,anomalous,0.4023711
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,estimated,0.2633227,of,0.52809477,chd,0.38898614
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,difference,0.212452,of,0.434909,stenosis,0.35809982
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ba,0.22531182,atresia,0.43842188,atresia,0.43842188
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,apparent,0.22756818,of,0.58568347,anomalous,0.46481445
Gated recurrent unit-based heart sound analysis for heart failure screening.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Gated recurrent unit-based heart sound analysis for heart failure screening.,framework,0.24920769,as,0.3324023,isomerism,0.32199267
Gated recurrent unit-based heart sound analysis for heart failure screening.,based,0.2494699,of,0.5443143,flow,0.34116954
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf-screening,0.38005215,congenital-heart-disease,0.40538788,congenital-heart-disease,0.40538788
Gated recurrent unit-based heart sound analysis for heart failure screening.,framework-based,0.21541582,as,0.32903636,isomerism,0.29238456
Gated recurrent unit-based heart sound analysis for heart failure screening.,conveys,0.23536476,of,0.50973374,anomalous,0.36803305
Gated recurrent unit-based heart sound analysis for heart failure screening.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Gated recurrent unit-based heart sound analysis for heart failure screening.,information,0.36363098,of,0.47314215,mi,0.39006084
Gated recurrent unit-based heart sound analysis for heart failure screening.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Gated recurrent unit-based heart sound analysis for heart failure screening.,information-related,0.34507117,of,0.5119876,congenital-heart-disease,0.42246407
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Gated recurrent unit-based heart sound analysis for heart failure screening.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Gated recurrent unit-based heart sound analysis for heart failure screening.,de,0.3474172,of,0.44628268,mi,0.41270334
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf-screening,0.38005215,congenital-heart-disease,0.40538788,congenital-heart-disease,0.40538788
Gated recurrent unit-based heart sound analysis for heart failure screening.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Gated recurrent unit-based heart sound analysis for heart failure screening.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Gated recurrent unit-based heart sound analysis for heart failure screening.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Gated recurrent unit-based heart sound analysis for heart failure screening.,reduced-ejection,0.30925128,ventricular,0.54094154,ventricular,0.54094154
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Gated recurrent unit-based heart sound analysis for heart failure screening.,preserved,0.24191171,with,0.53828907,deposits,0.44760028
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Gated recurrent unit-based heart sound analysis for heart failure screening.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Gated recurrent unit-based heart sound analysis for heart failure screening.,preserved-ejection,0.30263668,right-ventricle,0.576405,right-ventricle,0.576405
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Gated recurrent unit-based heart sound analysis for heart failure screening.,based,0.2494699,of,0.5443143,flow,0.34116954
Gated recurrent unit-based heart sound analysis for heart failure screening.,hidden,0.19940528,of,0.43001032,congenital-heart-disease,0.4254408
Gated recurrent unit-based heart sound analysis for heart failure screening.,semi,0.29128164,stiff,0.41709682,flow,0.35643217
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Gated recurrent unit-based heart sound analysis for heart failure screening.,early,0.34221643,of,0.5714519,mi,0.3991026
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf-early,0.33436352,premature,0.43409836,infarction,0.42962903
Gated recurrent unit-based heart sound analysis for heart failure screening.,early-screening,0.29922923,congenital-heart-disease,0.39525148,congenital-heart-disease,0.39525148
Gated recurrent unit-based heart sound analysis for heart failure screening.,gated,0.40131384,myocardial,0.49613813,myocardial,0.49613813
Gated recurrent unit-based heart sound analysis for heart failure screening.,recurrent,0.2713791,insufficiency,0.52224016,thrombosis,0.51575255
Gated recurrent unit-based heart sound analysis for heart failure screening.,unit,0.44734353,single,0.45938355,cardiology,0.44734353
Gated recurrent unit-based heart sound analysis for heart failure screening.,crafted,0.3813239,great,0.5074805,cardiology,0.3813239
Gated recurrent unit-based heart sound analysis for heart failure screening.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Gated recurrent unit-based heart sound analysis for heart failure screening.,extraction,0.25589973,of,0.42793012,flow,0.40312088
Gated recurrent unit-based heart sound analysis for heart failure screening.,feature-extraction,0.17565963,of,0.4033695,heartbeat,0.37684447
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Gated recurrent unit-based heart sound analysis for heart failure screening.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Gated recurrent unit-based heart sound analysis for heart failure screening.,caused,0.1752007,of,0.53973085,congenital,0.42777976
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Gated recurrent unit-based heart sound analysis for heart failure screening.,disease-caused,0.2379412,disease,0.6819074,congenital-heart-disease,0.5609107
Gated recurrent unit-based heart sound analysis for heart failure screening.,abnormal,0.28601512,abnormal,1.0,anomaly,0.55273944
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,structure,0.23256482,of,0.49829155,isomerism,0.4853079
Gated recurrent unit-based heart sound analysis for heart failure screening.,good,0.31429055,weak,0.60268193,venous-return,0.38116372
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Gated recurrent unit-based heart sound analysis for heart failure screening.,demonstrates,0.2093551,of,0.5866501,anomalous,0.37929255
Gated recurrent unit-based heart sound analysis for heart failure screening.,good-performance,0.31057426,venous-return,0.45517606,venous-return,0.45517606
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.23359099,rai,0.24164952,rai,0.24164952
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Gated recurrent unit-based heart sound analysis for heart failure screening.,gives,0.24181318,of,0.5415878,anomalous,0.4170431
Gated recurrent unit-based heart sound analysis for heart failure screening.,segment,0.20645988,interrupted,0.4524773,artery,0.44207752
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.251121,with,0.42329556,syndrome,0.38394833
Gated recurrent unit-based heart sound analysis for heart failure screening.,frames,0.26021102,interrupted,0.4600563,beats,0.40298417
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.23359099,rai,0.24164952,rai,0.24164952
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Gated recurrent unit-based heart sound analysis for heart failure screening.,early,0.34221643,of,0.5714519,mi,0.3991026
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Gated recurrent unit-based heart sound analysis for heart failure screening.,early-screening,0.29922923,congenital-heart-disease,0.39525148,congenital-heart-disease,0.39525148
Gated recurrent unit-based heart sound analysis for heart failure screening.,therefore,0.32687712,of,0.6409915,flow,0.39200473
Gated recurrent unit-based heart sound analysis for heart failure screening.,based,0.2494699,of,0.5443143,flow,0.34116954
Gated recurrent unit-based heart sound analysis for heart failure screening.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Gated recurrent unit-based heart sound analysis for heart failure screening.,learn,0.37636507,great,0.4351821,heartbeat,0.4190525
Gated recurrent unit-based heart sound analysis for heart failure screening.,normalized,0.3386992,abnormal,0.50572217,flow,0.40979832
Gated recurrent unit-based heart sound analysis for heart failure screening.,frames,0.26021102,interrupted,0.4600563,beats,0.40298417
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed-model,0.21347384,venous-return,0.44460833,venous-return,0.44460833
Gated recurrent unit-based heart sound analysis for heart failure screening.,markov,0.23270477,interrupted,0.356151,venous-return,0.35439837
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Gated recurrent unit-based heart sound analysis for heart failure screening.,markov-model,0.21261784,venous-return,0.39043754,venous-return,0.39043754
Gated recurrent unit-based heart sound analysis for heart failure screening.,timely,0.40103292,of,0.5138315,single-ventricle,0.40478224
Gated recurrent unit-based heart sound analysis for heart failure screening.,manner,0.18540666,with,0.42496896,contractions,0.388913
Gated recurrent unit-based heart sound analysis for heart failure screening.,satisfactory,0.23361701,great,0.46691352,venous-return,0.3805795
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Gated recurrent unit-based heart sound analysis for heart failure screening.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Gated recurrent unit-based heart sound analysis for heart failure screening.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Gated recurrent unit-based heart sound analysis for heart failure screening.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Gated recurrent unit-based heart sound analysis for heart failure screening.,learn,0.37636507,great,0.4351821,heartbeat,0.4190525
Gated recurrent unit-based heart sound analysis for heart failure screening.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Gated recurrent unit-based heart sound analysis for heart failure screening.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Gated recurrent unit-based heart sound analysis for heart failure screening.,implication,0.27063954,of,0.6111196,anomalous,0.39008152
Gated recurrent unit-based heart sound analysis for heart failure screening.,identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
Gated recurrent unit-based heart sound analysis for heart failure screening.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.251121,with,0.42329556,syndrome,0.38394833
Gated recurrent unit-based heart sound analysis for heart failure screening.,signals,0.2345418,heartbeat,0.4749927,heartbeat,0.4749927
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.251121,with,0.42329556,syndrome,0.38394833
Gated recurrent unit-based heart sound analysis for heart failure screening.,directly,0.2335313,of,0.58113813,flow,0.38857496
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart,0.57664216,heart,1.0,heart,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,sound,0.3181565,heartbeat,0.5337689,heartbeat,0.5337689
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart-sound,0.4672351,heartbeat,0.6882624,heartbeat,0.6882624
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart,0.57664216,heart,1.0,heart,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,expert,0.4946844,cardiology,0.4946844,cardiology,0.4946844
Gated recurrent unit-based heart sound analysis for heart failure screening.,knowledge,0.32453293,of,0.4580958,congenital-heart-disease,0.38427317
Gated recurrent unit-based heart sound analysis for heart failure screening.,expert-knowledge,0.39720508,congenital-heart-disease,0.4608471,congenital-heart-disease,0.4608471
Gated recurrent unit-based heart sound analysis for heart failure screening.,efficient,0.19720647,of,0.49297506,l-transposition,0.3745634
Gated recurrent unit-based heart sound analysis for heart failure screening.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
Gated recurrent unit-based heart sound analysis for heart failure screening.,deep,0.25718108,venous,0.51692,venous,0.51692
Gated recurrent unit-based heart sound analysis for heart failure screening.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Gated recurrent unit-based heart sound analysis for heart failure screening.,average,0.3160447,total,0.53346545,beats,0.33409712
Gated recurrent unit-based heart sound analysis for heart failure screening.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Gated recurrent unit-based heart sound analysis for heart failure screening.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Gated recurrent unit-based heart sound analysis for heart failure screening.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Gated recurrent unit-based heart sound analysis for heart failure screening.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Gated recurrent unit-based heart sound analysis for heart failure screening.,three-methods,0.24516365,single,0.4749393,double-outlet,0.3932898
Gated recurrent unit-based heart sound analysis for heart failure screening.,results,0.29712585,of,0.53157276,blood,0.36869162
Gated recurrent unit-based heart sound analysis for heart failure screening.,show,0.19476143,of,0.51487744,anomalous,0.38152152
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.251121,with,0.42329556,syndrome,0.38394833
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Gated recurrent unit-based heart sound analysis for heart failure screening.,comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
Gated recurrent unit-based heart sound analysis for heart failure screening.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.23359099,rai,0.24164952,rai,0.24164952
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.251121,with,0.42329556,syndrome,0.38394833
Gated recurrent unit-based heart sound analysis for heart failure screening.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Gated recurrent unit-based heart sound analysis for heart failure screening.,results,0.29712585,of,0.53157276,blood,0.36869162
Gated recurrent unit-based heart sound analysis for heart failure screening.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Gated recurrent unit-based heart sound analysis for heart failure screening.,comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Gated recurrent unit-based heart sound analysis for heart failure screening.,used,0.23211285,as,0.56584436,flow,0.35934073
Gated recurrent unit-based heart sound analysis for heart failure screening.,type,0.18854949,of,0.48202556,aortic,0.35779506
Gated recurrent unit-based heart sound analysis for heart failure screening.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Gated recurrent unit-based heart sound analysis for heart failure screening.,taken,0.3873873,of,0.53411245,blood,0.41476953
Gated recurrent unit-based heart sound analysis for heart failure screening.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Gated recurrent unit-based heart sound analysis for heart failure screening.,objective,0.2960808,of,0.5255821,flow,0.39260852
Gated recurrent unit-based heart sound analysis for heart failure screening.,nosing,0.20633751,with,0.5013081,l-transposition,0.41128877
Gated recurrent unit-based heart sound analysis for heart failure screening.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Gated recurrent unit-based heart sound analysis for heart failure screening.,means,0.25244248,of,0.5759921,flow,0.46121243
Gated recurrent unit-based heart sound analysis for heart failure screening.,input,0.31766397,of,0.44965258,flow,0.4458027
Gated recurrent unit-based heart sound analysis for heart failure screening.,independent,0.28915384,of,0.5904635,cad,0.4052443
Gated recurrent unit-based heart sound analysis for heart failure screening.,hand,0.3170963,right,0.5377352,hypoplastic-left,0.37238127
Gated recurrent unit-based heart sound analysis for heart failure screening.,function,0.2605439,of,0.55099833,flow,0.43324804
Gated recurrent unit-based heart sound analysis for heart failure screening.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Gated recurrent unit-based heart sound analysis for heart failure screening.,effectiveness,0.2947462,of,0.5160025,venous-return,0.352529
Gated recurrent unit-based heart sound analysis for heart failure screening.,develop,0.22949755,of,0.43968886,congestive-heart-failure,0.35599005
Gated recurrent unit-based heart sound analysis for heart failure screening.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Gated recurrent unit-based heart sound analysis for heart failure screening.,complete,0.20676532,of,0.51385504,l-transposition,0.42622632
Gated recurrent unit-based heart sound analysis for heart failure screening.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Gated recurrent unit-based heart sound analysis for heart failure screening.,background,0.2325702,of,0.51277274,congenital,0.3895001
Gated recurrent unit-based heart sound analysis for heart failure screening.,adopted,0.30375072,of,0.520591,single-ventricle,0.36077982
Gated recurrent unit-based heart sound analysis for heart failure screening.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.20100933,of,0.43435428,aortic,0.34993017
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,quartiles,0.30738634,chd,0.47932488,chd,0.47932488
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,produced,0.1871594,of,0.57611185,contractions,0.40176785
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,resolution,0.22951236,of,0.46130672,tof,0.40459827
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein-b,0.21784578,cholesterol,0.72414654,cholesterol,0.72414654
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,improve,0.31483245,great,0.49610043,flow,0.35876963
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,coronary,0.56409866,coronary,1.0,coronary,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,heart,0.57664216,heart,1.0,heart,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,coronary-heart,0.5715385,coronary-artery,0.8627513,coronary-artery,0.8627513
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,coronary-heart-disease,0.5209235,heart-disease,0.89567757,heart-disease,0.89567757
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,even,0.3054184,with,0.6390622,deposits,0.4270071
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,advanced,0.34864503,with,0.51267695,congestive,0.41393596
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,multivariate,0.22754261,artery-disease,0.3808375,artery-disease,0.3808375
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.26666296,of,0.45615864,rai,0.38170314
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subclass,0.17237923,isolated,0.38638192,deposits,0.36154523
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,data,0.31118363,of,0.5086956,mi,0.36251363
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein-subclass,0.2556545,cholesterol,0.6638038,cholesterol,0.6638038
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,advance,0.4594765,as,0.5027088,cardiology,0.4594765
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.48676962,chd,1.0,chd,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd-risk,0.33779937,chd,0.7474258,chd,0.7474258
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk-assessment,0.39875644,artery-disease,0.4224608,artery-disease,0.4224608
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.20100933,of,0.43435428,aortic,0.34993017
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,quartiles,0.30738634,chd,0.47932488,chd,0.47932488
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein-b,0.21784578,cholesterol,0.72414654,cholesterol,0.72414654
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,intelligence,0.331039,congenital-heart-disease,0.4281336,congenital-heart-disease,0.4281336
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,methodology,0.283471,of,0.41219762,single-ventricle,0.29670447
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,artificial-intelligence,0.30402216,venous-return,0.48337245,venous-return,0.48337245
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,also,0.36015856,of,0.65908813,flow,0.41040578
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,striking,0.23488128,of,0.56784827,anomalous,0.4391125
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,dose,0.35218355,single,0.47391105,blood,0.3763219
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,driven,0.27247697,of,0.47781104,flow,0.40639967
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.26666296,of,0.45615864,rai,0.38170314
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,profiles,0.15556863,of,0.5306897,flow,0.4074694
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,detailed,0.34579298,of,0.54393613,anomalous,0.44207406
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,profiles,0.15556863,of,0.5306897,flow,0.4074694
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,containing,0.1330749,of,0.51960796,deposits,0.3792259
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,particles,0.24042061,deposits,0.5375793,deposits,0.5375793
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,containing-lipoprotein,0.24402158,cholesterol,0.73905915,cholesterol,0.73905915
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein-particles,0.2753268,cholesterol,0.65342426,cholesterol,0.65342426
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,scale,0.29563683,great,0.37443155,venous-return,0.34418654
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.3190225,of,0.49866888,chd,0.40046495
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohorts,0.31992877,chd,0.47250944,chd,0.47250944
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population-cohorts,0.29281068,chd,0.49014825,chd,0.49014825
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,four,0.26703352,of,0.57211214,d-transposition,0.35247436
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.25496638,weak,0.3781725,mi,0.35374007
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,identified-four,0.18007949,single,0.4381229,double-outlet,0.36364913
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,mediated,0.18597665,of,0.5168716,contractions,0.37430054
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.48676962,chd,1.0,chd,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd-risk,0.33779937,chd,0.7474258,chd,0.7474258
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,define,0.26571727,of,0.514004,anomaly,0.3117352
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups,0.2488952,with,0.43536332,rai,0.40112627
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.2494699,of,0.5443143,flow,0.34116954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups-based,0.22362724,with,0.40069786,single-ventricle,0.33272845
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.20100933,of,0.43435428,aortic,0.34993017
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein-b,0.21784578,cholesterol,0.72414654,cholesterol,0.72414654
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,data,0.31118363,of,0.5086956,mi,0.36251363
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk-assessment,0.39875644,artery-disease,0.4224608,artery-disease,0.4224608
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.20100933,of,0.43435428,aortic,0.34993017
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.48676962,chd,1.0,chd,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd-risk,0.33779937,chd,0.7474258,chd,0.7474258
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,univariate,0.25618485,artery-disease,0.40312076,artery-disease,0.40312076
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.26666296,of,0.45615864,rai,0.38170314
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.3190225,of,0.49866888,chd,0.40046495
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.26666296,of,0.45615864,rai,0.38170314
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,unsupervised,0.26907045,heartbeat,0.44143736,heartbeat,0.44143736
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,data,0.31118363,of,0.5086956,mi,0.36251363
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,metabolism,0.25317088,cholesterol,0.4435029,cholesterol,0.4435029
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein-metabolism,0.26676118,cholesterol,0.7300997,cholesterol,0.7300997
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.2494699,of,0.5443143,flow,0.34116954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups,0.2488952,with,0.43536332,rai,0.40112627
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest,0.2895016,with,0.46268752,mi,0.35886955
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest-risk,0.3290013,chd,0.5293725,chd,0.5293725
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,would,0.35497403,of,0.55908126,flow,0.3796509
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,work,0.41337943,return,0.5383546,cardiology,0.41337943
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.25496638,weak,0.3781725,mi,0.35374007
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,response,0.2306606,of,0.52661085,contractions,0.38512754
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,behaviour,0.16569161,of,0.44472158,anomalous,0.39944327
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,organizing,0.37261796,of,0.42484042,pulmonary,0.39701754
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest,0.2895016,with,0.46268752,mi,0.35886955
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,concentrations,0.20313622,with,0.46930897,deposits,0.43182394
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,independent,0.28915384,of,0.5904635,cad,0.4052443
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,measures,0.2977168,of,0.4417776,venous-return,0.3984164
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.2494699,of,0.5443143,flow,0.34116954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based-cohort,0.28800708,congenital-heart-disease,0.4261526,congenital-heart-disease,0.4261526
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results,0.29712585,of,0.53157276,blood,0.36869162
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results-suggest,0.37769833,with,0.46542153,venous-return,0.4256721
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,highest,0.26377243,of,0.5054526,mi,0.33820426
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,concentrations,0.20313622,with,0.46930897,deposits,0.43182394
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.2494699,of,0.5443143,flow,0.34116954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup,0.2485567,with,0.4316542,heart-failure,0.38258135
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.48676962,chd,1.0,chd,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.25496638,weak,0.3781725,mi,0.35374007
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.3190225,of,0.49866888,chd,0.40046495
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.2494699,of,0.5443143,flow,0.34116954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup,0.2485567,with,0.4316542,heart-failure,0.38258135
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results,0.29712585,of,0.53157276,blood,0.36869162
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,highest,0.26377243,of,0.5054526,mi,0.33820426
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,v,0.240002,sv,0.44191512,sv,0.44191512
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,utilised,0.26656795,of,0.5237539,flow,0.3325811
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,therefore,0.32687712,of,0.6409915,flow,0.39200473
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,suggested,0.294477,of,0.6234695,anomalous,0.38919652
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,self,0.35339174,weak,0.46892393,arrythmia,0.44653496
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,non,0.3477749,with,0.61364555,mi,0.46788454
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,n,0.21850443,with,0.47536123,mi,0.3790054
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,means,0.25244248,of,0.5759921,flow,0.46121243
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,may,0.26963884,of,0.58654004,anomalous,0.366544
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,majority,0.28791377,of,0.48508087,l-transposition,0.36823815
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,large,0.31318635,great,0.5879582,deposits,0.4134889
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,however,0.30646515,of,0.624624,mi,0.41109186
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,explored,0.24943587,of,0.58866113,anomalous,0.34417656
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,explained,0.30903512,of,0.516951,anomalous,0.45372206
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,compared,0.26227483,with,0.62448335,mi,0.40925252
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,background,0.2325702,of,0.51277274,congenital,0.3895001
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,applied,0.31181335,of,0.5047146,flow,0.3948964
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,show,0.19476143,of,0.51487744,anomalous,0.38152152
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,instead,0.29061213,as,0.61385596,anomalous,0.41405156
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lower,0.26859394,with,0.5748005,venous,0.42565888
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.15734789,cholesterol,0.55069435,cholesterol,0.55069435
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lower-tg,0.18516712,cholesterol,0.37408805,cholesterol,0.37408805
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,targets,0.24361905,of,0.45244455,heart-attack,0.3073677
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,also,0.36015856,of,0.65908813,flow,0.41040578
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,partially,0.15156177,of,0.54725564,anomalous,0.39749575
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,reduces,0.1488205,of,0.53557026,heart-attack,0.33165377
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,c,0.21239448,with,0.46990636,ivs,0.34813386
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ascvd,0.4187932,chd,0.76672643,chd,0.76672643
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ascvd-risk,0.35199925,chd,0.71700764,chd,0.71700764
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,targets,0.24361905,of,0.45244455,heart-attack,0.3073677
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new-therapeutic,0.3994635,heart-failure,0.44081855,heart-failure,0.44081855
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,therapeutic-targets,0.33450398,great,0.4249402,heart-attack,0.35148945
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ascvd,0.4187932,chd,0.76672643,chd,0.76672643
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,abnormalities,0.32799944,abnormal,0.81413877,anomaly,0.6537851
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,characterized,0.12166704,isolated,0.60163844,anomalous,0.39773136
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,pharmacological,0.32797652,of,0.48491696,congestive-heart-failure,0.37223655
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,target,0.23866604,of,0.4775706,blood,0.34112448
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,pharmacological-target,0.33443084,of,0.43083405,congestive-heart-failure,0.4113269
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic,0.37899542,plaque,0.7153188,plaque,0.7153188
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic-cardiovascular,0.53334194,coronary,0.74648607,coronary,0.74648607
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic-cardiovascular-disease,0.5005094,coronary-artery-disease,0.75097334,coronary-artery-disease,0.75097334
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,induces,0.07553116,of,0.44929433,contractions,0.3030374
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,side,0.25860035,left,0.5740862,isomerism,0.37933958
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,side-effects,0.2311489,failure,0.4254561,bradycardia,0.4236935
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,clinical-trials,0.4117396,heart-failure,0.48685247,heart-failure,0.48685247
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lpl,0.1658878,cholesterol,0.5344877,cholesterol,0.5344877
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antagonizing,0.22108302,of,0.46640968,contractions,0.44982988
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,like,0.33787337,as,0.6495254,cardiac,0.3588698
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,proteins,0.21103716,of,0.46288005,deposits,0.3796569
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,like-proteins,0.17368957,of,0.4113212,deposits,0.35655946
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense,0.19332486,l-transposition,0.39142168,l-transposition,0.39142168
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,oligonucleotide,0.13312292,single,0.34076393,l-transposition,0.3115415
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense-oligonucleotide,0.13275804,l-transposition,0.3545466,l-transposition,0.3545466
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein-cholesterol,0.29643348,cholesterol,0.8591521,cholesterol,0.8591521
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density-lipoprotein-cholesterol,0.26042908,cholesterol,0.8576243,cholesterol,0.8576243
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,also,0.36015856,of,0.65908813,flow,0.41040578
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl-receptor,0.2595934,cholesterol,0.6340729,cholesterol,0.6340729
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.15734789,cholesterol,0.55069435,cholesterol,0.55069435
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.15734789,cholesterol,0.55069435,cholesterol,0.55069435
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma-tg,0.19060978,blood-clot,0.50363386,blood-clot,0.50363386
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,role,0.263546,of,0.49928063,anomalous,0.31226397
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense,0.19332486,l-transposition,0.39142168,l-transposition,0.39142168
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,oligonucleotides,0.13775429,l-transposition,0.34044692,l-transposition,0.34044692
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense-oligonucleotides,0.13089144,l-transposition,0.35457698,l-transposition,0.35457698
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antagonists,0.26629966,contractions,0.45131737,contractions,0.45131737
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,phase,0.19908471,of,0.4318388,flow,0.38942474
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipase,0.2244617,cholesterol,0.55736417,cholesterol,0.55736417
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein-lipase,0.24990302,cholesterol,0.74300635,cholesterol,0.74300635
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,still,0.38928428,of,0.5457471,arrythmia,0.4077646
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,needed,0.42938864,as,0.567801,cardiology,0.42938864
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,still-needed,0.46086007,return,0.52036804,cardiology,0.46086007
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,increase,0.32113555,of,0.60061187,flow,0.4086165
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,significant-increase,0.3630761,of,0.56957304,mi,0.47602522
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,provided,0.3710292,of,0.61110586,flow,0.38950795
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,data,0.31118363,of,0.5086956,mi,0.36251363
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,prandial,0.28448886,blood,0.44444025,blood,0.44444025
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma-levels,0.19990644,blood,0.45567802,blood,0.45567802
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,murine,0.19791704,isolated,0.48796523,l-transposition,0.371085
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal,0.21581441,deposits,0.38608515,deposits,0.38608515
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antibodies,0.23260128,deposits,0.41900253,deposits,0.41900253
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal-antibodies,0.20204918,plaque-deposits,0.39864457,plaque-deposits,0.39864457
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,marked,0.29036337,of,0.5952639,deposits,0.43943986
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,including,0.2742056,of,0.6619886,congenital,0.3605199
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,non,0.3477749,with,0.61364555,mi,0.46788454
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,primates,0.26833218,of,0.44591445,l-transposition,0.39368346
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic-studies,0.3437402,congenital-heart-disease,0.49969178,congenital-heart-disease,0.49969178
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function,0.2605439,of,0.55099833,flow,0.43324804
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,mutations,0.2006272,defect,0.46113265,congenital,0.42577744
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function-mutations,0.21500018,defect,0.43890125,l-transposition,0.4250971
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,experimental-evidence,0.28622484,of,0.48998067,congenital-heart-disease,0.44089335
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ltd,0.19889542,arrythmia,0.2606184,arrythmia,0.2606184
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,fasting,0.2756939,cholesterol,0.55686736,cholesterol,0.55686736
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,efficacy,0.20913124,of,0.47294754,lai,0.34146488
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,profile,0.19752568,of,0.5464045,flow,0.39967984
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,conclusive,0.305431,weak,0.49186498,anomaly,0.3753593
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,data,0.31118363,of,0.5086956,mi,0.36251363
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherogenic,0.31320724,cholesterol,0.67366207,cholesterol,0.67366207
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,dyslipidemias,0.4157706,chd,0.61045533,chd,0.61045533
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,apparently,0.2614608,of,0.6490056,l-transposition,0.48902217
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,animal,0.31228805,of,0.5431563,congenital-heart-disease,0.397049
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,animal-models,0.30730113,congenital-heart-disease,0.41481268,congenital-heart-disease,0.41481268
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,term-treatment,0.24493195,of,0.45787826,heart-failure,0.43962112
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,head,0.3349005,left,0.45687342,cardiac,0.357728
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,beyond,0.29394823,of,0.53781354,anomaly,0.34910303
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,low,0.33154353,with,0.5951388,flow,0.4108625
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich,0.21856433,deposits,0.47216946,deposits,0.47216946
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins,0.24732636,cholesterol,0.7522421,cholesterol,0.7522421
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich-lipoproteins,0.26328117,cholesterol,0.71565497,cholesterol,0.71565497
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.15734789,cholesterol,0.55069435,cholesterol,0.55069435
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,c,0.21239448,with,0.46990636,ivs,0.34813386
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lpl,0.1658878,cholesterol,0.5344877,cholesterol,0.5344877
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich,0.21856433,deposits,0.47216946,deposits,0.47216946
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,low,0.33154353,with,0.5951388,flow,0.4108625
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins,0.24732636,cholesterol,0.7522421,cholesterol,0.7522421
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,head,0.3349005,left,0.45687342,cardiac,0.357728
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,way,0.312438,of,0.5753952,anomalous,0.40993068
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,vldl,0.20742606,cholesterol,0.7049568,cholesterol,0.7049568
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,triglycerides,0.27892497,cholesterol,0.8155755,cholesterol,0.8155755
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,short,0.27641132,interrupted,0.5895587,d-transposition,0.38685596
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,safety,0.34595427,with,0.43122858,venous-return,0.3475874
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,remnants,0.2393628,deposits,0.5874132,deposits,0.5874132
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,relevance,0.3301295,of,0.5866257,congenital-heart-disease,0.34820747
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,regulating,0.24088989,of,0.5106726,anomalous,0.33040386
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,proven,0.2408872,with,0.550977,deposits,0.38689238
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,post,0.3914922,failure,0.52308416,mi,0.5076717
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,paved,0.3405935,great,0.6006109,single-ventricle,0.34355652
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,order,0.35672373,of,0.59467053,anomalous,0.37882286
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,modest,0.28656474,weak,0.54754966,bradycardia,0.3726757
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lrx,0.19105911,heart-failure,0.34681034,heart-failure,0.34681034
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,inhibition,0.21149129,of,0.51645476,contractions,0.42180917
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,independent,0.28915384,of,0.5904635,cad,0.4052443
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,indeed,0.2966041,of,0.64832246,l-transposition,0.40985703
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hypertriglyceridemia,0.3260976,cholesterol,0.6679379,cholesterol,0.6679379
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hydrolysis,0.13911352,contractions,0.4181497,contractions,0.4181497
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,humans,0.21283677,of,0.49299914,congenital-heart-disease,0.41938835
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,high,0.28122714,of,0.57459104,flow,0.3923195
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,found,0.2675444,with,0.6275196,deposits,0.41920424
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,former,0.3340419,of,0.5781311,mi,0.40843457
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,development,0.2877805,of,0.53581744,congenital,0.35419804
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,determinants,0.26580477,of,0.5299541,l-transposition,0.35732794
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,define,0.26571727,of,0.514004,anomaly,0.3117352
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cluster,0.23890439,of,0.42209566,mi,0.3468751
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,carriers,0.16960272,defect,0.36674175,chd,0.35253507
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angiopoietin,0.22269033,coronary-thrombosis,0.44044876,coronary-thrombosis,0.44044876
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,among,0.2573181,of,0.57348,chd,0.4274787
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3365241,with,0.4216323,cad,0.40088844
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,epithelial,0.16618782,of,0.3820966,atresia,0.37996423
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,acquire,0.20654312,of,0.46555445,congenital-heart,0.34617162
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,malignant,0.30670902,congenital,0.5068618,congenital,0.5068618
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,properties,0.16694331,of,0.4979031,anomalous,0.43609905
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-epithelial,0.24323511,congenital,0.40235752,congenital,0.40235752
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,epithelial-cells,0.15732202,blood-clot,0.36690652,blood-clot,0.36690652
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,approved,0.43221807,with,0.4535135,cardiology,0.43221807
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,targeting,0.23901626,of,0.47927672,l-transposition,0.3053895
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,approved-drug,0.433768,cardiology,0.433768,cardiology,0.433768
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,drug-targeting,0.22422144,great,0.36890054,congestive-heart-failure,0.30086887
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,combined,0.24027641,with,0.60924613,single-ventricle,0.4029721
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,mouse-model,0.15569708,congenital-heart-disease,0.38479128,congenital-heart-disease,0.38479128
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3365241,with,0.4216323,cad,0.40088844
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,human-breast,0.2724455,congenital-heart-disease,0.42750192,congenital-heart-disease,0.42750192
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.27508703,chd,0.40747812,chd,0.40747812
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3365241,with,0.4216323,cad,0.40088844
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,oncogene,0.23249717,l-transposition,0.34462073,l-transposition,0.34462073
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.27508703,chd,0.40747812,chd,0.40747812
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cancer-oncogene,0.2208263,disease,0.33794722,congenital-heart-disease,0.32520095
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3365241,with,0.4216323,cad,0.40088844
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.27508703,chd,0.40747812,chd,0.40747812
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cancer-associated,0.24102859,thrombosis,0.43263745,thrombosis,0.43263745
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer-associated,0.2749531,congenital-heart-disease,0.43119282,congenital-heart-disease,0.43119282
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3365241,with,0.4216323,cad,0.40088844
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,leading,0.25149748,of,0.59935343,congenital,0.40424997
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-tissue,0.29335016,congenital-heart,0.4201888,congenital-heart,0.4201888
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,donors,0.23155941,blood,0.42794293,blood,0.42794293
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,healthy-donors,0.22354674,congenital-heart-disease,0.4595778,congenital-heart-disease,0.4595778
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,tumour,0.20177953,of,0.39267477,clot,0.37704173
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,formation,0.20900506,of,0.50848174,deposits,0.47041997
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,vivo-tumour,0.15277518,blood-flow,0.39859912,blood-flow,0.39859912
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,tumour-formation,0.19125713,of,0.4800616,clot,0.41285864
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,serine,0.18330798,of,0.4176953,l-transposition,0.29880375
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,biosynthesis,0.21604595,l-transposition,0.3989579,l-transposition,0.3989579
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,serine-biosynthesis,0.19190824,l-transposition,0.4184784,l-transposition,0.4184784
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,biosynthesis-pathway,0.22639284,l-transposition,0.41025734,l-transposition,0.41025734
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,strategy,0.23048541,of,0.44841248,heart-attack,0.36277908
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,potential-therapeutic,0.3533869,great,0.45943362,heart-failure,0.4459909
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,considered,0.31302214,as,0.6929809,anomaly,0.43040824
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,responsible,0.22934824,of,0.5890902,congenital,0.37629318
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,connecting,0.21818273,interrupted,0.5068086,anomalous,0.41323483
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.37162852,chd,0.5639055,chd,0.5639055
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,pathway-connecting,0.20338719,interrupted,0.44094735,atrioventricular-septal-defect,0.4222564
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,grade,0.29756713,stenosis,0.4388027,stenosis,0.4388027
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,chronic-inflammation,0.20188652,disease,0.47903967,artery-disease,0.45320863
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3365241,with,0.4216323,cad,0.40088844
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.27508703,chd,0.40747812,chd,0.40747812
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,pharmacological,0.32797652,of,0.48491696,congestive-heart-failure,0.37223655
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,medium,0.23654787,of,0.43677273,cholesterol,0.3498541
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,conditioned,0.20121402,with,0.38909957,heart-attack,0.33657008
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,medium-conditioned,0.1940938,isolated,0.38102657,plaque-deposits,0.3291766
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,infiltrate,0.29913652,congestive,0.49980125,congestive,0.49980125
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,macrophages-derived,0.2209871,plaque-deposits,0.4536218,plaque-deposits,0.4536218
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.37162852,chd,0.5639055,chd,0.5639055
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,induced-obesity,0.2628126,chd,0.42859554,chd,0.42859554
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,homologue,0.16368301,isolated,0.43139672,l-transposition,0.39772302
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,formally,0.37392902,as,0.5286151,isomerism,0.3918404
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,fat,0.23246992,cholesterol,0.5448952,cholesterol,0.5448952
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,diet,0.35792264,cholesterol,0.47536165,cholesterol,0.47536165
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,fat-diet,0.2265124,cholesterol,0.4891073,cholesterol,0.4891073
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,driven,0.27247697,of,0.47781104,flow,0.40639967
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,downstream,0.20581535,of,0.42049676,l-transposition,0.37191287
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,target,0.23866604,of,0.4775706,blood,0.34112448
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,downstream-target,0.19932845,of,0.4245483,flow,0.38293615
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cellular,0.25397572,of,0.55018497,cardiac,0.40519243
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,metabolism,0.25317088,cholesterol,0.4435029,cholesterol,0.4435029
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cellular-metabolism,0.20877895,of,0.4459352,blood-flow,0.42916596
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,license,0.27964944,return,0.32606816,cardiology,0.27964944
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,higher,0.2654187,with,0.56796193,mi,0.398535
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,higher-risk,0.36496794,chd,0.5293444,chd,0.5293444
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.37162852,chd,0.5639055,chd,0.5639055
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,validated,0.27360892,of,0.4456607,cad,0.31460553
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,terms,0.2606851,as,0.559343,anomalous,0.40301287
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,reduce,0.22618136,of,0.4876061,heart-attack,0.3512283
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,mediated,0.18597665,of,0.5168716,contractions,0.37430054
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,low,0.33154353,with,0.5951388,flow,0.4108625
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,link,0.22664402,of,0.4376548,anomalous,0.34481645
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,high,0.28122714,of,0.57459104,flow,0.3923195
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,furthermore,0.18322246,of,0.5529862,plaque-deposits,0.34174067
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,finally,0.32854706,of,0.64012104,flow,0.39903617
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,fda,0.30979252,cardiology,0.30979252,cardiology,0.30979252
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,exposed,0.16702625,with,0.4779149,deposits,0.34760392
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,delayed,0.2475737,premature,0.5037098,anomalous,0.41196683
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,cc,0.28546643,with,0.41332918,ivs,0.39370883
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,amlexanox,0.17828146,contractions,0.28956428,contractions,0.28956428
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,altogether,0.20425558,of,0.46309736,l-transposition,0.3253976
Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway.,alteration,0.22564441,abnormal,0.63321257,anomaly,0.4587403
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,smart,0.30151582,great,0.4456077,venous-return,0.38551843
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,clothing,0.28826642,return,0.44498426,venous-return,0.37871403
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,targeting,0.23901626,of,0.47927672,l-transposition,0.3053895
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,high,0.28122714,of,0.57459104,flow,0.3923195
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,smart-clothing,0.3302451,venous-return,0.529163,venous-return,0.529163
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,system-targeting,0.25445718,of,0.40435976,heart-attack,0.3201995
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.34567022,great,0.44040805,cardiology,0.34567022
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mostly,0.33714116,of,0.58262587,deposits,0.46328008
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,target,0.23866604,of,0.4775706,blood,0.34112448
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.34109476,heart-failure,0.49915606,heart-failure,0.49915606
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.23809892,congenital-heart-disease,0.49235433,congenital-heart-disease,0.49235433
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,external,0.29746136,of,0.4755252,anomalous,0.3880807
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,using,0.20786116,with,0.58010674,flow,0.41007757
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,healthcare,0.47028068,cardiology,0.47028068,cardiology,0.47028068
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.34567022,great,0.44040805,cardiology,0.34567022
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,e,0.21868992,double,0.39788574,eb,0.38260236
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,anxiety,0.40205312,arrythmia,0.4905852,arrythmia,0.4905852
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.34505993,incompetence,0.48034143,heartbeat,0.4160184
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ubiquity,0.2735237,great,0.523538,l-transposition,0.34054774
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,construct,0.15341623,of,0.38565916,l-transposition,0.34442246
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,affects,0.1426264,of,0.5773267,anomaly,0.35788298
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearing,0.28664222,stiff,0.47228703,valve,0.3891998
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,smart,0.30151582,great,0.4456077,venous-return,0.38551843
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,clothes,0.27136445,return,0.40078035,arrythmia,0.31380385
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,sensor,0.18712729,great,0.36468887,heartbeat,0.3623
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.34567022,great,0.44040805,cardiology,0.34567022
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,represent,0.22206968,as,0.5763198,anomaly,0.3441872
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,sensor-technologies,0.35142928,venous-return,0.40532687,venous-return,0.40532687
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,including,0.2742056,of,0.6619886,congenital,0.3605199
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.34109476,heart-failure,0.49915606,heart-failure,0.49915606
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.23809892,congenital-heart-disease,0.49235433,congenital-heart-disease,0.49235433
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,using,0.20786116,with,0.58010674,flow,0.41007757
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,new-technology,0.46442446,cardiology,0.46442446,cardiology,0.46442446
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,hypothesized,0.21486883,of,0.5337665,anomalous,0.37173486
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,showed,0.21619865,with,0.57298803,flow,0.33828264
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,everyday,0.41402903,cardiology,0.41402903,cardiology,0.41402903
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,health-conditions,0.3067814,heart-disease,0.48502597,heart-disease,0.48502597
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,continuously,0.3186061,with,0.5311652,flow,0.48736566
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,recording,0.32492998,heartbeat,0.5129333,heartbeat,0.5129333
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,people,0.32132432,chd,0.4550472,chd,0.4550472
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,continuously-recording,0.29158434,heartbeat,0.52908516,heartbeat,0.52908516
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,among,0.2573181,of,0.57348,chd,0.4274787
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.34109476,heart-failure,0.49915606,heart-failure,0.49915606
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.23809892,congenital-heart-disease,0.49235433,congenital-heart-disease,0.49235433
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mobile,0.2783955,flow,0.38479,flow,0.38479
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wireless,0.31808507,heartbeat,0.47144055,heartbeat,0.47144055
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.34567022,great,0.44040805,cardiology,0.34567022
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mobile-wireless,0.29432547,venous-return,0.5010488,venous-return,0.5010488
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,acceptance,0.37556833,of,0.44270635,heart-failure,0.39365697
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology-acceptance,0.43984002,cardiology,0.43984002,cardiology,0.43984002
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,acceptance,0.37556833,of,0.44270635,heart-failure,0.39365697
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavior,0.1827973,of,0.47683254,anomalous,0.44146252
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology-acceptance,0.43984002,cardiology,0.43984002,cardiology,0.43984002
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,determining,0.24776678,of,0.6342732,anomalous,0.40420768
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.34109476,heart-failure,0.49915606,heart-failure,0.49915606
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.2883557,congestive-heart-failure,0.38387084,congestive-heart-failure,0.38387084
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.34109476,heart-failure,0.49915606,heart-failure,0.49915606
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.23809892,congenital-heart-disease,0.49235433,congenital-heart-disease,0.49235433
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,anxiety,0.40205312,arrythmia,0.4905852,arrythmia,0.4905852
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.34505993,incompetence,0.48034143,heartbeat,0.4160184
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ubiquity,0.2735237,great,0.523538,l-transposition,0.34054774
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable-devices,0.32403013,venous-return,0.47007155,venous-return,0.47007155
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,outpatients,0.4732141,cardiology,0.4732141,cardiology,0.4732141
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,relationships,0.21836808,of,0.44386625,anomalous,0.36739582
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,among,0.2573181,of,0.57348,chd,0.4274787
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.34505993,incompetence,0.48034143,heartbeat,0.4160184
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,usefulness,0.313766,of,0.48999286,coronary-artery-disease,0.3281965
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.34505993,incompetence,0.48034143,heartbeat,0.4160184
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ease,0.28369248,great,0.5234586,flow,0.39648485
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,user,0.31136972,venous-return,0.3720078,venous-return,0.3720078
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,groups,0.2612025,with,0.4941169,mi,0.3908207
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,user-groups,0.25950748,venous-return,0.36759695,venous-return,0.36759695
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,traditional,0.2995602,of,0.44896448,congestive-heart-failure,0.34226936
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,components,0.22271727,of,0.54551816,deposits,0.4215029
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,original,0.28927177,of,0.5401661,lai,0.40495938
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,constructs,0.1528165,stiff,0.38277417,l-transposition,0.32511675
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,negative,0.26947153,abnormal,0.48861286,blood,0.4176938
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,negative-effect,0.24999653,weak,0.4627537,heart-syndrome,0.3446836
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,may,0.26963884,of,0.58654004,anomalous,0.366544
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,enhance,0.2036996,of,0.49939367,flow,0.2972427
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,indirect,0.1473389,of,0.4198127,flow,0.36918765
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,indirect-effect,0.17480132,single,0.45434004,venous-return,0.3845134
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,biomedical,0.45757556,great,0.52482384,cardiology,0.45757556
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,signals,0.2345418,heartbeat,0.4749927,heartbeat,0.4749927
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavioral,0.28967425,of,0.41226506,bradycardia,0.38596666
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,intention,0.3008074,incompetence,0.47250608,heartbeat,0.37782234
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavioral-intention,0.29808137,venous-return,0.47187585,venous-return,0.47187585
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,affect,0.19231161,of,0.50835335,anomalous,0.31428474
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.2883557,congestive-heart-failure,0.38387084,congestive-heart-failure,0.38387084
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.23079486,lai,0.3595717,lai,0.3595717
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,extended,0.22422087,of,0.53787327,anomalous,0.39536422
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.23079486,lai,0.3595717,lai,0.3595717
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,extended-tam,0.19757973,venous-return,0.37699354,venous-return,0.37699354
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,risk-patients,0.37887704,heart-failure,0.57082677,heart-failure,0.57082677
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.36259568,great,0.43602386,cardiology,0.36259568
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wireless,0.31808507,heartbeat,0.47144055,heartbeat,0.47144055
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.2883557,congestive-heart-failure,0.38387084,congestive-heart-failure,0.38387084
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.23079486,lai,0.3595717,lai,0.3595717
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,validity,0.29181236,incompetence,0.38455218,venous-return,0.37441024
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,validated,0.27360892,of,0.4456607,cad,0.31460553
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,use,0.3219829,with,0.55726266,flow,0.40877783
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,understanding,0.3158453,great,0.5292363,anomalous,0.3759449
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,shown,0.20708838,of,0.5506151,l-transposition,0.3662261
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,results,0.29712585,of,0.53157276,blood,0.36869162
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,resistance,0.17926447,failure,0.42967105,d-transposition,0.40630686
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perception,0.31935233,heartbeat,0.49431077,heartbeat,0.49431077
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,obtain,0.32854,return,0.5372094,flow,0.39961314
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,interestingly,0.14391269,of,0.49645597,septal-defect,0.34386393
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,given,0.43020725,with,0.60330975,cardiology,0.43020725
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,general,0.45452207,of,0.5577996,cardiology,0.45452207
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,found,0.2675444,with,0.6275196,deposits,0.41920424
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,examine,0.30142456,of,0.5306053,cardiac,0.31194437
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,considered,0.31302214,as,0.6929809,anomaly,0.43040824
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,confirm,0.2632276,of,0.48014945,anomalous,0.34633434
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,characteristic,0.14630476,of,0.52064013,anomalous,0.42846608
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,change,0.3422248,of,0.5410254,flow,0.4111107
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,attitude,0.3436948,incompetence,0.4568861,congenital-heart-disease,0.4002452
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,advances,0.40024865,great,0.516971,cardiology,0.40024865
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,yet,0.32307938,as,0.52449846,cardiac,0.34347042
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,less,0.30277786,with,0.57537794,mi,0.38854462
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,met,0.3956383,with,0.43774676,cardiology,0.3956383
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.23698471,with,0.3629063,mi,0.3521915
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,met-f,0.088155046,single,0.26822257,blood-clot,0.24751191
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,four,0.26703352,of,0.57211214,d-transposition,0.35247436
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,thousand,0.28758052,total,0.4058061,beats,0.33699852
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hundred,0.2470684,total,0.3391304,d-transposition,0.30498838
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,thirty,0.23964897,isolated,0.3792717,artery,0.32498515
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,four-thousand,0.28801212,single,0.48054838,anomaly,0.39364052
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,thousand-three,0.22557962,single,0.47062182,d-transposition,0.37853128
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three-hundred,0.2595011,total,0.3971603,double-outlet,0.32139283
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hundred-thirty,0.24617845,d-transposition,0.3619439,d-transposition,0.3619439
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three-hundred-thirty,0.24619542,total,0.38137135,congenital-heart-disease,0.34162447
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,population,0.3190225,of,0.49866888,chd,0.40046495
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reporting,0.3682378,of,0.5139481,cardiology,0.3682378
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.26892817,cholesterol,0.48854637,cholesterol,0.48854637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.22118965,of,0.38525122,heartbeat,0.35453492
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nationally,0.40319204,chd,0.40529603,chd,0.40529603
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,representative,0.28836513,of,0.5635697,heart-attack,0.2974549
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,surveys,0.3482949,return,0.3625318,cardiology,0.3482949
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nationally-representative,0.36028463,of,0.42714164,congenital-heart-disease,0.42137337
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,males,0.27325124,chd,0.43028116,chd,0.43028116
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reported,0.2535432,of,0.6039252,l-transposition,0.37000108
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.26424953,of,0.4497146,mi,0.43278512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.26424953,of,0.4497146,mi,0.43278512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,meeting,0.617699,cardiology,0.617699,cardiology,0.617699
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,factors,0.24127257,of,0.49770784,chd,0.4172811
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd-risk,0.32460088,chd,0.6882602,chd,0.6882602
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk-factors,0.34496874,chd,0.61294127,chd,0.61294127
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt,0.19241512,cholesterol,0.36400923,cholesterol,0.36400923
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,use,0.3219829,with,0.55726266,flow,0.40877783
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.16569161,of,0.44472158,anomalous,0.39944327
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt-use,0.24018967,outlet,0.3627594,congestive-heart-failure,0.35453606
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.26892817,cholesterol,0.48854637,cholesterol,0.48854637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.22118965,of,0.38525122,heartbeat,0.35453492
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.26892817,cholesterol,0.48854637,cholesterol,0.48854637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.22118965,of,0.38525122,heartbeat,0.35453492
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours-related,0.28726667,of,0.4317839,congenital-heart-disease,0.3641588
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.22118965,of,0.38525122,heartbeat,0.35453492
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increases,0.258173,of,0.61963964,contractions,0.41607368
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,generalized,0.255516,with,0.47991234,deposits,0.3816749
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,linear,0.17840835,of,0.40123588,isomerism,0.35944843
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,generalized-linear,0.22713119,weak,0.42512012,venous-return,0.39133936
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.26892817,cholesterol,0.48854637,cholesterol,0.48854637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.16569161,of,0.44472158,anomalous,0.39944327
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,measurements,0.27821797,blood-flow,0.45775104,blood-flow,0.45775104
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,factors,0.24127257,of,0.49770784,chd,0.4172811
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd-risk,0.32460088,chd,0.6882602,chd,0.6882602
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk-factors,0.34496874,chd,0.61294127,chd,0.61294127
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,varying,0.23989387,of,0.6121373,anomalous,0.39641
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle,0.2588615,right,0.5402423,artery,0.5249288
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,income,0.33299255,chd,0.44654772,chd,0.44654772
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.35801637,congenital-heart-disease,0.39221284,congenital-heart-disease,0.39221284
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle-income,0.33562547,chd,0.43083435,chd,0.43083435
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,income-countries,0.3296476,chd,0.43530706,chd,0.43530706
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle-income-countries,0.3147507,congenital-heart-disease,0.43507746,congenital-heart-disease,0.43507746
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable,0.24309167,cholesterol,0.418402,cholesterol,0.418402
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,oil,0.19941315,cholesterol,0.44938076,cholesterol,0.44938076
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,rather,0.27469805,of,0.6500968,anomalous,0.42468947
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable-oil,0.15107292,cholesterol,0.41510105,cholesterol,0.41510105
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,understand,0.30193475,great,0.4775984,anomalous,0.3542228
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,associations,0.28502855,chd,0.42755333,chd,0.42755333
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,would,0.35497403,of,0.55908126,flow,0.3796509
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,change,0.3422248,of,0.5410254,flow,0.4111107
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,p,0.29391026,with,0.4559728,congestive,0.4058217
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.26892817,cholesterol,0.48854637,cholesterol,0.48854637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.22118965,of,0.38525122,heartbeat,0.35453492
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.26892817,cholesterol,0.48854637,cholesterol,0.48854637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.16569161,of,0.44472158,anomalous,0.39944327
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,meeting,0.617699,cardiology,0.617699,cardiology,0.617699
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.23698471,with,0.3629063,mi,0.3521915
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd-risk,0.32460088,chd,0.6882602,chd,0.6882602
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,subs,0.2444211,of,0.45519,deposits,0.39868647
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,manner,0.18540666,with,0.42496896,contractions,0.388913
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,poor,0.30703533,weak,0.56499845,congestive,0.42275512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.26424953,of,0.4497146,mi,0.43278512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,understand,0.30193475,great,0.4775984,anomalous,0.3542228
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increase,0.32113555,of,0.60061187,flow,0.4086165
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.23698471,with,0.3629063,mi,0.3521915
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,seven,0.24791667,of,0.554788,d-transposition,0.37799773
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.35801637,congenital-heart-disease,0.39221284,congenital-heart-disease,0.39221284
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,seven-countries,0.35439396,congenital-heart-disease,0.41225243,congenital-heart-disease,0.41225243
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,waist,0.28936046,cholesterol,0.47848698,cholesterol,0.47848698
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,circumference,0.2431153,chd,0.45483646,chd,0.45483646
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,waist-circumference,0.22281581,aortic-stenosis,0.43754733,aortic-stenosis,0.43754733
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgently,0.44090644,great,0.4754014,cardiology,0.44090644
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,needed,0.42938864,as,0.567801,cardiology,0.42938864
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgently-needed,0.4690665,return,0.55675256,venous-return,0.477359
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgent,0.5043684,cardiology,0.5043684,cardiology,0.5043684
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,action,0.29916856,of,0.5591097,contractions,0.50062907
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,two-participants,0.3402863,chd,0.44794947,chd,0.44794947
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,st,0.46681005,mi,0.5837832,mi,0.5837832
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vincent,0.45711547,cardiology,0.45711547,cardiology,0.45711547
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,st-vincent,0.5071159,cardiology,0.5071159,cardiology,0.5071159
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,small,0.28269485,great,0.5440953,deposits,0.39470115
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,proportion,0.23363663,total,0.537244,chd,0.3531295
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,small-proportion,0.27154443,single,0.5057373,venous-return,0.4718212
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,differences,0.24501437,of,0.48845208,anomalous,0.3514788
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex-differences,0.24606878,congenital-heart-disease,0.47222885,congenital-heart-disease,0.47222885
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nutrition,0.4216472,cardiology,0.4216472,cardiology,0.4216472
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,transition,0.26457083,of,0.45053744,anomalous,0.41481292
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,notably,0.28817534,of,0.64324886,deposits,0.40474877
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,lmic,0.3630936,single-ventricle,0.41794282,single-ventricle,0.41794282
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,leading,0.25149748,of,0.59935343,congenital,0.40424997
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,causes,0.22412287,of,0.55089116,congenital,0.49946666
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interaction,0.23807403,weak,0.5032127,isomerism,0.33030224
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,terms,0.2606851,as,0.559343,anomalous,0.40301287
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interaction-terms,0.24704547,of,0.44692641,congenital-heart-disease,0.43085992
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.35801637,congenital-heart-disease,0.39221284,congenital-heart-disease,0.39221284
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diets,0.24828126,cholesterol,0.44488218,cholesterol,0.44488218
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high,0.28122714,of,0.57459104,flow,0.3923195
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diagnosed,0.34882253,congenital,0.5294275,congenital,0.5294275
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diagnosed-hypertension,0.43189114,congestive-heart-failure,0.5828515,congestive-heart-failure,0.5828515
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cardiovascular-diseases,0.51660174,heart-disease,0.6925421,heart-disease,0.6925421
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,animal,0.31228805,of,0.5431563,congenital-heart-disease,0.397049
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fats,0.27169007,cholesterol,0.6105091,cholesterol,0.6105091
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,animal-fats,0.32005116,heart-disease,0.43589592,heart-disease,0.43589592
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,aid,0.30282542,of,0.5167762,anomaly,0.38754576
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,identification,0.20758381,of,0.5418171,d-transposition,0.3482393
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,0.240002,sv,0.44191512,sv,0.44191512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,intake,0.30005762,total,0.41514692,cholesterol,0.39030063
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.33106,congenital,0.5943837,congenital,0.5943837
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed-hypertension,0.42406446,congestive-heart-failure,0.6030434,congestive-heart-failure,0.6030434
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increasing,0.35820884,of,0.6603997,flow,0.41165438
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.25545907,disease,0.43233684,chd,0.4308555
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,data,0.31118363,of,0.5086956,mi,0.36251363
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher,0.2654187,with,0.56796193,mi,0.398535
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.25545907,disease,0.43233684,chd,0.4308555
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher-prevalence,0.3099206,chd,0.46114513,chd,0.46114513
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high,0.28122714,of,0.57459104,flow,0.3923195
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,wc,0.13868302,chd,0.40999746,chd,0.40999746
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high-wc,0.16856556,plaque-deposits,0.37236416,plaque-deposits,0.37236416
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,effective,0.20873946,as,0.5165305,contractions,0.33001167
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interventions,0.4352363,coronary,0.4378809,coronary,0.4378809
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,0.240002,sv,0.44191512,sv,0.44191512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recommendations,0.55450773,cardiology,0.55450773,cardiology,0.55450773
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.33106,congenital,0.5943837,congenital,0.5943837
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reporting,0.3682378,of,0.5139481,cardiology,0.3682378
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.23698471,with,0.3629063,mi,0.3521915
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,use,0.3219829,with,0.55726266,flow,0.40877783
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt,0.19241512,cholesterol,0.36400923,cholesterol,0.36400923
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,males,0.27325124,chd,0.43028116,chd,0.43028116
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable,0.24309167,cholesterol,0.418402,cholesterol,0.418402
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,p,0.29391026,with,0.4559728,congestive,0.4058217
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,0.240002,sv,0.44191512,sv,0.44191512
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.33106,congenital,0.5943837,congenital,0.5943837
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.25545907,disease,0.43233684,chd,0.4308555
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,wc,0.13868302,chd,0.40999746,chd,0.40999746
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recommendations,0.55450773,cardiology,0.55450773,cardiology,0.55450773
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interventions,0.4352363,coronary,0.4378809,coronary,0.4378809
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,women,0.355409,chd,0.4926289,chd,0.4926289
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetables,0.247134,chd,0.34594446,chd,0.34594446
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,value,0.3260533,of,0.52001536,flow,0.37269968
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,used,0.23211285,as,0.56584436,flow,0.35934073
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,twenty,0.24703324,with,0.39586556,d-transposition,0.336575
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,trend,0.33671963,great,0.4239449,flow,0.38420233
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sugar,0.2304321,cholesterol,0.47782528,cholesterol,0.47782528
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sexes,0.27026105,chd,0.4305882,chd,0.4305882
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reverse,0.24697368,flow,0.43068266,flow,0.43068266
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,results,0.29712585,of,0.53157276,blood,0.36869162
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,required,0.3213837,of,0.603855,l-transposition,0.3821326
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,parallel,0.21132064,double,0.5125164,flow,0.40946773
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nepal,0.32752794,great,0.34510684,rai,0.33297783
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,need,0.48421922,as,0.52987695,cardiology,0.48421922
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,men,0.36483365,chd,0.51057327,chd,0.51057327
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,low,0.33154353,with,0.5951388,flow,0.4108625
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,lmics,0.3762823,chd,0.41844082,chd,0.41844082
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,limited,0.29959464,of,0.6210327,deposits,0.40452772
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,kenya,0.2281538,paivs,0.32173717,paivs,0.32173717
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,investigated,0.19995229,of,0.6179704,anomalous,0.35378093
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,investigate,0.20519872,of,0.48247698,anomalous,0.30501914
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interactions,0.26582682,weak,0.48503923,isomerism,0.3771425
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,identifies,0.21676883,of,0.5022933,anomaly,0.33015844
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,however,0.30646515,of,0.624624,mi,0.41109186
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,guyana,0.34393597,truncus,0.37050128,truncus,0.37050128
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,grenadines,0.36832607,attack,0.4154122,heart-attack,0.402088
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,georgia,0.37862462,cardiology,0.37862462,cardiology,0.37862462
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,females,0.2732723,chd,0.41056532,chd,0.41056532
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fat,0.23246992,cholesterol,0.5448952,cholesterol,0.5448952
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,eswatini,0.41050476,cardiology,0.41050476,cardiology,0.41050476
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diet,0.35792264,cholesterol,0.47536165,cholesterol,0.47536165
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dataset,0.29588008,single,0.35144186,heartbeat,0.33722848
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,crucial,0.22890398,of,0.48424307,anomalous,0.3442307
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,country,0.42060405,disease,0.42175156,cardiology,0.42060405
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cooking,0.24116373,return,0.3541328,clot,0.31435534
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,bhutan,0.28554052,paivs,0.35295734,paivs,0.35295734
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,background,0.2325702,of,0.51277274,congenital,0.3895001
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,association,0.34312242,of,0.45371312,chd,0.39406395
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,added,0.39393532,with,0.6052638,cardiology,0.39393532
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plus,0.23337662,with,0.5874793,mi,0.38566378
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",norethisterone,0.23825249,cholesterol,0.45403922,cholesterol,0.45403922
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",acetate,0.16104199,with,0.35273406,cholesterol,0.35136923
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",daily,0.3620783,single,0.43283373,heartbeat,0.36777166
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",norethisterone-acetate,0.19035912,cholesterol,0.3934596,cholesterol,0.3934596
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",enriched,0.20288235,isolated,0.518345,deposits,0.38186842
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",subfraction,0.21380755,cholesterol,0.51231813,cholesterol,0.51231813
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",p,0.29391026,with,0.4559728,congestive,0.4058217
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.20859355,eb,0.34265935,eb,0.34265935
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lowered,0.26918596,with,0.5560069,cholesterol,0.45384544
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",total,0.22796647,total,0.9999999,cholesterol,0.4162783
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",concentrations,0.20313622,with,0.46930897,deposits,0.43182394
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",relative,0.20736288,of,0.6192827,mi,0.3804497
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma-total,0.1666316,total,0.57216996,blood-clot,0.4718595
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",total-cholesterol,0.25385433,cholesterol,0.87798285,cholesterol,0.87798285
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous,0.27512568,of,0.5723764,flow,0.484856
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",combined,0.24027641,with,0.60924613,single-ventricle,0.4029721
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",oestrogen,0.19520926,cholesterol,0.40978914,cholesterol,0.40978914
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plus,0.23337662,with,0.5874793,mi,0.38566378
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",progestogen,0.23940417,cholesterol,0.3808751,cholesterol,0.3808751
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous-combined,0.22766432,single,0.5239747,single-ventricle,0.45241475
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",combined-oestrogen,0.24706453,coronary-artery-disease,0.4220863,coronary-artery-disease,0.4220863
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",three,0.27802917,of,0.6048713,l-transposition,0.36917683
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",groups,0.2612025,with,0.4941169,mi,0.3908207
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",taking,0.4000069,with,0.54144406,cardiology,0.4000069
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",daily,0.3620783,single,0.43283373,heartbeat,0.36777166
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",three-groups,0.23971218,congestive-heart-failure,0.38256967,congestive-heart-failure,0.38256967
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",groups-taking,0.3262099,with,0.42353565,congestive-heart-failure,0.379984
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",suggesting,0.18459891,of,0.6157647,l-transposition,0.40478194
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",decreased,0.2912292,of,0.59706545,flow,0.4062525
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",loading,0.27387077,of,0.47450465,flow,0.45791614
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol-loading,0.2632799,cholesterol,0.80432534,cholesterol,0.80432534
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ai,0.21328095,rai,0.46950763,rai,0.46950763
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein-ai,0.22297347,cholesterol,0.7021296,cholesterol,0.7021296
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.20859355,eb,0.34265935,eb,0.34265935
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduces,0.1488205,of,0.53557026,heart-attack,0.33165377
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl-cholesterol,0.31078634,cholesterol,0.8532057,cholesterol,0.8532057
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.21118185,cholesterol,0.4333404,cholesterol,0.4333404
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduces,0.1488205,of,0.53557026,heart-attack,0.33165377
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum,0.2084733,cholesterol,0.504964,cholesterol,0.504964
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum-hdl,0.17631008,cholesterol,0.5916157,cholesterol,0.5916157
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",principal,0.23827076,of,0.51180303,anomalous,0.35342324
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein,0.17386194,of,0.4756804,cholesterol,0.3740363
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",component,0.2266389,of,0.52326363,deposits,0.38395098
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl-protein,0.28782326,cholesterol,0.6689555,cholesterol,0.6689555
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein-component,0.21428004,of,0.4796583,cholesterol,0.38693514
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",similarly,0.2457779,with,0.6309897,contractions,0.41134822
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",diminished,0.25230643,weak,0.58167773,congestive,0.40550786
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",relative,0.20736288,of,0.6192827,mi,0.3804497
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduced,0.22478527,of,0.6221848,contractions,0.3818075
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous,0.27512568,of,0.5723764,flow,0.484856
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",oral,0.3003844,of,0.46959797,plaque,0.38315025
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",oestradiol,0.18415761,cholesterol,0.45961508,cholesterol,0.45961508
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",concentrations,0.20313622,with,0.46930897,deposits,0.43182394
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",measured,0.2266986,of,0.539739,flow,0.4470259
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein-concentrations,0.2787572,cholesterol,0.69177085,cholesterol,0.69177085
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.21118185,cholesterol,0.4333404,cholesterol,0.4333404
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.20859355,eb,0.34265935,eb,0.34265935
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduced,0.22478527,of,0.6221848,contractions,0.3818075
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",main,0.28808993,of,0.60433525,anomalous,0.4090495
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",outcome,0.27011925,failure,0.48584157,single-ventricle,0.45794576
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",measures,0.2977168,of,0.4417776,venous-return,0.3984164
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",main-outcome,0.32521546,coronary-artery-disease,0.4872965,coronary-artery-disease,0.4872965
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",outcome-measures,0.38513947,venous-return,0.54144794,venous-return,0.54144794
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",fasting,0.2756939,cholesterol,0.55686736,cholesterol,0.55686736
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum,0.2084733,cholesterol,0.504964,cholesterol,0.504964
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",fasting-serum,0.19112274,cholesterol,0.44550878,cholesterol,0.44550878
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum-lipid,0.20699352,cholesterol,0.61733764,cholesterol,0.61733764
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cvd,0.31066263,chd,0.7323322,chd,0.7323322
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",needs,0.4746752,return,0.509715,cardiology,0.4746752
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cvd-risk,0.32460088,chd,0.6882602,chd,0.6882602
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",risk-needs,0.3900679,chd,0.43731123,chd,0.43731123
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",blind,0.24227464,double,0.5368825,double-outlet,0.41183934
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",blind-study,0.35535207,congenital-heart-disease,0.5064368,congenital-heart-disease,0.5064368
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study-patients,0.43761975,congenital-heart-disease,0.5513853,congenital-heart-disease,0.5513853
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.21118185,cholesterol,0.4333404,cholesterol,0.4333404
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein-cholesterol,0.29643348,cholesterol,0.8591521,cholesterol,0.8591521
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density-lipoprotein-cholesterol,0.26042908,cholesterol,0.8576243,cholesterol,0.8576243
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma-lipid,0.18726908,cholesterol,0.5560678,cholesterol,0.5560678
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",concentrations,0.20313622,with,0.46930897,deposits,0.43182394
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl-concentrations,0.25621736,cholesterol,0.5305064,cholesterol,0.5305064
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein,0.17386194,of,0.4756804,cholesterol,0.3740363
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",component,0.2266389,of,0.52326363,deposits,0.38395098
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein-component,0.21428004,of,0.4796583,cholesterol,0.38693514
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",post,0.3914922,failure,0.52308416,mi,0.5076717
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",months,0.2814955,failure,0.43657047,congestive,0.39787602
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",b,0.20100933,of,0.43435428,aortic,0.34993017
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein-b,0.21784578,cholesterol,0.72414654,cholesterol,0.72414654
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoproteins,0.26673466,cholesterol,0.7218003,cholesterol,0.7218003
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl-apolipoproteins,0.24390216,cholesterol,0.7466537,cholesterol,0.7466537
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",design,0.22387533,of,0.40440997,single-ventricle,0.33910608
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study-design,0.28830767,congestive-heart-failure,0.37532863,congestive-heart-failure,0.37532863
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cardiovascular-risk,0.54054093,chd,0.71753865,chd,0.71753865
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",sons,0.3803559,cardiology,0.3803559,cardiology,0.3803559
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ltd,0.19889542,arrythmia,0.2606184,arrythmia,0.2606184
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",respectively,0.23301381,with,0.4658343,mi,0.37010562
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",p,0.29391026,with,0.4559728,congestive,0.4058217
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",menopausal,0.302038,coronary,0.39124328,coronary,0.39124328
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",women,0.355409,chd,0.4926289,chd,0.4926289
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",menopausal-women,0.32075316,chd,0.42948937,chd,0.42948937
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",markers,0.24214233,of,0.43581337,deposits,0.3556608
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lesser,0.2212934,of,0.57503545,l-transposition,0.38630593
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",extent,0.2738167,of,0.64978826,deposits,0.4439485
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lesser-extent,0.21252291,of,0.5118722,l-transposition,0.44360402
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",post,0.3914922,failure,0.52308416,mi,0.5076717
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",greatest,0.28335303,great,0.6391654,mi,0.33438313
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",changes,0.30126634,of,0.5562258,flow,0.44305104
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",may,0.26963884,of,0.58654004,anomalous,0.366544
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",also,0.36015856,of,0.65908813,flow,0.41040578
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apparent,0.22756818,of,0.58568347,anomalous,0.46481445
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.20859355,eb,0.34265935,eb,0.34265935
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",significant,0.2800444,great,0.554224,stenosis,0.40396324
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,0.20909318,of,0.5657147,contractions,0.35284936
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",significant-effect,0.25542906,of,0.5299078,mi,0.43506783
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",greatest,0.28335303,great,0.6391654,mi,0.33438313
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,0.20909318,of,0.5657147,contractions,0.35284936
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.21118185,cholesterol,0.4333404,cholesterol,0.4333404
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,0.20909318,of,0.5657147,contractions,0.35284936
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",vldl,0.20742606,cholesterol,0.7049568,cholesterol,0.7049568
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",treatment,0.30650938,of,0.52012336,congestive,0.36983645
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",single,0.2571312,single,1.0,anomalous,0.40611145
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",results,0.29712585,of,0.53157276,blood,0.36869162
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",randomised,0.31315646,interrupted,0.37861115,congestive-heart-failure,0.3709271
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",placebo,0.23583846,heart-failure,0.4025175,heart-failure,0.4025175
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",one,0.3148334,single,0.6951874,anomaly,0.3884908
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",objective,0.2960808,of,0.5255821,flow,0.39260852
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",low,0.33154353,with,0.5951388,flow,0.4108625
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",investigation,0.31772497,of,0.61667234,anomaly,0.36676937
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",impact,0.2996394,of,0.5528908,single-ventricle,0.35865143
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",however,0.30646515,of,0.624624,mi,0.41109186
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",high,0.28122714,of,0.57459104,flow,0.3923195
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effects,0.19496669,of,0.53851616,contractions,0.39115262
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",double,0.18319796,double,1.0,double-outlet,0.4665496
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",contrast,0.2558416,of,0.5428885,mi,0.37385863
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",conclusion,0.24339199,of,0.51551676,artery,0.33304232
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",compare,0.27648047,of,0.5052448,venous-return,0.3454308
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",centre,0.41542518,single,0.419629,cardiology,0.41542518
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",baseline,0.37229544,return,0.53112984,mi,0.4760896
Heart Failure With Mid-range Ejection Fraction.,randomized,0.31567937,interrupted,0.40434858,congestive-heart-failure,0.39597732
Heart Failure With Mid-range Ejection Fraction.,controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
Heart Failure With Mid-range Ejection Fraction.,trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
Heart Failure With Mid-range Ejection Fraction.,exist,0.21226555,of,0.4884736,isomerism,0.35204807
Heart Failure With Mid-range Ejection Fraction.,randomized-controlled,0.32513475,congestive-heart-failure,0.41178715,congestive-heart-failure,0.41178715
Heart Failure With Mid-range Ejection Fraction.,controlled-trials,0.29649204,interrupted,0.37782174,congestive-heart-failure,0.36371502
Heart Failure With Mid-range Ejection Fraction.,randomized-controlled-trials,0.31378016,congestive-heart-failure,0.39758077,congestive-heart-failure,0.39758077
Heart Failure With Mid-range Ejection Fraction.,aha,0.4395023,cardiology,0.4395023,cardiology,0.4395023
Heart Failure With Mid-range Ejection Fraction.,american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
Heart Failure With Mid-range Ejection Fraction.,college,0.5654811,cardiology,0.5654811,cardiology,0.5654811
Heart Failure With Mid-range Ejection Fraction.,ef,0.4303254,mi,0.533185,mi,0.533185
Heart Failure With Mid-range Ejection Fraction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Heart Failure With Mid-range Ejection Fraction.,ef,0.4303254,mi,0.533185,mi,0.533185
Heart Failure With Mid-range Ejection Fraction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Heart Failure With Mid-range Ejection Fraction.,unique,0.20165175,of,0.5631099,anomalous,0.44501823
Heart Failure With Mid-range Ejection Fraction.,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
Heart Failure With Mid-range Ejection Fraction.,altogether,0.20425558,of,0.46309736,l-transposition,0.3253976
Heart Failure With Mid-range Ejection Fraction.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Heart Failure With Mid-range Ejection Fraction.,poorly,0.23539765,as,0.51719266,deposits,0.39493018
Heart Failure With Mid-range Ejection Fraction.,understood,0.27476305,as,0.45029238,anomalous,0.37772185
Heart Failure With Mid-range Ejection Fraction.,poorly-understood,0.25650564,as,0.46642807,congenital-heart-disease,0.4077103
Heart Failure With Mid-range Ejection Fraction.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Heart Failure With Mid-range Ejection Fraction.,rates,0.26658094,of,0.47081333,flow,0.4277016
Heart Failure With Mid-range Ejection Fraction.,among,0.2573181,of,0.57348,chd,0.4274787
Heart Failure With Mid-range Ejection Fraction.,mortality-rates,0.3018304,heart-failure,0.48453403,heart-failure,0.48453403
Heart Failure With Mid-range Ejection Fraction.,rates-among,0.21085376,venous-return,0.3617541,venous-return,0.3617541
Heart Failure With Mid-range Ejection Fraction.,include,0.27115557,of,0.60518813,atresia-with,0.36476195
Heart Failure With Mid-range Ejection Fraction.,overlap,0.19607264,with,0.4524176,anomaly,0.40907073
Heart Failure With Mid-range Ejection Fraction.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Heart Failure With Mid-range Ejection Fraction.,heterogeneous,0.2215862,irregular,0.5216255,deposits,0.44650552
Heart Failure With Mid-range Ejection Fraction.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Heart Failure With Mid-range Ejection Fraction.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Heart Failure With Mid-range Ejection Fraction.,clinical-characteristics,0.34754923,of,0.5452827,congenital-heart-disease,0.4584994
Heart Failure With Mid-range Ejection Fraction.,american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
Heart Failure With Mid-range Ejection Fraction.,heart,0.57664216,heart,1.0,heart,1.0
Heart Failure With Mid-range Ejection Fraction.,association,0.34312242,of,0.45371312,chd,0.39406395
Heart Failure With Mid-range Ejection Fraction.,heart-association,0.45964456,heart-disease,0.6606643,heart-disease,0.6606643
Heart Failure With Mid-range Ejection Fraction.,american-heart-association,0.50356925,congenital-heart-disease,0.64679414,congenital-heart-disease,0.64679414
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid,0.25606772,insufficiency,0.46684614,congestive,0.45785415
Heart Failure With Mid-range Ejection Fraction.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Heart Failure With Mid-range Ejection Fraction.,antagonists,0.26629966,contractions,0.45131737,contractions,0.45131737
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid-receptor,0.254681,congestive,0.43098098,congestive,0.43098098
Heart Failure With Mid-range Ejection Fraction.,receptor-antagonists,0.2558006,contractions,0.41648656,contractions,0.41648656
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid-receptor-antagonists,0.27392825,congestive,0.42555445,congestive,0.42555445
Heart Failure With Mid-range Ejection Fraction.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Heart Failure With Mid-range Ejection Fraction.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Heart Failure With Mid-range Ejection Fraction.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Heart Failure With Mid-range Ejection Fraction.,reduced-ejection,0.30925128,ventricular,0.54094154,ventricular,0.54094154
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Heart Failure With Mid-range Ejection Fraction.,preserved,0.24191171,with,0.53828907,deposits,0.44760028
Heart Failure With Mid-range Ejection Fraction.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Heart Failure With Mid-range Ejection Fraction.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Heart Failure With Mid-range Ejection Fraction.,preserved-ejection,0.30263668,right-ventricle,0.576405,right-ventricle,0.576405
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Heart Failure With Mid-range Ejection Fraction.,times,0.34326765,with,0.5386606,beats,0.44545606
Heart Failure With Mid-range Ejection Fraction.,resembles,0.11158832,isolated,0.4705496,anomalous,0.38757664
Heart Failure With Mid-range Ejection Fraction.,hfref,0.4643475,heart-failure,0.6873541,heart-failure,0.6873541
Heart Failure With Mid-range Ejection Fraction.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Heart Failure With Mid-range Ejection Fraction.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Heart Failure With Mid-range Ejection Fraction.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Heart Failure With Mid-range Ejection Fraction.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
Heart Failure With Mid-range Ejection Fraction.,receptor-blockers,0.33424258,bradycardia,0.4559213,bradycardia,0.4559213
Heart Failure With Mid-range Ejection Fraction.,angiotensin-receptor-blockers,0.3599828,congestive,0.50955385,congestive,0.50955385
Heart Failure With Mid-range Ejection Fraction.,range,0.29700014,of,0.40102404,cardiac,0.33579552
Heart Failure With Mid-range Ejection Fraction.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Heart Failure With Mid-range Ejection Fraction.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.46666002,heart-failure,0.5803928,heart-failure,0.5803928
Heart Failure With Mid-range Ejection Fraction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Heart Failure With Mid-range Ejection Fraction.,represent,0.22206968,as,0.5763198,anomaly,0.3441872
Heart Failure With Mid-range Ejection Fraction.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Heart Failure With Mid-range Ejection Fraction.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Heart Failure With Mid-range Ejection Fraction.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Heart Failure With Mid-range Ejection Fraction.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Heart Failure With Mid-range Ejection Fraction.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
Heart Failure With Mid-range Ejection Fraction.,heart,0.57664216,heart,1.0,heart,1.0
Heart Failure With Mid-range Ejection Fraction.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Heart Failure With Mid-range Ejection Fraction.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Heart Failure With Mid-range Ejection Fraction.,beta,0.2517134,of,0.43937695,cardiac,0.37025452
Heart Failure With Mid-range Ejection Fraction.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Heart Failure With Mid-range Ejection Fraction.,beta-blockers,0.43488634,congestive,0.5639546,congestive,0.5639546
Heart Failure With Mid-range Ejection Fraction.,ultimately,0.3156082,of,0.6012498,cardiac,0.3903123
Heart Failure With Mid-range Ejection Fraction.,came,0.5735084,return,0.592409,cardiology,0.5735084
Heart Failure With Mid-range Ejection Fraction.,though,0.33295327,with,0.59399855,clot,0.41905022
Heart Failure With Mid-range Ejection Fraction.,hfref,0.4643475,heart-failure,0.6873541,heart-failure,0.6873541
Heart Failure With Mid-range Ejection Fraction.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Heart Failure With Mid-range Ejection Fraction.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Heart Failure With Mid-range Ejection Fraction.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Heart Failure With Mid-range Ejection Fraction.,benefit,0.3251614,return,0.474311,heart-failure,0.40887886
Heart Failure With Mid-range Ejection Fraction.,others,0.32080752,with,0.5653113,heart-attack,0.43046573
Heart Failure With Mid-range Ejection Fraction.,still,0.38928428,of,0.5457471,arrythmia,0.4077646
Heart Failure With Mid-range Ejection Fraction.,neprilysin,0.28954732,heart-failure,0.40454558,heart-failure,0.40454558
Heart Failure With Mid-range Ejection Fraction.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.46666002,heart-failure,0.5803928,heart-failure,0.5803928
Heart Failure With Mid-range Ejection Fraction.,population,0.3190225,of,0.49866888,chd,0.40046495
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.46666002,heart-failure,0.5803928,heart-failure,0.5803928
Heart Failure With Mid-range Ejection Fraction.,gray,0.27915418,deposits,0.41757846,deposits,0.41757846
Heart Failure With Mid-range Ejection Fraction.,zone,0.21879986,deposits,0.46533495,deposits,0.46533495
Heart Failure With Mid-range Ejection Fraction.,gray-zone,0.20672724,abnormal,0.4526838,hypoplastic-left-heart,0.42589545
Heart Failure With Mid-range Ejection Fraction.,future,0.43508387,great,0.53022015,cardiology,0.43508387
Heart Failure With Mid-range Ejection Fraction.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Heart Failure With Mid-range Ejection Fraction.,future-research,0.37040812,venous-return,0.42101055,venous-return,0.42101055
Heart Failure With Mid-range Ejection Fraction.,complex,0.29298759,of,0.46002102,anomalous,0.41282338
Heart Failure With Mid-range Ejection Fraction.,disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
Heart Failure With Mid-range Ejection Fraction.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Heart Failure With Mid-range Ejection Fraction.,created,0.30611026,of,0.5643096,l-transposition,0.42097145
Heart Failure With Mid-range Ejection Fraction.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Heart Failure With Mid-range Ejection Fraction.,elucidate,0.22327457,of,0.44897896,anomalous,0.3341212
Heart Failure With Mid-range Ejection Fraction.,better-elucidate,0.3020121,of,0.4854777,congenital-heart-disease,0.38768116
Heart Failure With Mid-range Ejection Fraction.,others,0.32080752,with,0.5653113,heart-attack,0.43046573
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Heart Failure With Mid-range Ejection Fraction.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Heart Failure With Mid-range Ejection Fraction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Heart Failure With Mid-range Ejection Fraction.,ef,0.4303254,mi,0.533185,mi,0.533185
Heart Failure With Mid-range Ejection Fraction.,range,0.29700014,of,0.40102404,cardiac,0.33579552
Heart Failure With Mid-range Ejection Fraction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Heart Failure With Mid-range Ejection Fraction.,hfref,0.4643475,heart-failure,0.6873541,heart-failure,0.6873541
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.46666002,heart-failure,0.5803928,heart-failure,0.5803928
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Heart Failure With Mid-range Ejection Fraction.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Heart Failure With Mid-range Ejection Fraction.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Heart Failure With Mid-range Ejection Fraction.,review,0.438658,of,0.54425275,cardiology,0.438658
Heart Failure With Mid-range Ejection Fraction.,purpose,0.27727276,of,0.5072116,congenital,0.37470472
Heart Failure With Mid-range Ejection Fraction.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Heart Failure With Mid-range Ejection Fraction.,pathophysiology,0.33037353,syndrome,0.49234846,syndrome,0.49234846
Heart Failure With Mid-range Ejection Fraction.,needed,0.42938864,as,0.567801,cardiology,0.42938864
Heart Failure With Mid-range Ejection Fraction.,mid,0.36086994,right,0.5805234,stenosis,0.45125967
Heart Failure With Mid-range Ejection Fraction.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Heart Failure With Mid-range Ejection Fraction.,known,0.28223497,as,0.60071135,mi,0.41831112
Heart Failure With Mid-range Ejection Fraction.,group,0.2849201,with,0.5052614,mi,0.411738
Heart Failure With Mid-range Ejection Fraction.,epidemiology,0.3888463,disease,0.49020842,congenital-heart-disease,0.44211137
Heart Failure With Mid-range Ejection Fraction.,efs,0.21897848,contractions,0.41679746,contractions,0.41679746
Heart Failure With Mid-range Ejection Fraction.,describe,0.2106702,of,0.4752335,anomalous,0.4157361
Heart Failure With Mid-range Ejection Fraction.,condition,0.27496728,anomaly,0.4816988,anomaly,0.4816988
Heart Failure With Mid-range Ejection Fraction.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Heart Failure With Mid-range Ejection Fraction.,borderline,0.4063904,abnormal,0.5022286,tachycardia,0.48171943
Heart Failure With Mid-range Ejection Fraction.,assigned,0.23878475,single,0.39629948,mi,0.33124304
Heart Failure With Mid-range Ejection Fraction.,acc,0.35683244,with,0.43515804,mi,0.3707262
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,determine,0.2686271,of,0.55401844,flow,0.329725
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,consistent,0.2467189,with,0.5777458,anomalous,0.45292395
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,introducing,0.30832976,of,0.5443438,l-transposition,0.3978337
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,medicine,0.64505804,cardiology,0.64505804,cardiology,0.64505804
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,statistical,0.32752115,of,0.40241736,congenital-heart-disease,0.36489835
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,nonlinear,0.22733162,anomalous,0.48510507,anomalous,0.48510507
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,results,0.29712585,of,0.53157276,blood,0.36869162
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,simple,0.2050616,single,0.48191768,anomalous,0.4230147
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,adequate,0.31365085,return,0.54715043,venous,0.43256158
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,simple-adequate,0.26195064,congenital-heart-disease,0.40964675,congenital-heart-disease,0.40964675
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,obtain,0.32854,return,0.5372094,flow,0.39961314
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,efficient,0.19720647,of,0.49297506,l-transposition,0.3745634
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,femoral,0.36020508,venous,0.6135931,venous,0.6135931
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pulse,0.3453018,heartbeat,0.489731,heartbeat,0.489731
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,velocity,0.21773425,blood-flow,0.62262374,blood-flow,0.62262374
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,femoral-pulse,0.36898226,left-atrial,0.5458404,left-atrial,0.5458404
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pulse-wave,0.3778021,blood-flow,0.6011938,blood-flow,0.6011938
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,wave-velocity,0.25610933,blood-flow,0.572709,blood-flow,0.572709
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pulse-wave-velocity,0.3043403,blood-flow,0.6424626,blood-flow,0.6424626
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,networks,0.2352877,great,0.3902747,venous-return,0.35607615
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial-neural,0.22358572,congenital-heart-disease,0.49487492,congenital-heart-disease,0.49487492
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,neural-networks,0.2428932,heartbeat,0.4383191,heartbeat,0.4383191
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial-neural-networks,0.22075899,congenital-heart-disease,0.4619917,congenital-heart-disease,0.4619917
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,renal,0.43551624,pulmonary,0.5641475,pulmonary,0.5641475
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,circulations,0.34902307,arteries,0.67343265,arteries,0.67343265
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,measured,0.2266986,of,0.539739,flow,0.4470259
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,using,0.20786116,with,0.58010674,flow,0.41007757
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,carotid,0.44209525,artery,0.8054012,artery,0.8054012
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,mean,0.30953988,total,0.5000684,artery,0.37085557
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,blood,0.32078606,blood,1.0,blood,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,blood-pressure,0.37952203,blood,0.65126884,blood,0.65126884
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,mean-blood-pressure,0.36515477,blood-flow,0.6404159,blood-flow,0.6404159
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.25914288,aortic-coarctation,0.52365714,aortic-coarctation,0.52365714
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27677816,total,0.43109894,mi,0.39722836
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,determinations,0.2737924,of,0.5070617,blood,0.3935568
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,individual,0.26860815,of,0.6520203,anomalous,0.4023711
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.25914288,aortic-coarctation,0.52365714,aortic-coarctation,0.52365714
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27677816,total,0.43109894,mi,0.39722836
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,usual,0.30769795,with,0.43668455,venous-return,0.36025375
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,practice,0.5339576,cardiology,0.5339576,cardiology,0.5339576
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical-practice,0.51884663,cardiology,0.51884663,cardiology,0.51884663
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high,0.28122714,of,0.57459104,flow,0.3923195
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high-cardiovascular,0.5762588,chd,0.72270954,chd,0.72270954
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cardiovascular-risk,0.54054093,chd,0.71753865,chd,0.71753865
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high-cardiovascular-risk,0.5344586,chd,0.7380679,chd,0.7380679
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,large,0.31318635,great,0.5879582,deposits,0.4134889
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,arteries,0.33855987,arteries,1.0,arteries,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,large-arteries,0.37653527,arteries,0.79755044,arteries,0.79755044
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,angiographic,0.43790445,coronary-artery,0.6974274,coronary-artery,0.6974274
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.48676962,chd,1.0,chd,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decisions,0.42424518,return,0.4304611,cardiology,0.42424518
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.25914288,aortic-coarctation,0.52365714,aortic-coarctation,0.52365714
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,particularly,0.31718573,of,0.62868786,deposits,0.41094124
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,present,0.34922045,of,0.63723874,anomaly,0.40175247
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,review,0.438658,of,0.54425275,cardiology,0.438658
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,focuses,0.3185957,of,0.5351627,cardiology,0.3185957
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27677816,total,0.43109894,mi,0.39722836
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,involving,0.16359735,of,0.54600704,l-transposition,0.39006394
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,age,0.33659208,with,0.44369304,chd,0.42829025
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary,0.56409866,coronary,1.0,coronary,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart,0.57664216,heart,1.0,heart,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary-heart,0.5715385,coronary-artery,0.8627513,coronary-artery,0.8627513
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary-heart-disease,0.5209235,heart-disease,0.89567757,heart-disease,0.89567757
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.25914288,aortic-coarctation,0.52365714,aortic-coarctation,0.52365714
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27677816,total,0.43109894,mi,0.39722836
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,may,0.26963884,of,0.58654004,anomalous,0.366544
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,defined,0.2335411,as,0.60751194,stenosis,0.33817482
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.48676962,chd,1.0,chd,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,intelligence,0.331039,congenital-heart-disease,0.4281336,congenital-heart-disease,0.4281336
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial-intelligence,0.30402216,venous-return,0.48337245,venous-return,0.48337245
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary,0.56409866,coronary,1.0,coronary,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,particularly,0.31718573,of,0.62868786,deposits,0.41094124
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high,0.28122714,of,0.57459104,flow,0.3923195
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high-levels,0.17028418,of,0.46296257,l-transposition,0.32283404
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart,0.57664216,heart,1.0,heart,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart-rate,0.43613237,heartbeat,0.713904,heartbeat,0.713904
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical-characteristics,0.34754923,of,0.5452827,congenital-heart-disease,0.4584994
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.48676962,chd,1.0,chd,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,vulnerable,0.24965096,great,0.4247626,plaque-deposits,0.37868524
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,plaques,0.2778534,plaque,0.84552175,plaque,0.84552175
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,substantial,0.27155346,great,0.64504546,anomalous,0.3652059
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,marker,0.22334269,as,0.47600302,mi,0.37359565
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,works,0.3987892,as,0.48645952,cardiology,0.3987892
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,predictor,0.24674982,as,0.45541835,chd,0.39992505
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decision,0.46018064,cardiology,0.46018064,cardiology,0.46018064
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,tree,0.2472718,stenosis,0.3753883,stenosis,0.3753883
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decision-tree,0.32542065,venous-return,0.43177015,venous-return,0.43177015
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,aortic,0.44729716,aortic,1.0,aortic,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,stiffness,0.25981954,stiff,0.69937205,aortic-coarctation,0.45760834
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,also,0.36015856,of,0.65908813,flow,0.41040578
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,used,0.23211285,as,0.56584436,flow,0.35934073
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,widely,0.2665941,as,0.5225847,deposits,0.32680094
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,widely-associated,0.2145232,of,0.52741784,congenital,0.41520613
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,results,0.29712585,of,0.53157276,blood,0.36869162
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.25914288,aortic-coarctation,0.52365714,aortic-coarctation,0.52365714
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.48676962,chd,1.0,chd,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,review,0.438658,of,0.54425275,cardiology,0.438658
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,may,0.26963884,of,0.58654004,anomalous,0.366544
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,involving,0.16359735,of,0.54600704,l-transposition,0.39006394
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,variability,0.34141153,great,0.5091659,heartbeat,0.43780988
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,use,0.3219829,with,0.55726266,flow,0.40877783
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,together,0.25436696,with,0.5619427,l-transposition,0.3443408
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,symptoms,0.29561567,disease,0.5364805,syndrome,0.5318241
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,relation,0.2989607,of,0.5984683,anomalous,0.45674402
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,purpose,0.27727276,of,0.5072116,congenital,0.37470472
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,presence,0.20698525,of,0.6171463,deposits,0.45095456
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,possible,0.37040615,of,0.6754589,anomalous,0.44165242
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,parameter,0.27155933,as,0.4758621,flow,0.44832006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,measurement,0.2804429,of,0.51248544,blood-flow,0.45750505
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,interest,0.3943884,great,0.62165374,cardiology,0.3943884
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,improve,0.31483245,great,0.49610043,flow,0.35876963
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,imperfections,0.26886123,anomalous,0.49469665,anomalous,0.49469665
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,gender,0.3640193,congenital-heart-disease,0.45300186,congenital-heart-disease,0.45300186
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,damage,0.1804528,attack,0.48379204,deposits,0.44194233
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,constitute,0.18495496,of,0.5690476,l-transposition,0.34532386
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,considered,0.31302214,as,0.6929809,anomaly,0.43040824
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,consider,0.49515226,of,0.5644523,cardiology,0.49515226
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cerebrovascular,0.442694,coronary-artery,0.6639829,coronary-artery,0.6639829
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,calculation,0.3017112,of,0.45429695,anomalous,0.43531603
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.21863139,of,0.48460138,flow,0.38218224
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,compared,0.26227483,with,0.62448335,mi,0.40925252
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,across,0.2607503,of,0.44814807,flow,0.3484614
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-subsets,0.24364434,flow,0.38635406,flow,0.38635406
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,across-tissues,0.17819214,of,0.42404297,blood-flow,0.40632224
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,provide,0.3065295,of,0.4983799,flow,0.3409845
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,effective,0.20873946,as,0.5165305,contractions,0.33001167
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,recall,0.34358412,mi,0.38738698,mi,0.38738698
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,responses,0.18527287,contractions,0.4718574,contractions,0.4718574
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,draining,0.24976802,intact,0.5381355,clot,0.43053705
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lymph,0.15510646,artery-disease,0.4520587,artery-disease,0.4520587
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,node,0.2484928,atrioventricular,0.5392989,atrioventricular,0.5392989
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung-draining,0.17703976,pulmonary,0.49944794,pulmonary,0.49944794
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,draining-lymph,0.20209068,intact,0.48647994,clot,0.42113185
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lymph-node,0.13720873,artery-disease,0.4447528,artery-disease,0.4447528
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,draining-lymph-node,0.20622528,artery-disease,0.44003323,artery-disease,0.44003323
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,abundance,0.22053209,of,0.4682694,deposits,0.38831514
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,throughout,0.35300756,irregular,0.5089302,flow,0.39040673
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.21863139,of,0.48460138,flow,0.38218224
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-receptor,0.17982286,of,0.40034604,flow,0.34851956
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,receptor-analysis,0.29857308,of,0.41825622,heart-syndrome,0.38003296
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,recognize,0.2565519,attack,0.41373774,heart-attack,0.37831914
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,antigens,0.20505735,deposits,0.35015312,deposits,0.35015312
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,including,0.2742056,of,0.6619886,congenital,0.3605199
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,higher,0.2654187,with,0.56796193,mi,0.398535
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,higher-expression,0.23893026,of,0.45692122,septal-defect,0.41243678
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,precursor,0.17467758,of,0.4458534,deposits,0.3602497
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,pools,0.17050648,total,0.44223517,deposits,0.38750356
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,paired,0.21412359,single,0.5054873,heartbeat,0.36170572
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,human-lung,0.26601192,congenital-heart-disease,0.46596253,congenital-heart-disease,0.46596253
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,innate,0.22606428,great,0.4120917,l-transposition,0.3680464
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,receptors,0.20060575,of,0.401954,contractions,0.3900054
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,innate-immune,0.1484158,congenital-heart-disease,0.38581443,congenital-heart-disease,0.38581443
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune-receptors,0.17285165,disease,0.35659382,heart-attack,0.35346586
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,substantial,0.27155346,great,0.64504546,anomalous,0.3652059
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,differences,0.24501437,of,0.48845208,anomalous,0.3514788
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal,0.2366792,isolated,0.46519697,l-transposition,0.40041238
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,overlap,0.19607264,with,0.4524176,anomaly,0.40907073
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.21863139,of,0.48460138,flow,0.38218224
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,within,0.30995527,of,0.57602364,deposits,0.42065546
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-subsets,0.24364434,flow,0.38635406,flow,0.38635406
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.21863139,of,0.48460138,flow,0.38218224
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-subsets,0.24364434,flow,0.38635406,flow,0.38635406
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,responses,0.18527287,contractions,0.4718574,contractions,0.4718574
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune-responses,0.12557065,disease,0.35724023,congenital-heart-disease,0.35341072
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal,0.2366792,isolated,0.46519697,l-transposition,0.40041238
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,overlap,0.19607264,with,0.4524176,anomaly,0.40907073
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,transcriptional,0.24623448,l-transposition,0.44111192,l-transposition,0.44111192
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,landscape,0.2881531,great,0.43566948,flow,0.35615838
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,focused,0.3452875,of,0.5549927,cardiology,0.3452875
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,study-focused,0.43399438,cardiology,0.43399438,cardiology,0.43399438
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,separate,0.26202708,single,0.64554334,anomalous,0.42240894
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,roles,0.26051345,of,0.45427072,l-transposition,0.29379755
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,results,0.29712585,of,0.53157276,blood,0.36869162
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,results-suggest,0.37769833,with,0.46542153,venous-return,0.4256721
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,flow,0.27540267,flow,1.0,flow,1.0
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cytometry,0.26987028,flow,0.60937023,flow,0.60937023
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,flow-cytometry,0.2276194,flow,0.5899704,flow,0.5899704
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,specific,0.26268506,of,0.6059094,flow,0.40644997
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,specific-memory,0.22118455,of,0.42140907,congenital-heart-disease,0.39622977
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,many,0.34462097,great,0.5654564,deposits,0.36972266
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,persist,0.25892156,return,0.506247,l-transposition,0.3541326
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,originate,0.23350489,isolated,0.5336124,anomalous,0.4675871
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln,0.18899786,cholesterol,0.54186743,cholesterol,0.54186743
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,within,0.30995527,of,0.57602364,deposits,0.42065546
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln,0.18899786,cholesterol,0.54186743,cholesterol,0.54186743
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,validated,0.27360892,of,0.4456607,cad,0.31460553
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,using,0.20786116,with,0.58010674,flow,0.41007757
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,samples,0.20068786,isolated,0.4879529,blood,0.4540816
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,pathogen,0.20034528,disease,0.4754871,heart-attack,0.35139495
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,likely,0.34048563,of,0.55071557,congestive,0.42744756
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,greater,0.28239584,of,0.59163296,mi,0.40441626
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,exposure,0.19340545,of,0.47989124,deposits,0.29644954
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,differ,0.21590988,of,0.45475316,mi,0.32814133
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,determined,0.24003299,of,0.6221287,flow,0.40728092
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,array,0.2303186,single,0.46081746,flow,0.31905028
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,antigen,0.2033888,of,0.37284538,blood-clot,0.32891208
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,measure,0.22921617,as,0.5088453,flow,0.39704257
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr,0.13992053,atresia,0.3691952,atresia,0.3691952
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,function,0.2605439,of,0.55099833,flow,0.43324804
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,using,0.20786116,with,0.58010674,flow,0.41007757
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic,0.24249871,congenital,0.5244103,congenital,0.5244103
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,fibrosis,0.29325014,pulmonary,0.5077022,pulmonary,0.5077022
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic-fibrosis,0.2219999,congenital-heart-disease,0.50309,congenital-heart-disease,0.50309
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hipsc,0.30220437,hlhs,0.43378666,hlhs,0.43378666
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.20000894,pulmonary-venous,0.4246543,pulmonary-venous,0.4246543
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,organoids,0.2600742,atresia-with,0.42288455,atresia-with,0.42288455
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived-human,0.1384944,isolated,0.35595685,congenital-heart-disease,0.29601318
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human-intestinal,0.22559021,congenital-heart-disease,0.41718072,congenital-heart-disease,0.41718072
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,pluripotent,0.29733214,heart-syndrome,0.3878666,heart-syndrome,0.3878666
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,stem,0.2528829,hypoplastic,0.38906342,hypoplastic,0.38906342
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cell,0.21863139,of,0.48460138,flow,0.38218224
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human-induced,0.25222713,great,0.44587326,congenital-heart-disease,0.38330525
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,induced-pluripotent,0.21692634,septal-defect,0.3781092,septal-defect,0.3781092
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,pluripotent-stem,0.25225508,hypoplastic-left-heart,0.3746312,hypoplastic-left-heart,0.3746312
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,stem-cell,0.3073024,failure,0.40953812,single-ventricle,0.40389973
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,induced-pluripotent-stem,0.21345402,hypoplastic-left-heart,0.38127902,hypoplastic-left-heart,0.38127902
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,pluripotent-stem-cell,0.2784272,hypoplastic-left-heart,0.39431226,hypoplastic-left-heart,0.39431226
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.27289551,total,0.4907664,cardiac,0.38484737
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,organoids,0.2600742,atresia-with,0.42288455,atresia-with,0.42288455
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,expressing,0.19233966,of,0.42866248,septal-defect,0.35725144
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,characteristic,0.14630476,of,0.52064013,anomalous,0.42846608
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,throughout,0.35300756,irregular,0.5089302,flow,0.39040673
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed,0.31404623,of,0.55436456,flow,0.39248404
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,differentiation,0.23174062,of,0.45291108,l-transposition,0.3816795
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed-differentiation,0.24432272,of,0.45766556,l-transposition,0.40772164
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed,0.31404623,of,0.55436456,flow,0.39248404
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,differentiation,0.23174062,of,0.45291108,l-transposition,0.3816795
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,protocol,0.38874236,with,0.41014993,cardiology,0.38874236
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed-differentiation,0.24432272,of,0.45766556,l-transposition,0.40772164
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc,0.25850517,hlhs,0.37672743,hlhs,0.37672743
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,lines,0.23701838,intact,0.44574544,ivs,0.38147125
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc-lines,0.2779448,septal-defect,0.42367142,septal-defect,0.42367142
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.27289551,total,0.4907664,cardiac,0.38484737
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,defined,0.2335411,as,0.60751194,stenosis,0.33817482
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free-defined,0.22915326,of,0.47516567,plaque-deposits,0.38579863
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,proximal,0.19377108,arteries,0.5245569,arteries,0.5245569
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.20000894,pulmonary-venous,0.4246543,pulmonary-venous,0.4246543
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,lineages,0.27772555,l-transposition,0.4170297,l-transposition,0.4170297
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic,0.24249871,congenital,0.5244103,congenital,0.5244103
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,fibrosis,0.29325014,pulmonary,0.5077022,pulmonary,0.5077022
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic-fibrosis,0.2219999,congenital-heart-disease,0.50309,congenital-heart-disease,0.50309
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc,0.25850517,hlhs,0.37672743,hlhs,0.37672743
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,knock,0.25125682,double,0.40730658,l-transposition,0.38618279
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,bowel,0.29325753,valve,0.42750537,valve,0.42750537
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,inflammatory-bowel,0.19405718,disease,0.46724635,thrombosis,0.4305379
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,bowel-disease,0.24437362,disease,0.66691387,heart-disease,0.6338246
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,employ,0.18934157,of,0.40588045,heart-attack,0.3112145
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.2887091,return,0.38422632,atresia-with,0.35142198
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generated,0.23948207,of,0.55590856,flow,0.35901695
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr,0.13992053,atresia,0.3691952,atresia,0.3691952
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mutation,0.19931707,defect,0.4727108,anomaly,0.40015864
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr-mutation,0.16260695,avsd,0.41202384,avsd,0.41202384
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.27289551,total,0.4907664,cardiac,0.38484737
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.2887091,return,0.38422632,atresia-with,0.35142198
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,small,0.28269485,great,0.5440953,deposits,0.39470115
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.20000894,pulmonary-venous,0.4246543,pulmonary-venous,0.4246543
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,small-intestinal,0.20007119,pulmonary-venous,0.4167257,pulmonary-venous,0.4167257
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.20000894,pulmonary-venous,0.4246543,pulmonary-venous,0.4246543
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,progenitors,0.24171741,hypoplastic,0.44263977,hypoplastic,0.44263977
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,modeling,0.26009148,of,0.45934054,single-ventricle,0.35399336
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease-modeling,0.25606427,disease,0.59891784,artery-disease,0.4952406
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,would,0.35497403,of,0.55908126,flow,0.3796509
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,facilitate,0.2564506,of,0.4863937,flow,0.32320783
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,vitro,0.17831118,of,0.48112682,clot,0.34754837
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,vitro-models,0.15309191,plaque-deposits,0.34761935,plaque-deposits,0.34761935
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,using,0.20786116,with,0.58010674,flow,0.41007757
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,reporter,0.22805995,l-transposition,0.36128733,l-transposition,0.36128733
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,line,0.3054644,right,0.471364,venous,0.4344638
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,primed,0.14232576,with,0.4330321,l-transposition,0.33139062
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,towards,0.26525512,of,0.5319467,isomerism,0.33325064
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hindgut,0.1729397,truncus,0.4245007,truncus,0.4245007
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,progenitors,0.24171741,hypoplastic,0.44263977,hypoplastic,0.44263977
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,gastrointestinal,0.31402457,cardiac,0.44986403,cardiac,0.44986403
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,tract,0.2777627,stenosis,0.44710302,stenosis,0.44710302
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,gastrointestinal-tract,0.27492148,congestive-heart-failure,0.44030547,congestive-heart-failure,0.44030547
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,future,0.43508387,great,0.53022015,cardiology,0.43508387
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,robust,0.13868469,weak,0.46394548,heartbeat,0.35403174
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,0.25683564,of,0.5394852,contractions,0.39260584
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,efficient,0.19720647,of,0.49297506,l-transposition,0.3745634
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,0.25683564,of,0.5394852,contractions,0.39260584
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic,0.22677608,aortic,0.45954642,aortic,0.45954642
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,epithelium,0.1577432,atresia,0.4376575,atresia,0.4376575
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic-epithelium,0.1861634,atresia,0.4276025,atresia,0.4276025
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.2887091,return,0.38422632,atresia-with,0.35142198
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,0.25683564,of,0.5394852,contractions,0.39260584
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic,0.22677608,aortic,0.45954642,aortic,0.45954642
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,way,0.312438,of,0.5753952,anomalous,0.40993068
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,variety,0.24480078,great,0.49781102,l-transposition,0.37458777
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,track,0.40586048,return,0.49282968,cardiac,0.41771996
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,serum,0.2084733,cholesterol,0.504964,cholesterol,0.504964
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,report,0.3478901,of,0.56646246,anomaly,0.43710455
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,purification,0.16250482,isolated,0.49823564,l-transposition,0.29182673
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mesenchyme,0.22080573,hypoplastic,0.49233717,hypoplastic,0.49233717
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,kinetics,0.14638367,of,0.4826119,anomalous,0.4070374
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,enabling,0.21432984,of,0.55927515,flow,0.3709327
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,emergence,0.26180625,of,0.5167847,l-transposition,0.40268755
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,development,0.2877805,of,0.53581744,congenital,0.35419804
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,demonstrating,0.24106917,of,0.67624867,l-transposition,0.42949137
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,correction,0.31563723,defect,0.50822514,anomaly,0.4954214
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,affect,0.19231161,of,0.50835335,anomalous,0.31428474
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,center,0.4322113,single,0.4625442,cardiology,0.4322113
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,using,0.20786116,with,0.58010674,flow,0.41007757
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,validated,0.27360892,of,0.4456607,cad,0.31460553
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,center-studies,0.3987274,single,0.42722133,congenital-heart-disease,0.40690747
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,studies-using,0.347291,single,0.38078344,congenital-heart-disease,0.36483905
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.4643475,heart-failure,0.6873541,heart-failure,0.6873541
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study-included,0.35542327,congenital-heart-disease,0.49142548,congenital-heart-disease,0.49142548
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref-patients,0.37304074,heart-failure,0.6098556,heart-failure,0.6098556
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unknown,0.25035113,of,0.52799743,anomaly,0.4044414
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolite,0.16395271,isomerism,0.35460934,isomerism,0.35460934
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,demonstrating,0.24106917,of,0.67624867,l-transposition,0.42949137
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unknown-metabolite,0.18397224,of,0.4052924,congenital-heart-disease,0.37405503
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,potentially,0.22729951,of,0.5786935,cardiac,0.3729133
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,useful,0.19749163,great,0.46134508,anomalous,0.31390148
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.38202852,of,0.40210795,cardiology,0.38202852
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinically-useful,0.23796931,of,0.48739272,artery-disease,0.37706125
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,left,0.3872844,left,1.0,left-atrial,0.6573896
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ventricular-ejection,0.45086157,ventricular,0.8827383,ventricular,0.8827383
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,reduced-ejection,0.30925128,ventricular,0.54094154,ventricular,0.54094154
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.38202852,of,0.40210795,cardiology,0.38202852
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,value,0.3260533,of,0.52001536,flow,0.37269968
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,seems,0.27401996,of,0.5433607,flow,0.3556952
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic-value,0.37093383,congenital-heart-disease,0.45788142,congenital-heart-disease,0.45788142
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fitted,0.16704273,with,0.45058134,venous-return,0.4340434
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fasting,0.2756939,cholesterol,0.55686736,cholesterol,0.55686736
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,serum,0.2084733,cholesterol,0.504964,cholesterol,0.504964
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,samples,0.20068786,isolated,0.4879529,blood,0.4540816
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fasting-serum,0.19112274,cholesterol,0.44550878,cholesterol,0.44550878
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,serum-samples,0.24673909,blood,0.40866905,blood,0.40866905
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,controls,0.23145974,with,0.5052294,mi,0.41936132
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,controls-without,0.29418567,with,0.5349059,mi,0.46688402
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,innovative,0.37430918,great,0.5241181,single-ventricle,0.3790713
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.19209108,isolated,0.39664695,isomerism,0.39189023
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,correlated,0.19972287,with,0.55014,deposits,0.3674355
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,confirm,0.2632276,of,0.48014945,anomalous,0.34633434
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,utility,0.2794286,of,0.49793997,flow,0.31422362
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical-utility,0.40970027,congenital-heart-disease,0.48963425,congenital-heart-disease,0.48963425
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature-selection,0.19786239,l-transposition,0.47018635,l-transposition,0.47018635
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection-based,0.2395733,single,0.4254038,venous-return,0.37128174
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature-selection-based,0.18904684,l-transposition,0.40616006,l-transposition,0.40616006
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.19209108,isolated,0.39664695,isomerism,0.39189023
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.38202852,of,0.40210795,cardiology,0.38202852
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.4643475,heart-failure,0.6873541,heart-failure,0.6873541
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lvef,0.4608612,ventricular,0.63505256,ventricular,0.63505256
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lpc,0.14718682,cholesterol,0.46932918,cholesterol,0.46932918
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,isomers,0.16323714,isomerism,0.6848339,isomerism,0.6848339
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,value,0.3260533,of,0.52001536,flow,0.37269968
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,predictive-value,0.19463582,venous-return,0.3934921,venous-return,0.3934921
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,model-based,0.25989342,venous-return,0.41569927,venous-return,0.41569927
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,eight,0.257603,of,0.56028783,d-transposition,0.37704796
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.19209108,isolated,0.39664695,isomerism,0.39189023
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,uric,0.24018782,cholesterol,0.5691643,cholesterol,0.5691643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.16432983,with,0.42051664,cholesterol,0.37480527
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,uric-acid,0.13046364,cholesterol,0.44209802,cholesterol,0.44209802
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,test-set,0.2495839,congenital-heart-disease,0.38465905,congenital-heart-disease,0.38465905
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,resampled,0.32178983,single,0.39016476,venous-return,0.38170636
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,data,0.31118363,of,0.5086956,mi,0.36251363
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,derangement,0.340705,abnormal,0.6403115,anomaly,0.5045147
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,mass,0.21939,tof,0.43280137,tof,0.43280137
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,spectrometry,0.22872344,tof,0.44201183,tof,0.44201183
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,mass-spectrometry,0.22545692,tof,0.47137228,tof,0.47137228
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,liquid,0.19093904,flow,0.3839261,flow,0.3839261
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,chromatography,0.16021919,isolated,0.3684677,tof,0.3094717
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,liquid-chromatography,0.20161057,isomerism,0.36074242,isomerism,0.36074242
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,linear,0.17840835,of,0.40123588,isomerism,0.35944843
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,modelling,0.27325916,of,0.47411388,congenital-heart-disease,0.37253243
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,large,0.31318635,great,0.5879582,deposits,0.4134889
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,scale,0.29563683,great,0.37443155,venous-return,0.34418654
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,large-scale,0.25092757,great,0.46569955,flow,0.33918017
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,heart,0.57664216,heart,1.0,heart,1.0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,functional,0.2048316,of,0.51558334,l-transposition,0.40613407
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,enables,0.17423451,of,0.5211466,anomalous,0.37875658
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,identification,0.20758381,of,0.5418171,d-transposition,0.3482393
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,docosahexaenoic,0.15901533,cholesterol,0.52954984,cholesterol,0.52954984
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.16432983,with,0.42051664,cholesterol,0.37480527
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,docosahexaenoic-acid,0.14783753,cholesterol,0.5374532,cholesterol,0.5374532
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,deoxycholic,0.14410776,cholesterol,0.54475284,cholesterol,0.54475284
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.16432983,with,0.42051664,cholesterol,0.37480527
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,current,0.39557698,of,0.4991414,flow,0.39574015
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,knowledge,0.32453293,of,0.4580958,congenital-heart-disease,0.38427317
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,current-knowledge,0.3630215,venous-return,0.45650524,venous-return,0.45650524
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combined,0.24027641,with,0.60924613,single-ventricle,0.4029721
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combined-approach,0.23031643,single-ventricle,0.4678747,single-ventricle,0.4678747
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,check,0.48857665,arrythmia,0.52696586,arrythmia,0.52696586
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feasibility,0.2594404,great,0.45960844,venous-return,0.38982585
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,untargeted,0.21828038,tof,0.39960703,tof,0.39960703
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics,0.30122557,great,0.3474839,tof,0.34649515
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,untargeted-metabolomics,0.24182238,tof,0.3540744,tof,0.3540744
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.4643475,heart-failure,0.6873541,heart-failure,0.6873541
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics,0.30122557,great,0.3474839,tof,0.34649515
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,verified,0.3110122,of,0.5807613,flow,0.39278382
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unrestrained,0.22801638,intact,0.48542184,contractions,0.42267612
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,simple,0.2050616,single,0.48191768,anomalous,0.4230147
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,resulted,0.17505345,of,0.5964589,l-transposition,0.32549727
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,multi,0.3120417,single,0.49181098,cad,0.38921657
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,gaps,0.30158007,great,0.3833747,beats,0.36071926
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,followed,0.3600078,with,0.62115055,flow,0.4018712
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fingerprinted,0.22690591,isolated,0.4781579,tof,0.32402176
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,echocardiographic,0.5580573,ventricular,0.6825538,ventricular,0.6825538
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,crucial,0.22890398,of,0.48424307,anomalous,0.3442307
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,create,0.27092174,of,0.49308443,l-transposition,0.36650625
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,comparable,0.21267173,with,0.5389043,arteries,0.33967346
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,common,0.21206799,of,0.500178,anomaly,0.44165826
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combination,0.21742424,with,0.59363616,l-transposition,0.35203728
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,bnp,0.3800953,atrial,0.5341151,atrial,0.5341151
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,represents,0.17980367,of,0.5681683,anomaly,0.37360102
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,nowadays,0.36689612,great,0.5604809,congenital-heart-disease,0.36907315
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,provide,0.3065295,of,0.4983799,flow,0.3409845
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional,0.2048316,of,0.51558334,l-transposition,0.40613407
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,maps,0.33704984,arrythmia,0.42317414,arrythmia,0.42317414
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional-quantitative,0.26621553,blood-flow,0.46805927,blood-flow,0.46805927
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,maps,0.33704984,arrythmia,0.42317414,arrythmia,0.42317414
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,underlying,0.32773498,of,0.5517533,arrythmia,0.47153074
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,specific,0.26268506,of,0.6059094,flow,0.40644997
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,vascular,0.42921376,arteries,0.65181375,arteries,0.65181375
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,receptors,0.20060575,of,0.401954,contractions,0.3900054
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,reflecting,0.2570707,of,0.5920901,anomalous,0.42487013
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary,0.28374738,single,0.5002575,l-transposition,0.38192934
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red,0.30000225,blood,0.5179363,blood,0.5179363
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,blood,0.32078606,blood,1.0,blood,1.0
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red-blood,0.27590513,blood,0.72946876,blood,0.72946876
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,blood-cells,0.20783947,blood-clot,0.6994941,blood-clot,0.6994941
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red-blood-cells,0.2147468,blood-clot,0.6639062,blood-clot,0.6639062
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,probabilistic,0.2636112,venous-return,0.3982013,venous-return,0.3982013
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,framework,0.24920769,as,0.3324023,isomerism,0.32199267
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,probabilistic-framework,0.21540502,venous-return,0.38883647,venous-return,0.38883647
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,framework-based,0.21541582,as,0.32903636,isomerism,0.29238456
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,extracted,0.24302739,isolated,0.6058264,deposits,0.3322685
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary,0.28374738,single,0.5002575,l-transposition,0.38192934
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,information,0.36363098,of,0.47314215,mi,0.39006084
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary-information,0.30688265,of,0.46453452,congenital-heart-disease,0.4174854
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,pathological-conditions,0.27829546,congenital-heart-disease,0.50726974,congenital-heart-disease,0.50726974
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetic,0.14765573,of,0.4534034,anomalous,0.44480085
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetic-models,0.19665757,venous-return,0.40274054,venous-return,0.40274054
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator,0.19372997,as,0.58206296,myocardial,0.34490144
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dilution,0.22729766,flow,0.48002696,flow,0.48002696
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,principles,0.35859984,of,0.48384064,anomalous,0.37591463
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator-dilution,0.28068623,blood-flow,0.57990015,blood-flow,0.57990015
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,immense,0.29534966,great,0.7647128,anomalous,0.30541685
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,possibilities,0.36742434,great,0.5729408,congenital-heart-disease,0.41836447
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,molecular,0.2634613,of,0.516936,isomerism,0.33948874
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,modality,0.3416853,disease,0.42066878,single-ventricle,0.39747286
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,molecular-imaging,0.31953272,of,0.4211929,isomerism,0.39647406
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.43887246,blood-flow,0.45153797,blood-flow,0.45153797
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,contrast,0.2558416,of,0.5428885,mi,0.37385863
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,agents,0.28208297,as,0.4665778,congestive,0.34284872
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound-contrast,0.3427324,blood-flow,0.47845036,blood-flow,0.47845036
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,contrast-agents,0.2992383,blood-flow,0.49143827,blood-flow,0.49143827
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca,0.14225818,l-tga,0.29362,l-tga,0.29362
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,intravascular,0.36884665,thrombosis,0.60235244,thrombosis,0.60235244
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetics,0.14638367,of,0.4826119,anomalous,0.4070374
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,0.39735788,of,0.49393907,cardiology,0.39735788
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us-imaging,0.34332,blood-flow,0.40698415,blood-flow,0.40698415
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging-based,0.30201095,blood-flow,0.4352836,blood-flow,0.4352836
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional,0.2048316,of,0.51558334,l-transposition,0.40613407
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional-imaging,0.28605562,venous-return,0.44847488,venous-return,0.44847488
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca,0.14225818,l-tga,0.29362,l-tga,0.29362
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetics,0.14638367,of,0.4826119,anomalous,0.4070374
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,intravascular,0.36884665,thrombosis,0.60235244,thrombosis,0.60235244
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator,0.19372997,as,0.58206296,myocardial,0.34490144
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,available,0.34700432,with,0.5165225,cardiology,0.34700432
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.32038575,arteries,0.38766253,arteries,0.38766253
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,provide,0.3065295,of,0.4983799,flow,0.3409845
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.2373003,tof,0.34534097,tof,0.34534097
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,several,0.34988725,of,0.5990606,cardiac,0.37646228
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dynamic,0.26735556,of,0.4784561,blood-flow,0.47322053
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,contrast,0.2558416,of,0.5428885,mi,0.37385863
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dynamic-contrast,0.25770086,blood-flow,0.48374432,blood-flow,0.48374432
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic-accuracy,0.3361726,congenital-heart-disease,0.42620343,congenital-heart-disease,0.42620343
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,0.39735788,of,0.49393907,cardiology,0.39735788
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us-imaging,0.34332,blood-flow,0.40698415,blood-flow,0.40698415
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultimate,0.2537203,failure,0.5646148,heart-failure,0.40071073
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,spatiotemporal,0.24841172,of,0.47477257,heartbeat,0.47197446
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,rheology,0.2434195,blood-flow,0.4802131,blood-flow,0.4802131
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,comparable,0.21267173,with,0.5389043,arteries,0.33967346
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,introduction,0.3353318,of,0.5877248,l-transposition,0.4046045
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,optimal,0.22326279,of,0.49022785,single-ventricle,0.35533518
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combination,0.21742424,with,0.59363616,l-transposition,0.35203728
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,microbubbles,0.2936933,blood-flow,0.46365803,blood-flow,0.46365803
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,encapsulated,0.13925833,single,0.40860635,deposits,0.39137757
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,integrative,0.37561905,of,0.42041695,l-transposition,0.39531684
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,increased,0.32251194,of,0.64014816,mi,0.42637154
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complexity,0.33769363,of,0.53220767,anomaly,0.40085608
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,future,0.43508387,great,0.53022015,cardiology,0.43508387
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,perspective,0.42978266,of,0.46585026,cardiology,0.42978266
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,enhanced,0.24384218,of,0.59523904,anomalous,0.36034083
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.43887246,blood-flow,0.45153797,blood-flow,0.45153797
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,enhanced-ultrasound,0.3524396,venous-return,0.4273839,venous-return,0.4273839
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,emerging,0.36684948,great,0.54574025,cardiology,0.36684948
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,current,0.39557698,of,0.4991414,flow,0.39574015
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,value,0.3260533,of,0.52001536,flow,0.37269968
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,current-value,0.29191443,venous-return,0.45131308,venous-return,0.45131308
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,critically,0.3664999,of,0.5690512,single-ventricle,0.4336229
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,discussed,0.42584902,as,0.54987454,cardiology,0.42584902
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,review,0.438658,of,0.54425275,cardiology,0.438658
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combined,0.24027641,with,0.60924613,single-ventricle,0.4029721
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,use,0.3219829,with,0.55726266,flow,0.40877783
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combined-use,0.27343035,congestive-heart-failure,0.42623886,congestive-heart-failure,0.42623886
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biocompatible,0.18745643,stiff,0.42799878,plaque-deposits,0.36656636
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,shell,0.20844673,deposits,0.40724415,deposits,0.40724415
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,aiding,0.32906538,of,0.593449,anomalous,0.38555634
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.32038575,arteries,0.38766253,arteries,0.38766253
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,advanced,0.34864503,with,0.51267695,congestive,0.41393596
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.2373003,tof,0.34534097,tof,0.34534097
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,0.39735788,of,0.49393907,cardiology,0.39735788
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.43887246,blood-flow,0.45153797,blood-flow,0.45153797
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.32038575,arteries,0.38766253,arteries,0.38766253
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.2373003,tof,0.34534097,tof,0.34534097
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,vasculature,0.30299646,arteries,0.6942039,arteries,0.6942039
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,temporal,0.2527347,right,0.5001071,l-transposition,0.44301236
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,spatial,0.27024955,of,0.5094393,anomalous,0.43555915
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,requires,0.29668367,of,0.62298405,l-transposition,0.37602508
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,parallel,0.21132064,double,0.5125164,flow,0.40946773
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,opened,0.38387054,great,0.51085407,d-transposition,0.40826473
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,micro,0.2726289,of,0.4380535,flow,0.42580187
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,medicine,0.64505804,cardiology,0.64505804,cardiology,0.64505804
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,interpretation,0.40555787,of,0.50155956,anomaly,0.44596976
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,improving,0.3579299,great,0.54781544,congestive,0.39419994
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,extraction,0.25589973,of,0.42793012,flow,0.40312088
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,developed,0.25309682,of,0.5174131,congestive-heart-failure,0.37625062
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biology,0.41353095,great,0.48241207,cardiology,0.41353095
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,article,0.38574833,of,0.42562225,cardiology,0.38574833
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,advances,0.40024865,great,0.516971,cardiology,0.40024865
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.32028955,venous-return,0.38625103,venous-return,0.38625103
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,showed,0.21619865,with,0.57298803,flow,0.33828264
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile,0.30681816,contractions,0.7968296,contractions,0.7968296
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.2605439,of,0.55099833,flow,0.43324804
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression-level,0.17061952,of,0.3992381,heartbeat,0.3165024
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,level-showed,0.35029104,with,0.42649803,anomaly,0.42383528
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-contractile,0.4570146,cardiac,0.7259116,cardiac,0.7259116
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile-function,0.24642703,contractions,0.6141066,contractions,0.6141066
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,affecting,0.18051222,of,0.651947,congenital,0.44826868
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,factor-affecting,0.22186814,of,0.47946793,congenital-heart-disease,0.41779873
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patient-prognosis,0.37392303,congenital-heart-disease,0.5136652,congenital-heart-disease,0.5136652
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,several,0.34988725,of,0.5990606,cardiac,0.37646228
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.23977959,blood,0.5028399,blood,0.5028399
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,noncoding,0.26443604,l-transposition,0.42429376,l-transposition,0.42429376
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,rnas,0.20463507,l-transposition,0.39053744,l-transposition,0.39053744
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,long-noncoding,0.26525214,l-transposition,0.42481884,l-transposition,0.42481884
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,noncoding-rnas,0.21754201,l-transposition,0.40093064,l-transposition,0.40093064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,multivariate,0.22754261,artery-disease,0.3808375,artery-disease,0.3808375
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,indicated,0.26161766,of,0.5998554,cardiac,0.3719351
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,multivariate-regression,0.26787254,chd,0.42576665,chd,0.42576665
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,regression-analysis,0.2483352,congenital-heart-disease,0.45024,congenital-heart-disease,0.45024
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left,0.3872844,left,1.0,left-atrial,0.6573896
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ventricular-ejection,0.45086157,ventricular,0.8827383,ventricular,0.8827383
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.32028955,venous-return,0.38625103,venous-return,0.38625103
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,obviously,0.19413023,of,0.42061973,flow,0.32253027
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,obviously-decreased,0.19747737,of,0.53326905,septal-defect,0.40227705
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,stage,0.19545637,with,0.46458423,rai,0.38722774
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remain,0.33880928,intact,0.5185459,cardiac,0.3884099
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,unclear,0.3259948,of,0.5037956,mi,0.42927802
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,e,0.21868992,double,0.39788574,eb,0.38260236
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,h,0.20228642,of,0.4345476,mi,0.34808266
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile,0.30681816,contractions,0.7968296,contractions,0.7968296
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.2605439,of,0.55099833,flow,0.43324804
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-contractile,0.4570146,cardiac,0.7259116,cardiac,0.7259116
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile-function,0.24642703,contractions,0.6141066,contractions,0.6141066
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.35961753,ventricular,0.49573958,ventricular,0.49573958
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-remodeling,0.52174294,cardiac,0.74999714,cardiac,0.74999714
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls,0.23145974,with,0.5052294,mi,0.41936132
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls-without,0.29418567,with,0.5349059,mi,0.46688402
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left,0.3872844,left,1.0,left-atrial,0.6573896
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,short,0.27641132,interrupted,0.5895587,d-transposition,0.38685596
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression-level,0.17061952,of,0.3992381,heartbeat,0.3165024
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,time,0.350901,return,0.5513821,venous-return,0.44564146
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,points,0.2814706,of,0.4826713,venous,0.38039982
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,different-time,0.19536507,of,0.4149277,venous-return,0.40377223
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,time-points,0.20965667,single,0.36874315,arteries,0.35039324
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,process,0.25394285,of,0.51408124,anomalous,0.37625128
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,pathological-process,0.30203947,congenital-heart-disease,0.46069938,congenital-heart-disease,0.46069938
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute,0.3642026,infarction,0.6294521,infarction,0.6294521
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,myocardial,0.5198858,myocardial,1.0,myocardial,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,infarction,0.51348525,infarction,1.0,infarction,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute-myocardial,0.5089395,myocardial-infarction,0.8844812,myocardial-infarction,0.8844812
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,myocardial-infarction,0.5045562,myocardial-infarction,1.0,myocardial-infarction,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute-myocardial-infarction,0.5091164,myocardial-infarction,0.9688612,myocardial-infarction,0.9688612
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,axis,0.21481177,isomerism,0.42327482,isomerism,0.42327482
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,shortening,0.26567268,contractions,0.59034956,contractions,0.59034956
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.2605439,of,0.55099833,flow,0.43324804
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-function,0.53890264,cardiac,0.7516308,cardiac,0.7516308
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression-levels,0.16651088,of,0.415446,heart-failure,0.32725888
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.35961753,ventricular,0.49573958,ventricular,0.49573958
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-remodeling,0.52174294,cardiac,0.74999714,cardiac,0.74999714
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,stage,0.19545637,with,0.46458423,rai,0.38722774
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.23977959,blood,0.5028399,blood,0.5028399
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,h,0.20228642,of,0.4345476,mi,0.34808266
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,hypertrophy,0.39164293,ventricular,0.61984503,ventricular,0.61984503
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-hypertrophy,0.514227,cardiac,0.7407805,cardiac,0.7407805
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,substantially,0.28010243,of,0.5883337,mi,0.37401792
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,population,0.3190225,of,0.49866888,chd,0.40046495
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,days,0.30872357,return,0.45523614,beats,0.4033618
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,mortality-rate,0.32992098,heart-failure,0.5245548,heart-failure,0.5245548
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.23977959,blood,0.5028399,blood,0.5028399
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,lncrnas,0.20235431,hlhs,0.3260065,hlhs,0.3260065
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami-patients,0.40089917,heart-failure,0.59721494,heart-failure,0.59721494
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.32028955,venous-return,0.38625103,venous-return,0.38625103
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,standardized,0.29216456,of,0.41352266,flow,0.37584457
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,significantly,0.23700657,with,0.568532,mi,0.39826992
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,increased,0.32251194,of,0.64014816,mi,0.42637154
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,significantly-increased,0.27051136,with,0.5801536,mi,0.429283
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,reportedly,0.34747487,with,0.54191303,cardiac,0.41607368
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartile,0.30651978,chd,0.4760239,chd,0.4760239
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,values,0.29641503,with,0.49059534,flow,0.3883159
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,roles,0.26051345,of,0.45427072,l-transposition,0.29379755
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,positively,0.21362174,with,0.55060977,cholesterol,0.37044814
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,positively-associated,0.18648505,of,0.54713905,deposits,0.43823004
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,may,0.26963884,of,0.58654004,anomalous,0.366544
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,serve,0.23708555,as,0.69219697,heart-attack,0.28737742
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,independent,0.28915384,of,0.5904635,cad,0.4052443
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,predictor,0.24674982,as,0.45541835,chd,0.39992505
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,independent-predictor,0.29390222,venous-return,0.49250972,venous-return,0.49250972
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,grouped,0.3006582,isolated,0.51113355,artery-disease,0.3435273
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,according,0.3426876,as,0.48304257,rai,0.3796531
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,b,0.20100933,of,0.43435428,aortic,0.34993017
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,consecutively,0.3794828,with,0.50892293,cardiology,0.3794828
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,enrolled,0.4130389,cardiology,0.4130389,cardiology,0.4130389
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,consecutively-enrolled,0.34910113,single,0.42208743,single-ventricle,0.41945672
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,clinical-parameters,0.40269548,venous-return,0.50810385,venous-return,0.50810385
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiovascular-diseases,0.51660174,heart-disease,0.6925421,heart-disease,0.6925421
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,candidate,0.2506774,as,0.50267786,cad,0.32472426
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,biomarker,0.22552925,as,0.44500005,artery-disease,0.3425546
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,candidate-biomarker,0.2919228,artery-disease,0.41821122,artery-disease,0.41821122
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,blood,0.32078606,blood,1.0,blood,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,samples,0.20068786,isolated,0.4879529,blood,0.4540816
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,blood-samples,0.2633406,blood,0.64031124,blood,0.64031124
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,transcript,0.14997926,l-transposition,0.36229712,l-transposition,0.36229712
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,three-patients,0.30540746,congestive-heart-failure,0.5296627,congestive-heart-failure,0.5296627
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,highest,0.26377243,of,0.5054526,mi,0.33820426
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartiles,0.30738634,chd,0.47932488,chd,0.47932488
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,highest-quartiles,0.35878888,chd,0.49253953,chd,0.49253953
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.5391634,infarction,0.80551064,infarction,0.80551064
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls,0.23145974,with,0.5052294,mi,0.41936132
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.35961753,ventricular,0.49573958,ventricular,0.49573958
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartiles,0.30738634,chd,0.47932488,chd,0.47932488
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,lncrnas,0.20235431,hlhs,0.3260065,hlhs,0.3260065
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,v,0.240002,sv,0.44191512,sv,0.44191512
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,results,0.29712585,of,0.53157276,blood,0.36869162
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,post,0.3914922,failure,0.52308416,mi,0.5076717
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,phase,0.19908471,of,0.4318388,flow,0.38942474
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,p,0.29391026,with,0.4559728,congestive,0.4058217
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,measured,0.2266986,of,0.539739,flow,0.4470259
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,however,0.30646515,of,0.624624,mi,0.41109186
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,fifty,0.27976424,total,0.36383316,d-transposition,0.3353757
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,early,0.34221643,of,0.5714519,mi,0.3991026
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,compared,0.26227483,with,0.62448335,mi,0.40925252
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,background,0.2325702,of,0.51277274,congenital,0.3895001
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,goes,0.42333674,return,0.521834,anomaly,0.44362074
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,beyond,0.29394823,of,0.53781354,anomaly,0.34910303
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,standard,0.29642093,with,0.46176666,single-ventricle,0.33840466
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,beyond-standard,0.32001486,as,0.3997349,venous-return,0.39436114
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical-biomarkers,0.35244456,heart-disease,0.44833666,heart-disease,0.44833666
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,essential,0.26315036,of,0.53323644,cardiac,0.32177997
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,step,0.29224294,of,0.50852585,l-transposition,0.37552184
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,towards,0.26525512,of,0.5319467,isomerism,0.33325064
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,personalized,0.45995417,great,0.46509677,cardiology,0.45995417
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,poor,0.30703533,weak,0.56499845,congestive,0.42275512
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,outcome,0.27011925,failure,0.48584157,single-ventricle,0.45794576
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolic-health,0.37727228,chd,0.44543913,chd,0.44543913
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-outcome,0.35505724,congenital-heart-disease,0.47068334,congenital-heart-disease,0.47068334
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.3015176,great,0.41216543,single-ventricle,0.3761499
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,assessments,0.3989693,of,0.45010278,cardiology,0.3989693
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,unsupervised,0.26907045,heartbeat,0.44143736,heartbeat,0.44143736
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,machine,0.37199128,cad,0.41960585,cad,0.41960585
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,preventative,0.39801854,as,0.48935464,cardiology,0.39801854
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,risk,0.30685735,chd,0.5779637,chd,0.5779637
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,assessment,0.41014358,of,0.5184958,flow,0.45548397
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,preventative-health,0.4033103,heart-disease,0.46102196,heart-disease,0.46102196
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-risk,0.32792008,chd,0.51322144,chd,0.51322144
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,risk-assessment,0.39875644,artery-disease,0.4224608,artery-disease,0.4224608
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-risk-assessment,0.38640302,chd,0.44550955,chd,0.44550955
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subsets,0.23681092,of,0.4432634,flow,0.40812808
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,0.31118363,of,0.5086956,mi,0.36251363
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,features,0.24589524,of,0.5517558,anomaly,0.49347878
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data-features,0.28513998,heartbeat,0.44224247,heartbeat,0.44224247
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.3015176,great,0.41216543,single-ventricle,0.3761499
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.22552925,as,0.44500005,artery-disease,0.3425546
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.19695002,of,0.4672624,anomalous,0.4125278
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signature,0.17159154,of,0.43148303,anomalous,0.35161406
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,early,0.34221643,of,0.5714519,mi,0.3991026
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.19695002,of,0.4672624,anomalous,0.4125278
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential-early,0.2459723,anomalous,0.40686092,anomalous,0.40686092
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical-biomarkers,0.35244456,heart-disease,0.44833666,heart-disease,0.44833666
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,rapidly,0.2492792,of,0.5010817,deposits,0.33958977
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,moving,0.35411876,stiff,0.55220056,flow,0.4291703
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,towards,0.26525512,of,0.5319467,isomerism,0.33325064
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,rapidly-moving,0.2766256,of,0.4447991,heartbeat,0.42712906
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.3015176,great,0.41216543,single-ventricle,0.3761499
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,0.31118363,of,0.5086956,mi,0.36251363
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,integration,0.32180518,l-transposition,0.481107,l-transposition,0.481107
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data-integration,0.26154608,of,0.34224996,venous-return,0.33826643
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,statuses,0.2148955,with,0.38379776,rai,0.32720605
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-statuses,0.27254525,congenital-heart-disease,0.46502882,congenital-heart-disease,0.46502882
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,longitudinal,0.25857258,of,0.40970862,contractions,0.38807714
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,validation-cohort,0.3041053,congenital-heart-disease,0.44963866,congenital-heart-disease,0.44963866
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,lean,0.26298892,cholesterol,0.40847355,cholesterol,0.40847355
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass,0.21939,tof,0.43280137,tof,0.43280137
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,percentage,0.22564179,total,0.56536615,flow,0.3676573
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,lean-mass,0.2274222,tof,0.42430487,tof,0.42430487
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass-percentage,0.20639819,total,0.4458817,flow,0.37279359
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body,0.2371722,of,0.4173455,heartbeat,0.41062886
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass,0.21939,tof,0.43280137,tof,0.43280137
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,index,0.27677816,total,0.43109894,mi,0.39722836
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body-mass,0.2652352,chd,0.446849,chd,0.446849
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass-index,0.21219103,tof,0.35847235,tof,0.35847235
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body-mass-index,0.26269588,chd,0.40853202,chd,0.40853202
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uncovering,0.2823832,of,0.5671928,l-transposition,0.41987723
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,palmitoyl,0.1835505,cholesterol,0.51582646,cholesterol,0.51582646
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,found,0.2675444,with,0.6275196,deposits,0.41920424
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,associations,0.28502855,chd,0.42755333,chd,0.42755333
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.22552925,as,0.44500005,artery-disease,0.3425546
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.19695002,of,0.4672624,anomalous,0.4125278
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gut,0.1943257,of,0.3997327,heart,0.36844197
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.23782346,disease,0.38441348,congenital-heart-disease,0.35341972
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gut-microbiome,0.20175731,congenital-heart-disease,0.34766534,congenital-heart-disease,0.34766534
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome-health,0.34576982,congenital-heart-disease,0.43213677,congenital-heart-disease,0.43213677
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.23782346,disease,0.38441348,congenital-heart-disease,0.35341972
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genera,0.25614864,isolated,0.38867307,truncus,0.34796503
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,intestinimonas,0.24326804,truncus,0.4350179,truncus,0.4350179
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,driven,0.27247697,of,0.47781104,flow,0.40639967
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,paradigm,0.2731577,of,0.36300784,venous-return,0.34979025
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,based,0.2494699,of,0.5443143,flow,0.34116954
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,paradigm-based,0.37512684,venous-return,0.41920006,venous-return,0.41920006
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.22552925,as,0.44500005,artery-disease,0.3425546
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cardiometabolic,0.4184893,chd,0.65967995,chd,0.65967995
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,risk,0.30685735,chd,0.5779637,chd,0.5779637
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease-risk,0.2307109,disease,0.6917858,heart-disease,0.59362686
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.19695002,of,0.4672624,anomalous,0.4125278
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,method,0.18057065,of,0.41052854,anomaly,0.32515174
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,based,0.2494699,of,0.5443143,flow,0.34116954
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals-based,0.29830968,of,0.44557935,congenital-heart-disease,0.4450705
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uremic,0.24681911,insufficiency,0.5059016,heart-syndrome,0.46157768
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,toxin,0.17674324,of,0.39929807,l-transposition,0.35992947
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uremic-toxin,0.2282837,coronary-artery-disease,0.4840197,coronary-artery-disease,0.4840197
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,unclassified,0.21092707,isolated,0.4896676,hypoplastic,0.41952577
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genus,0.29988354,isolated,0.45238754,truncus,0.37378353
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subset,0.24246489,of,0.51671314,mi,0.37440532
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,membership,0.43327582,cardiology,0.43327582,cardiology,0.43327582
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modern,0.42028835,great,0.53404015,cardiology,0.42028835
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,medicine,0.64505804,cardiology,0.64505804,cardiology,0.64505804
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,integrated,0.3167261,of,0.46948645,single-ventricle,0.3645035
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,analysis,0.23442824,of,0.53198564,flow,0.34824157
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,resistance,0.17926447,failure,0.42967105,d-transposition,0.40630686
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,insulin-resistance,0.24971986,cholesterol,0.4604428,cholesterol,0.4604428
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,including,0.2742056,of,0.6619886,congenital,0.3605199
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolome,0.21230605,of,0.3771477,blood,0.36044168
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,erysipelotrichaceae,0.26229343,truncus,0.4179765,truncus,0.4179765
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,family,0.39850003,cardiology,0.39850003,cardiology,0.39850003
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,driven,0.27247697,of,0.47781104,flow,0.40639967
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diverse,0.3032622,of,0.5461366,cardiac,0.3471622
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modalities,0.38329607,failure,0.41704154,congenital-heart,0.39930683
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subtypes,0.18962988,of,0.41811728,paivs,0.3762575
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease-subtypes,0.20880938,disease,0.61093676,artery-disease,0.5267073
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,different,0.24309576,of,0.61590904,anomalous,0.37924677
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modalities,0.38329607,failure,0.41704154,congenital-heart,0.39930683
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cresol,0.2179606,weak,0.33671367,clot,0.32878008
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,sulfate,0.20965305,cholesterol,0.4141973,cholesterol,0.4141973
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,predictor,0.24674982,as,0.45541835,chd,0.39992505
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,another,0.37102824,single,0.67103195,mi,0.41113138
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolite,0.16395271,isomerism,0.35460934,isomerism,0.35460934
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,advanced,0.34864503,with,0.51267695,congestive,0.41393596
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,advanced-imaging,0.39593658,single-ventricle,0.44513568,single-ventricle,0.44513568
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results,0.29712585,of,0.53157276,blood,0.36869162
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results-demonstrate,0.35938346,of,0.5512711,venous-return,0.45336813
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.19695002,of,0.4672624,anomalous,0.4125278
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,0.31118363,of,0.5086956,mi,0.36251363
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.23782346,disease,0.38441348,congenital-heart-disease,0.35341972
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results,0.29712585,of,0.53157276,blood,0.36869162
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,utilized,0.28006944,of,0.59412074,flow,0.39086547
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stearoyl,0.14947651,cholesterol,0.49860644,cholesterol,0.49860644
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stages,0.18231006,of,0.45860782,deposits,0.40678376
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,set,0.43165553,of,0.5846941,cardiology,0.43165553
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,p,0.29391026,with,0.4559728,congestive,0.4058217
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,oleoyl,0.1589228,cholesterol,0.5082258,cholesterol,0.5082258
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methodology,0.283471,of,0.41219762,single-ventricle,0.29670447
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,linolenoyl,0.15842095,cholesterol,0.48211908,cholesterol,0.48211908
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identification,0.20758381,of,0.5418171,d-transposition,0.3482393
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gpc,0.1757393,ivs,0.3082713,ivs,0.3082713
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genetics,0.47455078,cardiology,0.47455078,cardiology,0.47455078
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,enyl,0.1653007,isomerism,0.42758608,isomerism,0.42758608
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,dihomo,0.190233,cholesterol,0.43370292,cholesterol,0.43370292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,conclusions,0.259925,with,0.50001186,artery,0.34474826
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,combination,0.21742424,with,0.59363616,l-transposition,0.35203728
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cinnamoylglycine,0.14376318,isomerism,0.36400795,isomerism,0.36400795
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,background,0.2325702,of,0.51277274,congenital,0.3895001
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,additionally,0.26417398,of,0.6596129,flow,0.38005078
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,abundance,0.22053209,of,0.4682694,deposits,0.38831514
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,analyses,0.1956715,of,0.44186428,deposits,0.31060207
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.26963884,of,0.58654004,anomalous,0.366544
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific,0.26268506,of,0.6059094,flow,0.40644997
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.3915413,attack,0.39841455,cardiology,0.3915413
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotypes,0.33858582,disease,0.42732275,single-ventricle,0.4160347
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,learning-analyses,0.3539902,congenital-heart-disease,0.44580126,congenital-heart-disease,0.44580126
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may-demonstrate,0.32238758,of,0.5578029,anomalous,0.4521674
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,demonstrate-specific,0.21284573,of,0.51647747,l-transposition,0.3939049
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific-food,0.23438935,of,0.40231144,flow,0.32787877
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-allergy,0.3174482,heart-disease,0.35407925,heart-disease,0.35407925
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.26858273,attack,0.4407363,pulmonary,0.43133485
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experience,0.38681114,of,0.5036937,congenital-heart-disease,0.45451656
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,stereotypical,0.24340266,irregular,0.4820822,heartbeat,0.45447457
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,symptoms,0.29561567,disease,0.5364805,syndrome,0.5318241
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,following,0.33078983,with,0.61268795,cardiac,0.4240192
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.19533649,pulmonary,0.36316633,pulmonary,0.36316633
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exposure,0.19340545,of,0.47989124,deposits,0.29644954
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic-patients,0.3505612,congenital-heart-disease,0.55810285,congenital-heart-disease,0.55810285
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patients-experience,0.4209547,congenital-heart-disease,0.55786085,congenital-heart-disease,0.55786085
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen-exposure,0.13926488,pulmonary,0.3834439,pulmonary,0.3834439
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,symptoms,0.29561567,disease,0.5364805,syndrome,0.5318241
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experienced,0.3416694,with,0.51668775,mitral-regurgitation,0.39382553
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,following,0.33078983,with,0.61268795,cardiac,0.4240192
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.19533649,pulmonary,0.36316633,pulmonary,0.36316633
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exposure,0.19340545,of,0.47989124,deposits,0.29644954
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen-exposure,0.13926488,pulmonary,0.3834439,pulmonary,0.3834439
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.19533649,pulmonary,0.36316633,pulmonary,0.36316633
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,immunotherapy,0.2323603,disease,0.34643897,rai,0.34326085
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.26963884,of,0.58654004,anomalous,0.366544
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,modulate,0.1707263,of,0.4374981,contractions,0.31312442
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen-immunotherapy,0.21208024,pulmonary,0.3534922,pulmonary,0.3534922
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,immunotherapy-may,0.24650095,rai,0.4158296,rai,0.4158296
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,selections,0.30054075,of,0.45600498,l-transposition,0.40875995
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.26963884,of,0.58654004,anomalous,0.366544
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impact,0.2996394,of,0.5528908,single-ventricle,0.35865143
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,upon,0.3047079,of,0.6212549,cardiac,0.40890452
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impact-upon,0.3171579,clot,0.42939276,clot,0.42939276
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,supervised,0.41056764,cardiology,0.41056764,cardiology,0.41056764
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,oral,0.3003844,of,0.46959797,plaque,0.38315025
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,challenge,0.2694021,great,0.4729702,single-ventricle,0.2998554
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-challenge,0.16004547,heart-attack,0.32121336,heart-attack,0.32121336
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,oral-food-challenge,0.16853413,heart-disease,0.346082,heart-disease,0.346082
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific,0.26268506,of,0.6059094,flow,0.40644997
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.17841876,attack,0.4534219,isomerism,0.37329036
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.21512172,defect,0.48261124,septal-defect,0.46157122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist,0.21226555,of,0.4884736,isomerism,0.35204807
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.3915413,attack,0.39841455,cardiology,0.3915413
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,encompasses,0.20780577,of,0.47999692,anomaly,0.32865775
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-allergy,0.3174482,heart-disease,0.35407925,heart-disease,0.35407925
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.31226635,attack,0.45969447,thrombosis,0.44926143
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.26963884,of,0.58654004,anomalous,0.366544
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-anaphylaxis,0.30508333,attack,0.43821493,bradycardia,0.43144655
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,unpublished,0.31881666,congenital-heart-disease,0.33518553,congenital-heart-disease,0.33518553
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,literature,0.36901063,of,0.4653955,anomaly,0.4380433
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,relating,0.3349253,of,0.6561698,anomalous,0.4465988
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,useful,0.19749163,great,0.46134508,anomalous,0.31390148
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinically-useful,0.23796931,of,0.48739272,artery-disease,0.37706125
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,applying,0.31743535,of,0.5178681,flow,0.39249074
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,unbiased,0.20180073,of,0.37744248,single-ventricle,0.31814313
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,facilitating,0.26191533,of,0.5844613,l-transposition,0.36947644
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk-stratification,0.45956326,congestive-heart-failure,0.50061274,congestive-heart-failure,0.50061274
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.17841876,attack,0.4534219,isomerism,0.37329036
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.21512172,defect,0.48261124,septal-defect,0.46157122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,theme,0.4220403,cardiology,0.4220403,cardiology,0.4220403
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.21512172,defect,0.48261124,septal-defect,0.46157122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experience,0.38681114,of,0.5036937,congenital-heart-disease,0.45451656
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical-experience,0.4146638,congenital-heart-disease,0.5367204,congenital-heart-disease,0.5367204
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.3915413,attack,0.39841455,cardiology,0.3915413
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-allergy,0.3174482,heart-disease,0.35407925,heart-disease,0.35407925
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.26858273,attack,0.4407363,pulmonary,0.43133485
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reactions,0.19414587,attack,0.51968586,isomerism,0.39114773
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic-reactions,0.29277354,attack,0.43249238,heart-disease,0.42220777
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.26858273,attack,0.4407363,pulmonary,0.43133485
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.17841876,attack,0.4534219,isomerism,0.37329036
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.21512172,defect,0.48261124,septal-defect,0.46157122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severe,0.29645193,insufficiency,0.65468115,stenosis,0.5520288
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,many,0.34462097,great,0.5654564,deposits,0.36972266
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,hypersensitivities,0.19372627,with,0.44051754,syndrome,0.43251532
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,pathophysiology,0.33037353,syndrome,0.49234846,syndrome,0.49234846
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,cohorts,0.31992877,chd,0.47250944,chd,0.47250944
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severe,0.29645193,insufficiency,0.65468115,stenosis,0.5520288
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.31226635,attack,0.45969447,thrombosis,0.44926143
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,practice,0.5339576,cardiology,0.5339576,cardiology,0.5339576
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical-practice,0.51884663,cardiology,0.51884663,cardiology,0.51884663
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.31226635,attack,0.45969447,thrombosis,0.44926143
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,caused,0.1752007,of,0.53973085,congenital,0.42777976
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,prescribe,0.39689106,failure,0.40008497,cardiology,0.39689106
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,eai,0.19398329,lai,0.46294764,lai,0.46294764
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,nonfood,0.21549867,mitral-regurgitation,0.3643021,mitral-regurgitation,0.3643021
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,triggers,0.19985464,of,0.51567614,heart-attack,0.39722702
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,integrating,0.34347022,of,0.50606865,single-ventricle,0.34793606
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,area,0.34147155,left,0.4808709,stenosis,0.41823816
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotype,0.29205388,single-ventricle,0.41166753,single-ventricle,0.41166753
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,discovery,0.32526702,of,0.46573353,d-transposition,0.33412263
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotype-discovery,0.34342974,congenital-heart-disease,0.45770967,congenital-heart-disease,0.45770967
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,current,0.39557698,of,0.4991414,flow,0.39574015
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,inability,0.237943,failure,0.52600026,clot,0.37616032
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient-management,0.49347812,cardiology,0.49347812,cardiology,0.49347812
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,one-patient,0.37053263,venous-return,0.47466394,venous-return,0.47466394
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,0.31118363,of,0.5086956,mi,0.36251363
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,sources,0.3096738,of,0.47692496,deposits,0.42191344
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data-sources,0.38091695,cardiology,0.38091695,cardiology,0.38091695
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,available,0.34700432,with,0.5165225,cardiology,0.34700432
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,0.31118363,of,0.5086956,mi,0.36251363
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,available-data,0.32734206,venous-return,0.44035366,venous-return,0.44035366
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,way,0.312438,of,0.5753952,anomalous,0.40993068
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,emerging,0.36684948,great,0.54574025,cardiology,0.36684948
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.2925127,of,0.4080668,mitral-regurgitation,0.37309355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.21512172,defect,0.48261124,septal-defect,0.46157122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist,0.21226555,of,0.4884736,isomerism,0.35204807
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,0.31118363,of,0.5086956,mi,0.36251363
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,way,0.312438,of,0.5753952,anomalous,0.40993068
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,emerging,0.36684948,great,0.54574025,cardiology,0.36684948
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,varies,0.25815567,of,0.58237076,anomalous,0.35784957
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severity,0.26182276,disease,0.53417194,stenosis,0.46909103
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,robust,0.13868469,weak,0.46394548,heartbeat,0.35403174
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,results,0.29712585,of,0.53157276,blood,0.36869162
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,relevance,0.3301295,of,0.5866257,congenital-heart-disease,0.34820747
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,range,0.29700014,of,0.40102404,cardiac,0.33579552
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,perhaps,0.30562022,of,0.598087,l-transposition,0.4098048
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,objective,0.2960808,of,0.5255821,flow,0.39260852
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,number,0.2521113,total,0.48291022,l-transposition,0.33454442
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,much,0.3522751,great,0.59738654,flow,0.382453
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,manner,0.18540666,with,0.42496896,contractions,0.388913
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,likely,0.34048563,of,0.55071557,congestive,0.42744756
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,improvements,0.3280268,great,0.45946363,single-ventricle,0.39016998
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impacting,0.2723326,of,0.59977853,deposits,0.3630358
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,given,0.43020725,with,0.60330975,cardiology,0.43020725
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,g,0.21858013,single,0.41386712,ivs,0.37229383
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,future,0.43508387,great,0.53022015,cardiology,0.43508387
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,e,0.21868992,double,0.39788574,eb,0.38260236
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,discuss,0.45486575,great,0.48184678,cardiology,0.45486575
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,determined,0.24003299,of,0.6221287,flow,0.40728092
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,decision,0.46018064,cardiology,0.46018064,cardiology,0.46018064
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,currently,0.4246831,of,0.5011201,cardiology,0.4246831
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,confirm,0.2632276,of,0.48014945,anomalous,0.34633434
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,community,0.41644448,great,0.43391618,cardiology,0.41644448
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clearly,0.29165617,of,0.5921297,deposits,0.43008348
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,asthma,0.33560252,pulmonary,0.50573623,pulmonary,0.50573623
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,another,0.37102824,single,0.67103195,mi,0.41113138
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,may,0.26963884,of,0.58654004,anomalous,0.366544
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,facilitate,0.2564506,of,0.4863937,flow,0.32320783
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,optimal,0.22326279,of,0.49022785,single-ventricle,0.35533518
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,candidate,0.2506774,as,0.50267786,cad,0.32472426
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,approaches-may,0.32705605,great,0.41130945,venous-return,0.38746348
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,candidate-selection,0.26738742,of,0.47542176,l-transposition,0.41872686
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,based-risk,0.24811566,chd,0.4742167,chd,0.4742167
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk-stratification,0.45956326,congestive-heart-failure,0.50061274,congestive-heart-failure,0.50061274
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,stratification-system,0.35641927,congenital-heart-disease,0.46504784,congenital-heart-disease,0.46504784
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.32738048,valve,0.51556367,valve,0.51556367
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,along,0.29572746,of,0.6050292,deposits,0.43321627
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.43114763,congenital-heart-disease,0.50982094,congenital-heart-disease,0.50982094
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-implantation,0.37094906,single-ventricle,0.5201714,single-ventricle,0.5201714
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,resynchronization,0.53864866,ventricular,0.6634342,ventricular,0.6634342
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.43114763,congenital-heart-disease,0.50982094,congenital-heart-disease,0.50982094
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiac-resynchronization,0.5445614,heart-failure,0.700041,heart-failure,0.700041
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.32738048,valve,0.51556367,valve,0.51556367
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.43114763,congenital-heart-disease,0.50982094,congenital-heart-disease,0.50982094
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-implantation,0.37094906,single-ventricle,0.5201714,single-ventricle,0.5201714
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.32738048,valve,0.51556367,valve,0.51556367
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.43114763,congenital-heart-disease,0.50982094,congenital-heart-disease,0.50982094
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-implantation,0.37094906,single-ventricle,0.5201714,single-ventricle,0.5201714
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver,0.2488175,stenosis,0.38058472,stenosis,0.38058472
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,operating,0.35147023,of,0.42011455,venous-return,0.38749343
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,characteristic,0.14630476,of,0.52064013,anomalous,0.42846608
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,curves,0.20727307,of,0.40860695,contractions,0.37883943
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver-operating,0.27902067,stenosis,0.41488302,stenosis,0.41488302
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,operating-characteristic,0.26187587,of,0.50360763,venous-return,0.39550078
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,characteristic-curves,0.16846442,anomalous,0.45860064,anomalous,0.45860064
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver-operating-characteristic,0.25317627,stenosis,0.38405818,stenosis,0.38405818
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,good,0.31429055,weak,0.60268193,venous-return,0.38116372
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,discriminative,0.21007073,of,0.40440422,heartbeat,0.33230054
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,capabilities,0.2622909,great,0.4978534,flow,0.35608345
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,seattle,0.4758947,cardiology,0.4758947,cardiology,0.4758947
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,heart,0.57664216,heart,1.0,heart,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,already,0.3845447,as,0.5674546,cardiology,0.3845447
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,existing,0.31199914,of,0.558287,venous-return,0.39574036
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,already-existing,0.27448764,of,0.5787356,congenital-heart-disease,0.41582265
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk-scores,0.35254818,chd,0.49175406,chd,0.49175406
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,deaths,0.3430967,chd,0.5073302,chd,0.5073302
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,oxford,0.32628262,cardiology,0.32628262,cardiology,0.32628262
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,university,0.5321148,cardiology,0.5321148,cardiology,0.5321148
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,press,0.43476897,cardiology,0.43476897,cardiology,0.43476897
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implant,0.30454606,valve,0.4764432,valve,0.4764432
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,clinical-features,0.37961507,congenital-heart-disease,0.49426478,congenital-heart-disease,0.49426478
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best,0.3534876,as,0.5428521,anomaly,0.36822265
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,performing,0.32193437,of,0.5269445,l-transposition,0.43296793
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best-performing,0.2736585,single,0.41598532,venous-return,0.33500934
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-patients,0.4327467,heart-failure,0.6089967,heart-failure,0.6089967
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,estimated,0.2633227,of,0.52809477,chd,0.38898614
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,existing,0.31199914,of,0.558287,venous-return,0.39574036
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,score,0.286516,total,0.3966952,stenosis,0.38543224
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-score,0.3197089,heart-failure,0.4269993,heart-failure,0.4269993
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,discriminative,0.21007073,of,0.40440422,heartbeat,0.33230054
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ability,0.2123124,of,0.53612673,cardiac,0.340167
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,score,0.286516,total,0.3966952,stenosis,0.38543224
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implant,0.30454606,valve,0.4764432,valve,0.4764432
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best,0.3534876,as,0.5428521,anomaly,0.36822265
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best-performance,0.2893415,venous-return,0.39736792,venous-return,0.39736792
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,training-cohort,0.39458346,venous-return,0.4664943,venous-return,0.4664943
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,retrospective,0.3446992,congenital-heart-disease,0.46667808,congenital-heart-disease,0.46667808
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,database,0.34863436,congenital-heart-disease,0.35068005,congenital-heart-disease,0.35068005
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,personalized,0.45995417,great,0.46509677,cardiology,0.45995417
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,linear,0.17840835,of,0.40123588,isomerism,0.35944843
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,association,0.34312242,of,0.45371312,chd,0.39406395
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,linear-association,0.28070003,of,0.47062337,anomalous,0.42709166
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,independent,0.28915384,of,0.5904635,cad,0.4052443
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,european,0.43573785,cardiology,0.43573785,cardiology,0.43573785
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,society,0.5570969,cardiology,0.5570969,cardiology,0.5570969
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause-death,0.28893504,heart-failure,0.53945255,heart-failure,0.53945255
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.39816982,failure,0.4387355,mi,0.41719383
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year-follow,0.47264957,cardiology,0.47264957,cardiology,0.47264957
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause-mortality,0.32417238,heart-disease,0.5488442,heart-disease,0.5488442
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,classifiers,0.28955632,congenital-heart-disease,0.36196706,congenital-heart-disease,0.36196706
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,pre,0.4298201,mi,0.50940144,mi,0.50940144
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.39816982,failure,0.4387355,mi,0.41719383
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year-mortality,0.3652275,chd,0.5247508,chd,0.5247508
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.39427227,cardiac,0.48111826,cardiac,0.48111826
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.39816982,failure,0.4387355,mi,0.41719383
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,pre,0.4298201,mi,0.50940144,mi,0.50940144
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,valid,0.20664714,of,0.3830687,venous-return,0.33503646
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,train,0.39593512,contractions,0.4625386,contractions,0.4625386
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,thirty,0.23964897,isolated,0.3792717,artery,0.32498515
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,tested,0.25299942,of,0.5634051,contractions,0.36297208
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,superior,0.22466877,left,0.47532085,artery,0.45800436
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweis,0.5036564,cardiology,0.5036564,cardiology,0.5036564
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,screen,0.294617,as,0.44903493,blood,0.3336369
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,results,0.29712585,of,0.53157276,blood,0.36869162
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,prognostication,0.4067774,infarction,0.46078825,infarction,0.46078825
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,period,0.34860444,return,0.46809125,venous-return,0.39146286
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,p,0.29391026,with,0.4559728,congestive,0.4058217
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,outperformed,0.21899322,with,0.34466875,mi,0.298222
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,non,0.3477749,with,0.61364555,mi,0.46788454
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,eaarn,0.2826893,lai,0.31374043,lai,0.31374043
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,develop,0.22949755,of,0.43968886,congestive-heart-failure,0.35599005
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,com,0.2641307,stenosis,0.41235548,stenosis,0.41235548
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ci,0.26988983,congestive,0.4084356,congestive,0.4084356
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,capturing,0.3552059,of,0.5090049,heart-attack,0.44546878
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,behalf,0.44911885,cardiology,0.44911885,cardiology,0.44911885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,available,0.34700432,with,0.5165225,cardiology,0.34700432
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,author,0.39858195,anomaly,0.4089887,anomaly,0.4089887
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,areas,0.32283562,deposits,0.49041492,deposits,0.49041492
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,among,0.2573181,of,0.57348,chd,0.4274787
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,separate,0.26202708,single,0.64554334,anomalous,0.42240894
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.3576874,heartbeat,0.49518034,heartbeat,0.49518034
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,types,0.20959784,of,0.5479486,deposits,0.41371265
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,leads,0.23349127,of,0.52666616,anomalous,0.39397147
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results,0.29712585,of,0.53157276,blood,0.36869162
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,obtains,0.25131318,of,0.51862717,heartbeat,0.37934202
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results,0.29712585,of,0.53157276,blood,0.36869162
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,compared,0.26227483,with,0.62448335,mi,0.40925252
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed-method,0.23571166,venous-return,0.4392628,venous-return,0.4392628
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results-compared,0.32890955,with,0.5227665,single-ventricle,0.44462198
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,considering,0.390096,of,0.67813045,anomaly,0.42943254
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signals,0.2345418,heartbeat,0.4749927,heartbeat,0.4749927
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,three-different,0.17349479,hypoplastic-left-heart,0.4551201,hypoplastic-left-heart,0.4551201
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,apply,0.35898855,as,0.49237603,flow,0.37139842
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,convolutional,0.30860516,venous-return,0.43876672,venous-return,0.43876672
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,networks,0.2352877,great,0.3902747,venous-return,0.35607615
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,neural-networks,0.2428932,heartbeat,0.4383191,heartbeat,0.4383191
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,convolutional-neural-networks,0.26347625,venous-return,0.4855036,venous-return,0.4855036
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,classical,0.20888516,of,0.5018253,anomalous,0.39610407
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,learning-approaches,0.28315347,single-ventricle,0.4005476,single-ventricle,0.4005476
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,tachycardia,0.51652616,tachycardia,1.0,tachycardia,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,arrhythmia,0.56890047,tachycardia,0.8145603,tachycardia,0.8145603
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular-tachycardia,0.55685866,tachycardia,0.87852144,tachycardia,0.87852144
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false,0.24112374,incompetence,0.47949332,congenital-heart-disease,0.4340317
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.3576874,heartbeat,0.49518034,heartbeat,0.49518034
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,task,0.3549496,heartbeat,0.41896272,heartbeat,0.41896272
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false-alarm,0.22466028,heartbeat,0.45504123,heartbeat,0.45504123
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,true,0.25466222,of,0.54722285,anomalous,0.4743598
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarms,0.4054026,beats,0.5311514,beats,0.5311514
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,using,0.20786116,with,0.58010674,flow,0.41007757
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,single,0.2571312,single,1.0,anomalous,0.40611145
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,evaluation,0.3957072,of,0.5653497,cardiology,0.3957072
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results,0.29712585,of,0.53157276,blood,0.36869162
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,demonstrate,0.17463154,of,0.5097414,anomalous,0.34764066
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results-demonstrate,0.35938346,of,0.5512711,venous-return,0.45336813
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,achieves,0.16942273,of,0.43828124,venous-return,0.3235216
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed-method,0.23571166,venous-return,0.4392628,venous-return,0.4392628
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,efficiently,0.20414653,with,0.45300508,l-transposition,0.3351345
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,using,0.20786116,with,0.58010674,flow,0.41007757
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,deep,0.25718108,venous,0.51692,venous,0.51692
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,deep-learning,0.30304694,venous-return,0.43025902,venous-return,0.43025902
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,challenge,0.2694021,great,0.4729702,single-ventricle,0.2998554
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,units,0.36851507,of,0.40316433,cardiology,0.36851507
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,term-memory,0.2171993,congenital-heart-disease,0.40778854,congenital-heart-disease,0.40778854
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,memory-units,0.2487119,heartbeat,0.3573246,heartbeat,0.3573246
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,temporal,0.2527347,right,0.5001071,l-transposition,0.44301236
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,information,0.36363098,of,0.47314215,mi,0.39006084
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,presented,0.34475142,with,0.61236936,anomaly,0.42759705
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,temporal-information,0.30582395,heartbeat,0.4658491,heartbeat,0.4658491
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,requiring,0.41966182,with,0.55874515,arrythmia,0.47569272
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,prior,0.4127312,with,0.61325395,mi,0.4958433
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,knowledge,0.32453293,of,0.4580958,congenital-heart-disease,0.38427317
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,prior-knowledge,0.3704738,congenital-heart-disease,0.45942605,congenital-heart-disease,0.45942605
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive,0.5087563,cardiology,0.5087563,cardiology,0.5087563
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,units,0.36851507,of,0.40316433,cardiology,0.36851507
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive-care,0.5471461,cardiology,0.5471461,cardiology,0.5471461
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,care-units,0.42415786,heart-failure,0.4271557,heart-failure,0.4271557
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive-care-units,0.48524326,heart-failure,0.52799934,heart-failure,0.52799934
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,extract,0.18317053,isolated,0.47450352,contractions,0.30578932
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,time,0.350901,return,0.5513821,venous-return,0.44564146
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,segmented,0.25126714,irregular,0.44090593,hypoplastic-left-heart,0.4250005
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,input,0.31766397,of,0.44965258,flow,0.4458027
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signal,0.21521182,abnormal,0.44133407,heartbeat,0.40503716
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,input-signal,0.21547571,heartbeat,0.45849827,heartbeat,0.45849827
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,step,0.29224294,of,0.50852585,l-transposition,0.37552184
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,step-training,0.40483746,contractions,0.48099697,contractions,0.48099697
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,e,0.21868992,double,0.39788574,eb,0.38260236
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,pre,0.4298201,mi,0.50940144,mi,0.50940144
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false,0.24112374,incompetence,0.47949332,congenital-heart-disease,0.4340317
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarms,0.4054026,beats,0.5311514,beats,0.5311514
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false-alarms,0.25599703,heartbeat,0.4634556,heartbeat,0.4634556
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.3576874,heartbeat,0.49518034,heartbeat,0.49518034
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,type,0.18854949,of,0.48202556,aortic,0.35779506
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.3576874,heartbeat,0.49518034,heartbeat,0.49518034
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,arrhythmia,0.56890047,tachycardia,0.8145603,tachycardia,0.8145603
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signal,0.21521182,abnormal,0.44133407,heartbeat,0.40503716
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,segments,0.19482392,arteries,0.5241684,arteries,0.5241684
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,g,0.21858013,single,0.41386712,ivs,0.37229383
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ignoring,0.3145688,great,0.45397657,anomalous,0.44817415
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposes,0.26639524,of,0.46535483,venous-return,0.35827467
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,physionet,0.4695096,cardiology,0.4695096,cardiology,0.4695096
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,computing,0.3731914,great,0.422275,heartbeat,0.39295244
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,modal,0.2255877,irregular,0.4551568,anomalous,0.45063016
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,biosignals,0.3511502,heartbeat,0.5645894,heartbeat,0.5645894
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,short,0.27641132,interrupted,0.5895587,d-transposition,0.38685596
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,long-short,0.23407672,interrupted,0.5268354,fibrillation,0.40672955
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,lead,0.2468082,of,0.48279357,anomalous,0.37930223
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ecg,0.51873946,tachycardia,0.60360324,tachycardia,0.60360324
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,lead-ecg,0.393147,myocardial-infarction,0.49941587,myocardial-infarction,0.49941587
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,invariant,0.1417568,anomalous,0.42377535,anomalous,0.42377535
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,regions,0.21387641,of,0.44606626,deposits,0.4394856
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,existing,0.31199914,of,0.558287,venous-return,0.39574036
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,engineered,0.19336581,great,0.44207865,septal-defect,0.3887356
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,either,0.20727676,with,0.6436424,l-transposition,0.41341084
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,rule,0.36790693,of,0.43182892,anomaly,0.41114575
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,effectively,0.23149472,with,0.5521965,flow,0.3457586
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,suppresses,0.10932903,of,0.44277707,contractions,0.31527296
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,dataset,0.29588008,single,0.35144186,heartbeat,0.33722848
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,provided,0.3710292,of,0.61110586,flow,0.38950795
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,build,0.3282647,return,0.41278917,venous-return,0.358903
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,rules,0.34928846,of,0.44750106,anomalous,0.37612158
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,based,0.2494699,of,0.5443143,flow,0.34116954
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,based-methods,0.24131359,congenital-heart-disease,0.33329123,congenital-heart-disease,0.33329123
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,attention,0.40598124,great,0.5764737,cardiology,0.40598124
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,current,0.39557698,of,0.4991414,flow,0.39574015
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,work,0.41337943,return,0.5383546,cardiology,0.41337943
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.3576874,heartbeat,0.49518034,heartbeat,0.49518034
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,single,0.2571312,single,1.0,anomalous,0.40611145
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,e,0.21868992,double,0.39788574,eb,0.38260236
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,work,0.41337943,return,0.5383546,cardiology,0.41337943
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,tuning,0.22240433,of,0.43968183,anomalous,0.42046592
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,specificity,0.22204962,of,0.4346917,cad,0.34837636
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,put,0.42820764,return,0.58753204,cardiology,0.42820764
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,multi,0.3120417,single,0.49181098,cad,0.38921657
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,literature,0.36901063,of,0.4653955,anomaly,0.4380433
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,likely,0.34048563,of,0.55071557,congestive,0.42744756
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,icus,0.58352995,cardiology,0.58352995,cardiology,0.58352995
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,hand,0.3170963,right,0.5377352,hypoplastic-left,0.37238127
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,fine,0.30469137,irregular,0.53885865,deposits,0.5266768
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,experiments,0.20130633,of,0.4657672,flow,0.3524469
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,emphasis,0.3753089,of,0.5659702,atresia-with,0.3835501
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,depending,0.2825969,of,0.5352007,cardiac,0.37022796
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,contribute,0.20002447,of,0.5196437,anomalous,0.32585382
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,consider,0.49515226,of,0.5644523,cardiology,0.49515226
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,capture,0.32566327,flow,0.4278125,flow,0.4278125
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,auc,0.18832418,chd,0.29138696,chd,0.29138696
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,investigate,0.20519872,of,0.48247698,anomalous,0.30501914
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.32078606,blood,1.0,blood,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.26906762,with,0.5145365,mi,0.4093958
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,among,0.2573181,of,0.57348,chd,0.4274787
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.25967306,blood,0.565806,blood,0.565806
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose-control,0.20702225,cholesterol,0.408536,cholesterol,0.408536
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back,0.4498716,return,0.6082387,arrythmia,0.4792254
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,propagation,0.22916555,of,0.4872983,flow,0.44104272
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back-propagation,0.28929222,heartbeat,0.44974694,heartbeat,0.44974694
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,propagation-artificial,0.22210151,heartbeat,0.4515155,heartbeat,0.4515155
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,artificial-neural,0.22358572,congenital-heart-disease,0.49487492,congenital-heart-disease,0.49487492
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,neural-network,0.2583411,heartbeat,0.44916824,heartbeat,0.44916824
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back-propagation-artificial,0.23607072,heartbeat,0.4575512,heartbeat,0.4575512
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,artificial-neural-network,0.22481197,congenital-heart-disease,0.4687531,congenital-heart-disease,0.4687531
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,common,0.21206799,of,0.500178,anomaly,0.44165826
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning-algorithms,0.3700234,heartbeat,0.46502528,heartbeat,0.46502528
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rf,0.26887482,right-atrial,0.36829585,right-atrial,0.36829585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,support,0.36322898,return,0.46409142,flow,0.36807415
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,vector,0.20063998,l-transposition,0.3898847,l-transposition,0.3898847
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,support-vector,0.27030843,single-ventricle,0.4165814,single-ventricle,0.4165814
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,vector-machine,0.30196983,single-ventricle,0.39982086,single-ventricle,0.39982086
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,support-vector-machine,0.316194,single-ventricle,0.43537825,single-ventricle,0.43537825
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.32078606,blood,1.0,blood,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,controlled-blood,0.2702959,blood,0.5723707,blood,0.5723707
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.25967306,blood,0.565806,blood,0.565806
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose-rate,0.223714,blood-flow,0.34377497,blood-flow,0.34377497
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.32078606,blood,1.0,blood,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,status,0.34122944,return,0.4773084,pulmonary,0.4225664
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.25967306,blood,0.565806,blood,0.565806
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic,0.37899542,plaque,0.7153188,plaque,0.7153188
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,history,0.40648568,with,0.47822285,arrythmia,0.4671815
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic-cardiovascular,0.53334194,coronary,0.74648607,coronary,0.74648607
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,disease-history,0.31536943,disease,0.7607082,artery-disease,0.64015657
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic-cardiovascular-disease,0.5005094,coronary-artery-disease,0.75097334,coronary-artery-disease,0.75097334
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,consecutive,0.30386817,total,0.4805001,d-transposition,0.38766134
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,recruited,0.36293948,of,0.42195517,cardiology,0.36293948
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,type,0.18854949,of,0.48202556,aortic,0.35779506
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,mellitus,0.3682191,congestive,0.568745,congestive,0.568745
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes-mellitus,0.33340782,chd,0.5153306,chd,0.5153306
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.32078606,blood,1.0,blood,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.26906762,with,0.5145365,mi,0.4093958
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.25967306,blood,0.565806,blood,0.565806
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose-control,0.20702225,cholesterol,0.408536,cholesterol,0.408536
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning-algorithms,0.3700234,heartbeat,0.46502528,heartbeat,0.46502528
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic,0.30842766,cholesterol,0.43206164,cholesterol,0.43206164
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.26906762,with,0.5145365,mi,0.4093958
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic-control,0.27046922,heart-failure,0.4453535,heart-failure,0.4453535
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor,0.30703533,weak,0.56499845,congestive,0.42275512
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic,0.30842766,cholesterol,0.43206164,cholesterol,0.43206164
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.26906762,with,0.5145365,mi,0.4093958
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor-glycemic,0.30156592,heart-failure,0.45201904,heart-failure,0.45201904
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic-control,0.27046922,heart-failure,0.4453535,heart-failure,0.4453535
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor-glycemic-control,0.29351228,heart-failure,0.47780025,heart-failure,0.47780025
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multivariable,0.28924093,chd,0.42614138,chd,0.42614138
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,found,0.2675444,with,0.6275196,deposits,0.41920424
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multivariable-analysis,0.29205993,congenital-heart-disease,0.40884006,congenital-heart-disease,0.40884006
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multicenter,0.40064782,congenital-heart-disease,0.42659694,congenital-heart-disease,0.42659694
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,aimed,0.2731712,of,0.52896386,congenital,0.32137418
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multicenter-study,0.39817134,congenital-heart-disease,0.4689145,congenital-heart-disease,0.4689145
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,study-aimed,0.43173265,cardiology,0.43173265,cardiology,0.43173265
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,via,0.2561984,of,0.50595546,flow,0.41023284
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,questionnaire,0.3388839,congenital-heart-disease,0.37297606,congenital-heart-disease,0.37297606
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,building,0.38390708,as,0.42331418,cardiology,0.38390708
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,address,0.4564506,great,0.47121263,cardiology,0.4564506
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,variable,0.221965,of,0.60098064,anomaly,0.4223012
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,collinearity,0.23629162,l-transposition,0.4428495,l-transposition,0.4428495
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,traditional,0.2995602,of,0.44896448,congestive-heart-failure,0.34226936
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-model,0.28147963,congenital-heart-disease,0.46833533,congenital-heart-disease,0.46833533
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,stepwise,0.2148184,of,0.40943736,isomerism,0.35930413
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,stepwise-logistic,0.2706561,venous-return,0.43522358,venous-return,0.43522358
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression-models,0.20554441,venous-return,0.40114802,venous-return,0.40114802
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-regression-models,0.23705584,artery-disease,0.4369967,artery-disease,0.4369967
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,developing,0.2713221,of,0.53584975,congestive-heart-failure,0.39774224
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetic,0.3646236,heart-failure,0.5228808,heart-failure,0.5228808
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,complications,0.3646976,thrombosis,0.54964757,thrombosis,0.54964757
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.32078606,blood,1.0,blood,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-pressure,0.37952203,blood,0.65126884,blood,0.65126884
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elastic,0.19137216,stiff,0.65165734,arteries,0.4509338
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elastic-network,0.19857799,stiff,0.5127349,plaque-deposits,0.412934
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm,0.23349956,double-outlet,0.34426278,double-outlet,0.34426278
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,family,0.39850003,cardiology,0.39850003,cardiology,0.39850003
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,history,0.40648568,with,0.47822285,arrythmia,0.4671815
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,family-history,0.369426,congenital-heart-disease,0.47663057,congenital-heart-disease,0.47663057
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,centers,0.4324913,cardiology,0.4324913,cardiology,0.4324913
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,january,0.3819933,paivs,0.3919103,paivs,0.3919103
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,december,0.4007524,cardiology,0.4007524,cardiology,0.4007524
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,history,0.40648568,with,0.47822285,arrythmia,0.4671815
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en,0.29726768,with,0.4152069,l-transposition,0.39625934
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,total-cholesterol,0.25385433,cholesterol,0.87798285,cholesterol,0.87798285
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,six,0.2417503,of,0.5504338,d-transposition,0.36408642
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cities,0.42628086,cardiology,0.42628086,cardiology,0.42628086
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,six-cities,0.34768462,of,0.4211473,venous-return,0.36967748
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,factors,0.24127257,of,0.49770784,chd,0.4172811
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk-factors,0.34496874,chd,0.61294127,chd,0.61294127
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,data,0.31118363,of,0.5086956,mi,0.36251363
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related-data,0.31551045,congenital-heart-disease,0.46838388,congenital-heart-disease,0.46838388
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,protective,0.14898418,of,0.4669182,heart-attack,0.34925088
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,factors,0.24127257,of,0.49770784,chd,0.4172811
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north,0.44313943,cardiology,0.44313943,cardiology,0.44313943
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,china,0.30905926,great,0.41031903,paivs,0.35474125
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north-china,0.31438464,lai,0.37214094,lai,0.37214094
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher,0.2654187,with,0.56796193,mi,0.398535
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher-risk,0.36496794,chd,0.5293444,chd,0.5293444
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycosylated,0.17247486,cholesterol,0.40775025,cholesterol,0.40775025
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hemoglobin,0.1774497,blood,0.51072896,blood,0.51072896
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycosylated-hemoglobin,0.16448104,blood-clot,0.42178616,blood-clot,0.42178616
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,figures,0.3465873,irregular,0.4320873,beats,0.37451494
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,increased,0.32251194,of,0.64014816,mi,0.42637154
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dimensional,0.25604147,anomalous,0.48529866,anomalous,0.48529866
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dimensional-reduction,0.24741676,venous-return,0.4551985,venous-return,0.4551985
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,closely,0.33319485,with,0.5531765,arrythmia,0.38487124
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,closely-related,0.20563623,isolated,0.46146688,l-transposition,0.35035712
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,central,0.34112307,of,0.50945216,venous,0.47422168
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,adiposity,0.28546625,chd,0.53226364,chd,0.53226364
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,biochemical,0.19784734,of,0.4984446,cardiac,0.33726048
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,indices,0.26546282,with,0.45559487,flow,0.43359074
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,basic,0.32800904,of,0.4978614,cardiac,0.36732858
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,information,0.36363098,of,0.47314215,mi,0.39006084
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,application,0.3034747,of,0.54379797,flow,0.3922925
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,value,0.3260533,of,0.52001536,flow,0.37269968
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,application-value,0.3292715,venous-return,0.43970987,venous-return,0.43970987
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,alternative,0.22123054,as,0.5288507,l-transposition,0.39336166
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,choices,0.34422296,great,0.4220829,single-ventricle,0.37251717
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,duration,0.2642262,of,0.44526798,fibrillation,0.4124629
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dose,0.35218355,single,0.47391105,blood,0.3763219
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin-dose,0.29541028,heart-failure,0.4657792,heart-failure,0.4657792
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher,0.2654187,with,0.56796193,mi,0.398535
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher-sensitivity,0.2561875,of,0.5459686,anomalous,0.41360497
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,ann,0.3185379,venous-return,0.33729267,venous-return,0.33729267
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.26906762,with,0.5145365,mi,0.4093958
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rf,0.26887482,right-atrial,0.36829585,right-atrial,0.36829585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,complications,0.3646976,thrombosis,0.54964757,thrombosis,0.54964757
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm,0.23349956,double-outlet,0.34426278,double-outlet,0.34426278
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en,0.29726768,with,0.4152069,l-transposition,0.39625934
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,ann,0.3185379,venous-return,0.33729267,venous-return,0.33729267
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,used,0.23211285,as,0.56584436,flow,0.35934073
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,simulate,0.18832195,of,0.4085042,anomalous,0.39357215
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,results,0.29712585,of,0.53157276,blood,0.36869162
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,moreover,0.16758724,of,0.5596781,plaque-deposits,0.35056823
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,half,0.2921754,of,0.529518,hypoplastic,0.36585724
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,explore,0.23689461,of,0.47429746,anomalous,0.30295405
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,exercise,0.41859597,myocardial,0.5311478,myocardial,0.5311478
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,curve,0.23990677,stenosis,0.35901296,stenosis,0.35901296
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,compare,0.27648047,of,0.5052448,venous-return,0.3454308
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,combining,0.238502,with,0.56878334,flow,0.37439224
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,bp,0.34582803,tachycardia,0.4765764,tachycardia,0.4765764
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,background,0.2325702,of,0.51277274,congenital,0.3895001
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,areas,0.32283562,deposits,0.49041492,deposits,0.49041492
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,additionally,0.26417398,of,0.6596129,flow,0.38005078
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,provider,0.5401046,cardiology,0.5401046,cardiology,0.5401046
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,networks,0.2352877,great,0.3902747,venous-return,0.35607615
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care,0.45659095,cardiology,0.45659095,cardiology,0.45659095
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care-provider,0.5017766,cardiology,0.5017766,cardiology,0.5017766
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care-provider,0.47569066,cardiology,0.47569066,cardiology,0.47569066
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,offered,0.3997217,with,0.5734371,cardiology,0.3997217
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,deploy,0.25279692,attack,0.37498468,venous-return,0.34819484
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,interventions,0.4352363,coronary,0.4378809,coronary,0.4378809
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,aimed,0.2731712,of,0.52896386,congenital,0.32137418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,interventions-aimed,0.5296292,cardiology,0.5296292,cardiology,0.5296292
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,compare,0.27648047,of,0.5052448,venous-return,0.3454308
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,learning-approaches,0.28315347,single-ventricle,0.4005476,single-ventricle,0.4005476
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.28184938,rai,0.33508995,rai,0.33508995
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,information,0.36363098,of,0.47314215,mi,0.39006084
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.47020248,return,0.52717197,cardiology,0.47020248
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,days,0.30872357,return,0.45523614,beats,0.4033618
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,greater,0.28239584,of,0.59163296,mi,0.40441626
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-days,0.306546,chd,0.40095443,chd,0.40095443
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,including,0.2742056,of,0.6619886,congenital,0.3605199
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,medicare,0.45578822,cardiology,0.45578822,cardiology,0.45578822
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,efficient,0.19720647,of,0.49297506,l-transposition,0.3745634
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling,0.26009148,of,0.45934054,single-ventricle,0.35399336
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling-approach,0.225325,single-ventricle,0.3948453,single-ventricle,0.3948453
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,approach-based,0.19961238,venous-return,0.39046317,venous-return,0.39046317
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boosted,0.20784065,with,0.45191312,lai,0.3683402
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling,0.26009148,of,0.45934054,single-ventricle,0.35399336
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,consistently,0.3148677,with,0.590214,flow,0.41162568
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,provided,0.3710292,of,0.61110586,flow,0.38950795
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.47020248,return,0.52717197,cardiology,0.47020248
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time,0.350901,return,0.5513821,venous-return,0.44564146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-time,0.3790452,venous-return,0.513999,venous-return,0.513999
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time-loss,0.26682335,venous-return,0.4630977,venous-return,0.4630977
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.47020248,return,0.52717197,cardiology,0.47020248
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,days,0.30872357,return,0.45523614,beats,0.4033618
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.34398016,chd,0.3749988,chd,0.3749988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-days,0.306546,chd,0.40095443,chd,0.40095443
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeled,0.21558793,of,0.49799097,anomalous,0.3977506
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf-outcomes,0.3715335,chd,0.5127233,chd,0.5127233
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hospitalization,0.4883753,failure,0.53211665,heart-failure,0.51238096
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf-hospitalization,0.50036544,heart-failure,0.62627625,heart-failure,0.62627625
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,professionals,0.5025177,cardiology,0.5025177,cardiology,0.5025177
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care,0.45659095,cardiology,0.45659095,cardiology,0.45659095
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care-professionals,0.48077875,cardiology,0.48077875,cardiology,0.48077875
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care-professionals,0.45986727,cardiology,0.45986727,cardiology,0.45986727
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.47020248,return,0.52717197,cardiology,0.47020248
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,days,0.30872357,return,0.45523614,beats,0.4033618
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-days,0.306546,chd,0.40095443,chd,0.40095443
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.47020248,return,0.52717197,cardiology,0.47020248
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time,0.350901,return,0.5513821,venous-return,0.44564146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-time,0.3790452,venous-return,0.513999,venous-return,0.513999
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time-loss,0.26682335,venous-return,0.4630977,venous-return,0.4630977
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,key-outcomes,0.3661542,venous-return,0.4728523,venous-return,0.4728523
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression-based,0.22176746,venous-return,0.44713378,venous-return,0.44713378
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression-based,0.24205163,venous-return,0.43847823,venous-return,0.43847823
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,threshold,0.25260836,of,0.41767043,beats,0.4031744
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,probabilities,0.2231575,of,0.39338166,venous-return,0.3904001
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,massachusetts,0.3940071,cardiology,0.3940071,cardiology,0.3940071
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,providers,0.5168287,cardiology,0.5168287,cardiology,0.5168287
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least,0.24824026,of,0.5946908,l-transposition,0.35232884
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,absolute,0.16486242,total,0.48867014,isomerism,0.4118287
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,shrinkage,0.09635708,flow,0.37796372,flow,0.37796372
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least-absolute,0.11763938,total,0.40034246,venous-return,0.39713323
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least-absolute-shrinkage,0.13016538,venous-return,0.40438494,venous-return,0.40438494
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic,0.34064275,isomerism,0.44657785,isomerism,0.44657785
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,medical,0.6019881,cardiology,0.6019881,cardiology,0.6019881
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,record,0.3503227,heartbeat,0.4047115,heartbeat,0.4047115
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic-medical,0.5034969,cardiology,0.5034969,cardiology,0.5034969
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,medical-record,0.44961625,congenital-heart-disease,0.46725702,congenital-heart-disease,0.46725702
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic-medical-record,0.44296956,congenital-heart-disease,0.45658094,congenital-heart-disease,0.45658094
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,accurate,0.25226092,of,0.4756247,anomalous,0.40025836
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,risk-stratification,0.45956326,congestive-heart-failure,0.50061274,congestive-heart-failure,0.50061274
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,traditional,0.2995602,of,0.44896448,congestive-heart-failure,0.34226936
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,operation,0.31241646,d-transposition,0.4979664,d-transposition,0.4979664
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.2494699,of,0.5443143,flow,0.34116954
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,appeared,0.29807338,with,0.6158701,deposits,0.45369077
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based-models,0.20372218,single,0.3450173,single-ventricle,0.3381522
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,lowest,0.2895016,with,0.46268752,mi,0.35886955
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier,0.3418228,venous-return,0.39726174,venous-return,0.39726174
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,data,0.31118363,of,0.5086956,mi,0.36251363
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,top,0.40076846,with,0.45628595,cardiology,0.40076846
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,decile,0.3962487,chd,0.52593005,chd,0.52593005
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net,0.2587682,total,0.48101264,flow,0.45533764
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,benefit,0.3251614,return,0.474311,heart-failure,0.40887886
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,estimates,0.26109022,of,0.42668635,venous-return,0.388119
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net-benefit,0.22259267,venous-return,0.3814569,venous-return,0.3814569
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,good,0.31429055,weak,0.60268193,venous-return,0.38116372
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calibration,0.31922334,venous-return,0.39590418,venous-return,0.39590418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,across,0.2607503,of,0.44814807,flow,0.3484614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,generally,0.29403654,with,0.608389,deposits,0.39144385
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.28184938,rai,0.33508995,rai,0.33508995
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.34398016,chd,0.3749988,chd,0.3749988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,testing,0.35133207,of,0.46778864,heart-failure,0.37850797
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,testing-set,0.29324245,venous-return,0.40900335,venous-return,0.40900335
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbms,0.19558026,hlhs,0.40545827,hlhs,0.40545827
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boosted,0.20784065,with,0.45191312,lai,0.3683402
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling,0.26009148,of,0.45934054,single-ventricle,0.35399336
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,networks,0.2352877,great,0.3902747,venous-return,0.35607615
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hospitalization,0.4883753,failure,0.53211665,heart-failure,0.51238096
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf-hospitalization,0.50036544,heart-failure,0.62627625,heart-failure,0.62627625
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using,0.20786116,with,0.58010674,flow,0.41007757
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.34398016,chd,0.3749988,chd,0.3749988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.34398016,chd,0.3749988,chd,0.3749988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net,0.2587682,total,0.48101264,flow,0.45533764
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,benefit,0.3251614,return,0.474311,heart-failure,0.40887886
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net-benefit,0.22259267,venous-return,0.3814569,venous-return,0.3814569
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,trees,0.2631234,great,0.38808686,arteries,0.3754926
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression-trees,0.20614281,venous-return,0.4213025,venous-return,0.4213025
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.28184938,rai,0.33508995,rai,0.33508995
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,january,0.3819933,paivs,0.3919103,paivs,0.3919103
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,december,0.4007524,cardiology,0.4007524,cardiology,0.4007524
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,training-set,0.3791533,venous-return,0.44417873,venous-return,0.44417873
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier,0.3418228,venous-return,0.39726174,venous-return,0.39726174
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,score,0.286516,total,0.3966952,stenosis,0.38543224
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier-score,0.30270728,venous-return,0.4449538,venous-return,0.4449538
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,augmenting,0.24243991,of,0.5467119,flow,0.41415423
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.34398016,chd,0.3749988,chd,0.3749988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,year,0.39816982,failure,0.4387355,mi,0.41719383
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,year-follow,0.47264957,cardiology,0.47264957,cardiology,0.47264957
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,recall,0.34358412,mi,0.38738698,mi,0.38738698
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,curves,0.20727307,of,0.40860695,contractions,0.37883943
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,forests,0.30814296,deposits,0.41884,deposits,0.41884
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,random-forests,0.2732313,venous-return,0.3937114,venous-return,0.3937114
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,limited,0.29959464,of,0.6210327,deposits,0.40452772
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improvement,0.36781824,return,0.5283363,congestive,0.42538065
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,includes,0.25888455,of,0.5967927,anomaly,0.3367726
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,physicians,0.6084627,cardiology,0.6084627,cardiology,0.6084627
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improve,0.31483245,great,0.49610043,flow,0.35876963
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,high,0.28122714,of,0.57459104,flow,0.3923195
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,high-cost,0.36661112,heart-failure,0.4448601,heart-failure,0.4448601
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,heart,0.57664216,heart,1.0,heart,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,decision,0.46018064,cardiology,0.46018064,cardiology,0.46018064
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,curves,0.20727307,of,0.40860695,contractions,0.37883943
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cause-mortality,0.32417238,heart-disease,0.5488442,heart-disease,0.5488442
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,c,0.21239448,with,0.46990636,ivs,0.34813386
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,statistics,0.39867812,cardiology,0.39867812,cardiology,0.39867812
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,c-statistics,0.38839424,chd,0.46431458,chd,0.46431458
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,added,0.39393532,with,0.6052638,cardiology,0.39393532
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,value,0.3260533,of,0.52001536,flow,0.37269968
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,added-value,0.34167832,as,0.41007465,venous-return,0.38100547
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improving,0.3579299,great,0.54781544,congestive,0.39419994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbm,0.19095092,paivs,0.32442364,paivs,0.32442364
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,enrolled,0.4130389,cardiology,0.4130389,cardiology,0.4130389
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,additional,0.34573856,of,0.63162684,cardiac,0.39887685
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,prognostic,0.31385523,infarction,0.42731366,infarction,0.42731366
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,highest,0.26377243,of,0.5054526,mi,0.33820426
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,discrimination,0.19044608,of,0.45023823,isomerism,0.35752335
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,higher,0.2654187,with,0.56796193,mi,0.398535
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,auprcs,0.2831738,plaque-deposits,0.34681126,plaque-deposits,0.34681126
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.34398016,chd,0.3749988,chd,0.3749988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbms,0.19558026,hlhs,0.40545827,hlhs,0.40545827
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,data,0.31118363,of,0.5086956,mi,0.36251363
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calibration,0.31922334,venous-return,0.39590418,venous-return,0.39590418
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,higher,0.2654187,with,0.56796193,mi,0.398535
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbm,0.19095092,paivs,0.32442364,paivs,0.32442364
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,discrimination,0.19044608,of,0.45023823,isomerism,0.35752335
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,auprcs,0.2831738,plaque-deposits,0.34681126,plaque-deposits,0.34681126
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,tested,0.25299942,of,0.5634051,contractions,0.36297208
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,setting,0.5175974,failure,0.54691184,cardiology,0.5175974
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,selecting,0.30355173,of,0.529858,d-transposition,0.36931235
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,sd,0.2346565,total,0.37023938,artery-disease,0.3595487
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,results,0.29712585,of,0.53157276,blood,0.36869162
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,relevance,0.3301295,of,0.5866257,congenital-heart-disease,0.34820747
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,quality,0.3148893,of,0.4192715,heartbeat,0.36860457
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,precision,0.33570096,great,0.43037808,heartbeat,0.35565016
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,period,0.34860444,return,0.46809125,venous-return,0.39146286
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,obtained,0.31282532,of,0.62274206,blood,0.41646662
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,objectives,0.3258235,of,0.53322846,congenital,0.39620093
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,measures,0.2977168,of,0.4417776,venous-return,0.3984164
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mean,0.30953988,total,0.5000684,artery,0.37085557
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,institutions,0.5212806,cardiology,0.5212806,cardiology,0.5212806
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,inclusion,0.282305,of,0.5064132,deposits,0.31816775
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,importance,0.3199574,of,0.5794183,anomaly,0.34929916
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,however,0.30646515,of,0.624624,mi,0.41109186
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gradient,0.24976638,flow,0.52486,flow,0.52486
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,focus,0.4045372,of,0.53003526,cardiology,0.4045372
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emrs,0.42110893,cardiology,0.42110893,cardiology,0.42110893
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,differences,0.24501437,of,0.48845208,anomalous,0.3514788
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,design,0.22387533,of,0.40440997,single-ventricle,0.33910608
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,critical,0.33451754,of,0.57185876,anomalous,0.39386463
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,comprise,0.19499265,of,0.5192354,anomaly,0.33266217
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,clinicians,0.494618,cardiology,0.494618,cardiology,0.494618
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,ci,0.26988983,congestive,0.4084356,congestive,0.4084356
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calculated,0.2812017,of,0.47861123,anomalous,0.38671362
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boston,0.4222508,cardiology,0.4222508,cardiology,0.4222508
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,area,0.34147155,left,0.4808709,stenosis,0.41823816
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,analyzed,0.25776637,of,0.58131987,flow,0.35350555
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,age,0.33659208,with,0.44369304,chd,0.42829025
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed,0.25776637,of,0.58131987,flow,0.35350555
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,using,0.20786116,with,0.58010674,flow,0.41007757
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,unsupervised,0.26907045,heartbeat,0.44143736,heartbeat,0.44143736
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed-using,0.27764484,with,0.48112288,venous-return,0.43780458
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,impairment,0.24527673,insufficiency,0.6033757,congenital,0.45398903
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,may,0.26963884,of,0.58654004,anomalous,0.366544
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,help,0.34956798,great,0.5039565,flow,0.3667982
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive-impairment,0.2558166,heart-failure,0.4199052,heart-failure,0.4199052
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,unsupervised,0.26907045,heartbeat,0.44143736,heartbeat,0.44143736
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,framework,0.24920769,as,0.3324023,isomerism,0.32199267
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,using,0.20786116,with,0.58010674,flow,0.41007757
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,feature-selection,0.19786239,l-transposition,0.47018635,l-transposition,0.47018635
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,within,0.30995527,of,0.57602364,deposits,0.42065546
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,may,0.26963884,of,0.58654004,anomalous,0.366544
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,help,0.34956798,great,0.5039565,flow,0.3667982
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,distinguish,0.15236557,as,0.43063623,anomalous,0.3493976
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subtle,0.22825554,abnormal,0.57150126,anomalous,0.4580143
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alterations,0.20877011,abnormal,0.63202363,anomaly,0.44557405
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early,0.34221643,of,0.5714519,mi,0.3991026
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening-early,0.36721432,congenital-heart-disease,0.38412434,congenital-heart-disease,0.38412434
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,framingham,0.45156312,chd,0.6649201,chd,0.6649201
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,heart,0.57664216,heart,1.0,heart,1.0
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,heart-study,0.526705,heart-disease,0.7386719,heart-disease,0.7386719
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,yielded,0.15376228,of,0.5085689,lai,0.28203836
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early,0.34221643,of,0.5714519,mi,0.3991026
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening,0.33582932,of,0.4313763,congenital,0.3888343
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early-ad,0.14182156,hlhs,0.36575422,hlhs,0.36575422
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,boston,0.4222508,cardiology,0.4222508,cardiology,0.4222508
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,naming,0.3450874,right,0.42838907,right-atrial,0.4035204
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,tests,0.28260767,abnormal,0.42899668,pulmonary,0.32613885
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,boston-naming,0.4020421,congenital-heart-disease,0.51143193,congenital-heart-disease,0.51143193
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,precede,0.21247531,abnormal,0.5128547,deposits,0.4057027
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed,0.25776637,of,0.58131987,flow,0.35350555
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,using,0.20786116,with,0.58010674,flow,0.41007757
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed-using,0.27764484,with,0.48112288,venous-return,0.43780458
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical-trials,0.4117396,heart-failure,0.48685247,heart-failure,0.48685247
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,practice,0.5339576,cardiology,0.5339576,cardiology,0.5339576
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical-practice,0.51884663,cardiology,0.51884663,cardiology,0.51884663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.39755744,sv,0.42594546,sv,0.42594546
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,tests,0.28260767,abnormal,0.42899668,pulmonary,0.32613885
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np-tests,0.3608808,cardiology,0.3608808,cardiology,0.3608808
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,visual,0.26844218,heartbeat,0.42746407,heartbeat,0.42746407
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,reproduction,0.3186481,of,0.46244383,heartbeat,0.39614147
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,visual-reproduction,0.23187625,heartbeat,0.4492556,heartbeat,0.4492556
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,viable,0.13554828,of,0.45317328,septal-defect,0.4065641
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,option,0.28522927,as,0.4659202,hypoplastic,0.3850722
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trails,0.27786732,return,0.39419588,flow,0.36976907
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,b,0.20100933,of,0.43435428,aortic,0.34993017
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trails-b,0.24353375,weak,0.34996596,flow,0.33529115
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,logical,0.3179636,as,0.4747456,l-transposition,0.39602196
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,memory,0.2714194,of,0.38706335,cardiac,0.34561598
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,logical-memory,0.19742139,congenital-heart-disease,0.3791942,congenital-heart-disease,0.3791942
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,including,0.2742056,of,0.6619886,congenital,0.3605199
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,age,0.33659208,with,0.44369304,chd,0.42829025
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,demographic,0.28516516,disease,0.3714661,congenital-heart-disease,0.36635384
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,data,0.31118363,of,0.5086956,mi,0.36251363
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,demographic-data,0.31766164,artery-disease,0.46904194,artery-disease,0.46904194
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed,0.2475737,premature,0.5037098,anomalous,0.41196683
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,recall,0.34358412,mi,0.38738698,mi,0.38738698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed-recall,0.26929307,congenital-heart-disease,0.3919061,congenital-heart-disease,0.3919061
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,coordinating,0.353057,of,0.43283156,isomerism,0.365175
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,center,0.4322113,single,0.4625442,cardiology,0.4322113
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,coordinating-center,0.35059518,single,0.42162114,isomerism,0.41898617
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,attractive,0.22626528,great,0.5259857,anomalous,0.30611852
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,modality,0.3416853,disease,0.42066878,single-ventricle,0.39747286
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,approach-could,0.28644782,venous-return,0.4502325,venous-return,0.4502325
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,longitudinal,0.25857258,of,0.40970862,contractions,0.38807714
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.39755744,sv,0.42594546,sv,0.42594546
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subsequent,0.26928416,of,0.65363204,cardiac,0.38847053
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,development,0.2877805,of,0.53581744,congenital,0.35419804
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk-individuals,0.2763764,chd,0.53857625,chd,0.53857625
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results,0.29712585,of,0.53157276,blood,0.36869162
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results-suggest,0.37769833,with,0.46542153,venous-return,0.4256721
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,national,0.46166456,cardiology,0.46166456,cardiology,0.46166456
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alzheimer,0.3308626,disease,0.5158516,fibrillation,0.46321332
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc,0.28467548,rai,0.341396,rai,0.341396
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.39755744,sv,0.42594546,sv,0.42594546
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results,0.29712585,of,0.53157276,blood,0.36869162
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc,0.28467548,rai,0.341396,rai,0.341396
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,development,0.2877805,of,0.53581744,congenital,0.35419804
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alzheimer,0.3308626,disease,0.5158516,fibrillation,0.46321332
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,testing,0.35133207,of,0.46778864,heart-failure,0.37850797
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subset,0.24246489,of,0.51671314,mi,0.37440532
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,specificity,0.22204962,of,0.4346917,cad,0.34837636
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,progression,0.2872493,disease,0.5879895,mi,0.4478637
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,processed,0.19679162,of,0.4513599,deposits,0.37629884
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,neuropsychological,0.3630672,single-ventricle,0.43420208,single-ventricle,0.43420208
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,n,0.21850443,with,0.47536123,mi,0.3790054
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,low,0.33154353,with,0.5951388,flow,0.4108625
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,introduction,0.3353318,of,0.5877248,l-transposition,0.4046045
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,immediate,0.2928927,return,0.5358162,l-transposition,0.41187346
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,high,0.28122714,of,0.57459104,flow,0.3923195
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,fhs,0.25815687,chd,0.47974366,chd,0.47974366
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,discussion,0.49886382,of,0.5109613,cardiology,0.49886382
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,context,0.3526281,of,0.54966336,congenital-heart-disease,0.38638416
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sits,0.28981316,weak,0.45936757,contractions,0.36867428
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,among,0.2573181,of,0.57348,chd,0.4274787
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,many,0.34462097,great,0.5654564,deposits,0.36972266
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,reporting,0.3682378,of,0.5139481,cardiology,0.3682378
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,difficulties,0.29815215,incompetence,0.5432733,anomalous,0.42300248
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,obtaining,0.315955,of,0.6090371,venous,0.3788731
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically,0.22203454,with,0.41206974,chd,0.3633579
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,studies-reporting,0.39828658,of,0.4025218,congenital-heart-disease,0.40078396
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically-significant,0.3079205,great,0.46452183,mitral-regurgitation,0.44900584
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,nephrology,0.7220895,cardiology,0.7220895,cardiology,0.7220895
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mellitus,0.3682191,congestive,0.568745,congestive,0.568745
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes-mellitus,0.33340782,chd,0.5153306,chd,0.5153306
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,wilcoxon,0.22279148,mitral-regurgitation,0.30214453,mitral-regurgitation,0.30214453
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,signed,0.47323126,cardiology,0.47323126,cardiology,0.47323126
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ranked,0.37995976,as,0.51157963,cardiology,0.37995976
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sum,0.307007,total,0.5639548,contractions,0.37221485
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,tests,0.28260767,abnormal,0.42899668,pulmonary,0.32613885
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,wilcoxon-signed,0.29087907,venous-return,0.35860062,venous-return,0.35860062
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,signed-ranked,0.32454324,venous-return,0.35882592,venous-return,0.35882592
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ranked-sum,0.3175763,venous-return,0.44167846,venous-return,0.44167846
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ongoing,0.44038102,of,0.5501542,mi,0.4593027
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,randomized,0.31567937,interrupted,0.40434858,congestive-heart-failure,0.39597732
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,trial,0.38247734,failure,0.44692248,congestive-heart-failure,0.41253513
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,randomized-trial,0.31516087,congestive-heart-failure,0.4097007,congestive-heart-failure,0.4097007
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson,0.33078,congestive,0.419017,congestive,0.419017
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comorbidity,0.32733637,disease,0.4984109,chd,0.490483
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,index,0.27677816,total,0.43109894,mi,0.39722836
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson-comorbidity,0.30620795,artery-disease,0.49502033,artery-disease,0.49502033
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comorbidity-index,0.29180467,artery-disease,0.4653037,artery-disease,0.4653037
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,index-scores,0.25524265,artery-disease,0.38985807,artery-disease,0.38985807
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson-comorbidity-index,0.2821542,venous-return,0.47841933,venous-return,0.47841933
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,professional,0.45251656,cardiology,0.45251656,cardiology,0.45251656
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collaboration,0.53562415,cardiology,0.53562415,cardiology,0.53562415
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,within,0.30995527,of,0.57602364,deposits,0.42065546
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collaboration-within,0.46670255,cardiology,0.46670255,cardiology,0.46670255
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,within-patient,0.3296379,venous-return,0.41425171,venous-return,0.41425171
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,compare,0.27648047,of,0.5052448,venous-return,0.3454308
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,frequencies,0.21388823,single,0.45050174,beats,0.35161406
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.4044739,return,0.43401748,venous-return,0.43193185
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically,0.22203454,with,0.41206974,chd,0.3633579
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically-significant,0.3079205,great,0.46452183,mitral-regurgitation,0.44900584
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,often,0.28905255,with,0.53610253,anomaly,0.426194
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,insufficiently,0.34129623,insufficiency,0.56555974,deposits,0.41958857
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,coordinated,0.342119,of,0.48005927,contractions,0.39283392
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multiple-chronic,0.3224688,failure,0.527743,congenital-heart-disease,0.5131192
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,chronic-conditions,0.25193945,congenital-heart-disease,0.5073191,congenital-heart-disease,0.5073191
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,total-care,0.4169385,total,0.5725716,chd,0.47056872
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.4044739,return,0.43401748,venous-return,0.43193185
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patterns,0.22309256,of,0.55208683,anomalous,0.46585032
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.4044739,return,0.43401748,venous-return,0.43193185
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,data,0.31118363,of,0.5086956,mi,0.36251363
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.4044739,return,0.43401748,venous-return,0.43193185
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.119325764,with,0.31593242,l-tga,0.314493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,recruited,0.36293948,of,0.42195517,cardiology,0.36293948
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients-recruited,0.34456873,heart-failure,0.4818145,heart-failure,0.4818145
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,innovative,0.37430918,great,0.5241181,single-ventricle,0.3790713
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,beyond,0.29394823,of,0.53781354,anomaly,0.34910303
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,including,0.2742056,of,0.6619886,congenital,0.3605199
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,data,0.31118363,of,0.5086956,mi,0.36251363
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.119325764,with,0.31593242,l-tga,0.314493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient-care,0.49764198,cardiology,0.49764198,cardiology,0.49764198
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated,0.3167261,of,0.46948645,single-ventricle,0.3645035
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,interventions,0.4352363,coronary,0.4378809,coronary,0.4378809
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated-care,0.41448116,venous-return,0.43718433,venous-return,0.43718433
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study-aims,0.4185288,congenital-heart-disease,0.44150627,congenital-heart-disease,0.44150627
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.4044739,return,0.43401748,venous-return,0.43193185
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.119325764,with,0.31593242,l-tga,0.314493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.31570435,of,0.5174322,flow,0.37966552
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,indicators,0.3010254,as,0.53604406,congenital-heart-disease,0.37085792
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient-characteristics,0.40659854,of,0.51131666,congenital-heart-disease,0.46941558
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc,0.13202924,mi,0.31066155,mi,0.31066155
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc-patients,0.29057294,heart-failure,0.48818576,heart-failure,0.48818576
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,traditional,0.2995602,of,0.44896448,congestive-heart-failure,0.34226936
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,traditional-care,0.4234848,venous-return,0.4407546,venous-return,0.4407546
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered,0.27710518,of,0.48641407,anomalous,0.3509084
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered-care,0.48009458,cardiology,0.48009458,cardiology,0.48009458
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,received,0.3772288,with,0.53732973,single-ventricle,0.39404702
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,providers,0.5168287,cardiology,0.5168287,cardiology,0.5168287
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-providers,0.4949677,cardiology,0.4949677,cardiology,0.4949677
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.119325764,with,0.31593242,l-tga,0.314493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,center,0.4322113,single,0.4625442,cardiology,0.4322113
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,groups,0.2612025,with,0.4941169,mi,0.3908207
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two-groups,0.21575314,congenital-heart-disease,0.3458546,congenital-heart-disease,0.3458546
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,arms,0.200523,stiff,0.4989786,ivs,0.36767378
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two-arms,0.19872306,double,0.4261187,double-outlet,0.3921766
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,several,0.34988725,of,0.5990606,cardiac,0.37646228
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnoses,0.39992523,congenital-heart-disease,0.45381218,congenital-heart-disease,0.45381218
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,regional,0.4145327,blood-flow,0.48738575,blood-flow,0.48738575
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,database,0.34863436,congenital-heart-disease,0.35068005,congenital-heart-disease,0.35068005
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,previous,0.37261367,with,0.5284412,mi,0.42555177
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,positive-effect,0.2574593,weak,0.4712395,lai,0.37032354
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,kidney-diseases,0.29658636,heart-disease,0.63771087,heart-disease,0.63771087
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,components,0.22271727,of,0.54551816,deposits,0.4215029
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,key-components,0.20033108,of,0.48689872,congenital-heart-disease,0.40805548
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,initial,0.36733395,of,0.6574379,cardiac,0.43063313
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high,0.28122714,of,0.57459104,flow,0.3923195
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilizers,0.29282358,as,0.4355353,lai,0.29916134
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high-utilizers,0.29191393,as,0.36484906,heart-failure,0.31841472
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high,0.28122714,of,0.57459104,flow,0.3923195
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high-level,0.18078135,of,0.4489509,l-transposition,0.3472531
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hereafter,0.27383962,as,0.5860431,anomaly,0.289544
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,referred,0.50172186,as,0.58807015,cardiology,0.50172186
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,specialties,0.6114915,cardiology,0.6114915,cardiology,0.6114915
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnoses,0.39992523,congenital-heart-disease,0.45381218,congenital-heart-disease,0.45381218
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,profiles,0.15556863,of,0.5306897,flow,0.4074694
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,descriptive,0.34310508,congenital-heart-disease,0.42470104,congenital-heart-disease,0.42470104
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistics,0.39867812,cardiology,0.39867812,cardiology,0.39867812
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,control,0.26906762,with,0.5145365,mi,0.4093958
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,group,0.2849201,with,0.5052614,mi,0.411738
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,control-group,0.26105496,heart-failure,0.42830202,heart-failure,0.42830202
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health-care,0.45659095,cardiology,0.45659095,cardiology,0.45659095
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.119325764,with,0.31593242,l-tga,0.314493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated,0.3167261,of,0.46948645,single-ventricle,0.3645035
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc,0.13202924,mi,0.31066155,mi,0.31066155
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health,0.42500588,cardiology,0.42500588,cardiology,0.42500588
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,variation,0.2960531,of,0.53702235,anomaly,0.45202243
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sub,0.26424953,of,0.4497146,mi,0.43278512
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sicker,0.46096265,heart-failure,0.5529679,heart-failure,0.5529679
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,shown,0.20708838,of,0.5506151,l-transposition,0.3662261
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,results,0.29712585,of,0.53157276,blood,0.36869162
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,rct,0.28963906,chd,0.37761855,chd,0.37761855
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,purpose,0.27727276,of,0.5072116,congenital,0.37470472
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,person,0.37019157,return,0.44421834,congenital-heart-disease,0.38474873
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,perform,0.31693935,return,0.4643785,venous-return,0.35410056
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multidisciplinary,0.56848633,cardiology,0.56848633,cardiology,0.56848633
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,intervention,0.4565987,mi,0.49382597,mi,0.49382597
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,inter,0.39922974,of,0.47223324,cardiology,0.39922974
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,intensive,0.5087563,cardiology,0.5087563,cardiology,0.5087563
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,informed,0.51307225,cardiology,0.51307225,cardiology,0.51307225
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,indication,0.42864725,of,0.5345758,anomaly,0.47863287
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,impact,0.2996394,of,0.5528908,single-ventricle,0.35865143
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,however,0.30646515,of,0.624624,mi,0.41109186
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,heart,0.57664216,heart,1.0,heart,1.0
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,explored,0.24943587,of,0.58866113,anomalous,0.34417656
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,explore,0.23689461,of,0.47429746,anomalous,0.30295405
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,experienced,0.3416694,with,0.51668775,mitral-regurgitation,0.39382553
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,expected,0.29812223,of,0.6009193,anomalous,0.399265
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,describe,0.2106702,of,0.4752335,anomalous,0.4157361
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,counterparts,0.16625127,with,0.39398032,d-transposition,0.3148753
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,beginning,0.42209855,of,0.52056587,cardiology,0.42209855
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.27145627,irregular,0.51868784,hypoplastic-left,0.45668647
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,might,0.24242394,of,0.5952132,anomalous,0.3600717
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improve,0.31483245,great,0.49610043,flow,0.35876963
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.42908797,avsd,0.6188972,avsd,0.6188972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.288921,anomalous,0.512723,anomalous,0.512723
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-diagnosis,0.38103244,congenital-heart-disease,0.5684955,congenital-heart-disease,0.5684955
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,extended,0.22422087,of,0.53787327,anomalous,0.39536422
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,extended-model,0.22650604,venous-return,0.41653565,venous-return,0.41653565
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model-especially,0.3756212,with,0.49603328,congenital-heart-disease,0.47263014
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improves,0.25111842,with,0.5313674,cardiac,0.39053214
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.42908797,avsd,0.6188972,avsd,0.6188972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-diagnosis,0.38103244,congenital-heart-disease,0.5684955,congenital-heart-disease,0.5684955
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improve,0.31483245,great,0.49610043,flow,0.35876963
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.42908797,avsd,0.6188972,avsd,0.6188972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-diagnosis,0.38103244,congenital-heart-disease,0.5684955,congenital-heart-disease,0.5684955
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.27145627,irregular,0.51868784,hypoplastic-left,0.45668647
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.288921,anomalous,0.512723,anomalous,0.512723
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.27145627,irregular,0.51868784,hypoplastic-left,0.45668647
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterizations,0.23024963,of,0.5086568,anomalous,0.44412795
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.288921,anomalous,0.512723,anomalous,0.512723
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.27145627,irregular,0.51868784,hypoplastic-left,0.45668647
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.288921,anomalous,0.512723,anomalous,0.512723
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,retrospective,0.3446992,congenital-heart-disease,0.46667808,congenital-heart-disease,0.46667808
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,consisting,0.19969599,with,0.5619323,deposits,0.3155145
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,retrospective-cohort,0.32250574,congenital-heart-disease,0.48279768,congenital-heart-disease,0.48279768
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,challenging,0.29561728,great,0.56316066,anomalous,0.40406942
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,negative,0.26947153,abnormal,0.48861286,blood,0.4176938
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,family,0.39850003,cardiology,0.39850003,cardiology,0.39850003
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,members,0.39841127,of,0.4264385,cardiology,0.39841127
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,negative-family,0.2973683,of,0.38872594,mi,0.34402633
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,family-members,0.36464673,heart-attack,0.3663415,heart-attack,0.3663415
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,external,0.29746136,of,0.4755252,anomalous,0.3880807
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,consisting,0.19969599,with,0.5619323,deposits,0.3155145
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combining,0.238502,with,0.56878334,flow,0.37439224
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,polynomial,0.2188054,double-outlet,0.39865416,double-outlet,0.39865416
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combining-new,0.28078264,great,0.42286268,venous-return,0.35231173
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,followed,0.3600078,with,0.62115055,flow,0.4018712
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hermite,0.27271134,anomalous,0.4098708,anomalous,0.4098708
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.40694636,tachycardia,0.61769444,tachycardia,0.61769444
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cut,0.23676394,stiff,0.4631475,artery,0.39199376
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best,0.3534876,as,0.5428521,anomaly,0.36822265
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,overall,0.28817955,of,0.5869458,chd,0.41920155
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best-overall,0.32582852,of,0.4431249,venous-return,0.42335236
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,overall-accuracy,0.21980104,venous-return,0.43442458,venous-return,0.43442458
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.40694636,tachycardia,0.61769444,tachycardia,0.61769444
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cut,0.23676394,stiff,0.4631475,artery,0.39199376
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.42908797,avsd,0.6188972,avsd,0.6188972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-patients,0.4296435,heart-failure,0.64131427,heart-failure,0.64131427
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg,0.23343061,beats,0.4055966,beats,0.4055966
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.40694636,tachycardia,0.61769444,tachycardia,0.61769444
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age,0.33659208,with,0.44369304,chd,0.42829025
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.27145627,irregular,0.51868784,hypoplastic-left,0.45668647
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.288921,anomalous,0.512723,anomalous,0.512723
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.34435666,beats,0.48032922,beats,0.48032922
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphologies,0.27283886,irregular,0.5189827,anomalous,0.48072308
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosing,0.30879682,disease,0.4482094,congenital,0.44018838
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.42908797,avsd,0.6188972,avsd,0.6188972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,genotype,0.2217733,chd,0.41627944,chd,0.41627944
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best,0.3534876,as,0.5428521,anomaly,0.36822265
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fit,0.21854927,stiff,0.4458263,venous-return,0.41494748
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best-fit,0.16406111,venous-return,0.361859,venous-return,0.361859
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,controls,0.23145974,with,0.5052294,mi,0.41936132
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,weight,0.24034786,total,0.39897376,heartbeat,0.36656758
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,coefficients,0.23706919,anomalous,0.43127996,anomalous,0.43127996
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,support,0.36322898,return,0.46409142,flow,0.36807415
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,precordial,0.46059632,tachycardia,0.5988731,tachycardia,0.5988731
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,leads,0.23349127,of,0.52666616,anomalous,0.39397147
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,low,0.33154353,with,0.5951388,flow,0.4108625
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,low-sensitivity,0.21756674,of,0.45371315,anomaly,0.37538743
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,linear,0.17840835,of,0.40123588,isomerism,0.35944843
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combination,0.21742424,with,0.59363616,l-transposition,0.35203728
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,linear-combination,0.15896071,single,0.49667364,l-transposition,0.44052178
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,limb,0.25241616,hypoplastic-left-heart,0.48669615,hypoplastic-left-heart,0.48669615
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,leads,0.23349127,of,0.52666616,anomalous,0.39397147
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,limb-leads,0.33304763,congenital-heart,0.5409819,congenital-heart,0.5409819
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosing,0.30879682,disease,0.4482094,congenital,0.44018838
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,considerable,0.28945285,great,0.7623683,l-transposition,0.36922836
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,overlap,0.19607264,with,0.4524176,anomaly,0.40907073
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,average,0.3160447,total,0.53346545,beats,0.33409712
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,complex,0.29298759,of,0.46002102,anomalous,0.41282338
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.3789807,tachycardia,0.59782374,tachycardia,0.59782374
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,syndrome,0.2608677,syndrome,1.0,syndrome,1.0
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt-syndrome,0.3721186,heart-syndrome,0.89118654,heart-syndrome,0.89118654
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,corrected,0.33473727,with,0.5097294,congenital,0.47328433
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.3789807,tachycardia,0.59782374,tachycardia,0.59782374
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,corrected-qt,0.3098273,tof,0.46190095,tof,0.46190095
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fed,0.28105107,with,0.48279458,cholesterol,0.39400005
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,healthy-subjects,0.23467843,congenital-heart-disease,0.4751811,congenital-heart-disease,0.4751811
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,finally,0.32854706,of,0.64012104,flow,0.39903617
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,used,0.23211285,as,0.56584436,flow,0.35934073
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.42908797,avsd,0.6188972,avsd,0.6188972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.40694636,tachycardia,0.61769444,tachycardia,0.61769444
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg,0.23343061,beats,0.4055966,beats,0.4055966
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age,0.33659208,with,0.44369304,chd,0.42829025
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.3789807,tachycardia,0.59782374,tachycardia,0.59782374
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,used,0.23211285,as,0.56584436,flow,0.35934073
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,controls,0.23145974,with,0.5052294,mi,0.41936132
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,vector,0.20063998,l-transposition,0.3898847,l-transposition,0.3898847
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,svm,0.23349956,double-outlet,0.34426278,double-outlet,0.34426278
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,stt,0.24241555,rai,0.40055206,rai,0.40055206
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,specific,0.26268506,of,0.6059094,flow,0.40644997
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,segments,0.19482392,arteries,0.5241684,arteries,0.5241684
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,robustness,0.2293376,heartbeat,0.41836193,heartbeat,0.41836193
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,results,0.29712585,of,0.53157276,blood,0.36869162
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,polynomials,0.25078806,double-outlet,0.38841233,double-outlet,0.38841233
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patient,0.47667986,with,0.5110891,cardiology,0.47667986
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,offs,0.33069468,return,0.44478267,heartbeat,0.33295453
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,objective,0.2960808,of,0.5255821,flow,0.39260852
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqt,0.32382852,heart-syndrome,0.59128094,heart-syndrome,0.59128094
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,interval,0.278329,congestive,0.41789418,congestive,0.41789418
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,ii,0.26288998,of,0.43728137,mi,0.35983312
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,gender,0.3640193,congenital-heart-disease,0.45300186,congenital-heart-disease,0.45300186
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,gauss,0.26848885,beats,0.37006903,beats,0.37006903
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fitting,0.20907207,with,0.4004053,venous-return,0.3979973
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fitted,0.16704273,with,0.45058134,venous-return,0.4340434
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,error,0.29040614,heartbeat,0.36637402,heartbeat,0.36637402
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,classified,0.22413155,as,0.5156816,rai,0.34119064
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,check,0.48857665,arrythmia,0.52696586,arrythmia,0.52696586
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterizing,0.2094489,of,0.6211066,anomalous,0.44346243
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterized,0.12166704,isolated,0.60163844,anomalous,0.39773136
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterize,0.19010037,of,0.50051045,anomalous,0.3649997
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,based,0.2494699,of,0.5443143,flow,0.34116954
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,background,0.2325702,of,0.51277274,congenital,0.3895001
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,adding,0.342934,with,0.6210071,mi,0.36751556
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,left,0.3872844,left,1.0,left-atrial,0.6573896
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ventricular-ejection,0.45086157,ventricular,0.8827383,ventricular,0.8827383
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid,0.25606772,insufficiency,0.46684614,congestive,0.45785415
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,antagonists,0.26629966,contractions,0.45131737,contractions,0.45131737
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor,0.254681,congestive,0.43098098,congestive,0.43098098
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-antagonists,0.2558006,contractions,0.41648656,contractions,0.41648656
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor-antagonists,0.27392825,congestive,0.42555445,congestive,0.42555445
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-blockers,0.33424258,bradycardia,0.4559213,bradycardia,0.4559213
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor-blockers,0.3599828,congestive,0.50955385,congestive,0.50955385
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced-ejection,0.30925128,ventricular,0.54094154,ventricular,0.54094154
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,remained,0.3110356,with,0.53534096,mi,0.3947517
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previously,0.21411541,as,0.54924536,l-transposition,0.42639655
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registries,0.4584577,congenital-heart-disease,0.49414733,congenital-heart-disease,0.49414733
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previously-published,0.32664487,of,0.4902569,venous-return,0.40298006
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.4418916,cardiology,0.4418916,cardiology,0.4418916
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart,0.57664216,heart,1.0,heart,1.0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reached,0.28958622,of,0.53159845,flow,0.3386585
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,target,0.23866604,of,0.4775706,blood,0.34112448
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,doses,0.30115995,with,0.44940743,contractions,0.3849393
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.4418916,cardiology,0.4418916,cardiology,0.4418916
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.52468073,cardiology,0.52468073,cardiology,0.52468073
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,despite,0.3297603,of,0.5583629,cardiac,0.39134312
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc-hf,0.4397089,heart-failure,0.5964376,heart-failure,0.5964376
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid,0.25606772,insufficiency,0.46684614,congestive,0.45785415
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,antagonists,0.26629966,contractions,0.45131737,contractions,0.45131737
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor,0.254681,congestive,0.43098098,congestive,0.43098098
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-antagonists,0.2558006,contractions,0.41648656,contractions,0.41648656
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor-antagonists,0.27392825,congestive,0.42555445,congestive,0.42555445
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.4418916,cardiology,0.4418916,cardiology,0.4418916
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.52468073,cardiology,0.52468073,cardiology,0.52468073
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,recommendations,0.55450773,cardiology,0.55450773,cardiology,0.55450773
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc-hf,0.4397089,heart-failure,0.5964376,heart-failure,0.5964376
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-blockers,0.33424258,bradycardia,0.4559213,bradycardia,0.4559213
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor-blockers,0.3599828,congestive,0.50955385,congestive,0.50955385
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,april,0.39595693,cardiology,0.39595693,cardiology,0.39595693
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting,0.35060608,of,0.48566324,atrial,0.43797946
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme,0.2546285,of,0.4396425,cholesterol,0.39044598
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme,0.37506402,congestive,0.4974824,congestive,0.4974824
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme-inhibitors,0.27471942,congestive-heart-failure,0.38239455,congestive-heart-failure,0.38239455
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme-inhibitors,0.33161855,congestive-heart-failure,0.4766807,congestive-heart-failure,0.4766807
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting,0.35060608,of,0.48566324,atrial,0.43797946
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme,0.2546285,of,0.4396425,cholesterol,0.39044598
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,inhibitor,0.23137593,of,0.37385303,congestive,0.302135
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme,0.37506402,congestive,0.4974824,congestive,0.4974824
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme-inhibitor,0.2564084,isomerism,0.38155574,isomerism,0.38155574
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme-inhibitor,0.3161693,congestive-heart-failure,0.46101397,congestive-heart-failure,0.46101397
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enrolled,0.4130389,cardiology,0.4130389,cardiology,0.4130389
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril,0.3795854,heart-failure,0.49538177,heart-failure,0.49538177
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,catalan,0.41001946,cardiology,0.41001946,cardiology,0.41001946
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.57852423,cardiology,0.57852423,cardiology,0.57852423
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results,0.29712585,of,0.53157276,blood,0.36869162
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,also,0.36015856,of,0.65908813,flow,0.41040578
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results-also,0.45058537,return,0.48413345,venous-return,0.45992327
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,outpatient,0.599135,cardiology,0.599135,cardiology,0.599135
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,clinics,0.57818425,cardiology,0.57818425,cardiology,0.57818425
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx,0.22827038,atresia-with,0.47461146,atresia-with,0.47461146
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.44611835,congenital-heart-disease,0.48533773,congenital-heart-disease,0.48533773
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,shows,0.24564052,of,0.56087804,anomalous,0.38309503
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,target,0.23866604,of,0.4775706,blood,0.34112448
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,doses,0.30115995,with,0.44940743,contractions,0.3849393
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart,0.57664216,heart,1.0,heart,1.0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.4418916,cardiology,0.4418916,cardiology,0.4418916
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.52468073,cardiology,0.52468073,cardiology,0.52468073
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc-guidelines,0.55899453,cardiology,0.55899453,cardiology,0.55899453
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,february,0.39036617,paivs,0.39606073,paivs,0.39606073
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,may,0.26963884,of,0.58654004,anomalous,0.366544
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previous,0.37261367,with,0.5284412,mi,0.42555177
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registries,0.4584577,congenital-heart-disease,0.49414733,congenital-heart-disease,0.49414733
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,pharmacological,0.32797652,of,0.48491696,congestive-heart-failure,0.37223655
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,recommendations,0.55450773,cardiology,0.55450773,cardiology,0.55450773
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf-drugs,0.29344928,heart-failure,0.52922136,heart-failure,0.52922136
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx,0.22827038,atresia-with,0.47461146,atresia-with,0.47461146
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.44611835,congenital-heart-disease,0.48533773,congenital-heart-disease,0.48533773
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sons,0.3803559,cardiology,0.3803559,cardiology,0.3803559
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ltd,0.19889542,arrythmia,0.2606184,arrythmia,0.2606184
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,version,0.28984672,with,0.34769157,venous-return,0.32283413
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,new-version,0.3487723,venous-return,0.47297412,venous-return,0.47297412
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,monotherapy,0.27727643,heart-failure,0.4191598,heart-failure,0.4191598
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low,0.33154353,with,0.5951388,flow,0.4108625
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,proportion,0.23363663,total,0.537244,chd,0.3531295
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low-proportion,0.22957143,venous-return,0.43810487,venous-return,0.43810487
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,john,0.33923185,cardiology,0.33923185,cardiology,0.33923185
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,wiley,0.3314681,cardiology,0.3314681,cardiology,0.3314681
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.57852423,cardiology,0.57852423,cardiology,0.57852423
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,according,0.3426876,as,0.48304257,rai,0.3796531
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,european,0.43573785,cardiology,0.43573785,cardiology,0.43573785
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,society,0.5570969,cardiology,0.5570969,cardiology,0.5570969
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,appropriate,0.3800038,with,0.5385787,cardiology,0.3800038
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,adherence,0.250551,lai,0.4137426,lai,0.4137426
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,appropriate-adherence,0.36770502,with,0.4839561,heart-failure,0.4456898
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,almost,0.23581058,of,0.57679296,deposits,0.3693066
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sectional,0.37195796,arteries,0.42924127,arteries,0.42924127
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sectional-study,0.29747638,artery-disease,0.4196763,artery-disease,0.4196763
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,higher,0.2654187,with,0.56796193,mi,0.398535
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,higher-level,0.30711952,of,0.42014354,single-ventricle,0.3631152
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.4418916,cardiology,0.4418916,cardiology,0.4418916
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.52468073,cardiology,0.52468073,cardiology,0.52468073
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril,0.3795854,heart-failure,0.49538177,heart-failure,0.49538177
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results,0.29712585,of,0.53157276,blood,0.36869162
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.44611835,congenital-heart-disease,0.48533773,congenital-heart-disease,0.48533773
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.57852423,cardiology,0.57852423,cardiology,0.57852423
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,valsartan,0.35073355,heart-failure,0.4610226,heart-failure,0.4610226
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,use,0.3219829,with,0.55726266,flow,0.40877783
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,titration,0.3082621,with,0.3918552,flow,0.37716165
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,released,0.2484777,of,0.48016924,deposits,0.40210602
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,quarter,0.33375067,single,0.45288786,anomaly,0.37591588
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,publication,0.46771824,cardiology,0.46771824,cardiology,0.46771824
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,prescription,0.40264392,heart-failure,0.4190284,heart-failure,0.4190284
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,prescribed,0.4051101,with,0.4445796,cardiology,0.4051101
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,population,0.3190225,of,0.49866888,chd,0.40046495
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,observational,0.42664766,congenital-heart-disease,0.47426757,congenital-heart-disease,0.47426757
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,multicentre,0.38225377,congenital-heart-disease,0.41147467,congenital-heart-disease,0.41147467
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,months,0.2814955,failure,0.43657047,congestive,0.39787602
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ivabradine,0.4460753,heart-failure,0.6088966,heart-failure,0.6088966
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,greater,0.28239584,of,0.59163296,mi,0.40441626
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,describe,0.2106702,of,0.4752335,anomalous,0.4157361
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cross,0.28978038,double,0.48992044,anomalous,0.35670662
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,consequence,0.20217416,as,0.60178614,anomalous,0.4669029
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,complexity,0.33769363,of,0.53220767,anomaly,0.40085608
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,compared,0.26227483,with,0.62448335,mi,0.40925252
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,class,0.2877068,of,0.3977759,d-transposition,0.36031434
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,beta,0.2517134,of,0.43937695,cardiac,0.37025452
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,behalf,0.44911885,cardiology,0.44911885,cardiology,0.44911885
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,accomplished,0.24342014,of,0.58169246,l-transposition,0.4368597
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,dihydropyridine,0.25740874,contractions,0.4092142,contractions,0.4092142
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium,0.2680287,cholesterol,0.4826102,cholesterol,0.4826102
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel,0.213781,outlet,0.38533387,atrioventricular,0.37955636
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,dihydropyridine-calcium,0.21767619,isomerism,0.36617693,isomerism,0.36617693
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel,0.32553506,heart-failure,0.4562675,heart-failure,0.4562675
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel-blockers,0.32383853,fibrillation,0.44691512,fibrillation,0.44691512
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel-blockers,0.3239074,fibrillation,0.46348688,fibrillation,0.46348688
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol,0.20196024,beats,0.37834996,beats,0.37834996
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine,0.33032572,cholesterol,0.43090975,cholesterol,0.43090975
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.3233322,single,0.40449998,beats,0.3867238
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic,0.3646236,heart-failure,0.5228808,heart-failure,0.5228808
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,hypertensive,0.4743544,congestive,0.561265,congestive,0.561265
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic-hypertensive,0.40813258,heart-failure,0.5715042,heart-failure,0.5715042
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients-treated,0.29297715,heart-failure,0.5073745,heart-failure,0.5073745
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium,0.2680287,cholesterol,0.4826102,cholesterol,0.4826102
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel,0.213781,outlet,0.38533387,atrioventricular,0.37955636
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel,0.32553506,heart-failure,0.4562675,heart-failure,0.4562675
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel-blockers,0.32383853,fibrillation,0.44691512,fibrillation,0.44691512
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel-blockers,0.3239074,fibrillation,0.46348688,fibrillation,0.46348688
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic,0.3646236,heart-failure,0.5228808,heart-failure,0.5228808
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,hypertensive,0.4743544,congestive,0.561265,congestive,0.561265
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic-hypertensive,0.40813258,heart-failure,0.5715042,heart-failure,0.5715042
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,validated,0.27360892,of,0.4456607,cad,0.31460553
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,digital,0.34962374,blood-flow,0.4564183,blood-flow,0.4564183
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,device,0.32167804,mitral-valve,0.45668685,mitral-valve,0.45668685
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significant,0.2800444,great,0.554224,stenosis,0.40396324
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,difference,0.212452,of,0.434909,stenosis,0.35809982
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,among,0.2573181,of,0.57348,chd,0.4274787
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significant-difference,0.3150959,of,0.46622813,mi,0.44138703
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,clinitek,0.3399889,cardiology,0.3399889,cardiology,0.3399889
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,device,0.32167804,mitral-valve,0.45668685,mitral-valve,0.45668685
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analyzer,0.2671876,blood-flow,0.3816265,blood-flow,0.3816265
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,aldosterone,0.33841828,atrial,0.5453626,atrial,0.5453626
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,system,0.21977381,of,0.44332683,anomaly,0.36816198
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,angiotensin-aldosterone,0.38179368,congestive,0.56833804,congestive,0.56833804
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mean,0.30953988,total,0.5000684,artery,0.37085557
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,age,0.33659208,with,0.44369304,chd,0.42829025
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mean-age,0.25966704,chd,0.4176549,chd,0.4176549
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,different,0.24309576,of,0.61590904,anomalous,0.37924677
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combinations,0.20387237,single,0.52298564,l-transposition,0.3216092
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,drug-combinations,0.28961977,heart-failure,0.43682212,heart-failure,0.43682212
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.3233322,single,0.40449998,beats,0.3867238
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albumin,0.24654618,cholesterol,0.49211323,cholesterol,0.49211323
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,unselected,0.357962,with,0.5118079,congenital-heart-disease,0.4884495
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,males,0.27325124,chd,0.43028116,chd,0.43028116
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,p,0.29391026,with,0.4559728,congestive,0.4058217
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine,0.30356342,aortic-coarctation,0.43746695,aortic-coarctation,0.43746695
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.3267367,heart-failure,0.4456096,heart-failure,0.4456096
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,macroalbuminuria,0.34349602,chd,0.5375465,chd,0.5375465
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol,0.20196024,beats,0.37834996,beats,0.37834996
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine,0.33032572,cholesterol,0.43090975,cholesterol,0.43090975
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.3233322,single,0.40449998,beats,0.3867238
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine,0.33032572,cholesterol,0.43090975,cholesterol,0.43090975
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ratio,0.18660581,total,0.40182298,tof,0.36502323
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,months,0.2814955,failure,0.43657047,congestive,0.39787602
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,urinary,0.23853776,insufficiency,0.4206198,venous,0.39477098
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albumin,0.24654618,cholesterol,0.49211323,cholesterol,0.49211323
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,urinary-albumin,0.21076728,blood-clot,0.46689695,blood-clot,0.46689695
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,several,0.34988725,of,0.5990606,cardiac,0.37646228
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combinations,0.20387237,single,0.52298564,l-transposition,0.3216092
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects,0.2924615,with,0.45921433,chd,0.45653754
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,effect,0.20909318,of,0.5657147,contractions,0.35284936
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,similar-effect,0.17017548,weak,0.46557683,l-transposition,0.41884673
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renal,0.43551624,pulmonary,0.5641475,pulmonary,0.5641475
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renal-outcomes,0.42390928,congestive-heart-failure,0.5384488,congestive-heart-failure,0.5384488
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,raas,0.35215056,aortic-coarctation,0.5229902,aortic-coarctation,0.5229902
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,raas-inhibitors,0.3015113,congestive-heart-failure,0.47362044,congestive-heart-failure,0.47362044
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,pait,0.4036368,arrythmia,0.4860661,arrythmia,0.4860661
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,survey,0.3773732,of,0.382426,cardiology,0.3773732
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,low,0.33154353,with,0.5951388,flow,0.4108625
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,number,0.2521113,total,0.48291022,l-transposition,0.33454442
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,low-number,0.2563045,single,0.41055697,anomalous,0.36284992
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,kidney,0.29311,heart,0.5663165,heart,0.5663165
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,kidney-disease,0.27286986,heart-disease,0.6544356,heart-disease,0.6544356
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,early,0.34221643,of,0.5714519,mi,0.3991026
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,marker,0.22334269,as,0.47600302,mi,0.37359565
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,early-marker,0.19775814,chd,0.36026895,chd,0.36026895
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,decreased,0.2912292,of,0.59706545,flow,0.4062525
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,occurrence,0.23615561,of,0.6225994,anomaly,0.44139424
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blood,0.32078606,blood,1.0,blood,1.0
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blood-pressure,0.37952203,blood,0.65126884,blood,0.65126884
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,without,0.27970245,with,0.7351919,cardiac,0.42947003
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.31299806,chd,0.51238084,chd,0.51238084
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,control,0.26906762,with,0.5145365,mi,0.4093958
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.31299806,chd,0.51238084,chd,0.51238084
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.31299806,chd,0.51238084,chd,0.51238084
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,translates,0.28088915,of,0.5055193,flow,0.335616
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,0.23700657,with,0.568532,mi,0.39826992
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lowered,0.26918596,with,0.5560069,cholesterol,0.45384544
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,0.23700657,with,0.568532,mi,0.39826992
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,higher,0.2654187,with,0.56796193,mi,0.398535
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly-higher,0.2440085,with,0.5364338,mi,0.3939989
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments,0.26635414,with,0.4610238,eb,0.319998
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,decrease,0.28522113,of,0.5904174,flow,0.42153293
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,previous,0.37261367,with,0.5284412,mi,0.42555177
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,previous-treatment,0.28161317,venous-return,0.48381627,venous-return,0.48381627
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,g,0.21858013,single,0.41386712,ivs,0.37229383
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril,0.35206187,heart-failure,0.4787848,heart-failure,0.4787848
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,compared,0.26227483,with,0.62448335,mi,0.40925252
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril-compared,0.3154751,heart-failure,0.537332,heart-failure,0.537332
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analysed,0.24992706,of,0.55535066,anomalous,0.3312636
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,data,0.31118363,of,0.5086956,mi,0.36251363
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.3267367,heart-failure,0.4456096,heart-failure,0.4456096
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,perindopril,0.36142457,aortic-coarctation,0.51783586,aortic-coarctation,0.51783586
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine-perindopril,0.33995584,aortic-coarctation,0.525669,aortic-coarctation,0.525669
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ramipril,0.3454432,heart-failure,0.5243782,heart-failure,0.5243782
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.31299806,chd,0.51238084,chd,0.51238084
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,p,0.29391026,with,0.4559728,congestive,0.4058217
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,macroalbuminuria,0.34349602,chd,0.5375465,chd,0.5375465
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine,0.30356342,aortic-coarctation,0.43746695,aortic-coarctation,0.43746695
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.3267367,heart-failure,0.4456096,heart-failure,0.4456096
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.31299806,chd,0.51238084,chd,0.51238084
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,0.23700657,with,0.568532,mi,0.39826992
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments,0.26635414,with,0.4610238,eb,0.319998
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects,0.2924615,with,0.45921433,chd,0.45653754
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ramipril,0.3454432,heart-failure,0.5243782,heart-failure,0.5243782
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,perindopril,0.36142457,aortic-coarctation,0.51783586,aortic-coarctation,0.51783586
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,g,0.21858013,single,0.41386712,ivs,0.37229383
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril,0.35206187,heart-failure,0.4787848,heart-failure,0.4787848
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,data,0.31118363,of,0.5086956,mi,0.36251363
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,verapamil,0.3494261,bradycardia,0.49162602,bradycardia,0.49162602
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,valsartan,0.35073355,heart-failure,0.4610226,heart-failure,0.4610226
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,using,0.20786116,with,0.58010674,flow,0.41007757
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,use,0.3219829,with,0.55726266,flow,0.40877783
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,trandolapril,0.38897562,heart-failure,0.50174034,heart-failure,0.50174034
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,showing,0.29306263,with,0.67394197,anomalous,0.42565343
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,results,0.29712585,of,0.53157276,blood,0.36869162
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renin,0.31312823,atrial,0.5063691,atrial,0.5063691
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,prevalence,0.25545907,disease,0.43233684,chd,0.4308555
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,present,0.34922045,of,0.63723874,anomaly,0.40175247
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,normoalbuminuria,0.32154,chd,0.52918863,chd,0.52918863
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,nitrendipine,0.31468165,contractions,0.4603902,contractions,0.4603902
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,microalbuminuria,0.38341475,chd,0.5601176,chd,0.5601176
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,measured,0.2266986,of,0.539739,flow,0.4470259
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,maintained,0.31429723,with,0.55760944,flow,0.41760272
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,loss,0.15467258,of,0.561642,anomaly,0.37637395
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,introduction,0.3353318,of,0.5877248,l-transposition,0.4046045
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,frequency,0.2575089,of,0.49752423,flow,0.40794802
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,felodipine,0.29481825,congestive,0.42881507,congestive,0.42881507
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,favoring,0.18931735,of,0.5335792,isomerism,0.36232197
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,due,0.3318616,of,0.5734476,anomaly,0.41796127
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,defined,0.2335411,as,0.60751194,stenosis,0.33817482
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,conclusions,0.259925,with,0.50001186,artery,0.34474826
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combined,0.24027641,with,0.60924613,single-ventricle,0.4029721
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,changes,0.30126634,of,0.5562258,flow,0.44305104
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,baseline,0.37229544,return,0.53112984,mi,0.4760896
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,assessed,0.32085416,of,0.605934,flow,0.3956796
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analyzed,0.25776637,of,0.58131987,flow,0.35350555
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognostic,0.31385523,infarction,0.42731366,infarction,0.42731366
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,model-using,0.3062802,venous-return,0.47759014,venous-return,0.47759014
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,constructed,0.15691337,interrupted,0.47456625,l-transposition,0.40224642
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,showed,0.21619865,with,0.57298803,flow,0.33828264
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,comparable,0.21267173,with,0.5389043,arteries,0.33967346
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,constructed,0.15691337,interrupted,0.47456625,l-transposition,0.40224642
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,computational,0.28820527,of,0.38567346,single-ventricle,0.3594826
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver,0.2488175,stenosis,0.38058472,stenosis,0.38058472
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,operating,0.35147023,of,0.42011455,venous-return,0.38749343
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,characteristic,0.14630476,of,0.52064013,anomalous,0.42846608
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,curve,0.23990677,stenosis,0.35901296,stenosis,0.35901296
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver-operating,0.27902067,stenosis,0.41488302,stenosis,0.41488302
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,operating-characteristic,0.26187587,of,0.50360763,venous-return,0.39550078
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,characteristic-curve,0.1781891,anomalous,0.43976218,anomalous,0.43976218
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver-operating-characteristic,0.25317627,stenosis,0.38405818,stenosis,0.38405818
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,e,0.21868992,double,0.39788574,eb,0.38260236
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,stained,0.24880892,deposits,0.52105916,deposits,0.52105916
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,whole,0.2498735,of,0.548425,blood,0.49452528
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,groups,0.2612025,with,0.4941169,mi,0.3908207
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,according,0.3426876,as,0.48304257,rai,0.3796531
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,term-survival,0.15355091,single-ventricle,0.43360496,single-ventricle,0.43360496
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,groups-according,0.33198965,as,0.41213372,congestive-heart-failure,0.38642532
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image,0.3220324,heartbeat,0.45858762,heartbeat,0.45858762
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image-features,0.26059413,heartbeat,0.44243276,heartbeat,0.44243276
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,west,0.45728073,cardiology,0.45728073,cardiology,0.45728073
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,china,0.30905926,great,0.41031903,paivs,0.35474125
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hospital,0.5604328,cardiology,0.5604328,cardiology,0.5604328
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,west-china,0.37090027,paivs,0.3832909,paivs,0.3832909
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm,0.20611128,rai,0.40812728,rai,0.40812728
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,staging,0.29892582,rai,0.49285498,rai,0.49285498
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,systems,0.2822709,of,0.44318485,flow,0.3656453
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm-staging,0.26114333,rai,0.46771735,rai,0.46771735
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,staging-systems,0.3415752,single-ventricle,0.43998855,single-ventricle,0.43998855
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm-staging-systems,0.31065404,rai,0.41665202,rai,0.41665202
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,fully,0.24119267,of,0.5259341,isomerism,0.3538288
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,automated,0.29324785,abnormal,0.41404682,heartbeat,0.3952852
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,pipeline,0.31322083,flow,0.36466506,flow,0.36466506
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,fully-automated,0.26099348,venous-return,0.40890667,venous-return,0.40890667
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,automated-pipeline,0.2762986,venous-return,0.4501225,venous-return,0.4501225
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,external,0.29746136,of,0.4755252,anomalous,0.3880807
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,sets,0.3191966,of,0.5187284,mi,0.39878035
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,external-validation,0.31959862,venous-return,0.4819317,venous-return,0.4819317
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,validation-sets,0.22635233,venous-return,0.40908638,venous-return,0.40908638
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,distinguish,0.15236557,as,0.43063623,anomalous,0.3493976
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatocellular,0.29323414,myocardial,0.43322873,myocardial,0.43322873
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,carcinoma,0.23419702,atresia,0.48376516,atresia,0.48376516
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatocellular-carcinoma,0.2291855,myocardial,0.40641323,myocardial,0.40641323
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,time,0.350901,return,0.5513821,venous-return,0.44564146
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,points,0.2814706,of,0.4826713,venous,0.38039982
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,different-time,0.19536507,of,0.4149277,venous-return,0.40377223
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,time-points,0.20965667,single,0.36874315,arteries,0.35039324
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,develop,0.22949755,of,0.43968886,congestive-heart-failure,0.35599005
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,genome,0.2711001,l-transposition,0.42332953,l-transposition,0.42332953
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,atlas,0.27821434,anomaly,0.37537187,anomaly,0.37537187
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,cancer-genome,0.27246958,congenital-heart-disease,0.33042622,congenital-heart-disease,0.33042622
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,genome-atlas,0.31608427,congenital-heart-disease,0.36287746,congenital-heart-disease,0.36287746
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assigned,0.23878475,single,0.39629948,mi,0.33124304
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assigned-risk,0.26863375,chd,0.4469512,chd,0.4469512
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,risk-scores,0.35254818,chd,0.49175406,chd,0.49175406
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent,0.16163272,deposits,0.45844048,deposits,0.45844048
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent-normal,0.17656593,abnormal,0.5535503,hypoplastic-left,0.5273769
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal-tissues,0.24752107,abnormal,0.45309216,blood-flow,0.43048656
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent,0.16163272,deposits,0.45844048,deposits,0.45844048
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent-normal,0.17656593,abnormal,0.5535503,hypoplastic-left,0.5273769
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal-tissue,0.25748524,blood-flow,0.4578339,blood-flow,0.4578339
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,diagnostic,0.41757601,abnormal,0.4175846,cardiology,0.41757601
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classifier,0.26326174,cad,0.36912674,cad,0.36912674
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classifier-based,0.27543524,double-outlet,0.39300787,double-outlet,0.39300787
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classify,0.19261536,as,0.39506868,artery-disease,0.33047467
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slides,0.30374995,deposits,0.44078195,deposits,0.44078195
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue-slides,0.2203773,plaque-deposits,0.44378293,plaque-deposits,0.44378293
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,microarray,0.23755707,of,0.37483644,flow,0.314666
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue-microarray,0.23453434,blood-flow,0.43134093,blood-flow,0.43134093
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,significantly,0.23700657,with,0.568532,mi,0.39826992
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,stratify,0.34915516,chd,0.40791327,chd,0.40791327
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,successfully,0.25479004,great,0.48915762,d-transposition,0.41823155
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,distinguish,0.15236557,as,0.43063623,anomalous,0.3493976
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.2944808,chd,0.42775357,chd,0.42775357
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognostic,0.31385523,infarction,0.42731366,infarction,0.42731366
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image,0.3220324,heartbeat,0.45858762,heartbeat,0.45858762
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image-features,0.26059413,heartbeat,0.44243276,heartbeat,0.44243276
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based-models,0.20372218,single,0.3450173,single-ventricle,0.3381522
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.24234259,deposits,0.45118088,deposits,0.45118088
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slides,0.30374995,deposits,0.44078195,deposits,0.44078195
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,statistical,0.32752115,of,0.40241736,congenital-heart-disease,0.36489835
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slide,0.35935634,with,0.42923054,flow,0.3943032
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.24234259,deposits,0.45118088,deposits,0.45118088
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc,0.18832418,chd,0.29138696,chd,0.29138696
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.2944808,chd,0.42775357,chd,0.42775357
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc-patients,0.28265512,heart-failure,0.47332928,heart-failure,0.47332928
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted,0.24302739,isolated,0.6058264,deposits,0.3322685
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgical,0.4755141,cardiology,0.4755141,cardiology,0.4755141
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,resection,0.26559794,right,0.48707062,stenosis,0.48653373
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgical-resection,0.249781,aortic-stenosis,0.4988181,aortic-stenosis,0.4988181
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.24234259,deposits,0.45118088,deposits,0.45118088
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slide,0.35935634,with,0.42923054,flow,0.3943032
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.2944808,chd,0.42775357,chd,0.42775357
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assist,0.42038903,return,0.4985461,cardiology,0.42038903
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,clinicians,0.494618,cardiology,0.494618,cardiology,0.494618
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis-prediction,0.32927758,heart-failure,0.49926502,heart-failure,0.49926502
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.2944808,chd,0.42775357,chd,0.42775357
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted,0.24302739,isolated,0.6058264,deposits,0.3322685
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc,0.18832418,chd,0.29138696,chd,0.29138696
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,used,0.23211285,as,0.56584436,flow,0.35934073
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,train,0.39593512,contractions,0.4625386,contractions,0.4625386
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgery,0.52026105,cardiology,0.52026105,cardiology,0.52026105
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,shorter,0.1831873,interrupted,0.49242672,right-atrial,0.3699446
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,objective,0.2960808,of,0.5255821,flow,0.39260852
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,moreover,0.16758724,of,0.5596781,plaque-deposits,0.35056823
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,longer,0.2500613,interrupted,0.5135091,right-atrial,0.39419138
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatectomy,0.24883531,single-ventricle,0.4286629,single-ventricle,0.4286629
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hematoxylin,0.2536906,deposits,0.44773144,deposits,0.44773144
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,h,0.20228642,of,0.4345476,mi,0.34808266
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,eosin,0.20281377,deposits,0.3814636,deposits,0.3814636
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,area,0.34147155,left,0.4808709,stenosis,0.41823816
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,analyze,0.22247948,of,0.49013835,anomalous,0.3403252
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,able,0.3130405,with,0.55771506,cardiac,0.38070798
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among,0.2573181,of,0.57348,chd,0.4274787
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.32132432,chd,0.4550472,chd,0.4550472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescribed,0.4051101,with,0.4445796,cardiology,0.4051101
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop,0.14408562,interrupted,0.45845878,ivs,0.35547963
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.39986306,congestive,0.593751,congestive,0.593751
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop-diuretics,0.2986417,congestive-heart-failure,0.54016435,congestive-heart-failure,0.54016435
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,less,0.30277786,with,0.57537794,mi,0.38854462
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,common,0.21206799,of,0.500178,anomaly,0.44165826
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among,0.2573181,of,0.57348,chd,0.4274787
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,less-common,0.13210395,single,0.41953135,l-transposition,0.37514058
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among-individuals,0.24577892,chd,0.42405927,chd,0.42405927
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,dimensional,0.25604147,anomalous,0.48529866,anomalous,0.48529866
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,dementia,0.3804462,disease,0.5290329,cad,0.49958262
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,scale,0.29563683,great,0.37443155,venous-return,0.34418654
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,assessment-scale,0.33665887,venous-return,0.4212966,venous-return,0.4212966
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,classes,0.3080849,of,0.44878983,cardiac,0.33523548
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among,0.2573181,of,0.57348,chd,0.4274787
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.32132432,chd,0.4550472,chd,0.4550472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug-classes,0.28561622,congestive-heart-failure,0.39978883,congestive-heart-failure,0.39978883
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,concerning,0.3830846,of,0.5967124,congenital,0.39754236
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,use,0.3219829,with,0.55726266,flow,0.40877783
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug-use,0.32648325,congestive-heart-failure,0.39953357,congestive-heart-failure,0.39953357
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,including,0.2742056,of,0.6619886,congenital,0.3605199
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.32132432,chd,0.4550472,chd,0.4550472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,performed-including,0.39507776,of,0.5789391,atresia-with,0.44530454
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,ii,0.26288998,of,0.43728137,mi,0.35983312
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin-ii,0.31497288,atrial,0.48099947,atrial,0.48099947
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,ii-receptor,0.2801689,congestive,0.4263869,congestive,0.4263869
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor-blockers,0.33424258,bradycardia,0.4559213,bradycardia,0.4559213
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin-ii-receptor,0.31185067,congestive,0.49079838,congestive,0.49079838
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,ii-receptor-blockers,0.33372557,congestive,0.4715014,congestive,0.4715014
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.32132432,chd,0.4550472,chd,0.4550472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescribed,0.4051101,with,0.4445796,cardiology,0.4051101
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,asa,0.39555937,cad,0.43010977,cad,0.43010977
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid,0.25606772,insufficiency,0.46684614,congestive,0.45785415
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,antagonists,0.26629966,contractions,0.45131737,contractions,0.45131737
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid-receptor,0.254681,congestive,0.43098098,congestive,0.43098098
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor-antagonists,0.2558006,contractions,0.41648656,contractions,0.41648656
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid-receptor-antagonists,0.27392825,congestive,0.42555445,congestive,0.42555445
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,questionnaire,0.3388839,congenital-heart-disease,0.37297606,congenital-heart-disease,0.37297606
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,surveys,0.3482949,return,0.3625318,cardiology,0.3482949
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,two-questionnaire,0.32632694,congenital-heart-disease,0.38700938,congenital-heart-disease,0.38700938
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,questionnaire-surveys,0.29266462,congenital-heart-disease,0.3673477,congenital-heart-disease,0.3673477
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,regarding,0.4430421,of,0.5573762,cardiology,0.4430421
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,adherence,0.250551,lai,0.4137426,lai,0.4137426
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting,0.35060608,of,0.48566324,atrial,0.43797946
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,enzyme,0.2546285,of,0.4396425,cholesterol,0.39044598
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting-enzyme,0.37506402,congestive,0.4974824,congestive,0.4974824
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,enzyme-inhibitors,0.27471942,congestive-heart-failure,0.38239455,congestive-heart-failure,0.38239455
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting-enzyme-inhibitors,0.33161855,congestive-heart-failure,0.4766807,congestive-heart-failure,0.4766807
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,factors,0.24127257,of,0.49770784,chd,0.4172811
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,within,0.30995527,of,0.57602364,deposits,0.42065546
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,associated-factors,0.23114035,of,0.4828459,chd,0.427502
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,elderly,0.36728853,insufficiency,0.5202712,heart-failure,0.49419144
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.32132432,chd,0.4550472,chd,0.4550472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.2469504,of,0.47259963,deposits,0.36684513
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,elderly-people,0.34052846,congenital-heart-disease,0.4794715,congenital-heart-disease,0.4794715
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people-living,0.2926893,chd,0.4129976,chd,0.4129976
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular-drug,0.550941,congestive-heart-failure,0.639843,congestive-heart-failure,0.639843
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug-treatment,0.24843037,heart-failure,0.4681347,heart-failure,0.4681347
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,severe,0.29645193,insufficiency,0.65468115,stenosis,0.5520288
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.24527673,insufficiency,0.6033757,congenital,0.45398903
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-impairment,0.2558166,heart-failure,0.4199052,heart-failure,0.4199052
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,increasing,0.35820884,of,0.6603997,flow,0.41165438
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.24527673,insufficiency,0.6033757,congenital,0.45398903
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-impairment,0.2558166,heart-failure,0.4199052,heart-failure,0.4199052
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,agents,0.28208297,as,0.4665778,congestive,0.34284872
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,used,0.23211285,as,0.56584436,flow,0.35934073
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four,0.26703352,of,0.57211214,d-transposition,0.35247436
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four-different,0.21194589,single,0.42057985,hypoplastic-left-heart,0.38606024
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different-levels,0.19815676,of,0.45131484,plaque-deposits,0.37482098
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop,0.14408562,interrupted,0.45845878,ivs,0.35547963
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.39986306,congestive,0.593751,congestive,0.593751
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop-diuretics,0.2986417,congestive-heart-failure,0.54016435,congestive-heart-failure,0.54016435
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.32132432,chd,0.4550472,chd,0.4550472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.24527673,insufficiency,0.6033757,congenital,0.45398903
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-impairment,0.2558166,heart-failure,0.4199052,heart-failure,0.4199052
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four,0.26703352,of,0.57211214,d-transposition,0.35247436
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four-levels,0.2186432,with,0.42652208,venous-return,0.36298263
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.2469504,of,0.47259963,deposits,0.36684513
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,patterns,0.22309256,of,0.55208683,anomalous,0.46585032
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different-drugs,0.2019881,of,0.41790655,congestive-heart-failure,0.3982408
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,function,0.2605439,of,0.55099833,flow,0.43324804
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-function,0.3009429,single-ventricle,0.44015783,single-ventricle,0.44015783
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,daily,0.3620783,single,0.43283373,heartbeat,0.36777166
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.2469504,of,0.47259963,deposits,0.36684513
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,daily-living,0.24739212,heart-failure,0.39449167,heart-failure,0.39449167
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,significantly,0.23700657,with,0.568532,mi,0.39826992
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,lower,0.26859394,with,0.5748005,venous,0.42565888
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,significantly-lower,0.25938573,with,0.53332967,congestive-heart-failure,0.4323113
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,nursing,0.54227597,cardiology,0.54227597,cardiology,0.54227597
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,homes,0.3918493,cardiology,0.3918493,cardiology,0.3918493
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,nursing-homes,0.43058693,cardiology,0.43058693,cardiology,0.43058693
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,northern,0.3091737,isolated,0.3890194,deposits,0.35277614
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,sweden,0.3256724,congenital-heart-disease,0.39799038,congenital-heart-disease,0.39799038
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mddas,0.21307397,rai,0.33120406,rai,0.33120406
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,heart,0.57664216,heart,1.0,heart,1.0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,describe,0.2106702,of,0.4752335,anomalous,0.4157361
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,changes,0.30126634,of,0.5562258,flow,0.44305104
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,atrial,0.52708566,atrial,1.0,atrial,1.0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,fibrillation,0.5347377,fibrillation,1.0,fibrillation,1.0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,atrial-fibrillation,0.46922478,fibrillation,0.887709,fibrillation,0.887709
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,compared,0.26227483,with,0.62448335,mi,0.40925252
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results,0.29712585,of,0.53157276,blood,0.36869162
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,indicate,0.15955864,of,0.50470227,anomalous,0.31785142
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results-indicate,0.372453,as,0.45080334,venous-return,0.39627838
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.39986306,congestive,0.593751,congestive,0.593751
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,use,0.3219829,with,0.55726266,flow,0.40877783
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,used,0.23211285,as,0.56584436,flow,0.35934073
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results,0.29712585,of,0.53157276,blood,0.36869162
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,compared,0.26227483,with,0.62448335,mi,0.40925252
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,warfarin,0.40191883,fibrillation,0.596888,fibrillation,0.596888
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,using,0.20786116,with,0.58010674,flow,0.41007757
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,room,0.40999863,return,0.5111984,arrythmia,0.4198049
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,relation,0.2989607,of,0.5984683,anomalous,0.45674402
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,purpose,0.27727276,of,0.5072116,congenital,0.37470472
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,proxy,0.33019635,as,0.5050032,venous-return,0.3841054
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,proportion,0.23363663,total,0.537244,chd,0.3531295
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescription,0.40264392,heart-failure,0.4190284,heart-failure,0.4190284
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,population,0.3190225,of,0.49866888,chd,0.40046495
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,pattern,0.22120216,irregular,0.5954343,flow,0.4913214
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,multi,0.3120417,single,0.49181098,cad,0.38921657
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mras,0.38003942,tof,0.4132527,tof,0.4132527
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,increased,0.32251194,of,0.64014816,mi,0.42637154
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,improvement,0.36781824,return,0.5283363,congestive,0.42538065
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,guidelines,0.52468073,cardiology,0.52468073,cardiology,0.52468073
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,functioning,0.27543187,intact,0.487641,single-ventricle,0.40496832
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,data,0.31118363,of,0.5086956,mi,0.36251363
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognition,0.33741745,single-ventricle,0.3851692,single-ventricle,0.3851692
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,arbs,0.36555648,heart-failure,0.5029925,heart-failure,0.5029925
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,analyse,0.2481221,of,0.49194902,congenital-heart-disease,0.33273923
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,adl,0.25946927,return,0.43352792,lai,0.36339438
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,activities,0.24356377,of,0.4766258,contractions,0.3709238
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,acei,0.42623463,congestive-heart-failure,0.5122055,congestive-heart-failure,0.5122055
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,beyond,0.29394823,of,0.53781354,anomaly,0.34910303
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk-markers,0.29644322,chd,0.47700548,chd,0.47700548
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,highly,0.19153738,of,0.51174253,deposits,0.36338457
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ubiquitous,0.24990834,of,0.42389148,deposits,0.35206008
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,posttranslational,0.27187058,of,0.41417846,l-transposition,0.35206828
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,modification,0.21674462,of,0.49259397,l-transposition,0.41912913
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,highly-controlled,0.20948952,of,0.45866978,plaque-deposits,0.34101567
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,posttranslational-modification,0.2637853,of,0.43756318,l-transposition,0.38556
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,applied,0.31181335,of,0.5047146,flow,0.3948964
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,clinically-applied,0.28205267,of,0.49193418,plaque,0.43828192
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk-prediction,0.345095,heart-disease,0.4934518,heart-disease,0.4934518
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,based,0.2494699,of,0.5443143,flow,0.34116954
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.18854949,of,0.48202556,aortic,0.35779506
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,score,0.286516,total,0.3966952,stenosis,0.38543224
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.16737057,deposits,0.35206968,deposits,0.35206968
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,improve,0.31483245,great,0.49610043,flow,0.35876963
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.18854949,of,0.48202556,aortic,0.35779506
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prospective,0.36785108,congenital-heart-disease,0.4437966,congenital-heart-disease,0.4437966
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,european,0.43573785,cardiology,0.43573785,cardiology,0.43573785
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prospective,0.36785108,congenital-heart-disease,0.4437966,congenital-heart-disease,0.4437966
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,investigation,0.31772497,of,0.61667234,anomaly,0.36676937
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,precisely,0.24528378,of,0.5838205,anomalous,0.42730176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prevention,0.37483034,thrombosis,0.45537552,thrombosis,0.45537552
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,precisely-targeted,0.27495527,of,0.48771894,l-transposition,0.33609468
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,primary-prevention,0.38680434,heart-failure,0.48069128,heart-failure,0.48069128
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,e,0.21868992,double,0.39788574,eb,0.38260236
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,myocardial,0.5198858,myocardial,1.0,myocardial,1.0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,infarction,0.51348525,infarction,1.0,infarction,1.0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,myocardial-infarction,0.5045562,myocardial-infarction,1.0,myocardial-infarction,1.0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finland,0.3322156,chd,0.38855922,chd,0.38855922
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular-risk,0.54054093,chd,0.71753865,chd,0.71753865
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,epic,0.41190353,mi,0.44234735,mi,0.44234735
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,potsdam,0.31892103,cardiology,0.31892103,cardiology,0.31892103
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.31428897,venous-return,0.4572277,venous-return,0.4572277
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c,0.21239448,with,0.46990636,ivs,0.34813386
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,index,0.27677816,total,0.43109894,mi,0.39722836
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c-index,0.282068,venous-return,0.40464628,venous-return,0.40464628
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.31428897,venous-return,0.4572277,venous-return,0.4572277
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c,0.21239448,with,0.46990636,ivs,0.34813386
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,indices,0.26546282,with,0.45559487,flow,0.43359074
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,men,0.36483365,chd,0.51057327,chd,0.51057327
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c-indices,0.28230828,congenital-heart-disease,0.39341512,congenital-heart-disease,0.39341512
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.1727596,cholesterol,0.36015394,cholesterol,0.36015394
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.21868834,of,0.4801969,flow,0.35136262
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,may,0.26963884,of,0.58654004,anomalous,0.366544
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,thus,0.30240285,of,0.6779618,flow,0.4474225
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan-profiling,0.21127516,of,0.35273886,plaque-deposits,0.333033
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.1727596,cholesterol,0.36015394,cholesterol,0.36015394
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.21868834,of,0.4801969,flow,0.35136262
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,integrates,0.264049,of,0.40476584,single-ventricle,0.29227298
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information,0.36363098,of,0.47314215,mi,0.39006084
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan-profiling,0.21127516,of,0.35273886,plaque-deposits,0.333033
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.31428897,venous-return,0.4572277,venous-return,0.4572277
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.18854949,of,0.48202556,aortic,0.35779506
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,association,0.34312242,of,0.45371312,chd,0.39406395
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,american-diabetes,0.35916603,chd,0.5847202,chd,0.5847202
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,verified,0.3110122,of,0.5807613,flow,0.39278382
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,incident,0.39301777,with,0.49337357,chd,0.47681805
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cases,0.2687057,of,0.51801866,congenital,0.5119436
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,nonlinear,0.22733162,anomalous,0.48510507,anomalous,0.48510507
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,building,0.38390708,as,0.42331418,cardiology,0.38390708
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,model-building,0.30681565,of,0.37688,congenital-heart-disease,0.3308419
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,enzymatic,0.16989645,of,0.4726654,l-transposition,0.38828325
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycosylation,0.17121023,of,0.36702627,cholesterol,0.3166435
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein-glycosylation,0.18630308,of,0.37366188,cholesterol,0.3433656
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,internal,0.33825016,artery,0.46088225,artery,0.46088225
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,internal-validation,0.32116336,venous-return,0.45430973,venous-return,0.45430973
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validation-cohort,0.3041053,congenital-heart-disease,0.44963866,congenital-heart-disease,0.44963866
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,samples,0.20068786,isolated,0.4879529,blood,0.4540816
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma-samples,0.2382548,blood,0.4557323,blood,0.4557323
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validated,0.27360892,of,0.4456607,cad,0.31460553
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.21850443,with,0.47536123,mi,0.3790054
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma-protein,0.20155817,blood-clot,0.53731006,blood-clot,0.53731006
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein-n,0.14425275,weak,0.3412373,cholesterol,0.33982134
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes-risk,0.33292332,chd,0.570731,chd,0.570731
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.21850443,with,0.47536123,mi,0.3790054
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk-stratification,0.45956326,congestive-heart-failure,0.50061274,congestive-heart-failure,0.50061274
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,applied,0.31181335,of,0.5047146,flow,0.3948964
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,separately,0.28943542,with,0.6193028,mi,0.39063978
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,chromatographic,0.1387158,isomerism,0.35841835,isomerism,0.35841835
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.21868834,of,0.4801969,flow,0.35136262
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular-diseases,0.51660174,heart-disease,0.6925421,heart-disease,0.6925421
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.21850443,with,0.47536123,mi,0.3790054
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma-n,0.100917265,blood-clot,0.42946815,blood-clot,0.42946815
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.21850443,with,0.47536123,mi,0.3790054
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.1727596,cholesterol,0.36015394,cholesterol,0.36015394
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,groups,0.2612025,with,0.4941169,mi,0.3908207
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,separately,0.28943542,with,0.6193028,mi,0.39063978
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,incidence,0.2980485,of,0.45446336,congenital,0.44341558
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd-incidence,0.2460983,chd,0.53531504,chd,0.53531504
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.21850443,with,0.47536123,mi,0.3790054
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.16737057,deposits,0.35206968,deposits,0.35206968
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,time,0.350901,return,0.5513821,venous-return,0.44564146
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ci,0.26988983,congestive,0.4084356,congestive,0.4084356
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,externally,0.28192362,stiff,0.4864562,contractions,0.4284226
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validated,0.27360892,of,0.4456607,cad,0.31460553
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,externally-validated,0.25906312,of,0.43791488,heartbeat,0.43702784
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,strongly,0.21161139,with,0.5793862,deposits,0.39283076
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,stroke,0.49447083,infarction,0.7648172,infarction,0.7648172
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,moderately,0.2506948,with,0.5918027,mitral-regurgitation,0.38894686
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,moderately-predictive,0.23580845,weak,0.46292683,congestive-heart-failure,0.41753024
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,design,0.22387533,of,0.40440997,single-ventricle,0.33910608
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,research-design,0.4188064,cardiology,0.4188064,cardiology,0.4188064
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,relative,0.20736288,of,0.6192827,mi,0.3804497
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,abundance,0.22053209,of,0.4682694,deposits,0.38831514
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,relative-abundance,0.2691533,of,0.49478447,anomalous,0.37424105
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,subsample,0.3027537,total,0.45634907,chd,0.4323845
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,incidence,0.2980485,of,0.45446336,congenital,0.44341558
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,median,0.25360596,total,0.41341874,single-ventricle,0.38815683
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,median-follow,0.33706227,venous-return,0.46466798,venous-return,0.46466798
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,constructed,0.15691337,interrupted,0.47456625,l-transposition,0.40224642
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,case,0.3395801,of,0.56877625,anomaly,0.566621
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohorts,0.31992877,chd,0.47250944,chd,0.47250944
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,including,0.2742056,of,0.6619886,congenital,0.3605199
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiometabolic,0.4184893,chd,0.65967995,chd,0.65967995
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,based,0.2494699,of,0.5443143,flow,0.34116954
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.1727596,cholesterol,0.36015394,cholesterol,0.36015394
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.16737057,deposits,0.35206968,deposits,0.35206968
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,men,0.36483365,chd,0.51057327,chd,0.51057327
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information,0.36363098,of,0.47314215,mi,0.39006084
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.21850443,with,0.47536123,mi,0.3790054
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,workflow,0.37975895,cardiology,0.37975895,cardiology,0.37975895
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,women,0.355409,chd,0.4926289,chd,0.4926289
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,useful,0.19749163,great,0.46134508,anomalous,0.31390148
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,results,0.29712585,of,0.53157276,blood,0.36869162
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,physician,0.58502996,cardiology,0.58502996,cardiology,0.58502996
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,objective,0.2960808,of,0.5255821,flow,0.39260852
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,investigate,0.20519872,of,0.48247698,anomalous,0.30501914
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycome,0.2128174,cholesterol,0.37245005,cholesterol,0.37245005
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,generated,0.23948207,of,0.55590856,flow,0.35901695
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finrisk,0.3927222,chd,0.5500123,chd,0.5500123
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finding,0.32543075,of,0.66083217,anomaly,0.5250346
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvds,0.47413605,chd,0.77004623,chd,0.77004623
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cross,0.28978038,double,0.48992044,anomalous,0.35670662
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,context,0.3526281,of,0.54966336,congenital-heart-disease,0.38638416
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,construction,0.20710385,of,0.48582235,d-transposition,0.48294175
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ability,0.2123124,of,0.53612673,cardiac,0.340167
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.2737545,cardiac,0.56529033,cardiac,0.56529033
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myoblasts,0.26519638,cardiac,0.45471105,cardiac,0.45471105
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,promoted,0.23820412,of,0.51878786,deposits,0.31934986
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myotube,0.2342701,contractions,0.4267141,contractions,0.4267141
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differentiation,0.23174062,of,0.45291108,l-transposition,0.3816795
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal-muscle,0.24555282,cardiac,0.53675044,cardiac,0.53675044
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mouse,0.18991067,isolated,0.46450102,septal-defect,0.36411005
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.2737545,cardiac,0.56529033,cardiac,0.56529033
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myoblast,0.305456,cardiac,0.5009155,cardiac,0.5009155
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell,0.21863139,of,0.48460138,flow,0.38218224
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,lines,0.23701838,intact,0.44574544,ivs,0.38147125
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,using,0.20786116,with,0.58010674,flow,0.41007757
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal-muscle,0.24555282,cardiac,0.53675044,cardiac,0.53675044
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell-lines,0.19909571,of,0.39812192,l-transposition,0.35238057
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,lines-using,0.2653146,with,0.45705608,venous-return,0.3976333
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,encodes,0.14072777,defect,0.36689624,l-transposition,0.34442028
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,isoforms,0.2027463,of,0.38292646,anomalous,0.34145898
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple-protein,0.22725277,single,0.500343,single-ventricle,0.3837833
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein-isoforms,0.18841878,of,0.42666993,deposits,0.33895528
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,found,0.2675444,with,0.6275196,deposits,0.41920424
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.32251194,of,0.64014816,mi,0.42637154
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein-levels,0.18630496,of,0.4625193,cholesterol,0.40958998
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,treating,0.3108214,with,0.5682972,syndrome,0.37830544
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.2737545,cardiac,0.56529033,cardiac,0.56529033
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.16222498,insufficiency,0.5020007,hypoplastic,0.44973484
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal-muscle,0.24555282,cardiac,0.53675044,cardiac,0.53675044
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-atrophy,0.2534613,truncus,0.46883982,truncus,0.46883982
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,activation,0.19568133,of,0.49422675,contractions,0.44479024
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene-activation,0.18536788,l-transposition,0.48884234,l-transposition,0.48884234
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,like,0.33787337,as,0.6495254,cardiac,0.3588698
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,growth,0.20394227,of,0.446648,flow,0.3683396
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,like-growth,0.13888638,of,0.405518,plaque-deposits,0.35505837
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,growth-factor,0.14957137,of,0.3701391,venous-return,0.30283865
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,systemic,0.28270477,pulmonary-venous,0.5600716,pulmonary-venous,0.5600716
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,versus,0.25452125,with,0.4865483,single-ventricle,0.3957923
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,localized,0.21042094,of,0.48577005,deposits,0.48172736
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,transcript,0.14997926,l-transposition,0.36229712,l-transposition,0.36229712
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.19414388,single,0.45241052,congenital,0.3967681
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna-transcript,0.092588946,l-transposition,0.34315056,l-transposition,0.34315056
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,transcript-variants,0.16738316,l-transposition,0.40658706,l-transposition,0.40658706
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class,0.2877068,of,0.3977759,d-transposition,0.36031434
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.19414388,single,0.45241052,congenital,0.3967681
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,isoforms,0.2027463,of,0.38292646,anomalous,0.34145898
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell,0.21863139,of,0.48460138,flow,0.38218224
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,culture,0.3135685,isolated,0.47652662,blood,0.44322234
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,media,0.26348433,of,0.40421075,mi,0.34874648
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell-culture,0.21778278,plaque-deposits,0.40820813,plaque-deposits,0.40820813
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,culture-media,0.32667047,clot,0.36485463,clot,0.36485463
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.19414388,single,0.45241052,congenital,0.3967681
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increasing,0.35820884,of,0.6603997,flow,0.41165438
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene-expression,0.22584388,of,0.41557923,l-transposition,0.3919022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,enhancing,0.19561118,of,0.54736304,deposits,0.33139667
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,key,0.25911495,of,0.48386168,anomalous,0.3123638
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,positive,0.24830037,weak,0.52645016,blood,0.3939535
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,regulator,0.20251182,as,0.42325643,l-transposition,0.2960012
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,positive-regulator,0.20702536,as,0.40938443,heart-syndrome,0.35668102
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna,0.16145559,l-transposition,0.38527653,l-transposition,0.38527653
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,target,0.23866604,of,0.4775706,blood,0.34112448
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,location,0.28520668,of,0.48746574,anomaly,0.44090638
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna-target,0.14522265,l-transposition,0.35628432,l-transposition,0.35628432
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,target-location,0.2573644,single,0.37707835,venous-return,0.3760394
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,diverse,0.3032622,of,0.5461366,cardiac,0.3471622
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,biology,0.41353095,great,0.48241207,cardiology,0.41353095
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,seen,0.46511754,with,0.6698557,septal,0.47136146
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.32251194,of,0.64014816,mi,0.42637154
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular,0.25397572,of,0.55018497,cardiac,0.40519243
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,phosphorylation,0.18752447,of,0.40713966,contractions,0.3800071
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential-therapeutic,0.3533869,great,0.45943362,heart-failure,0.4459909
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.26622152,single,0.5460852,l-transposition,0.39180565
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.16222498,insufficiency,0.5020007,hypoplastic,0.44973484
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-atrophy,0.2534613,truncus,0.46883982,truncus,0.46883982
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class,0.2877068,of,0.3977759,d-transposition,0.36031434
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,wasting,0.20892407,insufficiency,0.53559995,syndrome,0.4657119
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-wasting,0.2757051,heart-syndrome,0.54844046,heart-syndrome,0.54844046
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mass,0.21939,tof,0.43280137,tof,0.43280137
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-mass,0.22063132,contractions,0.4466982,contractions,0.4466982
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel-approach,0.20939457,d-transposition,0.37142077,d-transposition,0.37142077
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,selectively,0.19791934,of,0.49033487,arteries,0.36451197
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.32251194,of,0.64014816,mi,0.42637154
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,selectively-increased,0.27312055,of,0.5807165,pulmonary,0.4124615
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,induced,0.18249518,of,0.5615651,contractions,0.42990774
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.16222498,insufficiency,0.5020007,hypoplastic,0.44973484
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,induced-atrophy,0.1634192,insufficiency,0.43443412,congenital-heart-disease,0.42140967
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna,0.16145559,l-transposition,0.38527653,l-transposition,0.38527653
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,biology,0.41353095,great,0.48241207,cardiology,0.41353095
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular,0.25397572,of,0.55018497,cardiac,0.40519243
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,proliferation,0.20616576,of,0.43228433,flow,0.40051088
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular-proliferation,0.21156612,of,0.44547173,plaque-deposits,0.40135488
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,using,0.20786116,with,0.58010674,flow,0.41007757
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,tissue,0.23668498,of,0.5202017,venous,0.46895027
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,tissue-expression,0.20248328,l-transposition,0.4299017,l-transposition,0.4299017
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,prevented,0.19566363,of,0.49805415,contractions,0.37821114
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,dexamethasone,0.18871166,with,0.36540204,bradycardia,0.34757176
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,strategy,0.23048541,of,0.44841248,heart-attack,0.36277908
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,main,0.28808993,of,0.60433525,anomalous,0.4090495
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,effector,0.12987311,of,0.41672122,l-transposition,0.31630504
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,guide,0.3664873,of,0.44661915,single-ventricle,0.3858803
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,rna,0.18219137,of,0.4053282,l-transposition,0.40229958
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,guide-rna,0.30077693,l-transposition,0.392255,l-transposition,0.392255
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,genome,0.2711001,l-transposition,0.42332953,l-transposition,0.42332953
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,engineering,0.3611204,great,0.49121857,cardiology,0.3611204
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,genome-engineering,0.3510092,great,0.47628897,l-transposition,0.43371105
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differentiation,0.23174062,of,0.45291108,l-transposition,0.3816795
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,complicates,0.24759759,of,0.58318055,congenital,0.45009416
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,societies,0.5286464,cardiology,0.5286464,cardiology,0.5286464
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,also,0.36015856,of,0.65908813,flow,0.41040578
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,showed,0.21619865,with,0.57298803,flow,0.33828264
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,also-showed,0.36527142,of,0.49911186,anomaly,0.391895
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.32251194,of,0.64014816,mi,0.42637154
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,showed,0.21619865,with,0.57298803,flow,0.33828264
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,well,0.36427143,as,0.7685982,cardiac,0.4102829
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,vitro,0.17831118,of,0.48112682,clot,0.34754837
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,single,0.2571312,single,1.0,anomalous,0.40611145
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,recapitulate,0.22402468,septal-defect,0.39264274,septal-defect,0.39264274
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,quality,0.3148893,of,0.4192715,heartbeat,0.36860457
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potency,0.1786075,of,0.44235313,contractions,0.3903639
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,particularly,0.31718573,of,0.62868786,deposits,0.41094124
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,overexpression,0.20357901,l-transposition,0.40470022,l-transposition,0.40470022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,occur,0.18988883,of,0.53400475,anomaly,0.42337352
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myotubes,0.2284351,contractions,0.4609387,contractions,0.4609387
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,function,0.2605439,of,0.55099833,flow,0.43324804
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differ,0.21590988,of,0.45475316,mi,0.32814133
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,crispr,0.25303686,l-transposition,0.4237211,l-transposition,0.4237211
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,changing,0.38046157,of,0.60639,flow,0.42306173
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,age,0.33659208,with,0.44369304,chd,0.42829025
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,affects,0.1426264,of,0.5773267,anomaly,0.35788298
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,sod,0.18985274,total,0.3510092,cholesterol,0.34414905
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mda,0.17159602,cholesterol,0.39233512,cholesterol,0.39233512
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.20023789,eb,0.27315155,eb,0.27315155
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,0.21328095,rai,0.46950763,rai,0.46950763
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.21765137,heart-failure,0.34864438,heart-failure,0.34864438
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.21765137,heart-failure,0.34864438,heart-failure,0.34864438
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,0.21850443,with,0.47536123,mi,0.3790054
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,0.3462176,arrythmia,0.51753366,arrythmia,0.51753366
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spo,0.23690763,return,0.4028765,blood,0.39957523
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,0.21850443,with,0.47536123,mi,0.3790054
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.28288344,flow,0.44369423,flow,0.44369423
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.29391026,with,0.4559728,congestive,0.4058217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,h,0.20228642,of,0.4345476,mi,0.34808266
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.29391026,with,0.4559728,congestive,0.4058217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pao,0.15595339,pulmonary-venous,0.40835172,pulmonary-venous,0.40835172
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,qa,0.28821853,cardiology,0.28821853,cardiology,0.28821853
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tidal,0.2354418,flow,0.49343252,flow,0.49343252
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,carbon,0.20275286,of,0.388371,deposits,0.36439097
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dioxide,0.19154659,flow,0.38472435,flow,0.38472435
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial,0.05775037,of,0.4639197,anomalous,0.43674207
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.30169874,blood,0.5665527,blood,0.5665527
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,carbon-dioxide,0.17018127,blood-flow,0.3880448,blood-flow,0.3880448
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial-pressure,0.18423381,blood-flow,0.5282442,blood-flow,0.5282442
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial,0.38349736,venous,0.80489254,venous,0.80489254
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen,0.22998369,flow,0.5002598,flow,0.5002598
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial,0.05775037,of,0.4639197,anomalous,0.43674207
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.30169874,blood,0.5665527,blood,0.5665527
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,difference,0.212452,of,0.434909,stenosis,0.35809982
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial-oxygen,0.25043344,venous,0.64784133,venous,0.64784133
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial,0.15587205,venous-return,0.48289585,venous-return,0.48289585
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial-pressure,0.18423381,blood-flow,0.5282442,blood-flow,0.5282442
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure-difference,0.23019183,blood-flow,0.56797355,blood-flow,0.56797355
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial-pressure,0.1831976,blood-flow,0.5363698,blood-flow,0.5363698
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.20023789,eb,0.27315155,eb,0.27315155
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,apoptotic,0.16640727,of,0.3933456,flow,0.38513488
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,index,0.27677816,total,0.43109894,mi,0.39722836
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,apoptotic-index,0.21016726,hypoplastic-left-heart,0.38468546,hypoplastic-left-heart,0.38468546
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen,0.22998369,flow,0.5002598,flow,0.5002598
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial,0.05775037,of,0.4639197,anomalous,0.43674207
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.30169874,blood,0.5665527,blood,0.5665527
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial,0.15587205,venous-return,0.48289585,venous-return,0.48289585
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial-pressure,0.18423381,blood-flow,0.5282442,blood-flow,0.5282442
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial-pressure,0.1831976,blood-flow,0.5363698,blood-flow,0.5363698
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.24051979,mi,0.30050132,mi,0.30050132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cancer,0.29534408,disease,0.45700568,chd,0.41792578
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,thoracoscopic,0.3219844,single-ventricle,0.48950323,single-ventricle,0.48950323
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lobectomy,0.27747846,right,0.5103853,pulmonary,0.4490421
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-cancer,0.22815667,pulmonary,0.44066906,pulmonary,0.44066906
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,0.3462176,arrythmia,0.51753366,arrythmia,0.51753366
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen,0.22998369,flow,0.5002598,flow,0.5002598
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,saturation,0.24310313,flow,0.5376912,flow,0.5376912
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-saturation,0.18247786,blood-flow,0.5353949,blood-flow,0.5353949
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,heart,0.57664216,heart,1.0,heart,1.0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,rate,0.33912572,heart,0.49867767,heart,0.49867767
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,heart-rate,0.43613237,heartbeat,0.713904,heartbeat,0.713904
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,underwent,0.31797755,with,0.45424697,d-transposition,0.45269838
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elective,0.48767704,coronary-artery,0.5034912,coronary-artery,0.5034912
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,thoracoscopic,0.3219844,single-ventricle,0.48950323,single-ventricle,0.48950323
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lobectomy,0.27747846,right,0.5103853,pulmonary,0.4490421
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.24051979,mi,0.30050132,mi,0.30050132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.29391026,with,0.4559728,congestive,0.4058217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.24051979,mi,0.30050132,mi,0.30050132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hour,0.40765804,return,0.50698435,blood,0.44781947
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tnf,0.18194897,cholesterol,0.28765774,cholesterol,0.28765774
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protective,0.14898418,of,0.4669182,heart-attack,0.34925088
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,could,0.24107237,of,0.59299076,anomalous,0.37354472
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary-protective,0.30448484,pulmonary,0.6255876,pulmonary,0.6255876
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,binding,0.19702479,of,0.45710018,flow,0.3384309
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,homologous,0.17552397,l-transposition,0.50264454,l-transposition,0.50264454
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,binding-protein,0.17403214,of,0.3994724,cholesterol,0.3595101
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein-homologous,0.16942523,of,0.4126621,l-transposition,0.408292
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,homologous-protein,0.10914946,l-transposition,0.4405485,l-transposition,0.4405485
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,sod,0.18985274,total,0.3510092,cholesterol,0.34414905
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mda,0.17159602,cholesterol,0.39233512,cholesterol,0.39233512
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,0.21328095,rai,0.46950763,rai,0.46950763
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.24051979,mi,0.30050132,mi,0.30050132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,reducing,0.20510697,of,0.5635449,heart-attack,0.39589107
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.21765137,heart-failure,0.34864438,heart-failure,0.34864438
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.21765137,heart-failure,0.34864438,heart-failure,0.34864438
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean,0.30953988,total,0.5000684,artery,0.37085557
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial,0.38349736,venous,0.80489254,venous,0.80489254
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.30169874,blood,0.5665527,blood,0.5665527
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean-arterial,0.37011427,pulmonary-venous,0.67396075,pulmonary-venous,0.67396075
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial-pressure,0.27212667,blood-flow,0.69921815,blood-flow,0.69921815
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean-arterial-pressure,0.30003852,blood-flow,0.6884332,blood-flow,0.6884332
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.20023789,eb,0.27315155,eb,0.27315155
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,immediately,0.31744793,return,0.5527987,clot,0.40365046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.29391026,with,0.4559728,congestive,0.4058217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,airway,0.2880329,pulmonary,0.5942069,pulmonary,0.5942069
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.30169874,blood,0.5665527,blood,0.5665527
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.28288344,flow,0.44369423,flow,0.44369423
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,airway-pressure,0.23675506,pulmonary-venous,0.55962527,pulmonary-venous,0.55962527
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure-peak,0.21824835,blood-flow,0.5806668,blood-flow,0.5806668
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,alveolar,0.18835536,pulmonary,0.5995637,pulmonary,0.5995637
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,0.21328095,rai,0.46950763,rai,0.46950763
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.21765137,heart-failure,0.34864438,heart-failure,0.34864438
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.24051979,mi,0.30050132,mi,0.30050132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,unilateral,0.1753265,right,0.6197581,hypoplastic-left,0.59287703
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ventilation,0.32813263,pulmonary-venous,0.5243026,pulmonary-venous,0.5243026
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary-ventilation,0.38757113,pulmonary-venous,0.8345827,pulmonary-venous,0.8345827
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,bilateral,0.24653682,right,0.7469661,hypoplastic-left,0.5926822
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ventilation,0.32813263,pulmonary-venous,0.5243026,pulmonary-venous,0.5243026
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary-ventilation,0.38757113,pulmonary-venous,0.8345827,pulmonary-venous,0.8345827
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor,0.21814886,clot,0.4081839,clot,0.4081839
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,necrosis,0.22158405,failure,0.4695571,infarction,0.4620351
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor-necrosis,0.23147793,myocardial-infarction,0.40165275,myocardial-infarction,0.40165275
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,necrosis-factor,0.21652122,failure,0.46052828,artery-disease,0.4030116
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor-necrosis-factor,0.21119751,myocardial-infarction,0.36429393,myocardial-infarction,0.36429393
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super,0.30218548,with,0.50394803,anomalous,0.37623644
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxide,0.26166928,of,0.4075404,pulmonary,0.35886705
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dismutase,0.13126351,cholesterol,0.34112787,cholesterol,0.34112787
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super-oxide,0.23869152,plaque-deposits,0.39951217,plaque-deposits,0.39951217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super-oxide-dismutase,0.16052431,plaque-deposits,0.3655812,plaque-deposits,0.3655812
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,second,0.33869353,single,0.60913336,l-transposition,0.39804327
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,affiliated,0.4550591,cardiology,0.4550591,cardiology,0.4550591
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hospital,0.5604328,cardiology,0.5604328,cardiology,0.5604328
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,affiliated-hospital,0.5582623,cardiology,0.5582623,cardiology,0.5582623
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,improving,0.3579299,great,0.54781544,congestive,0.39419994
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxidative,0.17657238,of,0.4233053,myocardial,0.36701933
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,stress,0.28176898,of,0.4473127,myocardial,0.4140401
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxidative-stress,0.19486363,myocardial,0.388269,myocardial,0.388269
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly,0.36728853,insufficiency,0.5202712,heart-failure,0.49419144
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly-patients,0.34226418,heart-failure,0.5405189,heart-failure,0.5405189
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,end,0.28669232,interrupted,0.5072032,heart-failure,0.3686505
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,interleukin,0.17792475,cholesterol,0.3234432,cholesterol,0.3234432
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.2795998,bradycardia,0.46924534,bradycardia,0.46924534
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,could,0.24107237,of,0.59299076,anomalous,0.37354472
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,attenuate,0.16883563,of,0.38401958,contractions,0.35715842
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,0.21850443,with,0.47536123,mi,0.3790054
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous,0.20723629,premature,0.5203848,contractions,0.50457835
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery,0.21829644,return,0.6228477,venous-return,0.4171288
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous-breathing,0.25726968,heartbeat,0.52123356,heartbeat,0.52123356
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spo,0.23690763,return,0.4028765,blood,0.39957523
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cancer,0.29534408,disease,0.45700568,chd,0.41792578
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-cancer,0.22815667,pulmonary,0.44066906,pulmonary,0.44066906
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,0.30128342,arrythmia,0.39209986,arrythmia,0.39209986
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,0.3462176,arrythmia,0.51753366,arrythmia,0.51753366
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pmid,0.19630215,congestive,0.25211734,congestive,0.25211734
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,october,0.40187466,cardiology,0.40187466,cardiology,0.40187466
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,march,0.39432454,cardiology,0.39432454,cardiology,0.39432454
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous,0.20723629,premature,0.5203848,contractions,0.50457835
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous-breathing,0.25726968,heartbeat,0.52123356,heartbeat,0.52123356
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly,0.36728853,insufficiency,0.5202712,heart-failure,0.49419144
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly-patients,0.34226418,heart-failure,0.5405189,heart-failure,0.5405189
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.28288344,flow,0.44369423,flow,0.44369423
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tissue,0.23668498,of,0.5202017,venous,0.46895027
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-tissue,0.2001914,pulmonary,0.5629479,pulmonary,0.5629479
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-injury,0.19279312,pulmonary,0.55356824,pulmonary,0.55356824
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,alveolar,0.18835536,pulmonary,0.5995637,pulmonary,0.5995637
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,damage,0.1804528,attack,0.48379204,deposits,0.44194233
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery,0.21829644,return,0.6228477,venous-return,0.4171288
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,0.350901,return,0.5513821,venous-return,0.44564146
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery-time,0.30501464,venous-return,0.5867276,venous-return,0.5867276
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,zhengzhou,0.28050107,outlet,0.38782597,paivs,0.36808893
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,university,0.5321148,cardiology,0.5321148,cardiology,0.5321148
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,two,0.27358675,single,0.605739,l-transposition,0.37929946
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,groups,0.2612025,with,0.4941169,mi,0.3908207
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,two-groups,0.21575314,congenital-heart-disease,0.3458546,congenital-heart-disease,0.3458546
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tracheal,0.27079552,pulmonary,0.57135004,pulmonary,0.57135004
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,intubation,0.3756168,bradycardia,0.52796865,bradycardia,0.52796865
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tracheal-intubation,0.34882295,pulmonary-venous,0.54269195,pulmonary-venous,0.54269195
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly,0.23700657,with,0.568532,mi,0.39826992
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,shorter,0.1831873,interrupted,0.49242672,right-atrial,0.3699446
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly,0.23700657,with,0.568532,mi,0.39826992
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lower,0.26859394,with,0.5748005,venous,0.42565888
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly-lower,0.25938573,with,0.53332967,congestive-heart-failure,0.4323113
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly,0.23700657,with,0.568532,mi,0.39826992
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,higher,0.2654187,with,0.56796193,mi,0.398535
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly-higher,0.2440085,with,0.5364338,mi,0.3939989
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,random,0.2799046,single,0.49932328,venous-return,0.32442737
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,postoperative,0.36359894,insufficiency,0.48377612,venous,0.46946543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,awake,0.363532,bradycardia,0.5154203,bradycardia,0.5154203
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mediated,0.18597665,of,0.5168716,contractions,0.37430054
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,apoptosis,0.17540334,flow,0.39729238,flow,0.39729238
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mediated-apoptosis,0.16570355,of,0.3526044,flow,0.35008997
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,factors,0.24127257,of,0.49770784,chd,0.4172811
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,anesthetic,0.2999769,bradycardia,0.4293223,bradycardia,0.4293223
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,induction,0.22081468,of,0.52603287,l-transposition,0.39831883
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,agitation,0.3583692,arrythmia,0.5508999,arrythmia,0.5508999
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,occurrence,0.23615561,of,0.6225994,anomaly,0.44139424
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.2849201,with,0.5052614,mi,0.411738
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,c,0.21239448,with,0.46990636,ivs,0.34813386
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group-c,0.16433999,paivs,0.34176078,paivs,0.34176078
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.2795998,bradycardia,0.46924534,bradycardia,0.46924534
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.2849201,with,0.5052614,mi,0.411738
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,control,0.26906762,with,0.5145365,mi,0.4093958
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.2849201,with,0.5052614,mi,0.411738
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,control-group,0.26105496,heart-failure,0.42830202,heart-failure,0.42830202
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elapsed,0.24265175,return,0.4534738,rai,0.35415387
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,0.350901,return,0.5513821,venous-return,0.44564146
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elapsed-time,0.19329962,venous-return,0.45280242,venous-return,0.45280242
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.29391026,with,0.4559728,congestive,0.4058217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pao,0.15595339,pulmonary-venous,0.40835172,pulmonary-venous,0.40835172
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.28288344,flow,0.44369423,flow,0.44369423
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.24051979,mi,0.30050132,mi,0.30050132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tnf,0.18194897,cholesterol,0.28765774,cholesterol,0.28765774
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,end,0.28669232,interrupted,0.5072032,heart-failure,0.3686505
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.2795998,bradycardia,0.46924534,bradycardia,0.46924534
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.2849201,with,0.5052614,mi,0.411738
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,0.350901,return,0.5513821,venous-return,0.44564146
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,values,0.29641503,with,0.49059534,flow,0.3883159
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,total,0.22796647,total,0.9999999,cholesterol,0.4162783
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,surgery,0.52026105,cardiology,0.52026105,cardiology,0.52026105
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,results,0.29712585,of,0.53157276,blood,0.36869162
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,related,0.2662045,of,0.6150687,cardiac,0.37595052
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recorded,0.3132518,of,0.48745692,contractions,0.4181603
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ratios,0.16654095,double,0.37118572,tof,0.36179096
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,publisher,0.36323333,cardiology,0.36323333,cardiology,0.36323333
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,objective,0.2960808,of,0.5255821,flow,0.39260852
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,medline,0.3928258,cardiology,0.3928258,cardiology,0.3928258
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,malondialdehyde,0.17516989,cholesterol,0.44772312,cholesterol,0.44772312
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,j,0.24581458,lai,0.35768944,lai,0.35768944
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,issn,0.39159447,cardiology,0.39159447,cardiology,0.39159447
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,inhibition,0.21149129,of,0.51645476,contractions,0.42180917
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,indexed,0.4001288,left-atrial,0.43542364,left-atrial,0.43542364
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,extent,0.2738167,of,0.64978826,deposits,0.4439485
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,et,0.2693669,lai,0.43416882,lai,0.43416882
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,enhancer,0.17695922,of,0.37088183,l-transposition,0.3601861
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,effect,0.20909318,of,0.5657147,contractions,0.35284936
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,doi,0.19822392,lai,0.31615257,lai,0.31615257
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,divided,0.28726196,isolated,0.42207283,hypoplastic,0.3574583
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,detected,0.22363131,isolated,0.58991337,deposits,0.39107472
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,conscious,0.32308152,right-atrial,0.4876608,right-atrial,0.4876608
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,conclusions,0.259925,with,0.50001186,artery,0.34474826
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,compared,0.26227483,with,0.62448335,mi,0.40925252
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,co,0.36334935,with,0.46287042,cardiac,0.45921996
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cma,0.2696286,atresia,0.39975268,atresia,0.39975268
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ccaat,0.20916736,l-transposition,0.33753818,l-transposition,0.33753818
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,receiving,0.3588953,with,0.61827135,heart-failure,0.42732942
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide,0.22390819,atrial,0.42872304,atrial,0.42872304
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,administered,0.30782846,with,0.49496263,venous,0.3302617
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,via,0.2561984,of,0.50595546,flow,0.41023284
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,drinking,0.27975997,of,0.40325743,mi,0.35350513
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,water,0.24220353,of,0.46924597,flow,0.42210716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic-peptide,0.16210915,heart-attack,0.36906305,heart-attack,0.36906305
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide-administered,0.26107097,of,0.45770907,heart-failure,0.33982554
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,via-drinking,0.27911747,chd,0.4502709,chd,0.4502709
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,drinking-water,0.2331394,outlet,0.37385848,plaque,0.30742478
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat,0.23246992,cholesterol,0.5448952,cholesterol,0.5448952
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,diet,0.35792264,cholesterol,0.47536165,cholesterol,0.47536165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed,0.28105107,with,0.48279458,cholesterol,0.39400005
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat-diet,0.2265124,cholesterol,0.4891073,cholesterol,0.4891073
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,diet-fed,0.22334628,cholesterol,0.45834112,cholesterol,0.45834112
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed-mice,0.16629829,septal-defect,0.34443647,septal-defect,0.34443647
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved-insulin,0.30716795,heart-failure,0.45438057,heart-failure,0.45438057
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-sensitivity,0.25537086,cholesterol,0.44218144,cholesterol,0.44218144
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,sensitivity-associated,0.22493553,of,0.5229589,syndrome,0.37054634
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat-diet-fed,0.1792131,cholesterol,0.4615446,cholesterol,0.4615446
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide,0.22390819,atrial,0.42872304,atrial,0.42872304
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,administered,0.30782846,with,0.49496263,venous,0.3302617
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic-peptide,0.16210915,heart-attack,0.36906305,heart-attack,0.36906305
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide-administered,0.26107097,of,0.45770907,heart-failure,0.33982554
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,led,0.2739451,of,0.6366651,congenital,0.32305634
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment-led,0.33947256,congestive-heart-failure,0.46054164,congestive-heart-failure,0.46054164
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,data,0.31118363,of,0.5086956,mi,0.36251363
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,provides,0.22296365,of,0.5261056,flow,0.32656315
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compelling,0.30192256,great,0.54095733,anomalous,0.3707475
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,proof,0.22381467,of,0.48861662,heart-attack,0.34981003
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,data-provides,0.33747232,venous-return,0.38875455,venous-return,0.38875455
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,blood,0.32078606,blood,1.0,blood,1.0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clearance,0.20709568,blood-flow,0.42037752,blood-flow,0.42037752
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,blood-glucose,0.25967306,blood,0.565806,blood,0.565806
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-clearance,0.19713667,blood-flow,0.4789508,blood-flow,0.4789508
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high,0.28122714,of,0.57459104,flow,0.3923195
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,particles,0.24042061,deposits,0.5375793,deposits,0.5375793
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high-density,0.18783045,cholesterol,0.6462113,cholesterol,0.6462113
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipoprotein-particles,0.2753268,cholesterol,0.65342426,cholesterol,0.65342426
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high-density-lipoprotein,0.25604427,cholesterol,0.8117049,cholesterol,0.8117049
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,also,0.36015856,of,0.65908813,flow,0.41040578
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,showed,0.21619865,with,0.57298803,flow,0.33828264
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,altered,0.23629062,abnormal,0.6527077,anomalous,0.41416392
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,also-showed,0.36527142,of,0.49911186,anomaly,0.391895
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,altered-expression,0.18831845,of,0.47666562,l-transposition,0.431013
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.20106214,of,0.4827961,l-transposition,0.39687347
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,auc,0.18832418,chd,0.29138696,chd,0.29138696
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decrease,0.28522113,of,0.5904174,flow,0.42153293
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.26227483,with,0.62448335,mi,0.40925252
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.29294342,pulmonary,0.5380093,pulmonary,0.5380093
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophage,0.2274085,pulmonary,0.42684036,pulmonary,0.42684036
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,infiltration,0.184309,deposits,0.59239906,deposits,0.59239906
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophage-infiltration,0.1565916,plaque-deposits,0.48224396,plaque-deposits,0.48224396
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improve,0.31483245,great,0.49610043,flow,0.35876963
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-sensitivity,0.25537086,cholesterol,0.44218144,cholesterol,0.44218144
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide,0.22390819,atrial,0.42872304,atrial,0.42872304
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic-peptide,0.16210915,heart-attack,0.36906305,heart-attack,0.36906305
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.27737677,of,0.4583131,heart-failure,0.38217193
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved-insulin,0.30716795,heart-failure,0.45438057,heart-failure,0.45438057
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance,0.29435202,heart-failure,0.46721014,heart-failure,0.46721014
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.32791707,with,0.5777352,congestive,0.40790212
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,homeostasis,0.2088578,abnormal,0.4305867,cholesterol,0.39712244
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-homeostasis,0.18731211,cholesterol,0.41645718,cholesterol,0.41645718
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat,0.23246992,cholesterol,0.5448952,cholesterol,0.5448952
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,diet,0.35792264,cholesterol,0.47536165,cholesterol,0.47536165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat-diet,0.2265124,cholesterol,0.4891073,cholesterol,0.4891073
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.20106214,of,0.4827961,l-transposition,0.39687347
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decrease,0.28522113,of,0.5904174,flow,0.42153293
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.26227483,with,0.62448335,mi,0.40925252
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold-decrease,0.20729488,of,0.43688005,septal-defect,0.41066176
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.20106214,of,0.4827961,l-transposition,0.39687347
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,auc,0.18832418,chd,0.29138696,chd,0.29138696
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.26227483,with,0.62448335,mi,0.40925252
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.27737677,of,0.4583131,heart-failure,0.38217193
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tests,0.28260767,abnormal,0.42899668,pulmonary,0.32613885
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance,0.29435202,heart-failure,0.46721014,heart-failure,0.46721014
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance-tests,0.29187834,heart-failure,0.39866167,heart-failure,0.39866167
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.27737677,of,0.4583131,heart-failure,0.38217193
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance,0.29435202,heart-failure,0.46721014,heart-failure,0.46721014
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance-test,0.28085265,heart-failure,0.4045905,heart-failure,0.4045905
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance-test,0.29931563,heart-failure,0.4767286,heart-failure,0.4767286
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,resistance,0.17926447,failure,0.42967105,d-transposition,0.40630686
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,induced-insulin,0.24636081,heart-syndrome,0.41973203,heart-syndrome,0.41973203
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-resistance,0.24971986,cholesterol,0.4604428,cholesterol,0.4604428
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,option,0.28522927,as,0.4659202,hypoplastic,0.3850722
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,new-therapeutic,0.3994635,heart-failure,0.44081855,heart-failure,0.44081855
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,therapeutic-option,0.3969376,of,0.45803538,venous-return,0.43834904
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,intraperitoneal,0.1613082,single,0.38729912,pulmonary-venous,0.36487603
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,injection,0.19438815,single,0.47274786,flow,0.38053232
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,bi,0.14093477,rai,0.43951872,rai,0.43951872
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,intraperitoneal-injection,0.14884946,venous,0.3969556,venous,0.3969556
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.29294342,pulmonary,0.5380093,pulmonary,0.5380093
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic-mrna,0.15343618,pulmonary-venous,0.43459937,pulmonary-venous,0.43459937
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mrna-expression,0.15830496,of,0.356714,l-transposition,0.34163117
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,injected,0.18040332,with,0.45857137,ventricle,0.4063049
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,directly,0.2335313,of,0.58113813,flow,0.38857496
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,key-markers,0.20075232,of,0.42706645,heart-disease,0.36253124
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.27737677,of,0.4583131,heart-failure,0.38217193
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-tolerance,0.24560004,heart-failure,0.3856207,heart-failure,0.3856207
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance-test,0.28085265,heart-failure,0.4045905,heart-failure,0.4045905
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-tolerance-test,0.24949661,heart-failure,0.40357867,heart-failure,0.40357867
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduce,0.22618136,of,0.4876061,heart-attack,0.3512283
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.29294342,pulmonary,0.5380093,pulmonary,0.5380093
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.29294342,pulmonary,0.5380093,pulmonary,0.5380093
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.21196108,cholesterol,0.6155462,cholesterol,0.6155462
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test-whether,0.27666786,congenital-heart-disease,0.39595568,congenital-heart-disease,0.39595568
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,results,0.29712585,of,0.53157276,blood,0.36869162
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test-results,0.4057134,congenital-heart-disease,0.42344448,congenital-heart-disease,0.42344448
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,found,0.2675444,with,0.6275196,deposits,0.41920424
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.16515028,as,0.42508888,contractions,0.33963716
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.30969512,cholesterol,0.45558602,cholesterol,0.45558602
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,resistance,0.17926447,failure,0.42967105,d-transposition,0.40630686
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-resistance,0.24971986,cholesterol,0.4604428,cholesterol,0.4604428
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.20106214,of,0.4827961,l-transposition,0.39687347
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.26227483,with,0.62448335,mi,0.40925252
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,infiltration,0.184309,deposits,0.59239906,deposits,0.59239906
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced-expression,0.14950615,of,0.44529927,septal-defect,0.38007402
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.27737677,of,0.4583131,heart-failure,0.38217193
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-tolerance,0.24560004,heart-failure,0.3856207,heart-failure,0.3856207
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.29294342,pulmonary,0.5380093,pulmonary,0.5380093
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes,0.22443718,l-transposition,0.43358943,l-transposition,0.43358943
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes-associated,0.2260409,of,0.45976865,congenital-heart-disease,0.4151979
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes,0.22443718,l-transposition,0.43358943,l-transposition,0.43358943
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated-genes,0.29486093,of,0.4789861,congenital-heart-disease,0.38683486
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,0.2780378,heart-syndrome,0.43787095,heart-syndrome,0.43787095
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,showed,0.21619865,with,0.57298803,flow,0.33828264
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammatory-markers,0.1760628,disease,0.4356295,deposits,0.4079964
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed,0.28105107,with,0.48279458,cholesterol,0.39400005
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ifn,0.11950277,rai,0.30827016,rai,0.30827016
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,time,0.350901,return,0.5513821,venous-return,0.44564146
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pcr,0.18917134,isolated,0.34562874,l-transposition,0.34398216
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,time-pcr,0.18000644,flow,0.31304824,flow,0.31304824
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,respective,0.25664344,of,0.6179571,l-transposition,0.3794909
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,previously,0.21411541,as,0.54924536,l-transposition,0.42639655
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,previously-demonstrated,0.23116636,of,0.59028196,anomalous,0.4821761
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,male,0.3213997,with,0.46579415,mi,0.43337548
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,synthesis,0.18106574,of,0.43194294,isomerism,0.39529023
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipid-synthesis,0.22470796,cholesterol,0.5744232,cholesterol,0.5744232
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,length,0.20891969,interrupted,0.42926398,d-transposition,0.36449188
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.21196108,cholesterol,0.6155462,cholesterol,0.6155462
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hdls,0.2238858,cholesterol,0.6294123,cholesterol,0.6294123
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gluconeogenic,0.1967408,cholesterol,0.4088465,cholesterol,0.4088465
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,enzymes,0.32873723,of,0.43536004,l-transposition,0.38674402
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,five,0.2645896,of,0.58525,d-transposition,0.36288995
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weeks,0.3321507,with,0.44306946,congestive,0.3711909
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,five-weeks,0.24617212,heart-failure,0.37609905,heart-failure,0.37609905
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,feasible,0.22904666,single,0.44130802,single-ventricle,0.40733737
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clinically-feasible,0.28268754,single-ventricle,0.5027038,single-ventricle,0.5027038
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weeks,0.3321507,with,0.44306946,congestive,0.3711909
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,overall,0.28817955,of,0.5869458,chd,0.41920155
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppression,0.16740395,of,0.5172409,contractions,0.3880853
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,0.2780378,heart-syndrome,0.43787095,heart-syndrome,0.43787095
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high,0.28122714,of,0.57459104,flow,0.3923195
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,results,0.29712585,of,0.53157276,blood,0.36869162
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.21196108,cholesterol,0.6155462,cholesterol,0.6155462
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,0.2780378,heart-syndrome,0.43787095,heart-syndrome,0.43787095
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppression,0.16740395,of,0.5172409,contractions,0.3880853
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weekly,0.3507913,with,0.44733927,venous-return,0.3536768
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppressed,0.1626529,of,0.4633069,contractions,0.40291095
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suggesting,0.18459891,of,0.6157647,l-transposition,0.40478194
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,real,0.3591983,great,0.53489023,flow,0.42211816
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pepck,0.16503938,l-transposition,0.3680617,l-transposition,0.3680617
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,p,0.29391026,with,0.4559728,congestive,0.4058217
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,overnutrition,0.30871683,insufficiency,0.50683236,chd,0.4319784
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ns,0.35168546,with,0.45087615,sv,0.44443256
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetics,0.21599759,as,0.4229051,isomerism,0.3405366
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,liver,0.3089201,heart,0.53057235,heart,0.53057235
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipogenic,0.22857042,cholesterol,0.52218086,cholesterol,0.52218086
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,l,0.19137359,right,0.5803616,d-transposition,0.37858474
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,iv,0.31570345,ivs,0.5061623,ivs,0.5061623
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,il,0.24051979,mi,0.30050132,mi,0.30050132
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,iii,0.2178516,of,0.41610226,ivs,0.36350623
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ii,0.26288998,of,0.43728137,mi,0.35983312
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hfd,0.19190165,chd,0.37304172,chd,0.37304172
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gluconeogenesis,0.20809068,cholesterol,0.42044804,cholesterol,0.42044804
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,full,0.27856892,return,0.5029486,flow,0.3643403
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,emulate,0.22937195,as,0.41599947,heartbeat,0.35133523
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,development,0.2877805,of,0.53581744,congenital,0.35419804
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,contributes,0.18509582,of,0.5690483,anomalous,0.32952994
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,concept,0.3016893,of,0.52494144,congenital-heart-disease,0.38863477
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,chrebp,0.23888221,cholesterol,0.43508157,cholesterol,0.43508157
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,background,0.2325702,of,0.51277274,congenital,0.3895001
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,assessed,0.32085416,of,0.605934,flow,0.3956796
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,assess,0.37312466,of,0.49566716,pulmonary,0.375783
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apoa,0.22189355,cholesterol,0.6217662,cholesterol,0.6217662
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,orchestrating,0.30334544,of,0.44418228,l-transposition,0.3537342
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many,0.34462097,great,0.5654564,deposits,0.36972266
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cellular,0.25397572,of,0.55018497,cardiac,0.40519243
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,processes,0.23021427,of,0.4836276,deposits,0.42042395
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,including,0.2742056,of,0.6619886,congenital,0.3605199
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cell,0.21863139,of,0.48460138,flow,0.38218224
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,volume,0.3012385,flow,0.5655429,flow,0.5655429
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,regulation,0.29056856,of,0.5171884,l-transposition,0.37633666
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,processes-including,0.2403341,of,0.4942326,deposits,0.36910233
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cell-volume,0.2551187,blood-flow,0.5087638,blood-flow,0.5087638
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,volume-regulation,0.3103027,blood-flow,0.50576717,blood-flow,0.50576717
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,also,0.36015856,of,0.65908813,flow,0.41040578
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,several,0.34988725,of,0.5990606,cardiac,0.37646228
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,amino,0.15480278,of,0.41089293,isomerism,0.34674454
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,acid,0.16432983,with,0.42051664,cholesterol,0.37480527
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,molecular,0.2634613,of,0.516936,isomerism,0.33948874
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,features,0.24589524,of,0.5517558,anomaly,0.49347878
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,amino-acid,0.123041466,of,0.39980918,isomerism,0.33986712
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,acid-molecular,0.1725196,isomerism,0.4314028,isomerism,0.4314028
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics,0.3396046,cardiology,0.3396046,cardiology,0.3396046
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,focused,0.3452875,of,0.5549927,cardiology,0.3452875
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics-tools,0.3299154,cardiology,0.3299154,cardiology,0.3299154
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,matthews,0.21391009,lai,0.33131558,lai,0.33131558
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,correlation,0.27065358,weak,0.4595955,anomalous,0.39483362
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,coefficient,0.2424671,anomalous,0.41799563,anomalous,0.41799563
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,correlation-coefficient,0.25529933,anomalous,0.42784607,anomalous,0.42784607
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.24905129,cholesterol,0.38167936,cholesterol,0.38167936
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channel,0.213781,outlet,0.38533387,atrioventricular,0.37955636
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.16372266,isomerism,0.41228968,isomerism,0.41228968
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium-channel,0.22403446,atrioventricular,0.40118936,atrioventricular,0.40118936
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channel-ligand,0.20185651,isomerism,0.44999924,isomerism,0.44999924
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics,0.3396046,cardiology,0.3396046,cardiology,0.3396046
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,software,0.36227515,cardiology,0.36227515,cardiology,0.36227515
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,written,0.48084423,cardiology,0.48084423,cardiology,0.48084423
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics-software,0.3557163,cardiology,0.3557163,cardiology,0.3557163
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,python,0.23183492,congenital-heart-disease,0.31707737,congenital-heart-disease,0.31707737
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,programming,0.35134792,single-ventricle,0.42081308,single-ventricle,0.42081308
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,language,0.34072125,congenital-heart-disease,0.39143354,congenital-heart-disease,0.39143354
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,programming-language,0.377065,congenital-heart-disease,0.46411026,congenital-heart-disease,0.46411026
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,primary,0.31168944,of,0.5182241,congenital,0.3974473
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,structure,0.23256482,of,0.49829155,isomerism,0.4853079
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,information,0.36363098,of,0.47314215,mi,0.39006084
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,primary-structure,0.20739537,of,0.44118857,anomalous,0.40946853
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,structure-information,0.28267062,isomerism,0.45338959,isomerism,0.45338959
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptide,0.22390819,atrial,0.42872304,atrial,0.42872304
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligands,0.19009796,isomerism,0.42399952,isomerism,0.42399952
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptide-ligands,0.1862181,isomerism,0.441001,isomerism,0.441001
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,experimentally,0.106461,of,0.48755768,anomalous,0.4193704
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,verified,0.3110122,of,0.5807613,flow,0.39278382
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,activity,0.22675279,of,0.5327676,contractions,0.3920536
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,experimentally-verified,0.21437922,of,0.580878,congenital-heart-disease,0.47461808
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,electrical,0.2863626,contractions,0.511152,contractions,0.511152
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,impulse,0.25321972,heartbeat,0.5359955,heartbeat,0.5359955
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,formation,0.20900506,of,0.50848174,deposits,0.47041997
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,electrical-impulse,0.26766318,left-atrial,0.5031538,left-atrial,0.5031538
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,impulse-formation,0.22788356,of,0.47994304,anomalous,0.45027196
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,considered,0.31302214,as,0.6929809,anomaly,0.43040824
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,promising,0.2032688,great,0.5363789,anomalous,0.26476932
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,alternatives,0.30665383,as,0.5108851,d-transposition,0.38379884
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,network,0.27283338,of,0.38706863,venous-return,0.34682414
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial-neural,0.22358572,congenital-heart-disease,0.49487492,congenital-heart-disease,0.49487492
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,neural-network,0.2583411,heartbeat,0.44916824,heartbeat,0.44916824
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial-neural-network,0.22481197,congenital-heart-disease,0.4687531,congenital-heart-disease,0.4687531
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.16372266,isomerism,0.41228968,isomerism,0.41228968
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support,0.36322898,return,0.46409142,flow,0.36807415
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,vector,0.20063998,l-transposition,0.3898847,l-transposition,0.3898847
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,machine,0.37199128,cad,0.41960585,cad,0.41960585
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support-vector,0.27030843,single-ventricle,0.4165814,single-ventricle,0.4165814
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,vector-machine,0.30196983,single-ventricle,0.39982086,single-ventricle,0.39982086
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support-vector-machine,0.316194,single-ventricle,0.43537825,single-ventricle,0.43537825
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.24905129,cholesterol,0.38167936,cholesterol,0.38167936
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels,0.22131057,contractions,0.39898413,contractions,0.39898413
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,play,0.20504072,of,0.37973475,anomalous,0.28665382
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium-channels,0.23434001,atrioventricular,0.40942022,atrioventricular,0.40942022
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels-play,0.2765827,heartbeat,0.39653903,heartbeat,0.39653903
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high,0.28122714,of,0.57459104,flow,0.3923195
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predictive,0.28315032,of,0.43440902,cad,0.39744872
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,capacity,0.18606538,of,0.46851358,flow,0.42008954
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high-predictive,0.25770694,single,0.41769248,congenital-heart-disease,0.3981072
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predictive-capacity,0.22192067,venous-return,0.5003138,venous-return,0.5003138
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.16372266,isomerism,0.41228968,isomerism,0.41228968
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random,0.2799046,single,0.49932328,venous-return,0.32442737
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,forest,0.32507646,lai,0.44108117,lai,0.44108117
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,algorithm,0.31813926,heartbeat,0.4163586,heartbeat,0.4163586
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,biological,0.25037947,of,0.5642135,blood-clot,0.34982628
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,data,0.31118363,of,0.5086956,mi,0.36251363
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,0.23211285,as,0.56584436,flow,0.35934073
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,called,0.42588967,as,0.5104251,cardiology,0.42588967
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk,0.096021056,tapvr,0.327747,tapvr,0.327747
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool-called,0.41664153,cardiology,0.41664153,cardiology,0.41664153
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many,0.34462097,great,0.5654564,deposits,0.36972266
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many-diseases,0.29641196,congenital-heart-disease,0.6472318,congenital-heart-disease,0.6472318
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.16372266,isomerism,0.41228968,isomerism,0.41228968
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.24905129,cholesterol,0.38167936,cholesterol,0.38167936
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels,0.22131057,contractions,0.39898413,contractions,0.39898413
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium-channels,0.23434001,atrioventricular,0.40942022,atrioventricular,0.40942022
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random,0.2799046,single,0.49932328,venous-return,0.32442737
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,forest,0.32507646,lai,0.44108117,lai,0.44108117
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,current,0.39557698,of,0.4991414,flow,0.39574015
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tools,0.31670988,of,0.42782637,congenital-heart-disease,0.3213289
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high,0.28122714,of,0.57459104,flow,0.3923195
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,reliability,0.3161693,great,0.41052496,blood-flow,0.38828772
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high-reliability,0.37913227,great,0.43649727,venous-return,0.42886293
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,four,0.26703352,of,0.57211214,d-transposition,0.35247436
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,machine,0.37199128,cad,0.41960585,cad,0.41960585
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,four-machine,0.33652794,stiff,0.418487,heartbeat,0.4179032
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,specificity,0.22204962,of,0.4346917,cad,0.34837636
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,validating,0.2840522,of,0.533336,heart-failure,0.33166465
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,membrane,0.20611405,of,0.43286008,cholesterol,0.38573062
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,plasma-membrane,0.23175174,cholesterol,0.43036947,cholesterol,0.43036947
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,nearest,0.3206203,single,0.46444803,anomaly,0.3788818
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,neighbors,0.25709212,weak,0.41762197,beats,0.34371656
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,nearest-neighbors,0.24213433,isomerism,0.41405025,isomerism,0.41405025
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,molecules,0.22325355,of,0.48981342,isomerism,0.4059331
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,0.23211285,as,0.56584436,flow,0.35934073
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,generated,0.23948207,of,0.55590856,flow,0.35901695
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,model-generated,0.2603624,of,0.4797785,venous-return,0.39487553
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,key,0.25911495,of,0.48386168,anomalous,0.3123638
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,role,0.263546,of,0.49928063,anomalous,0.31226397
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,key-role,0.2565612,of,0.44771314,anomalous,0.31697574
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,hormone,0.22365327,insufficiency,0.4212082,rai,0.40404695
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,secretion,0.17649192,of,0.43475774,contractions,0.4186117
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,hormone-secretion,0.22020595,cholesterol,0.44546258,cholesterol,0.44546258
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,friendly,0.28007358,great,0.39680025,heart-attack,0.33442762
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,interface,0.2116723,deposits,0.33724806,deposits,0.33724806
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,different,0.24309576,of,0.61590904,anomalous,0.37924677
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,activities,0.24356377,of,0.4766258,contractions,0.3709238
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cardiovascular-diseases,0.51660174,heart-disease,0.6925421,heart-disease,0.6925421
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,applied,0.31181335,of,0.5047146,flow,0.3948964
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,research,0.4363063,great,0.4769435,cardiology,0.4363063
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,applied-research,0.4765182,cardiology,0.4765182,cardiology,0.4765182
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.20555672,of,0.41611826,atrial,0.34556425
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,0.23211285,as,0.56584436,flow,0.35934073
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk,0.096021056,tapvr,0.327747,tapvr,0.327747
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,work,0.41337943,return,0.5383546,cardiology,0.41337943
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,using,0.20786116,with,0.58010674,flow,0.41007757
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,showed,0.21619865,with,0.57298803,flow,0.33828264
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,regulating,0.24088989,of,0.5106726,anomalous,0.33040386
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,obtained,0.31282532,of,0.62274206,blood,0.41646662
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,none,0.3255544,with,0.59412724,mi,0.4215914
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ions,0.24628186,deposits,0.43820792,deposits,0.43820792
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,however,0.30646515,of,0.624624,mi,0.41109186
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,flow,0.27540267,flow,1.0,flow,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,discovery,0.32526702,of,0.46573353,d-transposition,0.33412263
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,developed,0.25309682,of,0.5174131,congestive-heart-failure,0.37625062
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,currently,0.4246831,of,0.5011201,cardiology,0.4246831
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,c,0.21239448,with,0.46990636,ivs,0.34813386
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,basic,0.32800904,of,0.4978614,cardiac,0.36732858
Machine learning: a long way from implementation in cardiovascular disease.,none,0.3255544,with,0.59412724,mi,0.4215914
Machine learning: a long way from implementation in cardiovascular disease.,declared,0.39503962,great,0.45297694,cardiology,0.39503962
Machine learning: a long way from implementation in cardiovascular disease.,interest,0.3943884,great,0.62165374,cardiology,0.3943884
Machine learning: a long way from implementation in cardiovascular disease.,statement,0.4898542,cardiology,0.4898542,cardiology,0.4898542
Machine learning: a long way from implementation in cardiovascular disease.,competing,0.29386833,of,0.49241257,heart-attack,0.37648118
Machine learning: a long way from implementation in cardiovascular disease.,interests,0.40537778,great,0.50362074,cardiology,0.40537778
Machine learning: a long way from implementation in cardiovascular disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning: a long way from implementation in cardiovascular disease.,pmid,0.19630215,congestive,0.25211734,congestive,0.25211734
Machine learning: a long way from implementation in cardiovascular disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning: a long way from implementation in cardiovascular disease.,conflict,0.28007084,incompetence,0.41645166,l-transposition,0.34232265
Machine learning: a long way from implementation in cardiovascular disease.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine learning: a long way from implementation in cardiovascular disease.,heartjnl,0.50367284,left-heart,0.6361464,left-heart,0.6361464
Machine learning: a long way from implementation in cardiovascular disease.,doi,0.19822392,lai,0.31615257,lai,0.31615257
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,groups,0.2612025,with,0.4941169,mi,0.3908207
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.21797335,paivs,0.41676176,paivs,0.41676176
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,echocardiogram,0.6444093,cardiology,0.6444093,cardiology,0.6444093
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,data,0.31118363,of,0.5086956,mi,0.36251363
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,obstructive,0.35222226,congestive,0.6328302,congestive,0.6328302
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,chronic-obstructive,0.35541248,congestive,0.63991463,congestive,0.63991463
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,obstructive-pulmonary,0.38661033,pulmonary,0.7739995,pulmonary,0.7739995
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,pulmonary-disease,0.37958944,pulmonary,0.7568126,pulmonary,0.7568126
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,including,0.2742056,of,0.6619886,congenital,0.3605199
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,biomarkers,0.27211508,as,0.41520637,heart-disease,0.3631038
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.21797335,paivs,0.41676176,paivs,0.41676176
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,plasma,0.21807674,blood,0.4915529,blood,0.4915529
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteins,0.21103716,of,0.46288005,deposits,0.3796569
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differed,0.21083209,of,0.50769126,lai,0.332736
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,plasma-proteins,0.21484597,blood-clot,0.5126982,blood-clot,0.5126982
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,days,0.30872357,return,0.45523614,beats,0.4033618
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,mid,0.36086994,right,0.5805234,stenosis,0.45125967
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,six,0.2417503,of,0.5504338,d-transposition,0.36408642
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.21797335,paivs,0.41676176,paivs,0.41676176
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified-six,0.18050137,single,0.4392651,congenital-heart-disease,0.36935776
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rennes,0.43446752,cardiology,0.43446752,cardiology,0.43446752
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cohort-study,0.36102197,congenital-heart-disease,0.49958968,congenital-heart-disease,0.49958968
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,preserved,0.24191171,with,0.53828907,deposits,0.44760028
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,preserved-ejection,0.30263668,right-ventricle,0.576405,right-ventricle,0.576405
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,laboratory,0.4092068,of,0.41161877,cardiology,0.4092068
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false,0.24112374,incompetence,0.47949332,congenital-heart-disease,0.4340317
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,discovery,0.32526702,of,0.46573353,d-transposition,0.33412263
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false-discovery,0.25247812,congenital-heart-disease,0.42190903,congenital-heart-disease,0.42190903
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false-discovery-rate,0.2989691,heartbeat,0.4820374,heartbeat,0.4820374
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,concomitant,0.24419764,of,0.6553842,l-transposition,0.46786642
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,atrial,0.52708566,atrial,1.0,atrial,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fibrillation,0.5347377,fibrillation,1.0,fibrillation,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,atrial-fibrillation,0.46922478,fibrillation,0.887709,fibrillation,0.887709
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite,0.22068933,failure,0.39251378,hypoplastic-left-heart,0.38025624
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,end,0.28669232,interrupted,0.5072032,heart-failure,0.3686505
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,point,0.29296726,of,0.5126515,anomaly,0.38572568
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite-end,0.2001445,plaque-deposits,0.38138792,plaque-deposits,0.38138792
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,end-point,0.24608193,failure,0.44530657,heart-failure,0.4336535
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,versus,0.25452125,with,0.4865483,single-ventricle,0.3957923
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.21797335,paivs,0.41676176,paivs,0.41676176
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,derive,0.25151137,of,0.52521205,anomalous,0.4030259
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,median,0.25360596,total,0.41341874,single-ventricle,0.38815683
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,years,0.34902757,disease,0.4160452,stenosis,0.41534603
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,right,0.35970405,right,1.0,right-atrial,0.63516104
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,function,0.2605439,of,0.55099833,flow,0.43324804
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,right-ventricular,0.4595427,right-ventricle,0.95768464,right-ventricle,0.95768464
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ventricular-function,0.43443817,ventricular,0.8066824,ventricular,0.8066824
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outpatients,0.4732141,cardiology,0.4732141,cardiology,0.4732141
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,af,0.46920872,fibrillation,0.7902067,fibrillation,0.7902067
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,anaemia,0.25326928,insufficiency,0.50891453,congenital,0.5057535
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,days,0.30872357,return,0.45523614,beats,0.4033618
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,compare,0.27648047,of,0.5052448,venous-return,0.3454308
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical-characteristics,0.34754923,of,0.5452827,congenital-heart-disease,0.4584994
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clustering,0.2623014,of,0.46563452,mi,0.36438894
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based-clustering,0.25842133,single,0.4115493,plaque-deposits,0.35337695
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,echocardiogram,0.6444093,cardiology,0.6444093,cardiology,0.6444093
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,days,0.30872357,return,0.45523614,beats,0.4033618
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney-disease,0.27286986,heart-disease,0.6544356,heart-disease,0.6544356
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteins,0.21103716,of,0.46288005,deposits,0.3796569
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,months,0.2814955,failure,0.43657047,congestive,0.39787602
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroup,0.22797777,paivs,0.42116413,paivs,0.42116413
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,function,0.2605439,of,0.55099833,flow,0.43324804
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney-function,0.27965558,heart-failure,0.45524523,heart-failure,0.45524523
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential,0.20091629,of,0.548336,anomalous,0.4855432
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,third,0.30185395,single,0.54406995,ventricle,0.44503468
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,experienced,0.3416694,with,0.51668775,mitral-regurgitation,0.39382553
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,stable,0.34140018,with,0.5258521,cardiac,0.42552614
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,condition,0.27496728,anomaly,0.4816988,anomaly,0.4816988
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,stable-condition,0.2593751,return,0.4310218,mi,0.40359792
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significantly,0.23700657,with,0.568532,mi,0.39826992
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significantly-different,0.19546317,with,0.5348198,mi,0.40989044
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differences,0.24501437,of,0.48845208,anomalous,0.3514788
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significant-differences,0.33371294,of,0.47654283,mi,0.4448076
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,see,0.50017273,cardiology,0.50017273,cardiology,0.50017273
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,secondary,0.296139,failure,0.5610231,congenital,0.42706454
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,analyses,0.1956715,of,0.44186428,deposits,0.31060207
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,factors,0.24127257,of,0.49770784,chd,0.4172811
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,risk-factors,0.34496874,chd,0.61294127,chd,0.61294127
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcome,0.27011925,failure,0.48584157,single-ventricle,0.45794576
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,primary-outcome,0.2731888,congenital-heart-disease,0.45671195,congenital-heart-disease,0.45671195
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,poorer,0.17765537,with,0.41130364,single-ventricle,0.36372644
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,diastolic,0.437353,ventricular,0.68328416,ventricular,0.68328416
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,higher,0.2654187,with,0.56796193,mi,0.398535
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,burden,0.27055943,disease,0.5228828,heart-disease,0.40476274
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,higher-burden,0.29838264,heart-failure,0.43822354,heart-failure,0.43822354
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heterogeneous,0.2215862,irregular,0.5216255,deposits,0.44650552
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,syndrome,0.2608677,syndrome,1.0,syndrome,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heart,0.57664216,heart,1.0,heart,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential,0.20091629,of,0.548336,anomalous,0.4855432
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cause-mortality,0.32417238,heart-disease,0.5488442,heart-disease,0.5488442
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,applied,0.31181335,of,0.5047146,flow,0.3948964
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term-follow,0.42250973,venous-return,0.46715605,venous-return,0.46715605
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rank,0.3096888,weak,0.36447465,cardiology,0.3096888
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,p,0.29391026,with,0.4559728,congestive,0.4058217
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rank-p,0.17604744,venous-return,0.2702204,venous-return,0.2702204
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,across,0.2607503,of,0.44814807,flow,0.3484614
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics,0.31459174,great,0.3623408,cardiology,0.31459174
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.21797335,paivs,0.41676176,paivs,0.41676176
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.4557951,heart-failure,0.67797935,heart-failure,0.67797935
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,af,0.46920872,fibrillation,0.7902067,fibrillation,0.7902067
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics,0.31459174,great,0.3623408,cardiology,0.31459174
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,p,0.29391026,with,0.4559728,congestive,0.4058217
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,used,0.23211285,as,0.56584436,flow,0.35934073
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,use,0.3219829,with,0.55726266,flow,0.40877783
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,thirds,0.27730593,hypoplastic,0.462789,hypoplastic,0.462789
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,short,0.27641132,interrupted,0.5895587,d-transposition,0.38685596
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,prevalence,0.25545907,disease,0.43233684,chd,0.4308555
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,permissions,0.4486413,return,0.46907276,cardiology,0.4486413
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,older,0.34109476,heart-failure,0.49915606,heart-failure,0.49915606
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,objective,0.2960808,of,0.5255821,flow,0.39260852
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,longer,0.2500613,interrupted,0.5135091,right-atrial,0.39419138
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,log,0.20004112,return,0.35992098,venous-return,0.31311154
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,karolinska,0.4302672,cardiology,0.4302672,cardiology,0.4302672
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,iqr,0.21552542,mitral,0.23662467,mitral,0.23662467
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hr,0.3462176,arrythmia,0.51753366,arrythmia,0.51753366
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hospitalisation,0.4399149,heart-failure,0.5099335,heart-failure,0.5099335
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,group,0.2849201,with,0.5052614,mi,0.411738
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fifteen,0.21406297,isolated,0.3971661,d-transposition,0.32482478
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,female,0.32612452,of,0.44902933,mi,0.41579333
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fdr,0.11854817,chd,0.3571666,chd,0.3571666
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,employer,0.3858688,return,0.41757125,cardiology,0.3858688
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,commercial,0.22465858,with,0.43286043,blood-clot,0.30509424
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ci,0.26988983,congestive,0.4084356,congestive,0.4084356
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,bmj,0.41164857,cardiology,0.41164857,cardiology,0.41164857
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,aimed,0.2731712,of,0.52896386,congenital,0.32137418
Machine Learning in Fetal Cardiology: What to Expect.,specific,0.26268506,of,0.6059094,flow,0.40644997
Machine Learning in Fetal Cardiology: What to Expect.,goals,0.4568534,return,0.46493247,cardiology,0.4568534
Machine Learning in Fetal Cardiology: What to Expect.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Machine Learning in Fetal Cardiology: What to Expect.,explicitly,0.31373203,anomalous,0.42082638,anomalous,0.42082638
Machine Learning in Fetal Cardiology: What to Expect.,programming,0.35134792,single-ventricle,0.42081308,single-ventricle,0.42081308
Machine Learning in Fetal Cardiology: What to Expect.,goals-without,0.4236644,return,0.52824587,venous-return,0.48727936
Machine Learning in Fetal Cardiology: What to Expect.,compromised,0.231265,abnormal,0.5768342,hypoplastic,0.45126313
Machine Learning in Fetal Cardiology: What to Expect.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Machine Learning in Fetal Cardiology: What to Expect.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Machine Learning in Fetal Cardiology: What to Expect.,potentially,0.22729951,of,0.5786935,cardiac,0.3729133
Machine Learning in Fetal Cardiology: What to Expect.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Machine Learning in Fetal Cardiology: What to Expect.,cardiovascular-system,0.5411608,cardiac,0.6277575,cardiac,0.6277575
Machine Learning in Fetal Cardiology: What to Expect.,potentially-associated,0.18028465,of,0.6185838,anomalous,0.40960354
Machine Learning in Fetal Cardiology: What to Expect.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Machine Learning in Fetal Cardiology: What to Expect.,doppler,0.4019922,blood-flow,0.6127864,blood-flow,0.6127864
Machine Learning in Fetal Cardiology: What to Expect.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Machine Learning in Fetal Cardiology: What to Expect.,among,0.2573181,of,0.57348,chd,0.4274787
Machine Learning in Fetal Cardiology: What to Expect.,others,0.32080752,with,0.5653113,heart-attack,0.43046573
Machine Learning in Fetal Cardiology: What to Expect.,tissue-doppler,0.37361673,blood-flow,0.6626015,blood-flow,0.6626015
Machine Learning in Fetal Cardiology: What to Expect.,doppler-imaging,0.3477204,blood-flow,0.6203699,blood-flow,0.6203699
Machine Learning in Fetal Cardiology: What to Expect.,still,0.38928428,of,0.5457471,arrythmia,0.4077646
Machine Learning in Fetal Cardiology: What to Expect.,challenging,0.29561728,great,0.56316066,anomalous,0.40406942
Machine Learning in Fetal Cardiology: What to Expect.,mainly,0.28163683,of,0.6151813,deposits,0.44905117
Machine Learning in Fetal Cardiology: What to Expect.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Machine Learning in Fetal Cardiology: What to Expect.,still-challenging,0.26971716,of,0.53465223,congenital-heart-disease,0.47681823
Machine Learning in Fetal Cardiology: What to Expect.,computer,0.3797791,heartbeat,0.4054125,heartbeat,0.4054125
Machine Learning in Fetal Cardiology: What to Expect.,science,0.46422392,cardiology,0.46422392,cardiology,0.46422392
Machine Learning in Fetal Cardiology: What to Expect.,discipline,0.5461015,cardiology,0.5461015,cardiology,0.5461015
Machine Learning in Fetal Cardiology: What to Expect.,focused,0.3452875,of,0.5549927,cardiology,0.3452875
Machine Learning in Fetal Cardiology: What to Expect.,computer-science,0.5029754,cardiology,0.5029754,cardiology,0.5029754
Machine Learning in Fetal Cardiology: What to Expect.,science-discipline,0.51557934,cardiology,0.51557934,cardiology,0.51557934
Machine Learning in Fetal Cardiology: What to Expect.,discipline-focused,0.50229645,cardiology,0.50229645,cardiology,0.50229645
Machine Learning in Fetal Cardiology: What to Expect.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Machine Learning in Fetal Cardiology: What to Expect.,structure,0.23256482,of,0.49829155,isomerism,0.4853079
Machine Learning in Fetal Cardiology: What to Expect.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Machine Learning in Fetal Cardiology: What to Expect.,acquired,0.2389528,congenital,0.54036444,congenital,0.54036444
Machine Learning in Fetal Cardiology: What to Expect.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Machine Learning in Fetal Cardiology: What to Expect.,primary-acquired,0.2701497,congenital-heart-disease,0.520876,congenital-heart-disease,0.520876
Machine Learning in Fetal Cardiology: What to Expect.,optimizing,0.29215556,of,0.511098,single-ventricle,0.37255126
Machine Learning in Fetal Cardiology: What to Expect.,image,0.3220324,heartbeat,0.45858762,heartbeat,0.45858762
Machine Learning in Fetal Cardiology: What to Expect.,acquisition,0.26129586,of,0.47551334,heartbeat,0.3913237
Machine Learning in Fetal Cardiology: What to Expect.,image-acquisition,0.3197969,heartbeat,0.47527605,heartbeat,0.47527605
Machine Learning in Fetal Cardiology: What to Expect.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Machine Learning in Fetal Cardiology: What to Expect.,ultrasound,0.43887246,blood-flow,0.45153797,blood-flow,0.45153797
Machine Learning in Fetal Cardiology: What to Expect.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Machine Learning in Fetal Cardiology: What to Expect.,several,0.34988725,of,0.5990606,cardiac,0.37646228
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Machine Learning in Fetal Cardiology: What to Expect.,remodeling,0.35961753,ventricular,0.49573958,ventricular,0.49573958
Machine Learning in Fetal Cardiology: What to Expect.,cardiac-remodeling,0.52174294,cardiac,0.74999714,cardiac,0.74999714
Machine Learning in Fetal Cardiology: What to Expect.,including,0.2742056,of,0.6619886,congenital,0.3605199
Machine Learning in Fetal Cardiology: What to Expect.,conventional,0.22839119,with,0.5078434,single-ventricle,0.3931944
Machine Learning in Fetal Cardiology: What to Expect.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine Learning in Fetal Cardiology: What to Expect.,help,0.34956798,great,0.5039565,flow,0.3667982
Machine Learning in Fetal Cardiology: What to Expect.,extract,0.18317053,isolated,0.47450352,contractions,0.30578932
Machine Learning in Fetal Cardiology: What to Expect.,measurements,0.27821797,blood-flow,0.45775104,blood-flow,0.45775104
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Machine Learning in Fetal Cardiology: What to Expect.,function,0.2605439,of,0.55099833,flow,0.43324804
Machine Learning in Fetal Cardiology: What to Expect.,cardiac-function,0.53890264,cardiac,0.7516308,cardiac,0.7516308
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,echocardiography,0.61625123,left-heart,0.6551631,left-heart,0.6551631
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,cardiology,0.99999994,cardiology,0.99999994,cardiology,0.99999994
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities,0.32799944,abnormal,0.81413877,anomaly,0.6537851
Machine Learning in Fetal Cardiology: What to Expect.,cardiac-abnormalities,0.5365435,abnormal,0.7404461,cardiac,0.7380848
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.31766903,congenital,0.57156426,congenital,0.57156426
Machine Learning in Fetal Cardiology: What to Expect.,heart,0.57664216,heart,1.0,heart,1.0
Machine Learning in Fetal Cardiology: What to Expect.,fetal-heart,0.5111752,congenital-heart,0.7697183,congenital-heart,0.7697183
Machine Learning in Fetal Cardiology: What to Expect.,small,0.28269485,great,0.5440953,deposits,0.39470115
Machine Learning in Fetal Cardiology: What to Expect.,size,0.2561645,irregular,0.4397795,ventricle,0.39808142
Machine Learning in Fetal Cardiology: What to Expect.,small-size,0.16704911,single,0.44042873,anomalous,0.38519576
Machine Learning in Fetal Cardiology: What to Expect.,prenatal,0.34792757,congenital,0.5673202,congenital,0.5673202
Machine Learning in Fetal Cardiology: What to Expect.,diagnoses,0.39992523,congenital-heart-disease,0.45381218,congenital-heart-disease,0.45381218
Machine Learning in Fetal Cardiology: What to Expect.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Machine Learning in Fetal Cardiology: What to Expect.,technologies,0.34567022,great,0.44040805,cardiology,0.34567022
Machine Learning in Fetal Cardiology: What to Expect.,new-technologies,0.38161337,great,0.4376729,cardiology,0.38161337
Machine Learning in Fetal Cardiology: What to Expect.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine Learning in Fetal Cardiology: What to Expect.,leaning,0.3983912,stiff,0.5770329,hypoplastic-left,0.43737435
Machine Learning in Fetal Cardiology: What to Expect.,machine-leaning,0.3413338,heartbeat,0.44056672,heartbeat,0.44056672
Machine Learning in Fetal Cardiology: What to Expect.,karger,0.44036424,cardiology,0.44036424,cardiology,0.44036424
Machine Learning in Fetal Cardiology: What to Expect.,ag,0.20830083,weak,0.3659965,sv,0.30808043
Machine Learning in Fetal Cardiology: What to Expect.,involuntary,0.2543157,contractions,0.5320911,contractions,0.5320911
Machine Learning in Fetal Cardiology: What to Expect.,movements,0.2660535,contractions,0.6169969,contractions,0.6169969
Machine Learning in Fetal Cardiology: What to Expect.,great,0.4193529,great,1.0,d-transposition,0.49969703
Machine Learning in Fetal Cardiology: What to Expect.,importance,0.3199574,of,0.5794183,anomaly,0.34929916
Machine Learning in Fetal Cardiology: What to Expect.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Machine Learning in Fetal Cardiology: What to Expect.,echocardiography,0.61625123,left-heart,0.6551631,left-heart,0.6551631
Machine Learning in Fetal Cardiology: What to Expect.,currently,0.4246831,of,0.5011201,cardiology,0.4246831
Machine Learning in Fetal Cardiology: What to Expect.,used,0.23211285,as,0.56584436,flow,0.35934073
Machine Learning in Fetal Cardiology: What to Expect.,currently-used,0.29277816,as,0.49292275,flow,0.3775698
Machine Learning in Fetal Cardiology: What to Expect.,brief,0.42772934,return,0.48305893,bradycardia,0.472566
Machine Learning in Fetal Cardiology: What to Expect.,overview,0.37038898,of,0.46372092,cardiology,0.37038898
Machine Learning in Fetal Cardiology: What to Expect.,perform,0.31693935,return,0.4643785,venous-return,0.35410056
Machine Learning in Fetal Cardiology: What to Expect.,tasks,0.32579935,heartbeat,0.39437467,heartbeat,0.39437467
Machine Learning in Fetal Cardiology: What to Expect.,optimal,0.22326279,of,0.49022785,single-ventricle,0.35533518
Machine Learning in Fetal Cardiology: What to Expect.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Machine Learning in Fetal Cardiology: What to Expect.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Machine Learning in Fetal Cardiology: What to Expect.,techniques,0.254115,great,0.3795752,single-ventricle,0.37415883
Machine Learning in Fetal Cardiology: What to Expect.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Machine Learning in Fetal Cardiology: What to Expect.,computer,0.3797791,heartbeat,0.4054125,heartbeat,0.4054125
Machine Learning in Fetal Cardiology: What to Expect.,help,0.34956798,great,0.5039565,flow,0.3667982
Machine Learning in Fetal Cardiology: What to Expect.,function,0.2605439,of,0.55099833,flow,0.43324804
Machine Learning in Fetal Cardiology: What to Expect.,perform,0.31693935,return,0.4643785,venous-return,0.35410056
Machine Learning in Fetal Cardiology: What to Expect.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Machine Learning in Fetal Cardiology: What to Expect.,heart,0.57664216,heart,1.0,heart,1.0
Machine Learning in Fetal Cardiology: What to Expect.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities,0.32799944,abnormal,0.81413877,anomaly,0.6537851
Machine Learning in Fetal Cardiology: What to Expect.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Machine Learning in Fetal Cardiology: What to Expect.,use,0.3219829,with,0.55726266,flow,0.40877783
Machine Learning in Fetal Cardiology: What to Expect.,therefore,0.32687712,of,0.6409915,flow,0.39200473
Machine Learning in Fetal Cardiology: What to Expect.,teaching,0.61801183,cardiology,0.61801183,cardiology,0.61801183
Machine Learning in Fetal Cardiology: What to Expect.,task,0.3549496,heartbeat,0.41896272,heartbeat,0.41896272
Machine Learning in Fetal Cardiology: What to Expect.,sonographers,0.51847386,cardiology,0.51847386,cardiology,0.51847386
Machine Learning in Fetal Cardiology: What to Expect.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Machine Learning in Fetal Cardiology: What to Expect.,rules,0.34928846,of,0.44750106,anomalous,0.37612158
Machine Learning in Fetal Cardiology: What to Expect.,review,0.438658,of,0.54425275,cardiology,0.438658
Machine Learning in Fetal Cardiology: What to Expect.,quantification,0.21082784,of,0.4907973,flow,0.38184565
Machine Learning in Fetal Cardiology: What to Expect.,provide,0.3065295,of,0.4983799,flow,0.3409845
Machine Learning in Fetal Cardiology: What to Expect.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Machine Learning in Fetal Cardiology: What to Expect.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Machine Learning in Fetal Cardiology: What to Expect.,mode,0.25871068,weak,0.46615613,flow,0.46415502
Machine Learning in Fetal Cardiology: What to Expect.,lack,0.27131414,of,0.6011338,l-transposition,0.36177164
Machine Learning in Fetal Cardiology: What to Expect.,improving,0.3579299,great,0.54781544,congestive,0.39419994
Machine Learning in Fetal Cardiology: What to Expect.,improve,0.31483245,great,0.49610043,flow,0.35876963
Machine Learning in Fetal Cardiology: What to Expect.,however,0.30646515,of,0.624624,mi,0.41109186
Machine Learning in Fetal Cardiology: What to Expect.,fetuses,0.25672635,hlhs,0.61322075,hlhs,0.61322075
Machine Learning in Fetal Cardiology: What to Expect.,fetus,0.26153296,arteriosus,0.5456365,arteriosus,0.5456365
Machine Learning in Fetal Cardiology: What to Expect.,expertise,0.49665302,cardiology,0.49665302,cardiology,0.49665302
Machine Learning in Fetal Cardiology: What to Expect.,evaluation,0.3957072,of,0.5653497,cardiology,0.3957072
Machine Learning in Fetal Cardiology: What to Expect.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Machine Learning in Fetal Cardiology: What to Expect.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Machine Learning in Fetal Cardiology: What to Expect.,basel,0.4182319,cardiology,0.4182319,cardiology,0.4182319
Machine Learning in Fetal Cardiology: What to Expect.,aid,0.30282542,of,0.5167762,anomaly,0.38754576
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,specific,0.26268506,of,0.6059094,flow,0.40644997
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive,0.28232595,anomalous,0.3734805,anomalous,0.3734805
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,index,0.27677816,total,0.43109894,mi,0.39722836
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,using,0.20786116,with,0.58010674,flow,0.41007757
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,correlative,0.35095048,of,0.56151533,anomalous,0.45223552
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,comprising,0.19319431,of,0.5419,deposits,0.28942207
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,odt,0.16635258,heartbeat,0.27394775,heartbeat,0.27394775
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,integrated,0.3167261,of,0.46948645,single-ventricle,0.3645035
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive-index,0.23375049,anomalous,0.46679282,anomalous,0.46679282
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,using,0.20786116,with,0.58010674,flow,0.41007757
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,optical,0.26125413,anomalous,0.45746398,anomalous,0.45746398
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,diffraction,0.2076031,anomalous,0.4873882,anomalous,0.4873882
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,tomography,0.3269008,coronary,0.38573277,coronary,0.38573277
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,optical-diffraction,0.23525,anomalous,0.4800223,anomalous,0.4800223
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,diffraction-tomography,0.28753406,anomalous,0.4413332,anomalous,0.4413332
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive,0.28232595,anomalous,0.3734805,anomalous,0.3734805
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,index,0.27677816,total,0.43109894,mi,0.39722836
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,measurement,0.2804429,of,0.51248544,blood-flow,0.45750505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive-index,0.23375049,anomalous,0.46679282,anomalous,0.46679282
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,high,0.28122714,of,0.57459104,flow,0.3923195
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose,0.13874811,cholesterol,0.42516115,cholesterol,0.42516115
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,specificity,0.22204962,of,0.4346917,cad,0.34837636
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,high-mannose,0.1679552,cholesterol,0.36660093,cholesterol,0.36660093
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose-receptor,0.14777772,isolated,0.32990462,cholesterol,0.32839444
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,receptor-specificity,0.22214024,of,0.42747414,l-transposition,0.36842403
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free,0.27289551,total,0.4907664,cardiac,0.38484737
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living,0.2469504,of,0.47259963,deposits,0.36684513
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.22729686,plaque-deposits,0.44227618,plaque-deposits,0.44227618
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free-living,0.2222987,of,0.3726974,congenital-heart-disease,0.33174005
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.25271258,plaque-deposits,0.5110331,plaque-deposits,0.5110331
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cellular,0.25397572,of,0.55018497,cardiac,0.40519243
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,techniques,0.254115,great,0.3795752,single-ventricle,0.37415883
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cellular-imaging,0.287623,blood-flow,0.47097167,blood-flow,0.47097167
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging-techniques,0.3404349,blood-flow,0.46181595,blood-flow,0.46181595
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional,0.25604147,anomalous,0.48529866,anomalous,0.48529866
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescence,0.19895127,flow,0.39652362,flow,0.39652362
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.38686287,blood-flow,0.4222771,blood-flow,0.4222771
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional-fluorescence,0.2588752,flow,0.48567095,flow,0.48567095
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescence-imaging,0.25275433,flow,0.3808485,flow,0.3808485
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living,0.2469504,of,0.47259963,deposits,0.36684513
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.22729686,plaque-deposits,0.44227618,plaque-deposits,0.44227618
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.25271258,plaque-deposits,0.5110331,plaque-deposits,0.5110331
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related-metabolic,0.27259743,congenital-heart-disease,0.44354802,congenital-heart-disease,0.44354802
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.22729686,plaque-deposits,0.44227618,plaque-deposits,0.44227618
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based,0.2494699,of,0.5443143,flow,0.34116954
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.25271258,plaque-deposits,0.5110331,plaque-deposits,0.5110331
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells-based,0.19833262,of,0.36282682,plaque-deposits,0.35829818
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,explore,0.23689461,of,0.47429746,anomalous,0.30295405
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,new-drugs,0.30006665,congestive-heart-failure,0.4236113,congestive-heart-failure,0.4236113
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,morphological,0.23301639,of,0.51360136,anomaly,0.4440594
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative-morphological,0.19664839,of,0.5171418,anomalous,0.43387252
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based,0.2494699,of,0.5443143,flow,0.34116954
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,image,0.3220324,heartbeat,0.45858762,heartbeat,0.45858762
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based-image,0.25150383,heartbeat,0.4021685,heartbeat,0.4021685
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,image-analysis,0.30505478,blood-flow,0.4198826,blood-flow,0.4198826
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,evaluation,0.3957072,of,0.5653497,cardiology,0.3957072
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic-evaluation,0.47165397,of,0.49927515,cardiology,0.47165397
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,odt,0.16635258,heartbeat,0.27394775,heartbeat,0.27394775
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.22729686,plaque-deposits,0.44227618,plaque-deposits,0.44227618
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.25271258,plaque-deposits,0.5110331,plaque-deposits,0.5110331
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free,0.27289551,total,0.4907664,cardiac,0.38484737
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,manner,0.18540666,with,0.42496896,contractions,0.388913
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional,0.25604147,anomalous,0.48529866,anomalous,0.48529866
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dynamics,0.26244372,of,0.47602248,anomalous,0.462408
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,biophysical,0.2982732,of,0.42944944,anomalous,0.38817298
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,intervention,0.4565987,mi,0.49382597,mi,0.49382597
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic-intervention,0.5153639,venous-return,0.5170255,venous-return,0.5170255
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic-effects,0.33525288,of,0.50355077,venous-return,0.38564527
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,delivery,0.30619597,of,0.44014573,single-ventricle,0.41750336
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,targeted-delivery,0.2627886,single,0.38081443,single-ventricle,0.35207653
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitatively,0.2185888,of,0.57824427,flow,0.4636413
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitatively-evaluated,0.30303094,of,0.5891716,plaque,0.41362867
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,promising,0.2032688,great,0.5363789,anomalous,0.26476932
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,polyethylene,0.16256788,stiff,0.4280754,cholesterol,0.33439374
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol,0.16384308,cholesterol,0.3375873,cholesterol,0.3375873
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,polyethylene-glycol,0.12060558,stiff,0.37303227,blood-clot,0.34115565
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,droplet,0.30678678,flow,0.4475255,flow,0.4475255
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lipid-droplet,0.23963434,cholesterol,0.54916716,cholesterol,0.54916716
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,limited,0.29959464,of,0.6210327,deposits,0.40452772
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,application,0.3034747,of,0.54379797,flow,0.3922925
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,limited-application,0.2810732,single,0.4458601,flow,0.39684862
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lapse,0.2687837,return,0.47383052,heartbeat,0.451244
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lapse-monitoring,0.388409,venous-return,0.4863769,venous-return,0.4863769
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,key-feature,0.25043473,heartbeat,0.4130242,heartbeat,0.4130242
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lds,0.30013445,cholesterol,0.4907011,cholesterol,0.4907011
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol,0.16384308,cholesterol,0.3375873,cholesterol,0.3375873
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,chitosan,0.1623339,great,0.3159172,blood-clot,0.2929917
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol-chitosan,0.1210573,stiff,0.30768543,plaque-deposits,0.30353194
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescein,0.20223573,flow,0.39650273,flow,0.39650273
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,isothiocyanate,0.10028672,flow,0.30002367,flow,0.30002367
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescein-isothiocyanate,0.11034027,flow,0.37554112,flow,0.37554112
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,exploiting,0.2237392,great,0.5525879,anomalous,0.39645672
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,despite,0.3297603,of,0.5583629,cardiac,0.39134312
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,advances,0.40024865,great,0.516971,cardiology,0.40024865
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,current,0.39557698,of,0.4991414,flow,0.39574015
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,noninvasive,0.346865,blood-flow,0.49185923,blood-flow,0.49185923
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cell,0.21863139,of,0.48460138,flow,0.38218224
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cell-level,0.19798163,of,0.42004254,heartbeat,0.34386507
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,attractive,0.22626528,great,0.5259857,anomalous,0.30611852
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,target,0.23866604,of,0.4775706,blood,0.34112448
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose,0.13874811,cholesterol,0.42516115,cholesterol,0.42516115
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,verifying,0.29430777,of,0.6268448,anomalous,0.38626397
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,time,0.350901,return,0.5513821,venous-return,0.44564146
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,single,0.2571312,single,1.0,anomalous,0.40611145
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,precisely,0.24528378,of,0.5838205,anomalous,0.42730176
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,nanodrug,0.28060156,great,0.3679726,plaque-deposits,0.29847232
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mmr,0.1842176,avsd,0.44299045,avsd,0.44299045
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobeglitazone,0.21462429,cholesterol,0.45690018,cholesterol,0.45690018
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobe,0.19622472,right,0.60330224,ventricle,0.49867284
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,ld,0.25832635,blood,0.37961912,blood,0.37961912
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,label,0.22360753,double,0.41220164,cholesterol,0.2931944
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,however,0.30646515,of,0.624624,mi,0.41109186
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,furthermore,0.18322246,of,0.5529862,plaque-deposits,0.34174067
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,designed,0.2395013,of,0.4984635,venous-return,0.32304075
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,constitutes,0.19771482,of,0.63473797,anomaly,0.37694407
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,atherosclerosis,0.43153092,coronary,0.678047,coronary,0.678047
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,affect,0.19231161,of,0.50835335,anomalous,0.31428474
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,accumulation,0.18045044,deposits,0.5375833,deposits,0.5375833
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.57664216,heart,1.0,heart,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Supervised machine learning models applied to disease diagnosis and prognosis.,data,0.31118363,of,0.5086956,mi,0.36251363
Supervised machine learning models applied to disease diagnosis and prognosis.,using,0.20786116,with,0.58010674,flow,0.41007757
Supervised machine learning models applied to disease diagnosis and prognosis.,five,0.2645896,of,0.58525,d-transposition,0.36288995
Supervised machine learning models applied to disease diagnosis and prognosis.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Supervised machine learning models applied to disease diagnosis and prognosis.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Supervised machine learning models applied to disease diagnosis and prognosis.,heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,disease-data,0.23445557,disease,0.6797526,artery-disease,0.57502115
Supervised machine learning models applied to disease diagnosis and prognosis.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.57664216,heart,1.0,heart,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Supervised machine learning models applied to disease diagnosis and prognosis.,data,0.31118363,of,0.5086956,mi,0.36251363
Supervised machine learning models applied to disease diagnosis and prognosis.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Supervised machine learning models applied to disease diagnosis and prognosis.,heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,disease-data,0.23445557,disease,0.6797526,artery-disease,0.57502115
Supervised machine learning models applied to disease diagnosis and prognosis.,licensee,0.3445976,cardiology,0.3445976,cardiology,0.3445976
Supervised machine learning models applied to disease diagnosis and prognosis.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Supervised machine learning models applied to disease diagnosis and prognosis.,press,0.43476897,cardiology,0.43476897,cardiology,0.43476897
Supervised machine learning models applied to disease diagnosis and prognosis.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Supervised machine learning models applied to disease diagnosis and prognosis.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Supervised machine learning models applied to disease diagnosis and prognosis.,using,0.20786116,with,0.58010674,flow,0.41007757
Supervised machine learning models applied to disease diagnosis and prognosis.,prediction-accuracy,0.24473807,heartbeat,0.4218127,heartbeat,0.4218127
Supervised machine learning models applied to disease diagnosis and prognosis.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Supervised machine learning models applied to disease diagnosis and prognosis.,data,0.31118363,of,0.5086956,mi,0.36251363
Supervised machine learning models applied to disease diagnosis and prognosis.,based,0.2494699,of,0.5443143,flow,0.34116954
Supervised machine learning models applied to disease diagnosis and prognosis.,test-data,0.27674094,congenital-heart-disease,0.40158722,congenital-heart-disease,0.40158722
Supervised machine learning models applied to disease diagnosis and prognosis.,data-based,0.3694023,congenital-heart-disease,0.41850758,congenital-heart-disease,0.41850758
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver,0.2488175,stenosis,0.38058472,stenosis,0.38058472
Supervised machine learning models applied to disease diagnosis and prognosis.,operating,0.35147023,of,0.42011455,venous-return,0.38749343
Supervised machine learning models applied to disease diagnosis and prognosis.,characteristic,0.14630476,of,0.52064013,anomalous,0.42846608
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver-operating,0.27902067,stenosis,0.41488302,stenosis,0.41488302
Supervised machine learning models applied to disease diagnosis and prognosis.,operating-characteristic,0.26187587,of,0.50360763,venous-return,0.39550078
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver-operating-characteristic,0.25317627,stenosis,0.38405818,stenosis,0.38405818
Supervised machine learning models applied to disease diagnosis and prognosis.,principal,0.23827076,of,0.51180303,anomalous,0.35342324
Supervised machine learning models applied to disease diagnosis and prognosis.,component,0.2266389,of,0.52326363,deposits,0.38395098
Supervised machine learning models applied to disease diagnosis and prognosis.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Supervised machine learning models applied to disease diagnosis and prognosis.,principal-component,0.19285686,anomalous,0.38114718,anomalous,0.38114718
Supervised machine learning models applied to disease diagnosis and prognosis.,component-regression,0.2301732,of,0.40517756,congenital-heart-disease,0.39118555
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.57664216,heart,1.0,heart,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Supervised machine learning models applied to disease diagnosis and prognosis.,heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,work,0.41337943,return,0.5383546,cardiology,0.41337943
Supervised machine learning models applied to disease diagnosis and prognosis.,analyses,0.1956715,of,0.44186428,deposits,0.31060207
Supervised machine learning models applied to disease diagnosis and prognosis.,work-analyses,0.4167816,congenital-heart-disease,0.4274693,congenital-heart-disease,0.4274693
Supervised machine learning models applied to disease diagnosis and prognosis.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Supervised machine learning models applied to disease diagnosis and prognosis.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Supervised machine learning models applied to disease diagnosis and prognosis.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
Supervised machine learning models applied to disease diagnosis and prognosis.,predictive,0.28315032,of,0.43440902,cad,0.39744872
Supervised machine learning models applied to disease diagnosis and prognosis.,ability,0.2123124,of,0.53612673,cardiac,0.340167
Supervised machine learning models applied to disease diagnosis and prognosis.,predictive-ability,0.25887254,venous-return,0.43538558,venous-return,0.43538558
Supervised machine learning models applied to disease diagnosis and prognosis.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Supervised machine learning models applied to disease diagnosis and prognosis.,variables,0.28295675,of,0.44578728,venous-return,0.39021647
Supervised machine learning models applied to disease diagnosis and prognosis.,best,0.3534876,as,0.5428521,anomaly,0.36822265
Supervised machine learning models applied to disease diagnosis and prognosis.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Supervised machine learning models applied to disease diagnosis and prognosis.,best-performance,0.2893415,venous-return,0.39736792,venous-return,0.39736792
Supervised machine learning models applied to disease diagnosis and prognosis.,also,0.36015856,of,0.65908813,flow,0.41040578
Supervised machine learning models applied to disease diagnosis and prognosis.,studied,0.2428486,of,0.63097596,anomalous,0.39203623
Supervised machine learning models applied to disease diagnosis and prognosis.,causes,0.22412287,of,0.55089116,congenital,0.49946666
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Supervised machine learning models applied to disease diagnosis and prognosis.,breast,0.3365241,with,0.4216323,cad,0.40088844
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Supervised machine learning models applied to disease diagnosis and prognosis.,breast-cancer,0.27508703,chd,0.40747812,chd,0.40747812
Supervised machine learning models applied to disease diagnosis and prognosis.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Supervised machine learning models applied to disease diagnosis and prognosis.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
Supervised machine learning models applied to disease diagnosis and prognosis.,ml-algorithms,0.33641046,venous-return,0.41967043,venous-return,0.41967043
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Supervised machine learning models applied to disease diagnosis and prognosis.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Supervised machine learning models applied to disease diagnosis and prognosis.,algorithms,0.3551841,heartbeat,0.4410367,heartbeat,0.4410367
Supervised machine learning models applied to disease diagnosis and prognosis.,roc,0.23340055,stenosis,0.34069353,stenosis,0.34069353
Supervised machine learning models applied to disease diagnosis and prognosis.,rf,0.26887482,right-atrial,0.36829585,right-atrial,0.36829585
Supervised machine learning models applied to disease diagnosis and prognosis.,provides,0.22296365,of,0.5261056,flow,0.32656315
Supervised machine learning models applied to disease diagnosis and prognosis.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Supervised machine learning models applied to disease diagnosis and prognosis.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Supervised machine learning models applied to disease diagnosis and prognosis.,pcr,0.18917134,isolated,0.34562874,l-transposition,0.34398216
Supervised machine learning models applied to disease diagnosis and prognosis.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Supervised machine learning models applied to disease diagnosis and prognosis.,curve,0.23990677,stenosis,0.35901296,stenosis,0.35901296
Supervised machine learning models applied to disease diagnosis and prognosis.,compute,0.24574788,anomalous,0.3814366,anomalous,0.3814366
Supervised machine learning models applied to disease diagnosis and prognosis.,compare,0.27648047,of,0.5052448,venous-return,0.3454308
Supervised machine learning models applied to disease diagnosis and prognosis.,author,0.39858195,anomaly,0.4089887,anomaly,0.4089887
Supervised machine learning models applied to disease diagnosis and prognosis.,analyzing,0.28163195,of,0.62098694,anomalous,0.39847034
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,increased,0.32251194,of,0.64014816,mi,0.42637154
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,within,0.30995527,of,0.57602364,deposits,0.42065546
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,minutes,0.33206832,beats,0.5359132,beats,0.5359132
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,phosphodiesterase,0.16195168,isolated,0.39280367,contractions,0.35395074
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-levels,0.2367914,contractions,0.44742668,contractions,0.44742668
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,levels-within,0.33065116,venous-return,0.4428867,venous-return,0.4428867
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,phosphodiesterase-inhibitors,0.2107741,isolated,0.38252562,congestive-heart-failure,0.37310416
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,'-,0.0434518,double-outlet,0.2696839,double-outlet,0.2696839
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cyclic,0.15624975,contractions,0.45148745,contractions,0.45148745
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,adenosine,0.22536264,l-transposition,0.43268204,l-transposition,0.43268204
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,monophosphate,0.10996126,l-transposition,0.40409607,l-transposition,0.40409607
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cyclic-adenosine,0.17489931,contractions,0.40831614,contractions,0.40831614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,adenosine-monophosphate,0.14543489,l-transposition,0.42451876,l-transposition,0.42451876
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cyclic-adenosine-monophosphate,0.13241804,l-transposition,0.39997324,l-transposition,0.39997324
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,impermeable,0.100371376,intact,0.4709576,deposits,0.3912902
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.15556112,insufficiency,0.380606,l-transposition,0.3524738
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,showed,0.21619865,with,0.57298803,flow,0.33828264
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,similarly,0.2457779,with,0.6309897,contractions,0.41134822
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rapid,0.25774473,of,0.52859515,flow,0.40399063
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,stimulation,0.24982259,contractions,0.54615366,contractions,0.54615366
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,similarly-rapid,0.18414432,of,0.46882498,heartbeat,0.45821252
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,airway,0.2880329,pulmonary,0.5942069,pulmonary,0.5942069
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,smooth,0.22600234,contractions,0.5797529,contractions,0.5797529
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,human-airway,0.27653217,pulmonary,0.45246238,pulmonary,0.45246238
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,smooth-muscle,0.25403732,contractions,0.5952677,contractions,0.5952677
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,airway-smooth-muscle,0.2400271,contractions,0.5059664,contractions,0.5059664
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g,0.21858013,single,0.41386712,ivs,0.37229383
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estrogen,0.22574326,cholesterol,0.4336136,cholesterol,0.4336136
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,antagonists,0.26629966,contractions,0.45131737,contractions,0.45131737
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g-protein,0.21410671,of,0.3605783,contractions,0.3435616
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,protein-estrogen,0.22358292,cholesterol,0.41967452,cholesterol,0.41967452
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estrogen-receptor,0.2107409,cholesterol,0.34779713,cholesterol,0.34779713
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,receptor-antagonists,0.2558006,contractions,0.41648656,contractions,0.41648656
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.23843989,of,0.42904675,l-transposition,0.41207945
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,modality,0.3416853,disease,0.42066878,single-ventricle,0.39747286
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,contributes,0.18509582,of,0.5690483,anomalous,0.32952994
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-signaling,0.21843904,l-transposition,0.3573977,l-transposition,0.3573977
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,time,0.350901,return,0.5513821,venous-return,0.44564146
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,dynamics,0.26244372,of,0.47602248,anomalous,0.462408
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,using,0.20786116,with,0.58010674,flow,0.41007757
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,time-camp,0.21103022,venous-return,0.37282002,venous-return,0.37282002
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,dynamics-using,0.3129825,with,0.43099296,venous-return,0.4073115
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,changes,0.30126634,of,0.5562258,flow,0.44305104
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene-expression,0.22584388,of,0.41557923,l-transposition,0.3919022
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,expression-changes,0.25537974,of,0.4583885,heart-failure,0.39297614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,changes-induced,0.27606642,of,0.49053898,contractions,0.45271152
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hours,0.38191575,return,0.507182,infarction,0.42204177
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hasm,0.21175727,contractions,0.46973035,contractions,0.46973035
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,virtually,0.20761354,of,0.5415002,l-transposition,0.3857622
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,eliminated,0.2077154,of,0.5635375,l-transposition,0.39554918
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.15556112,insufficiency,0.380606,l-transposition,0.3524738
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,diverse,0.3032622,of,0.5461366,cardiac,0.3471622
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell,0.21863139,of,0.48460138,flow,0.38218224
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell-signaling,0.22350955,of,0.40551755,congenital-heart-disease,0.33100727
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genes,0.22443718,l-transposition,0.43358943,l-transposition,0.43358943
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,represent,0.22206968,as,0.5763198,anomaly,0.3441872
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genes-represent,0.28051612,of,0.39416417,congenital-heart-disease,0.36159053
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,difference,0.212452,of,0.434909,stenosis,0.35809982
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,detector,0.25804573,tof,0.45266697,tof,0.45266697
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,difference-detector,0.23240265,single,0.44144392,tof,0.42485797
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,requires,0.29668367,of,0.62298405,l-transposition,0.37602508
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-levels,0.2367914,contractions,0.44742668,contractions,0.44742668
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,immortalized,0.21182652,isolated,0.4457245,septal-defect,0.36601242
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell,0.21863139,of,0.48460138,flow,0.38218224
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,lines,0.23701838,intact,0.44574544,ivs,0.38147125
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,immortalized-cell,0.1690959,septal-defect,0.38888565,septal-defect,0.38888565
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell-lines,0.19909571,of,0.39812192,l-transposition,0.35238057
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,faseb,0.3691387,cardiology,0.3691387,cardiology,0.3691387
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,journal,0.530411,cardiology,0.530411,cardiology,0.530411
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,journal-published,0.49370247,cardiology,0.49370247,cardiology,0.49370247
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,stimulated,0.23078603,isolated,0.49819338,contractions,0.49648702
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,responses,0.18527287,contractions,0.4718574,contractions,0.4718574
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-responses,0.19360076,contractions,0.39131343,contractions,0.39131343
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,production,0.1999099,of,0.51767635,flow,0.379918
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,via,0.2561984,of,0.50595546,flow,0.41023284
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-production,0.24768282,of,0.4389252,contractions,0.43504995
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,budesonide,0.14299916,pulmonary,0.34702283,pulmonary,0.34702283
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signature,0.17159154,of,0.43148303,anomalous,0.35161406
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown,0.18967783,l-transposition,0.35766447,l-transposition,0.35766447
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g,0.21858013,single,0.41386712,ivs,0.37229383
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g-protein,0.21410671,of,0.3605783,contractions,0.3435616
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.15556112,insufficiency,0.380606,l-transposition,0.3524738
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid-treatment,0.1754488,insufficiency,0.40559196,congenital-heart-disease,0.39057404
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,coupled,0.1969167,with,0.5215788,anomalous,0.37728786
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,coupled-receptor,0.23554222,contractions,0.37744403,contractions,0.37744403
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.23843989,of,0.42904675,l-transposition,0.41207945
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signature,0.17159154,of,0.43148303,anomalous,0.35161406
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic-signature,0.19982654,of,0.39892653,l-transposition,0.38103595
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell,0.21863139,of,0.48460138,flow,0.38218224
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,surface,0.17955789,of,0.46375725,deposits,0.44493395
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell-surface,0.1781917,of,0.3894903,plaque-deposits,0.3362108
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.23843989,of,0.42904675,l-transposition,0.41207945
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,actions,0.296938,contractions,0.5202074,contractions,0.5202074
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,small,0.28269485,great,0.5440953,deposits,0.39470115
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,small-effects,0.18874346,single,0.4896245,anomalous,0.41563404
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,wiley,0.3314681,cardiology,0.3314681,cardiology,0.3314681
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,periodicals,0.4928238,cardiology,0.4928238,cardiology,0.4928238
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,wiley-periodicals,0.4103245,cardiology,0.4103245,cardiology,0.4103245
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,widely,0.2665941,as,0.5225847,deposits,0.32680094
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,used,0.23211285,as,0.56584436,flow,0.35934073
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,widely-used,0.19366017,as,0.40963727,lai,0.28079027
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,swiftly,0.3062613,great,0.481162,heart-attack,0.38514286
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,increase,0.32113555,of,0.60061187,flow,0.4086165
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,situ,0.14777097,of,0.4240869,deposits,0.40929627
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,assay,0.19801754,of,0.37163246,flow,0.32158902
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,sirna,0.22748467,l-transposition,0.29439193,l-transposition,0.29439193
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown,0.18967783,l-transposition,0.35766447,l-transposition,0.35766447
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,sirna-knockdown,0.17744577,septal-defect,0.32366475,septal-defect,0.32366475
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,seq,0.23835643,venous-return,0.3696096,venous-return,0.3696096
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,seq-analysis,0.31086847,congenital-heart-disease,0.36247528,congenital-heart-disease,0.36247528
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,measuring,0.1845592,of,0.5194533,flow,0.39457345
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,real,0.3591983,great,0.53489023,flow,0.42211816
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,little,0.32411388,great,0.59987354,flow,0.33457753
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,leading,0.25149748,of,0.59935343,congenital,0.40424997
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,us,0.39735788,of,0.49393907,cardiology,0.39735788
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,class,0.2877068,of,0.3977759,d-transposition,0.36031434
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,biology,0.41353095,great,0.48241207,cardiology,0.41353095
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,exerts,0.13445285,of,0.4074493,contractions,0.31238157
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,activate,0.15978053,intact,0.37905625,contractions,0.35076305
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,societies,0.5286464,cardiology,0.5286464,cardiology,0.5286464
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.25270894,contractions,0.42394036,contractions,0.42394036
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.19463272,insufficiency,0.42130566,l-transposition,0.3525629
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,tested,0.25299942,of,0.5634051,contractions,0.36297208
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.19463272,insufficiency,0.42130566,l-transposition,0.3525629
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,alone,0.25829685,with,0.6517836,mi,0.40645403
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rapid,0.25774473,of,0.52859515,flow,0.40399063
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hasm,0.21175727,contractions,0.46973035,contractions,0.46973035
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.23843989,of,0.42904675,l-transposition,0.41207945
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,responses,0.18527287,contractions,0.4718574,contractions,0.4718574
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,production,0.1999099,of,0.51767635,flow,0.379918
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,budesonide,0.14299916,pulmonary,0.34702283,pulmonary,0.34702283
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.19463272,insufficiency,0.42130566,l-transposition,0.3525629
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,view,0.35575834,of,0.44850454,cardiology,0.35575834
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,variety,0.24480078,great,0.49781102,l-transposition,0.37458777
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,unappreciated,0.25693247,as,0.5191227,anomaly,0.41390684
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,third,0.30185395,single,0.54406995,ventricle,0.44503468
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,suppression,0.16740395,of,0.5172409,contractions,0.3880853
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,suggesting,0.18459891,of,0.6157647,l-transposition,0.40478194
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,shifts,0.263492,of,0.48006222,anomalous,0.42548075
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rna,0.18219137,of,0.4053282,l-transposition,0.40229958
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,reported,0.2535432,of,0.6039252,l-transposition,0.37000108
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,progesterone,0.22588801,cholesterol,0.476943,cholesterol,0.476943
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,prednisone,0.2713113,insufficiency,0.4500196,congestive,0.3989118
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,non,0.3477749,with,0.61364555,mi,0.46788454
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,membrane,0.20611405,of,0.43286008,cholesterol,0.38573062
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,initiated,0.4144449,of,0.59720325,cardiology,0.4144449
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,implying,0.13714507,of,0.5400089,l-transposition,0.3904614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hypothesize,0.16830604,of,0.46076187,anomalous,0.35479158
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,growing,0.29350758,great,0.54410803,deposits,0.31662738
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,found,0.2675444,with,0.6275196,deposits,0.41920424
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,fluticasone,0.20622851,pulmonary,0.33288878,pulmonary,0.33288878
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,federation,0.50071293,cardiology,0.50071293,cardiology,0.50071293
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estradiol,0.20497869,cholesterol,0.500805,cholesterol,0.500805
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,collectively,0.27017447,as,0.5129732,deposits,0.31934088
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,behalf,0.44911885,cardiology,0.44911885,cardiology,0.44911885
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;s&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,analyzed,0.25776637,of,0.58131987,flow,0.35350555
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",septic,0.36914045,failure,0.59729016,congestive,0.54611146
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",rats,0.18495534,with,0.41350603,arteries,0.40780795
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",demonstrated,0.21350801,of,0.6025795,flow,0.3810749
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased,0.32251194,of,0.64014816,mi,0.42637154
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial,0.20720324,of,0.48457187,l-transposition,0.36714125
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytosis,0.14436086,plaque-deposits,0.41833735,plaque-deposits,0.41833735
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial-phagocytosis,0.14528146,plaque-deposits,0.4348523,plaque-deposits,0.4348523
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",investigated,0.19995229,of,0.6179704,anomalous,0.35378093
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",whether,0.24223731,of,0.49140224,myocardial,0.30518332
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",prevented,0.19566363,of,0.49805415,contractions,0.37821114
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.27081648,failure,0.5063345,heart,0.4739595
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",dysfunction,0.3454026,insufficiency,0.6505209,congestive-heart-failure,0.5247797
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ-dysfunction,0.3379645,heart-syndrome,0.6062026,heart-syndrome,0.6062026
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sprague,0.19079143,isolated,0.3448987,arteries,0.3303411
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",dawley,0.15095097,arteries,0.3201794,arteries,0.3201794
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",rats,0.18495534,with,0.41350603,arteries,0.40780795
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",underwent,0.31797755,with,0.45424697,d-transposition,0.45269838
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sham,0.17824869,myocardial-infarction,0.3830036,myocardial-infarction,0.3830036
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",surgery,0.52026105,cardiology,0.52026105,cardiology,0.52026105
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sprague-dawley,0.14402539,arteries,0.33502525,arteries,0.33502525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sham-surgery,0.26684564,aortic-stenosis,0.42867082,aortic-stenosis,0.42867082
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sprague-dawley-rats,0.0996419,congenital-heart,0.364762,congenital-heart,0.364762
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",significantly,0.23700657,with,0.568532,mi,0.39826992
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.2912292,of,0.59706545,flow,0.4062525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial,0.20720324,of,0.48457187,l-transposition,0.36714125
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",levels,0.24129483,of,0.5074555,cholesterol,0.4301517
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",significantly-decreased,0.23290649,with,0.5789323,mi,0.42590043
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.32791707,with,0.5777352,congestive,0.40790212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",without,0.27970245,with,0.7351919,cardiac,0.42947003
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",compromising,0.21996349,of,0.5154775,flow,0.36019892
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen,0.20034528,disease,0.4754871,heart-attack,0.35139495
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clearance,0.20709568,blood-flow,0.42037752,blood-flow,0.42037752
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen-clearance,0.22296663,blood-clot,0.46454233,blood-clot,0.46454233
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",creatinine,0.33032572,cholesterol,0.43090975,cholesterol,0.43090975
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",ratios,0.16654095,double,0.37118572,tof,0.36179096
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",indicating,0.18618478,of,0.63023484,l-transposition,0.38276994
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.27081648,failure,0.5063345,heart,0.4739595
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protection,0.22196716,of,0.4576927,heart-attack,0.34616515
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",creatinine-ratios,0.26064223,venous-return,0.41342992,venous-return,0.41342992
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ-protection,0.27263194,heart-attack,0.43406492,heart-attack,0.43406492
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.2912292,of,0.59706545,flow,0.4062525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leukocyte,0.15960245,blood-clot,0.5572822,blood-clot,0.5572822
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",influx,0.17898923,contractions,0.439529,contractions,0.439529
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased,0.32251194,of,0.64014816,mi,0.42637154
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition-increased,0.22298011,of,0.5302738,contractions,0.39931002
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.32791707,with,0.5777352,congestive,0.40790212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",identified,0.21709195,isolated,0.60550874,anomaly,0.33388633
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protein,0.17386194,of,0.4756804,cholesterol,0.3740363
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kinase,0.17639789,of,0.32242787,myocardial,0.3009235
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",identified-protein,0.22338659,single,0.47270316,congenital-heart-disease,0.3705817
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protein-kinase,0.21248177,of,0.37827116,congestive,0.32201135
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kinase-c,0.15603757,contractions,0.30554152,contractions,0.30554152
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protein-kinase-c,0.18623246,of,0.34328723,cholesterol,0.32069913
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",exhibit,0.13290685,with,0.47864127,anomalous,0.41274607
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",direct,0.20486939,of,0.5187454,anomalous,0.3848631
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bactericidal,0.079383396,blood-clot,0.3884249,blood-clot,0.3884249
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",properties,0.16694331,of,0.4979031,anomalous,0.43609905
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",reduced,0.22478527,of,0.6221848,contractions,0.3818075
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood,0.32078606,blood,1.0,blood,1.0
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",urea,0.16199692,blood,0.42514712,blood,0.42514712
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",nitrogen,0.13745444,total,0.37970564,cholesterol,0.35112154
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",reduced-blood,0.21174239,blood,0.6077503,blood,0.6077503
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood-urea,0.22035475,blood-clot,0.6525449,blood-clot,0.6525449
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",urea-nitrogen,0.13079393,blood-flow,0.37584522,blood-flow,0.37584522
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood-urea-nitrogen,0.20123094,blood,0.54801726,blood,0.54801726
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.2912292,of,0.59706545,flow,0.4062525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.27081648,failure,0.5063345,heart,0.4739595
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",injury,0.24559022,infarction,0.52933943,infarction,0.52933943
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",enhanced,0.24384218,of,0.59523904,anomalous,0.36034083
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen,0.20034528,disease,0.4754871,heart-attack,0.35139495
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clearance,0.20709568,blood-flow,0.42037752,blood-flow,0.42037752
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen-clearance,0.22296663,blood-clot,0.46454233,blood-clot,0.46454233
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased,0.32251194,of,0.64014816,mi,0.42637154
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytic,0.1770455,blood-clot,0.4289866,blood-clot,0.4289866
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytic-activity,0.16172911,of,0.43905997,blood-clot,0.40612596
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.2912292,of,0.59706545,flow,0.4062525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",endothelial,0.27072835,arteries,0.52025723,arteries,0.52025723
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",permeability,0.12963712,blood-flow,0.4725433,blood-flow,0.4725433
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.23542011,pulmonary-venous,0.44399425,pulmonary-venous,0.44399425
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",chemokine,0.19004375,blood,0.33893266,blood,0.33893266
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",levels,0.24129483,of,0.5074555,cholesterol,0.4301517
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.32791707,with,0.5777352,congestive,0.40790212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",gas,0.19828166,flow,0.50715446,flow,0.50715446
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",exchange,0.23966244,anomalous,0.4229427,anomalous,0.4229427
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",gas-exchange,0.19160177,pulmonary-venous,0.52715313,pulmonary-venous,0.52715313
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive,0.5087563,cardiology,0.5087563,cardiology,0.5087563
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",units,0.36851507,of,0.40316433,cardiology,0.36851507
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive-care,0.5471461,cardiology,0.5471461,cardiology,0.5471461
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",care-units,0.42415786,heart-failure,0.4271557,heart-failure,0.4271557
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive-care-units,0.48524326,heart-failure,0.52799934,heart-failure,0.52799934
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",effectively,0.23149472,with,0.5521965,flow,0.3457586
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clear,0.2944979,weak,0.53911996,flow,0.39407748
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogens,0.23321638,disease,0.41366285,paivs,0.37078077
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.23542011,pulmonary-venous,0.44399425,pulmonary-venous,0.44399425
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",isolated,0.20391704,isolated,1.0,l-transposition,0.45230812
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal-macrophages,0.21709251,blood-clot,0.44366145,blood-clot,0.44366145
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",hours,0.38191575,return,0.507182,infarction,0.42204177
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",post,0.3914922,failure,0.52308416,mi,0.5076717
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",hours-post,0.3177346,return,0.475991,venous-return,0.42634872
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.32791707,with,0.5777352,congestive,0.40790212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kidney,0.29311,heart,0.5663165,heart,0.5663165
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",dysfunction,0.3454026,insufficiency,0.6505209,congestive-heart-failure,0.5247797
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibitor,0.23137593,of,0.37385303,congestive,0.302135
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.23542011,pulmonary-venous,0.44399425,pulmonary-venous,0.44399425
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cavity,0.21484229,ventricle,0.52176464,ventricle,0.52176464
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal-cavity,0.20156617,atrioventricular-septal-defect,0.44508523,atrioventricular-septal-defect,0.44508523
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",neutrophil,0.122151285,blood-clot,0.47926182,blood-clot,0.47926182
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",numbers,0.26338902,total,0.43914548,flow,0.35711005
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",macrophage,0.2274085,pulmonary,0.42684036,pulmonary,0.42684036
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phenotypes,0.21512172,defect,0.48261124,septal-defect,0.46157122
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leading,0.25149748,of,0.59935343,congenital,0.40424997
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cause,0.24258707,congenital,0.5065234,congenital,0.5065234
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leading-cause,0.30231607,chd,0.4955071,chd,0.4955071
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",therapeutics,0.39063048,great,0.49259353,cardiology,0.39063048
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",response,0.2306606,of,0.52661085,contractions,0.38512754
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory-response,0.189253,of,0.4226144,artery-disease,0.39525625
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",important,0.26857167,great,0.5369053,anomalous,0.32819813
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",regulator,0.20251182,as,0.42325643,l-transposition,0.2960012
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",important,0.26857167,great,0.5369053,anomalous,0.32819813
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",issue,0.45756358,great,0.48638582,cardiology,0.45756358
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",biology,0.41353095,great,0.48241207,cardiology,0.41353095
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cecal,0.1961924,outlet,0.41074097,aortic,0.41072106
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",ligation,0.2126418,artery,0.5155336,artery,0.5155336
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cecal-ligation,0.16139501,double,0.44195017,l-transposition,0.42922938
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",societies,0.5286464,cardiology,0.5286464,cardiology,0.5286464
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",administered,0.30782846,with,0.49496263,venous,0.3302617
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intra,0.347368,clot,0.42687327,clot,0.42687327
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",surgery,0.52026105,cardiology,0.52026105,cardiology,0.52026105
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",induce,0.10905008,of,0.40277672,contractions,0.3169827
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sepsis,0.42946094,failure,0.60021013,thrombosis,0.5304944
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood,0.32078606,blood,1.0,blood,1.0
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",post,0.3914922,failure,0.52308416,mi,0.5076717
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sepsis,0.42946094,failure,0.60021013,thrombosis,0.5304944
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",tracheally,0.28371978,pulmonary,0.53185564,pulmonary,0.53185564
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",thus,0.30240285,of,0.6779618,flow,0.4474225
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",spleen,0.15694124,heart,0.42438847,heart,0.42438847
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",puncture,0.3124418,venous,0.52649796,venous,0.52649796
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",previously,0.21411541,as,0.54924536,l-transposition,0.42639655
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pbs,0.073099524,eb,0.36350024,eb,0.36350024
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organs,0.20830885,heart,0.44025397,heart,0.44025397
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",mortality,0.3475203,chd,0.5562636,chd,0.5562636
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",morbidity,0.31568646,chd,0.50165594,chd,0.50165594
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kg,0.28628194,beats,0.3961782,beats,0.3961782
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inability,0.237943,failure,0.52600026,clot,0.37616032
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",importantly,0.21522325,of,0.5300726,plaque-deposits,0.3543815
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",immunosuppression,0.22554146,failure,0.45595235,congenital-heart-disease,0.3940202
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",evidence,0.26946932,of,0.5239626,congestive,0.36117315
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",development,0.2877805,of,0.53581744,congenital,0.35419804
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",delta,0.18833467,double,0.43849707,sv,0.3505053
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clp,0.19384651,hlhs,0.3700562,hlhs,0.3700562
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",associated,0.20417106,with,0.60998726,congenital,0.4144575
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",anti,0.24353361,weak,0.4726881,isomerism,0.366829
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",altered,0.23629062,abnormal,0.6527077,anomalous,0.41416392
Innovations in pharmacological treatment of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Innovations in pharmacological treatment of heart failure.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Innovations in pharmacological treatment of heart failure.,promising,0.2032688,great,0.5363789,anomalous,0.26476932
Innovations in pharmacological treatment of heart failure.,groups,0.2612025,with,0.4941169,mi,0.3908207
Innovations in pharmacological treatment of heart failure.,maximal,0.24672642,contractions,0.55468667,contractions,0.55468667
Innovations in pharmacological treatment of heart failure.,tolerated,0.35179177,as,0.5088804,arrythmia,0.43104008
Innovations in pharmacological treatment of heart failure.,doses,0.30115995,with,0.44940743,contractions,0.3849393
Innovations in pharmacological treatment of heart failure.,maximal-tolerated,0.31731492,contractions,0.44500253,contractions,0.44500253
Innovations in pharmacological treatment of heart failure.,hughe,0.27811062,valve,0.34645846,valve,0.34645846
Innovations in pharmacological treatment of heart failure.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Innovations in pharmacological treatment of heart failure.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Innovations in pharmacological treatment of heart failure.,clinical-research,0.40419233,congenital-heart-disease,0.46161553,congenital-heart-disease,0.46161553
Innovations in pharmacological treatment of heart failure.,renin,0.31312823,atrial,0.5063691,atrial,0.5063691
Innovations in pharmacological treatment of heart failure.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Innovations in pharmacological treatment of heart failure.,blockade,0.2635491,bradycardia,0.4963892,bradycardia,0.4963892
Innovations in pharmacological treatment of heart failure.,renin-angiotensin,0.36609128,congestive,0.49315637,congestive,0.49315637
Innovations in pharmacological treatment of heart failure.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Innovations in pharmacological treatment of heart failure.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Innovations in pharmacological treatment of heart failure.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
Innovations in pharmacological treatment of heart failure.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
Innovations in pharmacological treatment of heart failure.,receptor-blockers,0.33424258,bradycardia,0.4559213,bradycardia,0.4559213
Innovations in pharmacological treatment of heart failure.,angiotensin-receptor-blockers,0.3599828,congestive,0.50955385,congestive,0.50955385
Innovations in pharmacological treatment of heart failure.,others,0.32080752,with,0.5653113,heart-attack,0.43046573
Innovations in pharmacological treatment of heart failure.,perspective,0.42978266,of,0.46585026,cardiology,0.42978266
Innovations in pharmacological treatment of heart failure.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Innovations in pharmacological treatment of heart failure.,others-perspective,0.37415177,congenital-heart-disease,0.45555383,congenital-heart-disease,0.45555383
Innovations in pharmacological treatment of heart failure.,ace,0.38736114,intact,0.48079938,mi,0.47931165
Innovations in pharmacological treatment of heart failure.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Innovations in pharmacological treatment of heart failure.,intolerance,0.29832408,insufficiency,0.54997456,heart-syndrome,0.49629486
Innovations in pharmacological treatment of heart failure.,ace-inhibitors,0.43037638,congestive-heart-failure,0.5646721,congestive-heart-failure,0.5646721
Innovations in pharmacological treatment of heart failure.,heart,0.57664216,heart,1.0,heart,1.0
Innovations in pharmacological treatment of heart failure.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Innovations in pharmacological treatment of heart failure.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Innovations in pharmacological treatment of heart failure.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Innovations in pharmacological treatment of heart failure.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Innovations in pharmacological treatment of heart failure.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Innovations in pharmacological treatment of heart failure.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
Innovations in pharmacological treatment of heart failure.,heart,0.57664216,heart,1.0,heart,1.0
Innovations in pharmacological treatment of heart failure.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Innovations in pharmacological treatment of heart failure.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Innovations in pharmacological treatment of heart failure.,ace,0.38736114,intact,0.48079938,mi,0.47931165
Innovations in pharmacological treatment of heart failure.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Innovations in pharmacological treatment of heart failure.,ace-inhibitors,0.43037638,congestive-heart-failure,0.5646721,congestive-heart-failure,0.5646721
Innovations in pharmacological treatment of heart failure.,l,0.19137359,right,0.5803616,d-transposition,0.37858474
Innovations in pharmacological treatment of heart failure.,j,0.24581458,lai,0.35768944,lai,0.35768944
Innovations in pharmacological treatment of heart failure.,j,0.24581458,lai,0.35768944,lai,0.35768944
Innovations in pharmacological treatment of heart failure.,symptoms,0.29561567,disease,0.5364805,syndrome,0.5318241
Innovations in pharmacological treatment of heart failure.,relieve,0.2036906,outlet,0.4259461,stenosis,0.3720463
Innovations in pharmacological treatment of heart failure.,pharmacological,0.32797652,of,0.48491696,congestive-heart-failure,0.37223655
Innovations in pharmacological treatment of heart failure.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Innovations in pharmacological treatment of heart failure.,pharmacological-treatment,0.34400517,of,0.50281584,heart-failure,0.47495627
Innovations in pharmacological treatment of heart failure.,omecamtiv,0.37335563,congestive-heart-failure,0.4882269,congestive-heart-failure,0.4882269
Innovations in pharmacological treatment of heart failure.,mecarbil,0.29671428,heart-failure,0.42933375,heart-failure,0.42933375
Innovations in pharmacological treatment of heart failure.,omecamtiv-mecarbil,0.31346163,congestive-heart-failure,0.45587683,congestive-heart-failure,0.45587683
Innovations in pharmacological treatment of heart failure.,neprilysin,0.28954732,heart-failure,0.40454558,heart-failure,0.40454558
Innovations in pharmacological treatment of heart failure.,inhibitor,0.23137593,of,0.37385303,congestive,0.302135
Innovations in pharmacological treatment of heart failure.,neprilysin-inhibitor,0.24368644,congestive-heart-failure,0.39703363,congestive-heart-failure,0.39703363
Innovations in pharmacological treatment of heart failure.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Innovations in pharmacological treatment of heart failure.,goal,0.42704034,return,0.44766816,cardiology,0.42704034
Innovations in pharmacological treatment of heart failure.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Innovations in pharmacological treatment of heart failure.,trial,0.38247734,failure,0.44692248,congestive-heart-failure,0.41253513
Innovations in pharmacological treatment of heart failure.,hf-trial,0.31898674,heart-failure,0.4735047,heart-failure,0.4735047
Innovations in pharmacological treatment of heart failure.,glucose,0.26253542,cholesterol,0.5280895,cholesterol,0.5280895
Innovations in pharmacological treatment of heart failure.,co,0.36334935,with,0.46287042,cardiac,0.45921996
Innovations in pharmacological treatment of heart failure.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Innovations in pharmacological treatment of heart failure.,improvement,0.36781824,return,0.5283363,congestive,0.42538065
Innovations in pharmacological treatment of heart failure.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Innovations in pharmacological treatment of heart failure.,mellitus,0.3682191,congestive,0.568745,congestive,0.568745
Innovations in pharmacological treatment of heart failure.,diabetes-mellitus,0.33340782,chd,0.5153306,chd,0.5153306
Innovations in pharmacological treatment of heart failure.,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
Innovations in pharmacological treatment of heart failure.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Innovations in pharmacological treatment of heart failure.,acei,0.42623463,congestive-heart-failure,0.5122055,congestive-heart-failure,0.5122055
Innovations in pharmacological treatment of heart failure.,according,0.3426876,as,0.48304257,rai,0.3796531
Innovations in pharmacological treatment of heart failure.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Innovations in pharmacological treatment of heart failure.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Innovations in pharmacological treatment of heart failure.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Innovations in pharmacological treatment of heart failure.,drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
Innovations in pharmacological treatment of heart failure.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Innovations in pharmacological treatment of heart failure.,acei,0.42623463,congestive-heart-failure,0.5122055,congestive-heart-failure,0.5122055
Innovations in pharmacological treatment of heart failure.,valsartan,0.35073355,heart-failure,0.4610226,heart-failure,0.4610226
Innovations in pharmacological treatment of heart failure.,transporter,0.19359003,cholesterol,0.38158947,cholesterol,0.38158947
Innovations in pharmacological treatment of heart failure.,sodium,0.23421176,of,0.40018386,cholesterol,0.38060108
Innovations in pharmacological treatment of heart failure.,sacubitril,0.3795854,heart-failure,0.49538177,heart-failure,0.49538177
Innovations in pharmacological treatment of heart failure.,results,0.29712585,of,0.53157276,blood,0.36869162
Innovations in pharmacological treatment of heart failure.,replace,0.32033384,as,0.49907616,cardiac,0.32699728
Innovations in pharmacological treatment of heart failure.,quality,0.3148893,of,0.4192715,heartbeat,0.36860457
Innovations in pharmacological treatment of heart failure.,pmid,0.19630215,congestive,0.25211734,congestive,0.25211734
Innovations in pharmacological treatment of heart failure.,paradigm,0.2731577,of,0.36300784,venous-return,0.34979025
Innovations in pharmacological treatment of heart failure.,oedema,0.21230796,congestive,0.48717323,congestive,0.48717323
Innovations in pharmacological treatment of heart failure.,mra,0.37676618,tof,0.5229811,tof,0.5229811
Innovations in pharmacological treatment of heart failure.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Innovations in pharmacological treatment of heart failure.,morbidity,0.31568646,chd,0.50165594,chd,0.50165594
Innovations in pharmacological treatment of heart failure.,medline,0.3928258,cardiology,0.3928258,cardiology,0.3928258
Innovations in pharmacological treatment of heart failure.,life,0.2837531,of,0.41541263,single-ventricle,0.3985506
Innovations in pharmacological treatment of heart failure.,innovations,0.46606797,great,0.5164236,cardiology,0.46606797
Innovations in pharmacological treatment of heart failure.,indicated,0.26161766,of,0.5998554,cardiac,0.3719351
Innovations in pharmacological treatment of heart failure.,indexed,0.4001288,left-atrial,0.43542364,left-atrial,0.43542364
Innovations in pharmacological treatment of heart failure.,hospitalisations,0.441966,chd,0.53085876,chd,0.53085876
Innovations in pharmacological treatment of heart failure.,given,0.43020725,with,0.60330975,cardiology,0.43020725
Innovations in pharmacological treatment of heart failure.,dyspnoe,0.33702984,congestive,0.54855585,congestive,0.54855585
Innovations in pharmacological treatment of heart failure.,done,0.497195,with,0.531319,cardiology,0.497195
Innovations in pharmacological treatment of heart failure.,diuretics,0.39986306,congestive,0.593751,congestive,0.593751
Innovations in pharmacological treatment of heart failure.,digoxin,0.41813317,bradycardia,0.5069326,bradycardia,0.5069326
Innovations in pharmacological treatment of heart failure.,decrease,0.28522113,of,0.5904174,flow,0.42153293
Innovations in pharmacological treatment of heart failure.,cornerstone,0.37181455,great,0.47487095,congestive-heart-failure,0.37868112
Innovations in pharmacological treatment of heart failure.,case,0.3395801,of,0.56877625,anomaly,0.566621
Innovations in pharmacological treatment of heart failure.,betablockers,0.57088906,arrythmia,0.6333252,arrythmia,0.6333252
Innovations in pharmacological treatment of heart failure.,arni,0.37920314,congestive-heart-failure,0.46047437,congestive-heart-failure,0.46047437
Innovations in pharmacological treatment of heart failure.,arb,0.29520378,heart-failure,0.41936678,heart-failure,0.41936678
Innovations in pharmacological treatment of heart failure.,added,0.39393532,with,0.6052638,cardiology,0.39393532
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,showed,0.21619865,with,0.57298803,flow,0.33828264
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,improvement,0.36781824,return,0.5283363,congestive,0.42538065
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed-model,0.21347384,venous-return,0.44460833,venous-return,0.44460833
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,significant-improvement,0.3867895,with,0.48818237,congestive-heart-failure,0.48615187
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mmrc,0.30804065,rai,0.38027537,rai,0.38027537
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.3946247,cad,0.631319,cad,0.631319
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-assessment,0.4488905,congestive-heart-failure,0.49624246,congestive-heart-failure,0.49624246
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,assessment-test,0.37904495,venous-return,0.40948862,venous-return,0.40948862
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-assessment-test,0.39544398,coronary-artery-disease,0.47456968,coronary-artery-disease,0.47456968
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,modified,0.17522426,with,0.4820255,l-transposition,0.37445945
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,medical,0.6019881,cardiology,0.6019881,cardiology,0.6019881
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,research,0.4363063,great,0.4769435,cardiology,0.4363063
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,council,0.5676553,cardiology,0.5676553,cardiology,0.5676553
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,medical-research,0.49447146,cardiology,0.49447146,cardiology,0.49447146
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,research-council,0.5378105,cardiology,0.5378105,cardiology,0.5378105
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive,0.35222226,congestive,0.6328302,congestive,0.6328302
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic-obstructive,0.35541248,congestive,0.63991463,congestive,0.63991463
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive-pulmonary,0.38661033,pulmonary,0.7739995,pulmonary,0.7739995
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pulmonary-disease,0.37958944,pulmonary,0.7568126,pulmonary,0.7568126
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive,0.35222226,congestive,0.6328302,congestive,0.6328302
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic-obstructive,0.35541248,congestive,0.63991463,congestive,0.63991463
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive-lung,0.34715056,pulmonary,0.62696815,pulmonary,0.62696815
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,lung-disease,0.25834516,heart-disease,0.6463438,heart-disease,0.6463438
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,incorporates,0.22571635,of,0.47206804,venous-return,0.32319444
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously,0.21411541,as,0.54924536,l-transposition,0.42639655
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,parameters,0.27392536,of,0.4824913,flow,0.4253655
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously-proposed,0.18834867,of,0.50219274,venous-return,0.4176556
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously,0.21411541,as,0.54924536,l-transposition,0.42639655
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,reported,0.2535432,of,0.6039252,l-transposition,0.37000108
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.39955616,pulmonary,0.4980424,pulmonary,0.4980424
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously-reported,0.17569958,of,0.54962975,l-transposition,0.41867954
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,top,0.40076846,with,0.45628595,cardiology,0.40076846
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,global,0.29951438,of,0.4575415,right-ventricle,0.43006864
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,causes,0.22412287,of,0.55089116,congenital,0.49946666
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.3946247,cad,0.631319,cad,0.631319
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,within,0.30995527,of,0.57602364,deposits,0.42065546
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-patients,0.37116832,heart-failure,0.57114255,heart-failure,0.57114255
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients-within,0.3861819,congenital-heart-disease,0.5124204,congenital-heart-disease,0.5124204
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,cat,0.2539535,with,0.43162376,l-transposition,0.42415437
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,worn,0.28654796,stiff,0.49565277,valve,0.41449967
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,devices,0.3350111,single-ventricle,0.42037934,single-ventricle,0.42037934
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,wearable-devices,0.32403013,venous-return,0.47007155,venous-return,0.47007155
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,positive-prediction,0.32828933,congestive-heart-failure,0.4762977,congestive-heart-failure,0.4762977
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prediction-rate,0.24203561,venous-return,0.4927462,venous-return,0.4927462
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,minute,0.35392132,beats,0.61599827,beats,0.61599827
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,walking,0.25689575,stiff,0.45671353,heartbeat,0.42071927
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,distance,0.2336839,l-transposition,0.38519037,l-transposition,0.38519037
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,minute-walking,0.31540745,beats,0.5173295,beats,0.5173295
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,walking-distance,0.22527464,blood-flow,0.44144648,blood-flow,0.44144648
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,million,0.28288653,single,0.38531932,chd,0.35294682
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,lives,0.34364155,return,0.4625753,cad,0.35607928
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.3946247,cad,0.631319,cad,0.631319
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-patients,0.37116832,heart-failure,0.57114255,heart-failure,0.57114255
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.45830208,failure,0.52697515,chd,0.50281084
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,criteria,0.37083983,syndrome,0.39697075,syndrome,0.39697075
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ranked,0.37995976,as,0.51157963,cardiology,0.37995976
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,among,0.2573181,of,0.57348,chd,0.4274787
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physicians,0.6084627,cardiology,0.6084627,cardiology,0.6084627
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day,0.42316434,with,0.4708514,cardiology,0.42316434
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.45830208,failure,0.52697515,chd,0.50281084
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day-readmission,0.50799346,cardiology,0.50799346,cardiology,0.50799346
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission-risk,0.40380752,heart-failure,0.5298158,heart-failure,0.5298158
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,continuous,0.27512568,of,0.5723764,flow,0.484856
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.39955616,pulmonary,0.4980424,pulmonary,0.4980424
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa-monitoring,0.44269663,cardiology,0.44269663,cardiology,0.44269663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,existing,0.31199914,of,0.558287,venous-return,0.39574036
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed-model,0.21347384,venous-return,0.44460833,venous-return,0.44460833
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.3946247,cad,0.631319,cad,0.631319
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-patients,0.37116832,heart-failure,0.57114255,heart-failure,0.57114255
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test-subjects,0.21879548,heartbeat,0.42249364,heartbeat,0.42249364
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,clinical-assessment,0.44768912,artery-disease,0.46106637,artery-disease,0.46106637
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,qoa,0.19422291,lai,0.3219051,lai,0.3219051
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic-diseases,0.2730207,disease,0.6364124,heart-disease,0.6249868
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,statistical,0.32752115,of,0.40241736,congenital-heart-disease,0.36489835
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,statistical-model,0.32528663,congenital-heart-disease,0.42511737,congenital-heart-disease,0.42511737
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.45830208,failure,0.52697515,chd,0.50281084
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission-risk,0.40380752,heart-failure,0.5298158,heart-failure,0.5298158
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,global,0.29951438,of,0.4575415,right-ventricle,0.43006864
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,initiative,0.46867347,disease,0.46967724,cardiology,0.46867347
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,within,0.30995527,of,0.57602364,deposits,0.42065546
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,claimed,0.28695095,of,0.5287969,lai,0.33879983
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prevention,0.37483034,thrombosis,0.45537552,thrombosis,0.45537552
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.45830208,failure,0.52697515,chd,0.50281084
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,highest,0.26377243,of,0.5054526,mi,0.33820426
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,among,0.2573181,of,0.57348,chd,0.4274787
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,days,0.30872357,return,0.45523614,beats,0.4033618
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,parameter,0.27155933,as,0.4758621,flow,0.44832006
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,daily,0.3620783,single,0.43283373,heartbeat,0.36777166
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,living,0.2469504,of,0.47259963,deposits,0.36684513
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,daily-living,0.24739212,heart-failure,0.39449167,heart-failure,0.39449167
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,airflow,0.17025867,flow,0.51951516,flow,0.51951516
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstruction,0.2751228,stenosis,0.7130081,stenosis,0.7130081
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,airflow-obstruction,0.28016117,stenosis,0.6463892,stenosis,0.6463892
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,adopted,0.30375072,of,0.520591,single-ventricle,0.36077982
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,currently,0.4246831,of,0.5011201,cardiology,0.4246831
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,regularity,0.31836182,irregular,0.6917269,heartbeat,0.542221
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27677816,total,0.43109894,mi,0.39722836
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,regularity-index,0.24477331,irregular,0.4507776,heartbeat,0.44465485
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mass,0.21939,tof,0.43280137,tof,0.43280137
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27677816,total,0.43109894,mi,0.39722836
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mass-index,0.21219103,tof,0.35847235,tof,0.35847235
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physical,0.35664004,of,0.4425894,pulmonary,0.40153936
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physical-activity,0.27924114,of,0.43971512,chd,0.38809615
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,0.2494699,of,0.5443143,flow,0.34116954
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,wrist,0.32824314,right,0.5270491,venous,0.3968189
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,0.2494699,of,0.5443143,flow,0.34116954
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,indices,0.26546282,with,0.45559487,flow,0.43359074
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27677816,total,0.43109894,mi,0.39722836
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity-index,0.2526971,venous-return,0.438861,venous-return,0.438861
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital,0.5604328,cardiology,0.5604328,cardiology,0.5604328
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharge,0.4181137,return,0.5084258,infarction,0.44288716
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital-discharge,0.5148983,cardiology,0.5148983,cardiology,0.5148983
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.3946247,cad,0.631319,cad,0.631319
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.39955616,pulmonary,0.4980424,pulmonary,0.4980424
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,monitoring,0.39516973,of,0.47910637,flow,0.41718978
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27677816,total,0.43109894,mi,0.39722836
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,0.2494699,of,0.5443143,flow,0.34116954
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital,0.5604328,cardiology,0.5604328,cardiology,0.5604328
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharge,0.4181137,return,0.5084258,infarction,0.44288716
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,days,0.30872357,return,0.45523614,beats,0.4033618
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,sensitivity,0.21446684,of,0.47228155,flow,0.3595773
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ri,0.20611401,rai,0.45955482,rai,0.45955482
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,quality,0.3148893,of,0.4192715,heartbeat,0.36860457
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predicting,0.21648464,of,0.49732292,single-ventricle,0.35703716
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,paper,0.30468726,of,0.4606573,anomaly,0.36774796
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,moreover,0.16758724,of,0.5596781,plaque-deposits,0.35056823
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,introduced,0.295581,of,0.506906,l-transposition,0.39756888
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,gold,0.3219332,great,0.4375779,deposits,0.4183383
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,found,0.2675444,with,0.6275196,deposits,0.41920424
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,exercise,0.41859597,myocardial,0.5311478,myocardial,0.5311478
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,dyspnea,0.4236763,congestive,0.58805686,congestive,0.58805686
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharged,0.47408852,return,0.5059653,cardiology,0.47408852
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosed,0.34882253,congenital,0.5294275,congenital,0.5294275
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,data,0.31118363,of,0.5086956,mi,0.36251363
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,compared,0.26227483,with,0.62448335,mi,0.40925252
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,body,0.2371722,of,0.4173455,heartbeat,0.41062886
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,bode,0.32217985,congestive-heart-failure,0.41827625,congestive-heart-failure,0.41827625
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ai,0.21328095,rai,0.46950763,rai,0.46950763
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,accelerometer,0.27550948,heartbeat,0.46706662,heartbeat,0.46706662
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,bone,0.23573479,defect,0.426777,hypoplastic,0.42452562
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,marrow,0.2889946,blood,0.46922213,blood,0.46922213
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hematopoietic,0.28767306,blood,0.41977215,blood,0.41977215
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,stem,0.2528829,hypoplastic,0.38906342,hypoplastic,0.38906342
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cell,0.21863139,of,0.48460138,flow,0.38218224
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,bone-marrow,0.22534117,congenital-heart-disease,0.45402026,congenital-heart-disease,0.45402026
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,marrow-hematopoietic,0.22854361,hypoplastic,0.44841838,hypoplastic,0.44841838
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hematopoietic-stem,0.25372702,hypoplastic,0.42103457,hypoplastic,0.42103457
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,stem-cell,0.3073024,failure,0.40953812,single-ventricle,0.40389973
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hematopoietic-stem-cell,0.2750766,congenital-heart-disease,0.42507878,congenital-heart-disease,0.42507878
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,+/,0.20291029,septal-defect,0.33183157,septal-defect,0.33183157
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.23466776,pulmonary,0.50629014,pulmonary,0.50629014
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expansion,0.2473918,of,0.470402,flow,0.44736823
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hsc,0.26770616,hlhs,0.37196794,hlhs,0.37196794
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2188845,with,0.40949196,mi,0.36250302
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increased,0.32251194,of,0.64014816,mi,0.42637154
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice-exhibited,0.18049173,septal-defect,0.46227214,septal-defect,0.46227214
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytokine,0.17348188,of,0.3953519,flow,0.37844837
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory-cytokine,0.18650529,disease,0.4168914,congenital-heart-disease,0.3819989
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytokine-gene,0.14964779,congenital-heart-disease,0.35285103,congenital-heart-disease,0.35285103
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,gene-expression,0.22584388,of,0.41557923,l-transposition,0.3919022
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk,0.1421085,cholesterol,0.42106873,cholesterol,0.42106873
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac,0.17150196,atresia,0.5105675,atresia,0.5105675
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,origin,0.29532364,of,0.56003475,anomalous,0.5212826
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,drive,0.31886464,of,0.50037575,flow,0.43926787
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk-sac,0.13138737,atresia,0.398807,atresia,0.398807
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac-origin,0.19297066,l-transposition,0.54514825,l-transposition,0.54514825
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,flow,0.27540267,flow,1.0,flow,1.0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytometry,0.26987028,flow,0.60937023,flow,0.60937023
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,showed,0.21619865,with,0.57298803,flow,0.33828264
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,flow-cytometry,0.2276194,flow,0.5899704,flow,0.5899704
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,+/,0.20291029,septal-defect,0.33183157,septal-defect,0.33183157
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription,0.23967603,l-transposition,0.42481855,l-transposition,0.42481855
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors,0.24127257,of,0.49770784,chd,0.4172811
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent-transcription,0.27558154,of,0.4680979,l-transposition,0.42129436
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription-factors,0.21108805,l-transposition,0.4212831,l-transposition,0.4212831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors-involved,0.18090837,of,0.46247655,chd,0.36816162
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcriptional,0.24623448,l-transposition,0.44111192,l-transposition,0.44111192
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal,0.2773772,irregular,0.5422323,deposits,0.45507878
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,adhesion,0.16068175,blood-clot,0.42889386,blood-clot,0.42889386
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,kinase,0.17639789,of,0.32242787,myocardial,0.3009235
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal-adhesion,0.1778611,plaque-deposits,0.3812212,plaque-deposits,0.3812212
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,adhesion-kinase,0.18050414,coronary-thrombosis,0.37123415,coronary-thrombosis,0.37123415
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal-adhesion-kinase,0.18129545,myocardial-infarction,0.36763996,myocardial-infarction,0.36763996
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,downstream,0.20581535,of,0.42049676,l-transposition,0.37191287
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription,0.23967603,l-transposition,0.42481855,l-transposition,0.42481855
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors,0.24127257,of,0.49770784,chd,0.4172811
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription-factors,0.21108805,l-transposition,0.4212831,l-transposition,0.4212831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,response,0.2306606,of,0.52661085,contractions,0.38512754
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tissue-inflammatory,0.18271926,disease,0.46779728,blood-clot,0.44000918
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory-response,0.189253,of,0.4226144,artery-disease,0.39525625
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,arg,0.17173278,weak,0.30860084,l-tga,0.29769492
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,days,0.30872357,return,0.45523614,beats,0.4033618
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,post,0.3914922,failure,0.52308416,mi,0.5076717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,days-post,0.28726304,mi,0.43326238,mi,0.43326238
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.18690082,contractions,0.32064483,contractions,0.32064483
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inhibitor,0.23137593,of,0.37385303,congestive,0.302135
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,abrogated,0.16960719,of,0.37522316,contractions,0.30553448
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak-inhibitor,0.23039047,coronary-thrombosis,0.348888,coronary-thrombosis,0.348888
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inhibitor-abrogated,0.27934843,with,0.43041614,congestive-heart-failure,0.36518198
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cultured,0.28568515,isolated,0.63048816,blood,0.42295426
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,confirmed,0.27861494,of,0.58156097,anomalous,0.39478707
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.17815778,of,0.3472669,pulmonary,0.33981717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytokines,0.19207579,of,0.3877709,blood,0.33112538
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,response,0.2306606,of,0.52661085,contractions,0.38512754
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory-cytokines,0.16295479,of,0.3482368,heart-attack,0.3439548
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,causes,0.22412287,of,0.55089116,congenital,0.49946666
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.3771478,heart-disease,0.56711507,heart-disease,0.56711507
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.1929965,isolated,0.4683736,paivs,0.41344762
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected-mice,0.15364057,plaque-deposits,0.41433698,plaque-deposits,0.41433698
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice-treated,0.12951848,plaque-deposits,0.4405052,plaque-deposits,0.4405052
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically,0.22403723,with,0.4769764,heart-failure,0.40299213
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.1929965,isolated,0.4683736,paivs,0.41344762
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically-infected,0.1513539,congenital-heart-disease,0.44629586,congenital-heart-disease,0.44629586
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected-mice,0.15364057,plaque-deposits,0.41433698,plaque-deposits,0.41433698
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription,0.23967603,l-transposition,0.42481855,l-transposition,0.42481855
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors,0.24127257,of,0.49770784,chd,0.4172811
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription-factors,0.21108805,l-transposition,0.4212831,l-transposition,0.4212831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.1929965,isolated,0.4683736,paivs,0.41344762
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected-mice,0.15364057,plaque-deposits,0.41433698,plaque-deposits,0.41433698
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pathology,0.41792482,disease,0.61009455,deposits,0.5100304
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,0.32113555,of,0.60061187,flow,0.4086165
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,response,0.2306606,of,0.52661085,contractions,0.38512754
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.3771478,heart-disease,0.56711507,heart-disease,0.56711507
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.19391358,with,0.4337707,septal-defect,0.43083143
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.3771478,heart-disease,0.56711507,heart-disease,0.56711507
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.23466776,pulmonary,0.50629014,pulmonary,0.50629014
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2188845,with,0.40949196,mi,0.36250302
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,surface,0.17955789,of,0.46375725,deposits,0.44493395
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,surface-expression,0.16649804,of,0.4269124,lai,0.36484253
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.17815778,of,0.3472669,pulmonary,0.33981717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2188845,with,0.40949196,mi,0.36250302
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.23466776,pulmonary,0.50629014,pulmonary,0.50629014
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,compartment,0.20287497,defect,0.4576366,flow,0.41539007
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.23466776,pulmonary,0.50629014,pulmonary,0.50629014
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.1929965,isolated,0.4683736,paivs,0.41344762
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,trypanosoma,0.23610508,congenital-heart-disease,0.35797605,congenital-heart-disease,0.35797605
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cruzi,0.24940075,congenital-heart-disease,0.37454373,congenital-heart-disease,0.37454373
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,trypanosoma-cruzi,0.22588655,congenital-heart-disease,0.36913267,congenital-heart-disease,0.36913267
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sinusoidal,0.21522875,blood-flow,0.5121498,blood-flow,0.5121498
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,compartment,0.20287497,defect,0.4576366,flow,0.41539007
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,regulatory,0.26011577,of,0.45470995,cardiac,0.32849365
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,role,0.263546,of,0.49928063,anomalous,0.31226397
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.17815778,of,0.3472669,pulmonary,0.33981717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.17815778,of,0.3472669,pulmonary,0.33981717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,progenitor,0.266005,l-transposition,0.39856228,l-transposition,0.39856228
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,lineage,0.27720666,l-transposition,0.41267246,l-transposition,0.41267246
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pathogen,0.20034528,disease,0.4754871,heart-attack,0.35139495
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,stimulus,0.25988656,contractions,0.48612675,contractions,0.48612675
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proliferation,0.20616576,of,0.43228433,flow,0.40051088
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,contributing,0.2795704,of,0.63864183,chd,0.39223114
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myocardial,0.5198858,myocardial,1.0,myocardial,1.0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infiltration,0.184309,deposits,0.59239906,deposits,0.59239906
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,latin,0.39092642,congenital-heart-disease,0.4145373,congenital-heart-disease,0.4145373
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,america,0.41241246,cardiology,0.41241246,cardiology,0.41241246
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,latin-america,0.4110734,congenital-heart-disease,0.44491065,congenital-heart-disease,0.44491065
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inherent,0.24251254,great,0.58417034,anomalous,0.4908172
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,capability,0.20955494,great,0.5056628,flow,0.37804663
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infection,0.26741225,disease,0.482216,thrombosis,0.44838145
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,heart,0.57664216,heart,1.0,heart,1.0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,functional,0.2048316,of,0.51558334,l-transposition,0.40613407
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,frequent,0.37584627,irregular,0.537652,arrythmia,0.4617986
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phase,0.19908471,of,0.4318388,flow,0.38942474
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic-phase,0.24897382,heart-failure,0.43671107,heart-failure,0.43671107
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,also,0.36015856,of,0.65908813,flow,0.41040578
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,detected,0.22363131,isolated,0.58991337,deposits,0.39107472
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,agonistic,0.1575054,weak,0.463828,contractions,0.4256629
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,acute,0.3642026,infarction,0.6294521,infarction,0.6294521
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,parasitemia,0.21549477,blood,0.4622918,blood,0.4622918
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,reprogrammed,0.3740701,l-transposition,0.43841887,l-transposition,0.43841887
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dampened,0.33693334,return,0.49796277,venous,0.47092605
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.18690082,contractions,0.32064483,contractions,0.32064483
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,agonist,0.15691051,contractions,0.4673999,contractions,0.4673999
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cd,0.17779362,with,0.38340542,isomerism,0.34715796
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,0.32113555,of,0.60061187,flow,0.4086165
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced-increase,0.272246,of,0.46977872,cardiac,0.38554123
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk,0.1421085,cholesterol,0.42106873,cholesterol,0.42106873
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,showed,0.21619865,with,0.57298803,flow,0.33828264
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac,0.17150196,atresia,0.5105675,atresia,0.5105675
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increased,0.32251194,of,0.64014816,mi,0.42637154
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2188845,with,0.40949196,mi,0.36250302
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.23466776,pulmonary,0.50629014,pulmonary,0.50629014
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.1929965,isolated,0.4683736,paivs,0.41344762
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.17815778,of,0.3472669,pulmonary,0.33981717
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.18690082,contractions,0.32064483,contractions,0.32064483
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically,0.22403723,with,0.4769764,heart-failure,0.40299213
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.3771478,heart-disease,0.56711507,heart-disease,0.56711507
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,0.32113555,of,0.60061187,flow,0.4086165
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cd,0.17779362,with,0.38340542,isomerism,0.34715796
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,untreated,0.17660084,with,0.5793234,arteries,0.41665173
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tnf,0.18194897,cholesterol,0.28765774,cholesterol,0.28765774
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tc,0.225782,cholesterol,0.47715437,cholesterol,0.47715437
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,results,0.29712585,of,0.53157276,blood,0.36869162
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,respond,0.27449912,with,0.48762062,contractions,0.3223437
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pu,0.19442876,plaque-deposits,0.3441307,plaque-deposits,0.3441307
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phosphorylation,0.18752447,of,0.40713966,contractions,0.3800071
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,nf,0.21206217,eb,0.44363278,eb,0.44363278
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myocardium,0.38313717,myocardial,0.8277121,myocardial,0.8277121
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myb,0.15741849,l-transposition,0.31952864,l-transposition,0.31952864
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,monocytes,0.214702,blood,0.43067652,blood,0.43067652
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,monitored,0.3408969,with,0.53855443,flow,0.4368319
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,modulating,0.21320769,of,0.54269326,anomalous,0.34101686
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,migration,0.19722623,of,0.40778574,flow,0.39647174
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,maturation,0.2208648,of,0.4923094,atresia,0.44108218
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,markers,0.24214233,of,0.43581337,deposits,0.3556608
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,instead,0.29061213,as,0.61385596,anomalous,0.41405156
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,il,0.24051979,mi,0.30050132,mi,0.30050132
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,however,0.30646515,of,0.624624,mi,0.41109186
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,examined,0.2811494,of,0.66699874,flow,0.35738647
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,determined,0.24003299,of,0.6221287,flow,0.40728092
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,controlling,0.20302527,of,0.547873,heart-attack,0.35725042
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,control,0.26906762,with,0.5145365,mi,0.4093958
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,c,0.21239448,with,0.46990636,ivs,0.34813386
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,background,0.2325702,of,0.51277274,congenital,0.3895001
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,anti,0.24353361,weak,0.4726881,isomerism,0.366829
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,alter,0.19845097,of,0.49618223,contractions,0.33163282
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,acutely,0.3240602,with,0.49640208,cardiac,0.44301462
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multivariable,0.28924093,chd,0.42614138,chd,0.42614138
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cox,0.23944235,congestive,0.35998437,congestive,0.35998437
Mood disorders and increased risk of non-communicable disease in adults with HIV.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Mood disorders and increased risk of non-communicable disease in adults with HIV.,estimated,0.2633227,of,0.52809477,chd,0.38898614
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Mood disorders and increased risk of non-communicable disease in adults with HIV.,following,0.33078983,with,0.61268795,cardiac,0.4240192
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.38587958,chd,0.55558735,chd,0.55558735
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cox-models,0.23723227,artery-disease,0.44298136,artery-disease,0.44298136
Mood disorders and increased risk of non-communicable disease in adults with HIV.,models-estimated,0.2659646,venous-return,0.41469836,venous-return,0.41469836
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality-risk,0.34252965,chd,0.574576,chd,0.574576
Mood disorders and increased risk of non-communicable disease in adults with HIV.,examined,0.2811494,of,0.66699874,flow,0.35738647
Mood disorders and increased risk of non-communicable disease in adults with HIV.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Mood disorders and increased risk of non-communicable disease in adults with HIV.,prevalent,0.24773857,disease,0.4662928,chd,0.3997063
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.32260993,tachycardia,0.40858436,tachycardia,0.40858436
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.30838862,congenital,0.5785017,congenital,0.5785017
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorders,0.28033727,chd,0.44165903,chd,0.44165903
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Mood disorders and increased risk of non-communicable disease in adults with HIV.,following,0.33078983,with,0.61268795,cardiac,0.4240192
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.38587958,chd,0.55558735,chd,0.55558735
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality-risk,0.34252965,chd,0.574576,chd,0.574576
Mood disorders and increased risk of non-communicable disease in adults with HIV.,obesity,0.37162852,chd,0.5639055,chd,0.5639055
Mood disorders and increased risk of non-communicable disease in adults with HIV.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Mood disorders and increased risk of non-communicable disease in adults with HIV.,kidney,0.29311,heart,0.5663165,heart,0.5663165
Mood disorders and increased risk of non-communicable disease in adults with HIV.,chronic-kidney,0.2801576,congestive-heart-failure,0.55901396,congestive-heart-failure,0.55901396
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.39301777,with,0.49337357,chd,0.47681805
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.38587958,chd,0.55558735,chd,0.55558735
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adult,0.24953824,congenital-heart-disease,0.48874018,congenital-heart-disease,0.48874018
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
Mood disorders and increased risk of non-communicable disease in adults with HIV.,clinic,0.60041374,cardiology,0.60041374,cardiology,0.60041374
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv-clinic,0.40084535,congenital-heart-disease,0.45865262,congenital-heart-disease,0.45865262
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.32260993,tachycardia,0.40858436,tachycardia,0.40858436
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.30838862,congenital,0.5785017,congenital,0.5785017
Mood disorders and increased risk of non-communicable disease in adults with HIV.,documented,0.38350958,of,0.6228255,flow,0.42305836
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorders,0.28033727,chd,0.44165903,chd,0.44165903
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.32260993,tachycardia,0.40858436,tachycardia,0.40858436
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
Mood disorders and increased risk of non-communicable disease in adults with HIV.,diagnosed,0.34882253,congenital,0.5294275,congenital,0.5294275
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorder,0.23823923,chd,0.4242741,chd,0.4242741
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorder-diagnosed,0.28487632,anomaly,0.5218072,anomaly,0.5218072
Mood disorders and increased risk of non-communicable disease in adults with HIV.,bipolar,0.2476278,fibrillation,0.41859427,fibrillation,0.41859427
Mood disorders and increased risk of non-communicable disease in adults with HIV.,affective,0.33389944,congenital-heart-disease,0.4261326,congenital-heart-disease,0.4261326
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
Mood disorders and increased risk of non-communicable disease in adults with HIV.,bipolar-affective,0.23901528,congenital-heart-disease,0.40881294,congenital-heart-disease,0.40881294
Mood disorders and increased risk of non-communicable disease in adults with HIV.,affective-disorder,0.21853262,congenital-heart-disease,0.4580214,congenital-heart-disease,0.4580214
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adjusted,0.3251242,chd,0.47266376,chd,0.47266376
Mood disorders and increased risk of non-communicable disease in adults with HIV.,subhazard,0.28129518,chd,0.4185472,chd,0.4185472
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ratios,0.16654095,double,0.37118572,tof,0.36179096
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adjusted,0.3251242,chd,0.47266376,chd,0.47266376
Mood disorders and increased risk of non-communicable disease in adults with HIV.,subhazard,0.28129518,chd,0.4185472,chd,0.4185472
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ratio,0.18660581,total,0.40182298,tof,0.36502323
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.3605017,chd,0.577151,chd,0.577151
Mood disorders and increased risk of non-communicable disease in adults with HIV.,may,0.26963884,of,0.58654004,anomalous,0.366544
Mood disorders and increased risk of non-communicable disease in adults with HIV.,reduce,0.22618136,of,0.4876061,heart-attack,0.3512283
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,year,0.39816982,failure,0.4387355,mi,0.41719383
Mood disorders and increased risk of non-communicable disease in adults with HIV.,particularly,0.31718573,of,0.62868786,deposits,0.41094124
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Mood disorders and increased risk of non-communicable disease in adults with HIV.,syndrome,0.2608677,syndrome,1.0,syndrome,1.0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic-syndrome,0.3159048,heart-syndrome,0.7020769,heart-syndrome,0.7020769
Mood disorders and increased risk of non-communicable disease in adults with HIV.,experience,0.38681114,of,0.5036937,congenital-heart-disease,0.45451656
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high,0.28122714,of,0.57459104,flow,0.3923195
Mood disorders and increased risk of non-communicable disease in adults with HIV.,rates,0.26658094,of,0.47081333,flow,0.4277016
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high-rates,0.24454737,of,0.45933485,deposits,0.39863217
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.3605017,chd,0.577151,chd,0.577151
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.39301777,with,0.49337357,chd,0.47681805
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.3605017,chd,0.577151,chd,0.577151
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.21835357,chd,0.45354134,chd,0.45354134
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.32260993,tachycardia,0.40858436,tachycardia,0.40858436
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.30838862,congenital,0.5785017,congenital,0.5785017
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorders,0.28033727,chd,0.44165903,chd,0.44165903
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.39301777,with,0.49337357,chd,0.47681805
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.3605017,chd,0.577151,chd,0.577151
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Mood disorders and increased risk of non-communicable disease in adults with HIV.,group,0.2849201,with,0.5052614,mi,0.411738
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk-group,0.32744563,chd,0.50394654,chd,0.50394654
Mood disorders and increased risk of non-communicable disease in adults with HIV.,increased,0.32251194,of,0.64014816,mi,0.42637154
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Mood disorders and increased risk of non-communicable disease in adults with HIV.,increased-risk,0.38663232,chd,0.54914963,chd,0.54914963
Mood disorders and increased risk of non-communicable disease in adults with HIV.,competing,0.29386833,of,0.49241257,heart-attack,0.37648118
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Mood disorders and increased risk of non-communicable disease in adults with HIV.,competing-risk,0.34497595,chd,0.51093966,chd,0.51093966
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Mood disorders and increased risk of non-communicable disease in adults with HIV.,syndrome,0.2608677,syndrome,1.0,syndrome,1.0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic-syndrome,0.3159048,heart-syndrome,0.7020769,heart-syndrome,0.7020769
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
Mood disorders and increased risk of non-communicable disease in adults with HIV.,year,0.39816982,failure,0.4387355,mi,0.41719383
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first-year,0.4781972,cardiology,0.4781972,cardiology,0.4781972
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.38587958,chd,0.55558735,chd,0.55558735
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ci,0.26988983,congestive,0.4084356,congestive,0.4084356
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Mood disorders and increased risk of non-communicable disease in adults with HIV.,period,0.34860444,return,0.46809125,venous-return,0.39146286
Mood disorders and increased risk of non-communicable disease in adults with HIV.,study-period,0.33556777,venous-return,0.4602302,venous-return,0.4602302
Mood disorders and increased risk of non-communicable disease in adults with HIV.,people,0.32132432,chd,0.4550472,chd,0.4550472
Mood disorders and increased risk of non-communicable disease in adults with HIV.,living,0.2469504,of,0.47259963,deposits,0.36684513
Mood disorders and increased risk of non-communicable disease in adults with HIV.,people-living,0.2926893,chd,0.4129976,chd,0.4129976
Mood disorders and increased risk of non-communicable disease in adults with HIV.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Mood disorders and increased risk of non-communicable disease in adults with HIV.,depression,0.32770598,mi,0.47215778,mi,0.47215778
Mood disorders and increased risk of non-communicable disease in adults with HIV.,major-depression,0.26084903,tachycardia,0.45210528,tachycardia,0.45210528
Mood disorders and increased risk of non-communicable disease in adults with HIV.,liver,0.3089201,heart,0.53057235,heart,0.53057235
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Mood disorders and increased risk of non-communicable disease in adults with HIV.,liver-disease,0.26045334,disease,0.60845673,heart-disease,0.6064261
Mood disorders and increased risk of non-communicable disease in adults with HIV.,general,0.45452207,of,0.5577996,cardiology,0.45452207
Mood disorders and increased risk of non-communicable disease in adults with HIV.,population,0.3190225,of,0.49866888,chd,0.40046495
Mood disorders and increased risk of non-communicable disease in adults with HIV.,general-population,0.33551556,chd,0.4843045,chd,0.4843045
Mood disorders and increased risk of non-communicable disease in adults with HIV.,focused,0.3452875,of,0.5549927,cardiology,0.3452875
Mood disorders and increased risk of non-communicable disease in adults with HIV.,prevention,0.37483034,thrombosis,0.45537552,thrombosis,0.45537552
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.21835357,chd,0.45354134,chd,0.45354134
Mood disorders and increased risk of non-communicable disease in adults with HIV.,defining,0.28401682,of,0.5947579,anomaly,0.3484285
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cancers,0.2505658,disease,0.4458139,chd,0.42977926
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cumulative,0.223378,of,0.47800833,venous-return,0.37826067
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incidence,0.2980485,of,0.45446336,congenital,0.44341558
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cumulative-incidence,0.19561,congenital-heart-disease,0.4399032,congenital-heart-disease,0.4399032
Mood disorders and increased risk of non-communicable disease in adults with HIV.,confidence,0.2634279,chd,0.3685997,chd,0.3685997
Mood disorders and increased risk of non-communicable disease in adults with HIV.,interval,0.278329,congestive,0.41789418,congestive,0.41789418
Mood disorders and increased risk of non-communicable disease in adults with HIV.,confidence-interval,0.30343854,venous-return,0.40549245,venous-return,0.40549245
Mood disorders and increased risk of non-communicable disease in adults with HIV.,communicable,0.44860664,disease,0.53816366,congenital-heart-disease,0.5278866
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Mood disorders and increased risk of non-communicable disease in adults with HIV.,communicable-disease,0.40269086,disease,0.6205299,congenital-heart-disease,0.61042494
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusively,0.25337008,of,0.5433183,anomalous,0.38904467
Mood disorders and increased risk of non-communicable disease in adults with HIV.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusively-associated,0.21094178,of,0.5788169,deposits,0.40678114
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr,0.3592233,chd,0.42665493,chd,0.42665493
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ranging,0.30711752,with,0.48008,beats,0.3630554
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
Mood disorders and increased risk of non-communicable disease in adults with HIV.,clinic,0.60041374,cardiology,0.60041374,cardiology,0.60041374
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.3605017,chd,0.577151,chd,0.577151
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.21835357,chd,0.45354134,chd,0.45354134
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high,0.28122714,of,0.57459104,flow,0.3923195
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ci,0.26988983,congestive,0.4084356,congestive,0.4084356
Mood disorders and increased risk of non-communicable disease in adults with HIV.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr,0.3592233,chd,0.42665493,chd,0.42665493
Mood disorders and increased risk of non-communicable disease in adults with HIV.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Mood disorders and increased risk of non-communicable disease in adults with HIV.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Mood disorders and increased risk of non-communicable disease in adults with HIV.,tennessee,0.35353613,great,0.36740154,heart-attack,0.3579877
Mood disorders and increased risk of non-communicable disease in adults with HIV.,setting,0.5175974,failure,0.54691184,cardiology,0.5175974
Mood disorders and increased risk of non-communicable disease in adults with HIV.,results,0.29712585,of,0.53157276,blood,0.36869162
Mood disorders and increased risk of non-communicable disease in adults with HIV.,plwh,0.29586098,chd,0.46347034,chd,0.46347034
Mood disorders and increased risk of non-communicable disease in adults with HIV.,non,0.3477749,with,0.61364555,mi,0.46788454
Mood disorders and increased risk of non-communicable disease in adults with HIV.,nashville,0.44297355,cardiology,0.44297355,cardiology,0.44297355
Mood disorders and increased risk of non-communicable disease in adults with HIV.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Mood disorders and increased risk of non-communicable disease in adults with HIV.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hyperlipidemia,0.35826343,cholesterol,0.59936655,cholesterol,0.59936655
Mood disorders and increased risk of non-communicable disease in adults with HIV.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
Mood disorders and increased risk of non-communicable disease in adults with HIV.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Mood disorders and increased risk of non-communicable disease in adults with HIV.,dementia,0.3804462,disease,0.5290329,cad,0.49958262
Mood disorders and increased risk of non-communicable disease in adults with HIV.,death,0.30044052,failure,0.5122394,infarction,0.4996428
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Mood disorders and increased risk of non-communicable disease in adults with HIV.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Mood disorders and increased risk of non-communicable disease in adults with HIV.,calculated,0.2812017,of,0.47861123,anomalous,0.38671362
Mood disorders and increased risk of non-communicable disease in adults with HIV.,burden,0.27055943,disease,0.5228828,heart-disease,0.40476274
Mood disorders and increased risk of non-communicable disease in adults with HIV.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Mood disorders and increased risk of non-communicable disease in adults with HIV.,background,0.2325702,of,0.51277274,congenital,0.3895001
Mood disorders and increased risk of non-communicable disease in adults with HIV.,assessed,0.32085416,of,0.605934,flow,0.3956796
Mood disorders and increased risk of non-communicable disease in adults with HIV.,aids,0.33263704,congenital-heart-disease,0.4778832,congenital-heart-disease,0.4778832
Mood disorders and increased risk of non-communicable disease in adults with HIV.,accumulation,0.18045044,deposits,0.5375833,deposits,0.5375833
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ventricular,0.49640656,ventricular,1.0,ventricular,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.56890047,tachycardia,0.8145603,tachycardia,0.8145603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.2573181,of,0.57348,chd,0.4274787
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",danish,0.34904703,congenital-heart-disease,0.42653415,congenital-heart-disease,0.42653415
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",citizens,0.4502105,cardiology,0.4502105,cardiology,0.4502105
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",aged,0.28465265,with,0.40656772,congenital-heart-disease,0.40154532
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.52708566,atrial,1.0,atrial,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.5347377,fibrillation,1.0,fibrillation,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalization,0.4883753,failure,0.53211665,heart-failure,0.51238096
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.2573181,of,0.57348,chd,0.4274787
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",promethazine,0.26521116,bradycardia,0.4446783,bradycardia,0.4446783
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",users,0.2883557,congestive-heart-failure,0.38387084,congestive-heart-failure,0.38387084
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial-fibrillation,0.46922478,fibrillation,0.887709,fibrillation,0.887709
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ventricular,0.49640656,ventricular,1.0,ventricular,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.56890047,tachycardia,0.8145603,tachycardia,0.8145603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalizations,0.45230448,chd,0.5185937,chd,0.5185937
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher,0.2654187,with,0.56796193,mi,0.398535
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.2573181,of,0.57348,chd,0.4274787
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher-among,0.2667319,of,0.41036865,chd,0.38176197
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",found,0.2675444,with,0.6275196,deposits,0.41920424
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.2573181,of,0.57348,chd,0.4274787
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.52708566,atrial,1.0,atrial,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.5347377,fibrillation,1.0,fibrillation,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalizations,0.45230448,chd,0.5185937,chd,0.5185937
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial-fibrillation,0.46922478,fibrillation,0.887709,fibrillation,0.887709
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",prior,0.4127312,with,0.61325395,mi,0.4958433
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac,0.66620034,cardiac,1.0,cardiac,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.56890047,tachycardia,0.8145603,tachycardia,0.8145603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac-arrhythmia,0.62460613,cardiac,0.80060256,cardiac,0.80060256
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",statistically,0.22203454,with,0.41206974,chd,0.3633579
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",significant,0.2800444,great,0.554224,stenosis,0.40396324
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",differences,0.24501437,of,0.48845208,anomalous,0.3514788
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",statistically-significant,0.3079205,great,0.46452183,mitral-regurgitation,0.44900584
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",significant-differences,0.33371294,of,0.47654283,mi,0.4448076
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",regression-model,0.19899473,venous-return,0.41034126,venous-return,0.41034126
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic-regression-model,0.23356138,artery-disease,0.43839338,artery-disease,0.43839338
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conditional,0.23870562,double,0.4515407,septal-defect,0.43096223
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",inference,0.3017606,of,0.427243,mi,0.39377034
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",tree,0.2472718,stenosis,0.3753883,stenosis,0.3753883
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conditional-inference,0.253169,venous-return,0.5086335,venous-return,0.5086335
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",adjusted,0.3251242,chd,0.47266376,chd,0.47266376
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",odds,0.24028274,chd,0.47842962,chd,0.47842962
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ratios,0.16654095,double,0.37118572,tof,0.36179096
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",adjusted-odds,0.295285,chd,0.5323116,chd,0.5323116
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",odds-ratios,0.18273306,chd,0.46473777,chd,0.46473777
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute,0.3642026,infarction,0.6294521,infarction,0.6294521
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",myocardial,0.5198858,myocardial,1.0,myocardial,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",infarction,0.51348525,infarction,1.0,infarction,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute-myocardial,0.5089395,myocardial-infarction,0.8844812,myocardial-infarction,0.8844812
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",myocardial-infarction,0.5045562,myocardial-infarction,1.0,myocardial-infarction,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute-myocardial-infarction,0.5091164,myocardial-infarction,0.9688612,myocardial-infarction,0.9688612
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.52708566,atrial,1.0,atrial,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.5347377,fibrillation,1.0,fibrillation,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial-fibrillation,0.46922478,fibrillation,0.887709,fibrillation,0.887709
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",danish,0.34904703,congenital-heart-disease,0.42653415,congenital-heart-disease,0.42653415
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",registers,0.42113274,congenital-heart-disease,0.46249792,congenital-heart-disease,0.46249792
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac,0.66620034,cardiac,1.0,cardiac,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.56890047,tachycardia,0.8145603,tachycardia,0.8145603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac-arrhythmia,0.62460613,cardiac,0.80060256,cardiac,0.80060256
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",users,0.2883557,congestive-heart-failure,0.38387084,congestive-heart-failure,0.38387084
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",new-users,0.33975148,congestive-heart-failure,0.45775425,congestive-heart-failure,0.45775425
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",days,0.30872357,return,0.45523614,beats,0.4033618
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ci,0.26988983,congestive,0.4084356,congestive,0.4084356
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",found,0.2675444,with,0.6275196,deposits,0.41920424
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher,0.2654187,with,0.56796193,mi,0.398535
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher-risk,0.36496794,chd,0.5293444,chd,0.5293444
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",period,0.34860444,return,0.46809125,venous-return,0.39146286
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study-period,0.33556777,venous-return,0.4602302,venous-return,0.4602302
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study-outcomes,0.41471004,chd,0.47685623,chd,0.47685623
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",aimed,0.2731712,of,0.52896386,congenital,0.32137418
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study-aimed,0.43173265,cardiology,0.43173265,cardiology,0.43173265
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",respectively,0.23301381,with,0.4658343,mi,0.37010562
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant,0.3264072,of,0.5628227,anomalous,0.34380507
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",predictors,0.29199943,failure,0.45500726,congestive-heart-failure,0.42449278
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant,0.3264072,of,0.5628227,anomalous,0.34380507
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",predictor,0.24674982,as,0.45541835,chd,0.39992505
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",medical,0.6019881,cardiology,0.6019881,cardiology,0.6019881
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",history,0.40648568,with,0.47822285,arrythmia,0.4671815
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",medical-history,0.5424981,cardiology,0.5424981,cardiology,0.5424981
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",data,0.31118363,of,0.5086956,mi,0.36251363
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",sources,0.3096738,of,0.47692496,deposits,0.42191344
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",data-sources,0.38091695,cardiology,0.38091695,cardiology,0.38091695
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",stratification,0.4241129,infarction,0.4587313,infarction,0.4587313
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk-stratification,0.45956326,congestive-heart-failure,0.50061274,congestive-heart-failure,0.50061274
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",increased,0.32251194,of,0.64014816,mi,0.42637154
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",increased-risk,0.38663232,chd,0.54914963,chd,0.54914963
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",promethazine,0.26521116,bradycardia,0.4446783,bradycardia,0.4446783
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalization,0.4883753,failure,0.53211665,heart-failure,0.51238096
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",used,0.23211285,as,0.56584436,flow,0.35934073
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",unadjusted,0.30631244,chd,0.5249511,chd,0.5249511
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",triazolam,0.25480503,bradycardia,0.38231313,bradycardia,0.38231313
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",secondly,0.29930994,of,0.6712935,anomalous,0.4155471
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",results,0.29712585,of,0.53157276,blood,0.36869162
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",perform,0.31693935,return,0.4643785,venous-return,0.35410056
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",patient,0.47667986,with,0.5110891,cardiology,0.47667986
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",p,0.29391026,with,0.4559728,congestive,0.4058217
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",objectives,0.3258235,of,0.53322846,congenital,0.39620093
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",loratadine,0.20749123,bradycardia,0.3698791,bradycardia,0.3698791
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",investigation,0.31772497,of,0.61667234,anomaly,0.36676937
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",identify,0.21561515,of,0.45370293,congenital-heart-disease,0.31897438
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fractures,0.29375476,insufficiency,0.46822405,coarctation,0.43527287
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",followed,0.3600078,with,0.62115055,flow,0.4018712
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",domperidone,0.23595253,bradycardia,0.4558454,bradycardia,0.4558454
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conclusion,0.24339199,of,0.51551676,artery,0.33304232
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",compute,0.24574788,anomalous,0.3814366,anomalous,0.3814366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",compare,0.27648047,of,0.5052448,venous-return,0.3454308
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",betahistine,0.24204464,bradycardia,0.4005208,bradycardia,0.4005208
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,cleaned,0.28600872,intact,0.5662862,clot,0.40750706
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results,0.29712585,of,0.53157276,blood,0.36869162
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using,0.20786116,with,0.58010674,flow,0.41007757
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,conditional,0.23870562,double,0.4515407,septal-defect,0.43096223
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,field,0.348202,great,0.42638397,flow,0.40816107
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results-using,0.3529383,with,0.5411493,venous-return,0.4505809
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,random-field,0.27588767,anomalous,0.41900575,anomalous,0.41900575
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,five,0.2645896,of,0.58525,d-transposition,0.36288995
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.24537848,plaque,0.5478143,plaque,0.5478143
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,gave,0.27270165,with,0.5194038,tof,0.30671883
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,exact,0.23609093,of,0.44094244,anomalous,0.38800442
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,agreement,0.33515805,weak,0.4027754,anomalous,0.3554012
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,exact-agreement,0.36346698,venous-return,0.395467,venous-return,0.395467
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,altman,0.3049334,lai,0.33783454,lai,0.33783454
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,suggested,0.294477,of,0.6234695,anomalous,0.38919652
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,strong,0.22168292,weak,0.8655887,anomalous,0.40474734
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,correlation,0.27065358,weak,0.4595955,anomalous,0.39483362
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,altman-analysis,0.3339327,congenital-heart-disease,0.40901372,congenital-heart-disease,0.40901372
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,analysis-suggested,0.28419128,of,0.52648365,anomalous,0.42565817
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,strong-correlation,0.24614462,weak,0.5741691,anomalous,0.51269245
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,dataset,0.29588008,single,0.35144186,heartbeat,0.33722848
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,included,0.3195318,of,0.58040446,congenital-heart-disease,0.39125928
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.24494644,blood-flow,0.37441754,blood-flow,0.37441754
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,taken,0.3873873,of,0.53411245,blood,0.41476953
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,following,0.33078983,with,0.61268795,cardiac,0.4240192
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmentation,0.33666664,heartbeat,0.51603025,heartbeat,0.51603025
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,noise,0.3078395,heartbeat,0.5065144,heartbeat,0.5065144
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,cleaning,0.28804827,with,0.44151118,clot,0.37949526
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,noise-cleaning,0.28858012,heartbeat,0.46344483,heartbeat,0.46344483
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,part,0.37925124,of,0.6214935,anomaly,0.4202423
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,requires,0.29668367,of,0.62298405,l-transposition,0.37602508
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,full,0.27856892,return,0.5029486,flow,0.3643403
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attribution,0.27200067,of,0.46463606,anomalous,0.39813918
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,part-requires,0.28705648,of,0.52904314,l-transposition,0.37588128
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intravascular,0.36884665,thrombosis,0.60235244,thrombosis,0.60235244
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,optical,0.26125413,anomalous,0.45746398,anomalous,0.45746398
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coherence,0.3214059,anomalous,0.4371044,anomalous,0.4371044
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tomography,0.3269008,coronary,0.38573277,coronary,0.38573277
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intravascular-optical,0.35903904,blood-flow,0.5471861,blood-flow,0.5471861
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,optical-coherence,0.26532197,anomalous,0.4469647,anomalous,0.4469647
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coherence-tomography,0.34166628,venous-return,0.41583002,venous-return,0.41583002
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,optical-coherence-tomography,0.3050639,venous-return,0.4388365,venous-return,0.4388365
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,performing,0.32193437,of,0.5269445,l-transposition,0.43296793
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,percutaneous,0.43564647,coronary,0.5513066,coronary,0.5513066
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary,0.56409866,coronary,1.0,coronary,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,interventions,0.4352363,coronary,0.4378809,coronary,0.4378809
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,percutaneous-coronary,0.4862611,coronary,0.7447014,coronary,0.7447014
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,creative,0.4115675,great,0.4836368,cardiology,0.4115675
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,commons,0.3540963,great,0.4040861,cardiology,0.3540963
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attribution,0.27200067,of,0.46463606,anomalous,0.39813918
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,creative-commons,0.34805363,congenital-heart-disease,0.41999942,congenital-heart-disease,0.41999942
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,inhibit,0.1519609,of,0.39598104,contractions,0.35663724
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,proper,0.32222104,of,0.5900549,anomalous,0.43626118
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.4157105,stenosis,0.67866457,stenosis,0.67866457
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.32297635,aortic-stenosis,0.43400645,aortic-stenosis,0.43400645
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent-deployment,0.3447159,aortic-stenosis,0.62515175,aortic-stenosis,0.62515175
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually,0.3776499,with,0.46369636,heartbeat,0.4304673
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,annotated,0.30318314,isolated,0.3827675,l-transposition,0.3391384
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,ivoct,0.33082962,cad,0.40583622,cad,0.40583622
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,volumes,0.3279999,flow,0.5267465,flow,0.5267465
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually-annotated,0.33004352,heartbeat,0.4059962,heartbeat,0.4059962
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,determined,0.24003299,of,0.6221287,flow,0.40728092
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.29221767,deposits,0.60932636,deposits,0.60932636
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,depth,0.18972695,lai,0.39868793,lai,0.39868793
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically-determined,0.25211516,of,0.54335797,heartbeat,0.47745228
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary,0.56409866,coronary,1.0,coronary,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.29221767,deposits,0.60932636,deposits,0.60932636
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.24537848,plaque,0.5478143,plaque,0.5478143
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary-calcification,0.47602838,coronary-artery,0.7671321,coronary-artery,0.7671321
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.32297635,aortic-stenosis,0.43400645,aortic-stenosis,0.43400645
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.29221767,deposits,0.60932636,deposits,0.60932636
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.32297635,aortic-stenosis,0.43400645,aortic-stenosis,0.43400645
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.29221767,deposits,0.60932636,deposits,0.60932636
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,score,0.286516,total,0.3966952,stenosis,0.38543224
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,unported,0.30297306,return,0.48841816,venous-return,0.3920849
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,license,0.27964944,return,0.32606816,cardiology,0.27964944
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,pullbacks,0.43387482,venous-return,0.5277717,venous-return,0.5277717
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,expert,0.4946844,cardiology,0.4946844,cardiology,0.4946844
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,analysts,0.42961612,cardiology,0.42961612,cardiology,0.42961612
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,two-expert,0.3474537,congenital-heart-disease,0.43837193,congenital-heart-disease,0.43837193
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,expert-analysts,0.4324758,cardiology,0.4324758,cardiology,0.4324758
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,keeping,0.36682034,with,0.5744401,arrythmia,0.400786
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.24494644,blood-flow,0.37441754,blood-flow,0.37441754
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intact,0.18716241,intact,1.0,clot,0.43220323
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fujino,0.2884287,lai,0.35037538,lai,0.35037538
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,et,0.2693669,lai,0.43416882,lai,0.43416882
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,al,0.27921078,with,0.45562014,deposits,0.43978077
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,et-al,0.26238856,congestive-heart-failure,0.4042125,congestive-heart-failure,0.4042125
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,convolutional,0.30860516,venous-return,0.43876672,venous-return,0.43876672
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,neural-network,0.2583411,heartbeat,0.44916824,heartbeat,0.44916824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,approach-could,0.28644782,venous-return,0.4502325,venous-return,0.4502325
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained,0.31282532,of,0.62274206,blood,0.41646662
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.4157105,stenosis,0.67866457,stenosis,0.67866457
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically-obtained,0.28634167,of,0.54151726,heartbeat,0.44460878
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.31480348,heartbeat,0.5298092,heartbeat,0.5298092
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained,0.31282532,of,0.62274206,blood,0.41646662
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.29907668,clot,0.5128957,clot,0.5128957
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically-obtained,0.28634167,of,0.54151726,heartbeat,0.44460878
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,impact,0.2996394,of,0.5528908,single-ventricle,0.35865143
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using,0.20786116,with,0.58010674,flow,0.41007757
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.33178443,deposits,0.6236658,deposits,0.6236658
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using,0.20786116,with,0.58010674,flow,0.41007757
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.24537848,plaque,0.5478143,plaque,0.5478143
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,mixed,0.20806026,with,0.5015327,venous,0.39424977
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.24537848,plaque,0.5478143,plaque,0.5478143
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,mixed-lesions,0.20369604,plaque-deposits,0.45619884,plaque-deposits,0.45619884
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.29221767,deposits,0.60932636,deposits,0.60932636
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attributes,0.26087898,of,0.5137249,heartbeat,0.36006993
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained,0.31282532,of,0.62274206,blood,0.41646662
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,sensitivities,0.27830023,of,0.4284971,flow,0.34282336
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results,0.29712585,of,0.53157276,blood,0.36869162
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vascular,0.42921376,arteries,0.65181375,arteries,0.65181375
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.29907668,clot,0.5128957,clot,0.5128957
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vascular-lumen,0.35540926,venous,0.6469659,venous,0.6469659
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,planning,0.48000896,cardiology,0.48000896,cardiology,0.48000896
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,treatment-planning,0.37825304,venous-return,0.43822578,venous-return,0.43822578
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,classes,0.3080849,of,0.44878983,cardiac,0.33523548
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tissue-classes,0.26236698,plaque-deposits,0.43571645,plaque-deposits,0.43571645
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,thickness,0.23489445,deposits,0.44194955,deposits,0.44194955
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attributes,0.26087898,of,0.5137249,heartbeat,0.36006993
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,pretrained,0.31795344,with,0.4335522,contractions,0.4081529
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segnet,0.2990163,double-outlet,0.3544005,double-outlet,0.3544005
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,original,0.28927177,of,0.5401661,lai,0.40495938
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,publication,0.46771824,cardiology,0.46771824,cardiology,0.46771824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,great,0.4193529,great,1.0,d-transposition,0.49969703
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,concern,0.45242032,great,0.59480476,cardiology,0.45242032
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fold,0.20106214,of,0.4827961,l-transposition,0.39687347
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,cross,0.28978038,double,0.48992044,anomalous,0.35670662
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fold-cross,0.17662176,d-transposition,0.42916453,d-transposition,0.42916453
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,comprehensive,0.34833288,of,0.4912191,single-ventricle,0.3855936
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,software,0.36227515,cardiology,0.36227515,cardiology,0.36227515
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,applied,0.31181335,of,0.5047146,flow,0.3948964
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segment,0.20645988,interrupted,0.4524773,artery,0.44207752
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.33178443,deposits,0.6236658,deposits,0.6236658
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.33178443,deposits,0.6236658,deposits,0.6236658
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmented,0.25126714,irregular,0.44090593,hypoplastic-left-heart,0.4250005
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,regions,0.21387641,of,0.44606626,deposits,0.4394856
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,agreement,0.33515805,weak,0.4027754,anomalous,0.3554012
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.24494644,blood-flow,0.37441754,blood-flow,0.37441754
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.4157105,stenosis,0.67866457,stenosis,0.67866457
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually,0.3776499,with,0.46369636,heartbeat,0.4304673
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,ivoct,0.33082962,cad,0.40583622,cad,0.40583622
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,determined,0.24003299,of,0.6221287,flow,0.40728092
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.29907668,clot,0.5128957,clot,0.5128957
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.33178443,deposits,0.6236658,deposits,0.6236658
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmented,0.25126714,irregular,0.44090593,hypoplastic-left-heart,0.4250005
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,images,0.30434233,heartbeat,0.39122725,heartbeat,0.39122725
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,work,0.41337943,return,0.5383546,cardiology,0.41337943
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,whole,0.2498735,of,0.548425,blood,0.49452528
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,validation,0.3290826,of,0.43553495,heart-failure,0.3812675
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,task,0.3549496,heartbeat,0.41896272,heartbeat,0.41896272
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,spie,0.23895612,lai,0.35861897,lai,0.35861897
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,respectively,0.23301381,with,0.4658343,mi,0.37010562
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,reproduction,0.3186481,of,0.46244383,heartbeat,0.39614147
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,reported,0.2535432,of,0.6039252,l-transposition,0.37000108
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,refined,0.25127915,of,0.44195402,anomalous,0.35229188
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lipidous,0.34205067,cholesterol,0.6162026,cholesterol,0.6162026
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,interest,0.3943884,great,0.62165374,cardiology,0.3943884
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,including,0.2742056,of,0.6619886,congenital,0.3605199
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,good,0.31429055,weak,0.60268193,venous-return,0.38116372
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,giving,0.30807436,of,0.63071287,anomalous,0.42151296
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,four,0.26703352,of,0.57211214,d-transposition,0.35247436
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,encouraging,0.35832256,great,0.5666844,pulmonary,0.37278706
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,doi,0.19822392,lai,0.31615257,lai,0.31615257
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,distribution,0.24050617,of,0.5765607,deposits,0.45674896
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,data,0.31118363,of,0.5086956,mi,0.36251363
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,created,0.30611026,of,0.5643096,l-transposition,0.42097145
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,consensus,0.35071254,of,0.35320076,cardiology,0.35071254
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calculate,0.24520439,of,0.397066,venous-return,0.39258432
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcified,0.28080624,deposits,0.6129883,deposits,0.6129883
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,bland,0.35137054,irregular,0.48295653,deposits,0.3935271
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,assessment,0.41014358,of,0.5184958,flow,0.45548397
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,annotations,0.36359167,congenital-heart-disease,0.37051237,congenital-heart-disease,0.37051237
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,angle,0.2315434,isomerism,0.44443372,isomerism,0.44443372
Prediction of Left Ventricular Mechanics Using Machine Learning.,altered,0.23629062,abnormal,0.6527077,anomalous,0.41416392
Prediction of Left Ventricular Mechanics Using Machine Learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Prediction of Left Ventricular Mechanics Using Machine Learning.,optimal,0.22326279,of,0.49022785,single-ventricle,0.35533518
Prediction of Left Ventricular Mechanics Using Machine Learning.,latin,0.39092642,congenital-heart-disease,0.4145373,congenital-heart-disease,0.4145373
Prediction of Left Ventricular Mechanics Using Machine Learning.,hypercube,0.26315907,double-outlet,0.4355771,double-outlet,0.4355771
Prediction of Left Ventricular Mechanics Using Machine Learning.,design,0.22387533,of,0.40440997,single-ventricle,0.33910608
Prediction of Left Ventricular Mechanics Using Machine Learning.,latin-hypercube,0.21966231,hypoplastic-left-heart,0.46383518,hypoplastic-left-heart,0.46383518
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanics,0.31463253,stiff,0.5109209,single-ventricle,0.45957312
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulator,0.3085426,venous-return,0.39386487,venous-return,0.39386487
Prediction of Left Ventricular Mechanics Using Machine Learning.,using,0.20786116,with,0.58010674,flow,0.41007757
Prediction of Left Ventricular Mechanics Using Machine Learning.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Prediction of Left Ventricular Mechanics Using Machine Learning.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Prediction of Left Ventricular Mechanics Using Machine Learning.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanics,0.31463253,stiff,0.5109209,single-ventricle,0.45957312
Prediction of Left Ventricular Mechanics Using Machine Learning.,much,0.3522751,great,0.59738654,flow,0.382453
Prediction of Left Ventricular Mechanics Using Machine Learning.,faster,0.21381125,with,0.44214857,clot,0.36136425
Prediction of Left Ventricular Mechanics Using Machine Learning.,much-faster,0.24919362,great,0.458184,anomalous,0.36896837
Prediction of Left Ventricular Mechanics Using Machine Learning.,used,0.23211285,as,0.56584436,flow,0.35934073
Prediction of Left Ventricular Mechanics Using Machine Learning.,extreme,0.2346699,great,0.5039491,anomaly,0.45793658
Prediction of Left Ventricular Mechanics Using Machine Learning.,gradient,0.24976638,flow,0.52486,flow,0.52486
Prediction of Left Ventricular Mechanics Using Machine Learning.,boosting,0.20679975,with,0.42217714,lai,0.34504735
Prediction of Left Ventricular Mechanics Using Machine Learning.,gradient-boosting,0.21690626,venous-return,0.41583005,venous-return,0.41583005
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulation,0.36245072,of,0.40851003,venous-return,0.38664126
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Prediction of Left Ventricular Mechanics Using Machine Learning.,show,0.19476143,of,0.51487744,anomalous,0.38152152
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Prediction of Left Ventricular Mechanics Using Machine Learning.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Prediction of Left Ventricular Mechanics Using Machine Learning.,capture,0.32566327,flow,0.4278125,flow,0.4278125
Prediction of Left Ventricular Mechanics Using Machine Learning.,results-could,0.3724017,return,0.47488123,venous-return,0.4350573
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtain,0.32854,return,0.5372094,flow,0.39961314
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.27293414,deposits,0.36430332,deposits,0.36430332
Prediction of Left Ventricular Mechanics Using Machine Learning.,models,0.19961227,of,0.39522392,congenital-heart-disease,0.35803363
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe-models,0.22544217,deposits,0.3664916,deposits,0.3664916
Prediction of Left Ventricular Mechanics Using Machine Learning.,time,0.350901,return,0.5513821,venous-return,0.44564146
Prediction of Left Ventricular Mechanics Using Machine Learning.,left,0.3872844,left,1.0,left-atrial,0.6573896
Prediction of Left Ventricular Mechanics Using Machine Learning.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
Prediction of Left Ventricular Mechanics Using Machine Learning.,time-left,0.3401587,left,0.64232826,left-atrial,0.612318
Prediction of Left Ventricular Mechanics Using Machine Learning.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
Prediction of Left Ventricular Mechanics Using Machine Learning.,mean,0.30953988,total,0.5000684,artery,0.37085557
Prediction of Left Ventricular Mechanics Using Machine Learning.,absolute,0.16486242,total,0.48867014,isomerism,0.4118287
Prediction of Left Ventricular Mechanics Using Machine Learning.,errors,0.2912968,l-transposition,0.39197582,l-transposition,0.39197582
Prediction of Left Ventricular Mechanics Using Machine Learning.,mean-absolute,0.20040232,total,0.37979698,blood-flow,0.3782481
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict,0.19493632,of,0.46450508,venous-return,0.34201604
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior,0.1827973,of,0.47683254,anomalous,0.44146252
Prediction of Left Ventricular Mechanics Using Machine Learning.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Prediction of Left Ventricular Mechanics Using Machine Learning.,material,0.25157535,deposits,0.5195077,deposits,0.5195077
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.16694331,of,0.4979031,anomalous,0.43609905
Prediction of Left Ventricular Mechanics Using Machine Learning.,different-material,0.18130708,of,0.4416983,plaque-deposits,0.42999104
Prediction of Left Ventricular Mechanics Using Machine Learning.,material-properties,0.24830031,of,0.41912043,plaque-deposits,0.41685367
Prediction of Left Ventricular Mechanics Using Machine Learning.,reinforced,0.26257274,interrupted,0.5037184,venous-return,0.36400914
Prediction of Left Ventricular Mechanics Using Machine Learning.,material,0.25157535,deposits,0.5195077,deposits,0.5195077
Prediction of Left Ventricular Mechanics Using Machine Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Prediction of Left Ventricular Mechanics Using Machine Learning.,material-model,0.27011406,venous-return,0.40418896,venous-return,0.40418896
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,constitutive,0.14971268,of,0.46098697,l-transposition,0.38318366
Prediction of Left Ventricular Mechanics Using Machine Learning.,equation,0.29144466,anomalous,0.39339638,anomalous,0.39339638
Prediction of Left Ventricular Mechanics Using Machine Learning.,varied,0.2703963,of,0.56987137,flow,0.35170394
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.165449,stiff,0.446432,contractions,0.4151309
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.16694331,of,0.4979031,anomalous,0.43609905
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.165449,stiff,0.446432,contractions,0.4151309
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.16694331,of,0.4979031,anomalous,0.43609905
Prediction of Left Ventricular Mechanics Using Machine Learning.,govern,0.25791144,of,0.49943623,anomalous,0.41647255
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.3012385,flow,0.5655429,flow,0.5655429
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtained,0.31282532,of,0.62274206,blood,0.41646662
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume-results,0.35624892,venous-return,0.5028087,venous-return,0.5028087
Prediction of Left Ventricular Mechanics Using Machine Learning.,results-obtained,0.3495831,with,0.49948108,blood,0.45984882
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Prediction of Left Ventricular Mechanics Using Machine Learning.,based,0.2494699,of,0.5443143,flow,0.34116954
Prediction of Left Ventricular Mechanics Using Machine Learning.,model-based,0.25989342,venous-return,0.41569927,venous-return,0.41569927
Prediction of Left Ventricular Mechanics Using Machine Learning.,real,0.3591983,great,0.53489023,flow,0.42211816
Prediction of Left Ventricular Mechanics Using Machine Learning.,world,0.40370166,cardiology,0.40370166,cardiology,0.40370166
Prediction of Left Ventricular Mechanics Using Machine Learning.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
Prediction of Left Ventricular Mechanics Using Machine Learning.,real-world,0.32587075,congestive-heart-failure,0.41802934,congestive-heart-failure,0.41802934
Prediction of Left Ventricular Mechanics Using Machine Learning.,cross,0.28978038,double,0.48992044,anomalous,0.35670662
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber,0.2599843,myocardial,0.54673964,myocardial,0.54673964
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.28176898,of,0.4473127,myocardial,0.4140401
Prediction of Left Ventricular Mechanics Using Machine Learning.,varied,0.2703963,of,0.56987137,flow,0.35170394
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,0.2270833,with,0.53918797,contractions,0.3619916
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.16694331,of,0.4979031,anomalous,0.43609905
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.28176898,of,0.4473127,myocardial,0.4140401
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.2546068,of,0.40433967,anomalous,0.36208636
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.29712585,of,0.53157276,blood,0.36869162
Prediction of Left Ventricular Mechanics Using Machine Learning.,predicted,0.16610277,of,0.49135727,single-ventricle,0.35252047
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.165449,stiff,0.446432,contractions,0.4151309
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior,0.1827973,of,0.47683254,anomalous,0.44146252
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber,0.2599843,myocardial,0.54673964,myocardial,0.54673964
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.28176898,of,0.4473127,myocardial,0.4140401
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanical,0.25468335,stiff,0.5593581,valve,0.44819796
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.16694331,of,0.4979031,anomalous,0.43609905
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,stresses,0.23475446,stiff,0.46222487,flow,0.3858071
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressures,0.32778147,flow,0.5359129,flow,0.5359129
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv-pressure,0.26580334,right-ventricle,0.53882766,right-ventricle,0.53882766
Prediction of Left Ventricular Mechanics Using Machine Learning.,shear,0.21304493,flow,0.55354834,flow,0.55354834
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.28176898,of,0.4473127,myocardial,0.4140401
Prediction of Left Ventricular Mechanics Using Machine Learning.,shear-stress,0.22601092,flow,0.5010102,flow,0.5010102
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.165449,stiff,0.446432,contractions,0.4151309
Prediction of Left Ventricular Mechanics Using Machine Learning.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive-tissue,0.16294947,congenital-heart-disease,0.5155251,congenital-heart-disease,0.5155251
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Prediction of Left Ventricular Mechanics Using Machine Learning.,set,0.43165553,of,0.5846941,cardiology,0.43165553
Prediction of Left Ventricular Mechanics Using Machine Learning.,training-set,0.3791533,venous-return,0.44417873,venous-return,0.44417873
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber,0.2599843,myocardial,0.54673964,myocardial,0.54673964
Prediction of Left Ventricular Mechanics Using Machine Learning.,contractions,0.297018,contractions,1.0,contractions,1.0
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,0.2270833,with,0.53918797,contractions,0.3619916
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior,0.1827973,of,0.47683254,anomalous,0.44146252
Prediction of Left Ventricular Mechanics Using Machine Learning.,active-behavior,0.29433465,venous-return,0.34199828,venous-return,0.34199828
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.27293414,deposits,0.36430332,deposits,0.36430332
Prediction of Left Ventricular Mechanics Using Machine Learning.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe-method,0.21347454,venous-return,0.35772887,venous-return,0.35772887
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.27293414,deposits,0.36430332,deposits,0.36430332
Prediction of Left Ventricular Mechanics Using Machine Learning.,computations,0.27599603,isomerism,0.38880247,isomerism,0.38880247
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of Left Ventricular Mechanics Using Machine Learning.,mmhg,0.25914344,beats,0.4756977,beats,0.4756977
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of Left Ventricular Mechanics Using Machine Learning.,kpa,0.08529026,stiff,0.3941435,blood-flow,0.31901237
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.3012385,flow,0.5655429,flow,0.5655429
Prediction of Left Ventricular Mechanics Using Machine Learning.,loops,0.14776263,irregular,0.44318318,contractions,0.36839294
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume-loops,0.25335833,right-ventricle,0.54818135,right-ventricle,0.54818135
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.2546068,of,0.40433967,anomalous,0.36208636
Prediction of Left Ventricular Mechanics Using Machine Learning.,large,0.31318635,great,0.5879582,deposits,0.4134889
Prediction of Left Ventricular Mechanics Using Machine Learning.,group,0.2849201,with,0.5052614,mi,0.411738
Prediction of Left Ventricular Mechanics Using Machine Learning.,large-group,0.34221306,congestive-heart-failure,0.3870625,congestive-heart-failure,0.3870625
Prediction of Left Ventricular Mechanics Using Machine Learning.,hyperelastic,0.1891095,stiff,0.6356205,hypoplastic-left-heart,0.48003727
Prediction of Left Ventricular Mechanics Using Machine Learning.,fiber,0.2145364,of,0.39195073,clot,0.37473777
Prediction of Left Ventricular Mechanics Using Machine Learning.,heart,0.57664216,heart,1.0,heart,1.0
Prediction of Left Ventricular Mechanics Using Machine Learning.,resulting,0.18480285,of,0.6416826,anomalous,0.46019152
Prediction of Left Ventricular Mechanics Using Machine Learning.,finite,0.22657129,stiff,0.43534178,anomalous,0.43101376
Prediction of Left Ventricular Mechanics Using Machine Learning.,element,0.21579163,l-transposition,0.42461568,l-transposition,0.42461568
Prediction of Left Ventricular Mechanics Using Machine Learning.,finite-element,0.25433618,hypoplastic-left-heart,0.41698384,hypoplastic-left-heart,0.41698384
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.24704182,rai,0.38046446,rai,0.38046446
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.3012385,flow,0.5655429,flow,0.5655429
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.24704182,rai,0.38046446,rai,0.38046446
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.33296895,single,0.3442412,mitral-valve,0.3331717
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.3012385,flow,0.5655429,flow,0.5655429
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.33296895,single,0.3442412,mitral-valve,0.3331717
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.30169874,blood,0.5665527,blood,0.5665527
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.25306612,blood,0.42071202,blood,0.42071202
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Prediction of Left Ventricular Mechanics Using Machine Learning.,used,0.23211285,as,0.56584436,flow,0.35934073
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtain,0.32854,return,0.5372094,flow,0.39961314
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,0.46721146,cardiology,0.46721146,cardiology,0.46721146
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.27293414,deposits,0.36430332,deposits,0.36430332
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.3012385,flow,0.5655429,flow,0.5655429
Prediction of Left Ventricular Mechanics Using Machine Learning.,real,0.3591983,great,0.53489023,flow,0.42211816
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.2546068,of,0.40433967,anomalous,0.36208636
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,0.2270833,with,0.53918797,contractions,0.3619916
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.24704182,rai,0.38046446,rai,0.38046446
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.33296895,single,0.3442412,mitral-valve,0.3331717
Prediction of Left Ventricular Mechanics Using Machine Learning.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Prediction of Left Ventricular Mechanics Using Machine Learning.,volumes,0.3279999,flow,0.5267465,flow,0.5267465
Prediction of Left Ventricular Mechanics Using Machine Learning.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
Prediction of Left Ventricular Mechanics Using Machine Learning.,systole,0.4505175,ventricular,0.71310866,ventricular,0.71310866
Prediction of Left Ventricular Mechanics Using Machine Learning.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Prediction of Left Ventricular Mechanics Using Machine Learning.,smoother,0.25380057,irregular,0.5144891,plaque-deposits,0.41766173
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulations,0.31360254,anomalous,0.40051126,anomalous,0.40051126
Prediction of Left Ventricular Mechanics Using Machine Learning.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
Prediction of Left Ventricular Mechanics Using Machine Learning.,shape,0.24577355,irregular,0.568695,anomalous,0.47767532
Prediction of Left Ventricular Mechanics Using Machine Learning.,provide,0.3065295,of,0.4983799,flow,0.3409845
Prediction of Left Ventricular Mechanics Using Machine Learning.,prediction,0.25181523,of,0.47743863,congestive-heart-failure,0.36931968
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictability,0.27431297,of,0.48640513,heartbeat,0.3924607
Prediction of Left Ventricular Mechanics Using Machine Learning.,paper,0.30468726,of,0.4606573,anomaly,0.36774796
Prediction of Left Ventricular Mechanics Using Machine Learning.,myocardium,0.38313717,myocardial,0.8277121,myocardial,0.8277121
Prediction of Left Ventricular Mechanics Using Machine Learning.,improve,0.31483245,great,0.49610043,flow,0.35876963
Prediction of Left Ventricular Mechanics Using Machine Learning.,goal,0.42704034,return,0.44766816,cardiology,0.42704034
Prediction of Left Ventricular Mechanics Using Machine Learning.,follows,0.32510832,as,0.49607632,flow,0.34755546
Prediction of Left Ventricular Mechanics Using Machine Learning.,experiments,0.20130633,of,0.4657672,flow,0.3524469
Prediction of Left Ventricular Mechanics Using Machine Learning.,diastole,0.42445576,ventricular,0.67925537,ventricular,0.67925537
Prediction of Left Ventricular Mechanics Using Machine Learning.,describe,0.2106702,of,0.4752335,anomalous,0.4157361
Prediction of Left Ventricular Mechanics Using Machine Learning.,conducted,0.33747825,of,0.5328569,congenital-heart-disease,0.34614092
Prediction of Left Ventricular Mechanics Using Machine Learning.,added,0.39393532,with,0.6052638,cardiology,0.39393532
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",molecular,0.2634613,of,0.516936,isomerism,0.33948874
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",dynamic,0.26735556,of,0.4784561,blood-flow,0.47322053
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",simulations,0.31360254,anomalous,0.40051126,anomalous,0.40051126
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",showed,0.21619865,with,0.57298803,flow,0.33828264
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",molecular-dynamic,0.28171033,anomalous,0.4119444,anomalous,0.4119444
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",linking,0.24794237,of,0.57083666,deposits,0.34762245
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",two,0.27358675,single,0.605739,l-transposition,0.37929946
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",privileged,0.23116547,as,0.40899187,isomerism,0.3752759
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",scaffolds,0.24556409,stiff,0.4194969,hypoplastic-left-heart,0.3209323
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",monoamine,0.21343027,cholesterol,0.40701574,cholesterol,0.40701574
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",oxidases,0.23444521,l-transposition,0.3472023,l-transposition,0.3472023
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",hbuche,0.1339865,blood-clot,0.3136247,blood-clot,0.3136247
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",b,0.20100933,of,0.43435428,aortic,0.34993017
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",lipoxygenase,0.19185135,cholesterol,0.39085677,cholesterol,0.39085677
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",treat,0.3333781,as,0.4672093,congenital,0.37201887
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",neurodegenerative,0.2799778,disease,0.5945789,artery-disease,0.42222476
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",target,0.23866604,of,0.4775706,blood,0.34112448
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",directed,0.31404623,of,0.55436456,flow,0.39248404
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",ligands,0.19009796,isomerism,0.42399952,isomerism,0.42399952
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",target-directed,0.23474061,of,0.36982238,l-transposition,0.34892228
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",obtaining,0.315955,of,0.6090371,venous,0.3788731
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",effective,0.20873946,as,0.5165305,contractions,0.33001167
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",neurotoxic,0.14922827,plaque-deposits,0.41506717,plaque-deposits,0.41506717
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",cascades,0.20339525,of,0.38049874,deposits,0.3340844
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",could,0.24107237,of,0.59299076,anomalous,0.37354472
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",namely,0.2043892,as,0.609285,isomerism,0.39077944
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",human,0.20610836,of,0.5175895,l-transposition,0.36225826
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",cholinesterases,0.2059626,cholesterol,0.39932907,cholesterol,0.39932907
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",wanted,0.5057472,return,0.53229785,cardiology,0.5057472
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",remedies,0.36514208,great,0.4049356,heart-disease,0.37831366
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",long-wanted,0.36585918,of,0.5379546,bradycardia,0.37530518
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",could,0.24107237,of,0.59299076,anomalous,0.37354472
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",synergistically,0.12757866,with,0.43287516,contractions,0.321226
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",contribute,0.20002447,of,0.5196437,anomalous,0.32585382
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",hybrid,0.21175951,double,0.41174033,hypoplastic-left-heart,0.3919431
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",valid,0.20664714,of,0.3830687,venous-return,0.33503646
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",approach,0.24478336,of,0.42712367,l-transposition,0.40473902
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",type,0.18854949,of,0.48202556,aortic,0.35779506
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",screening,0.33582932,of,0.4313763,congenital,0.3888343
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",type-screening,0.283862,congenital-heart-disease,0.3660246,congenital-heart-disease,0.3660246
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",sigma,0.15403515,weak,0.34049752,lai,0.33265117
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",receptors,0.20060575,of,0.401954,contractions,0.3900054
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",sigma-receptors,0.2477577,contractions,0.44483876,contractions,0.44483876
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",repair,0.27227306,l-transposition,0.57925195,l-transposition,0.57925195
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",properties,0.16694331,of,0.4979031,anomalous,0.43609905
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",relevant,0.3264072,of,0.5628227,anomalous,0.34380507
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",protein,0.17386194,of,0.4756804,cholesterol,0.3740363
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",interactions,0.26582682,weak,0.48503923,isomerism,0.3771425
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",protein-interactions,0.25051507,weak,0.42847782,congenital-heart-disease,0.32049704
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",cns,0.26364732,cardiac,0.46716258,cardiac,0.46716258
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",neuronal,0.26215446,cardiac,0.46381855,cardiac,0.46381855
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",regeneration,0.1893481,defect,0.41669255,l-transposition,0.39260504
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",neurogenic,0.26768792,contractions,0.4710918,contractions,0.4710918
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",properties,0.16694331,of,0.4979031,anomalous,0.43609905
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",known,0.28223497,as,0.60071135,mi,0.41831112
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",activities,0.24356377,of,0.4766258,contractions,0.3709238
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",interesting,0.31298086,great,0.62348694,anomalous,0.47095627
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",mtd,0.13505019,rai,0.2911166,rai,0.2911166
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",highlighted,0.3702412,of,0.60523915,cardiology,0.3702412
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",due,0.3318616,of,0.5734476,anomaly,0.41796127
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",first,0.34597713,of,0.61145455,l-transposition,0.40511346
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",steps,0.27154136,of,0.47221574,l-transposition,0.36863482
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",first-steps,0.24024206,of,0.4581735,l-transposition,0.43468577
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",complex,0.29298759,of,0.46002102,anomalous,0.41282338
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",pathologies,0.32107803,disease,0.5931432,congenital,0.5365187
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",combine,0.27241892,with,0.52884185,anomalous,0.3754853
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",neuro,0.40481675,intact,0.47923797,arrythmia,0.47416523
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",biological,0.25037947,of,0.5642135,blood-clot,0.34982628
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",evaluation,0.3957072,of,0.5653497,cardiology,0.3957072
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",targets,0.24361905,of,0.45244455,heart-attack,0.3073677
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",involved,0.2655597,of,0.5396308,l-transposition,0.36373854
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",targets-involved,0.1766027,of,0.44702482,heart-attack,0.37707838
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",permeable,0.12360588,intact,0.4565693,deposits,0.38693988
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",flavonoid,0.20873049,cholesterol,0.38896334,cholesterol,0.38896334
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",nds,0.24799223,with,0.42040047,chd,0.39914104
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",dbma,0.11392264,eb,0.3074324,eb,0.3074324
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",hybrids,0.19303212,great,0.37870842,d-transposition,0.34170172
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",block,0.3085454,bradycardia,0.53909045,bradycardia,0.53909045
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",neurodegeneration,0.23566623,disease,0.5336287,plaque-deposits,0.44471723
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",targets,0.24361905,of,0.45244455,heart-attack,0.3073677
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",nds,0.24799223,with,0.42040047,chd,0.39914104
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",flavonoid,0.20873049,cholesterol,0.38896334,cholesterol,0.38896334
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",dbma,0.11392264,eb,0.3074324,eb,0.3074324
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",block,0.3085454,bradycardia,0.53909045,bradycardia,0.53909045
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",well,0.36427143,as,0.7685982,cardiac,0.4102829
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",subjected,0.18238434,isolated,0.5451176,flow,0.38988888
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",secretase,0.24416418,plaque,0.36707145,plaque,0.36707145
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",profile,0.19752568,of,0.5464045,flow,0.39967984
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",obtained,0.31282532,of,0.62274206,blood,0.41646662
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",nd,0.25433493,with,0.39603066,mi,0.34574953
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",n,0.21850443,with,0.47536123,mi,0.3790054
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",multi,0.3120417,single,0.49181098,cad,0.38921657
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",mtdls,0.21082193,as,0.34875154,plaque-deposits,0.29636467
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",methyl,0.2326467,isomerism,0.37112722,isomerism,0.37112722
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",hmao,0.1730882,chd,0.2709237,chd,0.2709237
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",hlox,0.13148168,eb,0.33806896,eb,0.33806896
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",hache,0.23982838,attack,0.31091765,heart-attack,0.2863369
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",funnel,0.23498772,outlet,0.47375473,double-outlet,0.4478019
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",fragments,0.12914608,deposits,0.49908635,deposits,0.49908635
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",dibenzyl,0.13541417,isomerism,0.43288743,isomerism,0.43288743
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",design,0.22387533,of,0.40440997,single-ventricle,0.33910608
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",battery,0.27496144,as,0.34236342,cardiac,0.3350237
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",amine,0.2530104,with,0.41443872,isomerism,0.3856011
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",alzheimer,0.3308626,disease,0.5158516,fibrillation,0.46321332
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimers disease endowed with neurogenic properties.",ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,exclusive,0.18425292,of,0.523538,anomalous,0.40981922
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,licensee,0.3445976,cardiology,0.3445976,cardiology,0.3445976
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,american,0.44040596,cardiology,0.44040596,cardiology,0.44040596
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,association,0.34312242,of,0.45371312,chd,0.39406395
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,display,0.17130375,of,0.48815864,anomalous,0.3659566
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,deficiency,0.19127867,insufficiency,0.6387409,congenital,0.57910484
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mapk,0.18517739,mitral-regurgitation,0.33024183,mitral-regurgitation,0.33024183
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mapk-signaling,0.1986012,atrioventricular,0.32741362,atrioventricular,0.32741362
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,signaling-pathway,0.19571406,of,0.3761694,atrioventricular-septal-defect,0.34819022
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,fibroblasts,0.2126699,defect,0.43574464,septal-defect,0.43517864
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,displayed,0.15759128,with,0.53959215,septal-defect,0.32967123
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,impaired,0.229642,abnormal,0.65608627,hypoplastic,0.420444
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mapk,0.18517739,mitral-regurgitation,0.33024183,mitral-regurgitation,0.33024183
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mapk-signaling,0.1986012,atrioventricular,0.32741362,atrioventricular,0.32741362
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,signaling-pathway,0.19571406,of,0.3761694,atrioventricular-septal-defect,0.34819022
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,signaling-pathways,0.1904434,of,0.37176776,atrioventricular,0.33244452
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,previously,0.21411541,as,0.54924536,l-transposition,0.42639655
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,undescribed,0.16238299,isolated,0.59626466,anomaly,0.5005418
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,form,0.22493605,of,0.55080163,anomalous,0.4120242
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,previously-undescribed,0.20624848,isolated,0.54115295,anomalous,0.49597538
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,extracellular,0.14791466,deposits,0.42989883,deposits,0.42989883
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,matrix,0.19602376,deposits,0.43658155,deposits,0.43658155
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,extracellular-matrix,0.16090658,plaque-deposits,0.42368352,plaque-deposits,0.42368352
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mucocutaneous,0.25502598,congenital,0.5306953,congenital,0.5306953
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,candidiasis,0.26766405,disease,0.45729935,congenital-heart-disease,0.45641375
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,causing,0.1717836,of,0.5218761,congenital,0.47086555
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,products,0.21706301,of,0.45431146,deposits,0.350613
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,gene-products,0.21165909,of,0.41891956,l-transposition,0.36474696
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,impaired,0.229642,abnormal,0.65608627,hypoplastic,0.420444
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ex,0.19497,flow,0.42250997,flow,0.42250997
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ex-vivo,0.1405592,blood-flow,0.43793744,blood-flow,0.43793744
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dietz,0.27637,truncus,0.42623076,truncus,0.42623076
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,syndrome,0.2608677,syndrome,1.0,syndrome,1.0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,caused,0.1752007,of,0.53973085,congenital,0.42777976
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,syndrome-caused,0.22387758,syndrome,0.80950654,syndrome,0.80950654
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,connective,0.27825242,deposits,0.5395862,deposits,0.5395862
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,disorders,0.30838862,congenital,0.5785017,congenital,0.5785017
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,connective-tissue,0.21074387,congenital-heart-disease,0.5365458,congenital-heart-disease,0.5365458
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,terminal,0.16295928,of,0.5041194,l-transposition,0.41455114
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,kinase,0.17639789,of,0.32242787,myocardial,0.3009235
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,terminal-kinase,0.15700658,l-transposition,0.41672248,l-transposition,0.41672248
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mucocutaneous,0.25502598,congenital,0.5306953,congenital,0.5306953
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,immunity,0.16870308,of,0.3862146,congenital-heart-disease,0.36780804
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,unusual,0.19115528,anomalous,0.5766048,anomalous,0.5766048
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ctd,0.17913967,tapvr,0.36576727,tapvr,0.36576727
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,gene,0.22998136,l-transposition,0.45660734,l-transposition,0.45660734
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,encoding,0.19080907,l-transposition,0.43134332,l-transposition,0.43134332
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,c,0.21239448,with,0.46990636,ivs,0.34813386
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,gene-encoding,0.16412446,l-transposition,0.46608377,l-transposition,0.46608377
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,disrupt,0.1392912,interrupted,0.41497582,eb,0.30670822
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,il,0.24051979,mi,0.30050132,mi,0.30050132
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,immunity,0.16870308,of,0.3862146,congenital-heart-disease,0.36780804
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,responsive,0.23913951,weak,0.46599144,tachycardia,0.32311696
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,induction,0.22081468,of,0.52603287,l-transposition,0.39831883
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,homeostasis,0.2088578,abnormal,0.4305867,cholesterol,0.39712244
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,danlos,0.33946362,syndrome,0.59967196,syndrome,0.59967196
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,syndrome,0.2608677,syndrome,1.0,syndrome,1.0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,danlos-syndrome,0.3025968,syndrome,0.81121325,syndrome,0.81121325
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,connective,0.27825242,deposits,0.5395862,deposits,0.5395862
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,tissues,0.16733295,of,0.47614664,arteries,0.46764413
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,connective-tissues,0.21101955,congenital-heart-disease,0.5253608,congenital-heart-disease,0.5253608
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,transcriptional,0.24623448,l-transposition,0.44111192,l-transposition,0.44111192
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,pattern,0.22120216,irregular,0.5954343,flow,0.4913214
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,probably,0.3232427,of,0.6189318,l-transposition,0.4302532
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,private,0.4710291,cardiology,0.4710291,cardiology,0.4710291
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,splice,0.1485447,ivs,0.44904575,ivs,0.44904575
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,original,0.28927177,of,0.5401661,lai,0.40495938
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,u,0.22611019,ivs,0.4367266,ivs,0.4367266
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,often,0.28905255,with,0.53610253,anomaly,0.426194
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,impair,0.1258316,abnormal,0.42633018,congenital,0.33415148
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,nature,0.28114077,of,0.5463233,anomalous,0.4306179
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,indicates,0.1844736,of,0.6366827,anomalous,0.38955534
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mucosal,0.122980855,of,0.4234106,venous,0.41766214
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,surfaces,0.18793865,deposits,0.47038668,deposits,0.47038668
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,incompletely,0.21466574,intact,0.49899268,hypoplastic,0.44186473
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,understood,0.27476305,as,0.45029238,anomalous,0.37772185
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,incompletely-understood,0.23379551,of,0.50949466,anomalous,0.47266787
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,government,0.4843917,cardiology,0.4843917,cardiology,0.4843917
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,works,0.3987892,as,0.48645952,cardiology,0.3987892
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,etiologies,0.3678462,congenital,0.5797959,congenital,0.5797959
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,generation,0.25683564,of,0.5394852,contractions,0.39260584
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,family,0.39850003,cardiology,0.39850003,cardiology,0.39850003
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,generation-family,0.29796726,of,0.47538757,congenital-heart-disease,0.43339208
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,clinically,0.2989028,with,0.5207711,artery-disease,0.40292245
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,overlaps,0.15819652,interrupted,0.43389368,anomaly,0.37276652
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,autosomal,0.19912295,congenital,0.6035224,congenital,0.6035224
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,dominant,0.19307572,anomalous,0.45553446,anomalous,0.45553446
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,autosomal-dominant,0.22887108,congenital,0.6066513,congenital,0.6066513
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,site,0.25050646,intact,0.50730455,deposits,0.38691008
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,variant,0.19136229,single,0.43584552,anomaly,0.40589562
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,jun,0.23980604,dorv,0.29875183,dorv,0.29875183
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,n,0.21850443,with,0.47536123,mi,0.3790054
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,jun-n,0.24075928,bradycardia,0.28859857,bradycardia,0.28859857
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,eds,0.36402285,syndrome,0.4358232,syndrome,0.4358232
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,impaired,0.229642,abnormal,0.65608627,hypoplastic,0.420444
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,fibroblasts,0.2126699,defect,0.43574464,septal-defect,0.43517864
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,displayed,0.15759128,with,0.53959215,septal-defect,0.32967123
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,il,0.24051979,mi,0.30050132,mi,0.30050132
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ctd,0.17913967,tapvr,0.36576727,tapvr,0.36576727
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,c,0.21239448,with,0.46990636,ivs,0.34813386
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,variant,0.19136229,single,0.43584552,anomaly,0.40589562
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,jun,0.23980604,dorv,0.29875183,dorv,0.29875183
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,eds,0.36402285,syndrome,0.4358232,syndrome,0.4358232
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,xxxf,0.2780378,heart-syndrome,0.43787095,heart-syndrome,0.43787095
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,whereas,0.19876172,of,0.61474305,contractions,0.3954193
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,vitro,0.17831118,of,0.48112682,clot,0.34754837
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,tgf,0.15675664,blood-flow,0.29633883,blood-flow,0.29633883
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,science,0.46422392,cardiology,0.46422392,cardiology,0.46422392
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,responses,0.18527287,contractions,0.4718574,contractions,0.4718574
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,response,0.2306606,of,0.52661085,contractions,0.38512754
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,report,0.3478901,of,0.56646246,anomaly,0.43710455
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,regulators,0.27927446,as,0.44389707,l-transposition,0.29768372
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,mutations,0.2006272,defect,0.46113265,congenital,0.42577744
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,moreover,0.16758724,of,0.5596781,plaque-deposits,0.35056823
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,loeys,0.23279017,tapvr,0.5237878,tapvr,0.5237878
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,involvement,0.23285815,of,0.5255257,anomaly,0.41808018
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,integrity,0.22758211,intact,0.58732235,clot,0.3996798
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,heterozygous,0.19243051,septal-defect,0.44642568,septal-defect,0.44642568
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,haploinsufficiency,0.21460101,heart-syndrome,0.56766784,heart-syndrome,0.56766784
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,furthermore,0.18322246,of,0.5529862,plaque-deposits,0.34174067
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,function,0.2605439,of,0.55099833,flow,0.43324804
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,f,0.23698471,with,0.3629063,mi,0.3521915
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,experiment,0.21804892,of,0.43378067,heartbeat,0.36693472
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,essential,0.26315036,of,0.53323644,cardiac,0.32177997
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ehlers,0.25923872,syndrome,0.45628226,syndrome,0.45628226
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ecm,0.23270065,plaque-deposits,0.44722003,plaque-deposits,0.44722003
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,development,0.2877805,of,0.53581744,congenital,0.35419804
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,ctds,0.22878373,chd,0.4549324,chd,0.4549324
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,consistently,0.3148677,with,0.590214,flow,0.41162568
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,components,0.22271727,of,0.54551816,deposits,0.4215029
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,component,0.2266389,of,0.52326363,deposits,0.38395098
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,complex,0.29298759,of,0.46002102,anomalous,0.41282338
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,combination,0.21742424,with,0.59363616,l-transposition,0.35203728
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,cmc,0.1777264,stiff,0.3222822,dtga,0.29968217
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,claim,0.2820414,return,0.35158285,heart-attack,0.33096245
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,candida,0.20147848,isolated,0.34541973,coronary-thrombosis,0.30472374
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,atf,0.19163401,intact,0.33123776,clot,0.30962884
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,advancement,0.42288852,great,0.5166844,l-transposition,0.4270221
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,accounting,0.25154918,of,0.55534834,anomaly,0.38962352
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-.,abolished,0.17287783,interrupted,0.44684386,contractions,0.4323145
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,coupled,0.1969167,with,0.5215788,anomalous,0.37728786
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward,0.23237023,contractions,0.54743814,contractions,0.54743814
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifier,0.24356112,atrioventricular,0.44388503,atrioventricular,0.44388503
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potassium,0.24905129,cholesterol,0.38167936,cholesterol,0.38167936
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,current,0.39557698,of,0.4991414,flow,0.39574015
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward-rectifier,0.23625499,contractions,0.42646372,contractions,0.42646372
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifier-potassium,0.26826876,atrioventricular,0.43087187,atrioventricular,0.43087187
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potassium-current,0.23294738,contractions,0.41753545,contractions,0.41753545
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,greater,0.28239584,of,0.59163296,mi,0.40441626
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slowing,0.3158311,of,0.5035058,bradycardia,0.48302567
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado-induced,0.26772738,of,0.52507687,contractions,0.49257487
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate-slowing,0.37280148,tachycardia,0.5342373,tachycardia,0.5342373
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward,0.23237023,contractions,0.54743814,contractions,0.54743814
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifying,0.2105702,anomalous,0.4071302,anomalous,0.4071302
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,current,0.39557698,of,0.4991414,flow,0.39574015
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward-rectifying,0.20908554,contractions,0.41491714,contractions,0.41491714
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifying-current,0.26061013,anomalous,0.4619618,anomalous,0.4619618
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated,0.26665276,septal,0.47697327,septal,0.47697327
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,patch,0.27746502,valve,0.44052872,valve,0.44052872
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,clamp,0.23580967,intact,0.38922173,left-atrial,0.37694782
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,recordings,0.32916608,heartbeat,0.5149152,heartbeat,0.5149152
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated-patch,0.24163279,double-outlet,0.49369767,double-outlet,0.49369767
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,patch-clamp,0.23003411,double-outlet,0.4267936,double-outlet,0.4267936
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated-patch-clamp,0.2211487,double-outlet,0.46612367,double-outlet,0.46612367
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,subsequent,0.26928416,of,0.65363204,cardiac,0.38847053
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative,0.26947153,abnormal,0.48861286,blood,0.4176938
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic,0.35805148,bradycardia,0.62137526,bradycardia,0.62137526
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative-chronotropic,0.30235642,right-atrial,0.5191392,right-atrial,0.5191392
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic-effects,0.30986688,bradycardia,0.54785705,bradycardia,0.54785705
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,exert,0.14779946,weak,0.43877944,contractions,0.33716455
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative,0.26947153,abnormal,0.48861286,blood,0.4176938
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic,0.35805148,bradycardia,0.62137526,bradycardia,0.62137526
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative-chronotropic,0.30235642,right-atrial,0.5191392,right-atrial,0.5191392
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic-effects,0.30986688,bradycardia,0.54785705,bradycardia,0.54785705
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,physiologically,0.1675667,of,0.47293383,contractions,0.38634834
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,concentrations,0.20313622,with,0.46930897,deposits,0.43182394
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,physiologically-relevant,0.16479836,of,0.53151315,blood-flow,0.35701853
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,selective,0.18057933,of,0.469292,l-transposition,0.40477294
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22820336,atrioventricular-septal-defect,0.38728654,atrioventricular-septal-defect,0.38728654
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,blocker,0.35916984,bradycardia,0.4897694,bradycardia,0.4897694
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22820336,atrioventricular-septal-defect,0.38728654,atrioventricular-septal-defect,0.38728654
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,enhances,0.14459226,of,0.5346574,anomalous,0.2913116
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ikado,0.19948874,lai,0.30952346,lai,0.30952346
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.42091805,cardiology,0.42091805,cardiology,0.42091805
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,pacemaker,0.48942834,arrythmia,0.63980883,arrythmia,0.63980883
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,pacemaker-cells,0.41317144,atrioventricular,0.64251536,atrioventricular,0.64251536
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slowing,0.3158311,of,0.5035058,bradycardia,0.48302567
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate-slowing,0.37280148,tachycardia,0.5342373,tachycardia,0.5342373
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22820336,atrioventricular-septal-defect,0.38728654,atrioventricular-septal-defect,0.38728654
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna-expression,0.15830496,of,0.356714,l-transposition,0.34163117
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced-chronic,0.17801794,congenital-heart-disease,0.44750378,congenital-heart-disease,0.44750378
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,diastolic,0.437353,ventricular,0.68328416,ventricular,0.68328416
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,depolarization,0.22689117,contractions,0.59865665,contractions,0.59865665
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,maximum,0.22974399,of,0.4677399,contractions,0.41615498
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,diastolic,0.437353,ventricular,0.68328416,ventricular,0.68328416
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,maximum-diastolic-potential,0.31752345,blood-flow,0.54737437,blood-flow,0.54737437
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22820336,atrioventricular-septal-defect,0.38728654,atrioventricular-septal-defect,0.38728654
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna,0.16775562,of,0.38412616,l-transposition,0.35627133
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,quantification,0.21082784,of,0.4907973,flow,0.38184565
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna-quantification,0.2505591,of,0.43189198,blood-flow,0.38231426
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22820336,atrioventricular-septal-defect,0.38728654,atrioventricular-septal-defect,0.38728654
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,blockade,0.2635491,bradycardia,0.4963892,bradycardia,0.4963892
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,may,0.26963884,of,0.58654004,anomalous,0.366544
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,canine,0.27630043,isolated,0.5317988,congenital-heart,0.44268316
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,selective,0.18057933,of,0.469292,l-transposition,0.40477294
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,antagonist,0.22172357,contractions,0.44449627,contractions,0.44449627
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bpm,0.31908628,beats,0.647497,beats,0.647497
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slope,0.22350413,outlet,0.41846848,flow,0.41822565
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,adenosine,0.22536264,l-transposition,0.43268204,l-transposition,0.43268204
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,receptors,0.20060575,of,0.401954,contractions,0.3900054
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq,0.13824886,isomerism,0.28846776,isomerism,0.28846776
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,prevented,0.19566363,of,0.49805415,contractions,0.37821114
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dpcpx,0.18031219,bradycardia,0.37226507,bradycardia,0.37226507
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,prevented,0.19566363,of,0.49805415,contractions,0.37821114
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ctl,0.1327637,rai,0.2871377,rai,0.2871377
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,firing,0.32287568,contractions,0.58541197,contractions,0.58541197
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,firing-rate,0.29262406,heartbeat,0.47883445,heartbeat,0.47883445
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.42091805,cardiology,0.42091805,cardiology,0.42091805
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sdd,0.15734527,eb,0.32484353,eb,0.32484353
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.42091805,cardiology,0.42091805,cardiology,0.42091805
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,useful,0.19749163,great,0.46134508,anomalous,0.31390148
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,strategy,0.23048541,of,0.44841248,heart-attack,0.36277908
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinus,0.45281008,tachycardia,0.689436,tachycardia,0.689436
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,arrest,0.38908607,mi,0.53575736,mi,0.53575736
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinus-arrest,0.4060559,bradycardia,0.5784664,bradycardia,0.5784664
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinoatrial,0.3901885,atrioventricular,0.80853266,atrioventricular,0.80853266
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,node,0.2484928,atrioventricular,0.5392989,atrioventricular,0.5392989
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinoatrial-node,0.3404545,atrioventricular,0.7619407,atrioventricular,0.7619407
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly,0.23700657,with,0.568532,mi,0.39826992
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,increased,0.32251194,of,0.64014816,mi,0.42637154
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly-increased,0.27051136,with,0.5801536,mi,0.429283
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly,0.23700657,with,0.568532,mi,0.39826992
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,controls,0.23145974,with,0.5052294,mi,0.41936132
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,normal-controls,0.17894001,abnormal,0.40670362,cad,0.38292557
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mitigate,0.21306966,great,0.40087038,plaque-deposits,0.31279248
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bradycardia,0.48126802,bradycardia,1.0,bradycardia,1.0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,membrane,0.20611405,of,0.43286008,cholesterol,0.38573062
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hyperpolarization,0.2598396,contractions,0.6084857,contractions,0.6084857
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,key-findings,0.35131258,congenital-heart-disease,0.44464862,congenital-heart-disease,0.44464862
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,heart,0.57664216,heart,1.0,heart,1.0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,g,0.21858013,single,0.41386712,ivs,0.37229383
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,g-protein,0.21410671,of,0.3605783,contractions,0.3435616
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,causing,0.1717836,of,0.5218761,congenital,0.47086555
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hyperpolarization,0.2598396,contractions,0.6084857,contractions,0.6084857
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bradycardia,0.48126802,bradycardia,1.0,bradycardia,1.0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,contributes,0.18509582,of,0.5690483,anomalous,0.32952994
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,brady,0.45217648,bradycardia,0.705533,bradycardia,0.705533
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,arrhythmias,0.54537594,tachycardia,0.7779059,tachycardia,0.7779059
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,brady-arrhythmias,0.5403278,tachycardia,0.8192025,tachycardia,0.8192025
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,assess,0.37312466,of,0.49566716,pulmonary,0.375783
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,contributions,0.3321044,of,0.54840314,anomalous,0.46282095
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,action,0.29916856,of,0.5591097,contractions,0.50062907
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potentials,0.25007966,contractions,0.46059752,contractions,0.46059752
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,action-potentials,0.27101842,contractions,0.5134718,contractions,0.5134718
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22820336,atrioventricular-septal-defect,0.38728654,atrioventricular-septal-defect,0.38728654
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.248385,l-transposition,0.42952093,l-transposition,0.42952093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,relevant,0.3264072,of,0.5628227,anomalous,0.34380507
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ikado,0.19948874,lai,0.30952346,lai,0.30952346
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.42091805,cardiology,0.42091805,cardiology,0.42091805
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq,0.13824886,isomerism,0.28846776,isomerism,0.28846776
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dpcpx,0.18031219,bradycardia,0.37226507,bradycardia,0.37226507
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ctl,0.1327637,rai,0.2871377,rai,0.2871377
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,adenosine,0.22536264,l-transposition,0.43268204,l-transposition,0.43268204
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,upregulated,0.16811627,isolated,0.3950042,arteries,0.32034808
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tachypacing,0.43898422,tachycardia,0.7175159,tachycardia,0.7175159
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tachy,0.44138175,tachycardia,0.70165867,tachycardia,0.70165867
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,studied,0.2428486,of,0.63097596,anomalous,0.39203623
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significance,0.3123301,of,0.55474335,anomaly,0.39406294
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,role,0.263546,of,0.49928063,anomalous,0.31226397
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,p,0.29391026,with,0.4559728,congestive,0.4058217
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,measured,0.2266986,of,0.539739,flow,0.4470259
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mdp,0.088078424,rai,0.2856303,rai,0.2856303
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,known,0.28223497,as,0.60071135,mi,0.41831112
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,isolated,0.20391704,isolated,1.0,l-transposition,0.45230812
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,investigated,0.19995229,of,0.6179704,anomalous,0.35378093
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,increase,0.32113555,of,0.60061187,flow,0.4086165
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,frequently,0.34173125,with,0.5701885,deposits,0.40674675
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dogs,0.25505015,congenital-heart-disease,0.4649043,congenital-heart-disease,0.4649043
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,currents,0.2616308,contractions,0.5413253,contractions,0.5413253
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,collected,0.2516878,isolated,0.54813415,blood,0.42449856
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,aps,0.42291188,fibrillation,0.47809157,fibrillation,0.47809157
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.38983548,pulmonary,0.55479974,pulmonary,0.55479974
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,behavior,0.1827973,of,0.47683254,anomalous,0.44146252
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systematically,0.3063522,of,0.5361867,anomalous,0.36930847
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulate,0.1707263,of,0.4374981,contractions,0.31312442
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.20930958,of,0.44888413,hypoplastic-left,0.43812016
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha,0.2262686,of,0.41602427,contractions,0.3112945
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.33092952,contractions,0.6351472,contractions,0.6351472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activities,0.24356377,of,0.4766258,contractions,0.3709238
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,across,0.2607503,of,0.44814807,flow,0.3484614
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cycles,0.21663785,interrupted,0.44052416,beats,0.42605734
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha-rhythmic,0.33114573,contractions,0.54696,contractions,0.54696
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha,0.2262686,of,0.41602427,contractions,0.3112945
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,range,0.29700014,of,0.40102404,cardiac,0.33579552
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,across,0.2607503,of,0.44814807,flow,0.3484614
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread,0.24299192,great,0.52951527,deposits,0.46310315
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,areas,0.32283562,deposits,0.49041492,deposits,0.49041492
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha-range,0.3023863,of,0.43773866,anomalous,0.39759815
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-areas,0.31628957,single-ventricle,0.44923478,single-ventricle,0.44923478
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frequency,0.2575089,of,0.49752423,flow,0.40794802
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.20930958,of,0.44888413,hypoplastic-left,0.43812016
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exhibits,0.106056735,of,0.46935922,anomalous,0.3859266
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,great,0.4193529,great,1.0,d-transposition,0.49969703
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,flexibility,0.21155077,stiff,0.48561442,isomerism,0.3721406
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical-phase,0.20295513,plaque-deposits,0.40728214,plaque-deposits,0.40728214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulated,0.22647466,of,0.5227381,anomalous,0.377194
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.20930958,of,0.44888413,hypoplastic-left,0.43812016
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal-breathing,0.27828258,hypoplastic-left-heart,0.51386213,hypoplastic-left-heart,0.51386213
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing-modulated,0.32842797,heartbeat,0.57188416,heartbeat,0.57188416
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical-phase,0.20295513,plaque-deposits,0.40728214,plaque-deposits,0.40728214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,unrelated,0.2251904,of,0.4738515,congenital-heart-disease,0.42151445
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,task,0.3549496,heartbeat,0.41896272,heartbeat,0.41896272
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,account,0.27722406,of,0.53262895,anomalous,0.4109847
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects-could,0.24087918,as,0.4118533,heart-attack,0.35547704
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,diametrically,0.23080812,as,0.5240729,arteries,0.42547846
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,opposed,0.2545999,as,0.64872366,flow,0.3768137
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,across,0.2607503,of,0.44814807,flow,0.3484614
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breaths,0.3122248,beats,0.5859031,beats,0.5859031
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,diametrically-opposed,0.19104525,of,0.49275064,anomalous,0.46540666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.5078748,beats,0.73981297,beats,0.73981297
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration,0.36189184,heartbeat,0.50958174,heartbeat,0.50958174
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,organize,0.3624756,return,0.37362087,cardiology,0.3624756
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.5078748,beats,0.73981297,beats,0.73981297
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced-breathing,0.39756915,bradycardia,0.61592996,bradycardia,0.61592996
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,dynamic,0.26735556,of,0.4784561,blood-flow,0.47322053
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neural,0.26662254,heartbeat,0.47604913,heartbeat,0.47604913
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,network,0.27283338,of,0.38706863,venous-return,0.34682414
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,integrated,0.3167261,of,0.46948645,single-ventricle,0.3645035
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neural-network,0.2583411,heartbeat,0.44916824,heartbeat,0.44916824
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,network-integrated,0.3002044,venous-return,0.44128448,venous-return,0.44128448
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.33092952,contractions,0.6351472,contractions,0.6351472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.20930958,of,0.44888413,hypoplastic-left,0.43812016
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread,0.24299192,great,0.52951527,deposits,0.46310315
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,areas,0.32283562,deposits,0.49041492,deposits,0.49041492
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-areas,0.31628957,single-ventricle,0.44923478,single-ventricle,0.44923478
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,organizing,0.37261796,of,0.42484042,pulmonary,0.39701754
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-processes,0.27197593,great,0.4065013,single-ventricle,0.38851926
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,angles,0.21105093,isomerism,0.4697792,isomerism,0.4697792
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,underlying,0.32773498,of,0.5517533,arrythmia,0.47153074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase-angles,0.19307329,anomalous,0.4818861,anomalous,0.4818861
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,track,0.40586048,return,0.49282968,cardiac,0.41771996
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.38983548,pulmonary,0.55479974,pulmonary,0.55479974
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.255673,contractions,0.4137666,contractions,0.4137666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,two,0.27358675,single,0.605739,l-transposition,0.37929946
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.33092952,contractions,0.6351472,contractions,0.6351472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systems,0.2822709,of,0.44318485,flow,0.3656453
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitionally,0.24988826,contractions,0.55874634,contractions,0.55874634
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,change,0.3422248,of,0.5410254,flow,0.4111107
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitionally-controlled,0.19615626,of,0.47202307,heartbeat,0.44688034
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,simple,0.2050616,single,0.48191768,anomalous,0.4230147
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,gas,0.19828166,flow,0.50715446,flow,0.50715446
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exchange,0.23966244,anomalous,0.4229427,anomalous,0.4229427
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,gas-exchange,0.19160177,pulmonary-venous,0.52715313,pulmonary-venous,0.52715313
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,recurrent,0.2713791,insufficiency,0.52224016,thrombosis,0.51575255
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,temporal,0.2527347,right,0.5001071,l-transposition,0.44301236
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frame,0.23715737,interrupted,0.42915684,l-transposition,0.33003348
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neither,0.17711422,of,0.49509227,l-transposition,0.3185464
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,fluctuations,0.26904,of,0.46820867,heartbeat,0.46759564
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neurophysiological,0.30281103,blood-flow,0.40183297,blood-flow,0.40183297
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systems,0.2822709,of,0.44318485,flow,0.3656453
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regularized,0.31327677,irregular,0.4842402,heartbeat,0.44828436
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,pattern,0.22120216,irregular,0.5954343,flow,0.4913214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase-pattern,0.18662572,irregular,0.48804358,septal-defect,0.48010355
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow-breathing,0.2686894,heartbeat,0.56451106,heartbeat,0.56451106
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regulate,0.21459617,of,0.4263422,anomalous,0.30279744
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,mental,0.44960287,congestive,0.4608202,congestive,0.4608202
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,magnetoencephalography,0.34753484,heartbeat,0.44682506,heartbeat,0.44682506
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,demonstrates,0.2093551,of,0.5866501,anomalous,0.37929255
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,consistent,0.2467189,with,0.5777458,anomalous,0.45292395
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,adjustment,0.32302567,failure,0.4557625,chd,0.44507587
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase-adjustment,0.28097692,venous-return,0.5393249,venous-return,0.5393249
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.20930958,of,0.44888413,hypoplastic-left,0.43812016
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical-phase,0.20295513,plaque-deposits,0.40728214,plaque-deposits,0.40728214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiratory,0.2748378,pulmonary,0.4931335,pulmonary,0.4931335
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.255673,contractions,0.4137666,contractions,0.4137666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,reorganize,0.283013,return,0.4050129,anomalous,0.2835914
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.38983548,pulmonary,0.55479974,pulmonary,0.55479974
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,measurements,0.27821797,blood-flow,0.45775104,blood-flow,0.45775104
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow-breathing,0.2686894,heartbeat,0.56451106,heartbeat,0.56451106
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythms,0.38085815,heartbeat,0.5610515,heartbeat,0.5610515
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-rhythms,0.35691935,heartbeat,0.544764,heartbeat,0.544764
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,noteworthy,0.27808547,great,0.5588658,anomaly,0.339082
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.5078748,beats,0.73981297,beats,0.73981297
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relative,0.20736288,of,0.6192827,mi,0.3804497
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulation,0.25770372,of,0.5526526,contractions,0.42109224
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration,0.36189184,heartbeat,0.50958174,heartbeat,0.50958174
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,stage,0.19545637,with,0.46458423,rai,0.38722774
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,became,0.37405798,with,0.5028454,tachycardia,0.3809393
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,structured,0.34557483,of,0.4458495,anomalous,0.35982317
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,pattern,0.22120216,irregular,0.5954343,flow,0.4913214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,simultaneous,0.16135281,of,0.5856672,anomalous,0.45917454
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,magnetoencephalography,0.34753484,heartbeat,0.44682506,heartbeat,0.44682506
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,mental,0.44960287,congestive,0.4608202,congestive,0.4608202
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regulation,0.29056856,of,0.5171884,l-transposition,0.37633666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,train,0.39593512,contractions,0.4625386,contractions,0.4625386
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relative,0.20736288,of,0.6192827,mi,0.3804497
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitional,0.2720839,contractions,0.5696139,contractions,0.5696139
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,control,0.26906762,with,0.5145365,mi,0.4093958
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitional-control,0.24720457,venous-return,0.50693476,venous-return,0.50693476
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,subject,0.33580956,of,0.55199313,anomaly,0.39822626
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,subject-level,0.26971275,venous-return,0.42624772,venous-return,0.42624772
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,structured,0.34557483,of,0.4458495,anomalous,0.35982317
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,manner,0.18540666,with,0.42496896,contractions,0.388913
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,specifically,0.26984817,of,0.59676015,mi,0.3534019
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,locked,0.23567647,stiff,0.48493698,l-transposition,0.37050438
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,results,0.29712585,of,0.53157276,blood,0.36869162
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,reveal,0.2379476,of,0.4893222,anomalous,0.39520228
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,numerous,0.31449497,great,0.52944255,deposits,0.44640934
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,information,0.36363098,of,0.47314215,mi,0.39006084
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,coding,0.28664,of,0.4699971,l-transposition,0.40437752
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,information-coding,0.3302455,l-transposition,0.44412056,l-transposition,0.44412056
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,indicating,0.18618478,of,0.63023484,l-transposition,0.38276994
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,unique,0.20165175,of,0.5631099,anomalous,0.44501823
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,external,0.29746136,of,0.4755252,anomalous,0.3880807
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,influences,0.2264357,of,0.5758742,anomalous,0.40226215
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,emotional,0.3916288,incompetence,0.42176452,arrythmia,0.40747583
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,functions,0.22935191,of,0.5148778,l-transposition,0.37660414
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,commonly,0.22061068,as,0.5649959,anomaly,0.38373345
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,commonly-associated,0.20561957,of,0.5553712,congenital,0.43028674
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frequency,0.2575089,of,0.49752423,flow,0.40794802
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.19908471,of,0.4318388,flow,0.38942474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.3337534,heartbeat,0.53096074,heartbeat,0.53096074
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.33092952,contractions,0.6351472,contractions,0.6351472
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,integrated,0.3167261,of,0.46948645,single-ventricle,0.3645035
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.255673,contractions,0.4137666,contractions,0.4137666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.29085433,irregular,0.5029593,contractions,0.453841
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,adjustment,0.32302567,failure,0.4557625,chd,0.44507587
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,well,0.36427143,as,0.7685982,cardiac,0.4102829
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,used,0.23211285,as,0.56584436,flow,0.35934073
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,timing,0.3297861,of,0.5694113,heartbeat,0.4286309
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,single,0.2571312,single,1.0,anomalous,0.40611145
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,revealing,0.27658927,of,0.6226121,anomalous,0.48853892
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,response,0.2306606,of,0.52661085,contractions,0.38512754
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,report,0.3478901,of,0.56646246,anomaly,0.43710455
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relationship,0.21630949,of,0.4831799,anomalous,0.3835627
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,provides,0.22296365,of,0.5261056,flow,0.32656315
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,often,0.28905255,with,0.53610253,anomaly,0.426194
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,middle,0.2588615,right,0.5402423,artery,0.5249288
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,low,0.33154353,with,0.5951388,flow,0.4108625
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,likely,0.34048563,of,0.55071557,congestive,0.42744756
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,hypothesized,0.21486883,of,0.5337665,anomalous,0.37173486
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,however,0.30646515,of,0.624624,mi,0.41109186
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,given,0.43020725,with,0.60330975,cardiology,0.43020725
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,found,0.2675444,with,0.6275196,deposits,0.41920424
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,essential,0.26315036,of,0.53323644,cardiac,0.32177997
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,complicated,0.3259474,insufficiency,0.557412,anomalous,0.48836467
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,based,0.2494699,of,0.5443143,flow,0.34116954
Implications for REDUCE IT in clinical practice.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Implications for REDUCE IT in clinical practice.,provides,0.22296365,of,0.5261056,flow,0.32656315
Implications for REDUCE IT in clinical practice.,additional,0.34573856,of,0.63162684,cardiac,0.39887685
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Implications for REDUCE IT in clinical practice.,risk-reduction,0.33166537,chd,0.4868799,chd,0.4868799
Implications for REDUCE IT in clinical practice.,triglyceride,0.26832727,cholesterol,0.8271723,cholesterol,0.8271723
Implications for REDUCE IT in clinical practice.,rich,0.21856433,deposits,0.47216946,deposits,0.47216946
Implications for REDUCE IT in clinical practice.,lipoproteins,0.24732636,cholesterol,0.7522421,cholesterol,0.7522421
Implications for REDUCE IT in clinical practice.,contribute,0.20002447,of,0.5196437,anomalous,0.32585382
Implications for REDUCE IT in clinical practice.,triglyceride-rich,0.26700047,cholesterol,0.75847816,cholesterol,0.75847816
Implications for REDUCE IT in clinical practice.,rich-lipoproteins,0.26328117,cholesterol,0.71565497,cholesterol,0.71565497
Implications for REDUCE IT in clinical practice.,triglyceride-rich-lipoproteins,0.26437896,cholesterol,0.782046,cholesterol,0.782046
Implications for REDUCE IT in clinical practice.,low,0.33154353,with,0.5951388,flow,0.4108625
Implications for REDUCE IT in clinical practice.,density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
Implications for REDUCE IT in clinical practice.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Implications for REDUCE IT in clinical practice.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Implications for REDUCE IT in clinical practice.,low-density,0.2138938,cholesterol,0.72914076,cholesterol,0.72914076
Implications for REDUCE IT in clinical practice.,density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
Implications for REDUCE IT in clinical practice.,lipoprotein-cholesterol,0.29643348,cholesterol,0.8591521,cholesterol,0.8591521
Implications for REDUCE IT in clinical practice.,low-density-lipoprotein,0.23075578,cholesterol,0.8098824,cholesterol,0.8098824
Implications for REDUCE IT in clinical practice.,density-lipoprotein-cholesterol,0.26042908,cholesterol,0.8576243,cholesterol,0.8576243
Implications for REDUCE IT in clinical practice.,type,0.18854949,of,0.48202556,aortic,0.35779506
Implications for REDUCE IT in clinical practice.,ii,0.26288998,of,0.43728137,mi,0.35983312
Implications for REDUCE IT in clinical practice.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Implications for REDUCE IT in clinical practice.,mellitus,0.3682191,congestive,0.568745,congestive,0.568745
Implications for REDUCE IT in clinical practice.,type-ii,0.0890629,anomalous,0.36715376,anomalous,0.36715376
Implications for REDUCE IT in clinical practice.,ii-diabetes,0.3225427,congestive-heart-failure,0.4519463,congestive-heart-failure,0.4519463
Implications for REDUCE IT in clinical practice.,diabetes-mellitus,0.33340782,chd,0.5153306,chd,0.5153306
Implications for REDUCE IT in clinical practice.,type-ii-diabetes,0.24739861,congestive-heart-failure,0.4210819,congestive-heart-failure,0.4210819
Implications for REDUCE IT in clinical practice.,especially,0.33332112,of,0.63661283,deposits,0.41181225
Implications for REDUCE IT in clinical practice.,among,0.2573181,of,0.57348,chd,0.4274787
Implications for REDUCE IT in clinical practice.,high,0.28122714,of,0.57459104,flow,0.3923195
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,high-risk,0.3763172,chd,0.5322769,chd,0.5322769
Implications for REDUCE IT in clinical practice.,substantial,0.27155346,great,0.64504546,anomalous,0.3652059
Implications for REDUCE IT in clinical practice.,residual,0.20644298,of,0.55126905,clot,0.49418566
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Implications for REDUCE IT in clinical practice.,kexin,0.22033545,cholesterol,0.46520597,cholesterol,0.46520597
Implications for REDUCE IT in clinical practice.,type,0.18854949,of,0.48202556,aortic,0.35779506
Implications for REDUCE IT in clinical practice.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Implications for REDUCE IT in clinical practice.,kexin-type,0.1941306,isolated,0.3996216,d-transposition,0.36559767
Implications for REDUCE IT in clinical practice.,markedly,0.23070404,with,0.5098928,contractions,0.37200773
Implications for REDUCE IT in clinical practice.,lower,0.26859394,with,0.5748005,venous,0.42565888
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,markedly-lower,0.27736422,left,0.50069106,congestive-heart-failure,0.4384452
Implications for REDUCE IT in clinical practice.,lower-risk,0.324707,chd,0.5097139,chd,0.5097139
Implications for REDUCE IT in clinical practice.,proprotein,0.2754936,cholesterol,0.47934797,cholesterol,0.47934797
Implications for REDUCE IT in clinical practice.,convertase,0.23770048,cholesterol,0.41399473,cholesterol,0.41399473
Implications for REDUCE IT in clinical practice.,subtilisin,0.16084972,clot,0.33537138,clot,0.33537138
Implications for REDUCE IT in clinical practice.,proprotein-convertase,0.23267773,cholesterol,0.44781646,cholesterol,0.44781646
Implications for REDUCE IT in clinical practice.,guide,0.3664873,of,0.44661915,single-ventricle,0.3858803
Implications for REDUCE IT in clinical practice.,combination,0.21742424,with,0.59363616,l-transposition,0.35203728
Implications for REDUCE IT in clinical practice.,lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
Implications for REDUCE IT in clinical practice.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
Implications for REDUCE IT in clinical practice.,atherosclerotic,0.37899542,plaque,0.7153188,plaque,0.7153188
Implications for REDUCE IT in clinical practice.,cvd,0.31066263,chd,0.7323322,chd,0.7323322
Implications for REDUCE IT in clinical practice.,atherosclerotic-cvd,0.36572623,coronary-artery,0.6797462,coronary-artery,0.6797462
Implications for REDUCE IT in clinical practice.,high,0.28122714,of,0.57459104,flow,0.3923195
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Implications for REDUCE IT in clinical practice.,high-risk,0.3763172,chd,0.5322769,chd,0.5322769
Implications for REDUCE IT in clinical practice.,risk-patients,0.37887704,heart-failure,0.57082677,heart-failure,0.57082677
Implications for REDUCE IT in clinical practice.,high-risk-patients,0.37083387,heart-failure,0.5414254,heart-failure,0.5414254
Implications for REDUCE IT in clinical practice.,high,0.28122714,of,0.57459104,flow,0.3923195
Implications for REDUCE IT in clinical practice.,ascvd,0.4187932,chd,0.76672643,chd,0.76672643
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,ascvd-risk,0.35199925,chd,0.71700764,chd,0.71700764
Implications for REDUCE IT in clinical practice.,residual,0.20644298,of,0.55126905,clot,0.49418566
Implications for REDUCE IT in clinical practice.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Implications for REDUCE IT in clinical practice.,statin,0.46838567,cholesterol,0.59401083,cholesterol,0.59401083
Implications for REDUCE IT in clinical practice.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Implications for REDUCE IT in clinical practice.,statin-treatment,0.31271905,heart-failure,0.54246676,heart-failure,0.54246676
Implications for REDUCE IT in clinical practice.,secondary,0.296139,failure,0.5610231,congenital,0.42706454
Implications for REDUCE IT in clinical practice.,prevention,0.37483034,thrombosis,0.45537552,thrombosis,0.45537552
Implications for REDUCE IT in clinical practice.,secondary-prevention,0.39585328,congestive-heart-failure,0.473358,congestive-heart-failure,0.473358
Implications for REDUCE IT in clinical practice.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Implications for REDUCE IT in clinical practice.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Implications for REDUCE IT in clinical practice.,icosapent,0.285451,cholesterol,0.53366494,cholesterol,0.53366494
Implications for REDUCE IT in clinical practice.,ethyl,0.22367015,isolated,0.33998215,isomerism,0.31112924
Implications for REDUCE IT in clinical practice.,icosapent-ethyl,0.23271978,cholesterol,0.46110815,cholesterol,0.46110815
Implications for REDUCE IT in clinical practice.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Implications for REDUCE IT in clinical practice.,triglycerides,0.27892497,cholesterol,0.8155755,cholesterol,0.8155755
Implications for REDUCE IT in clinical practice.,decision,0.46018064,cardiology,0.46018064,cardiology,0.46018064
Implications for REDUCE IT in clinical practice.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Implications for REDUCE IT in clinical practice.,decision-pathway,0.3011521,venous-return,0.41803974,venous-return,0.41803974
Implications for REDUCE IT in clinical practice.,current,0.39557698,of,0.4991414,flow,0.39574015
Implications for REDUCE IT in clinical practice.,guidelines,0.52468073,cardiology,0.52468073,cardiology,0.52468073
Implications for REDUCE IT in clinical practice.,ascvd,0.4187932,chd,0.76672643,chd,0.76672643
Implications for REDUCE IT in clinical practice.,events,0.3918235,of,0.4981169,mi,0.49371853
Implications for REDUCE IT in clinical practice.,statin,0.46838567,cholesterol,0.59401083,cholesterol,0.59401083
Implications for REDUCE IT in clinical practice.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Implications for REDUCE IT in clinical practice.,statin-therapy,0.39785022,heart-failure,0.5481496,heart-failure,0.5481496
Implications for REDUCE IT in clinical practice.,lowering,0.3031208,cholesterol,0.55465686,cholesterol,0.55465686
Implications for REDUCE IT in clinical practice.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Implications for REDUCE IT in clinical practice.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Implications for REDUCE IT in clinical practice.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Implications for REDUCE IT in clinical practice.,ascvd,0.4187932,chd,0.76672643,chd,0.76672643
Implications for REDUCE IT in clinical practice.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Implications for REDUCE IT in clinical practice.,synthesized,0.2057221,isolated,0.4628622,isomerism,0.36482388
Implications for REDUCE IT in clinical practice.,statins,0.4116977,cholesterol,0.593088,cholesterol,0.593088
Implications for REDUCE IT in clinical practice.,shown,0.20708838,of,0.5506151,l-transposition,0.3662261
Implications for REDUCE IT in clinical practice.,recently,0.3336877,as,0.5378315,cad,0.34116387
Implications for REDUCE IT in clinical practice.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Implications for REDUCE IT in clinical practice.,ezetimibe,0.2529185,cholesterol,0.6072894,cholesterol,0.6072894
Implications for REDUCE IT in clinical practice.,effective,0.20873946,as,0.5165305,contractions,0.33001167
Implications for REDUCE IT in clinical practice.,discussed,0.42584902,as,0.54987454,cardiology,0.42584902
Implications for REDUCE IT in clinical practice.,data,0.31118363,of,0.5086956,mi,0.36251363
Implications for REDUCE IT in clinical practice.,context,0.3526281,of,0.54966336,congenital-heart-disease,0.38638416
Implications for REDUCE IT in clinical practice.,atherogenesis,0.35990554,coronary-thrombosis,0.59492457,coronary-thrombosis,0.59492457
Implications for REDUCE IT in clinical practice.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Implications for REDUCE IT in clinical practice.,add,0.38621712,of,0.5041022,cardiology,0.38621712
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,preserved,0.24191171,with,0.53828907,deposits,0.44760028
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,left,0.3872844,left,1.0,left-atrial,0.6573896
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ventricular,0.49640656,ventricular,1.0,ventricular,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,systolic,0.48098868,ventricular,0.6719714,ventricular,0.6719714
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,function,0.2605439,of,0.55099833,flow,0.43324804
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,left-ventricular,0.47815377,ventricular,0.9088085,ventricular,0.9088085
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ventricular-systolic,0.498983,ventricular,0.8902809,ventricular,0.8902809
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,systolic-function,0.44505498,ventricular,0.5727781,ventricular,0.5727781
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity,0.18347614,heart-attack,0.45199558,heart-attack,0.45199558
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,score,0.286516,total,0.3966952,stenosis,0.38543224
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,matching,0.2777636,single,0.48957807,heartbeat,0.42221725
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,analysis,0.23442824,of,0.53198564,flow,0.34824157
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity-score,0.29849678,coronary-artery-disease,0.4735538,coronary-artery-disease,0.4735538
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,score-matching,0.31847477,congestive-heart-failure,0.4926387,congestive-heart-failure,0.4926387
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity-score-matching,0.29357332,congestive-heart-failure,0.4634212,congestive-heart-failure,0.4634212
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major,0.26991645,of,0.5153694,cardiac,0.3628927
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,end,0.28669232,interrupted,0.5072032,heart-failure,0.3686505
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,point,0.29296726,of,0.5126515,anomaly,0.38572568
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,end-point,0.24608193,failure,0.44530657,heart-failure,0.4336535
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical-end-point,0.36384842,venous-return,0.4847657,venous-return,0.4847657
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment,0.20645988,interrupted,0.4524773,artery,0.44207752
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,elevation,0.325918,infarction,0.53138053,infarction,0.53138053
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial,0.5198858,myocardial,1.0,myocardial,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,infarction,0.51348525,infarction,1.0,infarction,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment-elevation,0.4706582,infarction,0.69548696,infarction,0.69548696
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,elevation-myocardial,0.53387344,myocardial-infarction,0.85221326,myocardial-infarction,0.85221326
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial-infarction,0.5045562,myocardial-infarction,1.0,myocardial-infarction,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment-elevation-myocardial,0.5359957,myocardial-infarction,0.83597916,myocardial-infarction,0.83597916
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major,0.26991645,of,0.5153694,cardiac,0.3628927
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,adverse,0.3283087,failure,0.4862746,congestive-heart-failure,0.43527484
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,events,0.3918235,of,0.4981169,mi,0.49371853
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major-adverse,0.25712878,congenital-heart-disease,0.4734496,congenital-heart-disease,0.4734496
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,vs,0.34496382,mi,0.4353134,mi,0.4353134
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.36555648,heart-failure,0.5029925,heart-failure,0.5029925
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.2849201,with,0.5052614,mi,0.411738
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,recurrent,0.2713791,insufficiency,0.52224016,thrombosis,0.51575255
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial,0.5198858,myocardial,1.0,myocardial,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,infarction,0.51348525,infarction,1.0,infarction,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial-infarction,0.5045562,myocardial-infarction,1.0,myocardial-infarction,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical-outcomes,0.39127702,congenital-heart-disease,0.5111041,congenital-heart-disease,0.5111041
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,generation,0.25683564,of,0.5394852,contractions,0.39260584
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,new-generation,0.27306217,with,0.42088667,thrombosis,0.34814712
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting,0.35060608,of,0.48566324,atrial,0.43797946
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enzyme,0.2546285,of,0.4396425,cholesterol,0.39044598
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting-enzyme,0.37506402,congestive,0.4974824,congestive,0.4974824
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enzyme-inhibitors,0.27471942,congestive-heart-failure,0.38239455,congestive-heart-failure,0.38239455
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting-enzyme-inhibitors,0.33161855,congestive-heart-failure,0.4766807,congestive-heart-failure,0.4766807
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target,0.23866604,of,0.4775706,blood,0.34112448
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,vessel,0.2842016,arteries,0.73786265,arteries,0.73786265
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.47636238,coronary-artery,0.70679367,coronary-artery,0.70679367
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target-vessel,0.40494415,coronary-artery,0.65639186,coronary-artery,0.65639186
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,vessel-revascularization,0.42294413,myocardial-infarction,0.7133014,myocardial-infarction,0.7133014
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target,0.23866604,of,0.4775706,blood,0.34112448
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,lesion,0.23653449,plaque,0.5741841,plaque,0.5741841
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.47636238,coronary-artery,0.70679367,coronary-artery,0.70679367
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target-lesion,0.31168556,infarction,0.5301057,infarction,0.5301057
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target-lesion-revascularization,0.3907259,myocardial-infarction,0.68806434,myocardial-infarction,0.68806434
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.5261016,mi,0.99999994,mi,0.99999994
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,benefits,0.33820245,great,0.48839658,single-ventricle,0.3833536
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,blockers,0.38663626,bradycardia,0.4674531,bradycardia,0.4674531
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin-receptor,0.35618174,congestive,0.5088966,congestive,0.5088966
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,receptor-blockers,0.33424258,bradycardia,0.4559213,bradycardia,0.4559213
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin-receptor-blockers,0.3599828,congestive,0.50955385,congestive,0.50955385
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.3868778,congestive,0.5318181,congestive,0.5318181
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.2849201,with,0.5052614,mi,0.411738
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,showed,0.21619865,with,0.57298803,flow,0.33828264
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group-showed,0.25906897,with,0.48936495,atresia-with,0.38849965
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,maces,0.47506204,chd,0.6542505,chd,0.6542505
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,defined,0.2335411,as,0.60751194,stenosis,0.33817482
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,death,0.30044052,failure,0.5122394,infarction,0.4996428
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac-death,0.48684964,cardiac,0.7782619,cardiac,0.7782619
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.36555648,heart-failure,0.5029925,heart-failure,0.5029925
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.2849201,with,0.5052614,mi,0.411738
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat,0.37678185,abnormal,0.4185363,cardiac,0.39661732
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.47636238,coronary-artery,0.70679367,coronary-artery,0.70679367
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat-revascularization,0.45960498,myocardial-infarction,0.65848994,myocardial-infarction,0.65848994
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arb,0.29520378,heart-failure,0.41936678,heart-failure,0.41936678
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.2849201,with,0.5052614,mi,0.411738
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.3868778,congestive,0.5318181,congestive,0.5318181
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.2849201,with,0.5052614,mi,0.411738
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,acei,0.42623463,congestive-heart-failure,0.5122055,congestive-heart-failure,0.5122055
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.2849201,with,0.5052614,mi,0.411738
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.5261016,mi,0.99999994,mi,0.99999994
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,groups,0.2612025,with,0.4941169,mi,0.3908207
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,year,0.39816982,failure,0.4387355,mi,0.41719383
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,follow,0.49582598,cardiology,0.49582598,cardiology,0.49582598
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,year-follow,0.47264957,cardiology,0.47264957,cardiology,0.47264957
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,well,0.36427143,as,0.7685982,cardiac,0.4102829
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,established,0.29664493,of,0.60100454,l-transposition,0.35743332
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,well-established,0.26044455,as,0.5690939,l-transposition,0.35309997
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,significantly,0.23700657,with,0.568532,mi,0.39826992
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,higher,0.2654187,with,0.56796193,mi,0.398535
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,significantly-higher,0.2440085,with,0.5364338,mi,0.3939989
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,relative,0.20736288,of,0.6192827,mi,0.3804497
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,superiority,0.26282492,single,0.4359158,venous-return,0.36690065
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,prominent,0.29253632,abnormal,0.5569648,deposits,0.46347803
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ability,0.2123124,of,0.53612673,cardiac,0.340167
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hazard,0.22378854,chd,0.45025742,chd,0.45025742
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ratio,0.18660581,total,0.40182298,tof,0.36502323
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hazard-ratio,0.19644472,venous-return,0.44212234,venous-return,0.44212234
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,eluting,0.29619145,coronary,0.4426003,coronary,0.4426003
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,stents,0.3849274,stenosis,0.63866246,stenosis,0.63866246
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,eluting-stents,0.32458276,aortic-stenosis,0.5929122,aortic-stenosis,0.5929122
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cumulative,0.223378,of,0.47800833,venous-return,0.37826067
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,incidences,0.27920127,failure,0.44117478,congenital,0.43948564
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,confidence,0.2634279,chd,0.3685997,chd,0.3685997
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,interval,0.278329,congestive,0.41789418,congestive,0.41789418
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,confidence-interval,0.30343854,venous-return,0.40549245,venous-return,0.40549245
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,death,0.30044052,failure,0.5122394,infarction,0.4996428
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cause-death,0.28893504,heart-failure,0.53945255,heart-failure,0.53945255
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr,0.36646634,mitral,0.52119887,mitral,0.52119887
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,compared,0.26227483,with,0.62448335,mi,0.40925252
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.36555648,heart-failure,0.5029925,heart-failure,0.5029925
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.5261016,mi,0.99999994,mi,0.99999994
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,maces,0.47506204,chd,0.6542505,chd,0.6542505
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.3868778,congestive,0.5318181,congestive,0.5318181
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr,0.36646634,mitral,0.52119887,mitral,0.52119887
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,st,0.46681005,mi,0.5837832,mi,0.5837832
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,similar,0.23582149,with,0.5905923,anomalous,0.3839321
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,period,0.34860444,return,0.46809125,venous-return,0.39146286
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,p,0.29391026,with,0.4559728,congestive,0.4058217
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,occurrences,0.27203298,of,0.55326456,anomaly,0.43425465
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,nstemi,0.5443741,mi,0.71293795,mi,0.71293795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,non,0.3477749,with,0.61364555,mi,0.46788454
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,n,0.21850443,with,0.47536123,mi,0.3790054
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,however,0.30646515,of,0.624624,mi,0.41109186
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hence,0.27135032,of,0.69818234,anomalous,0.43981504
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,era,0.4033211,great,0.4145756,cardiology,0.4033211
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enrolled,0.4130389,cardiology,0.4130389,cardiology,0.4130389
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,decrease,0.28522113,of,0.5904174,flow,0.42153293
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,although,0.27773374,of,0.6190036,cardiac,0.39186808
Women had favourable reverse left ventricle remodelling after TAVR.,investigate,0.20519872,of,0.48247698,anomalous,0.30501914
Women had favourable reverse left ventricle remodelling after TAVR.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Women had favourable reverse left ventricle remodelling after TAVR.,gender,0.3640193,congenital-heart-disease,0.45300186,congenital-heart-disease,0.45300186
Women had favourable reverse left ventricle remodelling after TAVR.,difference,0.212452,of,0.434909,stenosis,0.35809982
Women had favourable reverse left ventricle remodelling after TAVR.,affects,0.1426264,of,0.5773267,anomaly,0.35788298
Women had favourable reverse left ventricle remodelling after TAVR.,investigate-whether,0.29625085,of,0.51440483,anomalous,0.38330853
Women had favourable reverse left ventricle remodelling after TAVR.,gender-difference,0.29540145,congenital-heart-disease,0.46232253,congenital-heart-disease,0.46232253
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable,0.28924093,chd,0.42614138,chd,0.42614138
Women had favourable reverse left ventricle remodelling after TAVR.,logistic,0.28053033,congenital-heart-disease,0.37702924,congenital-heart-disease,0.37702924
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Women had favourable reverse left ventricle remodelling after TAVR.,showed,0.21619865,with,0.57298803,flow,0.33828264
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable-logistic,0.25316238,venous-return,0.42628747,venous-return,0.42628747
Women had favourable reverse left ventricle remodelling after TAVR.,logistic-regression,0.2579405,artery-disease,0.45708418,artery-disease,0.45708418
Women had favourable reverse left ventricle remodelling after TAVR.,regression-analysis,0.2483352,congenital-heart-disease,0.45024,congenital-heart-disease,0.45024
Women had favourable reverse left ventricle remodelling after TAVR.,analysis-showed,0.2415868,of,0.43534696,congestive-heart-failure,0.36707744
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable-logistic-regression,0.23244387,artery-disease,0.4261393,artery-disease,0.4261393
Women had favourable reverse left ventricle remodelling after TAVR.,logistic-regression-analysis,0.25811133,congenital-heart-disease,0.4606786,congenital-heart-disease,0.4606786
Women had favourable reverse left ventricle remodelling after TAVR.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Women had favourable reverse left ventricle remodelling after TAVR.,since,0.44715995,of,0.60419816,cardiac,0.45060617
Women had favourable reverse left ventricle remodelling after TAVR.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.2814955,failure,0.43657047,congestive,0.39787602
Women had favourable reverse left ventricle remodelling after TAVR.,later,0.4300549,with,0.6111265,mi,0.46859914
Women had favourable reverse left ventricle remodelling after TAVR.,three-months,0.29811782,heart-failure,0.42466977,heart-failure,0.42466977
Women had favourable reverse left ventricle remodelling after TAVR.,months-later,0.361108,single-ventricle,0.4643444,single-ventricle,0.4643444
Women had favourable reverse left ventricle remodelling after TAVR.,three-months-later,0.35578233,congenital-heart-disease,0.48374647,congenital-heart-disease,0.48374647
Women had favourable reverse left ventricle remodelling after TAVR.,earlier,0.32264435,return,0.5301722,mi,0.3564632
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Women had favourable reverse left ventricle remodelling after TAVR.,mass,0.21939,tof,0.43280137,tof,0.43280137
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.3914922,failure,0.52308416,mi,0.5076717
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass,0.2639406,right-ventricle,0.5332997,right-ventricle,0.5332997
Women had favourable reverse left ventricle remodelling after TAVR.,mass-regression,0.22659707,venous-return,0.3848925,venous-return,0.3848925
Women had favourable reverse left ventricle remodelling after TAVR.,transcatheter,0.5177865,aortic-coarctation,0.6550355,aortic-coarctation,0.6550355
Women had favourable reverse left ventricle remodelling after TAVR.,aortic,0.44729716,aortic,1.0,aortic,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,valve,0.43505126,valve,1.0,valve,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,replacement,0.31602913,valve,0.5574485,valve,0.5574485
Women had favourable reverse left ventricle remodelling after TAVR.,aortic-valve,0.37780595,mitral-valve,0.83896065,mitral-valve,0.83896065
Women had favourable reverse left ventricle remodelling after TAVR.,valve-replacement,0.38788155,valve,0.76453304,valve,0.76453304
Women had favourable reverse left ventricle remodelling after TAVR.,aortic-valve-replacement,0.3912205,mitral-valve,0.794505,mitral-valve,0.794505
Women had favourable reverse left ventricle remodelling after TAVR.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Women had favourable reverse left ventricle remodelling after TAVR.,investigation,0.31772497,of,0.61667234,anomaly,0.36676937
Women had favourable reverse left ventricle remodelling after TAVR.,journal,0.530411,cardiology,0.530411,cardiology,0.530411
Women had favourable reverse left ventricle remodelling after TAVR.,foundation,0.44887322,great,0.4563089,cardiology,0.44887322
Women had favourable reverse left ventricle remodelling after TAVR.,clinical-investigation,0.4286641,of,0.5408074,congenital-heart-disease,0.51723003
Women had favourable reverse left ventricle remodelling after TAVR.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Women had favourable reverse left ventricle remodelling after TAVR.,investigation,0.31772497,of,0.61667234,anomaly,0.36676937
Women had favourable reverse left ventricle remodelling after TAVR.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Women had favourable reverse left ventricle remodelling after TAVR.,clinical-investigation,0.4286641,of,0.5408074,congenital-heart-disease,0.51723003
Women had favourable reverse left ventricle remodelling after TAVR.,indicating,0.18618478,of,0.63023484,l-transposition,0.38276994
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.32612452,of,0.44902933,mi,0.41579333
Women had favourable reverse left ventricle remodelling after TAVR.,gender,0.3640193,congenital-heart-disease,0.45300186,congenital-heart-disease,0.45300186
Women had favourable reverse left ventricle remodelling after TAVR.,female-gender,0.25800896,chd,0.46677798,chd,0.46677798
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.2814955,failure,0.43657047,congestive,0.39787602
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.3914922,failure,0.52308416,mi,0.5076717
Women had favourable reverse left ventricle remodelling after TAVR.,months-post,0.2774466,aortic-stenosis,0.42577657,aortic-stenosis,0.42577657
Women had favourable reverse left ventricle remodelling after TAVR.,repeated,0.31911406,single,0.57160586,contractions,0.41091657
Women had favourable reverse left ventricle remodelling after TAVR.,upon,0.3047079,of,0.6212549,cardiac,0.40890452
Women had favourable reverse left ventricle remodelling after TAVR.,discharge,0.4181137,return,0.5084258,infarction,0.44288716
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Women had favourable reverse left ventricle remodelling after TAVR.,mass,0.21939,tof,0.43280137,tof,0.43280137
Women had favourable reverse left ventricle remodelling after TAVR.,index,0.27677816,total,0.43109894,mi,0.39722836
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass,0.2639406,right-ventricle,0.5332997,right-ventricle,0.5332997
Women had favourable reverse left ventricle remodelling after TAVR.,mass-index,0.21219103,tof,0.35847235,tof,0.35847235
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass-index,0.25989372,right-ventricle,0.45553517,right-ventricle,0.45553517
Women had favourable reverse left ventricle remodelling after TAVR.,higher,0.2654187,with,0.56796193,mi,0.398535
Women had favourable reverse left ventricle remodelling after TAVR.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Women had favourable reverse left ventricle remodelling after TAVR.,rates,0.26658094,of,0.47081333,flow,0.4277016
Women had favourable reverse left ventricle remodelling after TAVR.,survival-rates,0.14520848,heart-failure,0.39659816,heart-failure,0.39659816
Women had favourable reverse left ventricle remodelling after TAVR.,stichting,0.3816824,cardiology,0.3816824,cardiology,0.3816824
Women had favourable reverse left ventricle remodelling after TAVR.,european,0.43573785,cardiology,0.43573785,cardiology,0.43573785
Women had favourable reverse left ventricle remodelling after TAVR.,society,0.5570969,cardiology,0.5570969,cardiology,0.5570969
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.36291775,ventricular,0.5723686,ventricular,0.5723686
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,occurred,0.23046352,of,0.5783524,l-transposition,0.38660532
Women had favourable reverse left ventricle remodelling after TAVR.,favourable,0.19239408,with,0.46347436,single-ventricle,0.3766626
Women had favourable reverse left ventricle remodelling after TAVR.,reverse,0.24697368,flow,0.43068266,flow,0.43068266
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.35974944,ventricular,0.49479768,ventricular,0.49479768
Women had favourable reverse left ventricle remodelling after TAVR.,reverse-remodelling,0.36725762,single-ventricle,0.5394625,single-ventricle,0.5394625
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,days,0.30872357,return,0.45523614,beats,0.4033618
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.3914922,failure,0.52308416,mi,0.5076717
Women had favourable reverse left ventricle remodelling after TAVR.,days-post,0.28726304,mi,0.43326238,mi,0.43326238
Women had favourable reverse left ventricle remodelling after TAVR.,favourable,0.19239408,with,0.46347436,single-ventricle,0.3766626
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.35974944,ventricular,0.49479768,ventricular,0.49479768
Women had favourable reverse left ventricle remodelling after TAVR.,lv-remodelling,0.42201245,myocardial-infarction,0.5935045,myocardial-infarction,0.5935045
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.28239584,of,0.59163296,mi,0.40441626
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.36291775,ventricular,0.5723686,ventricular,0.5723686
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.36291775,ventricular,0.5723686,ventricular,0.5723686
Women had favourable reverse left ventricle remodelling after TAVR.,regressed,0.23633021,with,0.48836464,hypoplastic,0.38898003
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.28239584,of,0.59163296,mi,0.40441626
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.36291775,ventricular,0.5723686,ventricular,0.5723686
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Women had favourable reverse left ventricle remodelling after TAVR.,mass,0.21939,tof,0.43280137,tof,0.43280137
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass,0.2639406,right-ventricle,0.5332997,right-ventricle,0.5332997
Women had favourable reverse left ventricle remodelling after TAVR.,european,0.43573785,cardiology,0.43573785,cardiology,0.43573785
Women had favourable reverse left ventricle remodelling after TAVR.,journal,0.530411,cardiology,0.530411,cardiology,0.530411
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.35974944,ventricular,0.49479768,ventricular,0.49479768
Women had favourable reverse left ventricle remodelling after TAVR.,lv-remodelling,0.42201245,myocardial-infarction,0.5935045,myocardial-infarction,0.5935045
Women had favourable reverse left ventricle remodelling after TAVR.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,early,0.34221643,of,0.5714519,mi,0.3991026
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,early-regression,0.24436645,congenital-heart-disease,0.4162745,congenital-heart-disease,0.4162745
Women had favourable reverse left ventricle remodelling after TAVR.,nine,0.2848479,with,0.5791308,d-transposition,0.38871926
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.2814955,failure,0.43657047,congestive,0.39787602
Women had favourable reverse left ventricle remodelling after TAVR.,nine-months,0.27769002,failure,0.39064896,congestive-heart-failure,0.38885134
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,days,0.30872357,return,0.45523614,beats,0.4033618
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.36291775,ventricular,0.5723686,ventricular,0.5723686
Women had favourable reverse left ventricle remodelling after TAVR.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.32612452,of,0.44902933,mi,0.41579333
Women had favourable reverse left ventricle remodelling after TAVR.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Women had favourable reverse left ventricle remodelling after TAVR.,female-sex,0.17946628,chd,0.34886223,chd,0.34886223
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.32612452,of,0.44902933,mi,0.41579333
Women had favourable reverse left ventricle remodelling after TAVR.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Women had favourable reverse left ventricle remodelling after TAVR.,female-patients,0.28755942,congenital-heart-disease,0.49672404,congenital-heart-disease,0.49672404
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,women,0.355409,chd,0.4926289,chd,0.4926289
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,men,0.36483365,chd,0.51057327,chd,0.51057327
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,g,0.21858013,single,0.41386712,ivs,0.37229383
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,achieved,0.22746107,of,0.5726348,l-transposition,0.3770222
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,women,0.355409,chd,0.4926289,chd,0.4926289
Women had favourable reverse left ventricle remodelling after TAVR.,exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
Women had favourable reverse left ventricle remodelling after TAVR.,sons,0.3803559,cardiology,0.3803559,cardiology,0.3803559
Women had favourable reverse left ventricle remodelling after TAVR.,ltd,0.19889542,arrythmia,0.2606184,arrythmia,0.2606184
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.35974944,ventricular,0.49479768,ventricular,0.49479768
Women had favourable reverse left ventricle remodelling after TAVR.,process,0.25394285,of,0.51408124,anomalous,0.37625128
Women had favourable reverse left ventricle remodelling after TAVR.,periprocedural,0.5056037,infarction,0.6541854,infarction,0.6541854
Women had favourable reverse left ventricle remodelling after TAVR.,complications,0.3646976,thrombosis,0.54964757,thrombosis,0.54964757
Women had favourable reverse left ventricle remodelling after TAVR.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Women had favourable reverse left ventricle remodelling after TAVR.,year,0.39816982,failure,0.4387355,mi,0.41719383
Women had favourable reverse left ventricle remodelling after TAVR.,one-year,0.37301552,failure,0.45880628,congestive-heart-failure,0.45256734
Women had favourable reverse left ventricle remodelling after TAVR.,men,0.36483365,chd,0.51057327,chd,0.51057327
Women had favourable reverse left ventricle remodelling after TAVR.,seemed,0.28733006,with,0.5814558,deposits,0.392466
Women had favourable reverse left ventricle remodelling after TAVR.,male,0.3213997,with,0.46579415,mi,0.43337548
Women had favourable reverse left ventricle remodelling after TAVR.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Women had favourable reverse left ventricle remodelling after TAVR.,male-patients,0.29872036,congenital-heart-disease,0.5069542,congenital-heart-disease,0.5069542
Women had favourable reverse left ventricle remodelling after TAVR.,left,0.3872844,left,1.0,left-atrial,0.6573896
Women had favourable reverse left ventricle remodelling after TAVR.,ventricle,0.37064588,ventricle,1.0,ventricle,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,left-ventricle,0.41379184,right-ventricle,0.93247366,right-ventricle,0.93247366
Women had favourable reverse left ventricle remodelling after TAVR.,john,0.33923185,cardiology,0.33923185,cardiology,0.33923185
Women had favourable reverse left ventricle remodelling after TAVR.,wiley,0.3314681,cardiology,0.3314681,cardiology,0.3314681
Women had favourable reverse left ventricle remodelling after TAVR.,independent,0.28915384,of,0.5904635,cad,0.4052443
Women had favourable reverse left ventricle remodelling after TAVR.,predictor,0.24674982,as,0.45541835,chd,0.39992505
Women had favourable reverse left ventricle remodelling after TAVR.,independent-predictor,0.29390222,venous-return,0.49250972,venous-return,0.49250972
Women had favourable reverse left ventricle remodelling after TAVR.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Women had favourable reverse left ventricle remodelling after TAVR.,role,0.263546,of,0.49928063,anomalous,0.31226397
Women had favourable reverse left ventricle remodelling after TAVR.,important-role,0.23339719,of,0.48539513,heart-attack,0.36441258
Women had favourable reverse left ventricle remodelling after TAVR.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Women had favourable reverse left ventricle remodelling after TAVR.,lvef,0.4608612,ventricular,0.63505256,ventricular,0.63505256
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Women had favourable reverse left ventricle remodelling after TAVR.,began,0.40363353,return,0.5446345,cardiology,0.40363353
Women had favourable reverse left ventricle remodelling after TAVR.,almost,0.23581058,of,0.57679296,deposits,0.3693066
Women had favourable reverse left ventricle remodelling after TAVR.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.49084872,valve,0.6515411,valve,0.6515411
Women had favourable reverse left ventricle remodelling after TAVR.,compared,0.26227483,with,0.62448335,mi,0.40925252
Women had favourable reverse left ventricle remodelling after TAVR.,follows,0.32510832,as,0.49607632,flow,0.34755546
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.49084872,valve,0.6515411,valve,0.6515411
Women had favourable reverse left ventricle remodelling after TAVR.,independently,0.2925495,with,0.5550943,cardiac,0.38836023
Women had favourable reverse left ventricle remodelling after TAVR.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Women had favourable reverse left ventricle remodelling after TAVR.,independently-associated,0.25097623,of,0.5774771,chd,0.3827371
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.49084872,valve,0.6515411,valve,0.6515411
Women had favourable reverse left ventricle remodelling after TAVR.,procedure,0.36597854,d-transposition,0.44744885,d-transposition,0.44744885
Women had favourable reverse left ventricle remodelling after TAVR.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.23907126,artery-disease,0.39331907,artery-disease,0.39331907
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.4064685,ventricular,0.8002727,ventricular,0.8002727
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.36291775,ventricular,0.5723686,ventricular,0.5723686
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.28239584,of,0.59163296,mi,0.40441626
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,0.37229544,return,0.53112984,mi,0.4760896
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.49084872,valve,0.6515411,valve,0.6515411
Women had favourable reverse left ventricle remodelling after TAVR.,process,0.25394285,of,0.51408124,anomalous,0.37625128
Women had favourable reverse left ventricle remodelling after TAVR.,procedure,0.36597854,d-transposition,0.44744885,d-transposition,0.44744885
Women had favourable reverse left ventricle remodelling after TAVR.,nine,0.2848479,with,0.5791308,d-transposition,0.38871926
Women had favourable reverse left ventricle remodelling after TAVR.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Women had favourable reverse left ventricle remodelling after TAVR.,woman,0.32633984,syndrome,0.44803536,syndrome,0.44803536
Women had favourable reverse left ventricle remodelling after TAVR.,total,0.22796647,total,0.9999999,cholesterol,0.4162783
Women had favourable reverse left ventricle remodelling after TAVR.,results,0.29712585,of,0.53157276,blood,0.36869162
Women had favourable reverse left ventricle remodelling after TAVR.,play,0.20504072,of,0.37973475,anomalous,0.28665382
Women had favourable reverse left ventricle remodelling after TAVR.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Women had favourable reverse left ventricle remodelling after TAVR.,p,0.29391026,with,0.4559728,congestive,0.4058217
Women had favourable reverse left ventricle remodelling after TAVR.,mxxx,0.21165076,isomerism,0.35886592,isomerism,0.35886592
Women had favourable reverse left ventricle remodelling after TAVR.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Women had favourable reverse left ventricle remodelling after TAVR.,median,0.25360596,total,0.41341874,single-ventricle,0.38815683
Women had favourable reverse left ventricle remodelling after TAVR.,materials,0.28523445,deposits,0.41271186,deposits,0.41271186
Women had favourable reverse left ventricle remodelling after TAVR.,increase,0.32113555,of,0.60061187,flow,0.4086165
Women had favourable reverse left ventricle remodelling after TAVR.,half,0.2921754,of,0.529518,hypoplastic,0.36585724
Women had favourable reverse left ventricle remodelling after TAVR.,gradual,0.2841432,of,0.57353985,flow,0.43979514
Women had favourable reverse left ventricle remodelling after TAVR.,enrolled,0.4130389,cardiology,0.4130389,cardiology,0.4130389
Women had favourable reverse left ventricle remodelling after TAVR.,echocardiography,0.61625123,left-heart,0.6551631,left-heart,0.6551631
Women had favourable reverse left ventricle remodelling after TAVR.,despite,0.3297603,of,0.5583629,cardiac,0.39134312
Women had favourable reverse left ventricle remodelling after TAVR.,contrast,0.2558416,of,0.5428885,mi,0.37385863
Women had favourable reverse left ventricle remodelling after TAVR.,considered,0.31302214,as,0.6929809,anomaly,0.43040824
Women had favourable reverse left ventricle remodelling after TAVR.,conclusion,0.24339199,of,0.51551676,artery,0.33304232
Women had favourable reverse left ventricle remodelling after TAVR.,behalf,0.44911885,cardiology,0.44911885,cardiology,0.44911885
Women had favourable reverse left ventricle remodelling after TAVR.,background,0.2325702,of,0.51277274,congenital,0.3895001
Women had favourable reverse left ventricle remodelling after TAVR.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Women had favourable reverse left ventricle remodelling after TAVR.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,proprotein,0.2754936,cholesterol,0.47934797,cholesterol,0.47934797
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,convertase,0.23770048,cholesterol,0.41399473,cholesterol,0.41399473
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subtilisin,0.16084972,clot,0.33537138,clot,0.33537138
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,kexin,0.22033545,cholesterol,0.46520597,cholesterol,0.46520597
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,type,0.18854949,of,0.48202556,aortic,0.35779506
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,proprotein-convertase,0.23267773,cholesterol,0.44781646,cholesterol,0.44781646
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subtilisin-kexin,0.25245252,cholesterol,0.43501025,cholesterol,0.43501025
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,kexin-type,0.1941306,isolated,0.3996216,d-transposition,0.36559767
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.28122714,of,0.57459104,flow,0.3923195
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,dose,0.35218355,single,0.47391105,blood,0.3763219
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.28122714,of,0.57459104,flow,0.3923195
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,potency,0.1786075,of,0.44235313,contractions,0.3903639
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,statins,0.4116977,cholesterol,0.593088,cholesterol,0.593088
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-dose,0.27235886,single-ventricle,0.38955262,single-ventricle,0.38955262
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,dose-high,0.18662405,rai,0.31999236,rai,0.31999236
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-potency,0.20927052,of,0.39842665,cholesterol,0.325822
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic,0.37899542,plaque,0.7153188,plaque,0.7153188
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular,0.53334194,coronary,0.74648607,coronary,0.74648607
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease-risk,0.2307109,disease,0.6917858,heart-disease,0.59362686
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular-disease,0.5005094,coronary-artery-disease,0.75097334,coronary-artery-disease,0.75097334
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldlr,0.2297699,cholesterol,0.6012795,cholesterol,0.6012795
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apolipoprotein,0.23127168,cholesterol,0.7092347,cholesterol,0.7092347
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,b,0.20100933,of,0.43435428,aortic,0.34993017
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apolipoprotein-b,0.21784578,cholesterol,0.72414654,cholesterol,0.72414654
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,frequent,0.37584627,irregular,0.537652,arrythmia,0.4617986
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,genetic,0.3038886,of,0.47143936,congenital-heart-disease,0.4219456
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,characterized,0.12166704,isolated,0.60163844,anomalous,0.39773136
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,equations,0.27554223,anomalous,0.3745166,anomalous,0.3745166
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,like,0.33787337,as,0.6495254,cardiac,0.3588698
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk-equations,0.3280302,chd,0.48697525,chd,0.48697525
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,like-one,0.2725402,heartbeat,0.40237087,heartbeat,0.40237087
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly,0.28163683,of,0.6151813,deposits,0.44905117
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary,0.56409866,coronary,1.0,coronary,1.0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heart,0.57664216,heart,1.0,heart,1.0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary-heart,0.5715385,coronary-artery,0.8627513,coronary-artery,0.8627513
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary-heart-disease,0.5209235,heart-disease,0.89567757,heart-disease,0.89567757
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,called,0.42588967,as,0.5104251,cardiology,0.42588967
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.13460028,chd,0.44572383,chd,0.44572383
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,phenocopy,0.2634087,heart-syndrome,0.5354343,heart-syndrome,0.5354343
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.21239448,with,0.46990636,ivs,0.34813386
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,since,0.44715995,of,0.60419816,cardiac,0.45060617
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,birth,0.30801767,premature,0.54811734,congenital,0.5025698
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c-levels,0.24047169,return,0.37156695,venous-return,0.36002916
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,since-birth,0.3750912,chd,0.5209483,chd,0.5209483
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic,0.37899542,plaque,0.7153188,plaque,0.7153188
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular,0.53334194,coronary,0.74648607,coronary,0.74648607
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular-disease,0.5005094,coronary-artery-disease,0.75097334,coronary-artery-disease,0.75097334
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,previous,0.37261367,with,0.5284412,mi,0.42555177
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular-disease,0.5121529,heart-disease,0.7106531,heart-disease,0.7106531
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subclinical,0.27780032,insufficiency,0.5876583,congenital-heart-disease,0.5151123
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary,0.56409866,coronary,1.0,coronary,1.0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerosis,0.43153092,coronary,0.678047,coronary,0.678047
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary-atherosclerosis,0.48726505,coronary-artery,0.8444845,coronary-artery,0.8444845
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,show,0.19476143,of,0.51487744,anomalous,0.38152152
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,regulate,0.21459617,of,0.4263422,anomalous,0.30279744
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,catabolism,0.18228799,cholesterol,0.44711894,cholesterol,0.44711894
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl-catabolism,0.21144456,cholesterol,0.5308472,cholesterol,0.5308472
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,better,0.32639185,with,0.56204724,single-ventricle,0.3852502
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,treat,0.3333781,as,0.4672093,congenital,0.37201887
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,latter,0.27988148,of,0.65402865,l-transposition,0.4336213
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.32884312,congenital,0.6040003,congenital,0.6040003
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,defects,0.22519255,defect,0.90605056,anomaly,0.6197927
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.28122714,of,0.57459104,flow,0.3923195
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-cardiovascular,0.5762588,chd,0.72270954,chd,0.72270954
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,approximately,0.27350825,of,0.56242454,contractions,0.35429108
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.28122714,of,0.57459104,flow,0.3923195
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-ldl,0.21329233,cholesterol,0.56527865,cholesterol,0.56527865
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.32884312,congenital,0.6040003,congenital,0.6040003
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low,0.33154353,with,0.5951388,flow,0.4108625
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated-low,0.23273304,return,0.3963865,venous-return,0.3918685
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,molecular,0.2634613,of,0.516936,isomerism,0.33948874
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,defects,0.22519255,defect,0.90605056,anomaly,0.6197927
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.21239448,with,0.46990636,ivs,0.34813386
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c-levels,0.24047169,return,0.37156695,venous-return,0.36002916
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.32884312,congenital,0.6040003,congenital,0.6040003
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.13460028,chd,0.44572383,chd,0.44572383
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh-patients,0.29855308,chd,0.50763404,chd,0.50763404
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl-receptor,0.2595934,cholesterol,0.6340729,cholesterol,0.6340729
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,normolipidemic,0.2688128,cholesterol,0.6342368,cholesterol,0.6342368
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,many,0.34462097,great,0.5654564,deposits,0.36972266
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.21239448,with,0.46990636,ivs,0.34813386
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lowering,0.3031208,cholesterol,0.55465686,cholesterol,0.55465686
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c-lowering,0.29363707,heart-failure,0.43807447,heart-failure,0.43807447
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,adequate,0.31365085,return,0.54715043,venous,0.43256158
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,safeheart,0.5694798,congestive-heart-failure,0.64861697,congestive-heart-failure,0.64861697
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,reduce,0.22618136,of,0.4876061,heart-attack,0.3512283
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,powered,0.24929042,single,0.41491857,single-ventricle,0.3774058
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,enough,0.3039021,weak,0.5626248,clot,0.4102653
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,polygenes,0.23779312,chd,0.424829,chd,0.424829
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,predominate,0.20811012,isolated,0.5088065,deposits,0.4079893
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,phenotype,0.18496922,defect,0.5358859,septal-defect,0.47960356
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,may,0.26963884,of,0.58654004,anomalous,0.366544
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,male,0.3213997,with,0.46579415,mi,0.43337548
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,male-sex,0.1750514,chd,0.3287017,chd,0.3287017
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,stain,0.28787863,deposits,0.48294893,deposits,0.48294893
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low,0.33154353,with,0.5951388,flow,0.4108625
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hdl,0.25075957,cholesterol,0.7834305,cholesterol,0.7834305
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low-hdl,0.2654041,cholesterol,0.63309073,cholesterol,0.63309073
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,familial,0.25805014,congenital,0.5832652,congenital,0.5832652
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hypercholesterolemia,0.36381626,cholesterol,0.6747927,cholesterol,0.6747927
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,early,0.34221643,of,0.5714519,mi,0.3991026
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,onset,0.2557202,of,0.49159142,fibrillation,0.43026125
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,early-onset,0.19962932,congenital,0.5110898,congenital,0.5110898
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly,0.28163683,of,0.6151813,deposits,0.44905117
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.13460028,chd,0.44572383,chd,0.44572383
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.22123666,chd,0.4783952,chd,0.4783952
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.21239448,with,0.46990636,ivs,0.34813386
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,used,0.23211285,as,0.56584436,flow,0.35934073
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subjects,0.2924615,with,0.45921433,chd,0.45653754
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,smoking,0.3135031,chd,0.5155174,chd,0.5155174
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,situations,0.33723134,return,0.44788587,congenital-heart-disease,0.43199956
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,presence,0.20698525,of,0.6171463,deposits,0.45095456
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,order,0.35672373,of,0.59467053,anomalous,0.37882286
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,obesity,0.37162852,chd,0.5639055,chd,0.5639055
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mutations,0.2006272,defect,0.46113265,congenital,0.42577744
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,medications,0.3929999,congestive,0.39840415,congestive,0.39840415
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lower,0.26859394,with,0.5748005,venous,0.42565888
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hypertension,0.48819616,congestive,0.66661584,congestive,0.66661584
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,however,0.30646515,of,0.624624,mi,0.41109186
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heterogenous,0.25708416,irregular,0.57629126,hypoplastic,0.45037094
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heterogeneity,0.22733976,of,0.46007073,anomaly,0.38874698
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,genes,0.22443718,l-transposition,0.43358943,l-transposition,0.43358943
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,gain,0.2829591,of,0.47916776,heartbeat,0.3683428
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,function,0.2605439,of,0.55099833,flow,0.43324804
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ezetimibe,0.2529185,cholesterol,0.6072894,cholesterol,0.6072894
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,exposed,0.16702625,with,0.4779149,deposits,0.34760392
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,explains,0.24965554,of,0.56729746,anomalous,0.49039742
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,encountered,0.32815522,of,0.5562181,anomaly,0.49482754
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,diabetes,0.39895988,chd,0.5466827,chd,0.5466827
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,detection,0.22305535,of,0.4642575,flow,0.35575604
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,depends,0.21898639,of,0.60277516,anomalous,0.37883127
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,caused,0.1752007,of,0.53973085,congenital,0.42777976
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,carrying,0.1541062,with,0.46680778,l-transposition,0.4339143
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,captured,0.31838775,of,0.48264515,flow,0.39587998
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,burden,0.27055943,disease,0.5228828,heart-disease,0.40476274
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apob,0.24761474,cholesterol,0.68698305,cholesterol,0.68698305
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,also,0.36015856,of,0.65908813,flow,0.41040578
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",rare,0.3006698,anomaly,0.5709667,anomaly,0.5709667
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",autosomal,0.19912295,congenital,0.6035224,congenital,0.6035224
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",dominant,0.19307572,anomalous,0.45553446,anomalous,0.45553446
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",immunodeficiency,0.21528868,congenital-heart-disease,0.49490765,congenital-heart-disease,0.49490765
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",attributable,0.2081298,of,0.54582804,chd,0.40869844
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",autosomal-dominant,0.22887108,congenital,0.6066513,congenital,0.6066513
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",severe,0.29645193,insufficiency,0.65468115,stenosis,0.5520288
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",neutropenia,0.28446373,bradycardia,0.4896416,bradycardia,0.4896416
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",international,0.4245627,cardiology,0.4245627,cardiology,0.4245627
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",registry,0.44611835,congenital-heart-disease,0.48533773,congenital-heart-disease,0.48533773
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",severe-chronic,0.18203893,insufficiency,0.5379262,congenital-heart-disease,0.4992344
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",quite,0.30668372,weak,0.55686647,anomalous,0.39372605
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",variable,0.221965,of,0.60098064,anomaly,0.4223012
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",across,0.2607503,of,0.44814807,flow,0.3484614
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient,0.47667986,with,0.5110891,cardiology,0.47667986
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cohorts,0.31992877,chd,0.47250944,chd,0.47250944
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",across-patient,0.38087448,venous-return,0.4515733,venous-return,0.4515733
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient-cohorts,0.36353126,venous-return,0.45031023,venous-return,0.45031023
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treat,0.3333781,as,0.4672093,congenital,0.37201887
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",infections,0.29786497,disease,0.45983067,thrombosis,0.45491943
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",based,0.2494699,of,0.5443143,flow,0.34116954
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",upon,0.3047079,of,0.6212549,cardiac,0.40890452
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",based-upon,0.21706815,as,0.41261694,venous-return,0.33762562
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",recurrent,0.2713791,insufficiency,0.52224016,thrombosis,0.51575255
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",otitis,0.26413444,atresia,0.44401607,atresia,0.44401607
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",media,0.26348433,of,0.40421075,mi,0.34874648
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",otitis-media,0.26148635,congenital-heart-disease,0.42647982,congenital-heart-disease,0.42647982
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human,0.20610836,of,0.5175895,l-transposition,0.36225826
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",papilloma,0.22453472,atresia,0.43492442,atresia,0.43492442
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",virus,0.21554038,paivs,0.45592806,paivs,0.45592806
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human-papilloma,0.21577239,paivs,0.42250058,paivs,0.42250058
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",papilloma-virus,0.19842955,paivs,0.41802076,paivs,0.41802076
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human-papilloma-virus,0.19945452,paivs,0.42715952,paivs,0.42715952
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",features,0.24589524,of,0.5517558,anomaly,0.49347878
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",occur,0.18988883,of,0.53400475,anomaly,0.42337352
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",consistently,0.3148677,with,0.590214,flow,0.41162568
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital,0.36728865,congenital,1.0,congenital,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",heart,0.57664216,heart,1.0,heart,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital-heart,0.4727098,congenital-heart,1.0,congenital-heart,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",heart-disease,0.44656026,heart-disease,1.0,heart-disease,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital-heart-disease,0.4578827,congenital-heart-disease,1.0,congenital-heart-disease,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",ongoing,0.44038102,of,0.5501542,mi,0.4593027
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical,0.40667677,of,0.48020738,cardiology,0.40667677
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical-trials,0.4117396,heart-failure,0.48685247,heart-failure,0.48685247
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",reviewed,0.48340788,of,0.5375547,cardiology,0.48340788
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical,0.40667677,of,0.48020738,cardiology,0.40667677
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",manifestations,0.32852295,disease,0.62007797,syndrome,0.60876584
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",another,0.37102824,single,0.67103195,mi,0.41113138
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",important,0.26857167,great,0.5369053,anomalous,0.32819813
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",complication,0.3279262,failure,0.55391526,thrombosis,0.5466996
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",respiratory,0.38983548,pulmonary,0.55479974,pulmonary,0.55479974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",infections,0.29786497,disease,0.45983067,thrombosis,0.45491943
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",respiratory-infections,0.28237566,pulmonary-venous,0.48175806,pulmonary-venous,0.48175806
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treat,0.3333781,as,0.4672093,congenital,0.37201887
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whims,0.3925637,congenital-heart-disease,0.4158479,congenital-heart-disease,0.4158479
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical,0.40667677,of,0.48020738,cardiology,0.40667677
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",consequences,0.25947732,of,0.54692155,anomaly,0.41809624
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical-consequences,0.32014787,of,0.5165924,congenital-heart-disease,0.47825587
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",diverse,0.3032622,of,0.5461366,cardiac,0.3471622
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",manifestations,0.32852295,disease,0.62007797,syndrome,0.60876584
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",families,0.2606998,chd,0.40051168,chd,0.40051168
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",within,0.30995527,of,0.57602364,deposits,0.42065546
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",families,0.2606998,chd,0.40051168,chd,0.40051168
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",within-families,0.22463623,congenital-heart-disease,0.44401804,congenital-heart-disease,0.44401804
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",term,0.2891546,premature,0.48331085,anomaly,0.40103653
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",observations,0.27909255,of,0.5493803,deposits,0.43099713
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",stimulating,0.21986872,of,0.4940443,contractions,0.40368563
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",factor,0.1861548,of,0.44319516,thrombosis,0.35690165
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",stimulating-factor,0.21484858,of,0.44190508,contractions,0.39972
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",recent,0.42971963,of,0.545993,cardiology,0.42971963
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",findings,0.33716512,of,0.51820576,anomaly,0.40461916
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",novel,0.15367755,single,0.47320092,d-transposition,0.3194505
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",agents,0.28208297,as,0.4665778,congestive,0.34284872
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",novel-agents,0.2527578,as,0.39458087,heart-attack,0.3663209
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",natural,0.16362667,of,0.532617,anomalous,0.3907894
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",history,0.40648568,with,0.47822285,arrythmia,0.4671815
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",natural-history,0.31669372,congenital-heart-disease,0.47757027,congenital-heart-disease,0.47757027
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",less,0.30277786,with,0.57537794,mi,0.38854462
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",commonly,0.22061068,as,0.5649959,anomaly,0.38373345
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",less-commonly,0.15092346,as,0.4819561,l-transposition,0.37639958
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hearing,0.28627017,congenital-heart,0.5228472,congenital-heart,0.5228472
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",loss,0.15467258,of,0.561642,anomaly,0.37637395
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hearing-loss,0.21298131,congenital-heart,0.50610554,congenital-heart,0.50610554
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",granulocyte,0.2071282,blood-clot,0.46418375,blood-clot,0.46418375
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",colony,0.19134386,of,0.3487906,clot,0.34250063
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",granulocyte-colony,0.19700652,blood-clot,0.38400424,blood-clot,0.38400424
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",family,0.39850003,cardiology,0.39850003,cardiology,0.39850003
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",concerns,0.41936314,great,0.5325278,cardiology,0.41936314
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",associated,0.20417106,with,0.60998726,congenital,0.4144575
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",malignancies,0.28991798,disease,0.4785459,congenital,0.4774157
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",enrolled,0.4130389,cardiology,0.4130389,cardiology,0.4130389
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim,0.24125664,heart-syndrome,0.38653183,heart-syndrome,0.38653183
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",syndrome,0.2608677,syndrome,1.0,syndrome,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim-syndrome,0.2207396,heart-syndrome,0.81135046,heart-syndrome,0.81135046
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",review,0.438658,of,0.54425275,cardiology,0.438658
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",indicates,0.1844736,of,0.6366827,anomalous,0.38955534
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",mild,0.26540622,with,0.5450069,stenosis,0.48330766
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hypogammaglobulinemia,0.21975793,congenital,0.57705784,congenital,0.57705784
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",immunodeficiency,0.21528868,congenital-heart-disease,0.49490765,congenital-heart-disease,0.49490765
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",expand,0.2895818,great,0.44435167,flow,0.3185755
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",understanding,0.3158453,great,0.5292363,anomalous,0.3759449
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient,0.47667986,with,0.5110891,cardiology,0.47667986
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",neutropenia,0.28446373,bradycardia,0.4896416,bradycardia,0.4896416
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",important,0.26857167,great,0.5369053,anomalous,0.32819813
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",complication,0.3279262,failure,0.55391526,thrombosis,0.5466996
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whims,0.3925637,congenital-heart-disease,0.4158479,congenital-heart-disease,0.4158479
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",understanding,0.3158453,great,0.5292363,anomalous,0.3759449
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",syndrome,0.2608677,syndrome,1.0,syndrome,1.0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",review,0.438658,of,0.54425275,cardiology,0.438658
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hypogammaglobulinemia,0.21975793,congenital,0.57705784,congenital,0.57705784
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",warts,0.2413415,congenital,0.38728702,congenital,0.38728702
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",vulvular,0.39380732,mitral,0.5787458,mitral,0.5787458
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treatment,0.30650938,of,0.52012336,congestive,0.36983645
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",summary,0.39694136,of,0.48017746,cardiology,0.39694136
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",source,0.28251278,as,0.48821616,deposits,0.35806987
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",purpose,0.27727276,of,0.5072116,congenital,0.37470472
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",prevent,0.21931013,of,0.49340016,thrombosis,0.361466
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",myelokathexis,0.16645613,heart-syndrome,0.513316,heart-syndrome,0.513316
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",mutations,0.2006272,defect,0.46113265,congenital,0.42577744
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",morbidity,0.31568646,chd,0.50165594,chd,0.50165594
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",lymphomas,0.23226991,congenital-heart-disease,0.40951252,congenital-heart-disease,0.40951252
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",lymphocytopenia,0.1884036,congenital-heart-disease,0.46532148,congenital-heart-disease,0.46532148
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",however,0.30646515,of,0.624624,mi,0.41109186
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",example,0.31337005,as,0.6449598,anomaly,0.4410865
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",effective,0.20873946,as,0.5165305,contractions,0.33001167
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",diversity,0.27962202,of,0.49246913,l-transposition,0.3706057
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",controversial,0.3314264,of,0.49207133,congenital,0.3995453
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",common,0.21206799,of,0.500178,anomaly,0.44165826
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cervical,0.25354704,stenosis,0.4408068,stenosis,0.4408068
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cellulitis,0.32172608,right,0.5060012,thrombosis,0.5017346
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cause,0.24258707,congenital,0.5065234,congenital,0.5065234
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",almost,0.23581058,of,0.57679296,deposits,0.3693066
Prime time for ticagrelor monotherapy.,n,0.21850443,with,0.47536123,mi,0.3790054
Prime time for ticagrelor monotherapy.,engl,0.2740543,lai,0.333085,lai,0.333085
Prime time for ticagrelor monotherapy.,j,0.24581458,lai,0.35768944,lai,0.35768944
Prime time for ticagrelor monotherapy.,med,0.4682718,cardiology,0.4682718,cardiology,0.4682718
Prime time for ticagrelor monotherapy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prime time for ticagrelor monotherapy.,nov,0.24035592,paivs,0.37080926,paivs,0.37080926
Prime time for ticagrelor monotherapy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prime time for ticagrelor monotherapy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prime time for ticagrelor monotherapy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prime time for ticagrelor monotherapy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Prime time for ticagrelor monotherapy.,comment,0.39368364,of,0.42755854,anomaly,0.4086154
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,time,0.350901,return,0.5513821,venous-return,0.44564146
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,quantitative,0.25902963,of,0.50591725,flow,0.42854387
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,polymerase,0.19583255,l-transposition,0.37304133,l-transposition,0.37304133
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,chain,0.21241923,interrupted,0.40972078,isomerism,0.3719264
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,reaction,0.17841876,attack,0.4534219,isomerism,0.37329036
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,time-quantitative,0.26383507,blood-flow,0.4268297,blood-flow,0.4268297
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,quantitative-polymerase,0.18744552,flow,0.38419175,flow,0.38419175
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,polymerase-chain,0.13050103,double,0.33321464,l-transposition,0.33175573
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,chain-reaction,0.17494181,of,0.3569991,isomerism,0.35615683
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,polymerase-chain-reaction,0.14632905,isolated,0.3387306,l-transposition,0.3272104
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mimic,0.15468699,as,0.46451622,heart-attack,0.34456238
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,partly,0.25834653,of,0.60417247,contractions,0.39469504
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,reverse,0.24697368,flow,0.43068266,flow,0.43068266
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,found,0.2675444,with,0.6275196,deposits,0.41920424
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.25555176,right,0.55372226,arrythmia,0.40748215
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,negatively,0.18867487,with,0.50144655,cholesterol,0.3726651
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,regulated,0.24102873,of,0.50586647,l-transposition,0.33494547
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.29465,cardiac,0.33710712,cardiac,0.33710712
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,negatively-regulated,0.1976735,of,0.51282024,l-transposition,0.37657547
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked,0.17091186,with,0.5041717,chd,0.33989683
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,immunosorbent,0.20176652,isolated,0.28124496,plaque-deposits,0.2765622
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,assay,0.19801754,of,0.37163246,flow,0.32158902
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,also,0.36015856,of,0.65908813,flow,0.41040578
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked-immunosorbent,0.18003406,plaque-deposits,0.3461055,plaque-deposits,0.3461055
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,immunosorbent-assay,0.1756781,blood-clot,0.31593472,blood-clot,0.31593472
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked-immunosorbent-assay,0.18171024,congenital-heart-disease,0.33312884,congenital-heart-disease,0.33312884
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear,0.36382627,of,0.4222371,cardiology,0.36382627
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,kappa,0.1823206,weak,0.3636362,rai,0.29203212
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,b,0.20100933,of,0.43435428,aortic,0.34993017
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear-factor,0.22014165,of,0.4173162,blood-clot,0.31464875
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor-kappa,0.20038992,mitral-regurgitation,0.32530564,mitral-regurgitation,0.32530564
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,kappa-b,0.19012833,deposits,0.298818,deposits,0.298818
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear-factor-kappa,0.21833506,of,0.34158355,l-transposition,0.32355893
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor-kappa-b,0.18255737,mitral-regurgitation,0.30661488,mitral-regurgitation,0.30661488
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,matrix,0.19602376,deposits,0.43658155,deposits,0.43658155
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,metalloproteinases,0.22464281,coronary-thrombosis,0.382625,coronary-thrombosis,0.382625
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,matrix-metalloproteinases,0.22160462,deposits,0.3906561,deposits,0.3906561
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,detect,0.19525596,of,0.45315933,flow,0.34090838
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor-levels,0.25205925,of,0.38602555,venous-return,0.36991385
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor,0.21814886,clot,0.4081839,clot,0.4081839
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,necrosis,0.22158405,failure,0.4695571,infarction,0.4620351
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor-necrosis,0.23147793,myocardial-infarction,0.40165275,myocardial-infarction,0.40165275
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,necrosis-factor,0.21652122,failure,0.46052828,artery-disease,0.4030116
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor-necrosis-factor,0.21119751,myocardial-infarction,0.36429393,myocardial-infarction,0.36429393
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,greatly,0.2957241,of,0.60406625,cardiac,0.366642
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,destructive,0.1611523,disease,0.5080888,deposits,0.4516594
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.29465,cardiac,0.33710712,cardiac,0.33710712
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury-model,0.24190447,infarction,0.4060843,infarction,0.4060843
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced-inflammatory,0.20548394,disease,0.4897437,syndrome,0.45202377
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,western,0.30529958,flow,0.3707292,flow,0.3707292
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,blot,0.22009271,isolated,0.38064194,flow,0.36927542
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tested,0.25299942,of,0.5634051,contractions,0.36297208
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,western-blot,0.20736519,isolated,0.33727774,flow,0.29961938
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,blot-tested,0.2843278,isolated,0.39176506,flow,0.35706344
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell,0.21863139,of,0.48460138,flow,0.38218224
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,viability,0.19813254,of,0.42581767,flow,0.41994306
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced-cell,0.11051001,of,0.46156126,flow,0.38240814
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell-viability,0.19357207,flow,0.41043574,flow,0.41043574
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.24051979,mi,0.30050132,mi,0.30050132
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,via,0.2561984,of,0.50595546,flow,0.41023284
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jnk,0.13334003,mitral-regurgitation,0.32413638,mitral-regurgitation,0.32413638
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.25555176,right,0.55372226,arrythmia,0.40748215
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inhibited,0.18171512,isolated,0.4526819,contractions,0.4334391
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.24051979,mi,0.30050132,mi,0.30050132
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,signaling-pathways,0.1904434,of,0.37176776,atrioventricular,0.33244452
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mimic,0.15468699,as,0.46451622,heart-attack,0.34456238
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.25555176,right,0.55372226,arrythmia,0.40748215
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inhibited,0.18171512,isolated,0.4526819,contractions,0.4334391
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factors,0.24127257,of,0.49770784,chd,0.4172811
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell,0.21863139,of,0.48460138,flow,0.38218224
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,viability,0.19813254,of,0.42581767,flow,0.41994306
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell-viability,0.19357207,flow,0.41043574,flow,0.41043574
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mmps,0.24054664,deposits,0.3897891,deposits,0.3897891
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,terminal,0.16295928,of,0.5041194,l-transposition,0.41455114
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,kinase,0.17639789,of,0.32242787,myocardial,0.3009235
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,terminal-kinase,0.15700658,l-transposition,0.41672248,l-transposition,0.41672248
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,proteins,0.21103716,of,0.46288005,deposits,0.3796569
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,related-proteins,0.24870159,of,0.4675978,congenital-heart-disease,0.3770905
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,preliminarily,0.3055941,of,0.54904556,clot,0.37238932
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,studied,0.2428486,of,0.63097596,anomalous,0.39203623
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,opposite,0.15786405,double,0.5265681,l-transposition,0.45230547
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jun,0.23980604,dorv,0.29875183,dorv,0.29875183
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,n,0.21850443,with,0.47536123,mi,0.3790054
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jun-n,0.24075928,bradycardia,0.28859857,bradycardia,0.28859857
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,high,0.28122714,of,0.57459104,flow,0.3923195
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,disability,0.28170583,disease,0.47105905,chd,0.4456595
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,high-disability,0.22756825,chd,0.4778881,chd,0.4778881
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,ankylosing,0.3116781,disease,0.49128255,congenital-heart-disease,0.44979563
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,spondylitis,0.31694204,disease,0.49878246,congenital-heart-disease,0.46025696
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,ankylosing-spondylitis,0.29768977,congenital-heart-disease,0.49555472,congenital-heart-disease,0.49555472
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration,0.19722623,of,0.40778574,flow,0.39647174
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,assays,0.23059516,of,0.36477953,blood-clot,0.30757627
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration-assays,0.1732143,flow,0.363322,flow,0.363322
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.29465,cardiac,0.33710712,cardiac,0.33710712
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.25555176,right,0.55372226,arrythmia,0.40748215
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,detect,0.19525596,of,0.45315933,flow,0.34090838
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.24051979,mi,0.30050132,mi,0.30050132
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tested,0.25299942,of,0.5634051,contractions,0.36297208
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jnk,0.13334003,mitral-regurgitation,0.32413638,mitral-regurgitation,0.32413638
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mmps,0.24054664,deposits,0.3897891,deposits,0.3897891
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration,0.19722623,of,0.40778574,flow,0.39647174
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,used,0.23211285,as,0.56584436,flow,0.35934073
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,transfection,0.23006131,l-transposition,0.36691725,l-transposition,0.36691725
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,showed,0.21619865,with,0.57298803,flow,0.33828264
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,real,0.3591983,great,0.53489023,flow,0.42211816
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nf,0.21206217,eb,0.44363278,eb,0.44363278
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,moreover,0.16758724,of,0.5596781,plaque-deposits,0.35056823
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,microrna,0.25350013,of,0.36797974,blood,0.3582111
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,interleukin,0.17792475,cholesterol,0.3234432,cholesterol,0.3234432
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,furthermore,0.18322246,of,0.5529862,plaque-deposits,0.34174067
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,functions,0.22935191,of,0.5148778,l-transposition,0.37660414
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,function,0.2605439,of,0.55099833,flow,0.43324804
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,finally,0.32854706,of,0.64012104,flow,0.39903617
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,expressions,0.19508134,of,0.43140122,flow,0.3462352
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,enzyme,0.2546285,of,0.4396425,cholesterol,0.39044598
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,downregulation,0.20097296,of,0.4149595,l-transposition,0.3758948
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,construct,0.15341623,of,0.38565916,l-transposition,0.34442246
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,changed,0.39587775,with,0.5434908,venous,0.4192535
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cck,0.16258201,contractions,0.4059432,contractions,0.4059432
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,c,0.21239448,with,0.46990636,ivs,0.34813386
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bilobalide,0.20919764,isolated,0.37491304,cholesterol,0.34237036
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,based,0.2494699,of,0.5443143,flow,0.34116954
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,additionally,0.26417398,of,0.6596129,flow,0.38005078
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ex,0.19497,flow,0.42250997,flow,0.42250997
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.294477,of,0.6234695,anomalous,0.38919652
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",decreased,0.2912292,of,0.59706545,flow,0.4062525
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache,0.20807938,weak,0.35617685,blood-clot,0.32616764
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ex-vivo,0.1405592,blood-flow,0.43793744,blood-flow,0.43793744
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo-studies,0.25743747,congenital-heart-disease,0.36922002,congenital-heart-disease,0.36922002
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies-suggested,0.41054344,of,0.47606468,congenital-heart-disease,0.42750886
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache-activity,0.22004214,of,0.4869771,contractions,0.4226874
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",behavioral,0.28967425,of,0.41226506,bradycardia,0.38596666
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",signified,0.28495395,of,0.6525098,anomalous,0.44969663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",parallel,0.21132064,double,0.5125164,flow,0.40946773
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",artificial,0.18797731,of,0.4265266,hypoplastic-left-heart,0.35529345
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",membrane,0.20611405,of,0.43286008,cholesterol,0.38573062
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",permeation,0.1356131,blood-clot,0.40747976,blood-clot,0.40747976
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",assay,0.19801754,of,0.37163246,flow,0.32158902
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",parallel-artificial,0.23827758,interrupted,0.455633,venous-return,0.44020492
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",artificial-membrane,0.2011394,of,0.46795905,mitral-valve,0.3797024
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",membrane-permeation,0.15935385,isolated,0.3809993,contractions,0.36853668
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",good,0.31429055,weak,0.60268193,venous-return,0.38116372
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oral,0.3003844,of,0.46959797,plaque,0.38315025
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",absorption,0.105243266,anomalous,0.4307732,anomalous,0.4307732
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",characteristics,0.21032988,of,0.5401758,anomalous,0.38450566
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained,0.29897088,of,0.5930543,chd,0.4536072
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oral-absorption,0.14391932,anomalous,0.40955597,anomalous,0.40955597
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroblastoma,0.23443615,cardiac,0.39462113,cardiac,0.39462113
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",cell,0.21863139,of,0.48460138,flow,0.38218224
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",lines,0.23701838,intact,0.44574544,ivs,0.38147125
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroblastoma-cell,0.21551138,heart-syndrome,0.41906974,heart-syndrome,0.41906974
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",cell-lines,0.19909571,of,0.39812192,l-transposition,0.35238057
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroblastoma-cell-lines,0.2116668,heart-syndrome,0.412804,heart-syndrome,0.412804
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",synthesized,0.2057221,isolated,0.4628622,isomerism,0.36482388
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compounds,0.20514143,isomerism,0.4353664,isomerism,0.4353664
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.294477,of,0.6234695,anomalous,0.38919652
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",significant,0.2800444,great,0.554224,stenosis,0.40396324
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",showed,0.21619865,with,0.57298803,flow,0.33828264
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",significant,0.2800444,great,0.554224,stenosis,0.40396324
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",displacement,0.1856063,l-transposition,0.48802197,l-transposition,0.48802197
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced,0.18249518,of,0.5615651,contractions,0.42990774
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",dysfunctions,0.30162042,insufficiency,0.5983866,heart-syndrome,0.5155183
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",performed,0.3394584,of,0.5502712,anomaly,0.3917434
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced-cognitive,0.2708265,congestive-heart-failure,0.4281525,congestive-heart-failure,0.4281525
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",terminal,0.16295928,of,0.5041194,l-transposition,0.41455114
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl,0.18621302,isomerism,0.4499982,isomerism,0.4499982
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ring,0.23602092,isomerism,0.4797002,isomerism,0.4797002
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",considered,0.31302214,as,0.6929809,anomaly,0.43040824
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl-ring,0.18070245,isomerism,0.53169197,isomerism,0.53169197
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",also,0.36015856,of,0.65908813,flow,0.41040578
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",anti,0.24353361,weak,0.4726881,isomerism,0.366829
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound,0.13575457,isomerism,0.41255152,isomerism,0.41255152
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",containing,0.1330749,of,0.51960796,deposits,0.3792259
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",butyrylcholinesterase,0.16386145,cholesterol,0.43268114,cholesterol,0.43268114
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",aggregation,0.22941348,clot,0.5090701,clot,0.5090701
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",synthesized,0.2057221,isolated,0.4628622,isomerism,0.36482388
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",molecular,0.2634613,of,0.516936,isomerism,0.33948874
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hybrids,0.19303212,great,0.37870842,d-transposition,0.34170172
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",peripheral,0.25941038,venous,0.56411976,venous,0.56411976
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",anionic,0.16715023,isomerism,0.43347138,isomerism,0.43347138
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",site,0.25050646,intact,0.50730455,deposits,0.38691008
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",anionic-site,0.16879019,isomerism,0.42693406,isomerism,0.42693406
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzyme,0.2546285,of,0.4396425,cholesterol,0.39044598
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",kinetics,0.14638367,of,0.4826119,anomalous,0.4070374
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzyme-kinetics,0.25992823,of,0.37562665,blood-flow,0.3626812
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",kinetics-study,0.40622944,venous-return,0.46433446,venous-return,0.46433446
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic,0.23256747,anomalous,0.41131243,anomalous,0.41131243
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",force,0.29564968,contractions,0.54413867,contractions,0.54413867
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",microscopy,0.25916165,deposits,0.45140553,deposits,0.45140553
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic-force,0.242117,stiff,0.38226932,anomalous,0.37621158
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",force-microscopy,0.26036343,stiff,0.41757417,blood-flow,0.39570612
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic-force-microscopy,0.24490291,stiff,0.3829053,plaque-deposits,0.36040068
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",balanced,0.2348954,with,0.48585773,flow,0.40074843
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",inhibitory,0.17329565,of,0.47840768,contractions,0.4383099
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential,0.23291323,of,0.5645705,cardiac,0.34140193
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris,0.2361333,lai,0.32582372,lai,0.32582372
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",water,0.24220353,of,0.46924597,flow,0.42210716
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",maze,0.301763,right-atrial,0.46226373,right-atrial,0.46226373
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris-water,0.23275238,lai,0.38960692,lai,0.38960692
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",water-maze,0.2338333,right-atrial,0.37459135,right-atrial,0.37459135
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris-water-maze,0.22114578,venous-return,0.3674526,venous-return,0.3674526
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pharmacokinetic,0.22140636,blood-flow,0.35424423,blood-flow,0.35424423
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound,0.13575457,isomerism,0.41255152,isomerism,0.41255152
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache,0.23982838,attack,0.31091765,heart-attack,0.2863369
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.294477,of,0.6234695,anomalous,0.38919652
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pampa,0.21306475,lai,0.39745027,lai,0.39745027
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced,0.18249518,of,0.5615651,contractions,0.42990774
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",thioflavin,0.19206303,plaque-deposits,0.47254145,plaque-deposits,0.47254145
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",afm,0.22845559,stiff,0.36187783,plaque-deposits,0.3207001
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential,0.23291323,of,0.5645705,cardiac,0.34140193
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",lead,0.2468082,of,0.48279357,anomalous,0.37930223
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",antioxidant,0.19507357,cholesterol,0.39006746,cholesterol,0.39006746
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential,0.23291323,of,0.5645705,cardiac,0.34140193
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",target,0.23866604,of,0.4775706,blood,0.34112448
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzymes,0.32873723,of,0.43536004,l-transposition,0.38674402
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",target-enzymes,0.27919185,blood-clot,0.4010569,blood-clot,0.4010569
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",propidium,0.17489411,flow,0.43358082,flow,0.43358082
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",iodide,0.1302534,rai,0.4101032,rai,0.4101032
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",propidium-iodide,0.14874634,rai,0.41383833,rai,0.41383833
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",prompted,0.38793564,of,0.65488327,congenital,0.38834798
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",researchers,0.42987615,great,0.51383656,cardiology,0.42987615
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroprotective,0.22589122,infarction,0.39975306,infarction,0.39975306
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ability,0.2123124,of,0.53612673,cardiac,0.340167
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morphological,0.23301639,of,0.51360136,anomaly,0.4440594
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",characterization,0.17958075,isolated,0.5420585,anomalous,0.37839413
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",mixed,0.20806026,with,0.5015327,venous,0.39424977
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",type,0.18854949,of,0.48202556,aortic,0.35779506
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",mixed-type,0.09511684,anomalous,0.41198537,anomalous,0.41198537
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",memory,0.2714194,of,0.38706335,cardiac,0.34561598
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",improvement,0.36781824,return,0.5283363,congestive,0.42538065
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",memory-improvement,0.39017665,congestive-heart-failure,0.45029882,congestive-heart-failure,0.45029882
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",functional,0.2048316,of,0.51558334,l-transposition,0.40613407
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",agents,0.28208297,as,0.4665778,congestive,0.34284872
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",excellent,0.27284765,great,0.59726465,anomalous,0.3843443
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",blood,0.32078606,blood,1.0,blood,1.0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",diverse,0.3032622,of,0.5461366,cardiac,0.3471622
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",nature,0.28114077,of,0.5463233,anomalous,0.4306179
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",difluoro,0.15173417,isomerism,0.41043094,isomerism,0.41043094
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",substitution,0.14179571,single,0.43493447,isomerism,0.41364825
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",difluoro-substitution,0.15099943,isomerism,0.5489937,isomerism,0.5489937
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",develop,0.22949755,of,0.43968886,congestive-heart-failure,0.35599005
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",multi,0.3120417,single,0.49181098,cad,0.38921657
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",barrier,0.1599386,blood-clot,0.47386622,blood-clot,0.47386622
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",brain-barrier,0.20506677,blood-clot,0.48407534,blood-clot,0.48407534
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",biological,0.25037947,of,0.5642135,blood-clot,0.34982628
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",activities,0.24356377,of,0.4766258,contractions,0.3709238
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache,0.20807938,weak,0.35617685,blood-clot,0.32616764
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",assay,0.19801754,of,0.37163246,flow,0.32158902
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained,0.29897088,of,0.5930543,chd,0.4536072
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl,0.18621302,isomerism,0.4499982,isomerism,0.4499982
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",also,0.36015856,of,0.65908813,flow,0.41040578
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",maze,0.301763,right-atrial,0.46226373,right-atrial,0.46226373
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache,0.23982838,attack,0.31091765,heart-attack,0.2863369
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",sh,0.20100626,with,0.47651428,sv,0.4422411
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",self,0.35339174,weak,0.46892393,arrythmia,0.44653496
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",secretase,0.24416418,plaque,0.36707145,plaque,0.36707145
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",scopolamine,0.25126985,bradycardia,0.4377203,bradycardia,0.4377203
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pyridylpiperazine,0.14089665,isomerism,0.38600534,isomerism,0.38600534
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",permeability,0.12963712,blood-flow,0.4725433,blood-flow,0.4725433
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pas,0.30763173,weak,0.43285283,pulmonary,0.40414587
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",particular,0.34937102,of,0.6936578,anomalous,0.4519893
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oxadiazoles,0.1979039,isomerism,0.37921378,isomerism,0.37921378
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",moreover,0.16758724,of,0.5596781,plaque-deposits,0.35056823
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ki,0.13847858,sv,0.31812656,sv,0.31812656
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",herein,0.24883758,as,0.46536857,isomerism,0.38748422
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hbche,0.13529846,blood-clot,0.34954292,blood-clot,0.34954292
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",designed,0.2395013,of,0.4984635,venous-return,0.32304075
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",beta,0.2517134,of,0.43937695,cardiac,0.37025452
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",bbb,0.26240468,blood-clot,0.48595268,blood-clot,0.48595268
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",alzheimer,0.3308626,disease,0.5158516,fibrillation,0.46321332
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ad,0.30320093,plaque-deposits,0.49593765,plaque-deposits,0.49593765
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",acetylcholinesterase,0.15409143,cholesterol,0.3715425,cholesterol,0.3715425
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",molecular,0.2634613,of,0.516936,isomerism,0.33948874
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",docking,0.24812675,weak,0.35536233,isomerism,0.33234513
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",data,0.31118363,of,0.5086956,mi,0.36251363
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",showed,0.21619865,with,0.57298803,flow,0.33828264
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",molecular-docking,0.23902455,of,0.39880395,isomerism,0.36369002
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",data-showed,0.37093204,atresia-with,0.406628,atresia-with,0.406628
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",synthesized,0.2057221,isolated,0.4628622,isomerism,0.36482388
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",sixteen,0.19443606,isolated,0.4006239,d-transposition,0.3580413
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",novel,0.15367755,single,0.47320092,d-transposition,0.3194505
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pyrazolo,0.15893432,isomerism,0.3104046,isomerism,0.3104046
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",active,0.2270833,with,0.53918797,contractions,0.3619916
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.13575457,isomerism,0.41255152,isomerism,0.41255152
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.16436684,isomerism,0.35843515,isomerism,0.35843515
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",binds,0.15888841,weak,0.40401107,deposits,0.33402145
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.2468082,of,0.48279357,anomalous,0.37930223
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.13575457,isomerism,0.41255152,isomerism,0.41255152
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.16436684,isomerism,0.35843515,isomerism,0.35843515
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",inhibited,0.18171512,isolated,0.4526819,contractions,0.4334391
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead-compound,0.17958876,isomerism,0.3694874,isomerism,0.3694874
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",reverse,0.24697368,flow,0.43068266,flow,0.43068266
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",transcriptase,0.184966,l-transposition,0.40094316,l-transposition,0.40094316
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",reverse-transcriptase,0.15171176,isolated,0.35012823,l-transposition,0.33707926
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",indices,0.26546282,with,0.45559487,flow,0.43359074
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nucleoside,0.10239762,l-transposition,0.39778262,l-transposition,0.39778262
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",binding,0.19702479,of,0.45710018,flow,0.3384309
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pocket,0.20075604,defect,0.36888126,clot,0.32027435
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nucleoside-binding,0.15028769,isolated,0.37752953,l-transposition,0.35705304
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",binding-pocket,0.17276871,of,0.36428118,isomerism,0.3463891
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",value,0.3260533,of,0.52001536,flow,0.37269968
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",resistant,0.19757473,isolated,0.4595236,l-transposition,0.3467009
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",isolates,0.24859512,isolated,0.54969156,paivs,0.41794133
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug-resistant,0.22502874,l-transposition,0.4081782,l-transposition,0.4081782
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",resistant-isolates,0.14863169,isolated,0.6174298,l-transposition,0.39699832
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",bl,0.16121624,eb,0.4236825,eb,0.4236825
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",cell,0.21863139,of,0.48460138,flow,0.38218224
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",line,0.3054644,right,0.471364,venous,0.4344638
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",bl-cell,0.14504799,of,0.39820755,eb,0.33690494
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",cell-line,0.1674143,isolated,0.3853577,l-transposition,0.32632858
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",find,0.24929896,of,0.4776212,anomalous,0.3889891
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",novel,0.15367755,single,0.47320092,d-transposition,0.3194505
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",anti,0.24353361,weak,0.4726881,isomerism,0.366829
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",development,0.2877805,of,0.53581744,congenital,0.35419804
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv-drug,0.18038198,heart-failure,0.35751083,heart-failure,0.35751083
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug-development,0.39041886,of,0.4376669,congestive-heart-failure,0.41587248
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.17434898,isolated,0.4202699,paivs,0.39669624
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype-c,0.16240284,paivs,0.40992397,paivs,0.40992397
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.13575457,isomerism,0.41255152,isomerism,0.41255152
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.16436684,isomerism,0.35843515,isomerism,0.35843515
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.2468082,of,0.48279357,anomalous,0.37930223
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.13575457,isomerism,0.41255152,isomerism,0.41255152
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead-compound,0.17958876,isomerism,0.3694874,isomerism,0.3694874
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",synthesized,0.2057221,isolated,0.4628622,isomerism,0.36482388
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.20514143,isomerism,0.4353664,isomerism,0.4353664
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.16436684,isomerism,0.35843515,isomerism,0.35843515
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",may,0.26963884,of,0.58654004,anomalous,0.366544
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",toa,0.25011706,venous-return,0.3448764,venous-return,0.3448764
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",assay,0.19801754,of,0.37163246,flow,0.32158902
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.17434898,isolated,0.4202699,paivs,0.39669624
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype-c,0.16240284,paivs,0.40992397,paivs,0.40992397
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.17434898,isolated,0.4202699,paivs,0.39669624
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",b,0.20100933,of,0.43435428,aortic,0.34993017
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype-b,0.16885082,paivs,0.38951537,paivs,0.38951537
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",indicated,0.26161766,of,0.5998554,cardiac,0.3719351
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pbmc,0.09047422,blood,0.3676474,blood,0.3676474
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",assays,0.23059516,of,0.36477953,blood-clot,0.30757627
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pbmc-assays,0.1751447,blood-clot,0.29936135,blood-clot,0.29936135
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",one,0.3148334,single,0.6951874,anomaly,0.3884908
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",derivatives,0.19256377,isomerism,0.4901438,isomerism,0.4901438
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",one-derivatives,0.16374822,isomerism,0.4950214,isomerism,0.4950214
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.20514143,isomerism,0.4353664,isomerism,0.4353664
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",continuing,0.5063519,of,0.56002724,cardiology,0.5063519
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",efforts,0.37674284,great,0.52488637,contractions,0.37890652
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.20514143,isomerism,0.4353664,isomerism,0.4353664
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",also,0.36015856,of,0.65908813,flow,0.41040578
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",tested,0.25299942,of,0.5634051,contractions,0.36297208
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv-activity,0.24308482,of,0.46926853,rai,0.3903855
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.16436684,isomerism,0.35843515,isomerism,0.35843515
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",active,0.2270833,with,0.53918797,contractions,0.3619916
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.2468082,of,0.48279357,anomalous,0.37930223
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.17434898,isolated,0.4202699,paivs,0.39669624
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",anti,0.24353361,weak,0.4726881,isomerism,0.366829
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxx,0.29417616,heart-syndrome,0.3825823,heart-syndrome,0.3825823
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxe,0.2379103,isomerism,0.40410686,isomerism,0.40410686
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",tzm,0.11650487,lai,0.372257,lai,0.372257
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",thus,0.30240285,of,0.6779618,flow,0.4474225
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",screened,0.30280048,isolated,0.5684401,congenital,0.33514416
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rxxx,0.268938,ivs,0.34379193,ivs,0.34379193
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",respectively,0.23301381,with,0.4658343,mi,0.37010562
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pyridin,0.14052208,isomerism,0.40827495,isomerism,0.40827495
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",non,0.3477749,with,0.61364555,mi,0.46788454
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nnrti,0.15478921,dtga,0.34513736,dtga,0.34513736
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nih,0.3394677,cardiology,0.3394677,cardiology,0.3394677
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nari,0.1941601,l-transposition,0.39252183,l-transposition,0.39252183
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",found,0.2675444,with,0.6275196,deposits,0.41920424
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",explored,0.24943587,of,0.58866113,anomalous,0.34417656
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",effectively,0.23149472,with,0.5521965,flow,0.3457586
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",dr,0.47122812,cardiology,0.47122812,cardiology,0.47122812
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",considered,0.31302214,as,0.6929809,anomaly,0.43040824
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",confirmed,0.27861494,of,0.58156097,anomalous,0.39478707
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",br,0.20490377,weak,0.44646287,sv,0.39765728
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal,0.17091028,blood-clot,0.34398812,blood-clot,0.34398812
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",four,0.26703352,of,0.57211214,d-transposition,0.35247436
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",decades,0.36429936,great,0.55805504,deposits,0.3755039
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",ago,0.36544353,great,0.40922195,arrythmia,0.40051526
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",four-decades,0.31705093,interrupted,0.44014317,congenital-heart-disease,0.43309274
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",dependent,0.22378129,of,0.585135,anomalous,0.36413002
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cell,0.21863139,of,0.48460138,flow,0.38218224
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",defense,0.23418245,attack,0.511938,heart-attack,0.43024665
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",dependent-cell,0.28489208,of,0.48933703,pulmonary,0.38283524
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cell-defense,0.16289097,heart-attack,0.38400054,heart-attack,0.38400054
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",defense-mechanism,0.21999028,attack,0.4074049,heart-attack,0.39549893
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",group,0.2849201,with,0.5052614,mi,0.411738
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",previously,0.21411541,as,0.54924536,l-transposition,0.42639655
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",reported,0.2535432,of,0.6039252,l-transposition,0.37000108
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.25627792,heart-failure,0.34963474,heart-failure,0.34963474
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",previously-reported,0.17569958,of,0.54962975,l-transposition,0.41867954
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",increased,0.32251194,of,0.64014816,mi,0.42637154
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",rate,0.33912572,heart,0.49867767,heart,0.49867767
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",survival-rate,0.16010165,heart-failure,0.4234901,heart-failure,0.4234901
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate,0.14326164,of,0.34952137,l-transposition,0.34051618
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",antagonist,0.22172357,contractions,0.44449627,contractions,0.44449627
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate-receptor,0.17255566,of,0.37427604,l-transposition,0.34590846
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",receptor-antagonist,0.23473161,contractions,0.4020874,contractions,0.4020874
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate-receptor-antagonist,0.20969945,contractions,0.40062377,contractions,0.40062377
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central,0.34112307,of,0.50945216,venous,0.47422168
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nervous,0.30080134,cardiac,0.48913407,cardiac,0.48913407
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",system,0.21977381,of,0.44332683,anomaly,0.36816198
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central-nervous,0.2418323,congenital-heart-disease,0.46254572,congenital-heart-disease,0.46254572
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nervous-system,0.18423605,congenital-heart-disease,0.49702293,congenital-heart-disease,0.49702293
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central-nervous-system,0.18305418,congenital-heart-disease,0.51315117,congenital-heart-disease,0.51315117
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cardiac,0.66620034,cardiac,1.0,cardiac,1.0
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitic,0.2660995,great,0.40768445,l-transposition,0.37185097
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",load,0.26050967,failure,0.48095816,flow,0.43062943
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",c,0.21239448,with,0.46990636,ivs,0.34813386
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.19391358,with,0.4337707,septal-defect,0.43083143
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",c-mice,0.19761941,congenital-heart,0.37563273,congenital-heart,0.37563273
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",serious,0.30573252,great,0.53050965,congenital,0.42736882
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",side,0.25860035,left,0.5740862,isomerism,0.37933958
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",effects,0.19496669,of,0.53851616,contractions,0.39115262
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",side-effects,0.2311489,failure,0.4254561,bradycardia,0.4236935
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",serious-side-effects,0.26936397,congestive-heart-failure,0.43920138,congestive-heart-failure,0.43920138
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",neglected,0.33547568,great,0.5606991,anomaly,0.47735482
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",tropical,0.33216682,great,0.43306735,congenital-heart-disease,0.342749
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",tropical-disease,0.29976112,heart-disease,0.5879061,heart-disease,0.5879061
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",million,0.28288653,single,0.38531932,chd,0.35294682
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",people,0.32132432,chd,0.4550472,chd,0.4550472
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",million-people,0.3403822,great,0.4633848,congenital-heart-disease,0.39582574
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results,0.29712585,of,0.53157276,blood,0.36869162
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",indicate,0.15955864,of,0.50470227,anomalous,0.31785142
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.25627792,heart-failure,0.34963474,heart-failure,0.34963474
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results-indicate,0.372453,as,0.45080334,venous-return,0.39627838
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal,0.17091028,blood-clot,0.34398812,blood-clot,0.34398812
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected,0.1929965,isolated,0.4683736,paivs,0.41344762
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",people,0.32132432,chd,0.4550472,chd,0.4550472
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected-people,0.29334888,congenital-heart-disease,0.4470963,congenital-heart-disease,0.4470963
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected,0.1929965,isolated,0.4683736,paivs,0.41344762
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.19391358,with,0.4337707,septal-defect,0.43083143
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected-mice,0.15364057,plaque-deposits,0.41433698,plaque-deposits,0.41433698
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",raw,0.20777354,of,0.39154416,clot,0.30473775
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",affects,0.1426264,of,0.5773267,anomaly,0.35788298
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",two,0.27358675,single,0.605739,l-transposition,0.37929946
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",compounds,0.20514143,isomerism,0.4353664,isomerism,0.4353664
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",present,0.34922045,of,0.63723874,anomaly,0.40175247
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",work,0.41337943,return,0.5383546,cardiology,0.41337943
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",present-work,0.4093831,return,0.49242604,venous-return,0.49037185
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",limited,0.29959464,of,0.6210327,deposits,0.40452772
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",due,0.3318616,of,0.5734476,anomaly,0.41796127
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",like,0.33787337,as,0.6495254,cardiac,0.3588698
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",death,0.30044052,failure,0.5122394,infarction,0.4996428
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",led,0.2739451,of,0.6366651,congenital,0.32305634
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",us,0.39735788,of,0.49393907,cardiology,0.39735788
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infiltrates,0.2902395,deposits,0.5251398,deposits,0.5251398
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",induce,0.10905008,of,0.40277672,contractions,0.3169827
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",apoptosis,0.17540334,flow,0.39729238,flow,0.39729238
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",induce-apoptosis,0.14657676,flow,0.3380973,flow,0.3380973
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",endemic,0.2688525,disease,0.42794544,congenital-heart-disease,0.39989817
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",areas,0.32283562,deposits,0.49041492,deposits,0.49041492
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",endemic-areas,0.32939315,congenital-heart-disease,0.46848002,congenital-heart-disease,0.46848002
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",eliminate,0.19141005,of,0.48193774,l-transposition,0.35397822
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitemia,0.21549477,blood,0.4622918,blood,0.4622918
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diminished,0.25230643,weak,0.58167773,congestive,0.40550786
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitemia,0.21549477,blood,0.4622918,blood,0.4622918
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",phase,0.19908471,of,0.4318388,flow,0.38942474
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chronic-phase,0.24897382,heart-failure,0.43671107,heart-failure,0.43671107
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chemotherapy,0.2891452,rai,0.48042315,rai,0.48042315
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",relies,0.23033907,of,0.5722904,l-transposition,0.3563916
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chagas,0.3771478,heart-disease,0.56711507,heart-disease,0.56711507
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",avoid,0.24694474,of,0.4299539,arrythmia,0.35135216
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",seroconversion,0.20998786,paivs,0.3958072,paivs,0.3958072
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",acute,0.3642026,infarction,0.6294521,infarction,0.6294521
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",phase,0.19908471,of,0.4318388,flow,0.38942474
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",acute-phase,0.18889838,blood-clot,0.4129093,blood-clot,0.4129093
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.19391358,with,0.4337707,septal-defect,0.43083143
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated-mice,0.15686835,septal-defect,0.35491055,septal-defect,0.35491055
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",candidate,0.2506774,as,0.50267786,cad,0.32472426
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",candidate-drug,0.31732365,heart-failure,0.417695,heart-failure,0.417695
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanosoma,0.23610508,congenital-heart-disease,0.35797605,congenital-heart-disease,0.35797605
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cruzi,0.24940075,congenital-heart-disease,0.37454373,congenital-heart-disease,0.37454373
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanosoma-cruzi,0.22588655,congenital-heart-disease,0.36913267,congenital-heart-disease,0.36913267
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",taken,0.3873873,of,0.53411245,blood,0.41476953
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",together,0.25436696,with,0.5619427,l-transposition,0.3443408
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",taken-together,0.356591,of,0.53769875,anomalous,0.4495479
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",oxidant,0.15248613,attack,0.44060636,myocardial,0.3350395
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",non,0.3477749,with,0.61364555,mi,0.46788454
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",also,0.36015856,of,0.65908813,flow,0.41040578
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able,0.3130405,with,0.55771506,cardiac,0.38070798
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated,0.18459547,of,0.4727149,contractions,0.34351796
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cells,0.18534905,of,0.46541262,deposits,0.38651246
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated-cells,0.12651454,of,0.3970211,plaque-deposits,0.37478206
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drugs,0.31268454,of,0.42460242,congestive-heart-failure,0.3923024
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.25627792,heart-failure,0.34963474,heart-failure,0.34963474
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results,0.29712585,of,0.53157276,blood,0.36869162
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",effects,0.19496669,of,0.53851616,contractions,0.39115262
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,0.30252236,disease,1.0,artery-disease,0.6557848
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",together,0.25436696,with,0.5619427,l-transposition,0.3443408
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",non,0.3477749,with,0.61364555,mi,0.46788454
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",macrophages,0.203103,deposits,0.44228378,deposits,0.44228378
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cruzi,0.24940075,congenital-heart-disease,0.37454373,congenital-heart-disease,0.37454373
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated,0.18459547,of,0.4727149,contractions,0.34351796
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able,0.3130405,with,0.55771506,cardiac,0.38070798
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",used,0.23211285,as,0.56584436,flow,0.35934073
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",use,0.3219829,with,0.55726266,flow,0.40877783
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treatment,0.30650938,of,0.52012336,congestive,0.36983645
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",time,0.350901,return,0.5513821,venous-return,0.44564146
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",showed,0.21619865,with,0.57298803,flow,0.33828264
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",reduce,0.22618136,of,0.4876061,heart-attack,0.3512283
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",proposed,0.25004908,as,0.53179914,anomalous,0.36534148
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",propose,0.18777283,of,0.46277136,anomalous,0.37135097
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",pro,0.2744282,of,0.38423508,mi,0.3509372
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",presently,0.4380554,with,0.53138906,arrythmia,0.46197897
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nifurtimox,0.19897173,l-transposition,0.32675308,l-transposition,0.32675308
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mammals,0.26571184,of,0.46694326,l-transposition,0.4414158
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",majority,0.28791377,of,0.48508087,l-transposition,0.36823815
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",lps,0.17403227,isolated,0.36516017,cholesterol,0.32035044
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",investigated,0.19995229,of,0.6179704,anomalous,0.35378093
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infection,0.26741225,disease,0.482216,thrombosis,0.44838145
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",however,0.30646515,of,0.624624,mi,0.41109186
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",finally,0.32854706,of,0.64012104,flow,0.39903617
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",fact,0.32475746,of,0.6460043,anomaly,0.44376248
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",entry,0.26764637,return,0.41855437,l-transposition,0.36560807
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diminish,0.23692822,weak,0.5123489,pulmonary,0.35149592
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diagnosed,0.34882253,congenital,0.5294275,congenital,0.5294275
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",caused,0.1752007,of,0.53973085,congenital,0.42777976
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cases,0.2687057,of,0.51801866,congenital,0.5119436
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",benznidazole,0.25567704,heart-failure,0.34428662,heart-failure,0.34428662
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",balb,0.14275813,septal-defect,0.40430707,septal-defect,0.40430707
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",americas,0.3830908,disease,0.4085186,paivs,0.40196127
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",alzheimer,0.3308626,disease,0.5158516,fibrillation,0.46321332
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",addition,0.30796275,of,0.6910241,l-transposition,0.4120413
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activate,0.15978053,intact,0.37905625,contractions,0.35076305
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.17317462,chd,0.36131495,chd,0.36131495
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,groups,0.2612025,with,0.4941169,mi,0.3908207
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,received,0.3772288,with,0.53732973,single-ventricle,0.39404702
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,doses,0.30115995,with,0.44940743,contractions,0.3849393
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa-groups,0.17096971,attack,0.32250965,paivs,0.30870032
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,three-different,0.17349479,hypoplastic-left-heart,0.4551201,hypoplastic-left-heart,0.4551201
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,different-doses,0.1642335,single,0.47208548,isomerism,0.35168886
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,traditional,0.2995602,of,0.44896448,congestive-heart-failure,0.34226936
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chinese,0.25444973,isolated,0.4188807,syndrome,0.4055319
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,drug,0.26470318,of,0.44600964,congestive-heart-failure,0.37473047
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,usually,0.27419958,with,0.5843393,anomaly,0.4739835
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,used,0.23211285,as,0.56584436,flow,0.35934073
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chinese-drug,0.24771532,heart-failure,0.38903815,heart-failure,0.38903815
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,drug-usually,0.33766645,with,0.4358415,tachycardia,0.4035607
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,usually-used,0.14239521,as,0.42701277,lai,0.3571976
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examined,0.2811494,of,0.66699874,flow,0.35738647
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,using,0.20786116,with,0.58010674,flow,0.41007757
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,recombinant,0.21714918,of,0.4109167,l-transposition,0.34227055
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il,0.24051979,mi,0.30050132,mi,0.30050132
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examined-using,0.33067566,with,0.4749008,venous-return,0.4382677
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,recombinant-human,0.1984994,single,0.4092157,septal-defect,0.3433944
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,assessed,0.32085416,of,0.605934,flow,0.3956796
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,using,0.20786116,with,0.58010674,flow,0.41007757
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,histopathological,0.24234259,deposits,0.45118088,deposits,0.45118088
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examinations,0.39517343,abnormal,0.4765272,cardiology,0.39517343
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,histopathological-examinations,0.34099305,artery-disease,0.4491582,artery-disease,0.4491582
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic,0.22257116,disease,0.40499496,aortic,0.3635254
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,unexplored,0.23394793,great,0.5098634,anomalous,0.36814857
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,signaling-pathways,0.1904434,of,0.37176776,atrioventricular,0.33244452
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,treat,0.3333781,as,0.4672093,congenital,0.37201887
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,cardiovascular-diseases,0.51660174,heart-disease,0.6925421,heart-disease,0.6925421
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,novel,0.15367755,single,0.47320092,d-transposition,0.3194505
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,strategy,0.23048541,of,0.44841248,heart-attack,0.36277908
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,novel-therapeutic,0.33192953,of,0.43286318,heart-failure,0.4084316
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal,0.2807777,abnormal,0.75253373,hypoplastic,0.51033473
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,control,0.26906762,with,0.5145365,mi,0.4093958
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,group,0.2849201,with,0.5052614,mi,0.411738
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal-control,0.20635998,with,0.40712914,heart-failure,0.3975628
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,control-group,0.26105496,heart-failure,0.42830202,heart-failure,0.42830202
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal-control-group,0.21003807,heart-failure,0.40450364,heart-failure,0.40450364
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocyte,0.24832806,myocardial,0.42977273,myocardial,0.42977273
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptosis,0.17540334,flow,0.39729238,flow,0.39729238
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,results,0.29712585,of,0.53157276,blood,0.36869162
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,indicate,0.15955864,of,0.50470227,anomalous,0.31785142
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo-results,0.28223878,clot,0.3693105,clot,0.3693105
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,results-indicate,0.372453,as,0.45080334,venous-return,0.39627838
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondroprotective,0.22402829,of,0.38508365,myocardial,0.37710297
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,secretion,0.17649192,of,0.43475774,contractions,0.4186117
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,factor-secretion,0.17958033,of,0.38443977,atrial,0.38316292
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit,0.18576992,isolated,0.5275491,contractions,0.40503076
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.22543454,defect,0.38940015,arteries,0.38319504
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.17317462,chd,0.36131495,chd,0.36131495
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,may,0.26963884,of,0.58654004,anomalous,0.366544
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic,0.22257116,disease,0.40499496,aortic,0.3635254
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit,0.18576992,isolated,0.5275491,contractions,0.40503076
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.22543454,defect,0.38940015,arteries,0.38319504
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective,0.14898418,of,0.4669182,heart-attack,0.34925088
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective-effects,0.19591494,of,0.43743068,congestive-heart-failure,0.34717304
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo,0.15940498,of,0.48691544,blood-flow,0.3973086
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo-studies,0.25743747,congenital-heart-disease,0.36922002,congenital-heart-disease,0.36922002
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,weeks,0.3321507,with,0.44306946,congestive,0.3711909
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,h,0.20228642,of,0.4345476,mi,0.34808266
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,western,0.30529958,flow,0.3707292,flow,0.3707292
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,blotting,0.22732782,flow,0.3911235,flow,0.3911235
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,western-blotting,0.21446323,isolated,0.3659687,flow,0.33423522
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,randomly,0.2794354,single,0.41250786,mi,0.31002665
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,divided,0.28726196,isolated,0.42207283,hypoplastic,0.3574583
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,partially,0.15156177,of,0.54725564,anomalous,0.39749575
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,regulated,0.24102873,of,0.50586647,l-transposition,0.33494547
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,key-findings,0.35131258,congenital-heart-disease,0.44464862,congenital-heart-disease,0.44464862
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,immunohistochemical,0.23617034,deposits,0.4091736,deposits,0.4091736
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,immunohistochemical-analysis,0.2615193,artery-disease,0.40924433,artery-disease,0.40924433
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inc,0.426326,arrythmia,0.44345117,arrythmia,0.44345117
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,broad,0.28305992,great,0.535347,anomalous,0.37478346
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,range,0.29700014,of,0.40102404,cardiac,0.33579552
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,broad-range,0.21188717,of,0.43773806,l-transposition,0.32708603
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptotic,0.16640727,of,0.3933456,flow,0.38513488
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,caspase,0.15000165,flow,0.3267874,flow,0.3267874
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptotic,0.16640727,of,0.3933456,flow,0.38513488
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bcl,0.13632175,eb,0.3905639,eb,0.3905639
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective,0.14898418,of,0.4669182,heart-attack,0.34925088
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective-effect,0.19158259,weak,0.4245109,congestive-heart-failure,0.34111816
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibitory,0.17329565,of,0.47840768,contractions,0.4383099
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibitory-effect,0.16092747,of,0.45387173,contractions,0.39241827
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.21786565,d-transposition,0.33970332,d-transposition,0.33970332
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibits,0.13198733,of,0.43557078,contractions,0.34870252
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.21786565,d-transposition,0.33970332,d-transposition,0.33970332
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,exerts,0.13445285,of,0.4074493,contractions,0.31238157
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,groups,0.2612025,with,0.4941169,mi,0.3908207
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.17317462,chd,0.36131495,chd,0.36131495
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il,0.24051979,mi,0.30050132,mi,0.30050132
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inflammatory,0.21855474,disease,0.5024026,pulmonary,0.40615118
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.22543454,defect,0.38940015,arteries,0.38319504
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.21786565,d-transposition,0.33970332,d-transposition,0.33970332
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vitro,0.17831118,of,0.48112682,clot,0.34754837
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,tumor,0.21814886,clot,0.4081839,clot,0.4081839
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,suppression,0.16740395,of,0.5172409,contractions,0.3880853
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,stimulates,0.16129762,of,0.45062223,contractions,0.3749793
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,significance,0.3123301,of,0.55474335,anomaly,0.39406294
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbits,0.20458812,intact,0.43736863,arteries,0.4265375
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,qrt,0.2973543,cardiology,0.2973543,cardiology,0.2973543
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,published,0.36480254,of,0.4442843,cardiology,0.36480254
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,provides,0.22296365,of,0.5261056,flow,0.32656315
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,prospects,0.34173816,great,0.5607226,cardiology,0.34173816
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,production,0.1999099,of,0.51767635,flow,0.379918
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pro,0.2744282,of,0.38423508,mi,0.3509372
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pcr,0.18917134,isolated,0.34562874,l-transposition,0.34398216
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,osteoarthritis,0.30271116,disease,0.43573147,artery-disease,0.42052913
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,nf,0.21206217,eb,0.44363278,eb,0.44363278
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,neuro,0.40481675,intact,0.47923797,arrythmia,0.47416523
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmps,0.24054664,deposits,0.3897891,deposits,0.3897891
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmp,0.24439868,mi,0.38423154,mi,0.38423154
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mapk,0.18517739,mitral-regurgitation,0.33024183,mitral-regurgitation,0.33024183
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,investigate,0.20519872,of,0.48247698,anomalous,0.30501914
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,insecticidal,0.12049304,isolated,0.3325575,d-transposition,0.30876952
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibition,0.21149129,of,0.51645476,contractions,0.42180917
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,however,0.30646515,of,0.624624,mi,0.41109186
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,decrease,0.28522113,of,0.5904174,flow,0.42153293
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,daphnetin,0.14969987,isolated,0.3407138,cholesterol,0.3345685
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,confirmed,0.27861494,of,0.58156097,anomalous,0.39478707
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bax,0.14232813,double,0.33354867,mitral-regurgitation,0.32380912
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bacterial,0.20720324,of,0.48457187,l-transposition,0.36714125
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,authors,0.35392871,of,0.46977854,congenital-heart-disease,0.4019465
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,attributed,0.20840791,of,0.5502684,anomalous,0.42453325
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,antioxidant,0.19507357,cholesterol,0.39006746,cholesterol,0.39006746
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,anti,0.24353361,weak,0.4726881,isomerism,0.366829
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,akt,0.13930276,myocardial-infarction,0.28031534,myocardial-infarction,0.28031534
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,aim,0.29447013,of,0.40951407,congenital-heart-disease,0.3139366
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,among,0.2573181,of,0.57348,chd,0.4274787
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,surgery,0.52026105,cardiology,0.52026105,cardiology,0.52026105
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term-survival,0.15355091,single-ventricle,0.43360496,single-ventricle,0.43360496
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients-undergoing,0.43114763,congenital-heart-disease,0.50982094,congenital-heart-disease,0.50982094
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cardiac-surgery,0.65383637,cardiac,0.7808479,cardiac,0.7808479
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,undergoing,0.342766,with,0.49681437,single-ventricle,0.47364002
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,coronary,0.56409866,coronary,1.0,coronary,1.0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,artery,0.42758748,artery,1.0,artery,1.0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,bypass,0.32112065,coronary-artery,0.6229601,coronary-artery,0.6229601
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,graft,0.27155316,artery,0.56162083,artery,0.56162083
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients-undergoing,0.43114763,congenital-heart-disease,0.50982094,congenital-heart-disease,0.50982094
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,coronary-artery,0.5136894,coronary-artery,1.0,coronary-artery,1.0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,artery-bypass,0.3480456,artery,0.7855307,artery,0.7855307
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,bypass-graft,0.26437205,aortic-stenosis,0.6385768,aortic-stenosis,0.6385768
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,coronary-artery-bypass,0.45924821,coronary-artery,0.93498343,coronary-artery,0.93498343
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,artery-bypass-graft,0.31387973,coronary-artery-disease,0.734328,coronary-artery-disease,0.734328
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,multicenter,0.40064782,congenital-heart-disease,0.42659694,congenital-heart-disease,0.42659694
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,retrospective,0.3446992,congenital-heart-disease,0.46667808,congenital-heart-disease,0.46667808
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,examines,0.30925715,of,0.5396682,anomalous,0.3434563
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,association,0.34312242,of,0.45371312,chd,0.39406395
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,multicenter-retrospective,0.40255696,congenital-heart-disease,0.4944083,congenital-heart-disease,0.4944083
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,retrospective-cohort,0.32250574,congenital-heart-disease,0.48279768,congenital-heart-disease,0.48279768
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cohort-study,0.36102197,congenital-heart-disease,0.49958968,congenital-heart-disease,0.49958968
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study-examines,0.42431533,congenital-heart-disease,0.45922184,congenital-heart-disease,0.45922184
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term,0.2891546,premature,0.48331085,anomaly,0.40103653
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,compared,0.26227483,with,0.62448335,mi,0.40925252
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term-mortality,0.3645475,congenital-heart-disease,0.5657598,congenital-heart-disease,0.5657598
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,mortality-rate,0.32992098,heart-failure,0.5245548,heart-failure,0.5245548
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduce,0.22618136,of,0.4876061,heart-attack,0.3512283
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,bias,0.21969397,weak,0.34950268,lai,0.32676864
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,treatment-selection,0.24930197,of,0.44654053,heart-failure,0.42412037
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,selection-bias,0.2156667,l-transposition,0.3989065,l-transposition,0.3989065
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,day,0.42316434,with,0.4708514,cardiology,0.42316434
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,compared,0.26227483,with,0.62448335,mi,0.40925252
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,day-mortality,0.40548804,chd,0.550995,chd,0.550995
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,propensity,0.18347614,heart-attack,0.45199558,heart-attack,0.45199558
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,scores,0.29026836,with,0.40729892,stenosis,0.37173432
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,matching,0.2777636,single,0.48957807,heartbeat,0.42221725
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,propensity-scores,0.2981617,chd,0.46297163,chd,0.46297163
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,angiotensin-system,0.35695744,congestive-heart-failure,0.517765,congestive-heart-failure,0.517765
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,system-inhibitors,0.25639448,weak,0.41587138,congestive-heart-failure,0.40516722
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,preoperative,0.3911886,insufficiency,0.47003764,stenosis,0.46291584
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.29352063,rai,0.4448999,rai,0.4448999
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.36359894,insufficiency,0.48377612,venous,0.46946543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.29352063,rai,0.4448999,rai,0.4448999
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,valve,0.43505126,valve,1.0,valve,1.0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,surgery,0.52026105,cardiology,0.52026105,cardiology,0.52026105
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,valve-surgery,0.47834778,valve,0.7666289,valve,0.7666289
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,shows,0.24564052,of,0.56087804,anomalous,0.38309503
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative,0.4665895,infarction,0.51029116,infarction,0.51029116
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.29352063,rai,0.4448999,rai,0.4448999
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,groups,0.2612025,with,0.4941169,mi,0.3908207
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,significant,0.2800444,great,0.554224,stenosis,0.40396324
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,benefit,0.3251614,return,0.474311,heart-failure,0.40887886
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,results,0.29712585,of,0.53157276,blood,0.36869162
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,suggest,0.18845408,of,0.5019331,anomalous,0.3196395
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,results-suggest,0.37769833,with,0.46542153,venous-return,0.4256721
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,remains,0.35578477,intact,0.51469785,arrythmia,0.4135992
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,disputable,0.39170945,great,0.5282525,congenital-heart-disease,0.45470983
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.36359894,insufficiency,0.48377612,venous,0.46946543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcome,0.27011925,failure,0.48584157,single-ventricle,0.45794576
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,effects,0.19496669,of,0.53851616,contractions,0.39115262
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcome-effects,0.2655434,congenital-heart-disease,0.42328268,congenital-heart-disease,0.42328268
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year,0.39816982,failure,0.4387355,mi,0.41719383
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative,0.4665895,infarction,0.51029116,infarction,0.51029116
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,use,0.3219829,with,0.55726266,flow,0.40877783
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.29352063,rai,0.4448999,rai,0.4448999
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.36359894,insufficiency,0.48377612,venous,0.46946543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year,0.39816982,failure,0.4387355,mi,0.41719383
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,use,0.3219829,with,0.55726266,flow,0.40877783
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,vs,0.34496382,mi,0.4353134,mi,0.4353134
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,using,0.20786116,with,0.58010674,flow,0.41007757
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,renin,0.31312823,atrial,0.5063691,atrial,0.5063691
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcomes,0.32847267,single-ventricle,0.47642118,single-ventricle,0.47642118
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,n,0.21850443,with,0.47536123,mi,0.3790054
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,exclusion,0.22903606,of,0.4770561,anomalous,0.4450267
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,divided,0.28726196,isolated,0.42207283,hypoplastic,0.3574583
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,pmid,0.19630215,congestive,0.25211734,congestive,0.25211734
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,rec,0.41108662,return,0.44009268,arrythmia,0.42912135
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,medline,0.3928258,cardiology,0.3928258,cardiology,0.3928258
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,j,0.24581458,lai,0.35768944,lai,0.35768944
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,indexed,0.4001288,left-atrial,0.43542364,left-atrial,0.43542364
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,doi,0.19822392,lai,0.31615257,lai,0.31615257
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat,0.16614825,isolated,0.55422306,contractions,0.39560723
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic,0.44729716,aortic,1.0,aortic,1.0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rings,0.24699095,arteries,0.54736257,arteries,0.54736257
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",relaxation,0.24232346,contractions,0.6300293,contractions,0.6300293
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",assay,0.19801754,of,0.37163246,flow,0.32158902
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat-aortic,0.38707042,aortic,0.79123044,aortic,0.79123044
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic-rings,0.34581614,aortic-coarctation,0.762136,aortic-coarctation,0.762136
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",relaxation-assay,0.18456864,contractions,0.48684555,contractions,0.48684555
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",phenylephrine,0.34807387,contractions,0.5870099,contractions,0.5870099
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",precontracted,0.30329797,contractions,0.7617508,contractions,0.7617508
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat,0.16614825,isolated,0.55422306,contractions,0.39560723
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic,0.44729716,aortic,1.0,aortic,1.0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rings,0.24699095,arteries,0.54736257,arteries,0.54736257
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",phenylephrine-precontracted,0.30227333,contractions,0.7248547,contractions,0.7248547
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat-aortic,0.38707042,aortic,0.79123044,aortic,0.79123044
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic-rings,0.34581614,aortic-coarctation,0.762136,aortic-coarctation,0.762136
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",brine,0.23801231,isolated,0.4276776,flow,0.36905706
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",shrimp,0.12634341,syndrome,0.27935916,syndrome,0.27935916
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",acute,0.3642026,infarction,0.6294521,infarction,0.6294521
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxicity,0.22547536,of,0.46452966,cardiac,0.36057627
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",brine-shrimp,0.14806646,isolated,0.34952658,blood-clot,0.32774636
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",acute-toxicity,0.23367178,failure,0.43406808,congestive-heart-failure,0.40239778
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxicity-test,0.25093618,heart-failure,0.3605552,heart-failure,0.3605552
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",highlights,0.3278191,of,0.5411649,l-transposition,0.33406124
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",potential,0.23291323,of,0.5645705,cardiac,0.34140193
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",benefits,0.33820245,great,0.48839658,single-ventricle,0.3833536
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study-highlights,0.40904564,of,0.4458207,congenital-heart-disease,0.41033304
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.19767809,truncus,0.31990623,truncus,0.31990623
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extract,0.18317053,isolated,0.47450352,contractions,0.30578932
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",exerted,0.16718982,of,0.5055257,contractions,0.44563764
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extract,0.20950049,plaque-deposits,0.33200306,plaque-deposits,0.33200306
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",viburnum,0.22542919,truncus,0.39744604,truncus,0.39744604
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.19767809,truncus,0.31990623,truncus,0.31990623
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.18750438,isolated,0.57493144,deposits,0.34916478
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extracts,0.2487531,isolated,0.34901094,plaque-deposits,0.34858477
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.30170906,tof,0.4466048,tof,0.4466048
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.18750438,isolated,0.57493144,deposits,0.34916478
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",showed,0.21619865,with,0.57298803,flow,0.33828264
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extracts,0.2487531,isolated,0.34901094,plaque-deposits,0.34858477
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.19767809,truncus,0.31990623,truncus,0.31990623
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extract,0.18317053,isolated,0.47450352,contractions,0.30578932
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extract,0.20950049,plaque-deposits,0.33200306,plaque-deposits,0.33200306
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",present,0.34922045,of,0.63723874,anomaly,0.40175247
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",investigated,0.19995229,of,0.6179704,anomalous,0.35378093
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",present-study,0.4388714,venous-return,0.47344702,venous-return,0.47344702
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study-investigated,0.38953993,of,0.57214093,congenital-heart-disease,0.47858927
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",complex,0.29298759,of,0.46002102,anomalous,0.41282338
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",metabolite,0.16395271,isomerism,0.35460934,isomerism,0.35460934
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",profiling,0.21868834,of,0.4801969,flow,0.35136262
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",metabolite-profiling,0.2474268,of,0.43037283,l-transposition,0.35562727
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",chlorogenic,0.19859749,cholesterol,0.3811108,cholesterol,0.3811108
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",acid,0.16432983,with,0.42051664,cholesterol,0.37480527
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",accounting,0.25154918,of,0.55534834,anomaly,0.38962352
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",significantly,0.23700657,with,0.568532,mi,0.39826992
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",weaker,0.21181089,weak,0.8096138,contractions,0.380821
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",highest,0.26377243,of,0.5054526,mi,0.33820426
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasorelaxant,0.27303374,contractions,0.4989661,contractions,0.4989661
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.25959164,isolated,0.33685628,lai,0.3114079
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.22366291,heartbeat,0.3868985,heartbeat,0.3868985
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.18750438,isolated,0.57493144,deposits,0.34916478
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extracts,0.2487531,isolated,0.34901094,plaque-deposits,0.34858477
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms,0.31332383,tof,0.53256655,tof,0.53256655
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",revealed,0.223917,of,0.55371094,anomalous,0.36589023
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms-studies,0.34671003,congenital-heart-disease,0.37952453,congenital-heart-disease,0.37952453
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",studies-revealed,0.38733977,of,0.43179974,cardiology,0.38733977
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",three,0.27802917,of,0.6048713,l-transposition,0.36917683
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.18750438,isolated,0.57493144,deposits,0.34916478
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mg,0.3233322,single,0.40449998,beats,0.3867238
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",cornus,0.23046957,truncus,0.42630547,truncus,0.42630547
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.30170906,tof,0.4466048,tof,0.4466048
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase,0.16623329,l-transposition,0.37527826,l-transposition,0.37527826
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase-activity,0.19062251,of,0.3852933,coronary-thrombosis,0.37949866
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",sorbus,0.2701956,isolated,0.38275528,truncus,0.3770599
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.25959164,isolated,0.33685628,lai,0.3114079
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",significant,0.2800444,great,0.554224,stenosis,0.40396324
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",inhibition,0.21149129,of,0.51645476,contractions,0.42180917
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",main,0.28808993,of,0.60433525,anomalous,0.4090495
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",important,0.26857167,great,0.5369053,anomalous,0.32819813
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",anti,0.24353361,weak,0.4726881,isomerism,0.366829
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelial,0.27072835,arteries,0.52025723,arteries,0.52025723
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",dysfunction,0.3454026,insufficiency,0.6505209,congestive-heart-failure,0.5247797
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelial-dysfunction,0.34353745,coronary-thrombosis,0.59907794,coronary-thrombosis,0.59907794
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",associated,0.20417106,with,0.60998726,congenital,0.4144575
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",diseases-associated,0.32132435,disease,0.67345273,congenital-heart-disease,0.5598812
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",declared,0.39503962,great,0.45297694,cardiology,0.39503962
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",non,0.3477749,with,0.61364555,mi,0.46788454
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",impaired,0.229642,abnormal,0.65608627,hypoplastic,0.420444
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.2905769,arteries,0.64268464,arteries,0.64268464
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arterial,0.38349736,venous,0.80489254,venous,0.80489254
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.2905769,arteries,0.64268464,arteries,0.64268464
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",respectively,0.23301381,with,0.4658343,mi,0.37010562
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ml,0.25306612,blood,0.42071202,blood,0.42071202
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.19767809,truncus,0.31990623,truncus,0.31990623
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.18750438,isolated,0.57493144,deposits,0.34916478
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.30170906,tof,0.4466048,tof,0.4466048
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms,0.31332383,tof,0.53256655,tof,0.53256655
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.25959164,isolated,0.33685628,lai,0.3114079
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.2905769,arteries,0.64268464,arteries,0.64268464
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",respectively,0.23301381,with,0.4658343,mi,0.37010562
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ml,0.25306612,blood,0.42071202,blood,0.42071202
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase,0.16623329,l-transposition,0.37527826,l-transposition,0.37527826
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",v,0.240002,sv,0.44191512,sv,0.44191512
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxic,0.1872769,of,0.45198524,deposits,0.41996452
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",tof,0.30241755,tof,1.0,tof,1.0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",q,0.32226428,infarction,0.37415013,infarction,0.37415013
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",proven,0.2408872,with,0.550977,deposits,0.38689238
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",hplc,0.1348955,isolated,0.34673145,tof,0.34420925
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",g,0.21858013,single,0.41386712,ivs,0.37229383
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",esi,0.19621015,tof,0.4484142,tof,0.4484142
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelium,0.27557477,arteries,0.631221,arteries,0.631221
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",effects,0.19496669,of,0.53851616,contractions,0.39115262
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",dependent,0.22378129,of,0.585135,anomalous,0.36413002
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",contrast,0.2558416,of,0.5428885,mi,0.37385863
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studied,0.2428486,of,0.63097596,anomalous,0.39203623
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",infectious,0.38974863,disease,0.5521544,congenital-heart-disease,0.4155373
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",molecular,0.2634613,of,0.516936,isomerism,0.33948874
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",clones,0.20437059,isolated,0.5129376,l-transposition,0.39970946
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acquisition,0.26129586,of,0.47551334,heartbeat,0.3913237
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",among,0.2573181,of,0.57348,chd,0.4274787
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",women,0.355409,chd,0.4926289,chd,0.4926289
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",using,0.20786116,with,0.58010674,flow,0.41007757
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",among-women,0.36741486,chd,0.46822387,chd,0.46822387
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",women-using,0.3051213,chd,0.43728626,chd,0.43728626
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.32612452,of,0.44902933,mi,0.41579333
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.31218794,of,0.40176448,atresia,0.3958943
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.2777627,stenosis,0.44710302,stenosis,0.44710302
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.18534905,of,0.46541262,deposits,0.38651246
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",compared,0.26227483,with,0.62448335,mi,0.40925252
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female-reproductive,0.20012262,congenital-heart-disease,0.3497358,congenital-heart-disease,0.3497358
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive-tract,0.26906708,congenital-heart-disease,0.48019508,congenital-heart-disease,0.48019508
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells-compared,0.22809193,with,0.41248918,single-ventricle,0.3968209
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",morbidity,0.31568646,chd,0.50165594,chd,0.50165594
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",worldwide,0.28260934,great,0.43362987,chd,0.3416611
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",among,0.2573181,of,0.57348,chd,0.4274787
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.31218794,of,0.40176448,atresia,0.3958943
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",lower,0.26859394,with,0.5748005,venous,0.42565888
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.31218794,of,0.40176448,atresia,0.3958943
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.2777627,stenosis,0.44710302,stenosis,0.44710302
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",due,0.3318616,of,0.5734476,anomaly,0.41796127
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive-tract,0.26906708,congenital-heart-disease,0.48019508,congenital-heart-disease,0.48019508
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract-due,0.24179941,right,0.4192457,stenosis,0.37588185
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper,0.2885543,right,0.6022309,venous,0.45085382
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.32612452,of,0.44902933,mi,0.41579333
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.31218794,of,0.40176448,atresia,0.3958943
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.2777627,stenosis,0.44710302,stenosis,0.44710302
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female-reproductive,0.20012262,congenital-heart-disease,0.3497358,congenital-heart-disease,0.3497358
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive-tract,0.26906708,congenital-heart-disease,0.48019508,congenital-heart-disease,0.48019508
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acting,0.24240543,as,0.61333185,contractions,0.41667253
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",injectable,0.2289668,great,0.37093765,venous-return,0.33672294
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",progestin,0.2357631,cholesterol,0.42428726,cholesterol,0.42428726
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptive,0.302746,infarction,0.37040934,infarction,0.37040934
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal,0.122980855,of,0.4234106,venous,0.41766214
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cell,0.21863139,of,0.48460138,flow,0.38218224
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",distribution,0.24050617,of,0.5765607,deposits,0.45674896
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal-immune,0.08879382,plaque-deposits,0.340613,plaque-deposits,0.340613
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune-cell,0.18475112,blood-clot,0.3845998,blood-clot,0.3845998
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cell-distribution,0.2402111,of,0.4831974,plaque-deposits,0.47327232
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",healthy,0.22719269,with,0.45490545,congenital-heart-disease,0.42990726
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.32612452,of,0.44902933,mi,0.41579333
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",volunteers,0.2759964,with,0.40866297,blood-flow,0.3867961
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",aged,0.28465265,with,0.40656772,congenital-heart-disease,0.40154532
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cisgender,0.28819835,chd,0.39988333,chd,0.39988333
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",women,0.355409,chd,0.4926289,chd,0.4926289
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",entry,0.26764637,return,0.41855437,l-transposition,0.36560807
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",using,0.20786116,with,0.58010674,flow,0.41007757
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal,0.122980855,of,0.4234106,venous,0.41766214
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.18534905,of,0.46541262,deposits,0.38651246
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal-immune,0.08879382,plaque-deposits,0.340613,plaque-deposits,0.340613
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune-cells,0.1737721,plaque-deposits,0.40589482,plaque-deposits,0.40589482
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",observational,0.42664766,congenital-heart-disease,0.47426757,congenital-heart-disease,0.47426757
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",suggest,0.18845408,of,0.5019331,anomalous,0.3196395
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studies-suggest,0.37267792,congenital-heart-disease,0.42009366,congenital-heart-disease,0.42009366
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",copper,0.17132206,deposits,0.4547737,deposits,0.4547737
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",intrauterine,0.24939093,premature,0.5332329,arteriosus,0.4862901
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",device,0.32167804,mitral-valve,0.45668685,mitral-valve,0.45668685
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",copper-intrauterine,0.22400135,premature,0.47133905,single-ventricle,0.428484
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",intrauterine-device,0.29401386,mitral-valve,0.49253607,mitral-valve,0.49253607
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",containing,0.1330749,of,0.51960796,deposits,0.3792259
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",oral,0.3003844,of,0.46959797,plaque,0.38315025
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptive,0.302746,infarction,0.37040934,infarction,0.37040934
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",oral-contraceptive,0.2752448,congenital-heart-disease,0.38626948,congenital-heart-disease,0.38626948
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.24503428,with,0.383631,l-transposition,0.35553074
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",assay,0.19801754,of,0.37163246,flow,0.32158902
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",participants,0.35857671,chd,0.46645594,chd,0.46645594
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",comparing,0.26645347,with,0.5715135,single-ventricle,0.3825506
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.24503428,with,0.383631,l-transposition,0.35553074
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.17929009,disease,0.40550914,congenital-heart-disease,0.32258368
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.24503428,with,0.383631,l-transposition,0.35553074
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.17929009,disease,0.40550914,congenital-heart-disease,0.32258368
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",iud,0.19018975,thrombosis,0.29261482,thrombosis,0.29261482
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel,0.2180939,cholesterol,0.351291,cholesterol,0.351291
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper,0.2885543,right,0.6022309,venous,0.45085382
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",compared,0.26227483,with,0.62448335,mi,0.40925252
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.18534905,of,0.46541262,deposits,0.38651246
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune-cells,0.1737721,plaque-deposits,0.40589482,plaque-deposits,0.40589482
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",entry,0.26764637,return,0.41855437,l-transposition,0.36560807
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.17929009,disease,0.40550914,congenital-heart-disease,0.32258368
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",containing,0.1330749,of,0.51960796,deposits,0.3792259
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",iud,0.19018975,thrombosis,0.29261482,thrombosis,0.29261482
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmission,0.18465236,of,0.4158437,congenital-heart-disease,0.34923676
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",infection,0.26741225,disease,0.482216,thrombosis,0.44838145
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",three,0.27802917,of,0.6048713,l-transposition,0.36917683
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",participants,0.35857671,chd,0.46645594,chd,0.46645594
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",variable,0.221965,of,0.60098064,anomaly,0.4223012
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effects,0.19496669,of,0.53851616,contractions,0.39115262
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",unexposed,0.17890666,with,0.3716902,hypoplastic,0.35181218
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",controls,0.23145974,with,0.5052294,mi,0.41936132
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",understanding,0.3158453,great,0.5292363,anomalous,0.3759449
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effects,0.19496669,of,0.53851616,contractions,0.39115262
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmitted,0.29742712,congenital-heart,0.44631845,congenital-heart,0.44631845
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",founder,0.41355887,cardiology,0.41355887,cardiology,0.41355887
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmitted-founder,0.36156714,congenital-heart-disease,0.4652353,congenital-heart-disease,0.4652353
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tissue,0.23668498,of,0.5202017,venous,0.46895027
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",composition,0.21594884,of,0.51248646,deposits,0.46536496
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tissue-composition,0.20287493,plaque-deposits,0.4766672,plaque-deposits,0.4766672
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",steroids,0.2655906,insufficiency,0.45060164,cholesterol,0.41560444
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",sex-steroids,0.20984028,cholesterol,0.4357879,cholesterol,0.4357879
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",potential,0.23291323,of,0.5645705,cardiac,0.34140193
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",peripheral,0.25941038,venous,0.56411976,venous,0.56411976
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",blood,0.32078606,blood,1.0,blood,1.0
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",peripheral-blood,0.22077957,blood,0.6257005,blood,0.6257005
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",medroxyprogesterone,0.21606997,cholesterol,0.4112171,cholesterol,0.4112171
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acetate,0.16104199,with,0.35273406,cholesterol,0.35136923
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",medroxyprogesterone-acetate,0.18699923,cholesterol,0.38098246,cholesterol,0.38098246
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",luteal,0.20914271,arteries,0.38187897,arteries,0.38187897
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",phase,0.19908471,of,0.4318388,flow,0.38942474
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",luteal-phase,0.18564317,venous-return,0.44840723,venous-return,0.44840723
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",little,0.32411388,great,0.59987354,flow,0.33457753
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",influence,0.22202107,of,0.5577396,anomalous,0.3532923
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",leading,0.25149748,of,0.59935343,congenital,0.40424997
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cause,0.24258707,congenital,0.5065234,congenital,0.5065234
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",leading-cause,0.30231607,chd,0.4955071,chd,0.4955071
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",increased,0.32251194,of,0.64014816,mi,0.42637154
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",risk,0.30685735,chd,0.5779637,chd,0.5779637
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",increased-risk,0.38663232,chd,0.54914963,chd,0.54914963
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",higher,0.2654187,with,0.56796193,mi,0.398535
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",rates,0.26658094,of,0.47081333,flow,0.4277016
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",higher-rates,0.29081392,with,0.4357262,venous-return,0.3872369
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",four,0.26703352,of,0.57211214,d-transposition,0.35247436
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",groups,0.2612025,with,0.4941169,mi,0.3908207
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",four-groups,0.2313892,congestive-heart-failure,0.3505623,congestive-heart-failure,0.3505623
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",endometrial,0.2984301,myocardial,0.38895005,myocardial,0.38895005
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",biopsies,0.26866582,deposits,0.4489481,deposits,0.4489481
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control,0.26906762,with,0.5145365,mi,0.4093958
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",chronic-control,0.27077052,congestive-heart-failure,0.50960773,congestive-heart-failure,0.50960773
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control,0.26906762,with,0.5145365,mi,0.4093958
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",samples,0.20068786,isolated,0.4879529,blood,0.4540816
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control-samples,0.22170186,venous-return,0.35472316,venous-return,0.35472316
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",based,0.2494699,of,0.5443143,flow,0.34116954
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studied,0.2428486,of,0.63097596,anomalous,0.39203623
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.18534905,of,0.46541262,deposits,0.38651246
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.17929009,disease,0.40550914,congenital-heart-disease,0.32258368
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel,0.2180939,cholesterol,0.351291,cholesterol,0.351291
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",samples,0.20068786,isolated,0.4879529,blood,0.4540816
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv,0.27039638,congenital-heart-disease,0.40357426,congenital-heart-disease,0.40357426
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",virus,0.21554038,paivs,0.45592806,paivs,0.45592806
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",virion,0.22859362,plaque,0.4321344,plaque,0.4321344
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",users,0.2883557,congestive-heart-failure,0.38387084,congestive-heart-failure,0.38387084
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",unclear,0.3259948,of,0.5037956,mi,0.42927802
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",subtype,0.17434898,isolated,0.4202699,paivs,0.39669624
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",role,0.263546,of,0.49928063,anomalous,0.31226397
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",origin,0.29532364,of,0.56003475,anomalous,0.5212826
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",none,0.3255544,with,0.59412724,mi,0.4215914
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",n,0.21850443,with,0.47536123,mi,0.3790054
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mid,0.36086994,right,0.5805234,stenosis,0.45125967
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mechanisms,0.19948575,of,0.51329505,l-transposition,0.37245494
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",measured,0.2266986,of,0.539739,flow,0.4470259
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",may,0.26963884,of,0.58654004,anomalous,0.366544
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",long,0.27184874,interrupted,0.56562316,l-transposition,0.3997872
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",likely,0.34048563,of,0.55071557,congestive,0.42744756
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",importance,0.3199574,of,0.5794183,anomaly,0.34929916
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",highlighting,0.31779927,of,0.6206035,l-transposition,0.3702503
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",globally,0.2850316,of,0.4747628,flow,0.3560362
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fuse,0.24892282,intact,0.39016876,anomaly,0.3761211
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",found,0.2675444,with,0.6275196,deposits,0.41920424
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",endometrium,0.22857246,arteries,0.41918254,arteries,0.41918254
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effect,0.20909318,of,0.5657147,contractions,0.35284936
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",differences,0.24501437,of,0.48845208,anomalous,0.3514788
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",differ,0.21590988,of,0.45475316,mi,0.32814133
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",depo,0.17281993,deposits,0.35444123,deposits,0.35444123
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",data,0.31118363,of,0.5086956,mi,0.36251363
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptives,0.3249496,thrombosis,0.42510825,thrombosis,0.42510825
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cervix,0.2349349,atresia,0.39368713,atresia,0.39368713
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",b,0.20100933,of,0.43435428,aortic,0.34993017
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",associated,0.20417106,with,0.60998726,congenital,0.4144575
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",aids,0.33263704,congenital-heart-disease,0.4778832,congenital-heart-disease,0.4778832
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",ability,0.2123124,of,0.53612673,cardiac,0.340167
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.33073232,heart-failure,0.49918163,heart-failure,0.49918163
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",treatment,0.30650938,of,0.52012336,congestive,0.36983645
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalized,0.3386992,abnormal,0.50572217,flow,0.40979832
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically,0.19735304,abnormal,0.54142636,deposits,0.5171819
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically-elevated,0.25949723,abnormal,0.6230533,deposits,0.5169733
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.29475835,blood-clot,0.49494922,blood-clot,0.49494922
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.2785672,atrial,0.4726013,atrial,0.4726013
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.28997296,blood-clot,0.49445236,blood-clot,0.49445236
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",targeting,0.23901626,of,0.47927672,l-transposition,0.3053895
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically,0.19735304,abnormal,0.54142636,deposits,0.5171819
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",may,0.26963884,of,0.58654004,anomalous,0.366544
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically-elevated,0.25949723,abnormal,0.6230533,deposits,0.5169733
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.29475835,blood-clot,0.49494922,blood-clot,0.49494922
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.2785672,atrial,0.4726013,atrial,0.4726013
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity-may,0.31578496,weak,0.42323494,heart-attack,0.40179458
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.28997296,blood-clot,0.49445236,blood-clot,0.49445236
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",concentrations,0.20313622,with,0.46930897,deposits,0.43182394
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.29475835,blood-clot,0.49494922,blood-clot,0.49494922
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.2785672,atrial,0.4726013,atrial,0.4726013
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.28997296,blood-clot,0.49445236,blood-clot,0.49445236
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reduced,0.22478527,of,0.6221848,contractions,0.3818075
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.29475835,blood-clot,0.49494922,blood-clot,0.49494922
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.2785672,atrial,0.4726013,atrial,0.4726013
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity-reduced,0.21961465,of,0.48371133,venous-return,0.3788568
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.28997296,blood-clot,0.49445236,blood-clot,0.49445236
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.33073232,heart-failure,0.49918163,heart-failure,0.49918163
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",improved,0.32791707,with,0.5777352,congestive,0.40790212
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac,0.66620034,cardiac,1.0,cardiac,1.0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic,0.48098868,ventricular,0.6719714,ventricular,0.6719714
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",function,0.2605439,of,0.55099833,flow,0.43324804
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic-function,0.44505498,ventricular,0.5727781,ventricular,0.5727781
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.29475835,blood-clot,0.49494922,blood-clot,0.49494922
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.2785672,atrial,0.4726013,atrial,0.4726013
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.28997296,blood-clot,0.49445236,blood-clot,0.49445236
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.22675279,of,0.5327676,contractions,0.3920536
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",retards,0.11473469,of,0.46905687,deposits,0.3881128
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.29475835,blood-clot,0.49494922,blood-clot,0.49494922
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.2785672,atrial,0.4726013,atrial,0.4726013
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.28997296,blood-clot,0.49445236,blood-clot,0.49445236
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",improving,0.3579299,great,0.54781544,congestive,0.39419994
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac,0.66620034,cardiac,1.0,cardiac,1.0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic,0.48098868,ventricular,0.6719714,ventricular,0.6719714
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",function,0.2605439,of,0.55099833,flow,0.43324804
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic-function,0.44505498,ventricular,0.5727781,ventricular,0.5727781
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly,0.23700657,with,0.568532,mi,0.39826992
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",alter,0.19845097,of,0.49618223,contractions,0.33163282
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",changes,0.30126634,of,0.5562258,flow,0.44305104
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathological-changes,0.32151052,disease,0.53831047,deposits,0.4922459
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",appropriately,0.3976931,with,0.5387873,cardiology,0.3976931
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",selected,0.31146818,of,0.6198958,d-transposition,0.3718648
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",appropriately-selected,0.37635246,with,0.5616883,d-transposition,0.39642093
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf-patients,0.42306063,heart-failure,0.64360976,heart-failure,0.64360976
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",direct,0.20486939,of,0.5187454,anomalous,0.3848631
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.31312823,atrial,0.5063691,atrial,0.5063691
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",inhibitor,0.23137593,of,0.37385303,congestive,0.302135
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-inhibitor,0.26610696,coronary-thrombosis,0.42961097,coronary-thrombosis,0.42961097
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",blinded,0.3934089,single,0.4328285,cardiology,0.3934089
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",fashion,0.20147611,with,0.4481435,l-transposition,0.40965575
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",beginning,0.42209855,of,0.52056587,cardiology,0.42209855
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",blinded-fashion,0.35015768,double,0.4368292,venous-return,0.43211085
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial,0.52708566,atrial,1.0,atrial,1.0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",natriuretic,0.381192,atrial,0.6450516,atrial,0.6450516
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",peptide,0.22390819,atrial,0.42872304,atrial,0.42872304
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial-natriuretic,0.4124434,atrial,0.7909212,atrial,0.7909212
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",natriuretic-peptide,0.30771548,atrial,0.5734308,atrial,0.5734308
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial-natriuretic-peptide,0.37703258,atrial,0.7249689,atrial,0.7249689
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.19545637,with,0.46458423,rai,0.38722774
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",c,0.21239448,with,0.46990636,ivs,0.34813386
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage-c,0.016169455,atresia,0.33856252,atresia,0.33856252
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",c-hf,0.29175973,heart-failure,0.5150939,heart-failure,0.5150939
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.19545637,with,0.46458423,rai,0.38722774
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",b,0.20100933,of,0.43435428,aortic,0.34993017
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage-b,0.10474165,rai,0.38000408,rai,0.38000408
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",b-hf,0.32327998,heart-failure,0.5503981,heart-failure,0.5503981
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",retarding,0.20769873,of,0.5068949,deposits,0.44119364
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21807674,blood,0.4915529,blood,0.4915529
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aldosterone,0.33841828,atrial,0.5453626,atrial,0.5453626
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-aldosterone,0.30244136,atrial,0.49571103,atrial,0.49571103
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly,0.23700657,with,0.568532,mi,0.39826992
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reduced,0.22478527,of,0.6221848,contractions,0.3818075
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly-reduced,0.22982919,with,0.58588755,mi,0.39889532
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",sarcopenia,0.29194587,heart-failure,0.5090842,heart-failure,0.5090842
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",p,0.29391026,with,0.4559728,congestive,0.4058217
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac,0.66620034,cardiac,1.0,cardiac,1.0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",output,0.37432313,return,0.52389014,flow,0.5028697
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac-output,0.5349641,cardiac,0.7844535,cardiac,0.7844535
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.19545637,with,0.46458423,rai,0.38722774
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",b,0.20100933,of,0.43435428,aortic,0.34993017
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage-b,0.10474165,rai,0.38000408,rai,0.38000408
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",frequently,0.34173125,with,0.5701885,deposits,0.40674675
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.33073232,heart-failure,0.49918163,heart-failure,0.49918163
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",human,0.20610836,of,0.5175895,l-transposition,0.36225826
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",relevant,0.3264072,of,0.5628227,anomalous,0.34380507
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",prolonged,0.23698492,return,0.5181756,bradycardia,0.47709072
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",progressive,0.24325345,failure,0.5760631,congestive,0.46137327
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stages,0.18231006,of,0.45860782,deposits,0.40678376
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",neprilysin,0.28954732,heart-failure,0.40454558,heart-failure,0.40454558
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",levels,0.24129483,of,0.5074555,cholesterol,0.4301517
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",lean,0.26298892,cholesterol,0.40847355,cholesterol,0.40847355
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mass,0.21939,tof,0.43280137,tof,0.43280137
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",lean-mass,0.2274222,tof,0.42430487,tof,0.42430487
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",heart,0.57664216,heart,1.0,heart,1.0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",female,0.32612452,of,0.44902933,mi,0.41579333
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mice,0.19391358,with,0.4337707,septal-defect,0.43083143
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",female-mice,0.1867521,congenital-heart-disease,0.40223765,congenital-heart-disease,0.40223765
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",extracellular,0.14791466,deposits,0.42989883,deposits,0.42989883
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",water,0.24220353,of,0.46924597,flow,0.42210716
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ejection,0.42473865,ventricular,0.6757684,ventricular,0.6757684
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",fraction,0.2824625,isolated,0.5140033,ventricular,0.42264658
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ejection-fraction,0.2780968,ventricular,0.50171983,ventricular,0.50171983
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dilated,0.38440502,ventricle,0.58307534,ventricle,0.58307534
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiomyopathy,0.5463724,congestive,0.6767609,congestive,0.6767609
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dilated-cardiomyopathy,0.5185985,myocardial-infarction,0.69644046,myocardial-infarction,0.69644046
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dcm,0.3689653,myocardial-infarction,0.5322505,myocardial-infarction,0.5322505
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",data,0.31118363,of,0.5086956,mi,0.36251363
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",suggest,0.18845408,of,0.5019331,anomalous,0.3196395
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",data-suggest,0.38913143,heartbeat,0.41105014,heartbeat,0.41105014
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",corin,0.32303125,atrial,0.45675313,atrial,0.45675313
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",levels,0.24129483,of,0.5074555,cholesterol,0.4301517
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",body,0.2371722,of,0.4173455,heartbeat,0.41062886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",fat,0.23246992,cholesterol,0.5448952,cholesterol,0.5448952
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",body-fat,0.20987341,cholesterol,0.44136077,cholesterol,0.44136077
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",angiotensin,0.34895274,congestive,0.49475524,congestive,0.49475524
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ii,0.26288998,of,0.43728137,mi,0.35983312
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",angiotensin-ii,0.31497288,atrial,0.48099947,atrial,0.48099947
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systemic,0.28270477,pulmonary-venous,0.5600716,pulmonary-venous,0.5600716
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",edema,0.2855428,congestive,0.52347773,congestive,0.52347773
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",longitudinal,0.25857258,of,0.40970862,contractions,0.38807714
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",development,0.2877805,of,0.53581744,congenital,0.35419804
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.38390464,heart-failure,0.63991886,heart-failure,0.63991886
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",sarcopenia,0.29194587,heart-failure,0.5090842,heart-failure,0.5090842
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",p,0.29391026,with,0.4559728,congestive,0.4058217
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",edema,0.2855428,congestive,0.52347773,congestive,0.52347773
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",development,0.2877805,of,0.53581744,congenital,0.35419804
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dcm,0.3689653,myocardial-infarction,0.5322505,myocardial-infarction,0.5322505
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",translationally,0.2295084,of,0.41956344,l-transposition,0.3556835
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",transition,0.26457083,of,0.45053744,anomalous,0.41481292
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",summary,0.39694136,of,0.48017746,cardiology,0.39694136
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significance,0.3123301,of,0.55474335,anomaly,0.39406294
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",replicates,0.15988047,l-transposition,0.38755253,l-transposition,0.38755253
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reducing,0.20510697,of,0.5635449,heart-attack,0.39589107
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",randomized,0.31567937,interrupted,0.40434858,congestive-heart-failure,0.39597732
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",progression,0.2872493,disease,0.5879895,mi,0.4478637
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalization,0.29672745,abnormal,0.55760914,blood-flow,0.44031575
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mortality,0.3475203,chd,0.5562636,chd,0.5562636
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",loss,0.15467258,of,0.561642,anomaly,0.37637395
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",examined,0.2811494,of,0.66699874,flow,0.35738647
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",controls,0.23145974,with,0.5052294,mi,0.41936132
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",comparison,0.25417167,with,0.5616678,congenital-heart-disease,0.35197458
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cachexia,0.27743402,congestive-heart-failure,0.500473,congestive-heart-failure,0.500473
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",beneficial,0.25004005,of,0.47944272,heart-attack,0.36086392
Sensor Networks for Aerospace Human-Machine Systems.,support,0.36322898,return,0.46409142,flow,0.36807415
Sensor Networks for Aerospace Human-Machine Systems.,diverse,0.3032622,of,0.5461366,cardiac,0.3471622
Sensor Networks for Aerospace Human-Machine Systems.,tasks,0.32579935,heartbeat,0.39437467,heartbeat,0.39437467
Sensor Networks for Aerospace Human-Machine Systems.,including,0.2742056,of,0.6619886,congenital,0.3605199
Sensor Networks for Aerospace Human-Machine Systems.,data,0.31118363,of,0.5086956,mi,0.36251363
Sensor Networks for Aerospace Human-Machine Systems.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Sensor Networks for Aerospace Human-Machine Systems.,tasks-including,0.33223087,of,0.40647778,congenital-heart-disease,0.37405935
Sensor Networks for Aerospace Human-Machine Systems.,data-processing,0.33597934,venous-return,0.36957443,venous-return,0.36957443
Sensor Networks for Aerospace Human-Machine Systems.,atm,0.11384821,tapvr,0.35317373,tapvr,0.35317373
Sensor Networks for Aerospace Human-Machine Systems.,commercial,0.22465858,with,0.43286043,blood-clot,0.30509424
Sensor Networks for Aerospace Human-Machine Systems.,airliner,0.3341295,heart-attack,0.38682228,heart-attack,0.38682228
Sensor Networks for Aerospace Human-Machine Systems.,single,0.2571312,single,1.0,anomalous,0.40611145
Sensor Networks for Aerospace Human-Machine Systems.,suitable,0.2168997,of,0.5238371,flow,0.3817314
Sensor Networks for Aerospace Human-Machine Systems.,data,0.31118363,of,0.5086956,mi,0.36251363
Sensor Networks for Aerospace Human-Machine Systems.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Sensor Networks for Aerospace Human-Machine Systems.,techniques,0.254115,great,0.3795752,single-ventricle,0.37415883
Sensor Networks for Aerospace Human-Machine Systems.,based,0.2494699,of,0.5443143,flow,0.34116954
Sensor Networks for Aerospace Human-Machine Systems.,data-analysis,0.37663472,congenital-heart-disease,0.41325346,congenital-heart-disease,0.41325346
Sensor Networks for Aerospace Human-Machine Systems.,techniques-based,0.2776655,venous-return,0.35240078,venous-return,0.35240078
Sensor Networks for Aerospace Human-Machine Systems.,obtain,0.32854,return,0.5372094,flow,0.39961314
Sensor Networks for Aerospace Human-Machine Systems.,accurate,0.25226092,of,0.4756247,anomalous,0.40025836
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Sensor Networks for Aerospace Human-Machine Systems.,state,0.27757272,of,0.48501438,anomalous,0.3514698
Sensor Networks for Aerospace Human-Machine Systems.,estimations,0.25688472,of,0.47139883,blood-flow,0.37158337
Sensor Networks for Aerospace Human-Machine Systems.,cognitive-state,0.30814204,congestive-heart-failure,0.4298652,congestive-heart-failure,0.4298652
Sensor Networks for Aerospace Human-Machine Systems.,including,0.2742056,of,0.6619886,congenital,0.3605199
Sensor Networks for Aerospace Human-Machine Systems.,air,0.2887124,return,0.45869708,flow,0.42904893
Sensor Networks for Aerospace Human-Machine Systems.,traffic,0.3018651,of,0.3987283,flow,0.3863122
Sensor Networks for Aerospace Human-Machine Systems.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Sensor Networks for Aerospace Human-Machine Systems.,air-traffic,0.29524854,outlet,0.4001472,pulmonary,0.3964292
Sensor Networks for Aerospace Human-Machine Systems.,traffic-management,0.45467988,cardiology,0.45467988,cardiology,0.45467988
Sensor Networks for Aerospace Human-Machine Systems.,paper,0.30468726,of,0.4606573,anomaly,0.36774796
Sensor Networks for Aerospace Human-Machine Systems.,discusses,0.37122712,of,0.49693072,cardiology,0.37122712
Sensor Networks for Aerospace Human-Machine Systems.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Sensor Networks for Aerospace Human-Machine Systems.,advances,0.40024865,great,0.516971,cardiology,0.40024865
Sensor Networks for Aerospace Human-Machine Systems.,many,0.34462097,great,0.5654564,deposits,0.36972266
Sensor Networks for Aerospace Human-Machine Systems.,unmanned,0.27888983,venous-return,0.37859553,venous-return,0.37859553
Sensor Networks for Aerospace Human-Machine Systems.,aircraft,0.29102927,venous-return,0.38612673,venous-return,0.38612673
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.2822709,of,0.44318485,flow,0.3656453
Sensor Networks for Aerospace Human-Machine Systems.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.30281103,blood-flow,0.40183297,blood-flow,0.40183297
Sensor Networks for Aerospace Human-Machine Systems.,measurements,0.27821797,blood-flow,0.45775104,blood-flow,0.45775104
Sensor Networks for Aerospace Human-Machine Systems.,used,0.23211285,as,0.56584436,flow,0.35934073
Sensor Networks for Aerospace Human-Machine Systems.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Sensor Networks for Aerospace Human-Machine Systems.,challenging,0.29561728,great,0.56316066,anomalous,0.40406942
Sensor Networks for Aerospace Human-Machine Systems.,aerospace,0.48585033,cardiology,0.48585033,cardiology,0.48585033
Sensor Networks for Aerospace Human-Machine Systems.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
Sensor Networks for Aerospace Human-Machine Systems.,techniques,0.254115,great,0.3795752,single-ventricle,0.37415883
Sensor Networks for Aerospace Human-Machine Systems.,allow,0.28258905,of,0.5533963,flow,0.40086067
Sensor Networks for Aerospace Human-Machine Systems.,processing,0.22384205,of,0.46388876,deposits,0.33125138
Sensor Networks for Aerospace Human-Machine Systems.,based,0.2494699,of,0.5443143,flow,0.34116954
Sensor Networks for Aerospace Human-Machine Systems.,inference,0.3017606,of,0.427243,mi,0.39377034
Sensor Networks for Aerospace Human-Machine Systems.,engine,0.35593832,cad,0.35784227,cad,0.35784227
Sensor Networks for Aerospace Human-Machine Systems.,sipo,0.24891245,lai,0.37970096,lai,0.37970096
Sensor Networks for Aerospace Human-Machine Systems.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Sensor Networks for Aerospace Human-Machine Systems.,space,0.17331463,deposits,0.39822596,deposits,0.39822596
Sensor Networks for Aerospace Human-Machine Systems.,operations,0.3484172,d-transposition,0.5020788,d-transposition,0.5020788
Sensor Networks for Aerospace Human-Machine Systems.,management,0.48033568,cardiology,0.48033568,cardiology,0.48033568
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.30281103,blood-flow,0.40183297,blood-flow,0.40183297
Sensor Networks for Aerospace Human-Machine Systems.,observations,0.27909255,of,0.5493803,deposits,0.43099713
Sensor Networks for Aerospace Human-Machine Systems.,becoming,0.40251914,with,0.54768723,cardiology,0.40251914
Sensor Networks for Aerospace Human-Machine Systems.,proper,0.32222104,of,0.5900549,anomalous,0.43626118
Sensor Networks for Aerospace Human-Machine Systems.,sensor,0.18712729,great,0.36468887,heartbeat,0.3623
Sensor Networks for Aerospace Human-Machine Systems.,selection,0.27297795,of,0.46267295,l-transposition,0.4192079
Sensor Networks for Aerospace Human-Machine Systems.,sensor-selection,0.21164955,d-transposition,0.4341482,d-transposition,0.4341482
Sensor Networks for Aerospace Human-Machine Systems.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Sensor Networks for Aerospace Human-Machine Systems.,state,0.27757272,of,0.48501438,anomalous,0.3514698
Sensor Networks for Aerospace Human-Machine Systems.,operational,0.3220483,of,0.48811585,venous-return,0.41610703
Sensor Networks for Aerospace Human-Machine Systems.,data,0.31118363,of,0.5086956,mi,0.36251363
Sensor Networks for Aerospace Human-Machine Systems.,exchange,0.23966244,anomalous,0.4229427,anomalous,0.4229427
Sensor Networks for Aerospace Human-Machine Systems.,data,0.31118363,of,0.5086956,mi,0.36251363
Sensor Networks for Aerospace Human-Machine Systems.,uas,0.10667741,l-transposition,0.33184242,l-transposition,0.33184242
Sensor Networks for Aerospace Human-Machine Systems.,paper,0.30468726,of,0.4606573,anomaly,0.36774796
Sensor Networks for Aerospace Human-Machine Systems.,addresses,0.38929057,of,0.5340178,cardiology,0.38929057
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Sensor Networks for Aerospace Human-Machine Systems.,states,0.32495102,of,0.46123946,anomalous,0.35751992
Sensor Networks for Aerospace Human-Machine Systems.,cognitive-states,0.31241435,congestive-heart-failure,0.42058736,congestive-heart-failure,0.42058736
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.33717254,heart-failure,0.42926842,heart-failure,0.42926842
Sensor Networks for Aerospace Human-Machine Systems.,aerospace,0.48585033,cardiology,0.48585033,cardiology,0.48585033
Sensor Networks for Aerospace Human-Machine Systems.,cyber,0.334661,arrythmia,0.3751449,arrythmia,0.3751449
Sensor Networks for Aerospace Human-Machine Systems.,physical,0.35664004,of,0.4425894,pulmonary,0.40153936
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.2822709,of,0.44318485,flow,0.3656453
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.2822709,of,0.44318485,flow,0.3656453
Sensor Networks for Aerospace Human-Machine Systems.,statistical,0.32752115,of,0.40241736,congenital-heart-disease,0.36489835
Sensor Networks for Aerospace Human-Machine Systems.,inference,0.3017606,of,0.427243,mi,0.39377034
Sensor Networks for Aerospace Human-Machine Systems.,statistical-inference,0.32092357,congenital-heart-disease,0.41132107,congenital-heart-disease,0.41132107
Sensor Networks for Aerospace Human-Machine Systems.,sensor,0.18712729,great,0.36468887,heartbeat,0.3623
Sensor Networks for Aerospace Human-Machine Systems.,networks,0.2352877,great,0.3902747,venous-return,0.35607615
Sensor Networks for Aerospace Human-Machine Systems.,pilot,0.34466958,of,0.42890126,venous-return,0.41839325
Sensor Networks for Aerospace Human-Machine Systems.,operations,0.3484172,d-transposition,0.5020788,d-transposition,0.5020788
Sensor Networks for Aerospace Human-Machine Systems.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
Sensor Networks for Aerospace Human-Machine Systems.,trusted,0.45854214,great,0.45956987,cardiology,0.45854214
Sensor Networks for Aerospace Human-Machine Systems.,autonomy,0.3056889,incompetence,0.5195898,congenital-heart-disease,0.37255907
Sensor Networks for Aerospace Human-Machine Systems.,technological,0.38485312,great,0.5247618,cardiology,0.38485312
Sensor Networks for Aerospace Human-Machine Systems.,developments,0.4323659,great,0.5226431,cardiology,0.4323659
Sensor Networks for Aerospace Human-Machine Systems.,states,0.32495102,of,0.46123946,anomalous,0.35751992
Sensor Networks for Aerospace Human-Machine Systems.,using,0.20786116,with,0.58010674,flow,0.41007757
Sensor Networks for Aerospace Human-Machine Systems.,states-using,0.30598843,with,0.4019808,venous-return,0.3911348
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.23341918,great,0.41634512,heartbeat,0.34583208
Sensor Networks for Aerospace Human-Machine Systems.,collect,0.2531668,return,0.44474143,flow,0.36699224
Sensor Networks for Aerospace Human-Machine Systems.,results,0.29712585,of,0.53157276,blood,0.36869162
Sensor Networks for Aerospace Human-Machine Systems.,show,0.19476143,of,0.51487744,anomalous,0.38152152
Sensor Networks for Aerospace Human-Machine Systems.,remote,0.31851736,mi,0.44405088,mi,0.44405088
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.23341918,great,0.41634512,heartbeat,0.34583208
Sensor Networks for Aerospace Human-Machine Systems.,reliable,0.18723083,great,0.4551165,blood-flow,0.38184124
Sensor Networks for Aerospace Human-Machine Systems.,methodology,0.283471,of,0.41219762,single-ventricle,0.29670447
Sensor Networks for Aerospace Human-Machine Systems.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Sensor Networks for Aerospace Human-Machine Systems.,characterisation,0.18883254,of,0.5609221,anomalous,0.37150598
Sensor Networks for Aerospace Human-Machine Systems.,operational,0.3220483,of,0.48811585,venous-return,0.41610703
Sensor Networks for Aerospace Human-Machine Systems.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Sensor Networks for Aerospace Human-Machine Systems.,notable,0.34667432,great,0.61987686,anomaly,0.41260397
Sensor Networks for Aerospace Human-Machine Systems.,advantages,0.24625129,great,0.5105034,d-transposition,0.36273855
Sensor Networks for Aerospace Human-Machine Systems.,mission,0.45744982,return,0.46691352,cardiology,0.45744982
Sensor Networks for Aerospace Human-Machine Systems.,execution,0.31608242,heartbeat,0.41912627,heartbeat,0.41912627
Sensor Networks for Aerospace Human-Machine Systems.,mission-execution,0.37641615,venous-return,0.40533894,venous-return,0.40533894
Sensor Networks for Aerospace Human-Machine Systems.,measurement,0.2804429,of,0.51248544,blood-flow,0.45750505
Sensor Networks for Aerospace Human-Machine Systems.,uncertainties,0.30739948,great,0.40908214,heartbeat,0.36339483
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Sensor Networks for Aerospace Human-Machine Systems.,monitors,0.40431792,heartbeat,0.4218869,heartbeat,0.4218869
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Sensor Networks for Aerospace Human-Machine Systems.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Sensor Networks for Aerospace Human-Machine Systems.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Sensor Networks for Aerospace Human-Machine Systems.,interfaces,0.2396768,deposits,0.3514824,deposits,0.3514824
Sensor Networks for Aerospace Human-Machine Systems.,information,0.36363098,of,0.47314215,mi,0.39006084
Sensor Networks for Aerospace Human-Machine Systems.,sharing,0.25722516,with,0.48750085,congenital-heart-disease,0.3638193
Sensor Networks for Aerospace Human-Machine Systems.,information-sharing,0.35741565,congenital-heart-disease,0.42966053,congenital-heart-disease,0.42966053
Sensor Networks for Aerospace Human-Machine Systems.,increasing,0.35820884,of,0.6603997,flow,0.41165438
Sensor Networks for Aerospace Human-Machine Systems.,level,0.2892119,of,0.54773176,cholesterol,0.39509016
Sensor Networks for Aerospace Human-Machine Systems.,increasing-level,0.3583924,of,0.5272798,venous-return,0.43197182
Sensor Networks for Aerospace Human-Machine Systems.,controlled,0.27810073,interrupted,0.47225165,fibrillation,0.3495557
Sensor Networks for Aerospace Human-Machine Systems.,remotely,0.3194455,with,0.4532978,heartbeat,0.41649884
Sensor Networks for Aerospace Human-Machine Systems.,art,0.4086473,venous-return,0.47565544,venous-return,0.47565544
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.23341918,great,0.41634512,heartbeat,0.34583208
Sensor Networks for Aerospace Human-Machine Systems.,also,0.36015856,of,0.65908813,flow,0.41040578
Sensor Networks for Aerospace Human-Machine Systems.,presented,0.34475142,with,0.61236936,anomaly,0.42759705
Sensor Networks for Aerospace Human-Machine Systems.,loop,0.14408562,interrupted,0.45845878,ivs,0.35547963
Sensor Networks for Aerospace Human-Machine Systems.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Sensor Networks for Aerospace Human-Machine Systems.,effective,0.20873946,as,0.5165305,contractions,0.33001167
Sensor Networks for Aerospace Human-Machine Systems.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Sensor Networks for Aerospace Human-Machine Systems.,tasks,0.32579935,heartbeat,0.39437467,heartbeat,0.39437467
Sensor Networks for Aerospace Human-Machine Systems.,support,0.36322898,return,0.46409142,flow,0.36807415
Sensor Networks for Aerospace Human-Machine Systems.,intelligent,0.34360585,great,0.4841298,heartbeat,0.4104058
Sensor Networks for Aerospace Human-Machine Systems.,automation,0.3789641,cardiology,0.3789641,cardiology,0.3789641
Sensor Networks for Aerospace Human-Machine Systems.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Sensor Networks for Aerospace Human-Machine Systems.,operator,0.30100167,d-transposition,0.41643852,d-transposition,0.41643852
Sensor Networks for Aerospace Human-Machine Systems.,human-operator,0.32549194,d-transposition,0.45923582,d-transposition,0.45923582
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.30281103,blood-flow,0.40183297,blood-flow,0.40183297
Sensor Networks for Aerospace Human-Machine Systems.,human,0.20610836,of,0.5175895,l-transposition,0.36225826
Sensor Networks for Aerospace Human-Machine Systems.,operator,0.30100167,d-transposition,0.41643852,d-transposition,0.41643852
Sensor Networks for Aerospace Human-Machine Systems.,automation,0.3789641,cardiology,0.3789641,cardiology,0.3789641
Sensor Networks for Aerospace Human-Machine Systems.,wearable,0.34054744,heartbeat,0.48144528,heartbeat,0.48144528
Sensor Networks for Aerospace Human-Machine Systems.,variety,0.24480078,great,0.49781102,l-transposition,0.37458777
Sensor Networks for Aerospace Human-Machine Systems.,time,0.350901,return,0.5513821,venous-return,0.44564146
Sensor Networks for Aerospace Human-Machine Systems.,synchronised,0.274365,heartbeat,0.5628074,heartbeat,0.5628074
Sensor Networks for Aerospace Human-Machine Systems.,seen,0.46511754,with,0.6698557,septal,0.47136146
Sensor Networks for Aerospace Human-Machine Systems.,relationship,0.21630949,of,0.4831799,anomalous,0.3835627
Sensor Networks for Aerospace Human-Machine Systems.,real,0.3591983,great,0.53489023,flow,0.42211816
Sensor Networks for Aerospace Human-Machine Systems.,propagation,0.22916555,of,0.4872983,flow,0.44104272
Sensor Networks for Aerospace Human-Machine Systems.,order,0.35672373,of,0.59467053,anomalous,0.37882286
Sensor Networks for Aerospace Human-Machine Systems.,operation,0.31241646,d-transposition,0.4979664,d-transposition,0.4979664
Sensor Networks for Aerospace Human-Machine Systems.,maximise,0.2702636,great,0.48998532,venous-return,0.3747058
Sensor Networks for Aerospace Human-Machine Systems.,making,0.3548795,of,0.57845646,flow,0.39122948
Sensor Networks for Aerospace Human-Machine Systems.,led,0.2739451,of,0.6366651,congenital,0.32305634
Sensor Networks for Aerospace Human-Machine Systems.,lastly,0.33464947,of,0.6291888,flow,0.38303292
Sensor Networks for Aerospace Human-Machine Systems.,introduced,0.295581,of,0.506906,l-transposition,0.39756888
Sensor Networks for Aerospace Human-Machine Systems.,interactions,0.26582682,weak,0.48503923,isomerism,0.3771425
Sensor Networks for Aerospace Human-Machine Systems.,integration,0.32180518,l-transposition,0.481107,l-transposition,0.481107
Sensor Networks for Aerospace Human-Machine Systems.,implementations,0.37094545,heartbeat,0.3776915,heartbeat,0.3776915
Sensor Networks for Aerospace Human-Machine Systems.,implementation,0.41635638,cardiology,0.41635638,cardiology,0.41635638
Sensor Networks for Aerospace Human-Machine Systems.,humans,0.21283677,of,0.49299914,congenital-heart-disease,0.41938835
Sensor Networks for Aerospace Human-Machine Systems.,focusing,0.29023415,of,0.5571873,anomalous,0.39552477
Sensor Networks for Aerospace Human-Machine Systems.,evolution,0.3366428,of,0.57603025,l-transposition,0.46824002
Sensor Networks for Aerospace Human-Machine Systems.,evaluate,0.33624867,of,0.4977158,pulmonary,0.34511766
Sensor Networks for Aerospace Human-Machine Systems.,enhanced,0.24384218,of,0.59523904,anomalous,0.36034083
Sensor Networks for Aerospace Human-Machine Systems.,effectiveness,0.2947462,of,0.5160025,venous-return,0.352529
Sensor Networks for Aerospace Human-Machine Systems.,due,0.3318616,of,0.5734476,anomaly,0.41796127
Sensor Networks for Aerospace Human-Machine Systems.,discussed,0.42584902,as,0.54987454,cardiology,0.42584902
Sensor Networks for Aerospace Human-Machine Systems.,development,0.2877805,of,0.53581744,congenital,0.35419804
Sensor Networks for Aerospace Human-Machine Systems.,decision,0.46018064,cardiology,0.46018064,cardiology,0.46018064
Sensor Networks for Aerospace Human-Machine Systems.,context,0.3526281,of,0.54966336,congenital-heart-disease,0.38638416
Sensor Networks for Aerospace Human-Machine Systems.,collaboration,0.53562415,cardiology,0.53562415,cardiology,0.53562415
Sensor Networks for Aerospace Human-Machine Systems.,closed,0.24981855,interrupted,0.5273638,l-transposition,0.41221613
Sensor Networks for Aerospace Human-Machine Systems.,approach,0.24478336,of,0.42712367,l-transposition,0.40473902
Sensor Networks for Aerospace Human-Machine Systems.,adoption,0.37081084,of,0.44224757,single-ventricle,0.3776039
Sensor Networks for Aerospace Human-Machine Systems.,adapts,0.19203207,heartbeat,0.37272072,heartbeat,0.37272072
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.37623936,heartbeat,0.39001763,heartbeat,0.39001763
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.20786116,with,0.58010674,flow,0.41007757
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,multimodal,0.3015176,great,0.41216543,single-ventricle,0.3761499
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.2345418,heartbeat,0.4749927,heartbeat,0.4749927
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,including,0.2742056,of,0.6619886,congenital,0.3605199
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,photoplethysmogram,0.2775614,blood-flow,0.585059,blood-flow,0.585059
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals-including,0.29001123,of,0.4878139,heartbeat,0.39105618
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,individually,0.23623335,single,0.58708346,chd,0.3561829
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,customized,0.26513624,with,0.4178707,single-ventricle,0.37518042
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,game,0.3649471,venous-return,0.44579732,venous-return,0.44579732
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.22305535,of,0.4642575,flow,0.35575604
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection-system,0.23398939,heartbeat,0.40612805,heartbeat,0.40612805
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third,0.30185395,single,0.54406995,ventricle,0.44503468
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.21804892,of,0.43378067,heartbeat,0.36693472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.20786116,with,0.58010674,flow,0.41007757
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classifiers,0.28955632,congenital-heart-disease,0.36196706,congenital-heart-disease,0.36196706
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment-using,0.2615549,venous-return,0.40551984,venous-return,0.40551984
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,presented,0.34475142,with,0.61236936,anomaly,0.42759705
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,short,0.27641132,interrupted,0.5895587,d-transposition,0.38685596
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video,0.34401283,heartbeat,0.4513059,heartbeat,0.4513059
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,clips,0.23969829,left,0.41668293,arteries,0.39440405
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video-clips,0.2772415,heartbeat,0.43486458,heartbeat,0.43486458
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,knn,0.24443169,heartbeat,0.29841074,heartbeat,0.29841074
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,centroid,0.21583225,irregular,0.36173442,isomerism,0.3578676
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,displacement,0.1856063,l-transposition,0.48802197,l-transposition,0.48802197
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,model,0.15189978,of,0.41477072,congenital-heart-disease,0.3376758
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,constructed,0.15691337,interrupted,0.47456625,l-transposition,0.40224642
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine-learning,0.36460787,heartbeat,0.42890018,heartbeat,0.42890018
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,model-constructed,0.20142367,interrupted,0.4525594,venous-return,0.44193316
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine-learning-model,0.32605174,heartbeat,0.44509917,heartbeat,0.44509917
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,various,0.2709849,of,0.6378319,l-transposition,0.3584417
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.2345418,heartbeat,0.4749927,heartbeat,0.4749927
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.2345418,heartbeat,0.4749927,heartbeat,0.4749927
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.22305535,of,0.4642575,flow,0.35575604
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection-system,0.23398939,heartbeat,0.40612805,heartbeat,0.40612805
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video,0.34401283,heartbeat,0.4513059,heartbeat,0.4513059
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,clips,0.23969829,left,0.41668293,arteries,0.39440405
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video-clips,0.2772415,heartbeat,0.43486458,heartbeat,0.43486458
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,internet,0.40568843,cardiology,0.40568843,cardiology,0.40568843
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.37623936,heartbeat,0.39001763,heartbeat,0.39001763
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,disorder,0.24185349,syndrome,0.53156126,syndrome,0.53156126
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,internet-gaming,0.36704573,congenital-heart-disease,0.38470027,congenital-heart-disease,0.38470027
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,features,0.24589524,of,0.5517558,anomaly,0.49347878
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,used,0.23211285,as,0.56584436,flow,0.35934073
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addictive,0.33476472,congestive-heart-failure,0.37758505,congestive-heart-failure,0.37758505
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,games,0.42515796,cardiology,0.42515796,cardiology,0.42515796
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,linear,0.17840835,of,0.40123588,isomerism,0.35944843
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,discriminant,0.23723195,artery-disease,0.36586708,artery-disease,0.36586708
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,linear-discriminant,0.1865668,weak,0.3833245,venous-return,0.36135852
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,discriminant-analysis,0.28643587,congenital-heart-disease,0.44577932,congenital-heart-disease,0.44577932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass,0.33753765,artery-disease,0.3627621,artery-disease,0.3627621
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,correlation,0.27065358,weak,0.4595955,anomalous,0.39483362
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,coefficient,0.2424671,anomalous,0.41799563,anomalous,0.41799563
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass-correlation,0.28664404,heartbeat,0.43562132,heartbeat,0.43562132
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,correlation-coefficient,0.25529933,anomalous,0.42784607,anomalous,0.42784607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass-correlation-coefficient,0.26247045,venous-return,0.4326023,venous-return,0.4326023
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,increasing,0.35820884,of,0.6603997,flow,0.41165438
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,public,0.4577744,cardiology,0.4577744,cardiology,0.4577744
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,concern,0.45242032,great,0.59480476,cardiology,0.45242032
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,galvanic,0.20006278,heartbeat,0.3454638,heartbeat,0.3454638
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,skin,0.25814313,intact,0.54987115,pulmonary,0.43537092
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,response,0.2306606,of,0.52661085,contractions,0.38512754
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,galvanic-skin,0.21502219,plaque-deposits,0.37475622,plaque-deposits,0.37475622
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,skin-response,0.20982274,l-transposition,0.40285128,l-transposition,0.40285128
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,cue,0.2559377,heartbeat,0.46748042,heartbeat,0.46748042
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,exposure,0.19340545,of,0.47989124,deposits,0.29644954
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,cue-exposure,0.18171209,congenital-heart-disease,0.31502044,congenital-heart-disease,0.31502044
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,exposure-therapy,0.25130686,rai,0.45785373,rai,0.45785373
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experimental,0.1877502,of,0.46885806,blood-flow,0.37892133
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,conditions,0.18750763,with,0.42849785,flow,0.36976144
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experimental-conditions,0.20202056,congenital-heart-disease,0.4319446,congenital-heart-disease,0.4319446
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.22305535,of,0.4642575,flow,0.35575604
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection-method,0.23494527,of,0.35173273,heartbeat,0.3374292
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support,0.36322898,return,0.46409142,flow,0.36807415
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,vector,0.20063998,l-transposition,0.3898847,l-transposition,0.3898847
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support-vector,0.27030843,single-ventricle,0.4165814,single-ventricle,0.4165814
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,vector-machine,0.30196983,single-ventricle,0.39982086,single-ventricle,0.39982086
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support-vector-machine,0.316194,single-ventricle,0.43537825,single-ventricle,0.43537825
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.28122714,of,0.57459104,flow,0.3923195
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,prevalence,0.25545907,disease,0.43233684,chd,0.4308555
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,rate,0.33912572,heart,0.49867767,heart,0.49867767
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-prevalence,0.29932746,congenital-heart-disease,0.4681489,congenital-heart-disease,0.4681489
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,prevalence-rate,0.22227637,venous-return,0.42413712,venous-return,0.42413712
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three,0.27802917,of,0.6048713,l-transposition,0.36917683
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,days,0.30872357,return,0.45523614,beats,0.4033618
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three-different,0.17349479,hypoplastic-left-heart,0.4551201,hypoplastic-left-heart,0.4551201
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous,0.37261367,with,0.5284412,mi,0.42555177
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,demonstrated,0.21350801,of,0.6025795,flow,0.3810749
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,fairly,0.32510388,weak,0.61160856,flow,0.40605107
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.28122714,of,0.57459104,flow,0.3923195
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,fairly-high,0.2617098,weak,0.41823173,venous-return,0.3856887
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-accuracy,0.23634554,single,0.39090675,anomalous,0.37268794
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accumulating,0.22638252,of,0.53668845,deposits,0.48348582
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third,0.30185395,single,0.54406995,ventricle,0.44503468
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.21804892,of,0.43378067,heartbeat,0.36693472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,achieved,0.22746107,of,0.5726348,l-transposition,0.3770222
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.20786116,with,0.58010674,flow,0.41007757
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system,0.21977381,of,0.44332683,anomaly,0.36816198
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,needs,0.4746752,return,0.509715,cardiology,0.4746752
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.22305535,of,0.4642575,flow,0.35575604
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based-detection,0.24387327,cad,0.39630347,cad,0.39630347
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.2226435,of,0.5364893,blood-flow,0.4181255
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,data,0.31118363,of,0.5086956,mi,0.36251363
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.37623936,heartbeat,0.39001763,heartbeat,0.39001763
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.24309576,of,0.61590904,anomalous,0.37924677
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,days,0.30872357,return,0.45523614,beats,0.4033618
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,knn,0.24443169,heartbeat,0.29841074,heartbeat,0.29841074
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous,0.37261367,with,0.5284412,mi,0.42555177
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,maintaining,0.28024212,of,0.53085643,flow,0.39609957
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detect,0.19525596,of,0.45315933,flow,0.34090838
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,states,0.32495102,of,0.46123946,anomalous,0.35751992
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,second,0.33869353,single,0.60913336,l-transposition,0.39804327
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.21804892,of,0.43378067,heartbeat,0.36693472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.28122714,of,0.57459104,flow,0.3923195
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-accuracy,0.23634554,single,0.39090675,anomalous,0.37268794
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,method,0.18057065,of,0.41052854,anomaly,0.32515174
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based-method,0.21300495,venous-return,0.33289063,venous-return,0.33289063
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous,0.37261367,with,0.5284412,mi,0.42555177
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiments,0.20130633,of,0.4657672,flow,0.3524469
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,young,0.29036346,congenital-heart-disease,0.50339997,congenital-heart-disease,0.50339997
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,adults,0.2573179,congenital-heart-disease,0.4712625,congenital-heart-disease,0.4712625
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,young-adults,0.17493157,congenital-heart-disease,0.44243318,congenital-heart-disease,0.44243318
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,still,0.38928428,of,0.5457471,arrythmia,0.4077646
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,questionable,0.40788776,right,0.5656891,arrythmia,0.49172127
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,selected,0.31146818,of,0.6198958,d-transposition,0.3718648
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.2494699,of,0.5443143,flow,0.34116954
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,selected-based,0.26125765,as,0.4164979,venous-return,0.386631
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,second,0.33869353,single,0.60913336,l-transposition,0.39804327
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiments,0.20130633,of,0.4657672,flow,0.3524469
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest,0.36044735,return,0.39812416,venous-return,0.38936514
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reliability,0.3161693,great,0.41052496,blood-flow,0.38828772
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest-reliability,0.315592,venous-return,0.40402687,venous-return,0.40402687
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,repeatedly,0.3204942,with,0.56851196,flow,0.39556423
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,applied,0.31181335,of,0.5047146,flow,0.3948964
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,random,0.2799046,single,0.49932328,venous-return,0.32442737
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,forest,0.32507646,lai,0.44108117,lai,0.44108117
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,random-forest,0.28051674,venous-return,0.39178413,venous-return,0.39178413
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practical,0.35148284,great,0.5327563,cardiology,0.35148284
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,use,0.3219829,with,0.55726266,flow,0.40877783
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practical-use,0.37854677,venous-return,0.47214952,venous-return,0.47214952
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,potential-risk,0.2640993,coronary-artery-disease,0.4146794,coronary-artery-disease,0.4146794
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,participant,0.34708518,return,0.42928267,venous-return,0.3987105
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experienced,0.3416694,with,0.51668775,mitral-regurgitation,0.39382553
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nine,0.2848479,with,0.5791308,d-transposition,0.38871926
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,participants,0.35857671,chd,0.46645594,chd,0.46645594
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nearest,0.3206203,single,0.46444803,anomaly,0.3788818
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,neighbors,0.25709212,weak,0.41762197,beats,0.34371656
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nearest-neighbors,0.24213433,isomerism,0.41405025,isomerism,0.41405025
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.28122714,of,0.57459104,flow,0.3923195
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-test,0.29510438,congenital-heart-disease,0.37663215,congenital-heart-disease,0.37663215
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,vectors,0.20899034,l-transposition,0.42368472,l-transposition,0.42368472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,feature-vectors,0.18266009,l-transposition,0.39809757,l-transposition,0.39809757
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,extensively,0.31807813,as,0.52447647,deposits,0.38734564
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,employed,0.22199236,of,0.536051,flow,0.34604663
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,core,0.30297595,of,0.49466735,deposits,0.3696978
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classification,0.28988627,of,0.3714074,anomaly,0.36596543
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,performance,0.28517076,with,0.40983945,venous-return,0.39986303
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,calibration,0.31922334,venous-return,0.39590418,venous-return,0.39590418
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,sessions,0.43432412,cardiology,0.43432412,cardiology,0.43432412
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,brain,0.2747014,cardiac,0.5094165,cardiac,0.5094165
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,functions,0.22935191,of,0.5148778,l-transposition,0.37660414
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,brain-functions,0.29249206,great,0.41898787,single-ventricle,0.41750014
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.20786116,with,0.58010674,flow,0.41007757
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classified,0.22413155,as,0.5156816,rai,0.34119064
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.37623936,heartbeat,0.39001763,heartbeat,0.39001763
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction,0.3970462,congestive-heart-failure,0.40696776,congestive-heart-failure,0.40696776
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction-treatment,0.31396127,congestive-heart-failure,0.49702817,congestive-heart-failure,0.49702817
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classifiers,0.28955632,congenital-heart-disease,0.36196706,congenital-heart-disease,0.36196706
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.26820397,heartbeat,0.41964832,heartbeat,0.41964832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,0.37199128,cad,0.41960585,cad,0.41960585
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,learning,0.33958644,of,0.40490282,single-ventricle,0.39502156
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.21804892,of,0.43378067,heartbeat,0.36693472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.3132518,of,0.48745692,contractions,0.4181603
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,datasets,0.30227715,heartbeat,0.35513443,heartbeat,0.35513443
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,0.30143785,of,0.38807675,heartbeat,0.37768018
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test,0.3036692,abnormal,0.42043465,heart-failure,0.3426016
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,data,0.31118363,of,0.5086956,mi,0.36251363
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classified,0.22413155,as,0.5156816,rai,0.34119064
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction,0.3970462,congestive-heart-failure,0.40696776,congestive-heart-failure,0.40696776
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,user,0.31136972,venous-return,0.3720078,venous-return,0.3720078
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,trained,0.42477915,with,0.43780488,cardiology,0.42477915
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,train,0.39593512,contractions,0.4625386,contractions,0.4625386
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,tool,0.29163375,as,0.4623517,artery-disease,0.31557494
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,thus,0.30240285,of,0.6779618,flow,0.4474225
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,suggesting,0.18459891,of,0.6157647,l-transposition,0.40478194
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reuse,0.29383639,venous-return,0.4309663,venous-return,0.4309663
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,repeated,0.31911406,single,0.57160586,contractions,0.41091657
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,relapse,0.15392828,disease,0.5014287,heart-failure,0.40474594
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reducing,0.20510697,of,0.5635449,heart-attack,0.39589107
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,proposed,0.25004908,as,0.53179914,anomalous,0.36534148
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practicality,0.3087467,great,0.49483317,venous-return,0.36696088
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,organizations,0.49014312,cardiology,0.49014312,cardiology,0.49014312
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,non,0.3477749,with,0.61364555,mi,0.46788454
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,monitor,0.39752877,arrythmia,0.53223604,arrythmia,0.53223604
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,k,0.28914,anomalous,0.35770777,anomalous,0.35770777
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,investigated,0.19995229,of,0.6179704,anomalous,0.35378093
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,initially,0.42635775,with,0.6516129,cardiac,0.4502698
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,importance,0.3199574,of,0.5794183,anomaly,0.34929916
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,implemented,0.39813042,as,0.43353057,cardiology,0.39813042
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,however,0.30646515,of,0.624624,mi,0.41109186
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,enhanced,0.24384218,of,0.59523904,anomalous,0.36034083
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,electrooculogram,0.3014716,heartbeat,0.4833398,heartbeat,0.4833398
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,efficacy,0.20913124,of,0.47294754,lai,0.34146488
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,effectiveness,0.2947462,of,0.5160025,venous-return,0.352529
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detected,0.22363131,isolated,0.58991337,deposits,0.39107472
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,designed,0.2395013,of,0.4984635,venous-return,0.32304075
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,demonstrating,0.24106917,of,0.67624867,l-transposition,0.42949137
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,day,0.42316434,with,0.4708514,cardiology,0.42316434
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,consequently,0.26509717,of,0.67593205,anomalous,0.41390514
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,computing,0.3731914,great,0.422275,heartbeat,0.39295244
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,comparable,0.21267173,with,0.5389043,arteries,0.33967346
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,characteristic,0.14630476,of,0.52064013,anomalous,0.42846608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,become,0.33934337,as,0.5136174,cardiology,0.33934337
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,alteration,0.22564441,abnormal,0.63321257,anomaly,0.4587403
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,adolescents,0.31509328,congenital-heart-disease,0.450537,congenital-heart-disease,0.450537
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addition,0.30796275,of,0.6910241,l-transposition,0.4120413
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,transient,0.25355834,of,0.5285465,bradycardia,0.47761184
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,receptor,0.20102352,of,0.4106264,bradycardia,0.3056367
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cation,0.191375,isomerism,0.39362815,isomerism,0.39362815
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,channel,0.213781,outlet,0.38533387,atrioventricular,0.37955636
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,subfamily,0.2679816,d-transposition,0.3113842,d-transposition,0.3113842
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,v,0.240002,sv,0.44191512,sv,0.44191512
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,transient-receptor,0.27912822,contractions,0.43802506,contractions,0.43802506
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,receptor-potential,0.18454984,of,0.36647648,atrioventricular-septal-defect,0.32025993
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential-cation,0.1968586,anomalous,0.4427764,anomalous,0.4427764
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cation-channel,0.18336974,anomalous,0.40235865,anomalous,0.40235865
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,transient-receptor-potential,0.23324943,weak,0.42064112,anomalous,0.40519345
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sensitive,0.20103613,of,0.46678513,flow,0.35194874
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,+-,0.23732778,total,0.37976825,mitral,0.34612054
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,permeable,0.12360588,intact,0.4565693,deposits,0.38693988
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,channel,0.213781,outlet,0.38533387,atrioventricular,0.37955636
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,causes,0.22412287,of,0.55089116,congenital,0.49946666
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sustained,0.28960043,of,0.5443902,contractions,0.4689327
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intracellular,0.17112827,of,0.45033878,myocardial,0.36194724
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,ameliorates,0.11741898,isolated,0.35701823,myocardial,0.32133764
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscle,0.23621407,contractions,0.6025082,contractions,0.6025082
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dysgenesis,0.1992943,hypoplastic,0.65384877,hypoplastic,0.65384877
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,target,0.23866604,of,0.4775706,blood,0.34112448
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential-therapeutic,0.3533869,great,0.45943362,heart-failure,0.4459909
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic-target,0.3254797,great,0.42578024,blood-clot,0.37926477
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,improve,0.31483245,great,0.49610043,flow,0.35876963
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiac,0.66620034,cardiac,1.0,cardiac,1.0
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,function,0.2605439,of,0.55099833,flow,0.43324804
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiac-function,0.53890264,cardiac,0.7516308,cardiac,0.7516308
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,degenerative,0.2734869,disease,0.53843975,stenosis,0.5298873
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.30333537,contractions,0.5338886,contractions,0.5338886
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,available,0.34700432,with,0.5165225,cardiology,0.34700432
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,applications,0.37267506,great,0.52479297,cardiology,0.37267506
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.30333537,contractions,0.5338886,contractions,0.5338886
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dystrophy,0.28827113,congenital,0.60385144,congenital,0.60385144
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.30333537,contractions,0.5338886,contractions,0.5338886
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,although,0.27773374,of,0.6190036,cardiac,0.39186808
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,options,0.36788544,with,0.45608714,congenital,0.397659
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,treatment-options,0.31623125,congestive-heart-failure,0.48439544,congestive-heart-failure,0.48439544
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,prognosis,0.34852993,disease,0.49260834,infarction,0.44962037
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,survival-prognosis,0.232103,heart-failure,0.48130745,heart-failure,0.48130745
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,reports,0.36682504,of,0.57092524,anomaly,0.3712601
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,showed,0.21619865,with,0.57298803,flow,0.33828264
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,reports,0.36682504,of,0.57092524,anomaly,0.3712601
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent,0.42971963,of,0.545993,cardiology,0.42971963
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,pathophysiological,0.29236275,disease,0.4513361,heart-syndrome,0.42778695
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,feature,0.23029326,of,0.53455734,anomaly,0.47132576
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,member,0.32565856,as,0.37597924,cardiology,0.32565856
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intractable,0.31011915,with,0.50674134,congenital,0.4950303
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intractable-diseases,0.31695744,disease,0.5769589,congenital-heart-disease,0.57519484
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,heart,0.57664216,heart,1.0,heart,1.0
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,failure,0.42322472,failure,0.99999994,heart-failure,0.7363615
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,heart-failure,0.5023692,heart-failure,1.0,heart-failure,1.0
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,current,0.39557698,of,0.4991414,flow,0.39574015
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,progress,0.48163038,great,0.5096084,cardiology,0.48163038
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,current-progress,0.3724552,single-ventricle,0.46273422,single-ventricle,0.46273422
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dilated,0.38440502,ventricle,0.58307534,ventricle,0.58307534
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.5463724,congestive,0.6767609,congestive,0.6767609
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dilated-cardiomyopathy,0.5185985,myocardial-infarction,0.69644046,myocardial-infarction,0.69644046
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.5463724,congestive,0.6767609,congestive,0.6767609
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy-associated,0.442766,heart-syndrome,0.61778873,heart-syndrome,0.61778873
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.5463724,congestive,0.6767609,congestive,0.6767609
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,stretch,0.16460006,contractions,0.56639194,contractions,0.56639194
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sarcolemma,0.28549698,myocardial,0.5143978,myocardial,0.5143978
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,review,0.438658,of,0.54425275,cardiology,0.438658
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recently,0.3336877,as,0.5378315,cad,0.34116387
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,myocytes,0.3514763,ventricular,0.61161995,ventricular,0.61161995
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,limited,0.29959464,of,0.6210327,deposits,0.40452772
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,introduce,0.30101174,as,0.42655605,l-transposition,0.3539302
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,increase,0.32113555,of,0.60061187,flow,0.4086165
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inactivation,0.12406366,of,0.46923038,l-transposition,0.4392429
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,furthermore,0.18322246,of,0.5529862,plaque-deposits,0.34174067
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,discuss,0.45486575,great,0.48184678,cardiology,0.45486575
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,development,0.2877805,of,0.53581744,congenital,0.35419804
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,concentrated,0.30728364,of,0.5680985,deposits,0.504317
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,clarified,0.34505677,of,0.5494089,anomalous,0.41025376
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyocytes,0.42256498,cardiac,0.65478754,cardiac,0.65478754
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,activated,0.18459547,of,0.4727149,contractions,0.34351796
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,without,0.27970245,with,0.7351919,cardiac,0.42947003
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.20662498,hlhs,0.39118612,hlhs,0.39118612
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,exhibited,0.12429051,with,0.5453967,plaque-deposits,0.32444406
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly,0.23700657,with,0.568532,mi,0.39826992
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,higher,0.2654187,with,0.56796193,mi,0.398535
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.21388823,single,0.45050174,beats,0.35161406
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients-without,0.38820982,heart-failure,0.536106,heart-failure,0.536106
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly-higher,0.2440085,with,0.5364338,mi,0.3939989
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,j,0.24581458,lai,0.35768944,lai,0.35768944
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,respir,0.38418707,arrythmia,0.42684317,arrythmia,0.42684317
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,crit,0.3619378,clot,0.4598145,clot,0.4598145
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,care,0.5496288,cardiology,0.5496288,cardiology,0.5496288
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,med,0.4682718,cardiology,0.4682718,cardiology,0.4682718
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,care-med,0.5876504,cardiology,0.5876504,cardiology,0.5876504
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive,0.35222226,congestive,0.6328302,congestive,0.6328302
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic-obstructive,0.35541248,congestive,0.63991463,congestive,0.63991463
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive-pulmonary,0.38661033,pulmonary,0.7739995,pulmonary,0.7739995
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary-disease,0.37958944,pulmonary,0.7568126,pulmonary,0.7568126
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,trend,0.33671963,great,0.4239449,flow,0.38420233
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,toward,0.25305566,of,0.52158976,isomerism,0.35675278
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,populations,0.25156635,of,0.4330697,congenital-heart-disease,0.343602
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regulating,0.24088989,of,0.5106726,anomalous,0.33040386
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pathologic,0.24539539,abnormal,0.57749593,deposits,0.45469806
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune-cells,0.1737721,plaque-deposits,0.40589482,plaque-deposits,0.40589482
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune-cells-regulating,0.196049,of,0.40642715,congenital-heart-disease,0.36699283
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,grade,0.29756713,stenosis,0.4388027,stenosis,0.4388027
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,within,0.30995527,of,0.57602364,deposits,0.42065546
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,h,0.20228642,of,0.4345476,mi,0.34808266
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial,0.24102922,pulmonary,0.52073187,pulmonary,0.52073187
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant,0.48739254,failure,0.577052,congestive-heart-failure,0.520841
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,recipients,0.30546528,congenital-heart-disease,0.5207373,congenital-heart-disease,0.5207373
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-disease,0.25834516,heart-disease,0.6463438,heart-disease,0.6463438
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease-transplant,0.28166583,disease,0.6821853,heart-disease,0.5887083
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant-recipients,0.2996087,congenital-heart-disease,0.54515266,congenital-heart-disease,0.54515266
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive,0.35222226,congestive,0.6328302,congestive,0.6328302
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary,0.44857517,pulmonary,1.0,pulmonary,1.0
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic-obstructive,0.35541248,congestive,0.63991463,congestive,0.63991463
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive-pulmonary,0.38661033,pulmonary,0.7739995,pulmonary,0.7739995
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary-disease,0.37958944,pulmonary,0.7568126,pulmonary,0.7568126
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,seven,0.24791667,of,0.554788,d-transposition,0.37799773
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,developed,0.25309682,of,0.5174131,congestive-heart-failure,0.37625062
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.20662498,hlhs,0.39118612,hlhs,0.39118612
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,seven-patients,0.33796522,heart-failure,0.4684702,heart-failure,0.4684702
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,derived,0.21087903,isolated,0.5940775,l-transposition,0.3332914
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,populations,0.25156635,of,0.4330697,congenital-heart-disease,0.343602
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly,0.23700657,with,0.568532,mi,0.39826992
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,decreased,0.2912292,of,0.59706545,flow,0.4062525
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.21388823,single,0.45050174,beats,0.35161406
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly-decreased,0.23290649,with,0.5789323,mi,0.42590043
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subset,0.24246489,of,0.51671314,mi,0.37440532
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,composition,0.21594884,of,0.51248646,deposits,0.46536496
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,within,0.30995527,of,0.57602364,deposits,0.42065546
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,elevated,0.30277047,abnormal,0.59151924,blood,0.4319806
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.21388823,single,0.45050174,beats,0.35161406
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial,0.24102922,pulmonary,0.52073187,pulmonary,0.52073187
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-disease,0.25834516,heart-disease,0.6463438,heart-disease,0.6463438
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant,0.48739254,failure,0.577052,congestive-heart-failure,0.520841
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,recipients,0.30546528,congenital-heart-disease,0.5207373,congenital-heart-disease,0.5207373
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-transplant,0.3370522,congestive-heart-failure,0.56867796,congestive-heart-failure,0.56867796
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant-recipients,0.2996087,congenital-heart-disease,0.54515266,congenital-heart-disease,0.54515266
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regulating,0.24088989,of,0.5106726,anomalous,0.33040386
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,injury,0.24559022,infarction,0.52933943,infarction,0.52933943
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-injury,0.19279312,pulmonary,0.55356824,pulmonary,0.55356824
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplantation,0.36332333,congenital-heart-disease,0.5087515,congenital-heart-disease,0.5087515
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-transplantation,0.33046046,congenital-heart-disease,0.58776927,congenital-heart-disease,0.58776927
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.19270411,l-transposition,0.40011403,l-transposition,0.40011403
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune,0.16377506,blood-clot,0.3914839,blood-clot,0.3914839
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor-immune,0.1433928,congenital-heart-disease,0.39978564,congenital-heart-disease,0.39978564
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune-cells,0.1737721,plaque-deposits,0.40589482,plaque-deposits,0.40589482
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural,0.16362667,of,0.532617,anomalous,0.3907894
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,killer,0.17595254,attack,0.3571167,heart-attack,0.35526538
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural-killer,0.14093256,l-transposition,0.3725539,l-transposition,0.3725539
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,killer-cells,0.12472527,l-transposition,0.36804983,l-transposition,0.36804983
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural-killer-cells,0.11676031,l-transposition,0.3832669,l-transposition,0.3832669
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,innate,0.22606428,great,0.4120917,l-transposition,0.3680464
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lymphoid,0.1656844,hypoplastic,0.4198414,hypoplastic,0.4198414
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lymphoid-cells,0.11712419,l-transposition,0.37654144,l-transposition,0.37654144
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,determine,0.2686271,of,0.55401844,flow,0.329725
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.20662498,hlhs,0.39118612,hlhs,0.39118612
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,jan,0.38265222,cardiology,0.38265222,cardiology,0.38265222
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,primary,0.31168944,of,0.5182241,congenital,0.3974473
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,graft,0.27155316,artery,0.56162083,artery,0.56162083
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,dysfunction,0.3454026,insufficiency,0.6505209,congestive-heart-failure,0.5247797
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,center,0.4322113,single,0.4625442,cardiology,0.4322113
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cohort,0.34353635,chd,0.50572824,chd,0.50572824
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cohort-study,0.36102197,congenital-heart-disease,0.49958968,congenital-heart-disease,0.49958968
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,beneficial,0.25004005,of,0.47944272,heart-attack,0.36086392
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,repair,0.27227306,l-transposition,0.57925195,l-transposition,0.57925195
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue-repair,0.20427234,l-transposition,0.46516836,l-transposition,0.46516836
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,distinct,0.19512047,of,0.5551601,anomalous,0.45986664
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.19270411,l-transposition,0.40011403,l-transposition,0.40011403
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue,0.23668498,of,0.5202017,venous,0.46895027
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,taken,0.3873873,of,0.53411245,blood,0.41476953
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor-tissue,0.22244585,congenital-heart-disease,0.45927843,congenital-heart-disease,0.45927843
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue-taken,0.31811103,blood-clot,0.5414407,blood-clot,0.5414407
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.19270411,l-transposition,0.40011403,l-transposition,0.40011403
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subset,0.24246489,of,0.51671314,mi,0.37440532
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.2621613,failure,0.5302759,congenital-heart,0.4696058
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.36306685,myocardial,0.7064705,myocardial,0.7064705
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,resulted,0.17505345,of,0.5964589,l-transposition,0.32549727
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.23681092,of,0.4432634,flow,0.40812808
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.29422066,pulmonary,0.7151791,pulmonary,0.7151791
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplantation,0.36332333,congenital-heart-disease,0.5087515,congenital-heart-disease,0.5087515
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-transplantation,0.33046046,congenital-heart-disease,0.58776927,congenital-heart-disease,0.58776927
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.20662498,hlhs,0.39118612,hlhs,0.39118612
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,development,0.2877805,of,0.53581744,congenital,0.35419804
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,whether,0.24223731,of,0.49140224,myocardial,0.30518332
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,changes,0.30126634,of,0.5562258,flow,0.44305104
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,surgical,0.4755141,cardiology,0.4755141,cardiology,0.4755141
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,biopsies,0.26866582,deposits,0.4489481,deposits,0.4489481
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,selective,0.18057933,of,0.469292,l-transposition,0.40477294
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,selective-reduction,0.23659454,l-transposition,0.45633495,l-transposition,0.45633495
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,poorly,0.23539765,as,0.51719266,deposits,0.39493018
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,understood,0.27476305,as,0.45029238,anomalous,0.37772185
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,poorly-understood,0.25650564,as,0.46642807,congenital-heart-disease,0.4077103
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,results,0.29712585,of,0.53157276,blood,0.36869162
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,main-results,0.40020984,atresia-with,0.46212858,atresia-with,0.46212858
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,leading,0.25149748,of,0.59935343,congenital,0.40424997
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cause,0.24258707,congenital,0.5065234,congenital,0.5065234
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,leading-cause,0.30231607,chd,0.4955071,chd,0.4955071
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immunologic,0.17626429,congenital-heart-disease,0.4258666,congenital-heart-disease,0.4258666
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,mechanisms,0.19948575,of,0.51329505,l-transposition,0.37245494
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilcs,0.19001342,atresia,0.3336461,atresia,0.3336461
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,may,0.26963884,of,0.58654004,anomalous,0.366544
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,heterogeneous,0.2215862,irregular,0.5216255,deposits,0.44650552
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,family,0.39850003,cardiology,0.39850003,cardiology,0.39850003
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,flow,0.27540267,flow,1.0,flow,1.0
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cytometry,0.26987028,flow,0.60937023,flow,0.60937023
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,flow-cytometry,0.2276194,flow,0.5899704,flow,0.5899704
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,early,0.34221643,of,0.5714519,mi,0.3991026
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,morbidity,0.31568646,chd,0.50165594,chd,0.50165594
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,characterized,0.12166704,isolated,0.60163844,anomalous,0.39773136
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,phenotypically,0.18139613,isolated,0.5285921,hypoplastic,0.4427356
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cell,0.21863139,of,0.48460138,flow,0.38218224
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,resolution,0.22951236,of,0.46130672,tof,0.40459827
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cell-resolution,0.22069429,single,0.4159906,flow,0.40514866
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.2621613,failure,0.5302759,congenital-heart,0.4696058
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.36306685,myocardial,0.7064705,myocardial,0.7064705
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.20662498,hlhs,0.39118612,hlhs,0.39118612
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.16814716,rai,0.37844273,rai,0.37844273
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.19270411,l-transposition,0.40011403,l-transposition,0.40011403
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,composition,0.21594884,of,0.51248646,deposits,0.46536496
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.36306685,myocardial,0.7064705,myocardial,0.7064705
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.2621613,failure,0.5302759,congenital-heart,0.4696058
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,changes,0.30126634,of,0.5562258,flow,0.44305104
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,suggesting,0.18459891,of,0.6157647,l-transposition,0.40478194
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,single,0.2571312,single,1.0,anomalous,0.40611145
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regardless,0.22391185,with,0.5621555,deposits,0.35170877
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,rationale,0.361174,of,0.5596026,congestive,0.38931155
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,performed,0.3394584,of,0.5502712,anomaly,0.3917434
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,percentage,0.22564179,total,0.56536615,flow,0.3676573
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,objectives,0.3258235,of,0.53322846,congenital,0.39620093
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,never,0.3470973,as,0.5116378,mi,0.39609608
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,mortality,0.3475203,chd,0.5562636,chd,0.5562636
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,methods,0.24111512,of,0.4498348,congenital-heart-disease,0.3509494
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,measurements,0.27821797,blood-flow,0.45775104,blood-flow,0.45775104
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immediately,0.31744793,return,0.5527987,clot,0.40365046
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,however,0.30646515,of,0.624624,mi,0.41109186
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,examined,0.2811494,of,0.66699874,flow,0.35738647
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,diagnosis,0.37467325,disease,0.5136548,congenital,0.477598
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,conversely,0.20391819,of,0.5762197,septal-defect,0.36792347
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,conclusions,0.259925,with,0.50001186,artery,0.34474826
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,comment,0.39368364,of,0.42755854,anomaly,0.4086154
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,assessed,0.32085416,of,0.605934,flow,0.3956796
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,altered,0.23629062,abnormal,0.6527077,anomalous,0.41416392
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,alterations,0.20877011,abnormal,0.63202363,anomaly,0.44557405
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,accompanied,0.24777448,of,0.57653445,anomalous,0.4097459
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,would,0.35497403,of,0.55908126,flow,0.3796509
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,thus,0.30240285,of,0.6779618,flow,0.4474225
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,appear,0.27871054,with,0.545245,deposits,0.40108463
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancer-treatment,0.28367215,heart-failure,0.40872627,heart-failure,0.40872627
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin,0.18391663,cholesterol,0.38347787,cholesterol,0.38347787
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,decreases,0.23090257,of,0.5934629,flow,0.39965624
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor,0.21814886,clot,0.4081839,clot,0.4081839
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,growth,0.20394227,of,0.446648,flow,0.3683396
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor-growth,0.05805087,blood-clot,0.3163988,blood-clot,0.3163988
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,substantial,0.27155346,great,0.64504546,anomalous,0.3652059
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,pathological,0.23465282,abnormal,0.59031224,deposits,0.44547588
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,processes,0.23021427,of,0.4836276,deposits,0.42042395
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,accompanying,0.27043706,of,0.62855226,anomalous,0.5131681
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,many,0.34462097,great,0.5654564,deposits,0.36972266
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,key,0.25911495,of,0.48386168,anomalous,0.3123638
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,circadian,0.30126956,heartbeat,0.48178667,heartbeat,0.48178667
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,genes,0.22443718,l-transposition,0.43358943,l-transposition,0.43358943
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,major,0.26991645,of,0.5153694,cardiac,0.3628927
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,signaling-pathways,0.1904434,of,0.37176776,atrioventricular,0.33244452
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,circadian,0.30126956,heartbeat,0.48178667,heartbeat,0.48178667
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,clock,0.34599662,heartbeat,0.4920978,heartbeat,0.4920978
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,disruption,0.17082699,abnormal,0.5182634,l-transposition,0.4034046
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,circadian-clock,0.25888187,heartbeat,0.46868372,heartbeat,0.46868372
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,clock-disruption,0.22949013,l-transposition,0.42314819,l-transposition,0.42314819
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,disruption-related,0.19639343,of,0.48686838,anomalous,0.36696965
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,circadian,0.30126956,heartbeat,0.48178667,heartbeat,0.48178667
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,clock,0.34599662,heartbeat,0.4920978,heartbeat,0.4920978
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,disruption,0.17082699,abnormal,0.5182634,l-transposition,0.4034046
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,circadian-clock,0.25888187,heartbeat,0.46868372,heartbeat,0.46868372
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,clock-disruption,0.22949013,l-transposition,0.42314819,l-transposition,0.42314819
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor,0.21814886,clot,0.4081839,clot,0.4081839
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,growth,0.20394227,of,0.446648,flow,0.3683396
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,control,0.26906762,with,0.5145365,mi,0.4093958
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor-growth,0.05805087,blood-clot,0.3163988,blood-clot,0.3163988
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,growth-control,0.19677526,of,0.41569775,l-transposition,0.3414454
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor-growth-control,0.113325536,of,0.36550438,l-transposition,0.32944852
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,control,0.26906762,with,0.5145365,mi,0.4093958
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,circadian,0.30126956,heartbeat,0.48178667,heartbeat,0.48178667
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,clocks,0.32175076,heartbeat,0.51339287,heartbeat,0.51339287
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,interesting,0.31298086,great,0.62348694,anomalous,0.47095627
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,strategy,0.23048541,of,0.44841248,heart-attack,0.36277908
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,stimulating,0.21986872,of,0.4940443,contractions,0.40368563
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,activity,0.22675279,of,0.5327676,contractions,0.3920536
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,activity-levels,0.24028474,return,0.46130675,venous-return,0.39305472
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,repress,0.20166329,l-transposition,0.39157647,l-transposition,0.39157647
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,chronic-inflammation,0.20188652,disease,0.47903967,artery-disease,0.45320863
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin,0.18391663,cholesterol,0.38347787,cholesterol,0.38347787
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,administration,0.30930176,of,0.50649554,contractions,0.38494927
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,participates,0.2452956,of,0.44325593,l-transposition,0.2932911
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin-administration,0.24457675,of,0.4422395,cholesterol,0.34915155
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin,0.18391663,cholesterol,0.38347787,cholesterol,0.38347787
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor,0.21814886,clot,0.4081839,clot,0.4081839
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,tumor-therapy,0.31013915,pulmonary-venous,0.42890579,pulmonary-venous,0.42890579
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,chronic,0.27239984,insufficiency,0.5876919,congestive,0.5749831
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,inflammation,0.21408866,disease,0.48826468,thrombosis,0.4633947
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,chronic-inflammation,0.20188652,disease,0.47903967,artery-disease,0.45320863
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,use,0.3219829,with,0.55726266,flow,0.40877783
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin,0.18391663,cholesterol,0.38347787,cholesterol,0.38347787
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,agonists,0.18739097,contractions,0.48351848,contractions,0.48351848
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,act,0.27575755,as,0.61612827,heart-attack,0.3494203
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin,0.18391663,cholesterol,0.38347787,cholesterol,0.38347787
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,act,0.27575755,as,0.61612827,heart-attack,0.3494203
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancer-therapy,0.32960105,heart-failure,0.41149467,heart-failure,0.41149467
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,process,0.25394285,of,0.51408124,anomalous,0.37625128
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,several,0.34988725,of,0.5990606,cardiac,0.37646228
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,hypotheses,0.28178155,congenital-heart-disease,0.42039585,congenital-heart-disease,0.42039585
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,review,0.438658,of,0.54425275,cardiology,0.438658
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,focuses,0.3185957,of,0.5351627,cardiology,0.3185957
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,positive-effect,0.2574593,weak,0.4712395,lai,0.37032354
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,oxidative,0.17657238,of,0.4233053,myocardial,0.36701933
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,stress,0.28176898,of,0.4473127,myocardial,0.4140401
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,oxidative-stress,0.19486363,myocardial,0.388269,myocardial,0.388269
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,opposed,0.2545999,as,0.64872366,flow,0.3768137
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,manner,0.18540666,with,0.42496896,contractions,0.388913
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,numerous,0.31449497,great,0.52944255,deposits,0.44640934
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,studies,0.29045615,of,0.5029958,congenital-heart-disease,0.31032717
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,catenin,0.29721078,abnormal,0.38211852,deposits,0.36489576
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,pathway,0.2320853,defect,0.42863637,l-transposition,0.37392026
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,regulating,0.24088989,of,0.5106726,anomalous,0.33040386
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,wnt,0.2880411,cholesterol,0.34338588,cholesterol,0.34338588
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,promoting,0.24732341,of,0.5530137,mi,0.31541625
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancers,0.2505658,disease,0.4458139,chd,0.42977926
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,thus,0.30240285,of,0.6779618,flow,0.4474225
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,involved,0.2655597,of,0.5396308,l-transposition,0.36373854
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,curcumin,0.18391663,cholesterol,0.38347787,cholesterol,0.38347787
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,administration,0.30930176,of,0.50649554,contractions,0.38494927
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,wnt,0.2880411,cholesterol,0.34338588,cholesterol,0.34338588
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,cancers,0.2505658,disease,0.4458139,chd,0.42977926
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,upregulation,0.18810809,of,0.41142595,l-transposition,0.35591248
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,upregulated,0.16811627,isolated,0.3950042,arteries,0.32034808
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,role,0.263546,of,0.49928063,anomalous,0.31226397
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,regulation,0.29056856,of,0.5171884,l-transposition,0.37633666
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,prevention,0.37483034,thrombosis,0.45537552,thrombosis,0.45537552
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,presented,0.34475142,with,0.61236936,anomaly,0.42759705
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,invasion,0.17245734,thrombosis,0.4312383,thrombosis,0.4312383
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,interest,0.3943884,great,0.62165374,cardiology,0.3943884
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,highlighted,0.3702412,of,0.60523915,cardiology,0.3702412
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,downregulation,0.20097296,of,0.4149595,l-transposition,0.3758948
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,common,0.21206799,of,0.500178,anomaly,0.44165826
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,co,0.36334935,with,0.46287042,cardiac,0.45921996
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,appears,0.27533382,with,0.5807384,cardiac,0.38053024
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,acts,0.16814218,as,0.565104,l-transposition,0.32615024
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,action,0.29916856,of,0.5591097,contractions,0.50062907
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/-catenin pathway.,acting,0.24240543,as,0.61333185,contractions,0.41667253
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,modify,0.16843617,of,0.39966768,heart-attack,0.28441656
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ectopic,0.2988271,abnormal,0.5350792,beats,0.4631192
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overexpression,0.20357901,l-transposition,0.40470022,l-transposition,0.40470022
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,driven,0.27247697,of,0.47781104,flow,0.40639967
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overexpression-driven,0.19113986,of,0.41415605,septal-defect,0.40119553
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,k,0.28914,anomalous,0.35770777,anomalous,0.35770777
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specific,0.26268506,of,0.6059094,flow,0.40644997
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,demethylase,0.2394788,l-transposition,0.44967687,l-transposition,0.44967687
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cofactor,0.20363837,defect,0.38733423,l-transposition,0.36461797
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,flavin,0.20259838,isomerism,0.37336656,isomerism,0.37336656
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,adenosine,0.22536264,l-transposition,0.43268204,l-transposition,0.43268204
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dinucleotide,0.16274917,l-transposition,0.39144802,l-transposition,0.39144802
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,flavin-adenosine,0.18426389,l-transposition,0.43267524,l-transposition,0.43267524
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,adenosine-dinucleotide,0.20369007,l-transposition,0.44819894,l-transposition,0.44819894
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,flavin-adenosine-dinucleotide,0.1857152,l-transposition,0.44262308,l-transposition,0.44262308
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specific,0.26268506,of,0.6059094,flow,0.40644997
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone,0.2509793,l-transposition,0.40541044,l-transposition,0.40541044
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,demethylase,0.2394788,l-transposition,0.44967687,l-transposition,0.44967687
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxxa,0.20837091,isomerism,0.4444403,isomerism,0.4444403
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone-demethylase,0.24695477,l-transposition,0.48352173,l-transposition,0.48352173
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,extra,0.32754168,of,0.5219209,anomaly,0.41795576
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,virgin,0.18651447,of,0.35021794,deposits,0.3289536
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,olive,0.22047192,cholesterol,0.351604,cholesterol,0.351604
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oil,0.19941315,cholesterol,0.44938076,cholesterol,0.44938076
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,extra-virgin,0.20983323,cholesterol,0.36657393,cholesterol,0.36657393
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,virgin-olive,0.20442498,double-outlet,0.3764724,double-outlet,0.3764724
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,olive-oil,0.1296856,cholesterol,0.40289944,cholesterol,0.40289944
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,virgin-olive-oil,0.15438138,cholesterol,0.36275396,cholesterol,0.36275396
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dynamic,0.26735556,of,0.4784561,blood-flow,0.47322053
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,simulation,0.36245072,of,0.40851003,venous-return,0.38664126
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,approaches,0.26600224,of,0.44207,single-ventricle,0.37762895
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,revealed,0.223917,of,0.55371094,anomalous,0.36589023
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dynamic-simulation,0.24523163,venous-return,0.45928913,venous-return,0.45928913
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,biophenol,0.22355618,cholesterol,0.34261796,cholesterol,0.34261796
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,secoiridoid,0.20438626,isomerism,0.3892334,isomerism,0.3892334
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally,0.14212249,isolated,0.52606833,isomerism,0.3697061
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,present,0.34922045,of,0.63723874,anomaly,0.40175247
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,biophenol-secoiridoid,0.1964138,isolated,0.4331153,isomerism,0.39028966
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally-present,0.16493464,of,0.41183567,heartbeat,0.32786262
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally,0.14212249,isolated,0.52606833,isomerism,0.3697061
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,occurring,0.21123242,of,0.6354642,anomaly,0.42218408
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,phenolic,0.21270555,isomerism,0.3866405,isomerism,0.3866405
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitor,0.23137593,of,0.37385303,congestive,0.302135
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally-occurring,0.122342624,isolated,0.52767384,isomerism,0.37614793
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,corest,0.36326683,with,0.44202673,cad,0.37490177
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,likely,0.34048563,of,0.55071557,congestive,0.42744756
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,disturbing,0.25493562,abnormal,0.5864875,anomalous,0.46500504
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,transcription,0.23967603,l-transposition,0.42481855,l-transposition,0.42481855
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,factor,0.1861548,of,0.44319516,thrombosis,0.35690165
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,transcription-factor,0.20170656,l-transposition,0.41892684,l-transposition,0.41892684
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,design,0.22387533,of,0.40440997,single-ventricle,0.33910608
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,secoiridoid,0.20438626,isomerism,0.3892334,isomerism,0.3892334
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,vitro,0.17831118,of,0.48112682,clot,0.34754837
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,assays,0.23059516,of,0.36477953,blood-clot,0.30757627
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,confirmed,0.27861494,of,0.58156097,anomalous,0.39478707
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,vitro-assays,0.19533163,isolated,0.31471503,plaque-deposits,0.30778757
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,targeted,0.29431283,of,0.52138686,cardiac,0.3262151
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,distal,0.17987399,right,0.5650882,artery,0.51595354
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,enhancer,0.17695922,of,0.37088183,l-transposition,0.3601861
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,sex,0.29196534,congenital-heart-disease,0.40851635,congenital-heart-disease,0.40851635
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,determining,0.24776678,of,0.6342732,anomalous,0.40420768
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,region,0.21842551,of,0.45814058,anomaly,0.39831
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,sex-determining,0.20258917,l-transposition,0.41573936,l-transposition,0.41573936
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,determining-region,0.22295015,of,0.5099188,l-transposition,0.4140011
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,central,0.34112307,of,0.50945216,venous,0.47422168
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,epigenetic,0.2629227,l-transposition,0.44087967,l-transposition,0.44087967
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,regulator,0.20251182,as,0.42325643,l-transposition,0.2960012
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,epigenetic-regulator,0.26166838,heart-syndrome,0.38884884,heart-syndrome,0.38884884
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,pluripotent,0.29733214,heart-syndrome,0.3878666,heart-syndrome,0.3878666
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,stem,0.2528829,hypoplastic,0.38906342,hypoplastic,0.38906342
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced-pluripotent,0.21692634,septal-defect,0.3781092,septal-defect,0.3781092
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,pluripotent-stem,0.25225508,hypoplastic-left-heart,0.3746312,hypoplastic-left-heart,0.3746312
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced-pluripotent-stem,0.21345402,hypoplastic-left-heart,0.38127902,hypoplastic-left-heart,0.38127902
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.21273248,cholesterol,0.41710073,cholesterol,0.41710073
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,fully,0.24119267,of,0.5259341,isomerism,0.3538288
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,suppressed,0.1626529,of,0.4633069,contractions,0.40291095
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based,0.2494699,of,0.5443143,flow,0.34116954
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.21273248,cholesterol,0.41710073,cholesterol,0.41710073
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,could,0.24107237,of,0.59299076,anomalous,0.37354472
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,0.23866604,of,0.4775706,blood,0.34112448
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone,0.2509793,l-transposition,0.40541044,l-transposition,0.40541044
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,hxxx,0.235608,isomerism,0.32887632,isomerism,0.32887632
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evoo,0.236093,cholesterol,0.39480388,cholesterol,0.39480388
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,direct,0.20486939,of,0.5187454,anomalous,0.3848631
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitor,0.23137593,of,0.37385303,congestive,0.302135
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,0.23866604,of,0.4775706,blood,0.34112448
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,recombinant,0.21714918,of,0.4109167,l-transposition,0.34227055
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,co,0.36334935,with,0.46287042,cardiac,0.45921996
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.21273248,cholesterol,0.41710073,cholesterol,0.41710073
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,failed,0.28042597,failure,0.5587824,mi,0.3746816
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specifically,0.26984817,of,0.59676015,mi,0.3534019
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,occurs,0.1640429,of,0.60348606,anomaly,0.420785
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,neurological,0.38897777,disease,0.50422406,cardiac,0.47628307
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,disorders,0.30838862,congenital,0.5785017,congenital,0.5785017
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,molecular,0.2634613,of,0.516936,isomerism,0.33948874
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,docking,0.24812675,weak,0.35536233,isomerism,0.33234513
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,molecular-docking,0.23902455,of,0.39880395,isomerism,0.36369002
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,metabolic,0.31231844,of,0.46523505,cardiac,0.4310553
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,reprogramming,0.34986037,l-transposition,0.51312506,l-transposition,0.51312506
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,higher,0.2654187,with,0.56796193,mi,0.398535
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,concentrations,0.20313622,with,0.46930897,deposits,0.43182394
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,high,0.28122714,of,0.57459104,flow,0.3923195
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,affinity,0.1784262,weak,0.44067597,flow,0.3238359
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,high-affinity,0.13317947,weak,0.37969676,l-transposition,0.31408745
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,first,0.34597713,of,0.61145455,l-transposition,0.40511346
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evidence,0.26946932,of,0.5239626,congestive,0.36117315
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,provide,0.3065295,of,0.4983799,flow,0.3409845
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evoo,0.236093,cholesterol,0.39480388,cholesterol,0.39480388
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,contains,0.14365944,of,0.48840532,deposits,0.33311546
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,constitutive,0.14971268,of,0.46098697,l-transposition,0.38318366
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,promoter,0.1920777,l-transposition,0.39260304,l-transposition,0.39260304
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,stem,0.2528829,hypoplastic,0.38906342,hypoplastic,0.38906342
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer-stem,0.13555044,artery-disease,0.3338545,artery-disease,0.3338545
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,binding,0.19702479,of,0.45710018,flow,0.3384309
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,site,0.25050646,intact,0.50730455,deposits,0.38691008
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,binding-site,0.18176517,of,0.3863058,l-transposition,0.3290122
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,associated,0.20417106,with,0.60998726,congenital,0.4144575
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,diseases,0.36311033,disease,0.77791697,heart-disease,0.5849265
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,associated-diseases,0.31951645,disease,0.6407131,heart-disease,0.61136323
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,also,0.36015856,of,0.65908813,flow,0.41040578
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,known,0.28223497,as,0.60071135,mi,0.41831112
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,box,0.20213163,interrupted,0.32596928,l-transposition,0.30131638
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low,0.33154353,with,0.5951388,flow,0.4108625
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,concentrations,0.20313622,with,0.46930897,deposits,0.43182394
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low-concentrations,0.19451658,of,0.50168,flow,0.44479245
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.21273248,cholesterol,0.41710073,cholesterol,0.41710073
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,0.23866604,of,0.4775706,blood,0.34112448
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based,0.2494699,of,0.5443143,flow,0.34116954
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low,0.33154353,with,0.5951388,flow,0.4108625
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer,0.29534408,disease,0.45700568,chd,0.41792578
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,use,0.3219829,with,0.55726266,flow,0.40877783
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,template,0.24788037,as,0.4608311,l-transposition,0.39453053
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,support,0.36322898,return,0.46409142,flow,0.36807415
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,repressor,0.19081134,l-transposition,0.4218288,l-transposition,0.4218288
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,predicted,0.16610277,of,0.49135727,single-ventricle,0.35252047
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overall,0.28817955,of,0.5869458,chd,0.41920155
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,obesity,0.37162852,chd,0.5639055,chd,0.5639055
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lysine,0.18055332,of,0.369767,l-transposition,0.3161099
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,like,0.33787337,as,0.6495254,cardiac,0.3588698
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,l,0.19137359,right,0.5803616,d-transposition,0.37858474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ips,0.30302376,return,0.36129868,cad,0.33632657
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,interaction,0.23807403,weak,0.5032127,isomerism,0.33030224
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,expression,0.1919756,of,0.5017252,l-transposition,0.40830338
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evaluated,0.3323459,of,0.6190806,flow,0.35268408
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,conversely,0.20391819,of,0.5762197,septal-defect,0.36792347
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,control,0.26906762,with,0.5145365,mi,0.4093958
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,chromatin,0.26340023,l-transposition,0.3840849,l-transposition,0.3840849
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,anchorage,0.20059596,stiff,0.43712968,l-transposition,0.3779847
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,alphascreen,0.257216,cad,0.32657832,cad,0.32657832
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,act,0.27575755,as,0.61612827,heart-attack,0.3494203
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ability,0.2123124,of,0.53612673,cardiac,0.340167
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jnk,0.13334003,mitral-regurgitation,0.32413638,mitral-regurgitation,0.32413638
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated,0.18597665,of,0.5168716,contractions,0.37430054
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptotic,0.16640727,of,0.3933456,flow,0.38513488
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,pathways,0.21818793,of,0.44726986,anomalous,0.36514243
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,compared,0.26227483,with,0.62448335,mi,0.40925252
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,tunel,0.15451965,flow,0.36905956,flow,0.36905956
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,positive,0.24830037,weak,0.52645016,blood,0.3939535
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptotic,0.16640727,of,0.3933456,flow,0.38513488
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,nuclei,0.23260237,deposits,0.39250332,deposits,0.39250332
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,positive-apoptotic,0.17724359,double,0.39769614,mi,0.36536187
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,akt,0.13930276,myocardial-infarction,0.28031534,myocardial-infarction,0.28031534
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell,0.21863139,of,0.48460138,flow,0.38218224
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,survival,0.18494695,failure,0.41816995,single-ventricle,0.40934175
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,signaling,0.2453397,of,0.40737927,contractions,0.3417532
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,molecules,0.22325355,of,0.48981342,isomerism,0.4059331
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell-survival,0.13534425,myocardial-infarction,0.3514772,myocardial-infarction,0.3514772
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,survival-signaling,0.16654012,of,0.3831381,congenital-heart-disease,0.37333935
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,signaling-molecules,0.22894613,of,0.4264331,isomerism,0.38205683
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated,0.18597665,of,0.5168716,contractions,0.37430054
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dutp,0.12265831,l-transposition,0.30240378,l-transposition,0.30240378
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,nick,0.22757664,l-transposition,0.3951258,l-transposition,0.3951258
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,end,0.28669232,interrupted,0.5072032,heart-failure,0.3686505
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated-dutp,0.21661215,l-transposition,0.41691777,l-transposition,0.41691777
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dutp-nick,0.2004014,double-outlet,0.32815439,double-outlet,0.32815439
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,nick-end,0.17379534,double-outlet,0.37397605,double-outlet,0.37397605
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dutp-nick-end,0.18515837,double-outlet,0.3600958,double-outlet,0.3600958
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,western,0.30529958,flow,0.3707292,flow,0.3707292
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,blotting,0.22732782,flow,0.3911235,flow,0.3911235
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,analysis,0.23442824,of,0.53198564,flow,0.34824157
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,revealed,0.223917,of,0.55371094,anomalous,0.36589023
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,western-blotting,0.21446323,isolated,0.3659687,flow,0.33423522
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,analysis-revealed,0.26325706,of,0.49318624,heart-attack,0.38747966
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,rescued,0.20542116,defect,0.47259724,septal-defect,0.45514897
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal,0.16295928,of,0.5041194,l-transposition,0.41455114
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,deoxynucleotide,0.094355375,l-transposition,0.44128498,l-transposition,0.44128498
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,transferase,0.23974168,cholesterol,0.45953423,cholesterol,0.45953423
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal-deoxynucleotide,0.11843121,l-transposition,0.47570547,l-transposition,0.47570547
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,underlying,0.32773498,of,0.5517533,arrythmia,0.47153074
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,molecular,0.2634613,of,0.516936,isomerism,0.33948874
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mechanism,0.1555937,of,0.5120126,anomalous,0.41311845
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,underlying-molecular,0.34374344,of,0.528108,isomerism,0.48318416
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,molecular-mechanism,0.2039429,of,0.48282912,isomerism,0.43086806
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sirna,0.22748467,l-transposition,0.29439193,l-transposition,0.29439193
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,completely,0.1890976,of,0.5188658,l-transposition,0.3790119
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,abrogated,0.16960719,of,0.37522316,contractions,0.30553448
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,related,0.2662045,of,0.6150687,cardiac,0.37595052
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neurodegenerative,0.2799778,disease,0.5945789,artery-disease,0.42222476
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,disorders,0.30838862,congenital,0.5785017,congenital,0.5785017
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive,0.18852003,attack,0.4490187,deposits,0.43040732
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxygen,0.22998369,flow,0.5002598,flow,0.5002598
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,species,0.21520105,of,0.4892193,deposits,0.38121843
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive-oxygen,0.1516819,attack,0.46617913,flow,0.38431627
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxygen-species,0.16442594,of,0.39938372,isomerism,0.3667486
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive-oxygen-species,0.13496147,of,0.4235342,plaque-deposits,0.3981558
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,quinazoline,0.21376899,isomerism,0.31885082,isomerism,0.31885082
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,alkaloid,0.20128573,isolated,0.39710638,isomerism,0.36619186
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,isolated,0.20391704,isolated,1.0,l-transposition,0.45230812
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protection,0.22196716,of,0.4576927,heart-attack,0.34616515
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,depended,0.2221984,of,0.59640336,anomalous,0.3506177
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,critically,0.3664999,of,0.5690512,single-ventricle,0.4336229
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mapk,0.18517739,mitral-regurgitation,0.33024183,mitral-regurgitation,0.33024183
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,c,0.21239448,with,0.46990636,ivs,0.34813386
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,adhatoda,0.18947676,truncus,0.41135576,truncus,0.41135576
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasica,0.23343079,truncus,0.37886724,truncus,0.37886724
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,plant,0.3530499,of,0.44666162,cardiology,0.3530499
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activated,0.18459547,of,0.4727149,contractions,0.34351796
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protein,0.17386194,of,0.4756804,cholesterol,0.3740363
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,kinase,0.17639789,of,0.32242787,myocardial,0.3009235
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activated-protein,0.19403742,of,0.44373557,heart-attack,0.33411452
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protein-kinase,0.21248177,of,0.37827116,congestive,0.32201135
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cellular,0.25397572,of,0.55018497,cardiac,0.40519243
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptosis,0.17540334,flow,0.39729238,flow,0.39729238
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced-cellular,0.1369234,of,0.5035354,plaque-deposits,0.44410267
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal,0.16295928,of,0.5041194,l-transposition,0.41455114
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,kinase,0.17639789,of,0.32242787,myocardial,0.3009235
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal-kinase,0.15700658,l-transposition,0.41672248,l-transposition,0.41672248
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell,0.21863139,of,0.48460138,flow,0.38218224
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,viability,0.19813254,of,0.42581767,flow,0.41994306
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell-viability,0.19357207,flow,0.41043574,flow,0.41043574
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,suppressed,0.1626529,of,0.4633069,contractions,0.40291095
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,generation,0.25683564,of,0.5394852,contractions,0.39260584
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protective,0.14898418,of,0.4669182,heart-attack,0.34925088
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protective-effect,0.19158259,weak,0.4245109,congestive-heart-failure,0.34111816
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,potential,0.23291323,of,0.5645705,cardiac,0.34140193
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,candidate,0.2506774,as,0.50267786,cad,0.32472426
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxidative,0.17657238,of,0.4233053,myocardial,0.36701933
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,stress,0.28176898,of,0.4473127,myocardial,0.4140401
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxidative-stress,0.19486363,myocardial,0.388269,myocardial,0.388269
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neuroprotective,0.22589122,infarction,0.39975306,infarction,0.39975306
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,effect,0.20909318,of,0.5657147,contractions,0.35284936
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neuroprotective-effect,0.24097511,myocardial,0.37280995,myocardial,0.37280995
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jun,0.23980604,dorv,0.29875183,dorv,0.29875183
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,n,0.21850443,with,0.47536123,mi,0.3790054
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jun-n,0.24075928,bradycardia,0.28859857,bradycardia,0.28859857
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,loss,0.15467258,of,0.561642,anomaly,0.37637395
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,findings,0.33716512,of,0.51820576,anomaly,0.40461916
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,indicated,0.26161766,of,0.5998554,cardiac,0.3719351
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dependent,0.22378129,of,0.585135,anomalous,0.36413002
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,manner,0.18540666,with,0.42496896,contractions,0.388913
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dependent-manner,0.2276189,of,0.44225368,mi,0.34053856
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.22381148,isomerism,0.37320775,isomerism,0.37320775
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reduced,0.22478527,of,0.6221848,contractions,0.3818075
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.22381148,isomerism,0.37320775,isomerism,0.37320775
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,increased,0.32251194,of,0.64014816,mi,0.42637154
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.18249518,of,0.5615651,contractions,0.42990774
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.22381148,isomerism,0.37320775,isomerism,0.37320775
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cells,0.18534905,of,0.46541262,deposits,0.38651246
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,treatment,0.30650938,of,0.52012336,congestive,0.36983645
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,treated,0.3223652,with,0.65053827,hypoplastic,0.4018695
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,study,0.327359,of,0.5728763,congestive-heart-failure,0.35066938
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,silencing,0.23634739,l-transposition,0.47900325,l-transposition,0.47900325
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sh,0.20100626,with,0.47651428,sv,0.4422411
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,ros,0.2997384,intact,0.42419577,flow,0.3921623
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,possibly,0.3128874,of,0.6252128,pulmonary,0.41755146
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,phosphorylation,0.18752447,of,0.40713966,contractions,0.3800071
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,parkinson,0.34187603,disease,0.55489707,cad,0.46425062
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,paraquat,0.16617376,of,0.35499278,myocardial,0.3318097
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,observed,0.23993361,with,0.6493877,deposits,0.43104827
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mitogen,0.14786698,isolated,0.37030208,contractions,0.34291202
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,labeling,0.19738346,of,0.3889702,flow,0.35952824
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,explored,0.24943587,of,0.58866113,anomalous,0.34417656
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,downregulated,0.1744174,isolated,0.3819149,hypoplastic,0.33087432
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dose,0.35218355,single,0.47391105,blood,0.3763219
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,disease,0.30252236,disease,1.0,artery-disease,0.6557848
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activation,0.19568133,of,0.49422675,contractions,0.44479024
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,0.21239448,with,0.46990636,ivs,0.34813386
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Practical guide for the use of PCSK9 inhibitors in Portugal.,persist,0.25892156,return,0.506247,l-transposition,0.3541326
Practical guide for the use of PCSK9 inhibitors in Portugal.,despite,0.3297603,of,0.5583629,cardiac,0.39134312
Practical guide for the use of PCSK9 inhibitors in Portugal.,optimal,0.22326279,of,0.49022785,single-ventricle,0.35533518
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
Practical guide for the use of PCSK9 inhibitors in Portugal.,c-levels,0.24047169,return,0.37156695,venous-return,0.36002916
Practical guide for the use of PCSK9 inhibitors in Portugal.,publicado,0.37646085,cardiology,0.37646085,cardiology,0.37646085
Practical guide for the use of PCSK9 inhibitors in Portugal.,por,0.23439053,sv,0.33617687,sv,0.33617687
Practical guide for the use of PCSK9 inhibitors in Portugal.,elsevier,0.3375554,cardiology,0.3375554,cardiology,0.3375554
Practical guide for the use of PCSK9 inhibitors in Portugal.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Practical guide for the use of PCSK9 inhibitors in Portugal.,reduces,0.1488205,of,0.53557026,heart-attack,0.33165377
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Practical guide for the use of PCSK9 inhibitors in Portugal.,new,0.35708106,of,0.526482,congestive-heart-failure,0.3801417
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapeutic,0.36109847,great,0.48941392,thrombosis,0.36398715
Practical guide for the use of PCSK9 inhibitors in Portugal.,option,0.28522927,as,0.4659202,hypoplastic,0.3850722
Practical guide for the use of PCSK9 inhibitors in Portugal.,new-therapeutic,0.3994635,heart-failure,0.44081855,heart-failure,0.44081855
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapeutic-option,0.3969376,of,0.45803538,venous-return,0.43834904
Practical guide for the use of PCSK9 inhibitors in Portugal.,density,0.19445077,cholesterol,0.42927843,cholesterol,0.42927843
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipoprotein,0.26318768,cholesterol,0.80184543,cholesterol,0.80184543
Practical guide for the use of PCSK9 inhibitors in Portugal.,cholesterol,0.2761673,cholesterol,0.99999994,cholesterol,0.99999994
Practical guide for the use of PCSK9 inhibitors in Portugal.,density-lipoprotein,0.24035887,cholesterol,0.7826578,cholesterol,0.7826578
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipoprotein-cholesterol,0.29643348,cholesterol,0.8591521,cholesterol,0.8591521
Practical guide for the use of PCSK9 inhibitors in Portugal.,density-lipoprotein-cholesterol,0.26042908,cholesterol,0.8576243,cholesterol,0.8576243
Practical guide for the use of PCSK9 inhibitors in Portugal.,consensus,0.35071254,of,0.35320076,cardiology,0.35071254
Practical guide for the use of PCSK9 inhibitors in Portugal.,document,0.44812122,of,0.5454849,cardiology,0.44812122
Practical guide for the use of PCSK9 inhibitors in Portugal.,aims,0.32326344,of,0.465683,congenital-heart-disease,0.358891
Practical guide for the use of PCSK9 inhibitors in Portugal.,achieve,0.23893768,of,0.48638898,venous-return,0.38442814
Practical guide for the use of PCSK9 inhibitors in Portugal.,recommended,0.46043187,with,0.54049706,cardiology,0.46043187
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Practical guide for the use of PCSK9 inhibitors in Portugal.,trials,0.34787738,failure,0.39036268,heart-failure,0.36908096
Practical guide for the use of PCSK9 inhibitors in Portugal.,translates,0.28088915,of,0.5055193,flow,0.335616
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical-trials,0.4117396,heart-failure,0.48685247,heart-failure,0.48685247
Practical guide for the use of PCSK9 inhibitors in Portugal.,good,0.31429055,weak,0.60268193,venous-return,0.38116372
Practical guide for the use of PCSK9 inhibitors in Portugal.,safety,0.34595427,with,0.43122858,venous-return,0.3475874
Practical guide for the use of PCSK9 inhibitors in Portugal.,profile,0.19752568,of,0.5464045,flow,0.39967984
Practical guide for the use of PCSK9 inhibitors in Portugal.,good-safety,0.41723317,venous-return,0.48598027,venous-return,0.48598027
Practical guide for the use of PCSK9 inhibitors in Portugal.,safety-profile,0.32105857,venous-return,0.4370942,venous-return,0.4370942
Practical guide for the use of PCSK9 inhibitors in Portugal.,higher,0.2654187,with,0.56796193,mi,0.398535
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Practical guide for the use of PCSK9 inhibitors in Portugal.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular-risk,0.54054093,chd,0.71753865,chd,0.71753865
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,0.21239448,with,0.46990636,ivs,0.34813386
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Practical guide for the use of PCSK9 inhibitors in Portugal.,c-levels,0.24047169,return,0.37156695,venous-return,0.36002916
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular,0.575528,chd,0.68271995,chd,0.68271995
Practical guide for the use of PCSK9 inhibitors in Portugal.,events,0.3918235,of,0.4981169,mi,0.49371853
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular-events,0.56915784,chd,0.68028665,chd,0.68028665
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Practical guide for the use of PCSK9 inhibitors in Portugal.,practice,0.5339576,cardiology,0.5339576,cardiology,0.5339576
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical-practice,0.51884663,cardiology,0.51884663,cardiology,0.51884663
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,0.28122714,of,0.57459104,flow,0.3923195
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Practical guide for the use of PCSK9 inhibitors in Portugal.,high-ldl,0.21329233,cholesterol,0.56527865,cholesterol,0.56527865
Practical guide for the use of PCSK9 inhibitors in Portugal.,xxx,0.3222348,dorv,0.4049663,dorv,0.4049663
Practical guide for the use of PCSK9 inhibitors in Portugal.,rights,0.3649758,incompetence,0.45336646,d-transposition,0.40694764
Practical guide for the use of PCSK9 inhibitors in Portugal.,reserved,0.3726897,with,0.5282947,hypoplastic,0.4747696
Practical guide for the use of PCSK9 inhibitors in Portugal.,inhibitors,0.26573044,as,0.38850647,congestive,0.32614616
Practical guide for the use of PCSK9 inhibitors in Portugal.,may,0.26963884,of,0.58654004,anomalous,0.366544
Practical guide for the use of PCSK9 inhibitors in Portugal.,benefit,0.3251614,return,0.474311,heart-failure,0.40887886
Practical guide for the use of PCSK9 inhibitors in Portugal.,make,0.35855716,great,0.52974176,cardiology,0.35855716
Practical guide for the use of PCSK9 inhibitors in Portugal.,recommendations,0.55450773,cardiology,0.55450773,cardiology,0.55450773
Practical guide for the use of PCSK9 inhibitors in Portugal.,main,0.28808993,of,0.60433525,anomalous,0.4090495
Practical guide for the use of PCSK9 inhibitors in Portugal.,data,0.31118363,of,0.5086956,mi,0.36251363
Practical guide for the use of PCSK9 inhibitors in Portugal.,important,0.26857167,great,0.5369053,anomalous,0.32819813
Practical guide for the use of PCSK9 inhibitors in Portugal.,strategies,0.27731135,of,0.46077913,congenital-heart-disease,0.36546677
Practical guide for the use of PCSK9 inhibitors in Portugal.,additional,0.34573856,of,0.63162684,cardiac,0.39887685
Practical guide for the use of PCSK9 inhibitors in Portugal.,reduction,0.2207006,of,0.5608181,l-transposition,0.38269264
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical,0.40667677,of,0.48020738,cardiology,0.40667677
Practical guide for the use of PCSK9 inhibitors in Portugal.,use,0.3219829,with,0.55726266,flow,0.40877783
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical-use,0.40372926,venous-return,0.46309835,venous-return,0.46309835
Practical guide for the use of PCSK9 inhibitors in Portugal.,lowering,0.3031208,cholesterol,0.55465686,cholesterol,0.55465686
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,0.28122714,of,0.57459104,flow,0.3923195
Practical guide for the use of PCSK9 inhibitors in Portugal.,proportion,0.23363663,total,0.537244,chd,0.3531295
Practical guide for the use of PCSK9 inhibitors in Portugal.,high-proportion,0.24646391,with,0.4314618,heart-failure,0.40911096
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing,0.20510697,of,0.5635449,heart-attack,0.39589107
Practical guide for the use of PCSK9 inhibitors in Portugal.,low,0.33154353,with,0.5951388,flow,0.4108625
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid,0.25036708,cholesterol,0.7013568,cholesterol,0.7013568
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,0.24129483,of,0.5074555,cholesterol,0.4301517
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,0.21239448,with,0.46990636,ivs,0.34813386
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.2433339,cholesterol,0.7500591,cholesterol,0.7500591
Practical guide for the use of PCSK9 inhibitors in Portugal.,risk,0.30685735,chd,0.5779637,chd,0.5779637
Practical guide for the use of PCSK9 inhibitors in Portugal.,profile,0.19752568,of,0.5464045,flow,0.39967984
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.40366784,failure,0.48316255,congestive,0.43509448
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,0.28122714,of,0.57459104,flow,0.3923195
Practical guide for the use of PCSK9 inhibitors in Portugal.,use,0.3219829,with,0.55726266,flow,0.40877783
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing,0.20510697,of,0.5635449,heart-attack,0.39589107
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost,0.3278179,total,0.46381748,heart-failure,0.3949646
Practical guide for the use of PCSK9 inhibitors in Portugal.,u,0.22611019,ivs,0.4367266,ivs,0.4367266
Practical guide for the use of PCSK9 inhibitors in Portugal.,therefore,0.32687712,of,0.6409915,flow,0.39200473
Practical guide for the use of PCSK9 inhibitors in Portugal.,take,0.42415583,return,0.53945684,cardiology,0.42415583
Practical guide for the use of PCSK9 inhibitors in Portugal.,summarize,0.32860965,of,0.42255872,cardiology,0.32860965
Practical guide for the use of PCSK9 inhibitors in Portugal.,statins,0.4116977,cholesterol,0.593088,cholesterol,0.593088
Practical guide for the use of PCSK9 inhibitors in Portugal.,significantly,0.23700657,with,0.568532,mi,0.39826992
Practical guide for the use of PCSK9 inhibitors in Portugal.,priority,0.45250517,great,0.4883302,cardiology,0.45250517
Practical guide for the use of PCSK9 inhibitors in Portugal.,portugal,0.38002768,cardiology,0.38002768,cardiology,0.38002768
Practical guide for the use of PCSK9 inhibitors in Portugal.,patients,0.35241044,disease,0.5065658,heart-failure,0.5065651
Practical guide for the use of PCSK9 inhibitors in Portugal.,one,0.3148334,single,0.6951874,anomaly,0.3884908
Practical guide for the use of PCSK9 inhibitors in Portugal.,lifestyle,0.33245334,chd,0.5047984,chd,0.5047984
Practical guide for the use of PCSK9 inhibitors in Portugal.,l,0.19137359,right,0.5803616,d-transposition,0.37858474
Practical guide for the use of PCSK9 inhibitors in Portugal.,however,0.30646515,of,0.624624,mi,0.41109186
Practical guide for the use of PCSK9 inhibitors in Portugal.,given,0.43020725,with,0.60330975,cardiology,0.43020725
Practical guide for the use of PCSK9 inhibitors in Portugal.,ezetimibe,0.2529185,cholesterol,0.6072894,cholesterol,0.6072894
Practical guide for the use of PCSK9 inhibitors in Portugal.,effectiveness,0.2947462,of,0.5160025,venous-return,0.352529
Practical guide for the use of PCSK9 inhibitors in Portugal.,account,0.27722406,of,0.53262895,anomalous,0.4109847
